FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Hartwell, KJ
LeMatty, T
McRae-Clark, AL
Gray, KM
George, MS
Brady, KT
AF Hartwell, Karen J.
LeMatty, Todd
McRae-Clark, Aimee L.
Gray, Kevin M.
George, Mark S.
Brady, Kathleen T.
TI Resisting the Urge to Smoke and Craving during a Smoking Quit Attempt on
Varenicline: Results from a Pilot fMRI Study
SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE
LA English
DT Article
ID NICOTINE DEPENDENCE; LABORATORY MODEL; CUE-REACTIVITY; ABSTINENCE;
CESSATION; ACTIVATION; BUPROPION; RESPONSES; COGNITION; MOOD
AB Background: Varenicline has been shown to reduce cigarette craving during a quit attempt. Objectives: Use BOLD fMRI to explore differences in smoking cue reactivity at baseline and after five weeks of varenicline smoking cessation treatment. Methods: Treatment-seeking nicotine-dependent adult smokers underwent BOLD fMRI scans with block presentation of visual smoking, neutral, and rest cues under two conditions: craving or resisting the urge to smoke at baseline and following 5 weeks of standard varenicline therapy. Data were analyzed using FMRI Expert Analysis Tool, version 5.98 of Functional Magnetic Imaging of the Brain Software Library focused on the smoking vs. neutral cue contrast at the individual and group level, Z>2.3 with cluster threshold p=0.05. Results: Twenty-one participants were scanned at baseline and 16 completed the study; 10 were abstinent at the 2nd session, confirmed with urinary cotinine. In the Crave Condition no significant differences were found between the abstinent and non-abstinent groups at either time point. During the baseline Resist Condition, the abstinent group compared to the non-abstinent group demonstrated activation in a distributed network involved in alertness, learning and memory. Additionally, within the abstinent group, increased activation of the superior frontal gyrus was found at baseline compared to week 5. Conclusion: Successful smoking cessation with varenicline is associated with increased activation, prior to a quit attempt, in brain areas related to attentiveness and memory while resisting the urge to smoke Scientific Significance: Varenicline may exert effects by both reducing craving and enhancing resistance to smoking urges during cue-elicited craving.
C1 [Hartwell, Karen J.; LeMatty, Todd; McRae-Clark, Aimee L.; Gray, Kevin M.; George, Mark S.; Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Hartwell, Karen J.; George, Mark S.; Brady, Kathleen T.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Hartwell, KJ (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 67 President St,MSC 861, Charleston, SC 29425 USA.
EM hartwelk@musc.edu
RI McRae-Clark, Aimee/I-3341-2013
OI McRae-Clark, Aimee/0000-0002-9774-318X
FU NCRR NIH HHS [UL1 RR029882]; NICHD NIH HHS [K12 HD055885, K12HD055885];
NIDA NIH HHS [5R21DA026085-02, R21 DA026085]
NR 33
TC 5
Z9 5
U1 2
U2 22
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0095-2990
J9 AM J DRUG ALCOHOL AB
JI Am. J. Drug Alcohol Abuse
PD MAR
PY 2013
VL 39
IS 2
BP 92
EP 98
DI 10.3109/00952990.2012.750665
PG 7
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 093IH
UT WOS:000315184600005
PM 23421569
ER
PT J
AU Oliva, EM
Trafton, JA
Harris, AHS
Gordon, AJ
AF Oliva, Elizabeth M.
Trafton, Jodie A.
Harris, Alex H. S.
Gordon, Adam J.
TI Trends in Opioid Agonist Therapy in the Veterans Health Administration:
Is Supply Keeping up with Demand?
SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE
LA English
DT Article
DE opioid agonist therapy; buprenorphine; veterans; office-based treatment;
VA; VHA; methadone
ID SUBSTANCE-ABUSE TREATMENT; BUPRENORPHINE; METHADONE; DEPENDENCE;
ADDICTION; ADOPTION; COSTS
AB Background: Opioid agonist therapy (OAT) through addiction specialty clinic settings (clinic-based OAT) using methadone or buprenorphine or office-based settings using buprenorphine (office-based OAT) is an evidence-based treatment for opioid dependence. The low number of clinic-based OATs available to veterans (N = 53) presents a barrier to OAT access; thus, the expansion in office-based OAT has been encouraged. Objectives: To examine trends in office-based OAT utilization over time and whether availability of office-based OAT improved the proportion of veterans with opioid use disorders treated with OAT. Methods: We examined Veterans Health Administration (VHA) administrative data for evidence of buprenorphine prescribing and clinic-based OAT clinic stops from October 2003 through September 2010 [fiscal years (FY) 2004-2010]. Results: The number of patients receiving buprenorphine increased from 300 at 27 facilities in FY2004 to 6147 at 118 facilities in FY2010. During this time, the number of patients diagnosed with an opioid use disorder increased by 45%; however, the proportion of opioid use disorder patients receiving OAT remained relatively stable, ranging from 25% to 27%, Conclusions: Office-based OAT utilization and the number of opioid use disorder veterans treated with OAT are increasing at the same rate over time, suggesting that office-based OAT is being used to meet the growing need for OAT care. Although office-based OAT is increasingly being used within the VHA and may be one way the VHA is keeping up with the demand for OAT, more research is needed to understand how to engage a greater proportion of opioid use disorder patients in treatment.
C1 [Oliva, Elizabeth M.; Trafton, Jodie A.; Harris, Alex H. S.] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA.
[Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Mental Hlth Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Gordon, Adam J.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA.
RP Oliva, EM (reprint author), VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, 795 Willow Rd,MPD 152, Menlo Pk, CA 94025 USA.
EM elizabeth.oliva@va.gov
NR 21
TC 8
Z9 8
U1 3
U2 9
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0095-2990
J9 AM J DRUG ALCOHOL AB
JI Am. J. Drug Alcohol Abuse
PD MAR
PY 2013
VL 39
IS 2
BP 103
EP 107
DI 10.3109/00952990.2012.741167
PG 5
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 093IH
UT WOS:000315184600007
PM 23421571
ER
PT J
AU Tanner, RM
Gutierrez, OM
Judd, S
McClellan, W
Bowling, CB
Bradbury, BD
Safford, MM
Cushman, M
Warnock, D
Muntner, P
AF Tanner, Rikki M.
Gutierrez, Orlando M.
Judd, Suzanne
McClellan, William
Bowling, C. Barrett
Bradbury, Brian D.
Safford, Monika M.
Cushman, Mary
Warnock, David
Muntner, Paul
TI Geographic Variation in CKD Prevalence and ESRD Incidence in the United
States: Results From the Reasons for Geographic and Racial Differences
in Stroke (REGARDS) Study
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Chronic kidney disease; geography; end-stage renal disease
ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; GLOMERULAR-FILTRATION-RATE;
RISK; POPULATION; JAPAN; DEATH; CARE
AB Background: It is not known whether geographic differences in the prevalence of chronic kidney disease exist and are associated with end-stage renal disease (ESRD) incidence rates across the United States.
Study Design: Cross-sectional and ecologic.
Setting & Participants: White (n = 16,410) and black (n = 11,109) participants from across the continental United States in the population-based Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.
Predictor: Geographic region, defined by the 18 networks of the US ESRD Network Program.
Outcomes & Measurements: Albuminuria, defined as albumin-creatinine ratio >= 30 mg/g, and decreased estimated glomerular filtration rate (eGFR), defined as <60 mL/min/1.73 m(2), were measured in the REGARDS Study. ESRD incidence rates were obtained from the US Renal Data System.
Results: For whites, the network-specific prevalence of albuminuria ranged from 8.4% (95% CI, 3.3%-13.5%) in Network 15 to 14.8% (95% CI, 8.0%-21.6%) in Network 3, and decreased eGFR ranged from 4.3% (95% CI, 2.0%-6.6%) in Network 4 to 16.7% (95% CI, 12.7%-20.7%) in Network 7. For blacks, the prevalence of albuminuria ranged from 12.1% (95% CI, 8.7%-15.5%) in Network 5 to 26.5% (95% CI, 16.7%-36.3%) in Network 4, and decreased eGFR ranged from 6.7% (95% CI, 5.0%-8.4%) in Network 17/18 to 13.4% (95% CI, 7.8%-19.1%) in Network 12. Spearman correlation coefficients for the prevalence of albuminuria and decreased eGFR with network-specific ESRD incidence rates were 0.49 and 0.24, respectively, for whites and 0.29 and 0.25, respectively, for blacks.
Limitations: There were few cases of albuminuria and decreased eGFR in some geographic regions.
Conclusions: In the United States, substantial geographic variations in the prevalence of albuminuria and decreased eGFR exist, but were correlated only modestly with ESRD incidence, suggesting the chronic kidney disease burden may not explain the geographic variation in ESRD incidence. Am J Kidney Dis. 61(3):395-403. (C) 2013 by the National Kidney Foundation, Inc.
C1 [Tanner, Rikki M.; Gutierrez, Orlando M.; Judd, Suzanne; Bowling, C. Barrett; Safford, Monika M.; Warnock, David; Muntner, Paul] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[McClellan, William] Emory Univ, Atlanta, GA 30322 USA.
[Bowling, C. Barrett] Birmingham VA Med Ctr, Birmingham, AL USA.
[Bradbury, Brian D.] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA 91320 USA.
[Bradbury, Brian D.] Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA USA.
[Cushman, Mary] Univ Vermont, Burlington, VT USA.
RP Muntner, P (reprint author), Univ Alabama Birmingham, Dept Epidemiol, 1665 Univ Blvd,Ste 230J, Birmingham, AL 35294 USA.
EM pmuntner@uab.edu
FU National Institute of Neurological Disorders and Stroke (NINDS),
National Institutes of Health (NIH), Department of Health and Human
Services [U01 NS041588]; Amgen Corp
FX Support: This research project is supported by cooperative agreement U01
NS041588 from the National Institute of Neurological Disorders and
Stroke (NINDS), National Institutes of Health (NIH), Department of
Health and Human Services. The content is solely the responsibility of
the authors and does not necessarily represent the official views of the
NINDS or NIH. Representatives of the funding agency were involved in the
review of the manuscript but not directly involved in the collection,
management, analysis, or interpretation of the data. Additional funding
was provided by an investigator-initiated grant-in-aid from Amgen Corp
to Dr Warnock.
NR 31
TC 10
Z9 11
U1 0
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD MAR
PY 2013
VL 61
IS 3
BP 395
EP 403
DI 10.1053/j.ajkd.2012.10.018
PG 9
WC Urology & Nephrology
SC Urology & Nephrology
GA 090GF
UT WOS:000314966600009
PM 23228944
ER
PT J
AU Zhao, W
Marchani, EE
Cheung, CYK
Steinbart, EJ
Schellenberg, GD
Bird, TD
Wijsman, EM
AF Zhao, Wei
Marchani, Elizabeth E.
Cheung, Charles Y. K.
Steinbart, Ellen J.
Schellenberg, Gerard D.
Bird, Thomas D.
Wijsman, Ellen M.
TI Genome scan in familial late-onset Alzheimer's disease: A locus on
chromosome 6 contributes to age-at-onset
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE linkage analysis; MCMC; oligogenic; dementia; age-censored
ID NEUROTROPHIC FACTOR BDNF; MONTE-CARLO SEGREGATION; LINKAGE ANALYSIS;
APOLIPOPROTEIN-E; GENETIC ASSOCIATION; MULTIPLE IMPUTATION; QUANTITATIVE
TRAIT; OF-ONSET; SYSTEMATIC METAANALYSES; OLIGOGENIC SEGREGATION
AB Alzheimer's disease (AD) is a common, genetically complex, fatal neurodegenerative disorder of late life. Although several genes are known to play a role in early-onset AD, identification of the genetic basis of late onset AD (LOAD) has been challenging, with only the APOE gene known to have a high contribution to both AD risk and age-at-onset. Here, we present the first genome-scan analysis of the complete, well-characterized University of Washington LOAD sample of 119 pedigrees, using age-at-onset as the trait of interest. The analysis approach used allows for a multilocus trait model while at the same time accommodating age censoring, effects of APOE as a known genetic covariate, and full pedigree and marker information. The results provide strong evidence for linkage of loci contributing to age-at-onset to genomic regions on chromosome 6q16.3, and to 19q13.42 in the region of the APOE locus. There was evidence for interaction between APOE and the locus on chromosome 6q and suggestive evidence for linkage to chromosomes 11p13, 15q12-14, and 19p13.12. These results provide the first independent confirmation of an AD age-at-onset locus on chromosome 6 and suggest that further efforts towards identifying the underlying causal locus or loci are warranted. (c) 2013 Wiley Periodicals, Inc.
C1 [Zhao, Wei; Cheung, Charles Y. K.; Wijsman, Ellen M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Marchani, Elizabeth E.; Bird, Thomas D.; Wijsman, Ellen M.] Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA.
[Steinbart, Ellen J.; Bird, Thomas D.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Steinbart, Ellen J.; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Schellenberg, Gerard D.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA.
[Wijsman, Ellen M.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
RP Wijsman, EM (reprint author), Univ Washington, Dept Med, Div Med Genet, Box 357720, Seattle, WA 98195 USA.
EM wijsman@u.washington.edu
OI Wijsman, Ellen/0000-0002-2725-6669
FU National Institutes of Health (NIH) [P50 AG005136, T32 AG000258, K99
AG040184]; Veterans Affairs Research Funds; Metropolitan Life
Foundation; [NIH U24 AG021886]
FX We thank the patients and their families, whose help and participation
made this work possible. We thank Leslie Leong and Hiep Nguyen for
technical assistance; Adele Sadovnick, Leonard Heston, and Haydeh Payami
for family material; and David Cook for discussions. Supported by
National Institutes of Health (NIH) grants P50 AG005136, T32 AG000258,
and K99 AG040184; Veterans Affairs Research Funds; and The Metropolitan
Life Foundation. Some samples used in this study were obtained from the
National Cell Repository for Alzheimer's Disease (NCRAD), supported by
NIH U24 AG021886.
NR 92
TC 1
Z9 1
U1 2
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4841
EI 1552-485X
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD MAR
PY 2013
VL 162B
IS 2
BP 201
EP 212
DI 10.1002/ajmg.b.32133
PG 12
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA 095JP
UT WOS:000315330800012
PM 23355194
ER
PT J
AU Fallows, RR
Hilsabeck, RC
AF Fallows, Robert R.
Hilsabeck, Robin C.
TI Comparing Two Methods of Delivering Neuropsychological Feedback
SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY
LA English
DT Article
DE Feedback; Written information; Neuropsychology
ID WRITTEN INFORMATION; CONTROLLED-TRIAL; NATIONAL-SURVEY; MIXED METHODS;
PERCEPTIONS; INTERVENTION; ADOLESCENT; SERVICE
AB Feedback methods have been studied in medical and psychotherapy settings, but limited research is available in neuropsychology. The purpose of this study was to examine whether supplementing oral feedback with written information would lead to greater retention of information and improved adherence to recommendations. Seventy-two veterans were enrolled in the study and randomized to receive oral feedback only or oral feedback with written information. The participants were then interviewed immediately after feedback and 1 month later by phone. Univariate analyses revealed that the written group freely recalled more recommendations at the phone interview; however, there were no differences in recall of diagnostic information or the number of recommendations attempted. Findings indicate that receiving supplemental written information improves recall of recommendations and that patients prefer to receive written information in addition to oral feedback. Recommendations to improve the retention of feedback information are discussed.
C1 [Fallows, Robert R.; Hilsabeck, Robin C.] S Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA.
[Hilsabeck, Robin C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
RP Hilsabeck, RC (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, MS 7792, San Antonio, TX 78229 USA.
EM hilsabeck@uthscsa.edu
NR 38
TC 4
Z9 4
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0887-6177
J9 ARCH CLIN NEUROPSYCH
JI Arch. Clin. Neuropsychol.
PD MAR
PY 2013
VL 28
IS 2
BP 180
EP 188
DI 10.1093/arclin/acs142
PG 9
WC Psychology, Clinical; Psychology
SC Psychology
GA 092YS
UT WOS:000315159500010
PM 23315402
ER
PT J
AU Cea, M
Cagnetta, A
Patrone, F
Nencioni, A
Gobbi, M
Anderson, KC
AF Cea, Michele
Cagnetta, Antonia
Patrone, Franco
Nencioni, Alessio
Gobbi, Marco
Anderson, Kenneth C.
TI Intracellular NAD(+) depletion induces autophagic death in multiple
myeloma cells
SO AUTOPHAGY
LA English
DT Editorial Material
DE multiple myeloma; nicotinamide phosphoribosyltransferase; PI3K/MTORC1;
TFEB; cancer treatment
AB Multiple myeloma (MM) is a clonal B-cell malignancy characterized by the proliferation of plasma cells in the bone marrow. Despite recent therapeutic advances, MM remains an incurable disease. Therefore, research has focused on defining new aspects in MM biology that can be therapeutically targeted. Compelling evidence suggests that malignant cells have a higher nicotinamide adenine dinucleotide (NAD+) turnover rate than normal cells, suggesting that this biosynthetic pathway represents an attractive target for cancer treatment. We recently reported that an intracellular NAD+-depleting agent, FK866, exerts its anti-MM effect by triggering autophagic cell death via transcriptional-dependent (transcription factor EB, TFEB) and -independent (PI3K-MTORC1) mechanisms. Our findings link intracellular NAD+ levels to autophagy in MM cells, providing the rationale for novel targeted therapies in MM.
C1 [Cea, Michele; Cagnetta, Antonia; Anderson, Kenneth C.] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA 02215 USA.
[Cea, Michele; Cagnetta, Antonia; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA.
[Cea, Michele; Cagnetta, Antonia; Patrone, Franco; Nencioni, Alessio; Gobbi, Marco] IRCCS Univ Hosp San Martino IST, Dept Hematol & Oncol, Genoa, Italy.
RP Cea, M (reprint author), Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA 02215 USA.
EM michele_cea@dfci.harvard.edu; kenneth_anderson@dfci.harvard.edu
FU NCI NIH HHS [P01 CA078378, P50 CA100707, P01 CA155258]; PHS HHS [R0-1
50947, R0-1 73878]
NR 0
TC 13
Z9 13
U1 0
U2 4
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1554-8627
J9 AUTOPHAGY
JI Autophagy
PD MAR
PY 2013
VL 9
IS 3
BP 410
EP 412
DI 10.4161/auto.22866
PG 3
WC Cell Biology
SC Cell Biology
GA 094XY
UT WOS:000315300000013
PM 23221771
ER
PT J
AU Wahler, A
Beyer, AS
Keller, IE
Schnack, C
von Einem, B
Propper, C
Boeckers, TM
Peltan, ID
Strickland, DK
Hyman, BT
von Arnim, CAF
AF Wahler, Anke
Beyer, Anja-Silke
Keller, Ilona E.
Schnack, Cathrin
von Einem, Bjoern
Proepper, Christian
Boeckers, Tobias M.
Peltan, Ithan D.
Strickland, Dudley K.
Hyman, Bradley T.
von Arnim, Christine A. F.
TI Engulfment adaptor phosphotyrosine-binding-domain-containing 1 (GULP1)
is a nucleocytoplasmic shuttling protein and is transactivationally
active together with low-density lipoprotein receptor-related protein 1
(LRP1)
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE adaptor protein; Alzheimer's disease; amyloid precursor protein;
engulfment adaptor phosphotyrosine-binding-domain-containing 1 (GULP1);
transactivation
ID AMYLOID PRECURSOR PROTEIN; INTRACELLULAR DOMAIN; APOPTOTIC CELLS;
TRANSCRIPTIONAL ACTIVATOR; ALZHEIMERS-DISEASE; FE65; LOCALIZATION;
PROTEOLYSIS; EXPRESSION; CLEARANCE
AB APP (amyloid precursor protein) and LRP1 (low-density lipoprotein receptor-related protein 1) have been implicated in the pathogenesis of AD (Alzheimer's disease). They are functionally linked by Fe65, a PTB (phosphotyrosine-binding)domain-containing adaptor protein that binds to intracellular NPxY-motifs of APP and LRP1, thereby influencing expression levels, cellular trafficking and processing. Additionally, Fe65 has been reported to mediate nuclear signalling in combination with intracellular domains of APP and LRP1. We have previously identified another adaptor protein, GULP1 (engulfment adaptor PTB-domain-containing 1). In the present study we characterize and compare nuclear trafficking and transactivation of GULP1 and Fe65 together with APP and LRP1 and report differential nuclear trafficking of adaptors when APP or LRP1 are co-expressed. The observed effects were additionally supported by a reporter-plasmid-based transactivation assay. The results from the present study indicate that Fe65 might have signalling properties together with APP and LRP1, whereas GULP1 only mediates LRP1 transactivation.
C1 [Wahler, Anke; Beyer, Anja-Silke; Keller, Ilona E.; Schnack, Cathrin; von Einem, Bjoern; von Arnim, Christine A. F.] Univ Ulm, Dept Neurol, D-89081 Ulm, Germany.
[Proepper, Christian; Boeckers, Tobias M.] Univ Ulm, Inst Anat & Cell Biol, D-89081 Ulm, Germany.
[Peltan, Ithan D.; Hyman, Bradley T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Alzheimers Dis Res Lab, Charlestown, MA 02129 USA.
[Strickland, Dudley K.] Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA.
RP von Arnim, CAF (reprint author), Univ Ulm, Dept Neurol, D-89081 Ulm, Germany.
EM christine.arnim@uni-ulm.de
OI Peltan, Ithan/0000-0003-1730-234X
FU Ernst Schering Foundation; Land Baden-Wurttemberg [1423/74]; National
Institutes for Health [HL050784, L054710]
FX A.W. is a recipient of a doctoral fellowship from the Ernst Schering
Foundation. This work was supported by Land Baden-Wurttemberg [grant
number 1423/74 (to C.A.F.v.A.)] and the National Institutes for Health
[grant numbers HL050784 and L054710 (to D K S.)]
NR 39
TC 1
Z9 1
U1 0
U2 6
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264-6021
J9 BIOCHEM J
JI Biochem. J.
PD MAR 1
PY 2013
VL 450
BP 333
EP 343
DI 10.1042/BJ20121100
PN 2
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 094HJ
UT WOS:000315253300009
PM 23167255
ER
PT J
AU Nanji, KC
Ferris, TG
Torchiana, DF
Meyer, GS
AF Nanji, Karen C.
Ferris, Timothy G.
Torchiana, David F.
Meyer, Gregg S.
TI Overarching goals: a strategy for improving healthcare quality and
safety?
SO BMJ QUALITY & SAFETY
LA English
DT Review
ID ADVERSE EVENTS; COMPETITION
AB The management literature reveals that many successful organisations have strategic plans that include a bold 'stretch-goal' to stimulate progress over a ten-to-thirty-year period. A stretch goal is clear, compelling and easily understood. It serves as a unifying focal point for organisational efforts. The ambitiousness of such goals has been emphasised with the phrase Big Hairy Audacious Goal ('BHAG'). President Kennedy's proclamation in 1961 that 'this Nation should commit itself to achieving the goal, before this decade is out, of landing a man on the moon and returning him safely to earth' provides a famous example. This goal energised the US National Aeronautics and Space Administration, and it captured the attention of the American public and resulted in one of the largest accomplishments of any organisation. The goal set by Sony, a small, cash-strapped electronics company in the 1950s, to change the poor image of Japanese products around the world represents a classic BHAG. Few examples of quality goals that conform to the BHAG definition exist in the healthcare literature. However, the concept may provide a useful framework for organisations seeking to transform the quality of care they deliver. This review examines the merits and cautions of setting overarching quality goals to catalyse quality improvement efforts, and assists healthcare organisations with determining whether to adopt these goals.
C1 [Nanji, Karen C.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Nanji, Karen C.; Ferris, Timothy G.; Torchiana, David F.; Meyer, Gregg S.] Harvard Univ, Sch Med, Boston, MA USA.
[Nanji, Karen C.; Ferris, Timothy G.; Torchiana, David F.; Meyer, Gregg S.] Massachusetts Gen Phys Org, Boston, MA USA.
RP Nanji, KC (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
EM knanji@partners.org
NR 35
TC 2
Z9 2
U1 1
U2 13
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-5415
J9 BMJ QUAL SAF
JI BMJ Qual. Saf.
PD MAR
PY 2013
VL 22
IS 3
BP 187
EP 193
DI 10.1136/bmjqs-2012-001082
PG 7
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 093JX
UT WOS:000315189200002
PM 23204514
ER
PT J
AU Armand, P
Welch, S
Kim, HT
LaCasce, AS
Jacobsen, ED
Davids, MS
Jacobson, C
Fisher, DC
Brown, JR
Coughlin, E
Freedman, AS
Chen, YB
AF Armand, Philippe
Welch, Sarah
Kim, Haesook T.
LaCasce, Ann S.
Jacobsen, Eric D.
Davids, Matthew S.
Jacobson, Caron
Fisher, David C.
Brown, Jennifer R.
Coughlin, Erin
Freedman, Arnold S.
Chen, Yi-Bin
TI Prognostic factors for patients with diffuse large B cell lymphoma and
transformed indolent lymphoma undergoing autologous stem cell
transplantation in the positron emission tomography era
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE prognostic factors; autologous stem cell transplant; diffuse large
B-cell lymphoma; transformed indolent lymphoma; PET
ID NON-HODGKINS-LYMPHOMA; HIGH-DOSE THERAPY; BONE-MARROW TRANSPLANTATION;
FOLLICULAR LYMPHOMA; SALVAGE CHEMOTHERAPY; RITUXIMAB; SURVIVAL; SUPPORT;
TRIAL; SCAN
AB In the positron emission tomography (PET) era, traditional prognostic factors may not apply for patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) undergoing autologous stem cell transplantation (ASCT). Moreover, little is known about prognostic factors in patients transplanted for transformed indolent lymphoma (TIL). We conducted a retrospective study of 143 patients with R/R DLBCL and TIL who were transplanted in the last decade and had a post-salvage PET scan. We examined prognostic factors in both groups, and constructed a prognostic score for DLBCL patients. For patients with DLBCL, post-salvage PET response was an important prognostic factor. Advanced age and symptomatic relapse were also significantly associated with outcome. A simple score could stratify patients into three risk groups with 4-year post-ASCT overall survival of 84%, 59%, and 10%, and 4-year progression-free survival of 67%, 41% and 0% (P<0 center dot 0001 for both). However, none of those factors (including PET response to salvage) appeared relevant for patients with TIL, despite their comparable overall outcome. Our prognostic score for DLBCL patients undergoing ASCT may be useful for prognostication, for stratification in clinical trials, and to motivate the design of new strategies for patients in the high-risk group, who may not derive benefit from standard ASCT.
C1 [Armand, Philippe; LaCasce, Ann S.; Jacobsen, Eric D.; Davids, Matthew S.; Jacobson, Caron; Fisher, David C.; Brown, Jennifer R.; Freedman, Arnold S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Welch, Sarah] Boston Univ, Sch Med, Div Grad Med Sci, Boston, MA 02118 USA.
[Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Coughlin, Erin; Chen, Yi-Bin] Massachusetts Gen Hosp, Div Hematol Oncol, Bone Marrow Transplant Unit, Boston, MA 02114 USA.
RP Armand, P (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM parmand@partners.org
FU American Society of Hematology Scholar Award; ASCO/Conquer Cancer
Foundation Career Development Award
FX P.A. is supported by an American Society of Hematology Scholar Award and
by an ASCO/Conquer Cancer Foundation Career Development Award.
NR 30
TC 20
Z9 20
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD MAR
PY 2013
VL 160
IS 5
BP 608
EP 617
DI 10.1111/bjh.12176
PG 10
WC Hematology
SC Hematology
GA 092AW
UT WOS:000315092200006
PM 23278720
ER
PT J
AU Hwang, JC
Sharma, AG
Eliott, D
AF Hwang, John Chopin
Sharma, Ashish G.
Eliott, Dean
TI Fellow eye vitrectomy for proliferative diabetic retinopathy in an inner
city population
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OUTCOMES
AB Aim To describe the rate of fellow eye vitrectomy for proliferative diabetic retinopathy in an inner city population.
Methods Retrospective interventional case series. Medical and surgical records of 434 consecutive eyes of 358 patients undergoing primary diabetic vitrectomy in an inner city institutional practice were reviewed. Kaplan-Meier statistical analysis was employed to evaluate the rate of fellow eye vitrectomy and visual outcomes were determined for patients with >= 3 months follow-up.
Results Fellow eyes underwent diabetic vitrectomy at a rate of 24% within 1 year, 34% within 3 years and 36% within 5 years of primary vitrectomy. A surgical indication of non-clearing vitreous haemorrhage (VH) in the primary eye was associated with a lower rate of fellow eye surgery compared with non-clearing VH with extrafoveal traction retinal detachment (TRD) at years 1, 3 and 5 (p <= 0.02), and TRD at years 3 and 5 (p <= 0.03). Younger patients underwent fellow eye vitrectomy at a higher rate than older patients (p <= 0.01). Surgical intervention was associated with improvement in mean visual acuity (p<0.01).
Conclusions Approximately a third of fellow eyes required diabetic vitrectomy within 3 years of primary eye vitrectomy. Primary eye surgical indication and younger age were significant predictors of need for fellow eye surgery.
C1 [Hwang, John Chopin] Retina Associates Orange Cty, Laguna Hills, CA USA.
[Sharma, Ashish G.] Retina Consultants SW Florida, Ft Myers, FL USA.
[Eliott, Dean] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
RP Eliott, D (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM Dean_Eliott@meei.harvard.edu
NR 7
TC 1
Z9 1
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2013
VL 97
IS 3
BP 297
EP 301
DI 10.1136/bjophthalmol-2012-302233
PG 5
WC Ophthalmology
SC Ophthalmology
GA 092ZW
UT WOS:000315162500012
PM 23314578
ER
PT J
AU Cooley, ME
Finn, KT
Wang, Q
Roper, K
Morones, S
Shi, L
Litrownik, D
Marcoux, JP
Zaner, K
Hayman, LL
AF Cooley, Mary E.
Finn, Kathleen T.
Wang, Qian
Roper, Kristin
Morones, Sandra
Shi, Ling
Litrownik, Dan
Marcoux, J. Paul
Zaner, Ken
Hayman, Laura L.
TI Health Behaviors, Readiness to Change, and Interest in Health Promotion
Programs Among Smokers With Lung Cancer and Their Family Members A Pilot
Study
SO CANCER NURSING
LA English
DT Article
DE Health promotion; Lung cancer; Multiple risk reduction interventions;
Patient-family member dyads
ID QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; POPULATION-BASED SURVEY;
PHYSICAL-ACTIVITY; SMOKING-CESSATION; RISK BEHAVIORS; SURVIVORS
ADHERENCE; STRESS-MANAGEMENT; BREAST-CANCER; HEART-DISEASE
AB Background: The diagnosis of lung cancer presents an opportunity to motivate individuals to adopt health-promoting behavior. Little attention has been given to using this opportunity to also motivate relatives to change their health behaviors. Objectives: The objectives of this study were to describe health behaviors and readiness to change lifestyle, identify interest in health promotion programs, and examine concordance of health behaviors among smokers with lung cancer and their family members. Methods: Cross-sectional data were collected once from 37 lung cancer patient-family member dyads. Standardized questionnaires were used to collect data. Descriptive statistics and percent agreement were used for analyses. Results: Lung cancer patients and their family members had high rates of continued smoking (43% vs 30%), low intake of fruits and vegetables (92% vs 95%), and high rates of physical inactivity (84% vs 84%). Patients and family members indicated readiness to change behaviors within the next 6 months ranging from 63% for physical activity, 73% for diet, and 88% to quit smoking for patients and 81% for physical activity, 58% for diet, and 91% to quit smoking for family members. Interest in participating in a multiple behavioral risk reduction program was high for patients and family members. Conclusions: The majority of patients and their family members have multiple behavioral risk factors placing them at risk for poor health outcomes. Implications for Practice: Oncology nurses are in a unique position to provide leadership in assessing health behaviors and implementing evidence-based interventions to enhance outcomes for patient-family member dyads with lung cancer.
C1 [Cooley, Mary E.; Wang, Qian; Roper, Kristin; Marcoux, J. Paul] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Morones, Sandra; Shi, Ling; Hayman, Laura L.] Univ Massachusetts, Boston, MA 02125 USA.
[Finn, Kathleen T.; Zaner, Ken] Boston Med Ctr, Boston, MA USA.
[Litrownik, Dan] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Cooley, ME (reprint author), Dana Farber Canc Inst, Cantor Ctr, Res Nursing Serv, 450 Brookline Ave,LW 521, Boston, MA 02115 USA.
EM mary_cooley@dfci.harvard.edu
FU National Cancer Institute [U56 CA 118635, K07 CA92696]
FX Source of support: National Cancer Institute U56 CA 118635 prepilot
funding awarded to Drs Cooley and Hayman (principal investigators Karen
M. Emmons and Adam Colon-Carmona) and K07 CA92696 (principal
investigator Dr Cooley).
NR 77
TC 11
Z9 11
U1 2
U2 27
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0162-220X
EI 1538-9804
J9 CANCER NURS
JI Cancer Nurs.
PD MAR-APR
PY 2013
VL 36
IS 2
BP 145
EP 154
DI 10.1097/NCC.0b013e31825e4359
PG 10
WC Oncology; Nursing
SC Oncology; Nursing
GA 093JT
UT WOS:000315188800013
PM 22791213
ER
PT J
AU Durand, ML
AF Durand, M. L.
TI Endophthalmitis
SO CLINICAL MICROBIOLOGY AND INFECTION
LA English
DT Review
DE Bacterial endophthalmitis; Candida endophthalmitis; endogenous
endophthalmitis; endophthalmitis; fungal endophthalmitis;
keratitis-related endophthalmitis; mould endophthalmitis; post-injection
endophthalmitis; postoperative endophthalmitis; post-traumatic
endophthalmitis
ID ENDOGENOUS BACTERIAL ENDOPHTHALMITIS; POSTCATARACT SURGERY
ENDOPHTHALMITIS; ANTERIOR SEGMENT SYNDROME; ENDOTHELIAL GROWTH-FACTOR;
CATARACT-SURGERY; INTRAVITREAL INJECTION; POSTOPERATIVE ENDOPHTHALMITIS;
RISK-FACTORS; POSTTRAUMATIC ENDOPHTHALMITIS; FUNGAL ENDOPHTHALMITIS
AB Endophthalmitis means bacterial or fungal infection inside the eye involving the vitreous and/or aqueous humors. Most cases are exogenous and occur after eye surgery, after penetrating ocular trauma, or as an extension of corneal infection. An increasing number of cases are occurring after intravitreal injections of anti-vascular endothelial growth factor (VEGF) medications. Endophthalmitis may also be endogenous, arising from bacteraemic or fungaemic seeding of the eye. The infected eye never serves as a source of bacteraemia or fungaemia, however. The most common pathogens in endophthalmitis vary by category. Coagulase-negative staphylococci are the most common causes of post-cataract endophthalmitis, and these bacteria and viridans streptococci cause most cases of post-intravitreal anti-VEGF injection endophthalmitis, Bacillus cereus is a major cause of post-traumatic endophthalmitis, and Staphylococcus aureus and streptococci are important causes of endogenous endophthalmitis associated with endocarditis. In Taiwan and other East Asian nations, Klebsiella pneumoniae causes most cases of endogenous endophthalmitis, in association with liver abscess. Endogenous fungal endophthalmitis in hospitalized patients is usually caused by Candida species, particularly Candida albicans. Acute endophthalmitis is a medical emergency. The most important component of treatment is the intravitreal injection of antibiotics, along with vitrectomy in severe cases. Systemic antibiotics should be used in cases of endogenous endophthalmitis and exogenous fungal endophthalmitis, but their role in exogenous bacterial endophthalmitis is uncertain. Repeated intravitreal injections of antibiotics may be necessary if there is no response to the initial therapy. Many eyes that receive prompt and appropriate treatment will recover useful vision.
C1 [Durand, M. L.] Massachusetts Eye & Ear Infirm, Infect Dis Serv, Boston, MA 02114 USA.
[Durand, M. L.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Durand, M. L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Durand, ML (reprint author), Massachusetts Gen Hosp, Cox 5,55 Fruit St, Boston, MA 02114 USA.
EM mdurand@partners.org
NR 58
TC 50
Z9 51
U1 0
U2 26
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1198-743X
J9 CLIN MICROBIOL INFEC
JI Clin. Microbiol. Infect.
PD MAR
PY 2013
VL 19
IS 3
BP 227
EP 234
DI 10.1111/1469-0691.12118
PG 8
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 096OY
UT WOS:000315415300012
PM 23438028
ER
PT J
AU Brown, JR
AF Brown, Jennifer R.
TI Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase)
Inhibitor in Clinical Trials
SO CURRENT HEMATOLOGIC MALIGNANCY REPORTS
LA English
DT Article
DE PCI32765; BTK; Kinase; Lymphocytosis; CLL; Ibrutinib
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; B-CELL RECEPTOR; FLUDARABINE; RITUXIMAB;
SURVIVAL; CYCLOPHOSPHAMIDE; OFATUMUMAB
AB Ibrutinib is a potent covalent kinase inhibitor that targets BTK. BTK, or Bruton's tyrosine kinase, is an obvious target for therapy of B cell diseases because inactivating mutations lead to B cell aplasia in humans and the disease X-linked agammaglobulinemia. Ibrutinib has modest cytotoxicity against CLL cells in vitro but also blocks trophic stimuli from the microenvironment. As with other inhibitors of the BCR pathway, ibrutinib causes rapid nodal reduction and response associated with rapid increase in lymphocytosis, which then returns to baseline over time. The ORR of ibrutinib in relapsed refractory CLL is 67 % with PFS 88 % at 15 months. In a cohort of untreated patients 65 years and over, the estimated 15 month PFS is 96 %. Registration trials have been initiated, and the difficult task that remains is to determine where in the course of CLL therapy this drug will have the greatest impact and benefit for patients.
C1 [Brown, Jennifer R.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Brown, JR (reprint author), Harvard Univ, Sch Med, 450 Brookline Ave, Boston, MA 02215 USA.
EM Jbrown2@partners.org
FU Sanofi; Pharmacyclics
FX J. Brown: consultant for Avila, Novartis, Emergent, Celgene, Genentech,
Pharmacyclics, Sanofi; received funding for investigator initiated
clinical trial from Genzyme (now Sanofi); travel/accommodation expenses
covered or reimbursed by Pharmacyclics.
NR 24
TC 30
Z9 34
U1 0
U2 29
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1558-8211
J9 CURR HEMATOL MALIG R
JI Curr. Hematol. Malig. Rep.
PD MAR
PY 2013
VL 8
IS 1
BP 1
EP 6
DI 10.1007/s11899-012-0147-9
PG 6
WC Oncology; Hematology
SC Oncology; Hematology
GA 095OO
UT WOS:000315344100001
PM 23296407
ER
PT J
AU Boot, M
Volkening, LK
Butler, DA
Laffel, LMB
AF Boot, M.
Volkening, L. K.
Butler, D. A.
Laffel, L. M. B.
TI The impact of blood glucose and HbA1c goals on glycaemic control in
children and adolescents with Type 1 diabetes
SO DIABETIC MEDICINE
LA English
DT Article
ID METABOLIC-CONTROL; MANAGEMENT; OUTCOMES; YOUTH; INVOLVEMENT; PREDICTORS;
ADHERENCE; MELLITUS; CARE
AB Aims To evaluate parents' goals and parents' perceptions of physicians' goals for blood glucose and HbA1c in children and adolescents with Type 1 diabetes. Methods In a cross-sectional observational assessment, parents (80% mothers) of 153 children/adolescents (56% female), aged 12.9 +/- 2.3years (range 816years) with Type 1 diabetes for 6.3 +/- 3.5years, completed surveys regarding their goals and their perceptions of physicians' goals for their child's blood glucose and HbA1c levels. Results Children/adolescents had a mean HbA1c of 69 +/- 16mmol/mol (8.4 +/- 1.4%) and checked blood glucose levels 3.8 +/- 1.2times/day; 23% received pump therapy. Almost half of parents reported a blood glucose goal of 130 (80180)mg/dl [7.2 (4.410)mmol/l]; 75% of parents reported a HbA1c goal of 4264mmol/mol (68%). HbA1c was significantly lower when parents reported HbA1c goals 64mmol/mol (8%) vs. >64mmol/mol (>8%) [67 +/- 14mmol/mol (8.3 +/- 1.2%) vs. 76 +/- 20mmol/mol (9.1 +/- 1.8%), respectively, P=0.02]. Parents' blood glucose and HbA1c goals were tightly linked with parents' perceptions of physicians' blood glucose and HbA1c goals (69% concordant, P<0.0001; 88% concordant, P<0.0001, respectively). Conclusions There was a significant association between lower parent HbA1c goals and lower child/adolescent HbA1c. Further, parents appear to set glycaemic goals based upon their perceptions of physician goals. Future studies should assess the relationship between parents' perceptions of health-care providers' goals and health-care providers' actual goals and the impact of unified family/provider goal-setting on glycaemic control.
C1 [Boot, M.; Volkening, L. K.; Butler, D. A.; Laffel, L. M. B.] Joslin Diabet Ctr, Pediat Adolescent & Young Adult Sect, Genet & Epidemiol Sect, Boston, MA 02215 USA.
RP Laffel, LMB (reprint author), Joslin Diabet Ctr, Pediat Adolescent & Young Adult Sect, Genet & Epidemiol Sect, Boston, MA 02215 USA.
EM lori.laffel@joslin.harvard.edu
FU Charles H. Hood Foundation; National Institute of Diabetes and Digestive
and Kidney Diseases [R01DK046887]; Diabetes and Endocrinology Research
Center [P30DK036836]; Katherine Adler Astrove Youth Education Fund;
Maria Griffin Drury Pediatric Fund
FX This study was supported in part by the Charles H. Hood Foundation,
grant R01DK046887 from the National Institute of Diabetes and Digestive
and Kidney Diseases, the Diabetes and Endocrinology Research Center
(P30DK036836), the Katherine Adler Astrove Youth Education Fund and the
Maria Griffin Drury Pediatric Fund.
NR 19
TC 3
Z9 3
U1 3
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3071
J9 DIABETIC MED
JI Diabetic Med.
PD MAR
PY 2013
VL 30
IS 3
BP 333
EP 337
DI 10.1111/dme.12083
PG 5
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 095MT
UT WOS:000315339300019
PM 23190135
ER
PT J
AU Sohn, K
Wende, AR
Abel, ED
Moreno, AP
Sachse, FB
Punske, BB
AF Sohn, Kwanghyun
Wende, Adam R.
Abel, E. Dale
Moreno, Alonso P.
Sachse, Frank B.
Punske, Bonnie B.
TI Absence of glucose transporter 4 diminishes electrical activity of mouse
hearts during hypoxia
SO EXPERIMENTAL PHYSIOLOGY
LA English
DT Article
ID GLUCOSE-TRANSPORTER GLUT4; VOLTAGE-SENSITIVE DYE; GUINEA-PIG HEARTS;
ACTION-POTENTIAL DURATION; RAT CARDIAC MYOCYTES; RATE-LIMITING STEPS;
PAPILLARY MUSCLE; CYTOCHALASIN-D; IN-VIVO; GLUT4-DEFICIENT HEARTS
AB New Findings center dot What is the central question of this study? The aim of this study was to examine quantitatively whether glucose transporter 4 deficiency leads to more severe alterations in cardiac electrical activity during cardiac stress. center dot What is the main finding and what is its importance? When compared with hearts from corresponding control littermates, the measured epicardial potentials from the surface of cardiac-selective glucose transporter 4-ablated mouse hearts during hypoxia showed the following differences: (i) significant decreases in the maximal downstroke of the potentials; (ii) increased activation time; and (iii) greater alterations in the activation sequence. Insulin resistance, which characterizes type 2 diabetes, is associated with reduced translocation of glucose transporter 4 (GLUT4) to the plasma membrane following insulin stimulation, and diabetic patients with insulin resistance show a higher incidence of ischaemia, arrhythmias and sudden cardiac death. The aim of this study was to examine whether GLUT4 deficiency leads to more severe alterations in cardiac electrical activity during cardiac stress due to hypoxia. To fulfil this aim, we compared cardiac electrical activity from cardiac-selective GLUT4-ablated (G4H/) mouse hearts and corresponding control (CTL) littermates. A custom-made cylindrical cage' electrode array measured potentials (Ves) from the epicardium of isolated, perfused mouse hearts. The normalized average of the maximal downstroke of Ves (|dVes/dtmin|na), which we previously introduced as an index of electrical activity in normal, ischaemic and hypoxic hearts, was used to assess the effects of GLUT4 deficiency on electrical activity. The |dVes/dtmin|na of G4H/ and CTL hearts decreased by 75 and 47%, respectively (P < 0.05), 30 min after the onset of hypoxia. Administration of insulin attenuated decreases in values of |dVes/dtmin|na in G4H/ hearts as well as in CTL hearts, during hypoxia. In general, however, G4H/ hearts showed a severe alteration of the propagation sequence and a prolonged total activation time. Results of this study demonstrate that reduced glucose availability associated with insulin resistance and a reduction in GLUT4-mediated glucose transport impairs electrical activity during hypoxia, and may contribute to cardiac vulnerability to arrhythmias in diabetic patients.
C1 [Sohn, Kwanghyun; Moreno, Alonso P.; Sachse, Frank B.; Punske, Bonnie B.] Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, Salt Lake City, UT 84112 USA.
[Sohn, Kwanghyun; Moreno, Alonso P.; Sachse, Frank B.; Punske, Bonnie B.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84112 USA.
[Sohn, Kwanghyun] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA.
[Wende, Adam R.; Abel, E. Dale] Univ Utah, Sch Med, Div Endocrinol Metab & Diabet, Program Mol Med, Salt Lake City, UT 84112 USA.
[Moreno, Alonso P.; Punske, Bonnie B.] Univ Utah, Sch Med, Div Cardiol, Salt Lake City, UT 84112 USA.
RP Punske, BB (reprint author), Univ Utah, Nora Eccles Harrison Cardiovasc Res & Training In, 95 South 2000 East, Salt Lake City, UT 84112 USA.
EM punske@cvrti.utah.edu
OI Sachse, Frank/0000-0003-4987-705X; Wende, Adam/0000-0002-5536-4675
FU Richard A. and Nora Eccles Fund for Cardiovascular Research; Nora Eccles
Treadwell Foundation; American Heart Association Western States
Affiliate Postdoctoral Fellowship; Juvenile Diabetes Research
Foundation; [UO1 HL087947]
FX This work was supported by the Richard A. and Nora Eccles Fund for
Cardiovascular Research and awards from the Nora Eccles Treadwell
Foundation. A. R. W. was supported by an American Heart Association
Western States Affiliate Postdoctoral Fellowship and an Advanced
Postdoctoral Fellowship from the Juvenile Diabetes Research Foundation.
E. D. A. was supported by UO1 HL087947. The authors wish to acknowledge
Dr Philip Ershler and Mr Bruce Steadman for the design and development
of the data acquisition hardware and Mr Ted Dustman for his efforts in
designing our data processing software. In addition, we would like to
acknowledge the technical expertise and support of Alicja Booth, Jayne
Davis and Nancy Allen.
NR 73
TC 3
Z9 4
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0958-0670
J9 EXP PHYSIOL
JI Exp. Physiol.
PD MAR
PY 2013
VL 98
IS 3
BP 746
EP 757
DI 10.1113/expphysiol.2012.070235
PG 12
WC Physiology
SC Physiology
GA 094XJ
UT WOS:000315298200020
PM 23180812
ER
PT J
AU Avci, P
Sadasivam, M
Gupta, A
De Melo, WCMA
Huang, YY
Yin, R
Chandran, R
Kumar, R
Otufowora, A
Nyame, T
Hamblin, MR
AF Avci, Pinar
Sadasivam, Magesh
Gupta, Asheesh
De Melo, Wanessa C. M. A.
Huang, Ying-Ying
Yin, Rui
Chandran, Rakkiyappan
Kumar, Raj
Otufowora, Ayodeji
Nyame, Theodore
Hamblin, Michael R.
TI Animal models of skin disease for drug discovery
SO EXPERT OPINION ON DRUG DISCOVERY
LA English
DT Review
DE alopecia; animal models; dermatitis; dermatology; dermatomyositis;
psoriasis; scleroderma; skin cancer; transgenic mouse models; wound
healing
ID CHEMOTHERAPY-INDUCED ALOPECIA; DYSTROPHIC EPIDERMOLYSIS-BULLOSA;
CUTANEOUS LUPUS-ERYTHEMATOSUS; ENGINEERED MOUSE MODELS;
ATOPIC-DERMATITIS; TRANSGENIC MICE; IN-VIVO; HAIR LOSS; MURINE MODEL;
THERAPEUTIC INTERVENTION
AB Introduction: Discovery of novel drugs, treatments, and testing of consumer products in the field of dermatology is a multi-billion dollar business. Due to the distressing nature of many dermatological diseases, and the enormous consumer demand for products to reverse the effects of skin photodamage, aging, and hair loss, this is a very active field.
Areas covered: In this paper, we will cover the use of animal models that have been reported to recapitulate to a greater or lesser extent the features of human dermatological disease. There has been a remarkable increase in the number and variety of transgenic mouse models in recent years, and the basic strategy for constructing them is outlined.
Expert opinion: Inflammatory and autoimmune skin diseases are all represented by a range of mouse models both transgenic and normal. Skin cancer is mainly studied in mice and fish. Wound healing is studied in a wider range of animal species, and skin infections such as acne and leprosy also have been studied in animal models. Moving to the more consumer-oriented area of dermatology, there are models for studying the harmful effect of sunlight on the skin, and testing of sunscreens, and several different animal models of hair loss or alopecia.
C1 [Avci, Pinar; Sadasivam, Magesh; Gupta, Asheesh; De Melo, Wanessa C. M. A.; Huang, Ying-Ying; Yin, Rui; Chandran, Rakkiyappan; Kumar, Raj; Otufowora, Ayodeji; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Avci, Pinar; Gupta, Asheesh; Huang, Ying-Ying; Yin, Rui; Kumar, Raj; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Nyame, Theodore] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Plast & Reconstruct Surg, Boston, MA 02115 USA.
[Gupta, Asheesh] Def Inst Physiol & Allied, Delhi 110054, India.
[De Melo, Wanessa C. M. A.] Univ Fed Sao Paulo, Sao Carlos, SP, Brazil.
[Yin, Rui] Third Mil Med Univ, Southwest Hosp, Dept Dermatol, Chongqing 400038, Peoples R China.
[Sadasivam, Magesh; Chandran, Rakkiyappan] Amity Univ Uttar Pradesh, Amity Inst Nanotechnol, Noida 201303, India.
[Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China.
[Hamblin, Michael R.] Harvard Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Hamblin, MR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomedicine, Boston, MA 02115 USA.
EM hamblin@helix.mgh.harvard.edu
RI Huang, Ying-ying/G-3153-2011; Kumar, Raj/M-3662-2014;
OI Huang, Ying-ying/0000-0003-3066-6981; Hamblin,
Michael/0000-0001-6431-4605
FU US NIH [R01AI050875]; Department of Science and Technology, Government
of India (BOYCAST Fellowship); National Natural Science Foundation of
China [81172495]
FX We are grateful to VJB de Arce for editorial assistance. Research in the
Hamblin laboratory is supported by the US NIH (R01AI050875). A Gupta was
supported by Department of Science and Technology, Government of India
(BOYCAST Fellowship 2010-11). Rui Yin was supported by the National
Natural Science Foundation of China (Grant No. 81172495).
NR 187
TC 10
Z9 10
U1 1
U2 36
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1746-0441
J9 EXPERT OPIN DRUG DIS
JI Expert. Opin. Drug Discov.
PD MAR
PY 2013
VL 8
IS 3
BP 331
EP 355
DI 10.1517/17460441.2013.761202
PG 25
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 093BF
UT WOS:000315166000007
PM 23293893
ER
PT J
AU Souter, I
Batsis, M
Karmon, AE
Petrozza, JC
AF Souter, Irene
Batsis, Maria
Karmon, Anatte E.
Petrozza, John C.
TI Should Infertile Women with Normal TSH Levels (> 5.0mIU/L) Strive for a
Stricter Preconception TSH cut-off? The Effects of a Lower TSH Threshold
on the Outcome of Ovulation Induction/Intrauterine Insemination (OI/IUI)
Cycles
SO FERTILITY AND STERILITY
LA English
DT Meeting Abstract
CT 61st Annual Meeting of the Pacific-Coast-Reproductive-Society (PCRS)
CY APR 17-21, 2013
CL Indian Wells, CA
SP Pacific Coast Reproduct Soc (PCRS)
C1 [Souter, Irene; Batsis, Maria; Karmon, Anatte E.; Petrozza, John C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Reprod Endocrinol & Infertil Div,Fertil Ctr,Dept, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
J9 FERTIL STERIL
JI Fertil. Steril.
PD MAR
PY 2013
VL 99
IS 3
SU S
BP S18
EP S19
PG 2
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA 094RP
UT WOS:000315281800033
ER
PT J
AU Dowty, JG
Win, AK
Buchanan, DD
Lindor, NM
Macrae, FA
Clendenning, M
Antill, YC
Thibodeau, SN
Casey, G
Gallinger, S
Le Marchand, L
Newcomb, PA
Haile, RW
Young, GP
James, PA
Giles, GG
Gunawardena, SR
Leggett, BA
Gattas, M
Boussioutas, A
Ahnen, DJ
Baron, JA
Parry, S
Goldblatt, J
Young, JP
Hopper, JL
Jenkins, MA
AF Dowty, James G.
Win, Aung K.
Buchanan, Daniel D.
Lindor, Noralane M.
Macrae, Finlay A.
Clendenning, Mark
Antill, Yoland C.
Thibodeau, Stephen N.
Casey, Graham
Gallinger, Steve
Le Marchand, Loic
Newcomb, Polly A.
Haile, Robert W.
Young, Graeme P.
James, Paul A.
Giles, Graham G.
Gunawardena, Shanaka R.
Leggett, Barbara A.
Gattas, Michael
Boussioutas, Alex
Ahnen, Dennis J.
Baron, John A.
Parry, Susan
Goldblatt, Jack
Young, Joanne P.
Hopper, John L.
Jenkins, Mark A.
TI Cancer Risks for MLH1 and MSH2 Mutation Carriers
SO HUMAN MUTATION
LA English
DT Article
DE Lynch syndrome; MLH1; MSH2; risk; penetrance; cancer; colorectal cancer;
endometrial cancer; segregation analysis; Colon CFR
ID NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH-REPAIR GENES; BODY-MASS INDEX;
LYNCH-SYNDROME; COLON-CANCER; FAMILY REGISTRY; BREAST-CANCER;
ENDOMETRIAL CANCER; GERMLINE MUTATIONS; PROSTATE-CANCER
AB We studied 17,576 members of 166 MLH1 and 224 MSH2 mutation-carrying families from the Colon Cancer Family Registry. Average cumulative risks of colorectal cancer (CRC), endometrial cancer (EC), and other cancers for carriers were estimated using modified segregation analysis conditioned on ascertainment criteria. Heterogeneity in risks was investigated using a polygenic risk modifier. Average CRC cumulative risks at the age of 70 years (95% confidence intervals) for MLH1 and MSH2 mutation carriers, respectively, were estimated to be 34% (25%50%) and 47% (36%60%) for male carriers and 36% (25%51%) and 37% (27%50%) for female carriers. Corresponding EC risks were 18% (9.1%34%) and 30% (18%45%). A high level of CRC risk heterogeneity was observed (P<0.001), with cumulative risks at the age of 70 years estimated to follow U-shaped distributions. For example, 17% of male MSH2 mutation carriers have estimated lifetime risks of 0%10% and 18% have risks of 90%100%. Therefore, average risks are similar for the two genes but there is so much individual variation about the average that large proportions of carriers have either very low or very high lifetime cancer risks. Our estimates of CRC and EC cumulative risks for MLH1 and MSH2 mutation carriers are the most precise currently available.
C1 [Dowty, James G.; Win, Aung K.; Hopper, John L.; Jenkins, Mark A.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Parkville, Vic 3010, Australia.
[Buchanan, Daniel D.; Clendenning, Mark; Young, Joanne P.] Queensland Inst Med Res, Familial Canc Lab, Brisbane, Qld 4006, Australia.
[Lindor, Noralane M.] Mayo Clin, Dept Med Genet, Rochester, MN USA.
[Macrae, Finlay A.] Royal Melbourne Hosp, Dept Colorectal Med & Genet, Parkville, Vic 3050, Australia.
[Antill, Yoland C.] Cabrini Hlth, Familial Canc Ctr, Melbourne, Vic, Australia.
[Antill, Yoland C.] So Hlth, Familial Canc Ctr, Clayton, Vic, Australia.
[Thibodeau, Stephen N.; Gunawardena, Shanaka R.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
[Casey, Graham; Haile, Robert W.] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.
[Gallinger, Steve] Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
[Le Marchand, Loic] Univ Hawaii, Canc Res Ctr, Honolulu, HI 96813 USA.
[Newcomb, Polly A.] Fred Hutchinson Canc Res Ctr, Canc Prevent Program, Seattle, WA 98104 USA.
[Young, Graeme P.] Flinders Univ S Australia, Ctr Canc Prevent & Control, Bedford Pk, SA, Australia.
[James, Paul A.; Boussioutas, Alex] Peter MacCallum Canc Ctr, Familial Canc Ctr, Melbourne, Vic, Australia.
[Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
[Leggett, Barbara A.] Royal Brisbane & Womens Hosp Res Fdn, Conjoint Gastroenterol Lab, Clin Res Ctr, Brisbane, Qld, Australia.
[Leggett, Barbara A.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia.
[Gattas, Michael] Royal Childrens Hosp, Queensland Clin Genet Serv, Herston, Qld, Australia.
[Boussioutas, Alex] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3010, Australia.
[Ahnen, Dennis J.] Univ Colorado, Sch Med, Dept Med, Denver, CO USA.
[Ahnen, Dennis J.] Denver VA Med Ctr, Denver, CO USA.
[Baron, John A.] Univ N Carolina, Dept Med, Chapel Hill, NC USA.
[Parry, Susan] Auckland City Hosp, New Zealand Familial Gastrointestinal Canc Regist, Auckland, New Zealand.
[Goldblatt, Jack] Univ Western Australia, Genet Serv & Familial Canc Program Western Austra, Sch Paediat & Child Hlth, Perth, WA 6009, Australia.
RP Dowty, JG (reprint author), Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Parkville, Vic 3010, Australia.
EM jdowty@unimelb.edu.au
RI Gallinger, Steven/E-4575-2013; James, Paul/G-2943-2014; Jenkins,
Mark/P-7803-2015; Leggett, Barbara/D-3579-2011;
OI Jenkins, Mark/0000-0002-8964-6160; Dowty, James/0000-0003-2383-0886;
Giles, Graham/0000-0003-4946-9099; Boussioutas,
Alex/0000-0002-8109-6897; Win, Aung Ko/0000-0002-2794-5261; Buchanan,
Daniel/0000-0003-2225-6675
FU NCI NIH HHS [R01 CA122340, CA-95-011, K05 CA152715, K22 CA095011, P50
CA116201, R01 CA128978, U01 CA069398, U01 CA069631, U01 CA074783, U01
CA074794, U01 CA074799, U01 CA074800, U01 CA074806, U01 CA097735, U24
CA074783, U24 CA074794, U24 CA074799, U24 CA074800, U24 CA074806, U24
CA097735]
NR 43
TC 44
Z9 44
U1 0
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1059-7794
J9 HUM MUTAT
JI Hum. Mutat.
PD MAR
PY 2013
VL 34
IS 3
BP 490
EP 497
DI 10.1002/humu.22262
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 093IX
UT WOS:000315186400011
PM 23255516
ER
PT J
AU Mahalingam, M
Hoang, MP
AF Mahalingam, Meera
Hoang, Mai P.
TI Porocarcinoma: an exceedingly rare tumor or a tumor eclipse
phenomenon?-Reply
SO HUMAN PATHOLOGY
LA English
DT Letter
C1 [Mahalingam, Meera] Boston Univ, Sch Med, Dermatopathol Sect, Dept Dermatol, Boston, MA 01228 USA.
[Hoang, Mai P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Mahalingam, M (reprint author), Boston Univ, Sch Med, Dermatopathol Sect, Dept Dermatol, Boston, MA 01228 USA.
EM mmahalin@bu.edu; mhoang@partners.org
OI Mahalingam, Meera/0000-0002-2800-9985
NR 2
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
J9 HUM PATHOL
JI Hum. Pathol.
PD MAR
PY 2013
VL 44
IS 3
BP 449
EP 449
DI 10.1016/j.humpath.2012.11.010
PG 1
WC Pathology
SC Pathology
GA 092MI
UT WOS:000315126300020
PM 23290010
ER
PT J
AU Hong, O
Chin, DL
Ronis, DL
AF Hong, OiSaeng
Chin, Dal Lae
Ronis, David L.
TI Predictors of Hearing Protection Behavior Among Firefighters in the
United States
SO INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE
LA English
DT Article
DE Hearing protection; Firefighter; Predictors; Noise-induced hearing loss
ID HEALTH-PROMOTION MODEL; CONSTRUCTION WORKERS USE; NOISE EXPOSURE;
INTERVENTION; EFFICACY
AB Noise-induced hearing loss (NIHL) is a major occupational health problem that can be prevented through the use of hearing protection devices (HPDs).
The purpose of this study is to identify significant factors related to firefighters' use of HPDs.
A total of 404 firefighters from 35 fire departments in multiple states in the United States participated in an Internet-based survey from March 2010 to May 2011.
Pearson correlations and multiple regression analysis suggested that several modifying and cognitive-perceptual factors were significantly related to HPD use, including noise exposure, interpersonal influences, organizational support, perceived barriers to HPD use, and perceived susceptibility to hearing loss. The multiple regression model explained 56% (R (2) = .56, adjusted R (2) = .54) of the variance in firefighters' use of HPDs (F (13, 372) = 35.65, p < .001).
Future research should focus on incorporating these significant predictors into effective behavioral interventions designed to promote the use of HPDs in this population.
C1 [Hong, OiSaeng; Chin, Dal Lae] Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA.
[Ronis, David L.] Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA.
[Ronis, David L.] US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI USA.
[Hong, OiSaeng] Univ Calif San Francisco, Sch Nursing, Occupat & Environm Hlth Nursing Program, San Francisco, CA 94143 USA.
RP Hong, O (reprint author), Univ Calif San Francisco, Sch Nursing, Occupat & Environm Hlth Nursing Program, 2 Koret Way,Room N 531D, San Francisco, CA 94143 USA.
EM oisaeng.hong@nursing.ucsf.edu
NR 37
TC 4
Z9 4
U1 1
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1070-5503
J9 INT J BEHAV MED
JI Int. J. Behav. Med.
PD MAR
PY 2013
VL 20
IS 1
BP 121
EP 130
DI 10.1007/s12529-011-9207-0
PG 10
WC Psychology, Clinical
SC Psychology
GA 094NQ
UT WOS:000315271400017
PM 22161219
ER
PT J
AU Wang, SK
Hu, Y
Simmer, JP
Seymen, F
Estrella, NMRP
Pal, S
Reid, BM
Yildirim, M
Bayram, M
Bartlett, JD
Hu, JCC
AF Wang, S. -K.
Hu, Y.
Simmer, J. P.
Seymen, F.
Estrella, N. M. R. P.
Pal, S.
Reid, B. M.
Yildirim, M.
Bayram, M.
Bartlett, J. D.
Hu, J. C. -C.
TI Novel KLK4 and MMP20 Mutations Discovered by Whole-exome Sequencing
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE dental enamel; amelogenesis imperfecta; tooth; metalloproteases; serine
proteases; human FAM83H protein
ID HYPOMATURATION AMELOGENESIS-IMPERFECTA; JUNCTIONAL
EPIDERMOLYSIS-BULLOSA; PEPTIDASE 4; ENAMEL; GENE; MMP-20; EXPRESSION;
DYSTROPHY; CLEAVAGE; FAM83H
AB Non-syndromic amelogenesis imperfecta (AI) is a collection of isolated inherited enamel malformations that follow X-linked, autosomal-dominant, or autosomal-recessive patterns of inheritance. The AI phenotype is also found in syndromes. We hypothesized that whole-exome sequencing of AI probands showing simplex or recessive patterns of inheritance would identify causative mutations among the known candidate genes for AI. DNA samples obtained from 12 unrelated probands with AI were analyzed. Disease-causing mutations were identified in three of the probands: a novel single-nucleotide deletion in both KLK4 alleles (g.6930delG; c.245delG; p.Gly82Alafs*87) that shifted the reading frame, a novel missense transition mutation in both MMP20 alleles (g.15390A>G; c.611A>G; p.His204Arg) that substituted arginine for an invariant histidine known to coordinate a structural zinc ion, and a previously described nonsense transition mutation in a single allele of FAM83H (c.1379G>A; g.5663G>A; p.W460*). Erupted molars and cross-sections from unerupted parts of the mandibular incisors of Mmp20 null mice were characterized by scanning electron microscopy. Their enamel malformations closely correlated with the enamel defects displayed by the proband with the MMP20 mutation. We conclude that whole-exome sequencing is an effective means of identifying disease-causing mutations in kindreds with AI, and this technique should prove clinically useful for this purpose.
C1 [Wang, S. -K.; Hu, Y.; Simmer, J. P.; Pal, S.; Reid, B. M.; Hu, J. C. -C.] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48108 USA.
[Seymen, F.; Yildirim, M.; Bayram, M.] Istanbul Univ, Fac Dent, Dept Pedodont, Istanbul, Turkey.
[Estrella, N. M. R. P.] Univ Michigan, Sch Dent, Dept Orthodont & Pediat Dent, Ann Arbor, MI 48108 USA.
[Bartlett, J. D.] Forsyth Inst, Dept Cytokine Biol, Cambridge, MA USA.
RP Simmer, JP (reprint author), Univ Michigan, Sch Dent, Dept Biol & Mat Sci, 1210 Eisenhower Pl, Ann Arbor, MI 48108 USA.
EM jsim-mer@umich.edu
FU NIDCR/NIH [DE019775, DE019622, DE015846]
FX We thank the families in this study for their participation. This work
was supported by the NIDCR/NIH (Grants DE019775, DE019622, and
DE015846). The authors declare no potential conflicts of interest with
respect to the authorship and/or publication of this article.
NR 30
TC 23
Z9 24
U1 2
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-0345
J9 J DENT RES
JI J. Dent. Res.
PD MAR
PY 2013
VL 92
IS 3
BP 266
EP 271
DI 10.1177/0022034513475626
PG 6
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 089MG
UT WOS:000314914100011
PM 23355523
ER
PT J
AU Jenkins, MK
Moon, JJ
AF Jenkins, Marc K.
Moon, James J.
TI Response to Comment on "The Role of Naive T Cell Precursor Frequency and
Recruitment in Dictating Immune Response Magnitude"
SO JOURNAL OF IMMUNOLOGY
LA English
DT Letter
C1 [Jenkins, Marc K.] Univ Minnesota, Sch Med, Dept Microbiol, Ctr Immunol, Minneapolis, MN 55455 USA.
[Moon, James J.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA 02129 USA.
[Moon, James J.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Moon, James J.] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Charlestown, MA 02129 USA.
RP Jenkins, MK (reprint author), Univ Minnesota, Sch Med, Dept Microbiol, Ctr Immunol, 2101 6th St SE,Campus Code 2641, Minneapolis, MN 55455 USA.
EM jenki002@umn.edu
RI Jenkins, Marc/G-1063-2012
OI Jenkins, Marc/0000-0001-8009-7655
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAR 1
PY 2013
VL 190
IS 5
BP 1896
EP 1896
DI 10.4049/jimmunol.1290080
PG 1
WC Immunology
SC Immunology
GA 091ZT
UT WOS:000315089100002
PM 23544199
ER
PT J
AU Sheth, SA
Eskandar, EN
AF Sheth, Sameer A.
Eskandar, Emad N.
TI Obsessive-compulsive disorder Response
SO JOURNAL OF NEUROSURGERY
LA English
DT Editorial Material
C1 [Sheth, Sameer A.; Eskandar, Emad N.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
RP Sheth, SA (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
J9 J NEUROSURG
JI J. Neurosurg.
PD MAR
PY 2013
VL 118
IS 3
BP 490
EP 490
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 094DW
UT WOS:000315244200002
ER
PT J
AU Sheth, SA
Neal, J
Tangherlini, F
Mian, MK
Gentil, A
Cosgrove, GR
Eskandar, EN
Dougherty, DD
AF Sheth, Sameer A.
Neal, Jonathan
Tangherlini, Frances
Mian, Matthew K.
Gentil, Andre
Cosgrove, G. Rees
Eskandar, Emad N.
Dougherty, Darin D.
TI Limbic system surgery for treatment-refractory obsessive-compulsive
disorder: a prospective long-term follow-up of 64 patients Clinical
article
SO JOURNAL OF NEUROSURGERY
LA English
DT Article
DE cingulotomy; obsessive-compulsive disorder; psychiatric neurosurgery;
depression; functional neurosurgery
ID DEEP BRAIN-STIMULATION; BASAL GANGLIA; CINGULOTOMY; DEPRESSION;
LEUCOTOMY; CIRCUITS; ILLNESS
AB Object. Obsessive-compulsive disorder (OCD) is a common and disabling psychiatric illness, and in a significant proportion of patients with OCD the disease is refractory to conventional pharmacotherapy and psychotherapy. For more than half a century, patients with severe, treatment-resistant OCD have been treated with stereotactic limbic system lesions, including dorsal anterior cingulotomy. The authors present their results describing the efficacy and durability of limbic system surgery for OCD, characterizing a large cohort of patients treated at a single institution with a mean follow-up of more than 5 years.
Methods. The authors identified 64 consecutive patients undergoing cingulotomy for refractory OCD at the Massachusetts General Hospital between 1989 and 2009. Changes in OCD and major depressive disorder symptom severity were assessed at both the initial and most recent postoperative follow-up by using the Yale-Brown Obsessive Compulsive Scale and the Beck Depression Inventory, respectively. Full and partial OCD symptom responses were defined as Yale-Brown Obsessive Compulsive Scale score reductions of a >= 35% and 25%-34%, respectively.
Results. Regarding OCD symptom improvement, at the first postoperative follow-up (mean 10.7 months), 35% of patients demonstrated a full response and 7% were partial responders. Thirty patients had a subsequent procedure (repeat cingulotomy or subcaudate tractotomy). By the most recent follow-up (mean 63.8 months), rates climbed to 47% and 22% for full and partial responses, respectively. Of the 24 patients with at least a partial response at initial follow-up, 20 (83%) retained at least a partial response at final follow-up. Comorbid major depressive disorder severity decreased by 17% at the most recent follow-up.
Conclusions. Limbic system surgery based on initial cingulotomy offers a durable and effective treatment option for appropriately selected patients with severe OCD who have not responded to conventional pharmacotherapy or psychotherapy. (http://thejns.org/doi/abs/10.3171/2012.11.JNS12389)
C1 [Sheth, Sameer A.; Neal, Jonathan; Tangherlini, Frances; Mian, Matthew K.; Eskandar, Emad N.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Dougherty, Darin D.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Mian, Matthew K.; Eskandar, Emad N.; Dougherty, Darin D.] Harvard Univ, Sch Med, Boston, MA USA.
[Gentil, Andre] Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil.
[Cosgrove, G. Rees] Brown Univ, Warren Alpert Med Sch, Dept Neurosurg, Providence, RI 02912 USA.
RP Sheth, SA (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, 55 Fruit St,White 502, Boston, MA 02114 USA.
EM sasheth@partners.org
NR 25
TC 25
Z9 25
U1 0
U2 5
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 0022-3085
J9 J NEUROSURG
JI J. Neurosurg.
PD MAR
PY 2013
VL 118
IS 3
BP 491
EP 497
DI 10.3171/2012.11.JNS12389
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 094DW
UT WOS:000315244200003
PM 23240700
ER
PT J
AU Hauptman, JS
Dadour, A
Oh, T
Baca, CB
Vickrey, BG
Vassar, SD
Sankar, R
Salamon, N
Vinters, HV
Mathern, GW
AF Hauptman, Jason S.
Dadour, Andrew
Oh, Taemin
Baca, Christine B.
Vickrey, Barbara G.
Vassar, Stefanie D.
Sankar, Raman
Salamon, Noriko
Vinters, Harry V.
Mathern, Gary W.
TI Sociodemographic changes over 25 years of pediatric epilepsy surgery at
UCLA
SO JOURNAL OF NEUROSURGERY-PEDIATRICS
LA English
DT Article
DE socioeconomic disparity; seizure; craniotomy; health inequity; epilepsy
ID TEMPORAL-LOBE EPILEPSY; UNITED-STATES; DISPARITIES; OUTCOMES;
RACE/ETHNICITY; CHILDREN; SEIZURE; ACCESS; CARE
AB Object. Low income, government insurance, and minority status are associated with delayed treatment for neurosurgery patients. Less is known about the influence of referral location and how socioeconomic factors and referral patterns evolve over time. For pediatric epilepsy surgery patients at the University of California, Los Angeles (UCLA), this study determined how referral location and sociodemographic features have evolved over 25 years.
Methods. Children undergoing epilepsy neurosurgery at UCLA (453 patients) were classified by location of residence and compared with clinical epilepsy and sociodemographic factors.
Results. From 1986 to 2010, referrals from Southern California increased (+33%) and referrals from outside of California decreased (-19%). Over the same period, the number of patients with preferred provider organization (PPO) and health maintenance organization (HMO) insurance increased (+148% and +69%, respectively) and indemnity insurance decreased (-96%). Likewise, the number of Hispanics (+117%) and Asians (100%) increased and Caucasians/whites decreased (-24%). The number of insurance companies decreased from 52 carriers per 100 surgical patients in 1986-1990 to 19 per 100 in 2006-2010. Patients living in the Eastern US had a younger age at surgery (-46%), shorter intervals from seizure onset to referral for evaluation (-28%) and from presurgical evaluation to surgery (-61%) compared with patients from Southern California. The interval from seizure onset to evaluation was shorter (-33%) for patients from Los Angeles County compared with those living in non-California Western US states.
Conclusions. Referral locations evolved over 25 years at UCLA, with more cases coming from local regions; the percentage of minority patients also increased. The interval from seizures onset to surgery was shortest for patients living farthest from UCLA but still within the US. Geographic location and race/ethnicity was not associated with differences in becoming seizure free after epilepsy surgery in children. (http://thejns.org/doi/abs/10.3171/2012.11.PEDS12359)
C1 [Hauptman, Jason S.; Dadour, Andrew; Oh, Taemin; Mathern, Gary W.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Neurosurg, Los Angeles, CA 90095 USA.
[Baca, Christine B.; Vickrey, Barbara G.; Vassar, Stefanie D.; Sankar, Raman; Vinters, Harry V.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Neurol, Los Angeles, CA 90095 USA.
[Sankar, Raman] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Pediat, Los Angeles, CA 90095 USA.
[Mathern, Gary W.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Psychiat & BioBehav Med, Los Angeles, CA 90095 USA.
[Sankar, Raman] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Div Pediat Neurol, Los Angeles, CA 90095 USA.
[Salamon, Noriko] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Div Neuroradiol, Los Angeles, CA 90095 USA.
[Vinters, Harry V.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Sect Neuropathol, Los Angeles, CA 90095 USA.
[Baca, Christine B.; Vickrey, Barbara G.] VA Greater Los Angeles Hlth Care Syst, Dept Neurol, Los Angeles, CA USA.
RP Mathern, GW (reprint author), 710 Westwood Plaza,Room 2123, Los Angeles, CA 90095 USA.
EM gmathern@ucla.edu
FU Epilepsy Foundation [213971]; NIH (National Institute on Aging, National
Institute of Neurological Disorders and Stroke); US Veterans
Administration Health Services Research and Development Service;
American Heart Association; SCAN Foundation; Kansas City Area Life
Sciences Institute; UCB Pharma; Sunovion; Upsher-Smith; Supernus;
Lundbeck Pharma; Pfizer; University of California Pediatric
Neuropathology Consortium; NeuroPace, Inc.; NIH [R01 NS38992];
[NIH-M11079933]
FX Dr. Baca receives salary support from the Epilepsy Foundation Grant
213971. Dr. Vickrey serves on scientific advisory boards for the Sports
Concussion Institute, National Multiple Sclerosis Society, and the NIH;
serves on the editorial boards of Neurorehabilitation and Neural Repair
and Circulation, Cardiovascular Quality and Outcomes, and is a section
editor for Stroke; receives research support from the NIH (National
Institute on Aging, National Institute of Neurological Disorders and
Stroke), the US Veterans Administration Health Services Research and
Development Service, the American Heart Association, and SCAN
Foundation; and received funding for travel and a speaker honorarium
from the Kansas City Area Life Sciences Institute. Dr. Sankar serves on
scientific advisory boards for and has received honoraria and funding
for travel from UCB Pharma, Sunovion, Upsher-Smith, Supernus, and
Lundbeck Pharma; receives royalties from the publication of Pediatric
Neurology, 3rd ed. (Demos Publishing, 2008) and Epilepsy: Mechanisms,
Models, and Translational Perspectives (CRC Press, 2011); serves on
speakers' bureaus for and has received speaker honoraria from UCB,
GlaxoSmithKline, and Lundbeck. He receives funding from NIH-M11079933
(co-primary investigator) and from Pfizer (Lyrica pediatric partial
seizures trial). He serves on the editorial board for Epilepsy &
Behavior. Dr. Vinters is on the editorial boards of Neuropathology and
Applied Neurobiology, Neuropathology, Journal of Neuroscience Research,
and the Korean Journal of Pathology. The Harry V. Vinters laboratory was
supported in part by the University of California Pediatric
Neuropathology Consortium, and Harry V. Vinters trust owns shares in and
receives dividends from the following makers of drugs and medical
equipment: GE, 3M, Pfizer, Teva Pharma, and GlaxoSmithKline. The Vinters
laboratory has received research funding in the past from NeuroPace,
Inc. Dr. Mathern received research funding from NIH grant R01 NS38992,
which partially supported this paper. He is also on the editorial boards
for Neurology, Epilepsy Research, Epileptic Disorders, and Epilepsy &
Seizures. He serves on the Data Management Committee for NeuroPace, Inc.
NR 16
TC 4
Z9 5
U1 0
U2 3
PU AMER ASSOC NEUROLOGICAL SURGEONS
PI ROLLING MEADOWS
PA 5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA
SN 1933-0707
J9 J NEUROSURG-PEDIATR
JI J. Neurosurg.-Pediatr.
PD MAR
PY 2013
VL 11
IS 3
BP 250
EP 255
DI 10.3171/2012.11.PEDS12359
PG 6
WC Clinical Neurology; Pediatrics; Surgery
SC Neurosciences & Neurology; Pediatrics; Surgery
GA 094DV
UT WOS:000315244100004
PM 23331214
ER
PT J
AU Hruby, A
Ngwa, JS
Renstrom, F
Wojczynski, MK
Ganna, A
Hallmans, G
Houston, DK
Jacques, PF
Kanoni, S
Lehtimaki, T
Lemaitre, RN
Manichaikul, A
North, KE
Ntalla, I
Sonestedt, E
Tanaka, T
van Rooij, FJA
Bandinelli, S
Djousse, L
Grigoriou, E
Johansson, I
Lohman, KK
Pankow, JS
Raitakari, OT
Riserus, U
Yannakoulia, M
Zillikens, MC
Hassanali, N
Liu, YM
Mozaffarian, D
Papoutsakis, C
Syvanen, AC
Uitterlinden, AG
Viikari, J
Groves, CJ
Hofman, A
Lind, L
McCarthy, MI
Mikkila, V
Mukamal, K
Franco, OH
Borecki, IB
Cupples, LA
Dedoussis, GV
Ferrucci, L
Hu, FB
Ingelsson, E
Kahonen, M
Kao, WHL
Kritchevsky, SB
Orho-Melander, M
Prokopenko, I
Rotter, JI
Siscovick, DS
Witteman, JCM
Franks, PW
Meigs, JB
McKeown, NM
Nettleton, JA
AF Hruby, Adela
Ngwa, Julius S.
Renstrom, Frida
Wojczynski, Mary K.
Ganna, Andrea
Hallmans, Goran
Houston, Denise K.
Jacques, Paul F.
Kanoni, Stavroula
Lehtimaki, Terho
Lemaitre, Rozenn N.
Manichaikul, Ani
North, Kari E.
Ntalla, Ioanna
Sonestedt, Emily
Tanaka, Toshiko
van Rooij, Frank J. A.
Bandinelli, Stefania
Djousse, Luc
Grigoriou, Efi.
Johansson, Ingegerd
Lohman, Kurt K.
Pankow, James S.
Raitakari, Olli T.
Riserus, Ulf
Yannakoulia, Mary
Zillikens, M. Carola
Hassanali, Neelam
Liu, Yongmei
Mozaffarian, Dariush
Papoutsakis, Constantina
Syvanen, Ann-Christine
Uitterlinden, Andre G.
Viikari, Jorma
Groves, Christopher J.
Hofman, Albert
Lind, Lars
McCarthy, Mark I.
Mikkila, Vera
Mukamal, Kenneth
Franco, Oscar H.
Borecki, Ingrid B.
Cupples, L. Adrienne
Dedoussis, George V.
Ferrucci, Luigi
Hu, Frank B.
Ingelsson, Erik
Kahonen, Mika
Kao, W. H. Linda
Kritchevsky, Stephen B.
Orho-Melander, Marju
Prokopenko, Inga
Rotter, Jerome I.
Siscovick, David S.
Witteman, Jacqueline C. M.
Franks, Paul W.
Meigs, James B.
McKeown, Nicola M.
Nettleton, Jennifer A.
TI Higher Magnesium Intake Is Associated with Lower Fasting Glucose and
Insulin, with No Evidence of Interaction with Select Genetic Loci, in a
Meta-Analysis of 15 CHARGE Consortium Studies
SO JOURNAL OF NUTRITION
LA English
DT Article
ID TYPE-2 DIABETES-MELLITUS; WHOLE-GRAIN INTAKE; DOUBLE-BLIND; COFFEE
CONSUMPTION; DIETARY MAGNESIUM; ENVIRONMENT INTERACTIONS;
CARDIOVASCULAR-DISEASE; NONDIABETIC SUBJECTS; METABOLIC SYNDROME;
PROSPECTIVE COHORT
AB Favorable associations between magnesium intake and glycemic traits, such as fasting glucose and insulin, are observed in observational and clinical studies, but whether genetic variation affects these associations is largely unknown. We hypothesized that single nucleotide polymorphisms (SNPs) associated with either glycemic traits or magnesium metabolism affect the association between magnesium intake and fasting glucose and insulin. Fifteen studies from the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) Consortium provided data from up to 52,684 participants of European descent without known diabetes. In fixed-effects meta-analyses, we quantified 1) cross-sectional associations of dietary magnesium intake with fasting glucose (mmol/L) and insulin (In-pmol/L) and 2) interactions between magnesium intake and SNPs related to fasting glucose (16 SNPs), insulin (2 SNPs), or magnesium (8 SNPs) on fasting glucose and insulin. After adjustment for age, sex, energy intake, BMI, and behavioral risk factors, magnesium (per 50-mg/d increment) was inversely associated with fasting glucose [beta = -0.009 mmol/L (95% CI: -0.013, -0.005), P< 0.0001] and insulin (-0.020 In-pmo/L (95% CI: -0.024, -0.017), P< 0.0001]. No magnesium-related SNP or interaction between any SNP and magnesium reached significance after correction for multiple testing. However, rs2274924 in magnesium transporter-encoding TRPM6 showed a nominal association (uncorrected P= 0.03) with glucose, and rs11558471 in SLC30A8and rs3740393 near CNNM2showed a nominal interaction (uncorrected, both P = 0.02) with magnesium on glucose. Consistent with other studies, a higher magnesium intake was associated with lower fasting glucose and insulin. Nominal evidence of TRPM6 influence and magnesium interaction with select loci suggests that further investigation is warranted. J. Nutr. 143: 345-353, 2013.
C1 [Hruby, Adela; Jacques, Paul F.; McKeown, Nicola M.] Tufts Univ, Friedman Sch Nutr Sci & Policy, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
[Ngwa, Julius S.; Cupples, L. Adrienne] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Renstrom, Frida; Hu, Frank B.; Franks, Paul W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Renstrom, Frida; Sonestedt, Emily; Orho-Melander, Marju; Franks, Paul W.] Lund Univ, Dept Clin Sci, Malmo, Sweden.
[Renstrom, Frida; Franks, Paul W.] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden.
[Wojczynski, Mary K.; Borecki, Ingrid B.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.
[Ganna, Andrea; Ingelsson, Erik] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden.
[Hallmans, Goran] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden.
[Houston, Denise K.; Kritchevsky, Stephen B.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA.
[Kanoni, Stavroula] Wellcome Trust Sanger Inst, Hinxton, England.
[Kanoni, Stavroula; Grigoriou, Efi.; Yannakoulia, Mary; Papoutsakis, Constantina; Dedoussis, George V.] Harokopio Univ Athens, Dept Nutr & Dietet, Athens, Greece.
[Lehtimaki, Terho] Fimlab Labs, Tampere, Finland.
[Lehtimaki, Terho] Univ Tampere, Sch Med, FIN-33101 Tampere, Finland.
[Lehtimaki, Terho] Tampere Univ Hosp, Tampere, Finland.
[Lemaitre, Rozenn N.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Manichaikul, Ani] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA.
[Manichaikul, Ani] Univ Virginia, Dept Publ Hlth Sci, Div Biostat & Epidemiol, Charlottesville, VA USA.
[North, Kari E.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[North, Kari E.] Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC USA.
[Ntalla, Ioanna; Tanaka, Toshiko; Ferrucci, Luigi] NIA, Clin Res Branch, Baltimore, MD 21224 USA.
[van Rooij, Frank J. A.; Zillikens, M. Carola; Uitterlinden, Andre G.; Hofman, Albert; Franco, Oscar H.; Witteman, Jacqueline C. M.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
[van Rooij, Frank J. A.; Zillikens, M. Carola; Uitterlinden, Andre G.; Hofman, Albert; Franco, Oscar H.; Witteman, Jacqueline C. M.] Netherlands Consortium Hlth Aging, Netherlands Genom Initiat, Leiden, Netherlands.
[Bandinelli, Stefania] Azienda Sanit Firenze, Geriatr Unit, Florence, Italy.
[Djousse, Luc] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Djousse, Luc; Meigs, James B.] Harvard Univ, Sch Med, Boston, MA USA.
[Djousse, Luc] Boston Vet Affairs Healthcare Syst, Massachusetts Vet Epidemiol & Res Informat Ctr, Boston, MA USA.
[Djousse, Luc] Boston Vet Affairs Healthcare Syst, Ctr Geriatr Res Educ & Clin, Boston, MA USA.
[Johansson, Ingegerd] Umea Univ, Dept Odontol, Umea, Sweden.
[Lohman, Kurt K.] Wake Forest Sch Med, Dept Biostat Sci, Div Publ Hlth Sci, Winston Salem, NC USA.
[Pankow, James S.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Raitakari, Olli T.] Turku Univ Hosp, Dept Clin Physiol & Nucl Med, FIN-20520 Turku, Finland.
[Raitakari, Olli T.] Univ Turku, Res Ctr Appl & Prevent Cardiovasc Med, Turku, Finland.
[Riserus, Ulf] Uppsala Univ, Dept Publ Hlth & Caring Sci Clin Nutr & Metab, Uppsala, Sweden.
[Zillikens, M. Carola; Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
[Hassanali, Neelam; Groves, Christopher J.; McCarthy, Mark I.; Prokopenko, Inga] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England.
[Liu, Yongmei] Wake Forest Sch Med, Dept Epidemiol & Prevent, Div Publ Hlth Sci, Winston Salem, NC USA.
[Mozaffarian, Dariush] Harvard Univ, Sch Publ Hlth, Dept Epidemiol & Nutr, Boston, MA 02115 USA.
[Mozaffarian, Dariush] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc Med, Boston, MA 02115 USA.
[Syvanen, Ann-Christine] Uppsala Univ, Mol Med & Sci Life Lab, Dept Med Sci, Uppsala, Sweden.
[Viikari, Jorma] Univ Turku, Dept Med, Turku, Finland.
[Viikari, Jorma] Turku Univ Hosp, FIN-20520 Turku, Finland.
[Lind, Lars] Uppsala Univ, Dept Med Sci, Uppsala, Sweden.
[McCarthy, Mark I.] Churchill Hosp, Oxford NIHR Biomed Res Ctr, Oxford OX3 7LJ, England.
[Mikkila, Vera] Univ Helsinki, Dept Food & Environm Sci, Helsinki, Finland.
[Mukamal, Kenneth] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA.
[Cupples, L. Adrienne] Framingham Heart Dis Epidemiol Study, Framingham, MA USA.
[Kahonen, Mika] Tampere Univ Hosp, Dept Clin Physiol, Tampere, Finland.
[Kahonen, Mika] Univ Tampere, FIN-33101 Tampere, Finland.
[Kao, W. H. Linda] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Prokopenko, Inga] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England.
[Rotter, Jerome I.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
[Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Clin Epidemiol Unit, Boston, MA 02114 USA.
[Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Diabet Res Unit, Boston, MA 02114 USA.
[Nettleton, Jennifer A.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Div Epidemiol Human Genet & Environm Sci, Houston, TX USA.
RP McKeown, NM (reprint author), Tufts Univ, Friedman Sch Nutr Sci & Policy, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
EM nicola.mckeown@tufts.edu
RI Prokopenko, Inga/H-3241-2014; Sonestedt, Emily/I-3814-2016; Djousse,
Luc/F-5033-2017;
OI Prokopenko, Inga/0000-0003-1624-7457; Sonestedt,
Emily/0000-0002-0747-4562; Djousse, Luc/0000-0002-9902-3047; Cupples, L.
Adrienne/0000-0003-0273-7965; Kritchevsky, Stephen/0000-0003-3336-6781;
Franks, Paul/0000-0002-0520-7604; Ganna, Andrea/0000-0002-8147-240X
FU Pfizer Nutrition
FX The full author list and affiliations are included in Supplemental Table
4 in the "Online Supporting Material" link in the online posting of the
article and from the same link in the online table of contents at
http://jn.nutrition.org. O.H.F. is the recipient of a grant from Pfizer
Nutrition to establish a center for research on aging (ErasmusAGE). All
other authors declared no conflicts of interest
NR 40
TC 23
Z9 23
U1 1
U2 10
PU AMER SOC NUTRITION-ASN
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3166
J9 J NUTR
JI J. Nutr.
PD MAR
PY 2013
VL 143
IS 3
BP 345
EP 353
DI 10.3945/jn.112.172049
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 093EC
UT WOS:000315173500014
PM 23343670
ER
PT J
AU Shah, GN
Price, TO
Banks, WA
Morofuji, Y
Kovac, A
Ercal, N
Sorenson, CM
Shin, ES
Sheibani, N
AF Shah, Gul N.
Price, Tulin O.
Banks, William A.
Morofuji, Yoichi
Kovac, Andrej
Ercal, Nuran
Sorenson, Christine M.
Shin, Eui S.
Sheibani, Nader
TI Pharmacological Inhibition of Mitochondrial Carbonic Anhydrases Protects
Mouse Cerebral Pericytes from High Glucose-Induced Oxidative Stress and
Apoptosis
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID BLOOD-BRAIN-BARRIER; MICROVASCULAR PERICYTES; ENDOTHELIAL-CELLS;
NITRIC-OXIDE; HYPERGLYCEMIA; EXPRESSION; COMPLICATIONS; PLURIPOTENT;
DAMAGE; MODEL
AB Diabetes-associated complications in the microvasculature of the brain are caused by oxidative stress, generated by overproduction of reactive oxygen species from hyperglycemia-induced accelerated oxidative metabolism of glucose. Pericytes, essential for the viability of the microvasculature, are especially susceptible to oxidative stress. Mitochondrial carbonic anhydrases, regulators of the oxidative metabolism of glucose, determine the rate of reactive oxygen species production and inhibition of mitochondrial carbonic anhydrases rescues glucose-induced pericyte loss in the diabetic mouse brain. We hypothesized that high glucose induces intracellular oxidative stress and pericyte apoptosis and that inhibition of mitochondrial carbonic anhydrases protects pericytes from oxidative stress-induced apoptosis. To validate our hypothesis, conditionally immortalized cerebral pericyte (IPC) cultures were established from Immortomice to investigate the effect of high glucose on oxidative stress and pericyte apoptosis. The IPCs expressed pericyte markers and induced high transendothelial electrical resistance and low permeability in brain endothelial cell monolayers comparable with pericytes in primary cultures. The IPCs also secreted cytokines constitutively and in response to lipopolysaccharide similar to pericytes. High glucose caused oxidative stress and apoptosis of these cells, with both oxidative stress and apoptosis significantly reduced after mitochondrial carbonic anhydrase inhibition. These results provide the first evidence that pharmacological inhibition of mitochondrial carbonic anhydrases attenuates pericyte apoptosis caused by high glucose-induced oxidative stress. Carbonic anhydrase inhibitors have a long history of safe clinical use and can be immediately evaluated for this new indication in translational research. Thus, mitochondrial carbonic anhydrases may provide a new therapeutic target for oxidative stress-related illnesses of the brain.
C1 [Shah, Gul N.; Price, Tulin O.] St Louis Univ, Dept Internal Med, Edward A Doisy Res Ctr, Div Endocrinol, St Louis, MO 63104 USA.
[Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Banks, William A.; Morofuji, Yoichi; Kovac, Andrej] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA.
[Ercal, Nuran] Missouri Univ Sci & Technol, Dept Chem, Rolla, MO USA.
[Sorenson, Christine M.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA.
[Shin, Eui S.; Sheibani, Nader] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
RP Shah, GN (reprint author), St Louis Univ, Dept Internal Med, Edward A Doisy Res Ctr, Div Endocrinol, 1100 S Grand Blvd,DRC 315, St Louis, MO 63104 USA.
EM shahgn@slu.edu
FU National Institutes of Health [R01-DK083485, RC4-EY021357, EY016695,
P30-EY016665, P30-CA014520]
FX This study was supported by the National Institutes of Health [Grants
R01-DK083485, RC4-EY021357, EY016695, P30-EY016665, and P30-CA014520].
NR 40
TC 13
Z9 14
U1 0
U2 5
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD MAR
PY 2013
VL 344
IS 3
BP 637
EP 645
DI 10.1124/jpet.112.201400
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 093LD
UT WOS:000315192500010
PM 23249625
ER
PT J
AU Robinson-Cohen, C
Littman, AJ
Duncan, GE
Roshanravan, B
Ikizler, TA
Himmelfarb, J
Kestenbaum, BR
AF Robinson-Cohen, Cassianne
Littman, Alyson J.
Duncan, Glen E.
Roshanravan, Baback
Ikizler, T. Alp
Himmelfarb, Jonathan
Kestenbaum, Bryan R.
TI Assessment of Physical Activity in Chronic Kidney Disease
SO JOURNAL OF RENAL NUTRITION
LA English
DT Article
ID OLDER-ADULTS; ACTIVITY QUESTIONNAIRE; ACTIVITY SCALE; UNITED-STATES;
ELDERLY PASE; EXERCISE; ACCELEROMETER; HEALTH; HEMODIALYSIS;
INFLAMMATION
AB Background: Physical inactivity plays an important role in the development of kidney disease and its complications; however, the validity of standard tools for measuring physical activity (PA) is not well understood.
Study Design: We investigated the performance of several readily available and widely used PA and physical function questionnaires, individually and in combination, against accelerometry among a cohort of chronic kidney disease (CKD) participants.
Setting and Participants: Forty-six participants from the Seattle Kidney Study, an observational cohort study of persons with CKD, completed the Physical Activity Scale for the Elderly, Human Activity Profile (HAP), Medical Outcomes Study SF-36 questionnaire, and the Four-week Physical Activity History questionnaires. We simultaneously measured PA using an Actigraph GT3X accelerometer during a 14-day period. We estimated the validity of each instrument by testing its associations with log-transformed accelerometry counts. We used the Akaike information criterion to investigate the performance of combinations of questionnaires.
Results: All questionnaire scores were significantly associated with log-transformed accelerometry counts. The HAP correlated best with accelerometry counts (r(2) = 0.32) followed by SF-36 (r(2) = 0.23). Forty-three percent of the variability in accelerometry counts data was explained by a model that combined the HAP, SF-36, and Four-week Physical Activity History questionnaires.
Conclusion: A combination of measurement tools can account for a modest component of PA in patients with CKD; however, a substantial proportion of PA is not captured by standard assessments. (c) 2013 by the National Kidney Foundation, Inc. All rights reserved.
C1 [Robinson-Cohen, Cassianne; Littman, Alyson J.; Duncan, Glen E.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Robinson-Cohen, Cassianne; Roshanravan, Baback; Himmelfarb, Jonathan; Kestenbaum, Bryan R.] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA.
[Littman, Alyson J.] VA Puget Sound Hlth Care Syst, Seattle Epidemiol Res & Informat Ctr, Seattle, WA USA.
[Duncan, Glen E.] Univ Washington, Nutr Sci Program, Seattle, WA 98195 USA.
[Roshanravan, Baback; Himmelfarb, Jonathan; Kestenbaum, Bryan R.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA.
[Ikizler, T. Alp] Vet Adm Tennessee Valley Healthcare Syst, Nashville, TN USA.
[Ikizler, T. Alp] Vanderbilt Univ, Div Nephrol, Nashville, TN USA.
RP Robinson-Cohen, C (reprint author), Univ Washington, Harborview Med Ctr, Kidney Res Inst, Box 359606,325 9th Ave, Seattle, WA 98104 USA.
EM cassyrc@u.washington.edu
RI Duncan, Glen/A-3771-2008;
OI Duncan, Glen/0000-0001-6909-1869; Robinson-Cohen,
Cassianne/0000-0003-4783-7046
FU Office of Research and Development Cooperative Studies Program,
Department of Veterans Affairs; Seattle Epidemiologic Research and
Information Center of the Department of Veterans Affairs; VA
Rehabilitation Career Development Award [6982]
FX This material is based on work supported in part by the Office of
Research and Development Cooperative Studies Program, Department of
Veterans Affairs. The contents do not represent the views of the
Department of Veterans Affairs or the United States Government. The
Seattle Epidemiologic Research and Information Center of the Department
of Veterans Affairs supported the involvement of all of the authors in
this research. A.J.L. was supported by VA Rehabilitation Career
Development Award (#6982).
NR 40
TC 12
Z9 12
U1 2
U2 17
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1051-2276
J9 J RENAL NUTR
JI J. Renal Nutr.
PD MAR
PY 2013
VL 23
IS 2
BP 123
EP 131
DI 10.1053/j.jrn.2012.04.008
PG 9
WC Nutrition & Dietetics; Urology & Nephrology
SC Nutrition & Dietetics; Urology & Nephrology
GA 093NN
UT WOS:000315198700014
PM 22739659
ER
PT J
AU Weiner, RB
Picard, MH
AF Weiner, Rory B.
Picard, Michael H.
TI Quality in Echocardiography: Does It Make a Difference?
SO JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY
LA English
DT Editorial Material
ID CENTER THINK-TANK; PROGNOSTIC IMPLICATIONS; ACHIEVING QUALITY; OUTCOMES
RESEARCH; AMERICAN-SOCIETY; OF-CARDIOLOGY; RECOMMENDATIONS;
REGURGITATION; COLLEGE; HEART
C1 Massachusetts Gen Hosp, Div Cardiol, Cardiac Ultrasound Lab, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Picard, MH (reprint author), Cardiac Ultrasound Lab, Yawkey 5E,55 Fruit St, Boston, MA 02114 USA.
EM mhpicard@partners.org
OI Picard, Michael/0000-0002-9264-3243
NR 17
TC 2
Z9 2
U1 0
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0894-7317
J9 J AM SOC ECHOCARDIOG
JI J. Am. Soc. Echocardiogr.
PD MAR
PY 2013
VL 26
IS 3
BP 243
EP 245
DI 10.1016/j.echo.2013.01.009
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 094US
UT WOS:000315290200005
PM 23439073
ER
PT J
AU Rojas, CA
Jaimes, C
Abbara, S
AF Rojas, Carlos Andres
Jaimes, Camilo
Abbara, Suhny
TI Ventricular Septal Defects Embryology and Imaging Findings
SO JOURNAL OF THORACIC IMAGING
LA English
DT Article
DE ventricular septal defects; interventricular septum; congenital heart
disease
ID CONGENITAL HEART-DISEASE; INVASIVE OXIMETRY; QUANTIFICATION; CLOSURE;
ADULTS; CT
AB Ventricular septal defects are the most common congenital abnormality diagnosed in children and the second most common congenital heart condition diagnosed in adults. Depending on their location in the interventricular septum, ventricular septal defects are described as perimembranous, muscular, subarterial, and inflow. Awareness of the embryologic basis of these defects helps understand the anatomy and recognize their typical appearance on imaging. Diagnostic imaging plays a role in the characterization of the defect, identification of associated anomalies, and evaluation of hemodynamic repercussion, all of which contribute to guide treatment.
C1 [Rojas, Carlos Andres] Univ S Florida, Dept Radiol, Tampa, FL 33612 USA.
[Jaimes, Camilo] Childrens Hosp Philadelphia, Dept Radiol, Philadelphia, PA 19104 USA.
[Abbara, Suhny] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol,Div Cardiovasc Imaging, Boston, MA USA.
RP Rojas, CA (reprint author), Univ S Florida, Dept Radiol, 12901 Bruce B Downs Blvd POB 17, Tampa, FL 33612 USA.
EM caranrojas@gmail.com
NR 30
TC 1
Z9 1
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0883-5993
J9 J THORAC IMAG
JI J. Thorac. Imaging
PD MAR
PY 2013
VL 28
IS 2
BP W28
EP W34
DI 10.1097/RTI.0b013e31824b5b95
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 095QX
UT WOS:000315350700002
PM 22516928
ER
PT J
AU Kibel, AS
AF Kibel, Adam S.
TI To Biopsy or Not to Biopsy: Minimizing the Risk of Prostate Needle
Biopsy
SO JOURNAL OF UROLOGY
LA English
DT Editorial Material
ID PROPHYLAXIS; CANCER
C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Urol,Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Kibel, AS (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Urol,Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 10
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD MAR
PY 2013
VL 189
IS 3
BP 796
EP 797
DI 10.1016/j.juro.2012.12.015
PG 2
WC Urology & Nephrology
SC Urology & Nephrology
GA 092HB
UT WOS:000315109600002
PM 23246850
ER
PT J
AU Barry, MJ
Cantor, A
Roehrborn, CG
AF Barry, Michael J.
Cantor, Alan
Roehrborn, Claus G.
CA CAMUS Study Grp
TI Relationships Among Participant International Prostate Symptom Score,
Benign Prostatic Hyperplasia Impact Index Changes and Global Ratings of
Change in a Trial of Phytotherapy in Men with Lower Urinary Tract
Symptoms
SO JOURNAL OF UROLOGY
LA English
DT Article
DE prostate; prostatic hyperplasia; lower urinary tract symptoms; health
status index; psychometrics
ID HEALTH-STATUS; COMBAT TRIAL; SATISFACTION; MODERATE; OVERLAP; WOMEN
AB Purpose: We related changes in American Urological Association symptom index scores with bother measures and global ratings of change in men with lower urinary tract symptoms who were enrolled in a saw palmetto trial.
Materials and Methods: To be eligible for study men were 45 years old or older, and had a peak uroflow of 4 ml per second or greater and an American Urological Association symptom index score of 8 to 24. Participants self-administered the American Urological Association symptom index, International Prostate Symptom Score quality of life item, Benign Prostatic Hyperplasia Impact Index and 2 global change questions at baseline, and at 24, 48 and 72 weeks.
Results: In 357 participants global ratings of a little better were associated with a mean decrease in American Urological Association symptom index scores from 2.8 to 4.1 points across 3 time points. The analogous range for mean decreases in Benign Prostatic Hyperplasia Impact Index scores was 1.0 to 1.7 points and for the International Prostate Symptom Score quality of life item it was 0.5 to 0.8 points. At 72 weeks for the first global change question each change measure discriminated between participants who rated themselves at least a little better vs unchanged or worse 70% to 72% of the time. A multivariate model increased discrimination to 77%. For the second global change question each change measure correctly discriminated ratings of at least a little better vs unchanged or worse 69% to 74% of the time and a multivariate model increased discrimination to 79%.
Conclusions: Changes in American Urological Association symptom index scores could discriminate between participants rating themselves at least a little better vs unchanged or worse. Our findings support the practice of powering studies to detect group mean differences in American Urological Association symptom index scores of at least 3 points.
C1 [Barry, Michael J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Cantor, Alan] Univ Alabama Birmingham, Birmingham, AL USA.
[Roehrborn, Claus G.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
RP Barry, MJ (reprint author), Massachusetts Gen Hosp, Div Gen Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM mbarry@partners.org
FU National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases [U01 DK63795, U01 DK63797, U01 DK63825,
U01 DK63835, U01 DK63866, U01 DK63833, U01 DK63862, U01 DK63840, U01
DK63883, U01 DK63831, U01 DK63778, U01 DK63788]; National Center for
Complementary and Alternative Medicine; Office of Dietary Supplements,
National Institutes of Health
FX Supported by National Institutes of Health, National Institute of
Diabetes and Digestive and Kidney Diseases Cooperative Agreements U01
DK63795, U01 DK63797, U01 DK63825, U01 DK63835, U01 DK63866, U01
DK63833, U01 DK63862, U01 DK63840, U01 DK63883, U01 DK63831, U01 DK63778
and U01 DK63788, the National Center for Complementary and Alternative
Medicine, and the Office of Dietary Supplements, National Institutes of
Health.
NR 12
TC 10
Z9 10
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD MAR
PY 2013
VL 189
IS 3
BP 987
EP 992
DI 10.1016/j.juro.2012.08.257
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 092HB
UT WOS:000315109600062
PM 23017510
ER
PT J
AU Gaughan, EM
Cryer, SK
Yeap, BY
Jackman, DM
Costa, DB
AF Gaughan, Elizabeth M.
Cryer, Sarah K.
Yeap, Beow Y.
Jackman, David M.
Costa, Daniel B.
TI Family history of lung cancer in never smokers with non-small-cell lung
cancer and its association with tumors harboring EGFR mutations
SO LUNG CANCER
LA English
DT Article
DE Lung cancer; Non-small-cell lung cancer; Family history; Never smokers;
Epidermal growth factor receptor; EGFR; Anaplastic lymphoma kinase; ALK;
KRAS
ID GENETIC-VARIANTS; RISK-FACTORS; SUSCEPTIBILITY; RESISTANCE; ERLOTINIB;
DISEASE
AB Introduction: Inherited susceptibility to lung cancer is understudied. Never smokers are an important subgroup of patients enriched for tumors harboring oncogene aberrations in the EGFR and ALK genes. We aimed to better characterize the incidence of family history of lung cancer among never smokers with NSCLC.
Methods: Clinicopathologic data, tumor genotype, family history of cancer, and specifically family history of lung cancer from 230 consecutive never smokers was retrospectively compiled and analyzed.
Results: In our cohort, the median age was 56 years, 67% were women, 75% were white, 59% had advanced NSCLC and 87% had adenocarcinoma histology. In these tumors, 98/230 (42%) had an EGFR mutation, 17/155 (11%) had KRAS mutations and 27/127 (21%) had an ALK translocation. Family history of any cancer was common (57%) and specific family history of lung cancer was present in 42/230 cases (18%). The percentage of cases with family history of lung cancer was higher in the EGFR mutated versus EGFR wild-type NSCLCs. Out of the cases with a family history of any cancer, 22/53 (41.5%) EGFR mutated, 1/5 (20%) KRAS mutated and 3/19 (15.5%) ALK translocated cohorts had a family history of lung cancer. The ratio of family history of lung cancer to family history of cancer was significantly higher in the EGFR mutated cohort when compared to the ALK translocated plus KRAS mutated cohorts (p = 0.039).
Conclusions: Family history of lung cancer is common in never smokers with NSCLC, and there seems to be a particular link in families in which the proband has an EGFR mutated tumor when compared to ALK translocated or KRAS mutated tumors. Further study of families with EGFR-mutated NSCLC may yield insights into the pathogenesis of this tumor type. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Gaughan, Elizabeth M.; Costa, Daniel B.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol Oncol,Dept Med, Boston, MA 02215 USA.
[Cryer, Sarah K.; Jackman, David M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lowe Ctr Thorac Oncol,Dept Med Oncol, Boston, MA 02115 USA.
[Yeap, Beow Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Costa, DB (reprint author), Beth Israel Deaconess Med Ctr, Div Hematol Oncol, 330 Brookline Ave, Boston, MA 02215 USA.
EM dbcosta@bidmc.harvard.edu
OI Costa, Daniel/0000-0002-0689-395X
FU American Society of Clinical Oncology Conquer Cancer Foundation;
American Cancer Society grant [RSG 11-186]; National Institutes of
Health [CA090578]; Pfizer; Roche; AstraZeneca; Genentech; Foundation
Medicine
FX This work was funded in part through fellowships from the American
Society of Clinical Oncology Conquer Cancer Foundation (DBC), an
American Cancer Society grant RSG 11-186 (DBC), and National Institutes
of Health grants CA090578 (BYY, DMJ, DBC).; DBC has received consulting
fees from Pfizer, Roche and AstraZeneca. DMJ has received consulting
fees from Genentech and Foundation Medicine. EMG, BYY and SKC have no
conflicts to disclose. No other conflict of interest is stated.
NR 23
TC 12
Z9 12
U1 1
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0169-5002
J9 LUNG CANCER
JI Lung Cancer
PD MAR
PY 2013
VL 79
IS 3
BP 193
EP 197
DI 10.1016/j.lungcan.2012.12.002
PG 5
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 094BV
UT WOS:000315238900001
PM 23273562
ER
PT J
AU Nishino, M
Cardarella, S
Dahlberg, SE
Jackman, DM
Ramaiya, NH
Hatabu, H
Rabin, MS
Janne, PA
Johnson, BE
AF Nishino, Mizuki
Cardarella, Stephanie
Dahlberg, Suzanne E.
Jackman, David M.
Ramaiya, Nikhil H.
Hatabu, Hiroto
Rabin, Michael S.
Jaenne, Pasi A.
Johnson, Bruce E.
TI Radiographic assessment and therapeutic decisions at RECIST progression
in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors
SO LUNG CANCER
LA English
DT Article
DE Lung cancer; Computed tomography; Drug resistance; Epidermal growth
factor receptor mutations; EGFR tyrosine kinase inhibitors; RECIST
ID CELL LUNG-CANCER; GROWTH-FACTOR RECEPTOR; RESPONSE EVALUATION CRITERIA;
GUIDELINE VERSION 1.1; ACQUIRED-RESISTANCE; SOLID TUMORS; 1ST-LINE
TREATMENT; IMATINIB MESYLATE; CLINICAL-TRIAL; OPEN-LABEL
AB Purpose: Advanced NSCLC harboring epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors (TKIs) typically progresses after initial response due to acquired resistance. TKIs are often continued beyond progressive disease by RECIST. We investigated the practice of continuing EGFR-TKIs after RECIST-PD via CT findings.
Methods: Among 101 advanced NSCLC patients with sensitizing EGFR mutations treated with first-line EGFR-TKIs, 70 patients had baseline and at least one follow-up CT for retrospective radiographic assessments using RECIST1.1; 56 patients had experienced PD by the data closure date of June 2011.
Results:Among 56 patients experiencing PD, 82% were female, median age was 63 years, 50% were never-smokers, 57% had distant metastasis, 57% had exon 19 deletion, and 89% were treated with erlotinib. 49 patients (88%) continued TKI therapy beyond retrospectively assessed PD. 31/32 (97%) patients who progressed by an increase in their target lesions continued TKI. 13/16 (81%) patients who progressed by appearance of a new lesion remained on TKI. 5/6 (83%) patients with both increase of target lesions and new lesion at PD continued TKI. Two patients with PD in non-target lesions discontinued therapy at PD. In 49 continuing patients, the median time from retrospectively assessed RECIST-PD to termination of TKI was 10.1 months.
Conclusions: 88% of EFGR-mutant NSCLC patients who progressed on first-line TKI continued therapy beyond RECIST-PD, which is not the single determining factor for terminating TKI in EGFR-mutant NSCLC patients. Additional radiographically defined progression criteria are needed for this population. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Nishino, Mizuki; Ramaiya, Nikhil H.] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02215 USA.
[Cardarella, Stephanie; Jackman, David M.; Rabin, Michael S.; Jaenne, Pasi A.; Johnson, Bruce E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Cardarella, Stephanie; Jackman, David M.; Rabin, Michael S.; Jaenne, Pasi A.; Johnson, Bruce E.] Brigham & Womens Hosp, Boston, MA 02215 USA.
[Dahlberg, Suzanne E.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Nishino, Mizuki; Ramaiya, Nikhil H.; Hatabu, Hiroto] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02215 USA.
RP Nishino, M (reprint author), Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02215 USA.
EM Mizuki_Nishino@DFCI.HARVARD.EDU
FU NCI [1K23CA157631]; National Institutes of Health [1RO1CA114465-01, 5R21
CA11627-02]; National Cancer Institute Specialized Program of Research
Excellence in Lung Cancer [2P50CA090578-06]; Genentech Inc; Doris and
William Krupp Research Fund in Thoracic Oncology; American Society of
Clinical Oncology Translational Research Professorship
FX The investigators were supported by 1K23CA157631 (NCI) (M.N.), Grants
1RO1CA114465-01 (B.E.J. and P.A.J.) and 5R21 CA11627-02 (H.H.) from the
National Institutes of Health, Grant No. 2P50CA090578-06 (B.E.J. and
P.A.J.) from the National Cancer Institute Specialized Program of
Research Excellence in Lung Cancer, and a grant from Genentech Inc, as
well as by the Doris and William Krupp Research Fund in Thoracic
Oncology and American Society of Clinical Oncology Translational
Research Professorship.
NR 41
TC 28
Z9 30
U1 0
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0169-5002
J9 LUNG CANCER
JI Lung Cancer
PD MAR
PY 2013
VL 79
IS 3
BP 283
EP 288
DI 10.1016/j.lungcan.2012.11.007
PG 6
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA 094BV
UT WOS:000315238900014
PM 23254265
ER
PT J
AU Qin, L
Schmidt, EJ
Tse, ZTH
Santos, J
Hoge, WS
Tempany-Afdhal, C
Butts-Pauly, K
Dumoulin, CL
AF Qin, Lei
Schmidt, Ehud J.
Tse, Zion Tsz Ho
Santos, Juan
Hoge, William S.
Tempany-Afdhal, Clare
Butts-Pauly, Kim
Dumoulin, Charles L.
TI Prospective motion correction using tracking coils
SO MAGNETIC RESONANCE IN MEDICINE
LA English
DT Article
DE intracavity coil imaging; prospective motion correction; cardiac MRI;
tracking coils
ID SPHERICAL NAVIGATOR ECHOES; MAGNETIC-RESONANCE; PROSTATE-CANCER;
INTRAVASCULAR MRI; SURFACE COIL; LOOP COIL; CATHETER; INTERVENTIONS;
SWINE; ARRAY
AB Intracavity imaging coils provide higher signal-to-noise than surface coils and have the potential to provide higher spatial resolution in shorter acquisition times. However, images from these coils suffer from physiologically induced motion artifacts, as both the anatomy and the coils move during image acquisition. We developed prospective motion-correction techniques for intracavity imaging using an array of tracking coils. The system had <50 ms latency between tracking and imaging, so that the images from the intracavity coil were acquired in a frame of reference defined by the tracking array rather than by the system's gradient coils. Two-dimensional gradient-recalled and three-dimensional electrocardiogram-gated inversion-recovery-fast-gradient-echo sequences were tested with prospective motion correction using ex vivo hearts placed on a moving platform simulating both respiratory and cardiac motion. Human abdominal tests were subsequently conducted. The tracking array provided a positional accuracy of 0.7 +/- 0.5 mm, 0.6 +/- 0.4 mm, and 0.1 +/- 0.1 mm along the X, Y, and Z directions at a rate of 20 frames-per-second. The ex vivo and human experiments showed significant image quality improvements for both in-plane and through-plane motion correction, which although not performed in intracavity imaging, demonstrates the feasibility of implementing such a motion-correction system in a future design of combined tracking and intracavity coil. Magn Reson Med, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Qin, Lei] Dana Farber Canc Inst, Dept Radiol, Boston, MA 02215 USA.
[Schmidt, Ehud J.; Tse, Zion Tsz Ho; Hoge, William S.; Tempany-Afdhal, Clare] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Santos, Juan] Heart Vista Inc, Palo Alto, CA USA.
[Butts-Pauly, Kim] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA.
[Dumoulin, Charles L.] Cincinnati Childrens Hosp Med Ctr, Dept Radiol, Cincinnati, OH USA.
RP Qin, L (reprint author), Dana Farber Canc Inst, Boston, MA 02215 USA.
EM lei_qin@dfci.harvard.edu
FU NIH [P41 RR019703, R01 CA11288, R01 CA111981-01, AHA 10SDG261039]
FX Grant sponsor: NIH; Grant numbers: P41 RR019703, R01 CA11288, R01
CA111981-01, and AHA 10SDG261039.
NR 35
TC 17
Z9 17
U1 0
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0740-3194
J9 MAGN RESON MED
JI Magn. Reson. Med.
PD MAR
PY 2013
VL 69
IS 3
BP 749
EP 759
DI 10.1002/mrm.24310
PG 11
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 095JU
UT WOS:000315331300016
PM 22565377
ER
PT J
AU Kong, J
Jensen, K
Loiotile, R
Cheetham, A
Wey, HY
Tan, Y
Rosen, B
Smoller, JW
Kaptchuk, TJ
Gollub, RL
AF Kong, Jian
Jensen, Karin
Loiotile, Rita
Cheetham, Alexandra
Wey, Hsiao-Ying
Tan, Ying
Rosen, Bruce
Smoller, Jordan W.
Kaptchuk, Ted J.
Gollub, Randy L.
TI Functional connectivity of the frontoparietal network predicts cognitive
modulation of pain
SO PAIN
LA English
DT Article
DE Cue effect; Expectancy; fMRI; Functional connectivity; Independent
component analysis; Placebo analgesia; Resting state
ID ANTERIOR CINGULATE CORTEX; RESTING HUMAN BRAIN; PLACEBO ANALGESIA;
INDIVIDUAL-DIFFERENCES; MEMORY PERFORMANCE; STATE; ANTICIPATION;
EXPERIENCE; SYSTEM; FMRI
AB The experience of pain can be significantly influenced by expectancy (predictive cues). This ability to modulate pain has the potential to affect therapeutic analgesia substantially and constitutes a foundation for nonpharmacological pain relief. In this study, we investigated (1) brain regions involved in visual cue modulation of pain during anticipation of pain, pain administration, and pain rating; and (2) the association between pretest resting state functional connectivity and the magnitude of cue effects on pain ratings. We found that after cue conditioning, visual cues can significantly modulate subjective pain ratings. Functional magnetic resonance imaging results suggested that brain regions pertaining to the frontoparietal network (prefrontal and parietal cortex) and a pain/emotion modulatory region (rostral anterior cingulate cortex) are involved in cue modulation during both pain anticipation and administration stage. Most interestingly, we found that pretest resting state functional connectivity between the frontoparietal network (as identified by independent component analysis) and the rostral anterior cingulate cortex/medial prefrontal cortex was positively associated with cue effects on pain rating changes. We believe that these findings will shed new light on our understanding of variable cue/expectancy effects across individuals and how the intrinsic connectivity of the brain may influence expectancy-induced modulation of pain. (C) 2012 International Association for the Study of Pain. Published by Elsevier B. V. All rights reserved.
C1 [Kong, Jian; Jensen, Karin; Loiotile, Rita; Cheetham, Alexandra; Wey, Hsiao-Ying; Tan, Ying; Smoller, Jordan W.; Gollub, Randy L.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA.
[Kong, Jian; Wey, Hsiao-Ying; Rosen, Bruce; Gollub, Randy L.] MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA USA.
[Kaptchuk, Ted J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Program Placebo Studies, Boston, MA 02215 USA.
RP Kong, J (reprint author), 120 2nd Ave,Room 101C, Charlestown, MA 02129 USA.
EM kongj@nmr.mgh.harvard.edu
OI Gollub, Randy L./0000-0002-9434-4044; Jensen, Karin/0000-0003-2521-3160
FU National Center for Complementary and Alternative Medicine (NCCAM)
[KO1AT003883]; NCCAM [R21AT004497, R01AT005280, R01AT006364,
K24AT004095, PO1-AT002048]; National Institute on Drug Abuse (NIDA)
[R03AT218317]; National Center for Research Resources [M01-RR-01066, UL1
RR025758-01, P41RR14075]; Swedish Society for Medical Research; Swedish
Council for Working Life and Social Research
FX This work was supported by KO1AT003883 National Center for Complementary
and Alternative Medicine (NCCAM), R21AT004497 (NCCAM), R03AT218317
National Institute on Drug Abuse (NIDA), R01AT006364 (NCCAM) to Jian
Kong, R01AT005280 (NCCAM) to Randy Gollub, K24AT004095 (NCCAM) to Ted
Kaptchuk, PO1-AT002048 (NCCAM) to Bruce Rosen, M01-RR-01066 and UL1
RR025758-01 for Clinical Research Center Biomedical Imaging Core from
National Center for Research Resources, and P41RR14075 for Center for
Functional Neuroimaging Technologies from National Center for Research
Resources. Karin Jensen receives support from the Swedish Society for
Medical Research and the Swedish Council for Working Life and Social
Research. The authors thank Dr. Tom Zeffiro for his valuable suggestions
and consultation on data analysis methods and Mr. Magnus Gyllensward for
his help in figure preparation.
NR 62
TC 37
Z9 38
U1 6
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-3959
J9 PAIN
JI Pain
PD MAR
PY 2013
VL 154
IS 3
BP 459
EP 467
DI 10.1016/j.pain.2012.12.004
PG 9
WC Anesthesiology; Clinical Neurology; Neurosciences
SC Anesthesiology; Neurosciences & Neurology
GA 094XW
UT WOS:000315299800020
PM 23352757
ER
PT J
AU Wang, P
Schuetz, C
Ross, A
Dai, GP
Markmann, JF
Moore, A
AF Wang, Ping
Schuetz, Christian
Ross, Alana
Dai, Guangping
Markmann, James F.
Moore, Anna
TI Immune Rejection after Pancreatic Islet Cell Transplantation: In Vivo
Dual Contrast-enhanced MR Imaging in a Mouse Model
SO RADIOLOGY
LA English
DT Article
ID ENDOTHELIAL-CELLS; T-CELLS; GRAFT COPOLYMER; XENOGRAFTS;
REVASCULARIZATION; SURVIVAL; MICE
AB Purpose: To detect adoptively transferred immune attack in a mouse model of islet cell transplantation by using a long-circulating paramagnetic T1 contrast agent, a protected graft copolymer (PGC) that is covalently linked to gadolinium- diethylenetriaminepentaacetic acid with fluorescein isothiocyanate (Gd-DTPA-F), which accumulates in the sites of inflammation that are characterized by vascular disruption.
Materials and Methods: All animal experiments were performed in compliance with institutional guidelines and approved by the subcommittee on research animal care. Six nonobese diabetic severe combined immunodeficiency mice received transplanted human islet cells under the kidney capsule and adoptively transferred 5 X 10(6) splenocytes from 6-weekold nonobese diabetic mice. These mice also served as control subjects for comparison of pre-and postadoptive transfer MR imaging results. Mice that received phosphate-buffered saline solution only were included as nonadoptive-transfer control subjects (n = 2). In vivo magnetic resonance (MR) imaging was performed before and 17 hours after intravenous injections of PGC-Gd-DTPA-F, followed by histologic examination. Statistical differences were analyzed by means of a paired Student t test and repeated two-way analysis of variance.
Results: MR imaging results showed significantly greater accumulation of PGC-Gd-DTPA-F in the graft area after immune attack initiated by adoptive transfer of splenocytes compared with that of the same area before the transfer (T1, 137.2 msec +/- 39.3 and 239.5 msec +/- 17.6, respectively; P < .001). These results were confirmed at histologic examination, which showed considerable leakage of the contrast agent into the islet cell interstitium.
Conclusion: PGC-Gd-DTPA-F-enhanced MR imaging allows for the in vivo assessment of vascular damage of the graft T cell challenge. (C) RSNA, 2012
C1 [Wang, Ping; Ross, Alana; Dai, Guangping; Moore, Anna] Harvard Univ, Massachusetts Gen Hosp, MGH MIT HMS Athinoula Martinos Ctr Biomed Imaging, Mol Imaging Lab,Dept Radiol,Med Sch, Boston, MA 02129 USA.
[Schuetz, Christian; Markmann, James F.] Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Div Transplantat,Med Sch, Boston, MA 02129 USA.
RP Moore, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, MGH MIT HMS Athinoula Martinos Ctr Biomed Imaging, Mol Imaging Lab,Dept Radiol,Med Sch, Bldg 75,149 13th St, Boston, MA 02129 USA.
EM amoore@helix.mgh.harvard.edu
OI Schuetz, Christian/0000-0002-6828-4543; Wang, Ping/0000-0001-6712-8939
FU NIAID NIH HHS [R01 AI057851]; NIDDK NIH HHS [R01 DK072137, R01DK072137]
NR 35
TC 5
Z9 5
U1 0
U2 41
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD MAR
PY 2013
VL 266
IS 3
BP 822
EP 830
DI 10.1148/radiol.12121129
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 094YC
UT WOS:000315300400014
PM 23264346
ER
PT J
AU Pandharipande, PV
Eisenberg, JD
Lee, RJ
Gilmore, ME
Turan, EA
Singh, S
Kalra, MK
Liu, B
Kong, CY
Gazelle, GS
AF Pandharipande, Pari V.
Eisenberg, Jonathan D.
Lee, Richard J.
Gilmore, Michael E.
Turan, Ekin A.
Singh, Sarabjeet
Kalra, Mannudeep K.
Liu, Bob
Kong, Chung Yin
Gazelle, G. Scott
TI Patients with Testicular Cancer Undergoing CT Surveillance Demonstrate a
Pitfall of Radiation-induced Cancer Risk Estimates: The Timing Paradox
SO RADIOLOGY
LA English
DT Article
ID COMPUTED-TOMOGRAPHY SCANS; STAGE HODGKINS LYMPHOMA; INFORMED-CONSENT;
LIFE EXPECTANCY; CONVENIENT APPROXIMATION; IONIZING-RADIATION;
DECISION-MAKING; DOSE-RESPONSE; I SEMINOMA; EXPOSURE
AB Purpose: To demonstrate a limitation of lifetime radiation-induced cancer risk metrics in the setting of testicular cancer surveillance-in particular, their failure to capture the delayed timing of radiation-induced cancers over the course of a patient's lifetime.
Materials and Methods: Institutional review board approval was obtained for the use of computed tomographic (CT) dosimetry data in this study. Informed consent was waived. This study was HIPAA compliant. A Markov model was developed to project outcomes in patients with testicular cancer who were undergoing CT surveillance in the decade after orchiectomy. To quantify effects of early versus delayed risks, life expectancy losses and lifetime mortality risks due to testicular cancer were compared with life expectancy losses and lifetime mortality risks due to radiation-induced cancers from CT. Projections of life expectancy loss, unlike lifetime risk estimates, account for the timing of risks over the course of a lifetime, which enabled evaluation of the described limitation of lifetime risk estimates. Markov chain Monte Carlo methods were used to estimate the uncertainty of the results.
Results: As an example of evidence yielded, 33-year-old men with stage I seminoma who were undergoing CT surveillance were projected to incur a slightly higher lifetime mortality risk from testicular cancer (598 per 100 000; 95% uncertainty interval [UI]: 302, 894) than from radiation-induced cancers (505 per 100 000; 95% UI: 280, 730). However, life expectancy loss attributable to testicular cancer (83 days; 95% UI: 42, 124) was more than three times greater than life expectancy loss attributable to radiation-induced cancers (24 days; 95% UI: 13, 35). Trends were consistent across modeled scenarios.
Conclusion: Lifetime radiation risk estimates, when used for decision making, may overemphasize radiation-induced cancer risks relative to short-term health risks. (C) RSNA, 2012
C1 [Pandharipande, Pari V.; Eisenberg, Jonathan D.; Gilmore, Michael E.; Turan, Ekin A.; Kong, Chung Yin; Gazelle, G. Scott] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
[Pandharipande, Pari V.; Eisenberg, Jonathan D.; Gilmore, Michael E.; Turan, Ekin A.; Singh, Sarabjeet; Kalra, Mannudeep K.; Liu, Bob; Kong, Chung Yin; Gazelle, G. Scott] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Lee, Richard J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Pandharipande, Pari V.; Lee, Richard J.; Singh, Sarabjeet; Kalra, Mannudeep K.; Liu, Bob; Kong, Chung Yin; Gazelle, G. Scott] Harvard Univ, Sch Med, Boston, MA USA.
RP Pandharipande, PV (reprint author), Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA.
EM pari@mgh-ita.org
FU Medical Imaging and Technology Alliance
FX Financial activities related to the present article: none to disclose.
Financial activities not related to the present article: institution
receives grant from Medical Imaging and Technology Alliance, a Division
of the National Electrical Manufacturers Association ( research grant
for unrelated research, but pertinent to CT, author is principle
investigator). Other relationships: none to disclose. J.D.E. No relevant
conflicts of interest to disclose. R.J.L. No relevant conflicts of
interest to disclose. M.E.G. No relevant conflicts of interest to
disclose. E.A.T. No relevant conflicts of interest to disclose. S.S. No
relevant conflicts of interest to disclose. M.K.K. Financial activities
related to the present article: none to disclose. Financial activities
not related to the present article: author receives payment for lecture
from GE Healthcare for continuing education-accredited course lecture;
author receives money for travel from GE Healthcare for continuing
education-accredited course. Other relationships: none to disclose. B.L.
No relevant conflicts of interest to disclose. C.Y.K. No relevant
conflicts of interest to disclose. G.S.G. Financial activities related
to the present article: none to disclose. Financial activities not
related to the present article: author is consultant for GE Healthcare.
Other relationships: none to disclose.
NR 50
TC 21
Z9 21
U1 0
U2 3
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD MAR
PY 2013
VL 266
IS 3
BP 896
EP 904
DI 10.1148/radiol.12121015
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 094YC
UT WOS:000315300400022
PM 23249573
ER
PT J
AU Muir, ER
Zhang, Y
Nateras, OSE
Peng, Q
Duong, TQ
AF Muir, Eric R.
Zhang, Yi
Nateras, Oscar San Emeterio
Peng, Qi
Duong, Timothy Q.
TI Human Vitreous: MR Imaging of Oxygen Partial Pressure
SO RADIOLOGY
LA English
DT Article
ID PROLIFERATIVE DIABETIC-RETINOPATHY; NUCLEAR CATARACT; RETINAL
OXYGENATION; TEMPERATURE; VITRECTOMY; EYE; BODY; TENSION; LENS; AGE
AB Purpose: To develop a magnetic resonance (MR) imaging approach to noninvasively image quantitative Po-2 in the human vitreous. Materials and Methods: Human studies were approved by the institutional review board with informed consent obtained from all subjects and were HIPAA compliant. Animal studies were performed with animal care committee approval. An MR imaging method to measure the longitudinal relaxation rate, or R1, of water was implemented with a 3.0-T MR imager. R1 was calibrated in water phantoms at multiple Po-2 and temperature conditions (n = 10) and in ex vivo animal vitreous (n = 2). Vitreous Po-2 was imaged in three human volunteers (age range, 26-28 years) in multiple sessions on separate days to evaluate reproducibility. The effects of temperature and ambient air were evaluated by acquiring data with the eye open and closed. Statistical analysis consisted of t tests, with P less than .05 indicating significant difference. Results: Calibrations of phantoms and ex vivo vitreous yielded an R1 association with oxygen of 0.209 sec(-1) + Po-2 . 2.07 X 10(-4) sec(-1)/mm Hg at 37 degrees C, and an association with temperature (Delta[1/R1]/Delta Temperature) of 0.106 sec/degrees C +/- 0.009 (standard deviation). A difference in R1 was found between the phantoms and vitreous. If uncorrected, vitreal Po2 would be significantly overestimated (P,.001). In vivo human vitreous Po-2 maps were spatially heterogeneous, with a whole vitreous Po 2 of 16.7 mm Hg 6 6.5 (eye closed). Measurements between open and closed eyes showed spatially dependent R1 differences, which translated to temperature differences of 0.34-0.83 C across the eye. Conclusion: This study established an MR imaging protocol to image quantitative vitreous Po-2 noninvasively and evaluated effects from vitreal macromolecules, temperature gradients, and ambient air on vitreal Po-2 values. Measurement of vitreous Po-2 with MR imaging has the potential to be used to study eye diseases noninvasively. (C) RSNA, 2012
C1 [Muir, Eric R.; Zhang, Yi; Nateras, Oscar San Emeterio; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Zhang, Yi; Nateras, Oscar San Emeterio; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Duong, Timothy Q.] SW Natl Primate Res Ctr, San Antonio, TX USA.
[Peng, Qi] Albert Einstein Coll Med, Dept Radiol, New York, NY USA.
[Peng, Qi] Montefiore Med Ctr, New York, NY USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM duongt@uthscsa.edu
RI Duong, Timothy/B-8525-2008; Muir, Eric/H-8830-2013
FU NEI NIH HHS [EY018855, R01 EY018855, R01 EY014211]; NHLBI NIH HHS [T32
HL007446, T32HL007446]; NIH HHS [P51 OD011133]
NR 29
TC 5
Z9 5
U1 0
U2 8
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD MAR
PY 2013
VL 266
IS 3
BP 905
EP 911
DI 10.1148/radiol.12120777
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 094YC
UT WOS:000315300400023
PM 23220896
ER
PT J
AU Loustau, M
Wiendl, H
Ferrone, S
Carosella, ED
AF Loustau, M.
Wiendl, H.
Ferrone, S.
Carosella, E. D.
TI HLA-G 2012 conference: the 15-year milestone update
SO TISSUE ANTIGENS
LA English
DT Review
DE human leukocyte antigen-G
ID NATURAL-KILLER-CELLS; REGULATORY T-CELLS; MULTIPLE-SCLEROSIS;
UP-REGULATION; G MOLECULE; INHIBITORY RECEPTOR; DENDRITIC CELLS; G
EXPRESSION; G ANTIGEN; PATHWAY
AB The non-classical human leukocyte antigen (HLA) Class I molecule HLA-G is best known for its tolerogenic function at the maternal-fetal interface, where it protects the fetus from destruction by the immune system of its mother. Yet, HLA-G has been the topic of intense investigations and its functions reach much further than originally believed. International conferences on HLA-G have taken place every 3 years since 1998, and the Sixth International Conference on HLA-G, that took place in Paris in July 2012. It counted 180 attendees from 28 countries, 35 speakers in plenary sessions, and 63 presentations of research in symposia and poster sessions, bringing new insight in HLA-G research. Here we summarize the major advances on the function and nature of HLA-G molecule that were reported, with particular interest on the findings in new mechanisms of action through regulatory cells, its relevance in cancer as well as in the molecular structure and functions of HLA-G, which are key for its clinical application.
C1 [Loustau, M.; Carosella, E. D.] Hop St Louis, CEA, Inst Emerging Dis & Innovat Therapies iMETI, Res Div Hematol & Immunol SRHI, Paris, France.
[Loustau, M.; Carosella, E. D.] Univ Paris Diderot, UMR E Inst Univ Hematol 5, St Louis Hosp, F-75475 Paris, France.
[Wiendl, H.] Univ Munster, Dept Neurol Inflammatory Disorders Nervous Syst &, D-48149 Munster, Germany.
[Ferrone, S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
RP Carosella, ED (reprint author), Hop St Louis, CEA, Inst Emerging Dis & Innovat Therapies iMETI, Res Div Hematol & Immunol SRHI, Paris, France.
EM Edgardo.Carosella@cea.fr
NR 31
TC 12
Z9 14
U1 1
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-2815
J9 TISSUE ANTIGENS
JI Tissue Antigens
PD MAR
PY 2013
VL 81
IS 3
BP 127
EP 136
DI 10.1111/tan.12053
PG 10
WC Cell Biology; Immunology; Pathology
SC Cell Biology; Immunology; Pathology
GA 089PF
UT WOS:000314921800001
PM 23347068
ER
PT J
AU Zhang, G
Wang, P
Qiu, Z
Qin, X
Lin, X
Li, N
Huang, H
Liu, H
Hua, W
Chen, Z
Zhao, H
Li, W
Shen, H
AF Zhang, G.
Wang, P.
Qiu, Z.
Qin, X.
Lin, X.
Li, N.
Huang, H.
Liu, H.
Hua, W.
Chen, Z.
Zhao, H.
Li, W.
Shen, H.
TI Distant lymph nodes serve as pools of Th1 cells induced by neonatal BCG
vaccination for the prevention of asthma in mice
SO ALLERGY
LA English
DT Article
DE asthma; Bacillus CalmetteGuerin; migration; neonatal vaccination; Th1
cells
ID INDUCED AIRWAY HYPERRESPONSIVENESS; MEMORY T-CELLS;
MYCOBACTERIUM-TUBERCULOSIS; CYTOKINE PRODUCTION; IMMUNE-RESPONSES;
DENDRITIC CELLS; IFN-GAMMA; INFECTION; INTERLEUKIN-12; INFLAMMATION
AB Background Neonatal Bacillus CalmetteGuerin (BCG) vaccination induces vigorous T-helper type 1 (Th1) responses and inhibits allergy-related airway dysfunction, but the exact mechanisms remain unclear. The objective of this study was to address where the Th1 cells induced by neonatal BCG vaccination are generated and stored, and how they are recruited into the inflamed airway for the prevention of allergen-induced airway inflammation. Methods We vaccinated neonatal C57BL/6 mice with BCG in a mouse model of asthma and analyzed the expression and function of Th1 cells in vivo and in vitro. Results BCG vaccinationinduced Th1 cells in the local inguinal lymph nodes (ILN) migrated into the lungs upon inhaled ovalbumin (OVA) challenge in OVA-sensitized mice. These CD4+ T cells in the ILN exhibited potentials of activation, proliferation and cytokine secretion and expressed high levels of CXCR3. Adoptive transfer of CD4+ T cells from BCG-treated ILN significantly decreased allergic airway responses. In addition, the protective effect of BCG vaccination against allergic airway inflammation was lost upon the excision of the ILN. Conclusions These data demonstrate that ILN serves as a weapon' pool of Th1 cells following BCG vaccination, and these cells are ready for the migration into the inflamed lungs upon the allergen challenge, thereby inhibiting allergen-induced airway disorder.
C1 [Zhang, G.; Wang, P.; Qiu, Z.; Lin, X.; Li, N.; Huang, H.; Liu, H.; Hua, W.; Chen, Z.; Li, W.; Shen, H.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Resp & Crit Care Med, Hangzhou 310009, Zhejiang, Peoples R China.
[Qin, X.] Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Resp Dis, Nanning, Peoples R China.
[Zhao, H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit, Boston, MA USA.
[Shen, H.] State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China.
RP Shen, H (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Resp & Crit Care Med, Hangzhou 310009, Zhejiang, Peoples R China.
EM hh_shen@yahoo.com.cn
FU National Natural Science Foundation of China for Distinguished Young
Scholars [30825019]; National Natural Science Foundation of China
[81070013]; Major and Key Program of Zhejiang Province [2008C03002-2]
FX We would like to thank Drs. Ming Yan (College of Biomedical Engineering
& Instrument Science, Zhejiang University), Zhijian Cai (Institute of
Immunology, Zhejiang University), Yungui Wang (Institute of Hematology,
Zhejiang University), and Youfa Zhu (Department of Pathology, Zhejiang
University) for their technical assistance. This study was supported in
part by the grants from National Natural Science Foundation of China for
Distinguished Young Scholars (No. 30825019, Shen HH) and National
Natural Science Foundation of China (No. 81070013, Shen HH), and Major
and Key Program of Zhejiang Province (2008C03002-2, Li W).
NR 32
TC 5
Z9 6
U1 3
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
J9 ALLERGY
JI Allergy
PD MAR
PY 2013
VL 68
IS 3
BP 330
EP 338
DI 10.1111/all.12099
PG 9
WC Allergy; Immunology
SC Allergy; Immunology
GA 089NG
UT WOS:000314916700008
PM 23346957
ER
PT J
AU Nargiso, JE
Friend, KB
Egan, C
Florin, P
Stevenson, J
Amodei, B
Barovier, L
AF Nargiso, Jessica E.
Friend, Karen B.
Egan, Crystelle
Florin, Paul
Stevenson, John
Amodei, Brenda
Barovier, Linda
TI Coalitional Capacities and Environmental Strategies to Prevent Underage
Drinking
SO AMERICAN JOURNAL OF COMMUNITY PSYCHOLOGY
LA English
DT Article
DE Coalitions; Prevention; Capacity; Measurement; Training and technical
assistance
ID COMMUNITY-BASED PREVENTION; HEALTH PROMOTION; DRUG-ABUSE; ALCOHOL;
SYSTEMS; TRIAL; INTERVENTIONS; PENNSYLVANIA; PARTNERSHIPS; PREVALENCE
AB Coalitions are the most common platform for implementing community-level environmental strategies (ES), such as media, policy, or enforcement for substance use prevention. The current study examines the associations between two types of coalition capacity (general and innovation-specific) and ES implementation efforts and outputs within 14 intervention communities over a three-year period. Efforts refer to the amount of energy exerted to implement an ES while outputs refer to the materials produced through these efforts. Quantitative measures of capacity were provided by coalition key informants and expert-raters. Additionally, Training and Technical Assistance (TTA) provided proactively to improve the implementation of ES was also examined. Greater general capacity, as rated by a coalition informant, was associated with more ES policy effort. Both expert-rated general and innovation-specific capacity, however, were associated with greater ES outputs. Study results also found that community coalitions that endorsed weaker mobilization, structure and task leadership, (measures of general capacity), utilized more TTA compared to those who perceived their coalition as having greater capacity. Moreover, communities that utilized more TTA resources reported a greater number of successful policy changes. The study supports the need to consider both general and innovation-specific capacity for ES implementation and offers promising preliminary findings regarding the role of TTA for improving coalitions' capacity to facilitate policy change.
C1 [Nargiso, Jessica E.; Friend, Karen B.] Brown Univ, Ctr Alcohol & Addict Studies, Warren Alpert Med Sch, Providence, RI 02912 USA.
[Friend, Karen B.] Pacific Inst Res & Evaluat, Decis Sci Inst, Pawtucket, RI 02860 USA.
[Egan, Crystelle] Univ Calif San Francisco, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Florin, Paul; Stevenson, John] Univ Rhode Isl, Dept Psychol, Kingston, RI 02881 USA.
[Amodei, Brenda] Dev Disabil & Hosp, Dept Behav Healthcare, Cranston, RI 02920 USA.
[Barovier, Linda] Educ Dev Ctr Inc, Waltham, MA 02453 USA.
RP Nargiso, JE (reprint author), Brown Univ, Ctr Alcohol & Addict Studies, Warren Alpert Med Sch, Box G-S121-4, Providence, RI 02912 USA.
EM Jessica_Nargiso@brown.edu
NR 33
TC 8
Z9 8
U1 2
U2 15
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0091-0562
J9 AM J COMMUN PSYCHOL
JI Am. J. Community Psychol.
PD MAR
PY 2013
VL 51
IS 1-2
BP 222
EP 231
DI 10.1007/s10464-012-9536-4
PG 10
WC Public, Environmental & Occupational Health; Psychology,
Multidisciplinary; Social Work
SC Public, Environmental & Occupational Health; Psychology; Social Work
GA 088KV
UT WOS:000314834100019
PM 22752558
ER
PT J
AU Levy, BP
AF Levy, Bruce P.
TI Implementation and User Satisfaction With Forensic Laboratory
Information Systems in Death Investigation Offices
SO AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY
LA English
DT Article
DE coroner; laboratory information management system; medical examiner
ID MEDICAL-EXAMINERS; SURVEILLANCE; LIMS; PREVENTION; MANAGEMENT; COMPUTER;
DATABASE; STATES
AB The use of laboratory information management systems (LIMSs) in forensic pathology and death investigation systems has lagged behind the greater pathology community. Yet the logistical needs of a modern medical examiner or coroner office could be well served by a robust forensic LIMS, and the data stored in a forensic LIMS could be effectively mined for the protection of the public's health and safety.
In spring 2007, the National Association of Medical Examiners conducted a survey of its members to determine the use of and satisfaction with forensic LIMS. This survey was repeated in the fall of 2011. The responses to the 2 surveys were compared to note any trends or changes to LIMS use by medical examiners and coroners.
Although the use of LIMS has increased in the 4 1/2 years between surveys, 18% of death investigation systems still do not have a forensic LIMS. The percentage of offices with home-developed systems has increased, whereas the user's satisfaction with these systems has decreased. This may be due to limited budgets to either purchase or develop systems. The integration of images into these systems has increased, but not nearly to the level that should be present in an image-dependent field. Users of these systems are cognizant of the features that a forensic LIMS should have to ensure the smooth operation of a death investigation office.
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Levy, BP (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM forensicdoc@me.com
NR 22
TC 0
Z9 0
U1 2
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0195-7910
EI 1533-404X
J9 AM J FOREN MED PATH
JI Am. J. Forensic Med. Pathol.
PD MAR
PY 2013
VL 34
IS 1
BP 63
EP 67
DI 10.1097/PAF.0b013e31827ab5c6
PG 5
WC Medicine, Legal; Pathology
SC Legal Medicine; Pathology
GA 089NI
UT WOS:000314916900018
PM 23361076
ER
PT J
AU Ahn, R
Alpert, EJ
Purcell, G
Konstantopoulos, WM
McGahan, A
Cafferty, E
Eckardt, M
Conn, KL
Cappetta, K
Burke, TF
AF Ahn, Roy
Alpert, Elaine J.
Purcell, Genevieve
Konstantopoulos, Wendy Macias
McGahan, Anita
Cafferty, Elizabeth
Eckardt, Melody
Conn, Kathryn L.
Cappetta, Kate
Burke, Thomas F.
TI Human Trafficking Review of Educational Resources for Health
Professionals
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Review
ID SEX TRAFFICKING; VIOLENCE; WOMEN; EXPLOITATION; GIRLS
AB Context: Human trafficking is an increasingly well-recognized human rights violation that is estimated to involve more than 2 million victims worldwide each year. The health consequences of this issue bring victims into contact with health systems and healthcare providers, thus providing the potential for identification and intervention. A robust healthcare response, however, requires a healthcare workforce that is aware of the health impact of this issue; educated about how to identify and treat affected individuals in a compassionate, culturally aware, and trauma-informed manner; and trained about how to collaborate efficiently with law enforcement, case management, and advocacy partners. This article describes existing educational offerings about human trafficking designed for a healthcare audience and makes recommendations for further curriculum development.
Evidence acquisition: A keyword search and structured analysis of peer-reviewed and gray literature, conducted in 2011 and 2012, yielded 27 items that provide basic guidance to health professionals on human trafficking.
Evidence synthesis: The 27 resources differed substantially in format, length, scope, and intended audience. Topic areas covered by these resources included trafficking definitions and scope, health consequences, victim identification, appropriate treatment, referral to services, legal issues, and security. None of the educational resources has been rigorously evaluated.
Conclusions: There is a clear need to develop, implement, and evaluate high-quality education and training programs that focus on human trafficking for healthcare providers. (Am J Prev Med 2013;44(3):283-289) (C) 2013 American Journal of Preventive Medicine
C1 [Ahn, Roy; Alpert, Elaine J.; Purcell, Genevieve; Konstantopoulos, Wendy Macias; McGahan, Anita; Cafferty, Elizabeth; Eckardt, Melody; Conn, Kathryn L.; Cappetta, Kate; Burke, Thomas F.] Massachusetts Gen Hosp, Dept Emergency Med, Div Global Hlth & Human Rights, Boston, MA 02114 USA.
[Burke, Thomas F.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Burke, Thomas F.] Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA.
[Ahn, Roy; Konstantopoulos, Wendy Macias; Burke, Thomas F.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[McGahan, Anita] Univ Toronto, Rotman Sch Management, Toronto, ON, Canada.
[McGahan, Anita] Univ Toronto, Munk Sch Global Affairs, Toronto, ON, Canada.
[Alpert, Elaine J.] Univ British Columbia, Coll Hlth Disciplines, Vancouver, BC V5Z 1M9, Canada.
RP Ahn, R (reprint author), Massachusetts Gen Hosp, 0 Emerson Pl,Suite 104, Boston, MA 02114 USA.
EM RAHN@partners.org
OI Eckardt, Melody/0000-0001-9066-9856
FU Give Way to Freedom
FX The authors acknowledge Give Way to Freedom, a private foundation, for
providing financial support to complete this review.
NR 48
TC 16
Z9 16
U1 5
U2 67
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD MAR
PY 2013
VL 44
IS 3
BP 283
EP 289
DI 10.1016/j.amepre.2012.10.025
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 090FZ
UT WOS:000314965900013
PM 23415126
ER
PT J
AU Boudreau, ADA
Kurowski, DS
Gonzalez, WI
Dimond, MA
Oreskovic, NM
AF Boudreau, Alexy D. Arauz
Kurowski, Daniel S.
Gonzalez, Wanda I.
Dimond, Melissa A.
Oreskovic, Nicolas M.
TI Latino Families, Primary Care, and Childhood Obesity A Randomized
Controlled Trial
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID QUALITY-OF-LIFE; GENERIC CORE SCALES; PHYSICAL-ACTIVITY; EARLY
INTERVENTION; CLINICAL-TRIALS; UNITED-STATES; US CHILDREN; OVERWEIGHT;
HEALTH; PREVALENCE
AB Background: Few successful treatment modalities exist to address childhood obesity. Given Latinos' strong identity with family, a family-focused intervention may be able to control Latino childhood obesity.
Purpose: To assess the feasibility and effectiveness of a family-centered, primary care-based approach to control childhood obesity through lifestyle choices.
Design: Randomized waitlist controlled trial in which control participants received the intervention 6 months after the intervention group.
Setting/participants: Forty-one Latino children with BMI >85%, aged 9-12 years, and their caregivers were recruited from an urban community health center located in a predominantly low-income community.
Intervention: Children and their caregivers received 6 weeks of interactive group classes followed by 6 months of culturally sensitive monthly in-person or phone coaching to empower families to incorporate learned lifestyles and to address both family and social barriers to making changes.
Main outcomes measures: Caregiver report on child and child self-reported health-related quality of life (HRQoL); metabolic markers of obesity; BMI; and accelerometer-based physical activity were measured July 2010-November 2011 and compared with post-intervention assessments conducted at 6 months and as a function of condition assignment. Data were analyzed in 2012.
Results: Average attendance rate to each group class was 79%. Socio-environmental and family factors, along with knowledge, were cited as barriers to changing lifestyles to control obesity. Caregiver proxy and child self-reported HRQoL improved for both groups with a larger but not nonsignificant difference among intervention vs control group children (p=0.33). No differences were found between intervention and control children for metabolic markers of obesity, BMI, or physical activity.
Conclusions: Latino families are willing to participate in group classes and health coaching to control childhood obesity. It may be necessary for primary care to partner with community initiatives to address childhood obesity in a more intense manner.
C1 [Boudreau, Alexy D. Arauz; Oreskovic, Nicolas M.] Harvard Univ, Sch Med, Ctr Child & Adolescent Hlth Res & Policy, Boston, MA USA.
[Gonzalez, Wanda I.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mass Gen Hosp Children, Boston, MA USA.
[Dimond, Melissa A.] MGH Ctr Community Hlth Improvement, Boston, MA USA.
[Kurowski, Daniel S.] Ctr Home Care Policy & Res, New York, NY USA.
RP Boudreau, ADA (reprint author), Massachusetts Gen Hosp, Mass Gen Hosp Children, Ctr Child & Adolescent Hlth Res & Policy, 100 Cambridge St,15th Floor, Boston, MA 02114 USA.
EM aarauz@partners.org
OI Oreskovic, Nicolas/0000-0001-8702-8636
FU Robert Wood Johnson Foundation; Robert Wood Johnson Foundation through
its national program, SaludAmerica! The RWJF Research Network to Prevent
Obesity Among Latino Children; Massachusetts General Hospital
Multicultural Affairs Career Development Award; Harvard Catalyst
Clinical Research Center, NIH, National Center for Research Resources,
General Clinical Research Centers Program [1 UL1 RR025758-01]
FX Publication of this article was supported by the Robert Wood Johnson
Foundation.; This study was funded by the Robert Wood Johnson Foundation
through its national program, SaludAmerica! The RWJF Research Network to
Prevent Obesity Among Latino Children (www.salud-america.org). Salud
America!, led by the Institute for Health Promotion Research at The
University of Texas Health Science Center at San Antonio, Texas, unites
Latino researchers and advocates seeking environmental and policy
solutions to the epidemic.; The study was also supported by the
Massachusetts General Hospital Multicultural Affairs Career Development
Award. The authors acknowledge the partnership of the Massachusetts
General Hospital Disparities Solution Center. In addition, the authors
acknowledge the generous support from the Harvard Catalyst Clinical
Research Center, Grant No. 1 UL1 RR025758-01, NIH, National Center for
Research Resources, General Clinical Research Centers Program. Finally,
we would like to acknowledge Dhruv Khullar for his excellent work as a
research assistant in helping to set up the initial phase of this
project.
NR 56
TC 17
Z9 17
U1 4
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD MAR
PY 2013
VL 44
IS 3
SU 3
BP S247
EP S257
DI 10.1016/j.amepre.2012.11.026
PG 11
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 090FD
UT WOS:000314963700012
ER
PT J
AU Cortes, DE
Millan-Ferro, A
Schneider, K
Vega, RR
Caballero, AE
AF Cortes, Dharma E.
Millan-Ferro, Andreina
Schneider, Karen
Vega, Rodolfo R.
Caballero, A. Enrique
TI Food Purchasing Selection Among Low-Income, Spanish-Speaking Latinos
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID UNITED-STATES; DIABETES-MELLITUS; OBESITY; CONSUMPTION; ADOLESCENTS;
CHILDREN; PRICES; RISK
AB Background: In the U.S., poverty has been linked to both obesity and disease burden. Latinos in the U.S. are disproportionately affected by poverty, and over the past 10 years, the percentage of overweight U.S. Latino youth has approximately doubled. Buying low-cost food that is calorie-dense and filling has been linked to obesity. Low-income individuals tend to favor energy-dense foods because of their low cost, and economic decisions made during food purchasing have physiologic repercussions. Diets based on energy-dense foods tend to be high in processed staples, such as refined grains, added sugars, and added fats. These diets have been linked to a higher risk of obesity, type 2 diabetes, and cardiovascular disease.
Purpose: This pilot study conducted ethnographic qualitative analyses combined with quantitative analyses to understand grocery shopping practices among 20 Spanish-speaking, low-income Latino families. The purpose was to analyze food selection practices in order to determine the effect of nutrition education on changes in shopping practices to later develop educational tools to promote selection of healthier food options.
Methods: Participants received tailored, interactive, nutrition education during three to five home visits and a supermarket tour. Grocery store receipts for grocery purchases collected at baseline and at the end of the project were analyzed for each family to extract nutritional content of purchased foods. Nutritional content was measured with these factors in mind: quantity, calories, fats, carbohydrates, fiber, protein, and percentage of sugary beverages and processed food. Data were collected in 2010-2011 and analyzed in 2011-2012.
Results: After receiving between three and five home-based nutrition education sessions and a supermarket tour over a 6-month period, many families adopted instructions on buying budget-friendly, healthier alternative foods. Findings indicate that participating families decreased the total number of calories and calories per dollar purchased from baseline to post-education (median total calories: baseline, 20,191; post-education, 15,991, p=0.008); median calories per dollar: baseline, 404; post-education, 320, p=0.008). The median grams of carbohydrates per dollar (baseline, 66, post-education, 45) and median calories from processed food (baseline, 11,000, post-education, 7845) were not reduced (p=0.06).
Conclusions: This pilot study demonstrated that grocery shopping practices are an important factor to address in nutrition education among Spanish-speaking, low-income individuals, and that there maybe ways to encourage low-income, Latino families to purchase healthier foods. Findings challenged arguments suggesting that such an approach is not possible because of the high cost of healthier foods. (Am J Prev Med 2013;44(3S3):S267-S273) (c) 2013 American Journal of Preventive Medicine
C1 [Cortes, Dharma E.] Univ Massachusetts Boston, Mauricio Gaston Inst Latino Community Dev & Publ, Boston, MA 02125 USA.
[Millan-Ferro, Andreina; Caballero, A. Enrique] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Schneider, Karen; Vega, Rodolfo R.] JSI Res & Training Inst Inc, Boston, MA USA.
RP Cortes, DE (reprint author), Univ Massachusetts Boston, Mauricio Gaston Inst Latino Community Dev & Publ, 100 Morrissey Blvd, Boston, MA 02125 USA.
EM decortes@aol.com
FU Robert Wood Johnson Foundation; Robert Wood Johnson Foundation through
its national program, Salud America! The RWJF Research Network to
Prevent Obesity among Latino Children
FX Publication of this article was supported by the Robert Wood Johnson
Foundation.; This study was funded by the Robert Wood Johnson Foundation
through its national program, Salud America! The RWJF Research Network
to Prevent Obesity among Latino Children (www.salud-america.org). Salud
America!, led by the Institute for Health Promotion Research at The
University of Texas Health Science Center at San Antonio, Texas, unites
Latino researchers and advocates seeking environmental and policy
solutions to the epidemic.
NR 27
TC 16
Z9 16
U1 1
U2 58
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD MAR
PY 2013
VL 44
IS 3
SU 3
BP S267
EP S273
DI 10.1016/j.amepre.2012.11.012
PG 7
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA 090FD
UT WOS:000314963700014
PM 23415192
ER
PT J
AU Antonescu, CR
Romeo, S
Zhang, L
Nafa, K
Hornick, JL
Nielsen, GP
Mino-Kenudson, M
Huang, HY
Mosquera, JM
Dei Tos, PA
Fletcher, CDM
AF Antonescu, Cristina R.
Romeo, Salvatore
Zhang, Lei
Nafa, Khedoudja
Hornick, Jason L.
Nielsen, Gunnlaugur Petur
Mino-Kenudson, Mari
Huang, Hsuan-Ying
Mosquera, Juan-Miguel
Dei Tos, Paolo A.
Fletcher, Christopher D. M.
TI Dedifferentiation in Gastrointestinal Stromal Tumor to an Anaplastic
KIT-negative Phenotype: A Diagnostic Pitfall Morphologic and Molecular
Characterization of 8 Cases Occurring Either De Novo or After Imatinib
Therapy
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE gastrointestinal stromal tumor; dedifferentiation; KIT; imatinib
ID IMATINIB MESYLATE; BRAF MUTATIONS; RESISTANCE; INHIBITOR;
LEIOMYOSARCOMA; HETEROGENEITY; MECHANISMS; GIST
AB Most gastrointestinal stromal tumors (GISTs) can be recognized by their monotonous cytologic features and overexpression of KIT oncoprotein. Altered morphology and loss of CD117 reactivity has been described previously after chronic imatinib treatment; however, this phenomenon has not been reported in imatinib-naive tumors. Eight patients with abrupt transition from a classic CD117-positive spindle cell GIST to an anaplastic CD117-negative tumor were investigated for underlying molecular mechanisms of tumor progression. Pathologic and molecular analysis was performed on each of the 2 components. Genomic DNA polymerase chain reaction for KIT, PDGFRA, BRAF, and KRAS hot spot mutations and fluorescence in situ hybridization for detecting KIT gene copy number alterations were performed. TP53 mutational analysis was performed in 5 cases. There were 7 men and 1 woman, with an age range of 23 to 65 years. Five of the primary tumors were located in the stomach, and 1 case each originated in the small bowel, colon, and rectum. In 3 patients, the dedifferentiated component occurred in the setting of imatinib resistance, whereas the remaining 5 occurred de novo. The dedifferentiated component had an anaplastic appearance, including 1 angio-sarcomatous phenotype, with high mitotic activity and necrosis, and showed complete loss of CD117 (8/8) and CD34 (5/8) expression and de novo expression of either cytokeratin (4/8) or desmin (1/8). There was no difference in the KIT genotype between the 2 components. However, 2 imatinib-resistant tumors showed coexistence of KIT exon 11 and exon 13 mutations. Fluorescence in situ hybridization showed loss of 1 KIT gene in 3 cases and low-level amplification of KIT in 2 other cases in the CD117-negative component, compared with the CD117-positive area. TP53 mutation was identified in 1/5 cases tested, being present in both components. In summary, dedifferentiation in GIST may occur either de novo or after chronic imatinib exposure and can represent a diagnostic pitfall. This phenomenon is not related to additional KIT mutations, but might be secondary to genetic instability, either represented by loss of heterozygosity or low level of KIT amplification.
C1 [Antonescu, Cristina R.; Zhang, Lei; Nafa, Khedoudja] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA.
[Mosquera, Juan-Miguel] Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
[Hornick, Jason L.; Fletcher, Christopher D. M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Nielsen, Gunnlaugur Petur; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Romeo, Salvatore; Dei Tos, Paolo A.] Treviso Gen Hosp, Treviso, Italy.
[Huang, Hsuan-Ying] Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan.
[Huang, Hsuan-Ying] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.
RP Antonescu, CR (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
EM antonesc@mskcc.org
FU ACS MRSG [CCE-106841, P01CA47179, P50 CA 140146-01]; Life Raft Group;
GIST Cancer Research Fund; Shuman Family Fund for GIST Research
FX Supported in part by ACS MRSG CCE-106841 (CRA), P01CA47179 (CRA), P50 CA
140146-01 (CRA), Life Raft Group (CRA), GIST Cancer Research Fund (CRA),
and Shuman Family Fund for GIST Research (CRA). The authors have
disclosed that they have no significant relationships with, or financial
interest in, any commercial companies pertaining to this article.
NR 24
TC 20
Z9 24
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0147-5185
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD MAR
PY 2013
VL 37
IS 3
BP 385
EP 392
DI 10.1097/PAS.0b013e31826c1761
PG 8
WC Pathology; Surgery
SC Pathology; Surgery
GA 092BY
UT WOS:000315095000008
PM 23348204
ER
PT J
AU Young, RH
Ulbright, TM
Policarpio-Nicolas, MLC
AF Young, Robert H.
Ulbright, Thomas M.
Policarpio-Nicolas, Maria Luisa C.
TI Yolk Sac Tumor With a Prominent Polyvesicular Vitelline Pattern A Report
of Three Cases
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE ovary; yolk sac tumor; polyvesicular vitelline
ID ENDODERMAL SINUS TUMOR; OVARY; CARCINOMA; PURE
AB We report 3 cases of the rare polyvesicular vitelline variant of ovarian yolk sac tumor (YST). The patients were 23, 29, and 43 years old, and all presented with large unilateral adnexal masses confined to the ovary. One tumor was predominantly cystic, and the other 2 had prominent cystic components; all 3 also had solid components. Microscopic examination of the cystic regions showed dilated cysts that largely effaced the stroma resulting in a honeycomb-like appearance. The solid foci were characterized predominantly by small tubules in a fibrous stroma; the tubules exhibited variably conspicuous cystic dilatation to merge with the microcystic appearance. The tumor cells varied from large and primitive-appearing to flattened and deceptively innocuous when lining large cysts. They were immunoreactive for a-fetoprotein and glypican-3. Non-polyvesicular vitelline components of YST were present focally in 2 cases (hepatoid in one, reticular and endometrioid like in the second). Two patients are disease free after 20 and 26 years, respectively; disease-free follow-up is of short duration in the third case (2 years). The good long-term outcome in 2 cases supports prior evidence that suggests that the natural history of this form of YST may be more indolent than conventional forms of the tumor.
C1 [Young, Robert H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, Boston, MA 02114 USA.
[Ulbright, Thomas M.] Indiana Univ, Indiana Univ Sch Med, Hlth Pathol Lab, Indianapolis, IN 46204 USA.
[Policarpio-Nicolas, Maria Luisa C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
RP Young, RH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, 55 Fruit St, Boston, MA 02114 USA.
EM rhyoung@partners.org
NR 18
TC 6
Z9 6
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0147-5185
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD MAR
PY 2013
VL 37
IS 3
BP 393
EP 398
DI 10.1097/PAS.0b013e31827dcc2b
PG 6
WC Pathology; Surgery
SC Pathology; Surgery
GA 092BY
UT WOS:000315095000009
PM 23348213
ER
PT J
AU Levine, DJ
Riley, DJ
Jorgensen, JH
McClain, WD
Tio, F
Visvesvara, GS
Abboud-Werner, SL
AF Levine, Deborah J.
Riley, Daniel J.
Jorgensen, James H.
McClain, William D.
Tio, Fermin
Visvesvara, Govinda S.
Abboud-Werner, Sherry L.
TI Key Diagnostic Features of Granulomatous Interstitial Nephritis Due to
Encephalitozoon cuniculi in a Lung Transplant Recipient
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE microsporidia; lung; kidney; transplant; albendazole
ID BONE-MARROW-TRANSPLANTATION; ENTEROCYTOZOON-BIENEUSI; MICROSPORIDIOSIS;
AIDS; INFECTION; MYOSITIS; PATIENT; GENOTYPES
AB Microsporidia are increasingly recognized as opportunistic pathogens in immunocompromised organ transplant recipients (OTR). Disseminated infection due to Encephalitozoon sp. is reported mainly in human immunodeficiency virus (HIV)-positive patients and rarely in HIV-negative OTR. The clinical spectrum ranges from keratoconjunctivitis, to pneumonitis, to acute kidney injury. The kidney is a common site for disseminated infection; however, specialized techniques are required for definitive diagnosis. We report the first case of disseminated Encephalitozoon cuniculi infection in an HIV-negative lung transplant recipient diagnosed on renal biopsy. Five months after transplant, he presented with fever and a lung infiltrate and developed acute kidney injury. Renal biopsy showed granulomatous interstitial nephritis with gram-positive rod-shaped organisms with a "belt-like stripe" in tubular epithelial cells. Electron microscopy, polymerase chain reaction, and mammalian cell cultures of the urine sediment confirmed E. cuniculi infection. Retrospective review of a previous lung biopsy showed similar organisms. On the basis of electron microscopy findings, the patient was treated with albendazole, and immunosuppressive therapy was reduced. However, the patient expired due to Aspergillus pneumonia and disseminated E. cuniculi infection. Microsporidia should be considered in cases of fever of unknown origin and/or multiorgan infection in HIV-negative OTR when other causes have been excluded, as successful treatment requires early detection.
C1 [Levine, Deborah J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Pulm Dis, San Antonio, TX 78229 USA.
[Riley, Daniel J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Jorgensen, James H.; McClain, William D.; Tio, Fermin; Abboud-Werner, Sherry L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Jorgensen, James H.; McClain, William D.; Tio, Fermin; Abboud-Werner, Sherry L.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Visvesvara, Govinda S.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA.
RP Abboud-Werner, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM abboudwerner@uthscsa.edu
NR 33
TC 4
Z9 4
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0147-5185
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD MAR
PY 2013
VL 37
IS 3
BP 447
EP 452
DI 10.1097/PAS.0b013e31827e1968
PG 6
WC Pathology; Surgery
SC Pathology; Surgery
GA 092BY
UT WOS:000315095000017
PM 23388129
ER
PT J
AU Young, RH
AF Young, Robert H.
TI Robert E. Scully, MD OBITUARY
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Biographical-Item
C1 [Young, Robert H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, James Homer Wright Pathol Labs, Boston, MA USA.
RP Young, RH (reprint author), Massachusetts Gen Hosp, James Homer Wright Pathol Labs, 55 Fruit St, Boston, MA 02114 USA.
EM rhyoung@partners.org
NR 1
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0147-5185
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD MAR
PY 2013
VL 37
IS 3
BP 464
EP 466
DI 10.1097/PAS.0b013e318280c2ce
PG 3
WC Pathology; Surgery
SC Pathology; Surgery
GA 092BY
UT WOS:000315095000023
PM 23520610
ER
PT J
AU Lawson, KM
Back, SE
Hartwell, KJ
Maria, MMS
Brady, KT
AF Lawson, Katie M.
Back, Sudie E.
Hartwell, Karen J.
Maria, Megan Moran-Santa
Brady, Kathleen T.
TI A Comparison of Trauma Profiles among Individuals with Prescription
Opioid, Nicotine, or Cocaine Dependence
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; SEXUAL ABUSE; DSM-IV; ASSOCIATION;
POPULATION; PREVALENCE; SMOKING; PTSD
AB Background and Objectives Exposure to traumatic events is common among individuals with substance use disorders. Little is known, however, about the trauma histories among individuals with various types of addiction. Methods The present study compared the trauma histories (general, sexual, physical and emotional) of non-treatment seeking outpatients dependent on prescription opioids (n=41), nicotine (n=87) or cocaine (n=73). The Life Stressor ChecklistRevised (LSC-R) was completed by participants to assess childhood and adult trauma. Results The findings revealed that all three groups endorsed high levels of trauma exposure, with 96.5% of the entire sample experiencing at least one traumatic event in their lifetime. The prescription opiate group experienced a greater number of general and total traumas than the nicotine group. However, no group differences in the number of emotional, physical, or sexual traumas were revealed. The prescription opiate group reported a younger age of first traumatic event than the cocaine group, and was significantly more likely to report childhood traumatic events than both the cocaine and nicotine groups. Conclusions and Scientific Significance The findings provide clinically relevant information that may help improve screening, interventions, and preventative efforts. (Am J Addict 2013;22:127-131)
C1 [Back, Sudie E.; Hartwell, Karen J.; Maria, Megan Moran-Santa; Brady, Kathleen T.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Hartwell, Karen J.; Brady, Kathleen T.] Ralph H Johnson VAMC, Charleston, SC USA.
RP Lawson, KM (reprint author), 430 Biobehav Hlth Bldg, University Pk, PA 16802 USA.
EM kml5509@psu.edu
FU NCRR NIH HHS [UL1 RR029882]; NICHD NIH HHS [K12 HD055885, 5 K12
HD055885‐02]; NIDA NIH HHS [K23 DA021228, K24 DA000435, K24 DA00435, R33
DA036085‐03]
NR 22
TC 7
Z9 7
U1 2
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PD MAR-APR
PY 2013
VL 22
IS 2
BP 127
EP 131
DI 10.1111/j.1521-0391.2013.00319.x
PG 5
WC Substance Abuse
SC Substance Abuse
GA 092AK
UT WOS:000315091000007
PM 23414497
ER
PT J
AU Lozano, BE
LaRowe, SD
Smith, JP
Tuerk, P
Roitzsch, J
AF Lozano, Brian E.
LaRowe, Steven D.
Smith, Joshua P.
Tuerk, Peter
Roitzsch, John
TI Brief Motivational Feedback May Enhance Treatment Entry in Veterans with
Comorbid Substance Use and Psychiatric Disorders
SO AMERICAN JOURNAL ON ADDICTIONS
LA English
DT Article
ID INTERVENTION; DRINKING
AB Background and Objectives There are limited investigations of brief interventions to facilitate treatment entry among individuals with substance use disorders. This study investigated the effectiveness of brief motivational feedback (BMF) for increasing entry into intensive substance abuse treatment in veteran patients. Methods Veteran patients (N=84) with substance use disorders referred for an intake assessment in a substance abuse specialty clinic received either (i) intake assessment plus BMF or (ii) intake assessment as usual (AAU). BMF consisted of brief motivational enhancement feedback pertaining to estimates of alcohol and drug consumption, money spent on drugs and alcohol, and self-reported problems due to substance abuse. Primary outcome was entry in treatment groups in an intensive outpatient program for substance abuse. Results Patients in BMF and AAU conditions did not significantly differ on indices of treatment entry. However, among patients with comorbid substance dependence and psychiatric disorders, those who received BMF were significantly more likely to enter outpatient treatment groups. Conclusions and Scientific Significance The addition of motivational feedback to a standard intake assessment enhanced substance abuse treatment entry among veteran patients with comorbid substance use disorders and psychiatric disorders. These preliminary findings extend the use of motivational feedback to facilitate entry into substance abuse treatment among veteran patients with comorbid substance use and psychiatric disorders. Furthermore, they suggest opportunity for more effective patient-treatment matching based on initial motivation and other individual factors such as psychiatric comorbidity. (Am J Addict 2013;22:132-135)
C1 [Lozano, Brian E.; LaRowe, Steven D.; Tuerk, Peter] Ralph H Johnson VAMC, Charleston, SC 29401 USA.
[Lozano, Brian E.; LaRowe, Steven D.; Smith, Joshua P.; Tuerk, Peter; Roitzsch, John] Med Univ S Carolina, Charleston, SC 29425 USA.
RP Lozano, BE (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA.
EM brian.lozano@va.gov
NR 11
TC 1
Z9 1
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1055-0496
J9 AM J ADDICTION
JI Am. J. Addict.
PD MAR-APR
PY 2013
VL 22
IS 2
BP 132
EP 135
DI 10.1111/j.1521-0391.2013.00315.x
PG 4
WC Substance Abuse
SC Substance Abuse
GA 092AK
UT WOS:000315091000008
PM 23414498
ER
PT J
AU Lee, LN
Susarla, SM
Hohman, MH
Henstrom, DK
Cheney, ML
Hadlock, TA
AF Lee, Linda N.
Susarla, Srinivas M.
Hohman, Marc H.
Henstrom, Douglas K.
Cheney, Mack L.
Hadlock, Tessa A.
TI A Comparison of Facial Nerve Grading Systems
SO ANNALS OF PLASTIC SURGERY
LA English
DT Article
DE facial paralysis; facial analysis; House-Brackmann; Facogram; facial
nerve; facial nerve grading system
ID HOUSE-BRACKMANN; PARALYSIS; FACE
AB Purpose: This study aimed to compare a computerized tool to standard objective clinical scales for global and zone-specific assessment of facial nerve function.
Methods: This was a retrospective review of 77 patients with facial paralysis who underwent facial videography. Videos were independently scored by 3 facial nerve specialists using the House-Brackmann Scales (HBI and HBII). Digital scoring was performed with Facogram software. Scores were recorded and compared using intraclass and Pearson (r) correlations.
Results: Interobserver correlation was high with HBII, with overall scores in excellent agreement (intraclass correlation range, 0.78-0.95; P <= 0.0001). There were strong correlations between Facogram and HBII (r >= 0.67, P <= 0.0001) and strong intraobserver correlations between HBI and HBII (r >= 0.71, P <= 0.0001). The HBII required more clinician time [mean (SD), 72 (21) seconds per case], compared with Facogram, which did not require any clinician time.
Conclusions: An automated, zone-specific facial analysis tool can eliminate clinician subjectivity and allow standardized assessment of facial paralysis.
C1 [Lee, Linda N.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Lee, Linda N.; Hohman, Marc H.; Cheney, Mack L.; Hadlock, Tessa A.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA.
[Susarla, Srinivas M.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Susarla, Srinivas M.] Massachusetts Gen Hosp, Dept Oral Maxillofacial Surg, Boston, MA 02114 USA.
[Hohman, Marc H.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Head & Neck Surg, Boston, MA 02114 USA.
[Henstrom, Douglas K.] Univ Iowa, Dept Otolaryngol, Div Facial Plast & Reconstruct Surg, Iowa, IA USA.
[Cheney, Mack L.; Hadlock, Tessa A.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Facial Nerve Ctr, Div Head & Neck Surg, Boston, MA 02114 USA.
RP Lee, LN (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM Linda_lee@meei.harvard.edu
OI Susarla, Srinivas/0000-0003-0155-8260
NR 15
TC 10
Z9 12
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-7043
J9 ANN PLAS SURG
JI Ann. Plast. Surg.
PD MAR
PY 2013
VL 70
IS 3
BP 313
EP 316
DI 10.1097/SAP.0b013e31826acb2c
PG 4
WC Surgery
SC Surgery
GA 092BI
UT WOS:000315093400014
PM 23241802
ER
PT J
AU Ashitate, Y
Lee, BT
Laurence, RG
Lunsford, E
Hutteman, M
Oketokoun, R
Choi, HS
Frangioni, JV
AF Ashitate, Yoshitomo
Lee, Bernard T.
Laurence, Rita G.
Lunsford, Elaine
Hutteman, Merlijn
Oketokoun, Rafiou
Choi, Hak Soo
Frangioni, John V.
TI Intraoperative Prediction of Postoperative Flap Outcome Using the
Near-Infrared Fluorophore Methylene Blue
SO ANNALS OF PLASTIC SURGERY
LA English
DT Article
DE flap perfusion; predictive capability; methylene blue; near-infrared
fluorescence imaging
ID FLUORESCENCE IMAGING-SYSTEM; FREE-TISSUE TRANSFER; REAL-TIME; VASCULAR
COMPROMISE; INDOCYANINE GREEN; BLOOD-FLOW; ANGIOGRAPHY; PERFUSION;
RECONSTRUCTION; IDENTIFICATION
AB Methylene blue (MB) is a near-infrared fluorophore that provides a stable visual map of skin perfusion after intravenous injection. We explored the capability of MB to predict submental flap postoperative outcome using a single intraoperative measurement. Submental flaps were created in N = 15 pigs and imaged using the FLARE imaging system immediately after surgery and at 72 hours. Using the first 3 pigs, optimal MB dosing was found to be 2.0 mg/kg. Training and validation sets of 6 pigs each were then used for receiver operating characteristic analysis. In the training set, a contrast-to-background ratio (CBR) threshold of 1.24 provided the highest sensitivity and specificity to predict tissue necrosis at 72 hours. In the validation set, this threshold provided a prediction sensitivity of 95.3% and a specificity of 98.0%. We demonstrate that a single intraoperative near-infrared measurement can predict submental flap outcome at 72 hours.
C1 [Ashitate, Yoshitomo; Laurence, Rita G.; Lunsford, Elaine; Hutteman, Merlijn; Oketokoun, Rafiou; Choi, Hak Soo; Frangioni, John V.] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA.
[Ashitate, Yoshitomo] Hokkaido Univ, Grad Sch Med, Div Canc Diagnost & Therapeut, Sapporo, Hokkaido, Japan.
[Lee, Bernard T.] Beth Israel Deaconess Med Ctr, Dept Surg, Div Plast & Reconstruct Surg, Boston, MA 02215 USA.
[Hutteman, Merlijn] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RA Leiden, Netherlands.
[Frangioni, John V.] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA.
RP Frangioni, JV (reprint author), BIDMC, Room SL B05,330 Brookline Ave, Boston, MA 02215 USA.
EM jfrangio@bidmc.harvard.edu
RI Choi, Hak Soo/C-9954-2011; Lee, Bernard/K-1106-2016
OI Lee, Bernard/0000-0002-5533-3166
FU National Institutes of Health [R01-CA-115296, R01-EB-005805]
FX Author J.V.F. supported by funds from National Institutes of Health
grants R01-CA-115296 (National Cancer Institute) and R01-EB-005805
(National Institute of Biomedical Imaging and Bioengineering). The other
authors have nothing to declare.
NR 31
TC 7
Z9 7
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0148-7043
J9 ANN PLAS SURG
JI Ann. Plast. Surg.
PD MAR
PY 2013
VL 70
IS 3
BP 360
EP 365
DI 10.1097/SAP.0b013e318236babe
PG 6
WC Surgery
SC Surgery
GA 092BI
UT WOS:000315093400023
PM 22395044
ER
PT J
AU Margalit, DN
Sreedhara, M
Chen, YH
Catalano, PJ
Nguyen, PL
Golshan, M
Overmoyer, BA
Harris, JR
Brock, JE
AF Margalit, Danielle N.
Sreedhara, Meera
Chen, Yu-Hui
Catalano, Paul J.
Nguyen, Paul L.
Golshan, Mehra
Overmoyer, Beth A.
Harris, Jay R.
Brock, Jane E.
TI Microinvasive Breast Cancer: ER, PR, and HER-2/neu Status and Clinical
Outcomes after Breast-Conserving Therapy or Mastectomy
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID CARCINOMA-IN-SITU; INVASIVE DUCTAL CARCINOMA; LYMPH-NODE METASTASIS;
LONG-TERM; PROGESTERONE-RECEPTOR; PATHOLOGICAL FINDINGS;
ESTROGEN-RECEPTOR; NEGATIVITY; RECURRENCE; EXPRESSION
AB Contemporary clinical outcomes of microinvasive breast cancer (MIBC), defined as no focus > 1 mm, are not well characterized. We document the immunophenotype, incidence of axillary metastases, and rate of recurrence in a well-defined case series.
We reviewed 83 consecutive patients with MIBC from 1997 to 2005. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2/neu) receptor status were assessed. The cumulative incidence of local recurrence (LR) and nodal/distant recurrence was calculated. Predictors of recurrence were identified and effect estimates determined.
Fifty-two patients (63 %) underwent breast-conserving therapy (BCT) and 31 (37 %) underwent mastectomy. Sixty-one percent had ER-positive disease and 49 % had HER-2/neu-positive disease. Three (4 %) of 68 patients with sentinel node mapping or axillary dissection had single node micrometastases, and none had macrometastases or multiple nodes involved. Median follow-up was 6.4 years, with 6 LRs, 2 regional nodal recurrences, and 2 concurrent local/distant recurrences. The 5-year cumulative incidence of recurrence (local, nodal, or distant) was 5.3 % (95 % confidence interval [CI] 2.0-13.4) for all patients, and among BCT patients, the 5-year cumulative incidence of LR was 4.2 % (95 % CI 0.7-12.7). HER-2/neu overexpression was not associated with recurrence (P = 0.46). Close/positive margins (a parts per thousand currency sign2 mm) were significantly associated with an increased risk of LR after BCT or mastectomy (hazard ratio 8.8; 95 % CI 1.6-48.8; P = 0.003).
MIBC has a favorable prognosis, and HER-2/neu overexpression, although highly prevalent, is not significantly associated with recurrence. Axillary metastases at diagnosis are small and infrequent. The cumulative incidence of LR after BCT is acceptable; however, our data confirm that negative margins (> 2 mm) are required for optimal BCT outcomes.
C1 [Margalit, Danielle N.; Sreedhara, Meera; Nguyen, Paul L.; Harris, Jay R.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Chen, Yu-Hui; Catalano, Paul J.] Brigham & Womens Hosp, Dana Farber Canc Inst, Harvard Canc Consortium, Boston, MA 02115 USA.
[Golshan, Mehra] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Surg, Boston, MA 02115 USA.
[Overmoyer, Beth A.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Brock, Jane E.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Pathol, Boston, MA 02115 USA.
RP Margalit, DN (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.
EM jebrock@partners.org
NR 27
TC 9
Z9 10
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD MAR
PY 2013
VL 20
IS 3
BP 811
EP 818
DI 10.1245/s10434-012-2640-8
PG 8
WC Oncology; Surgery
SC Oncology; Surgery
GA 090RW
UT WOS:000314998000017
PM 22956068
ER
PT J
AU Camp, MS
Greenup, RA
Taghian, A
Coopey, SB
Specht, M
Gadd, M
Hughes, K
Smith, BL
AF Camp, Melissa S.
Greenup, Rachel A.
Taghian, Alphonse
Coopey, Suzanne B.
Specht, Michelle
Gadd, Michele
Hughes, Kevin
Smith, Barbara L.
TI Application of ACOSOG Z0011 Criteria Reduces Perioperative Costs
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID LYMPH-NODE DISSECTION; BREAST-CANCER; AXILLARY DISSECTION; NEOADJUVANT
CHEMOTHERAPY; BIOPSY; COMPLICATIONS; TRIAL; WOMEN; MODEL; CARE
AB The ACOSOG Z0011 (Z0011) trial concluded that sentinel lymph node biopsy (SLNB) without completion axillary lymph node dissection (ALND) provides excellent regional control in women with T1-T2 sentinel lymph node (SLN) positive breast cancers receiving breast conservation therapy. We determined whether application of Z0011 guidelines would reduce costs.
A retrospective chart review of patients with invasive breast cancer treated with lumpectomy and SLNB at our institution during 2009 was performed. We determined the number of overnight hospital admissions following ALND and estimated costs pertaining to the perioperative surgical management of the axilla patients actually received, and compared those to the estimated number of inpatient days and perioperative costs if Z0011 guidelines had been followed for eligible patients. The 2011 Medicare Fee Schedule was used to estimate costs for procedures, and costs for OR time were estimated using procedure length and cost of OR time per minute.
A total of 71 patients underwent lumpectomy with SLNB and had at least 1 positive SLN. Estimated costs related to perioperative surgical management of the axilla were $322,775, and there were 36 overnight admissions. Applying Z0011 criteria, 51 patients (72 %) would have been eligible to forego completion ALND. Estimated costs would have been $264,513 with 13 overnight admissions, translating into a cost savings of $58,262 and 23 fewer overnight admissions.
Application of Z0011 guidelines resulted in cost savings, with a 64 % reduction in inpatient hospital days and an 18 % reduction in early perioperative costs.
C1 [Camp, Melissa S.; Greenup, Rachel A.; Coopey, Suzanne B.; Specht, Michelle; Gadd, Michele; Hughes, Kevin; Smith, Barbara L.] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA.
[Taghian, Alphonse] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Camp, MS (reprint author), Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA.
EM Blsmith1@partners.org
OI Hughes, Kevin/0000-0003-4084-6484
NR 16
TC 12
Z9 13
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD MAR
PY 2013
VL 20
IS 3
BP 836
EP 841
DI 10.1245/s10434-012-2664-0
PG 6
WC Oncology; Surgery
SC Oncology; Surgery
GA 090RW
UT WOS:000314998000020
PM 23010735
ER
PT J
AU Kaufman, KM
Zhao, J
Kelly, JA
Hughes, T
Adler, A
Sanchez, E
Ojwang, JO
Langefeld, CD
Ziegler, JT
Williams, AH
Comeau, ME
Marion, MC
Glenn, SB
Cantor, RM
Grossman, JM
Hahn, BH
Song, YW
Yu, CY
James, JA
Guthridge, JM
Brown, EE
Alarcon, GS
Kimberly, RP
Edberg, JC
Ramsey-Goldman, R
Petri, MA
Reveille, JD
Vila, LM
Anaya, JM
Boackle, SA
Stevens, AM
Freedman, BI
Criswell, LA
Pons-Estel, BA
Lee, JH
Lee, JS
Chang, DM
Scofield, RHA
Gilkeson, GS
Merrill, JT
Niewold, TB
Vyse, TJ
Bae, SC
Alarcon-Riquelme, ME
Jacob, CO
Sivils, KM
Gaffney, PM
Harley, JB
Sawalha, AH
Tsao, BP
AF Kaufman, Kenneth M.
Zhao, Jian
Kelly, Jennifer A.
Hughes, Travis
Adler, Adam
Sanchez, Elena
Ojwang, Joshua O.
Langefeld, Carl D.
Ziegler, Julie T.
Williams, Adrienne H.
Comeau, Mary E.
Marion, Miranda C.
Glenn, Stuart B.
Cantor, Rita M.
Grossman, Jennifer M.
Hahn, Bevra H.
Song, Yeong Wook
Yu, Chack-Yung
James, Judith A.
Guthridge, Joel M.
Brown, Elizabeth E.
Alarcon, Graciela S.
Kimberly, Robert P.
Edberg, Jeffrey C.
Ramsey-Goldman, Rosalind
Petri, Michelle A.
Reveille, John D.
Vila, Luis M.
Anaya, Juan-Manuel
Boackle, Susan A.
Stevens, Anne M.
Freedman, Barry I.
Criswell, Lindsey A.
Pons-Estel, Bernardo A.
Lee, Joo-Hyun
Lee, Ji-Seon
Chang, Deh-Ming
Scofield, R. Hal A.
Gilkeson, Gary S.
Merrill, Joan T.
Niewold, Timothy B.
Vyse, Timothy James
Bae, Sang-Cheol
Alarcon-Riquelme, Marta E.
Jacob, Chaim O.
Sivils, Kathy Moser
Gaffney, Patrick M.
Harley, John B.
Sawalha, Amr H.
Tsao, Betty P.
CA Argentine Collaborat Grp
Biolupus Network
TI Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for
systemic lupus erythematosus in multiple ancestral groups
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; KAPPA-B ACTIVATION; ACETYLTRANSFERASE ARD1;
GENETIC SUSCEPTIBILITY; BINDING-PROTEIN; IDENTIFICATION; HAPLOTYPE;
REPLICATION; VARIANTS; INSIGHTS
AB Objectives The Xq28 region containing IRAK1 and MECP2 has been identified as a risk locus for systemic lupus erythematosus (SLE) in previous genetic association studies. However, due to the strong linkage disequilibrium between IRAK1 and MECP2, it remains unclear which gene is affected by the underlying causal variant(s) conferring risk of SLE.
Methods We fine-mapped >= 136 SNPs in a similar to 227 kb region on Xq28, containing IRAK1, MECP2 and seven adjacent genes (L1CAM, AVPR2, ARHGAP4, NAA10, RENBP, HCFC1 and TMEM187), for association with SLE in 15 783 case-control subjects derived from four different ancestral groups.
Results Multiple SNPs showed strong association with SLE in European Americans, Asians and Hispanics at p < 5 x 10(-8) with consistent association in subjects with African ancestry. Of these, six SNPs located in the TMEM187-IRAK1-MECP2 region captured the underlying causal variant(s) residing in a common risk haplotype shared by all four ancestral groups. Among them, rs1059702 best explained the Xq28 association signals in conditional testings and exhibited the strongest p value in transancestral meta-analysis (p(meta) = 1.3 x 10(-27), OR = 1.43), and thus was considered to be the most likely causal variant. The risk allele of rs1059702 results in the amino acid substitution S196F in IRAK1 and had previously been shown to increase NF-kappa B activity in vitro. We also found that the homozygous risk genotype of rs1059702 was associated with lower mRNA levels of MECP2, but not IRAK1, in SLE patients (p = 0.0012) and healthy controls (p = 0.0064).
Conclusions These data suggest contributions of both IRAK1 and MECP2 to SLE susceptibility.
C1 [Kaufman, Kenneth M.; Harley, John B.] Cincinnati Childrens Hosp, Med Ctr, Div Rheumatol, Cincinnati, OH USA.
[Kaufman, Kenneth M.; Harley, John B.] Cincinnati Childrens Hosp, Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH USA.
[Kaufman, Kenneth M.; Merrill, Joan T.; Harley, John B.] US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA.
[Zhao, Jian; Grossman, Jennifer M.; Hahn, Bevra H.; Tsao, Betty P.] Univ Calif Los Angeles, Div Rheumatol, Los Angeles, CA USA.
[Kelly, Jennifer A.; Hughes, Travis; Adler, Adam; Sanchez, Elena; Glenn, Stuart B.; James, Judith A.; Guthridge, Joel M.; Scofield, R. Hal A.; Alarcon-Riquelme, Marta E.; Sivils, Kathy Moser; Gaffney, Patrick M.; Sawalha, Amr H.] Oklahoma Med Res Fdn, Arthritis & Clin Immunol Program, Oklahoma City, OK 73104 USA.
[Ojwang, Joshua O.] Brevard Coll, Dept Chem, Palm Bay, FL USA.
[Langefeld, Carl D.; Ziegler, Julie T.; Williams, Adrienne H.; Comeau, Mary E.; Marion, Miranda C.] Wake Forest Sch Med, Dept Biostat, Winston Salem, NC USA.
[Cantor, Rita M.] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA USA.
[Song, Yeong Wook] Seoul Natl Univ, Div Rheumatol, Seoul, South Korea.
[Yu, Chack-Yung] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA.
[James, Judith A.; Scofield, R. Hal A.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA.
[Brown, Elizabeth E.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA.
[Brown, Elizabeth E.; Alarcon, Graciela S.; Kimberly, Robert P.; Edberg, Jeffrey C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Ramsey-Goldman, Rosalind] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Chicago, IL 60611 USA.
[Petri, Michelle A.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Reveille, John D.] Univ Texas Houston, Hlth Sci Ctr, Dept Internal Med, Houston, TX 77225 USA.
[Vila, Luis M.] Univ Puerto Rico, Dept Med, San Juan, PR 00936 USA.
[Anaya, Juan-Manuel] Univ Rosario, Ctr Autoimmune Dis Res, Bogota, Colombia.
[Boackle, Susan A.] Univ Colorado Denver, Div Rheumatol, Aurora, CO USA.
[Stevens, Anne M.] Univ Washington, Dept Pediat, Div Rheumatol, Seattle, WA 98195 USA.
[Stevens, Anne M.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA.
[Freedman, Barry I.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA.
[Criswell, Lindsey A.] Univ Calif San Francisco, Dept Med, Rosalind Russell Med Res Ctr Arthrit, San Francisco, CA USA.
[Pons-Estel, Bernardo A.; Argentine Collaborat Grp] Dept Med, Rosario, Santa Fe, Argentina.
[Lee, Joo-Hyun] Inje Univ, Coll Med, Ilsan Paik Hosp, Dept Rheumatol, Gimhae, South Korea.
[Lee, Ji-Seon; Bae, Sang-Cheol] Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, Seoul 133791, South Korea.
[Chang, Deh-Ming] Natl Def Med Ctr, Taipei, Taiwan.
[Scofield, R. Hal A.] US Dept Vet Affairs, Med Ctr, Oklahoma City, OK USA.
[Gilkeson, Gary S.] Med Univ S Carolina, Dept Med, Div Rheumatol, Charleston, SC 29425 USA.
[Merrill, Joan T.] Oklahoma Med Res Fdn, Clin Pharmacol Program, Oklahoma City, OK 73104 USA.
[Niewold, Timothy B.] Univ Chicago, Rheumatol Sect, Chicago, IL 60637 USA.
[Niewold, Timothy B.] Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA.
[Vyse, Timothy James] Kings Coll London, Div Genet & Mol Med, London WC2R 2LS, England.
[Vyse, Timothy James] Kings Coll London, Div Immunol, London WC2R 2LS, England.
[Alarcon-Riquelme, Marta E.; Biolupus Network] Pfizer Univ Granada Junta Andalucia, Ctr Genom Invest Oncol GENYO, Granada, Spain.
[Jacob, Chaim O.] Univ So Calif, Keck Sch Med, Dept Med, Los Angeles, CA 90033 USA.
RP Kaufman, KM (reprint author), MLC 15012,3333 Burnet Ave, Cincinnati, OH 45229 USA.
EM kaufman.kenneth@cchmc.org
RI Zhao, Jian/E-6292-2012; Yu, Chack-Yung/E-4360-2011; Anaya,
Juan-Manuel/J-1960-2016; Sanchez, Elena/B-4140-2017;
OI Anaya, Juan-Manuel/0000-0002-6444-1249; Sanchez,
Elena/0000-0002-7041-5485; Universidad del Rosario,
Biblioteca/0000-0003-3491-9392; Kimberly, Robert/0000-0002-5330-3086;
Alarcon Riquelme, Marta Eugenia/0000-0002-7632-4154; Niewold,
Timothy/0000-0003-3532-6660
FU US National Institutes of Health [R01AR43814, R01AR043274, R01AI063274,
N01AR62277, R3724717, AR042460, P01AI083194, P20RR020143, R01AR33062,
P30AR055385, 5UL1RR025777, P30048311, K08AI083790, LRPAI071651,
R01CA141700]; Lupus Research Institute; Merit Award from the US
Department of Veterans Affairs; Alliance for Lupus Research; Arthritis
National Research Foundation Eng Tan Scholar Award; Arthritis
Foundation; Korea Healthcare Technology R&D Project, Ministry for Health
and Welfare, Republic of Korea [A111218-11-GM01]; Korean R&D Programme
of MKE/KEIT [10035615]; Swedish Research Council; Swedish Association
Against Rheumatism; King Gustaf Vth 80th Jubilee Foundation; Fundacion
Instituto de Salud Carlos III [PS0900129]; European FEDER funds;
Consejeria de Salud de Andalucia [PI-0012]; Wenner Gren Foundation;
Wellcome Trust; Arthritis Research UK; CTSA Grant from the National
Center for Research Resources, Kirkland Scholar Award [I ULI
RR025014-02]; Wake Forest University Health Sciences Center for Public
Health Genomics; Federico Wilhelm Agricola Foundation Research; US
National Institutes of Health. [RC1AR058621, UL1RR024999, K24AR002138,
P602AR30692, P01AR49084, UL1RR025741, R01AR051545-01A2, P30AR053483,
P30GM103510, U19AI082714, R21AI070304, 1U54RR23417-01, P60AR053308,
M01RR-00079, P60AR049459, UL1RR029882]
FX Support for this work was obtained from the US National Institutes of
Health grants: R01AR43814 (BPT), R01AR043274 (KLM), R01AI063274 (PMG),
N01AR62277 (JBH), R3724717 (JBH), AR042460 (JBH), P01AI083194 (JBH),
P20RR020143 (JBH), P01AR49084 (RPK and EEB), R01AR33062 (RPK),
P30AR055385 (EEB), 5UL1RR025777 (RPK and JCE), R01AR33062 (RPK),
P01AR49084 (RPK, JCE, EEB, GSA, JDR, RRG, LMB and MAP), P30048311 (EEB),
K08AI083790 (TBN), LRPAI071651 (TBN), R01CA141700 (MEAR), RC1AR058621
(MEAR) and UL1RR024999 (TBN), K24AR002138 (RRG), P602AR30692 (RRG),
P01AR49084 (RRG), UL1RR025741 (RRG), R01AR051545-01A2 (AMS), P30AR053483
(JAJ and JMG), P30GM103510 (JAJ), U19AI082714 (JAJ and JMG), R21AI070304
(SAB), 1U54RR23417-01 (JDR), P60AR053308 (LAC), M01RR-00079 (LAC),
P60AR049459 (DLK) and UL1RR029882 (DLK). This study was also supported
by a grant from Lupus Research Institute (BPT, TBN), the Merit Award
from the US Department of Veterans Affairs (JBH and GSG), The Alliance
for Lupus Research (KLM, TBN, LAC and COJ), the Arthritis National
Research Foundation Eng Tan Scholar Award (TBN), the Arthritis
Foundation (AMS and PMG), the Korea Healthcare Technology R&D Project,
Ministry for Health and Welfare, Republic of Korea (A111218-11-GM01;
SCB) and Korean R&D Programme of MKE/KEIT (10035615; YWS). Additional
funding awarded from the Swedish Research Council, Swedish Association
Against Rheumatism and the King Gustaf Vth 80th Jubilee Foundation and
the Fundacion Instituto de Salud Carlos III PS0900129 partially funded
through European FEDER funds and the Consejeria de Salud de Andalucia
PI-0012, the Wenner Gren Foundation for support (CG), the Wellcome Trust
(TJV), Arthritis Research UK (TJV), CTSA Grant Number I ULI RR025014-02
(AMS) from the National Center for Research Resources, Kirkland Scholar
Award (LAC), Wake Forest University Health Sciences Center for Public
Health Genomics (CDL, MCC, MCM, and PSR) and the Federico Wilhelm
Agricola Foundation Research grant (BAPE).
NR 40
TC 29
Z9 30
U1 3
U2 14
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD MAR
PY 2013
VL 72
IS 3
BP 437
EP 444
DI 10.1136/annrheumdis-2012-201851
PG 8
WC Rheumatology
SC Rheumatology
GA 088BQ
UT WOS:000314809200021
PM 22904263
ER
PT J
AU Dai, TH
Gupta, A
Huang, YY
Yin, R
Murray, CK
Vrahas, MS
Sherwood, ME
Tegos, GP
Hamblin, MR
AF Dai, Tianhong
Gupta, Asheesh
Huang, Ying-Ying
Yin, Rui
Murray, Clinton K.
Vrahas, Mark S.
Sherwood, Margaret E.
Tegos, George P.
Hamblin, Michael R.
TI Blue Light Rescues Mice from Potentially Fatal Pseudomonas aeruginosa
Burn Infection: Efficacy, Safety, and Mechanism of Action
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID ANTIMICROBIAL PHOTODYNAMIC THERAPY; MRSA IN-VITRO; WOUND INFECTIONS;
HELICOBACTER-PYLORI; ULTRAVIOLET-LIGHT; VISIBLE-LIGHT; INACTIVATION;
BACTERIA; MODEL; RESISTANCE
AB Blue light has attracted increasing attention due to its intrinsic antimicrobial effect without the addition of exogenous photosensitizers. However, the use of blue light for wound infections has not been established yet. In this study, we demonstrated the efficacy of blue light at 415 nm for the treatment of acute, potentially lethal Pseudomonas aeruginosa burn infections in mice. Our in vitro studies demonstrated that the inactivation rate of P. aeruginosa cells by blue light was approximately 35-fold higher than that of keratinocytes (P = 0.0014). Transmission electron microscopy revealed blue light-mediated intracellular damage to P. aeruginosa cells. Fluorescence spectroscopy suggested that coproporphyrin III and/or uroporphyrin III are possibly the intracellular photosensitive chromophores associated with the blue light inactivation of P. aeruginosa. In vivo studies using an in vivo bioluminescence imaging technique and an area-under-the-bioluminescence-time-curve (AUBC) analysis showed that a single exposure of blue light at 55.8 J/cm(2), applied 30 min after bacterial inoculation to the infected mouse burns, reduced the AUBC by approximately 100-fold in comparison with untreated and infected mouse burns (P < 0.0001). Histological analyses and terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assays indicated no significant damage in the mouse skin exposed to blue light at the effective antimicrobial dose. Survival analyses revealed that blue light increased the survival rate of the infected mice from 18.2% to 100% (P < 0.0001). In conclusion, blue light therapy might offer an effective and safe alternative to conventional antimicrobial therapy for P. aeruginosa burn infections.
C1 [Dai, Tianhong; Gupta, Asheesh; Huang, Ying-Ying; Yin, Rui; Sherwood, Margaret E.; Tegos, George P.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Dai, Tianhong; Gupta, Asheesh; Huang, Ying-Ying; Yin, Rui; Tegos, George P.; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Gupta, Asheesh] Def Inst Physiol & Allied Sci, Delhi, India.
[Huang, Ying-Ying] Guangxi Med Univ, Dept Pathol, Nanning, Guangxi, Peoples R China.
[Gupta, Asheesh] Third Mil Med Univ, Southwest Hosp, Dept Dermatol, Chongqing, Peoples R China.
[Murray, Clinton K.] Brooke Army Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA.
[Vrahas, Mark S.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
[Tegos, George P.] Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA.
[Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
EM hamblin@helix.mgh.harvard.edu
RI Huang, Ying-ying/G-3153-2011;
OI Huang, Ying-ying/0000-0003-3066-6981; Hamblin,
Michael/0000-0001-6431-4605
FU Airlift Research Foundation [109421]; COTA/Smith Nephew grant [2012-16];
CIMIT Innovation grant [13-1033]; NIH [RO1AI050875]
FX This study was supported in part by Airlift Research Foundation
Extremity Trauma Research grant 109421 (to T. D.), COTA/Smith & Nephew
grant 2012-16 (to T. D.), CIMIT Innovation grant 13-1033 (to T. D.), and
NIH grant RO1AI050875 (to M. R. H.). The funders had no role in the
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 50
TC 28
Z9 33
U1 2
U2 29
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAR
PY 2013
VL 57
IS 3
BP 1238
EP 1245
DI 10.1128/AAC.01652-12
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 090GU
UT WOS:000314968100018
PM 23262998
ER
PT J
AU Naar, AM
AF Naeaer, Anders M.
TI Anti-atherosclerosis or No Anti-atherosclerosis That is the miR-33
question
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Editorial Material
DE mir-33; atherosclerosis; LDLr; HDL-C; antisense
ID CHOLESTEROL HOMEOSTASIS; METABOLIC-DISORDERS; HDL
C1 Harvard Univ, Dept Cell Biol, Sch Med, Massachusetts Gen Hosp,Canc Ctr, Charlestown, MA 02129 USA.
RP Naar, AM (reprint author), Harvard Univ, Dept Cell Biol, Sch Med, Massachusetts Gen Hosp,Canc Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.
EM naar@helix.mgh.harvard.edu
FU NIDDK NIH HHS [R01 DK094184]
NR 16
TC 9
Z9 9
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD MAR
PY 2013
VL 33
IS 3
BP 447
EP 448
DI 10.1161/ATVBAHA.112.301021
PG 2
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 089DS
UT WOS:000314890200006
PM 23407174
ER
PT J
AU Koseoglu, S
Dilks, JR
Peters, CG
Fitch-Tewfik, JL
Fadel, NA
Jasuja, R
Italiano, JE
Haynes, CL
Flaumenhaft, R
AF Koseoglu, Secil
Dilks, James R.
Peters, Christian G.
Fitch-Tewfik, Jennifer L.
Fadel, Nathalie A.
Jasuja, Reema
Italiano, Joseph E., Jr.
Haynes, Christy L.
Flaumenhaft, Robert
TI Dynamin-Related Protein-1 Controls Fusion Pore Dynamics During Platelet
Granule Exocytosis
SO ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
LA English
DT Article
DE dynamin-related protein-1; exocytosis; fusion pore; platelets;
thrombosis
ID ISCHEMIA-REPERFUSION INJURY; SINGLE VESICLE RELEASE; MITOCHONDRIAL
DIVISION; CHROMAFFIN CELLS; QUANTAL SIZE; MOUSE MODEL; MEMBRANE;
FISSION; DRP1; INHIBITORS
AB Objective-Platelet granule exocytosis serves a central role in hemostasis and thrombosis. Recently, single-cell amperometry has shown that platelet membrane fusion during granule exocytosis results in the formation of a fusion pore that subsequently expands to enable the extrusion of granule contents. However, the molecular mechanisms that control platelet fusion pore expansion and collapse are not known.
Methods and Results-We identified dynamin-related protein-1 (Drp1) in platelets and found that an inhibitor of Drp1, mdivi-1, blocked exocytosis of both platelet dense and a-granules. We used single-cell amperometry to monitor serotonin release from individual dense granules and, thereby, measured the effect of Drp1 inhibition on fusion pore dynamics. Inhibition of Drp1 increased spike width and decreased prespike foot events, indicating that Drp1 influences fusion pore formation and expansion. Platelet-mediated thrombus formation in vivo after laser-induced injury of mouse cremaster arterioles was impaired after infusion of mdivi-1.
Conclusion-These results demonstrate that inhibition of Drp1 disrupts platelet fusion pore dynamics and indicate that Drp1 can be targeted to control thrombus formation in vivo. (Arterioscler Thromb Vasc Biol. 2013;33:481-488.)
C1 [Dilks, James R.; Peters, Christian G.; Fitch-Tewfik, Jennifer L.; Fadel, Nathalie A.; Jasuja, Reema; Flaumenhaft, Robert] Harvard Univ, Sch Med, Dept Med, Div Hemostasis & Thrombosis,BIDMC, Boston, MA USA.
[Koseoglu, Secil; Haynes, Christy L.] Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA.
[Italiano, Joseph E., Jr.] Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA.
[Italiano, Joseph E., Jr.] Childrens Hosp, Dept Surg, Vasc Biol Program, Boston, MA 02115 USA.
RP Flaumenhaft, R (reprint author), Beth Israel Deaconess Med Ctr, Ctr Life Sci, Room 939,3 Blackfan Circle, Boston, MA 02215 USA.
EM rflaumen@bidmc.harvard.edu
OI Haynes, Christy/0000-0002-5420-5867
FU National Institutes of Health (NIH) [HL87203]; NIH New Innovator Award
[OD004258-01]; American Heart Association [0840043 N]
FX This work was supported by National Institutes of Health (NIH) grant
HL87203 (R. Flaumenhaft) and NIH New Innovator Award to C. L. Haynes
(OD004258-01). R. Flaumenhaft is a recipient of an Established
Investigator Award from the American Heart Association (0840043 N).
NR 44
TC 9
Z9 9
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1079-5642
J9 ARTERIOSCL THROM VAS
JI Arterioscler. Thromb. Vasc. Biol.
PD MAR
PY 2013
VL 33
IS 3
BP 481
EP +
DI 10.1161/ATVBAHA.112.255737
PG 18
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA 089DS
UT WOS:000314890200012
PM 23288151
ER
PT J
AU Liu, J
Feener, EP
AF Liu, Jia
Feener, Edward P.
TI Plasma kallikrein-kinin system and diabetic retinopathy
SO BIOLOGICAL CHEMISTRY
LA English
DT Review
DE bradykinin receptor; diabetic retinopathy; plasma kallikrein-kinin
system; retina; vascular permeability
ID RETINAL VASCULAR-PERMEABILITY; B-1 RECEPTOR ANTAGONIST; NITRIC-OXIDE
SYNTHASE; FACTOR-XII; IN-VIVO; HEREDITARY ANGIOEDEMA; THROMBUS
FORMATION; UP-REGULATION; RISK-FACTORS; BRADYKININ
AB Diabetic retinopathy (DR) occurs, to some extent, in most people with at least 20 years' duration of diabetes mellitus. The progression of DR to its sight-threatening stages is usually associated with the worsening of underlying retinal vascular dysfunction and disease. The plasma kallikrein-kinin system (KKS) is activated during vascular injury, where it mediates important functions in innate inflammation, blood flow, and coagulation. Recent findings from human vitreous proteomics and experimental studies on diabetic animal models have implicated the KKS in contributing to DR. Vitreous fluid from people with advanced stages of DR contains increased levels of plasma KKS components, including plasma kallikrein (PK), coagulation factor XII, and high-molecular-weight kininogen. Both bradykinin B1 and B2 receptor isoforms (B1R and B2R, respectively) are expressed in human retina, and retinal B1R levels are increased in diabetic rodents. The activation of the intraocular KKS induces retinal vascular permeability, vasodilation, and retinal thickening, and these responses are exacerbated in diabetic rats. Preclinical studies have shown that the administration of PK inhibitors and B1R antagonists to diabetic rats ameliorates retinal vascular hyperpermeability and inflammation. These findings suggest that components of plasma KKS are potential therapeutic targets for diabetic macular edema.
C1 [Liu, Jia; Feener, Edward P.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Dept Med,Res Div, Boston, MA 02215 USA.
RP Feener, EP (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Dept Med,Res Div, 1 Joslin Pl, Boston, MA 02215 USA.
EM edward.feener@joslin.harvard.edu
FU US National Institutes of Health [EY019029, DK36836]; JDRF [17-2011-251]
FX This work was supported in part by the US National Institutes of Health
(grants EY019029 and DK36836) and the JDRF grant 17-2011-251.
NR 77
TC 13
Z9 13
U1 0
U2 20
PU WALTER DE GRUYTER & CO
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1431-6730
J9 BIOL CHEM
JI Biol. Chem.
PD MAR
PY 2013
VL 394
IS 3
BP 319
EP 328
DI 10.1515/hsz-2012-0316
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 087JN
UT WOS:000314757700002
PM 23362193
ER
PT J
AU Zhan, HC
Cardozo, C
Yu, WN
Wang, AT
Moliterno, AR
Dang, CV
Spivak, JL
AF Zhan, Huichun
Cardozo, Christopher
Yu, Wayne
Wang, Antai
Moliterno, Alison R.
Dang, Chi V.
Spivak, Jerry L.
TI MicroRNA deregulation in polycythemia vera and essential thrombocythemia
patients
SO BLOOD CELLS MOLECULES AND DISEASES
LA English
DT Article
DE MicroRNA; Myeloproliferative neoplasm; Polycythemia vera; Essential
thrombocythemia; Hematopoiesis
ID HEMATOPOIETIC STEM-CELLS; TYROSINE KINASE JAK2; MYELOPROLIFERATIVE
DISORDERS; ERYTHROID-DIFFERENTIATION; SECONDARY MYELOFIBROSIS; MYELOID
METAPLASIA; EXPRESSION; MUTATION; ERYTHROPOIESIS; JAK2V617F
AB Polycythemia vera (PV) and essential thrombocythemia (ET) are the two most common myeloproliferative neoplasms. The same JAK2(V617F) mutation can be found in both disorders and is able to recapitulate many of the phenotypic abnormalities of these diseases in the murine models. The disease phenotype is also influenced by other unknown genetic or epigenetic factors. MicroRNAs (miRNA) are 18-24 nucleotides single-stranded non-protein-coding RNAs that function primarily as gene repressors by binding to their target messenger RNAs. We performed miRNA expression profiling by oligonucleotide microarray analysis in purified peripheral blood CD34+ cells from eight JAK2(V617F)-positive PV patients and six healthy donors. A quantitative reverse-transcription polymerase chain reaction assay was used to verify differential miRNA expression. Since erythrocytosis is the only feature that distinguishes PV from ET, we also compared specific miRNA expression in the nucleated erythroid cells directly descended from the early erythroid progenitor cells of PV and ET patients. Our data indicate that significant miRNA deregulation occurs in PV CD34+ cells and confirm a genetic basis for the gender-specific differences that characterize PV with respect to miRNA. The results of our study also suggest that deregulated miRNAs may represent an important mechanism by which the PV erythrocytosis and ET thrombocytosis phenotypes are determined. Published by Elsevier Inc.
C1 [Zhan, Huichun; Cardozo, Christopher] James J Peters VA Med Ctr, Bronx, NY 10468 USA.
[Zhan, Huichun; Wang, Antai] Columbia Univ, Med Ctr, New York, NY USA.
[Cardozo, Christopher] Mt Sinai Sch Med, New York, NY USA.
[Yu, Wayne; Moliterno, Alison R.; Spivak, Jerry L.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Dang, Chi V.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
RP Zhan, HC (reprint author), James J Peters VA Med Ctr, Room 3F-12,130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Huichun.Zhan@va.gov
FU Veterans Affairs Career Development Award [10959632]; Veterans Affairs
Rehabilitation Research and Development Service grant [B9212-C]
FX Huichun Zhan is currently supported by the Veterans Affairs Career
Development Award (grant 10959632) and Veterans Affairs Rehabilitation
Research and Development Service grant B9212-C. We would like to thank
Drs. Katia Basso, David Dominguez, and Riccardo Dalla-Favera from
Columbia University for their assistance in microRNA analysis. We thank
Drs. Min Lu and Ronald Hoffman from Mount Sinai School of Medicine for
their assistance in the colony formation assay. We thank Drs. Yan
Makeyev and Imitiaz Patel for providing precious patient samples. We
thank Hai Xu from Johns Hopkins University for his assistance in
microRNA microarray experiments. We thank Drs. Azra Raza and Naomi
Galili from Columbia University Medical Center, Drs. Erik Langhoff, Mary
Sano, and Elisa Sanchez-Valencia from James J. Peters VA Medical Center,
and Dr. Robert Brodsky from Johns Hopkins University for their
continuing support throughout this work.
NR 50
TC 9
Z9 9
U1 0
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1079-9796
J9 BLOOD CELL MOL DIS
JI Blood Cells Mol. Dis.
PD MAR
PY 2013
VL 50
IS 3
BP 190
EP 195
DI 10.1016/j.bcmd.2012.11.009
PG 6
WC Hematology
SC Hematology
GA 091UE
UT WOS:000315074500010
PM 23265742
ER
PT J
AU Smucny, J
Rojas, DC
Eichman, LC
Tregellas, JR
AF Smucny, Jason
Rojas, Donald C.
Eichman, Lindsay C.
Tregellas, Jason R.
TI Neuronal effects of auditory distraction on visual attention
SO BRAIN AND COGNITION
LA English
DT Article
DE Attention; Dorsolateral prefrontal cortex; Fusiform gyrus;
Pre-supplementary motor area; Posterior cingulate; Distraction
ID ANTERIOR CINGULATE CORTEX; PREFRONTAL CORTEX; SUSTAINED ATTENTION;
HEMODYNAMIC-RESPONSE; SELECTIVE ATTENTION; FUNCTIONAL-ANATOMY;
PERFORMANCE; BRAIN; TASK; FMRI
AB Selective attention in the presence of distraction is a key aspect of healthy cognition. The underlying neurobiological processes, have not, however, been functionally well characterized. In the present study, we used functional magnetic resonance imaging to determine how ecologically relevant distracting noise affects cortical activity in 27 healthy adults during two versions of the visual Sustained Attention To Response Task (SARI) that differ in difficulty (and thus attentional load). A significant condition (noise or silence) by task (easy or difficult) interaction was observed in several areas, including dorsolateral prefrontal cortex (DLPFC), fusiform gyrus (FG), posterior cingulate (PCC), and pre-supplementary motor area (PreSMA). Post hoc analyses of interaction effects revealed deactivation of DLPFC, PCC, and PreSMA during distracting noise under conditions of low attentional load, and activation of FG and PCC during distracting noise under conditions of high attentional load. These results suggest that distracting noise may help alert subjects to task goals and reduce demands on cortical resources during tasks of low difficulty and attentional load. Under conditions of higher load, however, additional cognitive resources may be required in the presence of noise. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Smucny, Jason; Rojas, Donald C.; Tregellas, Jason R.] Univ Colorado, Neurosci Program, Aurora, CO 80045 USA.
[Smucny, Jason; Rojas, Donald C.; Eichman, Lindsay C.; Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Denver, CO USA.
[Rojas, Donald C.; Eichman, Lindsay C.; Tregellas, Jason R.] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA.
RP Tregellas, JR (reprint author), Univ Colorado, Dept Psychiat, Anschutz Med Campus,Bldg 500,4th Floor, Aurora, CO 80045 USA.
EM Jason.Smucny@ucdenver.edu; Don.Rojas@ucden-ver.edu;
Lindsay.Eichman@ucdenver.edu; Jason.Tregel-las@ucdenver.edu
RI Tregellas, Jason/J-3637-2015;
OI Rojas, Don/0000-0001-6560-9616; Smucny, Jason/0000-0001-5656-7987
FU VA Biomedical Laboratory and Clinical Science Research and Development
Service; National Association for Research in Schizophrenia and
Affective Disorders (NARSAD); Blowitz-Ridgeway Foundation
FX The authors thank Debra Singel for help with fMRI data acquisition. The
research was supported by the VA Biomedical Laboratory and Clinical
Science Research and Development Service, the National Association for
Research in Schizophrenia and Affective Disorders (NARSAD) and the
Blowitz-Ridgeway Foundation.
NR 49
TC 8
Z9 8
U1 2
U2 38
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0278-2626
J9 BRAIN COGNITION
JI Brain Cogn.
PD MAR
PY 2013
VL 81
IS 2
BP 263
EP 270
DI 10.1016/j.bandc.2012.11.008
PG 8
WC Neurosciences; Psychology, Experimental
SC Neurosciences & Neurology; Psychology
GA 091RN
UT WOS:000315067600012
PM 23291265
ER
PT J
AU Liu, YH
Wang, AL
Marchese, AD
Kacmarek, RM
Jiang, Y
AF Liu, Y. H.
Wang, A. L.
Marchese, A. D.
Kacmarek, R. M.
Jiang, Y.
TI Jet or intensive care unit ventilator during simulated percutaneous
transtracheal ventilation: a lung model study
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Article
DE airway obstruction; equipment; ventilators; ventilation; transtracheal
ID DIFFICULT-AIRWAY; MAJOR COMPLICATIONS; NATIONAL-SURVEY; MANAGEMENT;
ANESTHESIA; AVAILABILITY; UK; ANESTHETISTS; INTUBATION; GUIDELINES
AB Percutaneous transtracheal ventilation (PTV) via a jet ventilator (PTJV) is considered a rescue technique in difficult airway management. However, whether a conventional ventilator can generate adequate ventilation via PTV is not known. Our goal was to evaluate the tidal volume (V-T) generated by a conventional ventilator during simulated PTV compared with PTJV in a lung model.
A lung model simulating an adult lung was used. A catheter was inserted throughthe artificial trachea and connected to either a jet ventilator or a conventional ventilator. The direction of catheter insertion was perpendicular to the trachea, pointing towards the lung and away from the lung. The jet ventilator was operated at 344.7 kPa. The conventional ventilator was operated in the pressure mode at peak inspiratory pressures of 4090 cm H2O.
The jet ventilator generated larger V-T [817 (336) ml] when the catheter was pointing towards the lung than when pointing away from the lung or perpendicular to the trachea [121 (41) and 69 (24) ml, respectively, P0.01]. With the conventional ventilator, changes in V-T at different direction of catheter insertion were much less [222 (81) ml catheter pointing towards the lung, 229 (121) ml perpendicular to the trachea, and 187 (97) ml away from the lung].
Our result demonstrated that PTJV was effective only when the catheter was pointing towards the lung and requires high operating pressure. A conventional ventilator can generate reasonable minute ventilation through the transtracheal catheter less dependent on directions of catheter insertion and should be considered during emergent PTV.
C1 [Liu, Y. H.] Chinese Peoples Liberat Army Gen Hosp, Anaesthesia & Operat Ctr, Beijing, Peoples R China.
[Liu, Y. H.; Kacmarek, R. M.; Jiang, Y.] Massachusetts Gen Hosp, Dept Anaesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Marchese, A. D.; Kacmarek, R. M.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA.
[Wang, A. L.] Jining Med Coll, Dept Surg, Jining, Peoples R China.
RP Jiang, Y (reprint author), Massachusetts Gen Hosp, Dept Anaesthesia Crit Care & Pain Med, 55 Fruit St,Jackson 422, Boston, MA 02114 USA.
EM yjiang@partners.org
FU Department of Anaesthesia, Critical Care, and Pain Medicine; Department
of Respiratory Care, Massachusetts General Hospital, Boston, MA, USA
FX This project was funded by the Department of Anaesthesia, Critical Care,
and Pain Medicine and the Department of Respiratory Care, Massachusetts
General Hospital, Boston, MA, USA.
NR 19
TC 2
Z9 2
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-0912
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD MAR
PY 2013
VL 110
IS 3
BP 456
EP 462
DI 10.1093/bja/aes417
PG 7
WC Anesthesiology
SC Anesthesiology
GA 092LR
UT WOS:000315123800019
PM 23171722
ER
PT J
AU Leenders, M
Bhattacharjee, S
Vineis, P
Stevens, V
Bueno-de-Mesquita, H
Shu, XO
Amundadottir, L
Gross, M
Tobias, GS
Wactawski-Wende, J
Arslan, AA
Duell, EJ
Fuchs, CS
Gallinger, S
Hartge, P
Hoover, RN
Holly, EA
Jacobs, EJ
Klein, AP
Kooperberg, C
LaCroix, A
Li, DH
Mandelson, MT
Olson, SH
Petersen, G
Risch, HA
Yu, K
Wolpin, BM
Zheng, W
Agalliu, I
Albanes, D
Boutron-Ruault, MC
Bracci, PM
Buring, JE
Canzian, F
Chang, K
Chanock, SJ
Cotterchio, M
Gaziano, JM
Giovanucci, EL
Goggins, M
Hallmans, G
Hankinson, SE
Hoffman-Bolton, JA
Hunter, DJ
Hutchinson, A
Jacobs, KB
Jenab, M
Khaw, KT
Kraft, P
Krogh, V
Kurtz, RC
McWilliams, RR
Mendelsohn, JB
Patel, AV
Rabe, KG
Riboli, E
Tjonneland, A
Trichopoulos, D
Virtamo, J
Visvanathan, K
Elena, JW
Yu, H
Zeleniuch-Jacquotte, A
Stolzenberg-Solomon, RZ
AF Leenders, Max
Bhattacharjee, Samsiddhi
Vineis, Paolo
Stevens, Victoria
Bueno-de-Mesquita, H. Bas
Shu, Xiao-Ou
Amundadottir, Laufey
Gross, Myron
Tobias, Geoffrey S.
Wactawski-Wende, Jean
Arslan, Alan A.
Duell, Eric J.
Fuchs, Charles S.
Gallinger, Steven
Hartge, Patricia
Hoover, Robert N.
Holly, Elizabeth A.
Jacobs, Eric J.
Klein, Alison P.
Kooperberg, Charles
LaCroix, Andrea
Li, Donghui
Mandelson, Margaret T.
Olson, Sara H.
Petersen, Gloria
Risch, Harvey A.
Yu, Kai
Wolpin, Brian M.
Zheng, Wei
Agalliu, Ilir
Albanes, Demetrius
Boutron-Ruault, Marie-Christine
Bracci, Paige M.
Buring, Julie E.
Canzian, Federico
Chang, Kenneth
Chanock, Stephen J.
Cotterchio, Michelle
Gaziano, J. Michael
Giovanucci, Edward L.
Goggins, Michael
Hallmans, Goeran
Hankinson, Susan E.
Hoffman-Bolton, Judith A.
Hunter, David J.
Hutchinson, Amy
Jacobs, Kevin B.
Jenab, Mazda
Khaw, Kay-Tee
Kraft, Peter
Krogh, Vittorio
Kurtz, Robert C.
McWilliams, Robert R.
Mendelsohn, Julie B.
Patel, Alpa V.
Rabe, Kari G.
Riboli, Elio
Tjonneland, Anne
Trichopoulos, Dimitrios
Virtamo, Jarmo
Visvanathan, Kala
Elena, Joanne W.
Yu, Herbert
Zeleniuch-Jacquotte, Anne
Stolzenberg-Solomon, Rachael Z.
TI Polymorphisms in genes related to one-carbon metabolism are not related
to pancreatic cancer in PanScan and PanC4
SO CANCER CAUSES & CONTROL
LA English
DT Article
DE Pancreatic cancer; One-carbon metabolism; Polymorphisms; Biomarkers;
Epidemiology
ID GENOME-WIDE ASSOCIATION; FOLATE INTAKE; DNA METHYLATION; RISK;
METAANALYSIS; DIETARY; HOMOCYSTEINE; CARCINOGENESIS; SUSCEPTIBILITY;
PROSTATE
AB The evidence of a relation between folate intake and one-carbon metabolism (OCM) with pancreatic cancer (PanCa) is inconsistent. In this study, the association between genes and single-nucleotide polymorphisms (SNPs) related to OCM and PanCa was assessed.
Using biochemical knowledge of the OCM pathway, we identified thirty-seven genes and 834 SNPs to examine in association with PanCa. Our study included 1,408 cases and 1,463 controls nested within twelve cohorts (PanScan). The ten SNPs and five genes with lowest p values (< 0.02) were followed up in 2,323 cases and 2,340 controls from eight case-control studies (PanC4) that participated in PanScan2. The correlation of SNPs with metabolite levels was assessed for 649 controls from the European Prospective Investigation into Cancer and Nutrition.
When both stages were combined, we observed suggestive associations with PanCa for rs10887710 (MAT1A) (OR 1.13, 95 %CI 1.04-1.23), rs1552462 (SYT9) (OR 1.27, 95 %CI 1.02-1.59), and rs7074891 (CUBN) (OR 1.91, 95 %CI 1.12-3.26). After correcting for multiple comparisons, no significant associations were observed in either the first or second stage. The three suggested SNPs showed no correlations with one-carbon biomarkers.
This is the largest genetic study to date to examine the relation between germline variations in OCM-related genes polymorphisms and the risk of PanCa. Suggestive evidence for an association between polymorphisms and PanCa was observed among the cohort-nested studies, but this did not replicate in the case-control studies. Our results do not strongly support the hypothesis that genes related to OCM play a role in pancreatic carcinogenesis.
C1 [Leenders, Max; Vineis, Paolo; Riboli, Elio] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England.
[Leenders, Max; Bueno-de-Mesquita, H. Bas] Univ Med Ctr Utrecht, Dept Gastroenterol & Hepatol, NL-3508 GA Utrecht, Netherlands.
[Bhattacharjee, Samsiddhi; Amundadottir, Laufey; Tobias, Geoffrey S.; Hartge, Patricia; Hoover, Robert N.; Yu, Kai; Albanes, Demetrius; Chanock, Stephen J.; Hutchinson, Amy; Jacobs, Kevin B.; Mendelsohn, Julie B.; Stolzenberg-Solomon, Rachael Z.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Vineis, Paolo] HuGeF Fdn, Turin, Italy.
[Stevens, Victoria; LaCroix, Andrea; Patel, Alpa V.] Amer Canc Soc, Dept Epidemiol, Atlanta, GA 30329 USA.
[Bueno-de-Mesquita, H. Bas] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands.
[Shu, Xiao-Ou; Zheng, Wei] Vanderbilt Univ, Dept Med, Vanderbilt Epidemiol Ctr, Div Epidemiol,Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Amundadottir, Laufey; Chanock, Stephen J.] NCI, Lab Translat Genom, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Gross, Myron] Univ Minnesota, Sch Med, Dept Lab Med Pathol, Minneapolis, MN 55455 USA.
[Wactawski-Wende, Jean] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA.
[Arslan, Alan A.] NYU, Dept Obstet & Gynecol, Sch Med, New York, NY 10016 USA.
[Arslan, Alan A.; Zeleniuch-Jacquotte, Anne] NYU, Dept Environm Med, Sch Med, New York, NY 10016 USA.
[Arslan, Alan A.; Zeleniuch-Jacquotte, Anne] NYU, Inst Canc, New York, NY USA.
[Duell, Eric J.] Catalan Inst Oncol ICO IDIBELL, Barcelona, Spain.
[Fuchs, Charles S.; Wolpin, Brian M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Fuchs, Charles S.; Wolpin, Brian M.; Giovanucci, Edward L.; Hankinson, Susan E.; Hunter, David J.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
[Fuchs, Charles S.; Wolpin, Brian M.; Buring, Julie E.; Gaziano, J. Michael; Giovanucci, Edward L.; Hankinson, Susan E.; Hunter, David J.] Harvard Univ, Sch Med, Boston, MA USA.
[Gallinger, Steven] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
[Holly, Elizabeth A.; Bracci, Paige M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Jacobs, Eric J.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.
[Klein, Alison P.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
[Klein, Alison P.] Johns Hopkins Med Inst, Dept Epidemiol, Bloomberg Sch Publ Heath, Sol Goldman Pancreat Res Ctr, Baltimore, MD 21205 USA.
[Kooperberg, Charles; Mandelson, Margaret T.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
[Li, Donghui] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.
[Mandelson, Margaret T.] Grp Hlth Ctr Hlth Studies, Seattle, WA USA.
[Olson, Sara H.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
[Petersen, Gloria; Rabe, Kari G.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
[Risch, Harvey A.; Yu, Kai] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
[Agalliu, Ilir] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Boutron-Ruault, Marie-Christine] Univ Paris 11, Inst Gustave Roussy, INSERM, Villejuif, France.
[Buring, Julie E.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.
[Buring, Julie E.] Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA 02115 USA.
[Buring, Julie E.] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA.
[Canzian, Federico] German Canc Res Ctr DFKZ, Div Canc Epidemiol, Heidelberg, Germany.
[Chang, Kenneth] Univ Calif Irvine, Irvine Med Ctr, Comprehens Digest Dis Ctr, Orange, CA 92668 USA.
[Cotterchio, Michelle] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
[Cotterchio, Michelle] Canc Care Ontario, Prevent & Canc Control, Toronto, ON, Canada.
[Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Phys Hlth Study, Div Aging, Boston, MA 02115 USA.
[Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Phys Hlth Study, Div Cardiovasc Med, Boston, MA 02115 USA.
[Gaziano, J. Michael] Brigham & Womens Hosp, Dept Med, Phys Hlth Study, Div Prevent Med, Boston, MA 02115 USA.
[Gaziano, J. Michael] Vet Affairs Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA.
[Giovanucci, Edward L.; Hankinson, Susan E.; Hunter, David J.; Kraft, Peter; Trichopoulos, Dimitrios] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Giovanucci, Edward L.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Goggins, Michael] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
[Goggins, Michael] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
[Goggins, Michael] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Hallmans, Goeran] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden.
[Hoffman-Bolton, Judith A.; Visvanathan, Kala] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Hutchinson, Amy; Jacobs, Kevin B.] NCI, Core Genotyping Facil, Adv Technol Program, SAIC Frederick Inc, Frederick, MD 21701 USA.
[Jacobs, Kevin B.] Bioinformed Consulting Serv, Gaithersburg, MD USA.
[Jenab, Mazda] WHO, IARC, Lyon, France.
[Khaw, Kay-Tee] Univ Cambridge, Addenbrookes Hosp, Dept Publ Hlth & Primary Care, Cambridge CB2 2QQ, England.
[Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Krogh, Vittorio] Ist Nazl Tumori, Fdn Ist Recovero & Cura Carattere Sci IRCCS, Nutr Epidemiol Unit, I-20133 Milan, Italy.
[Kurtz, Robert C.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
[McWilliams, Robert R.] Mayo Clin, Div Med Oncol, Rochester, MN USA.
[Tjonneland, Anne] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark.
[Trichopoulos, Dimitrios] Acad Athens, Bur Epidemiol Res, Athens, Greece.
[Virtamo, Jarmo] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland.
[Elena, Joanne W.] NCI, Div Canc Prevent & Populat Control, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA.
RP Leenders, M (reprint author), Univ Med Ctr Utrecht, Dept Gastroenterol & Hepatol, F02-618,Postal Box 85500, NL-3508 GA Utrecht, Netherlands.
EM M.Leenders-6@umcutrecht.nl
RI Boutron Ruault, Marie-Christine/G-3705-2013; Gallinger,
Steven/E-4575-2013; Boutron, Marie-Christine/K-8168-2013; Albanes,
Demetrius/B-9749-2015; Boutron-Ruault, Marie-Christine/H-3936-2014;
Krogh, Vittorio/K-2628-2016; Amundadottir, Laufey/L-7656-2016; Tobias,
Geoffrey/M-4135-2016;
OI Zeleniuch-Jacquotte, Anne/0000-0001-9350-1303; Krogh,
Vittorio/0000-0003-0122-8624; Amundadottir, Laufey/0000-0003-1859-8971;
Tobias, Geoffrey/0000-0002-2878-8253; Duell, Eric J/0000-0001-5256-0163
FU Intramural Research Program of the National Institutes of Health,
Division of Cancer Epidemiology and Genetics, National Cancer Institute,
National Institutes of Health, Department of Health and Human Services;
World Cancer Research Fund [2008/51]
FX This research was supported by the Intramural Research Program of the
National Institutes of Health, Division of Cancer Epidemiology and
Genetics, National Cancer Institute, National Institutes of Health,
Department of Health and Human Services. This study has been funded by
the World Cancer Research Fund (Grant No. 2008/51 to PV). For full
acknowledgments, please see electronic supplementary material.
NR 32
TC 2
Z9 2
U1 0
U2 14
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-5243
J9 CANCER CAUSE CONTROL
JI Cancer Causes Control
PD MAR
PY 2013
VL 24
IS 3
BP 595
EP 602
DI 10.1007/s10552-012-0138-0
PG 8
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA 090KC
UT WOS:000314976900019
PM 23334854
ER
PT J
AU Hoang, MT
Mock, JR
Hoang, MP
Cohen, JB
Le, LQ
AF Hoang, M. T.
Mock, J. R.
Hoang, M. P.
Cohen, J. B.
Le, L. Q.
TI An exophytic, bleeding nodule on the left malar region Sebaceous
carcinoma (SC)
SO CLINICAL AND EXPERIMENTAL DERMATOLOGY
LA English
DT Editorial Material
ID MUIR-TORRE-SYNDROME; TUMORS
C1 [Hoang, M. T.; Mock, J. R.; Cohen, J. B.; Le, L. Q.] Univ Texas SW Med Ctr Dallas, Dept Dermatol, Dallas, TX 75390 USA.
[Hoang, M. P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Hoang, M. P.] Harvard Univ, Sch Med, Boston, MA USA.
RP Le, LQ (reprint author), Univ Texas SW Med Ctr Dallas, Dept Dermatol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM lu.le@utsouthwestern.edu
NR 6
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0307-6938
J9 CLIN EXP DERMATOL
JI Clin. Exp. Dermatol.
PD MAR
PY 2013
VL 38
IS 2
BP 217
EP 218
DI 10.1111/j.1365-2230.2012.04400.x
PG 2
WC Dermatology
SC Dermatology
GA 090JR
UT WOS:000314975800029
PM 22681240
ER
PT J
AU Atherton, S
Holmquist, J
AF Atherton, S.
Holmquist, J.
TI Transitions in Care: Clinical Nurse Specialist Developed Patient Safety
Measures for Prevention of Healthcare-Associated Infections
SO CLINICAL NURSE SPECIALIST
LA English
DT Meeting Abstract
C1 [Atherton, S.; Holmquist, J.] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0887-6274
J9 CLIN NURSE SPEC
JI Clin. Nurse Spec.
PD MAR-APR
PY 2013
VL 27
IS 2
BP E60
EP E60
PG 1
WC Nursing
SC Nursing
GA 088YK
UT WOS:000314873600154
ER
PT J
AU David, CM
Shaffer, B
Zellars, R
AF David, C. M.
Shaffer, B.
Zellars, R.
TI Clinical Nurse Specialist Led Fall Program: Improving Performance
Through Environment Sweeps
SO CLINICAL NURSE SPECIALIST
LA English
DT Meeting Abstract
C1 [David, C. M.; Shaffer, B.; Zellars, R.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0887-6274
J9 CLIN NURSE SPEC
JI Clin. Nurse Spec.
PD MAR-APR
PY 2013
VL 27
IS 2
BP E12
EP E13
PG 2
WC Nursing
SC Nursing
GA 088YK
UT WOS:000314873600031
ER
PT J
AU Loudon, T
AF Loudon, T.
TI Identification of Clinical Deterioration: Clinical Nurse Specialist
Implementation of Modified Early Warning System (MEWS) to Support
Transition to Higher Level of Care in the Acute Care Setting
SO CLINICAL NURSE SPECIALIST
LA English
DT Meeting Abstract
C1 [Loudon, T.] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0887-6274
J9 CLIN NURSE SPEC
JI Clin. Nurse Spec.
PD MAR-APR
PY 2013
VL 27
IS 2
BP E61
EP E61
PG 1
WC Nursing
SC Nursing
GA 088YK
UT WOS:000314873600156
ER
PT J
AU Richardson, J
AF Richardson, J.
TI The Inpatient to Outpatient Transition: Clinical Nurse Specialist
Facilitating Evidence-Based Practice in Primary Care
SO CLINICAL NURSE SPECIALIST
LA English
DT Meeting Abstract
C1 [Richardson, J.] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0887-6274
J9 CLIN NURSE SPEC
JI Clin. Nurse Spec.
PD MAR-APR
PY 2013
VL 27
IS 2
BP E60
EP E61
PG 2
WC Nursing
SC Nursing
GA 088YK
UT WOS:000314873600155
ER
PT J
AU Richardson, J
Atherton, S
Holmquist, J
Loudon, T
AF Richardson, J.
Atherton, S.
Holmquist, J.
Loudon, T.
TI The Value of the Clinical Nurse Specialist: Improving Patient Outcomes
Across Transitions in Care
SO CLINICAL NURSE SPECIALIST
LA English
DT Meeting Abstract
C1 [Richardson, J.; Atherton, S.; Holmquist, J.; Loudon, T.] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0887-6274
J9 CLIN NURSE SPEC
JI Clin. Nurse Spec.
PD MAR-APR
PY 2013
VL 27
IS 2
BP E60
EP E60
PG 1
WC Nursing
SC Nursing
GA 088YK
UT WOS:000314873600153
ER
PT J
AU Ballen, KK
Barker, JN
AF Ballen, Karen K.
Barker, Juliet N.
TI Has umbilical cord blood transplantation for AML become mainstream?
SO CURRENT OPINION IN HEMATOLOGY
LA English
DT Review
DE acute myeloid leukemia; allogeneic transplantation; umbilical cord blood
ID STEM-CELL TRANSPLANTATION; ANTI-HLA ANTIBODIES; MYELOABLATIVE
CONDITIONING REGIMEN; UNRELATED DONORS; ACUTE-LEUKEMIA; BONE-MARROW;
HEMATOLOGICAL MALIGNANCIES; HEMATOPOIETIC ENGRAFTMENT; RETROSPECTIVE
ANALYSIS; ADULT RECIPIENTS
AB Purpose of review
We discuss outcomes after umbilical cord blood (UCB) transplantation (UCBT) for patients with acute myeloid leukemia (AML) and compare these outcomes to results after transplantation of other allogeneic graft sources.
Recent findings
Survival after UCBT has improved considerably over the past 10 years. Multiple retrospective studies using either myeloablative or reduced intensity conditioning have shown disease-free survival after UCBT that is comparable to that of matched related or unrelated donors. Improved unit selection, conditioning, graft manipulation, and supportive care are all emerging strategies to further improve outcomes, although disease status and center expertise remain key components of successful UCBT outcome.
Summary
UCBT should be considered in all high-risk AML patients in whom allogeneic stem cell transplantation is indicated but who lack a matched related or unrelated donor. UCBT can thereby now be thought of as a 'mainstream' treatment of high-risk AML.
C1 [Ballen, Karen K.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Barker, Juliet N.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
RP Ballen, KK (reprint author), Massachusetts Gen Hosp, Ctr Canc, Div Hematol Oncol, 0 Emerson,Suite 118, Boston, MA 02114 USA.
EM kballen@partners.org
FU NCI NIH HHS [P30 CA008748]
NR 39
TC 6
Z9 6
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1065-6251
J9 CURR OPIN HEMATOL
JI Curr. Opin. Hematol.
PD MAR
PY 2013
VL 20
IS 2
BP 144
EP 149
DI 10.1097/MOH.0b013e32835dd936
PG 6
WC Hematology
SC Hematology
GA 088OI
UT WOS:000314844100010
PM 23314845
ER
PT J
AU Abel, GA
Koreth, J
AF Abel, Gregory A.
Koreth, John
TI Optimal positioning of hematopoietic stem cell transplantation for older
patients with myelodysplastic syndromes
SO CURRENT OPINION IN HEMATOLOGY
LA English
DT Review
DE allogeneic transplantation; hypomethylating agent; myelodysplasia;
quality of life; reduced-intensity conditioning
ID ACUTE MYELOID-LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; QUALITY-OF-LIFE;
PROGNOSTIC SCORING SYSTEM; BONE-MARROW-TRANSPLANTATION; 1ST COMPLETE
REMISSION; COMORBIDITY INDEX; UNRELATED DONORS; PHASE-III;
MYELOPROLIFERATIVE DISORDERS
AB Purpose of review
This review examines reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for older patients (age >60 years) with myelodysplastic syndromes (MDS), focusing on how to choose candidates for HSCT as well as data on the comparative effectiveness of RIC HSCT versus other treatment approaches.
Recent findings
For some older patients with MDS, there may be a survival advantage for RIC HSCT compared with nontransplantation approaches. Health service approaches suggest that optimal treatment choice varies with MDS risk. For those with low/intermediate-1 International Prognostic Scoring System (IPSS) risk, non-HSCT treatments may be preferred, but for intermediate-2/high IPSS patients, RIC HSCT may be better, even after adjusting for quality of life (QoL).
Summary
The optimal positioning of HSCT for older patients with MDS is evolving. Available data suggest that for older patients with higher risk MDS, if their QoL is affected and they are medically fit, RIC HSCT may lead to more favourable outcomes. Prospective trials in older patients with MDS are necessary to confirm the putative benefit of RIC HSCT.
C1 [Abel, Gregory A.; Koreth, John] Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02215 USA.
[Abel, Gregory A.] Dana Farber Canc Inst, Dept Med Oncol, Div Populat Sci, Boston, MA 02215 USA.
RP Koreth, J (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Oncol, D1B05,450 Brookline Ave, Boston, MA 02215 USA.
EM john_koreth@dfci.harvard.edu
FU Leukemia and Lymphoma Society
FX We thank Drs. Joseph Antin, Corey Cutler and David Steensma for their
helpful comments and suggestions on this manuscript. This work was
partially supported by a scholar in clinical research award from the
Leukemia and Lymphoma Society.
NR 52
TC 7
Z9 8
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1065-6251
EI 1531-7048
J9 CURR OPIN HEMATOL
JI Curr. Opin. Hematol.
PD MAR
PY 2013
VL 20
IS 2
BP 150
EP 156
DI 10.1097/MOH.0b013e32835d8e8e
PG 7
WC Hematology
SC Hematology
GA 088OI
UT WOS:000314844100011
PM 23298879
ER
PT J
AU Moatamed, NA
Apple, SK
Bennett, CJ
Aronson, WJ
Klisak, I
Shirley, BJ
Moatamed, F
AF Moatamed, Neda A.
Apple, Sophia K.
Bennett, Carol J.
Aronson, William J.
Klisak, Ivana
Shirley, Bobbi-Jo
Moatamed, Farhad
TI Exclusion of the uniform tetraploid cells significantly improves
specificity of the urine fish assay
SO DIAGNOSTIC CYTOPATHOLOGY
LA English
DT Article
DE voided urine; bladder wash; FISH; sensitivity; specificity
ID IN-SITU HYBRIDIZATION; SUPERFICIAL BLADDER-CANCER; BTA TRAK ASSAY;
VOIDED URINE; UROTHELIAL CARCINOMA; FLOW-CYTOMETRY; FOLLOW-UP;
PAPANICOLAOU EXAMINATION; INTERPHASE CYTOGENETICS; DNA-PLOIDY
AB The urine fluorescence in situ hybridization (FISH) assay (UroVysion), with the current scoring criteria, has a higher sensitivity than routine cytopathology but a lower specificity. Among 215 urine FISH tests we performed, 45 had associated histopathology and clinical follow up. In this study, a cell with four signals for each probe was classified as a uniform tetraploid cell (UTC); a presumed reparative cell which is currently classified as an abnormal cell in the FDA approved assay. By using the existing criteria, the tests were scored as positive or negative before and after exclusion of the UTCs. Before the exclusion, 24 positive, 13 negative, seven false positive, and one false negative result were obtained with 96% sensitivity and 65% specificity. After the exclusion, the results changed to 22 positive, 19 negative, one false positive, and three false negatives resulting in a 88% sensitivity of 88% and a 95% specificity; a significant improvement in the specificity. We conclude that exclusion of the UTCs as abnormal cells would result in a more solid performance of the FISH assay. Diagn. Cytopathol. 2013. (c) 2011 Wiley Periodicals, Inc.
C1 [Moatamed, Neda A.; Apple, Sophia K.; Moatamed, Farhad] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Klisak, Ivana; Shirley, Bobbi-Jo; Moatamed, Farhad] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Bennett, Carol J.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA.
RP Moatamed, NA (reprint author), Dept Pathol & Lab Med, 10833 Le Conte Ave,BOX 951732,1P-241 CHS, Los Angeles, CA 90095 USA.
EM nmoatamed@mednet.ucla.edu
FU Department of Veterans Affairs, as part of the Laboratory Quality
Assurance program
FX Contract grant sponsor: Department of Veterans Affairs, as part of the
Laboratory Quality Assurance program.
NR 49
TC 4
Z9 4
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 8755-1039
J9 DIAGN CYTOPATHOL
JI Diagn. Cytopathol.
PD MAR
PY 2013
VL 41
IS 3
BP 218
EP 225
DI 10.1002/dc.21831
PG 8
WC Medical Laboratory Technology; Pathology
SC Medical Laboratory Technology; Pathology
GA 092EH
UT WOS:000315101500006
PM 21987521
ER
PT J
AU Moussa, I
Hermann, A
Messenger, JC
Dehmer, GJ
Weaver, WD
Rumsfeld, JS
Masoudi, FA
AF Moussa, Issam
Hermann, Anthony
Messenger, John C.
Dehmer, Gregory J.
Weaver, W. Douglas
Rumsfeld, John S.
Masoudi, Frederick A.
TI The NCDR CathPCI Registry: a US national perspective on care and
outcomes for percutaneous coronary intervention
SO HEART
LA English
DT Article
ID CARDIOVASCULAR DATA REGISTRY; MORTALITY RISK PREDICTION; STRATEGIES
AB Aims: The NCDR CathPCI Registry collects detailed clinical, process-of-care and outcomes data for patients undergoing coronary angiography and percutaneous coronary intervention (PCI) in the USA. The registry contributes to quality of care by providing data feedback on a wide range of performance metrics to participating centres and by facilitating local and national quality improvement efforts.
Interventions: No treatments are mandated, participating centres receive routine quality-of-care and outcomes performance feedback reports and access to a quality dashboard for personalized performance reports.
Population: Patients undergoing cardiac catheterization and PCI are retrospectively identified. No informed consent is required, as data are anonymised. From inception in 1998, more than 12 million records have been submitted from 1577 participating US centres.
Baseline data: Approximately 250 fields encompassing patient demographics, medical history and risk factors, hospital presentation, initial cardiac status, procedural details, medications, laboratory values, and in-hospital outcomes. Linkages with outside sources of data have permitted longitudinal outcomes assessment in some cases. Centre personnel enter the data into the registry, in some cases facilitated by software vendors. There are non-financial incentives for centre participation. Data completeness is noteworthy with most fields missing at rates less than 5%. A comprehensive data quality program is employed to enhance data validity.
Endpoints: Main outcome measures include quality process metrics and in-hospital patient outcomes. Data are available for research by application to: http://www.ncdr.com
C1 [Moussa, Issam] Mayo Clin, Div Cardiol, Jacksonville, FL 32224 USA.
[Hermann, Anthony] Amer Coll Cardiol Fdn, Washington, DC USA.
[Messenger, John C.; Masoudi, Frederick A.] Univ Colorado, Div Cardiol, Cardiac & Vasc Ctr, Aurora, CO 80045 USA.
[Dehmer, Gregory J.] Scott & White Healthcare, Div Cardiol, Coll Med, Texas A&M Hlth Sci Ctr, Temple, TX USA.
[Weaver, W. Douglas] Henry Ford Hosp, Div Cardiol, Detroit, MI 48202 USA.
[Rumsfeld, John S.] Denver VA Med Ctr, Cardiol Sect, Denver, CO USA.
RP Masoudi, FA (reprint author), Univ Colorado, Div Cardiol, Anschutz Med Campus,Box B132,12401 17th Ave, Aurora, CO 80045 USA.
EM fred.masoudi@ucdenver.edu
NR 12
TC 25
Z9 25
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1355-6037
J9 HEART
JI Heart
PD MAR
PY 2013
VL 99
IS 5
BP 297
EP 303
DI 10.1136/heartjnl-2012-303379
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 091EX
UT WOS:000315033300004
PM 23322530
ER
PT J
AU Schwacke, JH
Spainhour, JCG
Ierardi, JL
Chaves, JM
Arthur, JM
Janech, MG
Velez, JCQ
AF Schwacke, John H.
Spainhour, John Christian G.
Ierardi, Jessalyn L.
Chaves, Jose M.
Arthur, John M.
Janech, Michael G.
Velez, Juan Carlos Q.
TI Network Modeling Reveals Steps in Angiotensin Peptide Processing
SO HYPERTENSION
LA English
DT Article
DE mass spectrometry; proteomics; renin-angiotensin system; systems biology
ID CONVERTING ENZYME-INHIBITION; AMINOPEPTIDASE-A; DIABETIC-NEPHROPATHY;
BAYESIAN NETWORKS; PARTIAL ESCAPE; RAT; RECEPTOR; SYSTEM; KIDNEY; ACE
AB New insights into the intrarenal renin-angiotensin (Ang) system have modified our traditional view of the system. However, many finer details of this network of peptides and associated peptidases remain unclear. We hypothesized that a computational systems biology approach, applied to peptidomic data, could help to unravel the network of enzymatic conversions. We built and refined a Bayesian network model and a dynamic systems model starting from a skeleton created with established elements of the renin-Ang system and further developed it with archived matrix-assisted laser desorption ionization-time of flight mass spectra from experiments conducted in mouse podocytes exposed to exogenous Ang substrates. The model-building process suggested previously unrecognized steps, 3 of which were confirmed in vitro, including the conversion of Ang(2-10) to Ang(2-7) by neprilysin, Ang(1-9) to Ang(2-9), and Ang(1-7) to Ang(2-7) by aminopeptidase A. These data suggest a wider role of neprilysin and aminopeptidase A in glomerular formation of bioactive Ang peptides and shunting their formation. Other steps were also suggested by the model, and supporting evidence for those steps was evaluated using model-comparison methods. Our results demonstrate that systems biology methods applied to peptidomic data are effective in identifying novel steps in the Ang peptide processing network, and these findings improve our understanding of the glomerular renin-Ang system. (Hypertension. 2013;61:690-700.). circle Online Data Supplement
C1 [Schwacke, John H.; Spainhour, John Christian G.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
[Ierardi, Jessalyn L.; Chaves, Jose M.; Arthur, John M.; Janech, Michael G.; Velez, Juan Carlos Q.] Med Univ S Carolina, Dept Med, Div Nephrol, Charleston, SC 29425 USA.
[Arthur, John M.; Janech, Michael G.; Velez, Juan Carlos Q.] Ralph H Johnson Vet Affairs Med Ctr, Med Serv, Charleston, SC USA.
[Arthur, John M.; Janech, Michael G.; Velez, Juan Carlos Q.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA.
RP Velez, JCQ (reprint author), Med Univ S Carolina, Div Nephrol, Clin Sci Bldg,829 96 Jonathan Lucas St, Charleston, SC 29425 USA.
EM velezj@musc.edu
RI Velez, Juan Carlos/N-3782-2016;
OI Janech, Michael/0000-0002-3202-4811
FU National Institute of General Medicine [5T32GM74934-8]; Department of
Veterans' Affairs [CDA-2]; Nephcure Foundation; National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) of the National
Institutes of Health (NIH) [DK080944-04]; Dialysis Clinics Incorporated;
NIDDK of the NIH [1R01DK080234]
FX J.C.G. Spainhour was supported under a training grant from the National
Institute of General Medicine (5T32GM74934-8). M. G. Janech was
supported by Career Development Awards (CDA) through the Department of
Veterans' Affairs (CDA-2) and the Nephcure Foundation. J.C.Q. Velez is
supported by a grant from the National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK) of the National Institutes of
Health (NIH) (DK080944-04) and Dialysis Clinics Incorporated. J.H.
Schwacke was supported, in part, by a grant from NIDDK of the NIH
(1R01DK080234).
NR 69
TC 12
Z9 12
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD MAR
PY 2013
VL 61
IS 3
BP 690
EP +
DI 10.1161/HYPERTENSIONAHA.111.00318
PG 18
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 089DC
UT WOS:000314888600023
PM 23283355
ER
PT J
AU Gaur, AH
Bundy, DG
Gao, C
Werner, EJ
Billett, AL
Hord, JD
Siegel, JD
Dickens, D
Winkle, C
Miller, MR
AF Gaur, Aditya H.
Bundy, David G.
Gao, Cuilan
Werner, Eric J.
Billett, Amy L.
Hord, Jeff D.
Siegel, Jane D.
Dickens, David
Winkle, Cindi
Miller, Marlene R.
CA Children's Hosp Assoc Hematology O
TI Surveillance of Hospital-Acquired Central Line-Associated Bloodstream
Infections in Pediatric Hematology-Oncology Patients: Lessons Learned,
Challenges Ahead
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Article
ID INTENSIVE-CARE-UNIT; CHILDREN; CANCER
AB Across 36 US pediatric oncology centers, 576 central line-associated bloodstream infections (CLABSIs) were reported over a 21-month period. Most infections occurred in those with leukemia and/or profound neutropenia. The contribution of viridans streptococci infections was striking. Study findings depict the contemporary epidemiology of CLABSIs in hospitalized pediatric cancer patients. Infect Control Hosp Epidemiol 2013;34(3):316-320
C1 [Gaur, Aditya H.; Gao, Cuilan] St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
[Bundy, David G.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Werner, Eric J.] Hosp Kings Daughters, Norfolk, VA USA.
[Billett, Amy L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Billett, Amy L.] Boston Childrens Hosp, Boston, MA USA.
[Hord, Jeff D.] Akron Childrens Hosp, Akron, OH USA.
[Siegel, Jane D.] Childrens Med Ctr, Dallas, TX 75235 USA.
[Dickens, David] Helen DeVos Childrens Hosp, Grand Rapids, MI USA.
[Winkle, Cindi] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Miller, Marlene R.] Childrens Hosp Assoc, Alexandria, VA USA.
RP Gaur, AH (reprint author), St Jude Childrens Res Hosp, Dept Infect Dis, MS 600,262 Danny Thomas Pl, Memphis, TN 38105 USA.
EM aditya.gaur@stjude.org
OI Dickens, David/0000-0001-8821-6022
FU Agency for Healthcare Research and Quality [R18HS019590]; American
Lebanese Syrian Associated Charities
FX This work was supported by the Agency for Healthcare Research and
Quality (R18HS019590) and the American Lebanese Syrian Associated
Charities. The funding sources had no role or input into the design or
conduct of the study; collection, management, analysis, or
interpretation of the data; or preparation, review, or approval of the
manuscript.
NR 20
TC 10
Z9 10
U1 0
U2 9
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD MAR
PY 2013
VL 34
IS 3
BP 316
EP 320
DI 10.1086/669513
PG 5
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 088CG
UT WOS:000314810800016
PM 23388370
ER
PT J
AU Semaan, A
Mert, I
Munkarah, AR
Bandyopadhyay, S
Mahdi, HS
Winer, IS
Nucci, MR
Hussein, Y
Quershi, F
Hayek, K
Tabassum, F
Alosh, B
Schultz, DS
Cote, ML
Van de Vijver, KK
Morris, RT
Oliva, E
Ali-Fehmi, R
AF Semaan, Assaad
Mert, Ismail
Munkarah, Adnan R.
Bandyopadhyay, Sudeshna
Mahdi, Haider S.
Winer, Ira S.
Nucci, Marisa R.
Hussein, Yaser
Quershi, Faisal
Hayek, Kinda
Tabassum, Farah
Alosh, Baraa
Schultz, Daniel S.
Cote, Michele L.
Van de Vijver, Koen K.
Morris, Robert T.
Oliva, Esther
Ali-Fehmi, Rouba
TI Clinical and Pathologic Characteristics of Serous Carcinoma Confined to
the Endometrium: A Multi-institutional Study
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
LA English
DT Article
DE Serous endometrial cancer; Endometrial polyp; No myometrial invasion
ID PAPILLARY; CANCERS; SPREAD; POLYPS
AB The objective of this study was to analyze the clinical and pathologic factors in patients with uterine serous carcinoma confined to the endometrium. A total of 236 uterine serous carcinoma patients from the pathology databases of 4 large academic institutions were included in the study. Clinical and pathologic variables were analyzed, including patient demographics, tumor size (<= 2 vs. >2cm), myometrial invasion, lymphovascular invasion, lymph node status, tumor location (endometrium vs. polyp), cervical involvement, lower uterine segment involvement, FIGO stage, pelvic washings, recurrence, overall survival, and progression-free survival. Of 236 patients, 55 (23%) had tumors limited to the endometrium. Forty-four patients (80%) had Stage IA tumors. The tumor was confined to a polyp in 17 (30.9%) patients. Twenty patients (36.4%) had tumor sizes >2cm and 12 (21.8%) exhibited lymphovascular invasion. Only 3 patients (5.4 %) had cervical stromal involvement. Thirty-three (66%) patients underwent pelvic and para-aortic lymphadenectomy with 2 positive para-aortic lymph nodes identified. Seven (12.7%) patients had positive washings, whereas 8 patients (14.5 %) had disease recurrence. At a median follow-up of 46 months, there was no difference in overall survival (P = 0.216) or progression-free survival (P = 0.063) between patients with tumors confined to a polyp, patients with tumors confined to the endometrium, and patients with tumors present in both polyp and the endometrium. Uterine serous carcinoma with only endometrial involvement, even when confined to a polyp, can be associated with poor prognosis, further stressing the importance of complete surgical staging and adjuvant treatment in this setting.
C1 [Semaan, Assaad; Mert, Ismail; Winer, Ira S.; Morris, Robert T.] Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI 48201 USA.
[Munkarah, Adnan R.] Henry Ford Hlth Syst, Dept Obstet & Gynecol, Detroit, MI USA.
[Bandyopadhyay, Sudeshna; Hussein, Yaser; Quershi, Faisal; Hayek, Kinda; Tabassum, Farah; Alosh, Baraa; Ali-Fehmi, Rouba] Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA.
[Mahdi, Haider S.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA.
[Nucci, Marisa R.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Schultz, Daniel S.] Henry Ford Hlth Syst, Dept Pathol, Detroit, MI USA.
[Cote, Michele L.] Wayne State Univ, Dept Oncol, Detroit, MI 48201 USA.
[Van de Vijver, Koen K.; Oliva, Esther] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Ali-Fehmi, R (reprint author), Wayne State Univ, Dept Pathol, 3990 John R, Detroit, MI 48201 USA.
EM rali@med.wayne.edu
NR 18
TC 9
Z9 10
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-1691
J9 INT J GYNECOL PATHOL
JI Int. J. Gynecol. Pathol.
PD MAR
PY 2013
VL 32
IS 2
BP 181
EP 187
DI 10.1097/PGP.0b013e318273fc55
PG 7
WC Obstetrics & Gynecology; Pathology
SC Obstetrics & Gynecology; Pathology
GA 089LZ
UT WOS:000314913400009
PM 23370657
ER
PT J
AU Young, RH
AF Young, Robert H.
TI Robert E. Scully, MD Obituary
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
LA English
DT Biographical-Item
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Young, RH (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM rhyoung@partners.org
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-1691
J9 INT J GYNECOL PATHOL
JI Int. J. Gynecol. Pathol.
PD MAR
PY 2013
VL 32
IS 2
BP 242
EP 245
DI 10.1097/PGP.0b013e3182830a1c
PG 4
WC Obstetrics & Gynecology; Pathology
SC Obstetrics & Gynecology; Pathology
GA 089LZ
UT WOS:000314913400019
PM 23534067
ER
PT J
AU Roth, LM
Young, RH
AF Roth, Lawrence M.
Young, Robert H.
TI Aleksander Talerman, MD, Ph.D., FRC Path. Obituary
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
LA English
DT Biographical-Item
C1 [Roth, Lawrence M.; Young, Robert H.] Indiana Univ Sch Med, Dept Pathol, Indianapolis, IN 46202 USA.
[Roth, Lawrence M.; Young, Robert H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA USA.
RP Roth, LM (reprint author), Indiana Univ Sch Med, Dept Pathol, Van Nuys Med Sci Bldg 128,635 Barnhill Dr, Indianapolis, IN 46202 USA.
EM lroth@iupui.edu
NR 1
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-1691
J9 INT J GYNECOL PATHOL
JI Int. J. Gynecol. Pathol.
PD MAR
PY 2013
VL 32
IS 2
BP 246
EP 247
DI 10.1097/PGP.0b013e3182830a30
PG 2
WC Obstetrics & Gynecology; Pathology
SC Obstetrics & Gynecology; Pathology
GA 089LZ
UT WOS:000314913400020
PM 23534068
ER
PT J
AU Lu, XM
Tompkins, RG
Fischman, AJ
AF Lu, X. -M.
Tompkins, R. G.
Fischman, A. J.
TI Nitric oxide activates intradomain disulfide bond formation in the
kinase loop of Akt1/PKB alpha after burn injury
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE Akt1/protein kinase B alpha; S-nitrosylation; disulfide bond; MS/MS
ID INDUCED INSULIN-RESISTANCE; S-NITROSYLATED PROTEINS; CAPLC-Q-TOFMICRO;
SKELETAL-MUSCLE; CRYSTAL-STRUCTURE; TARGETED DISRUPTION;
MASS-SPECTROMETRY; CRITICALLY-ILL; THERMAL-INJURY; AKT
AB Severe burn injury is an acute inflammatory state with massive alterations in gene expression and levels of growth factors, cytokines and free radicals. During the catabolic processes, changes in insulin sensitivity and skeletal muscle wasting (unintended loss of 5-15% of lean body mass) are observed clinically. Here, we reveal a novel molecular mechanism of Akt1/protein kinase B alpha (Akt1/PKB alpha) regulated via cross-talking between dephosphorylation of Thr(308) and S-nitrosylation of CyS296 post severe burn injury, which were characterized using nano-LC interfaced with tandem quadrupole time-of-fight mass spectrometry (Q-TOF)(micro) tandem mass spectrometry in both in vitro and in vivo studies. For the in vitro studies, Akt1/PKB alpha was S-nitrosylated with S-nitrosoglutathione and derivatized by three methods. The derivatives were isolated by SDS-PAGE, trypsinized and analyzed by the tandem MS. For the in vivo studies, Akt1/PKB alpha in muscle lysates from burned rats was immuno-precipitated, derivatized with HPDP-Biotin and analyzed as above. The studies demonstrated that the NO free radical reacts with the free thiol of Cys(296) to produce a Cys(296)-SNO intermediate which accelerates interaction with Cys(310) to form Cys(296)-Cys(310) in the kinase loop. MS/MS sequence analysis indicated that the dipeptide, linked via Cys(296)-Cys(310), underwent dephosphorylation at Thr(308). These effects were not observed in lysates from sham animals. As a result of this dual effect of burn injury, the loose conformation that is slightly stabilized by the Lys(297)-Thr(308) salt bridge may be replaced by a more rigid structure which may block substrate access. Together with the findings of our previous report concerning mild IRS-1 integrity changes post burn, it is reasonable to conclude that the impaired Akt1/PKB alpha has a major impact on FOXO3 subcellular distribution and activities.
C1 [Lu, X. -M.; Tompkins, R. G.] Massachusetts Gen Hosp, Surg Serv, Boston, MA 02114 USA.
[Lu, X. -M.; Tompkins, R. G.; Fischman, A. J.] Harvard Univ, Sch Med, Boston, MA USA.
[Lu, X. -M.; Tompkins, R. G.; Fischman, A. J.] Shriners Hosp Children, Boston, MA 02114 USA.
RP Fischman, AJ (reprint author), Shriners Hosp Children, 51 Blossom St, Boston, MA 02114 USA.
EM aajjff@gmail.com
FU National Institutes of Health [NIGMS P50 GM21000]; Shriners Hospital for
Children
FX This study was supported in part by grants from the National Institutes
of Health (NIGMS P50 GM21000) and Shriners Hospital for Children.
NR 48
TC 5
Z9 5
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD MAR
PY 2013
VL 31
IS 3
BP 740
EP 750
DI 10.3892/ijmm.2013.1241
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 089IZ
UT WOS:000314905500031
PM 23314241
ER
PT J
AU Likhacheva, A
Pinnix, CC
Parikh, NR
Allen, PK
McAleer, MF
Chiu, MS
Sulman, EP
Mahajan, A
Guha-Thakurta, N
Prabhu, SS
Cahill, DP
Luo, D
Shiu, AS
Brown, PD
Chang, EL
AF Likhacheva, Anna
Pinnix, Chelsea C.
Parikh, Neil R.
Allen, Pamela K.
McAleer, Mary F.
Chiu, Max S.
Sulman, Erik P.
Mahajan, Anita
Guha-Thakurta, Nandita
Prabhu, Sujit S.
Cahill, Daniel P.
Luo, Dershan
Shiu, Almon S.
Brown, Paul D.
Chang, Eric L.
TI Predictors of Survival in Contemporary Practice After Initial
Radiosurgery for Brain Metastases
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID GAMMA-KNIFE SURGERY; STEREOTACTIC RADIOSURGERY; RADIATION-THERAPY;
RANDOMIZED-TRIAL; SINGLE METASTASES; CLINICAL ARTICLE; RADIOTHERAPY;
NUMBER; TUMORS
AB Purpose: The number of brain metastases (BM) is a major consideration in determining patient eligibility for stereotactic radiosurgery (SRS), but the evidence for this popular practice is equivocal. The purpose of this study was to determine whether, following multivariate adjustment, the number and volume of BM held prognostic significance in a cohort of patients initially treated with SRS alone.
Methods and Materials: A total of 251 patients with primary malignancies, including non-small cell lung cancer (34%), melanoma (30%), and breast carcinoma (16%), underwent SRS for initial treatment of BM. SRS was used as the sole management (62% of patients) or was combined with salvage treatment with SRS (22%), whole-brain radiation therapy (WBRT; 13%), or resection (3%). Median follow-up time was 9.4 months. Survival was determined using the Kaplan-Meier method. Cox regression was used to assess the effects of patient factors on distant brain failure (DBF), local control (LC), and overall survival (OS).
Results: LC at 1 year was 94.6%, and median time to DBF was 10 months. Median OS was 11.1 months. On multivariate analysis, statistically significant predictors of OS were presence of extracranial disease (hazard ratio [HR], 4.2, P<.001), total tumor volume greater than 2 cm(3) (HR, 1.98; P<.001), age >= 60 years (HR, 1.67; P=.002), and diagnosis-specific graded prognostic assessment (HR, 0.71; P<.001). The presence of extracranial disease was a statistically significant predictor of DBF (HR, 2.15), and tumor volume was predictive of LC (HR, 4.56 for total volume >2 cm(3)). The number of BM was not predictive of DBF, LC, or OS.
Conclusions: The number of BM is not a strong predictor for clinical outcomes following initial SRS for newly diagnosed BM. Other factors including total treatment volume and systemic disease status are better determinants of outcome and may facilitate appropriate use of SRS or WBRT. (C) 2013 Elsevier Inc.
C1 [Likhacheva, Anna; Pinnix, Chelsea C.; Allen, Pamela K.; McAleer, Mary F.; Sulman, Erik P.; Mahajan, Anita; Brown, Paul D.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA.
[Parikh, Neil R.] Baylor Coll Med, Houston, TX 77030 USA.
[Chiu, Max S.] Univ Nebraska, Lincoln, NE USA.
[Guha-Thakurta, Nandita] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA.
[Prabhu, Sujit S.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA.
[Cahill, Daniel P.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Luo, Dershan; Shiu, Almon S.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA.
[Chang, Eric L.] Univ So Calif, Dept Radiat Oncol, Los Angeles, CA USA.
RP Chang, EL (reprint author), USC Norris Canc Hosp, Dept Radiat Oncol, USC Keck Sch Med, 1441 Eastlake Ave,NOR G-356, Los Angeles, CA 90033 USA.
EM eric.chang@med.usc.edu
OI Cahill, Daniel/0000-0003-2552-6546
FU NCI NIH HHS [P30 CA016672]
NR 27
TC 29
Z9 30
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD MAR 1
PY 2013
VL 85
IS 3
BP 656
EP 661
DI 10.1016/j.ijrobp.2012.05.047
PG 6
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 086MA
UT WOS:000314687000026
PM 22898384
ER
PT J
AU Adakun, SA
Siedner, MJ
Muzoora, C
Haberer, JE
Tsai, AC
Hunt, PW
Martin, JN
Bangsberg, DR
AF Adakun, Susan A.
Siedner, Mark J.
Muzoora, Conrad
Haberer, Jessica E.
Tsai, Alexander C.
Hunt, Peter W.
Martin, Jeff N.
Bangsberg, David R.
TI Higher Baseline CD4 Cell Count Predicts Treatment Interruptions and
Persistent Viremia in Patients Initiating ARVs in Rural Uganda
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article; Proceedings Paper
CT 7th Conference of the
International-Association-of-Physicians-in-AIDS-Care
CY JUN, 2012
CL Miami, FL
SP Int Assoc Phys AIDS Care
DE adherence; test and treat; Uganda; HIV/AIDS; adherence monitoring; MEMS
ID ACTIVE ANTIRETROVIRAL THERAPY; HIV-INFECTED ADULTS; NORTH-AMERICA;
ADHERENCE; IMPACT; AIDS; PROPHYLAXIS; PREVENTION; HOUSEHOLDS; AFRICA
AB We examined the association between CD4 cell count and adherence in a cohort of Ugandans initiating antiretrovirals (ARVs). Outcomes were (a) adherence <90%; (b) any treatment interruptions. >72 hours; (c) number of treatment interruptions; and (d) HIV-RNA >400 copies/mL. We fit regression models to estimate associations with our exposure of interest, baseline CD4 cell count >= 250 cells/mu L (n = 60) vs <250 cells/mu L (n = 413). CD4 cell count >250 cells/mu L was independently associated with increased odds and number of treatment interruptions and increased odds of persistent viremia. Interventions to support adherence in patients with higher CD4 cell counts should be considered as drug availability to this population increases.
C1 [Adakun, Susan A.; Muzoora, Conrad; Bangsberg, David R.] Mbarara Univ Sci & Technol, Dept Med, Mbarara, Uganda.
[Siedner, Mark J.; Bangsberg, David R.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Ctr Global Hlth, Boston, MA 02114 USA.
[Haberer, Jessica E.] Massachusetts Gen Hosp, Dept Med, Ctr Global Hlth, Div Internal Med, Boston, MA 02114 USA.
[Tsai, Alexander C.] Massachusetts Gen Hosp, Dept Psychiat, Div Global Psychiat, Ctr Global Hlth, Boston, MA 02114 USA.
[Hunt, Peter W.] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA USA.
[Martin, Jeff N.] Univ Calif San Francisco, Div Clin Epidemiol, Dept Epidemiol & Biostat, San Francisco, CA USA.
[Bangsberg, David R.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Boston, MA USA.
RP Adakun, SA (reprint author), Mbarara Univ Sci & Technol, POB 1410, Mbarara, Uganda.
EM adakunsusan@yahoo.com
OI Tsai, Alexander/0000-0001-6397-7917
FU FIC NIH HHS [R24 TW007988]; NIAID NIH HHS [P30 AI27763, T32 AI007433,
P30 AI027763]; NIMH NIH HHS [K23 MH087228, K23 MH096620, K24 MH087227,
K24 MH87227, R01 MH054907, R01MH54907]
NR 31
TC 19
Z9 19
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD MAR 1
PY 2013
VL 62
IS 3
BP 317
EP 321
DI 10.1097/QAI.0b013e3182800daf
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 088WT
UT WOS:000314869300020
PM 23242160
ER
PT J
AU Hernandez, R
Prohaska, TR
Wang, PC
Sarkisian, CA
AF Hernandez, Rosalba
Prohaska, Thomas R.
Wang, Pin-Chieh
Sarkisian, Catherine A.
TI The Longitudinal Relationship Between Depression and Walking Behavior in
Older Latinos: The "(sic)Caminemos!" Study
SO JOURNAL OF AGING AND HEALTH
LA English
DT Article
DE older adults; Hispanics; Latinos; depressive symptomatology; physical
activity; longitudinal analyses
ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; PHYSICAL-ACTIVITY;
MEXICAN-AMERICANS; SOCIAL SUPPORT; DOSE-RESPONSE; SELF-EFFICACY; ADULTS;
EXERCISE; PARTICIPATION
AB Objectives: This study sought to evaluate the relationship between baseline depression and prospective engagement in walking and exercise behavior after enrollment in an exercise intervention. Methods: The study used baseline, 1-month, 12-month, and 24-month in-person interview and pedometer data collected from Latinos aged > 60 years participating in an exercise intervention (AiCaminemos!) at 27 senior centers (n = 572). Results: After joining an exercise intervention, and when using continuous pedometer data and scores from the Yale Physical Activity Survey (YPAS) as the outcomes of interest, older adults with baseline depression exhibited comparable levels of physical activity across time when compared to their nondepressed counterparts. Significant difference in physical activity levels between the depressed and nondepressed subgroups no longer existed within one month of initiating the exercise intervention. Discussion: Among sedentary older Latino adults, having depression may not delay exercise initiation nor does it appear to prevent achievement or maintenance of an exercise program.
C1 [Hernandez, Rosalba] NW Feinberg Sch Med, Dept Prevent Med, Chicago, IL USA.
[Hernandez, Rosalba; Prohaska, Thomas R.] Univ Illinois, Sch Publ Hlth, Chicago, IL USA.
[Prohaska, Thomas R.] George Mason Univ, Coll Hlth & Human Serv, Fairfax, VA 22030 USA.
[Wang, Pin-Chieh; Sarkisian, Catherine A.] Vet Adm Greater Los Angeles Healthcare Syst, Geriatr Res Educ Clin Ctr, Los Angeles, CA USA.
[Wang, Pin-Chieh; Sarkisian, Catherine A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA.
RP Hernandez, R (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1400, Chicago, IL 60611 USA.
EM rosalba.hernandez@northwestern.edu
FU NHLBI NIH HHS [5T32 HL069771-10, T32 HL069771]; NIA NIH HHS [R01
AG024460, R01 AG024460-05, P30 AG028748, P30AG028748]
NR 57
TC 4
Z9 4
U1 3
U2 17
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0898-2643
J9 J AGING HEALTH
JI J. Aging Health
PD MAR
PY 2013
VL 25
IS 2
BP 319
EP 341
DI 10.1177/0898264312468488
PG 23
WC Gerontology; Health Policy & Services
SC Geriatrics & Gerontology; Health Care Sciences & Services
GA 087NV
UT WOS:000314769500006
PM 23264440
ER
PT J
AU Rosenfeld, A
Christensen, V
Daya, M
AF Rosenfeld, Anne
Christensen, Vivian
Daya, Mohamud
TI Long Enough to Act? Symptom and Behavior Patterns Prior to
Out-of-Hospital Sudden Cardiac Death
SO JOURNAL OF CARDIOVASCULAR NURSING
LA English
DT Article
DE myocardial infarction; narrative analysis; out-of-hospital death; sudden
cardiac death; symptoms
ID ACUTE MYOCARDIAL-INFARCTION; ACUTE CORONARY SYNDROMES; TREATMENT-SEEKING
DELAY; HEART-DISEASE; UNITED-STATES; FAMILY REPORTS; REDUCE DELAY;
WOMEN; ARREST; CARE
AB Background: Sudden cardiac death is a major cause of death in the United States. Most cases occur outside the hospital, yet little is known about the symptoms and actions of individuals who die before reaching the hospital. Objective: The purpose of this study was to describe the symptoms, symptom management, and care-seeking patterns in sudden cardiac death victims. Methods: This cross-sectional study used qualitative and quantitative data collection methods to obtain descriptions of symptoms and treatment-seeking delay from family members and bystanders (respondents) in 140 cases of sudden cardiac death due to presumed myocardial infarction. Decedents were identified from death certificate data from the state of Oregon in the United States. Respondents completed a survey of demographics and myocardial infarction symptoms and an in-depth interview. Narrative analysis was used to analyze qualitative data. Results: Three behavior patterns or trajectory types were developed focusing on key characteristics of the symptom patterns, the meanings attributed to those symptoms, the actions taken by the decedents and their family members or bystanders, and the time course of events. Each case was categorized as 1 trajectory type. The trajectory types are Normal Day (n = 49), Something Not Right (n = 62), and Thought It Was Something Else (n = 29). The key distinction across the trajectory types is the perception and interpretation of symptoms and the resulting actions between symptom perception and death. Conclusions: This study is 1 of the first to describe what victims of sudden cardiac death are doing and thinking during the period between symptom onset and collapse. The trajectory types identified in this study suggest that misinterpretation of symptoms (the Something Not Right and Thought It Was Something Else groups) is common among victims and bystanders.
C1 [Rosenfeld, Anne] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA.
[Christensen, Vivian] Portland VA Med Ctr, Evidence Based Synth Program, Coordinating Ctr, Portland, OR USA.
[Daya, Mohamud] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA.
RP Rosenfeld, A (reprint author), Univ Arizona, Coll Nursing, POB 210203, Tucson, AZ 85721 USA.
EM arosenfeld@nursing.arizona.edu
FU American Heart Association Pacific Mountain Affiliate [0450040Z]
FX This study was funded by American Heart Association Pacific Mountain
Affiliate Grant in Aid 0450040Z.
NR 45
TC 0
Z9 0
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0889-4655
J9 J CARDIOVASC NURS
JI J. Cardiovasc. Nurs.
PD MAR-APR
PY 2013
VL 28
IS 2
BP 166
EP 175
DI 10.1097/JCN.0b013e3182452410
PG 10
WC Cardiac & Cardiovascular Systems; Nursing
SC Cardiovascular System & Cardiology; Nursing
GA 091AR
UT WOS:000315021600015
PM 22343214
ER
PT J
AU Ananthakrishnan, AN
McGinley, EL
AF Ananthakrishnan, Ashwin N.
McGinley, Emily L.
TI Infection-related hospitalizations are associated with increased
mortality in patients with inflammatory bowel diseases
SO JOURNAL OF CROHNS & COLITIS
LA English
DT Article
DE Infections; Immunosuppression; Crohn's disease; Ulcerative colitis
ID CLOSTRIDIUM-DIFFICILE INFECTION; SAFETY PROFILE; INFLIXIMAB; DIARRHEA;
OUTCOMES; IMPACT; RISKS
AB Introduction: Serious infections are an important side effect of immunosuppressive therapy used to treat Crohn's disease (CD) and ulcerative colitis (UC). There have been no nationally representative studies examining the spectrum of infection related hospitalizations in patients with IBD.
Methods: Our study consisted of all adult CD and UC related hospitalizations from the Nationwide Inpatient Sample 2007, a national hospitalization database in the United States. We then identified all infection-related hospitalizations through codes for either the specific infections or disease processes (sepsis, pneumonia, etc.). Predictors of infections as well as the excess morbidity associated with infections were determined using multivariate regression models.
Results: There were an estimated 67,221 hospitalizations related to infections in IBD patients, comprising 27.5% of all IBD hospitalizations. On multivariate analysis, infections were independently associated with age, co-morbidity, malnutrition, TPN, and bowel surgery. Infection-related hospitalizations had a four-fold greater mortality (OR 4.4, 95% CI 3.7-5.2). However, this varied by type of infection with the strongest effect seen for sepsis (OR 15.3, 95% CI 12.4-18.6), pneumonia (OR 3.6, 95% CI 2.9-4.5) and C. difficile (OR 3.2, 95% CI 2.6-4.0), and weaker effects for urinary infections (OR 1.4, 95%Cl 1.1-1.7). Infections were also associated with an estimated 2.3 days excess hospital stay (95% CI 2.2-2.5) and $12,482 in hospitalization charges.
Conclusion: Infections account for significant morbidity and mortality in patients with IBD and disproportionately impact older IBD patients with greater co-morbidity. Pneumonia, sepsis and C difficile infection are associated with the greatest excess mortality risk. (C) 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
C1 [Ananthakrishnan, Ashwin N.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Ananthakrishnan, Ashwin N.] Harvard Univ, Sch Med, Boston, MA USA.
[McGinley, Emily L.] Med Coll Wisconsin, Ctr Patient Care & Outcomes & Res, Milwaukee, WI 53226 USA.
RP Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA.
EM aananthakrishnan@partners.org
FU American Gastroenterological Association
FX Ananthakrishnan is supported in part by a grant from the American
Gastroenterological Association.
NR 23
TC 30
Z9 31
U1 1
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1873-9946
J9 J CROHNS COLITIS
JI J. Crohns Colitis
PD MAR 1
PY 2013
VL 7
IS 2
BP 107
EP 112
DI 10.1016/j.crohns.2012.02.015
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 089HK
UT WOS:000314901400002
PM 22440891
ER
PT J
AU Schuster, MG
Meibohm, A
Lloyd, L
Strom, B
AF Schuster, Mindy G.
Meibohm, Anne
Lloyd, Lisa
Strom, Brian
TI Risk factors and outcomes of Candida krusei bloodstream infection: A
matched, case-control study
SO JOURNAL OF INFECTION
LA English
DT Article
DE Candida krusei; Candidemia; Risk factors; Case-control
ID INTENSIVE-CARE-UNIT; ANTIMICROBIAL SURVEILLANCE PROGRAM;
BONE-MARROW-TRANSPLANTATION; IN-VITRO SUSCEPTIBILITIES;
IMMUNOCOMPROMISED PATIENTS; ANTIFUNGAL SUSCEPTIBILITY; ATTRIBUTABLE
MORTALITY; NOSOCOMIAL CANDIDEMIA; CHANGING EPIDEMIOLOGY; SPECIES
DISTRIBUTION
AB Objectives: To investigate the risk factors and outcomes associated with Candida krusei bloodstream.
Methods: We performed a case control study of patients with C. krusei bloodstream infection at the University of Pennsylvania from 1982 to 2010. Controls were without candidemia, and matched to cases on duration of hospitalization and underlying disease.
Results: We enrolled 34 cases and 114 matched controls. Most subjects (62%) had hematologic malignancies. In the multivariate model, including a priori the duration of fluconazole use (OR 1.06; 95% CI 1.00, 1.11) and days of neutropenia (OR 1.01; 95% CI 0.98, 1.13), risk factors associated with C. krusei bloodstream infection were splenectomy (OR 11.66; 95% CI 1.04, 130.64), and exposure to antimicrobials with anaerobic activity (OR 5.74; 95% CI 1.76, 18.67). Outcomes of infected patients were poor. Only 32% of case patients survived to hospital discharge, compared to 89% of controls. For 48% death was attributed to C. krusei infection.
Conclusions: C. krusei bloodstream infection occurs most commonly in neutropenic patients with hematologic malignancy. The association with prior fluconazole exposure is less marked than previously described. Splenectomy and the receipt of antimicrobials with anaerobic activity are significant risk factors. The outcome of infected patients remains poor, despite appropriate antifungal therapy. (C) 2012 Published by Elsevier Ltd on behalf of The British Infection Association.
C1 [Schuster, Mindy G.; Strom, Brian] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Lloyd, Lisa] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
RP Schuster, MG (reprint author), Univ Penn, 3 Silverstein,Suite E,3400 Spruce St, Philadelphia, PA 19104 USA.
EM Mindy.Schuster2@uphs.upenn.edu
NR 37
TC 6
Z9 6
U1 0
U2 9
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0163-4453
J9 J INFECTION
JI J. Infect.
PD MAR
PY 2013
VL 66
IS 3
BP 278
EP 284
DI 10.1016/j.jinf.2012.11.002
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA 087ZP
UT WOS:000314803900008
PM 23174708
ER
PT J
AU Hansson, EM
Lendahl, U
AF Hansson, E. M.
Lendahl, U.
TI Regenerative medicine for the treatment of heart disease
SO JOURNAL OF INTERNAL MEDICINE
LA English
DT Review
DE biomaterials; cell therapy; ES cell; iPS cell; myocardial infarction;
stem cell
ID PLURIPOTENT STEM-CELLS; ACUTE MYOCARDIAL-INFARCTION; BONE-MARROW-CELLS;
RANDOMIZED CONTROLLED-TRIAL; MYOBLAST TRANSPLANTATION; PROGENITOR CELLS;
ISCHEMIC CARDIOMYOPATHY; FUNCTIONAL-PROPERTIES; PARACRINE MECHANISMS;
DEFINED FACTORS
AB Hansson EM, Lendahl U (Harvard University, Cambridge, USA; Massachusetts General Hospital, Boston, USA; Karolinska Institute, Stockholm, Sweden). Regenerative medicine for the treatment of heart disease (Review). J Intern Med 2013; 273: 235-245.
Heart failure is a major cause of mortality worldwide with a steady increase in prevalence. There is currently no available cure beyond orthotopic heart transplantation, which for a number of reasons is an option only for a small fraction of all patients. Considerable hope has therefore been placed on the possibility of treating a failing heart by replacing lost cardiomyocytes, either through transplantation of various types of stem cells or by boosting endogenous regenerative mechanisms in the heart. Here, we review the current status of stem and progenitor cell-based therapies for heart disease. We discuss the pros and cons of different stem and progenitor cell types that can be considered for transplantation and describe recent advances in the understanding of how cardiomyocytes normally differentiate and how these cells can be generated from more immature cells ex vivo. Finally, we consider the possibility of activation of endogenous stem and progenitor cells to treat heart failure.
C1 [Hansson, E. M.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Hansson, E. M.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Richard B Simches Res Ctr CPZN 3200, Boston, MA 02114 USA.
[Lendahl, U.] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, SE, Sweden.
RP Hansson, EM (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Richard B Simches Res Ctr CPZN 3200, 185 Cambridge St, Boston, MA 02114 USA.
EM ehansson@partners.org
OI Lendahl, Urban/0000-0001-9543-8141
FU Hjart-lungfonden; Swedish Research Council; Theme Center for
Regenerative Medicine; Swedish Cancer Society; Knut och Alice
Wallenbergs Stiftelse
FX We apologize to our colleagues whose work could not be cited due to
limitations to the length of this review. EMH is a Wenner-Gren
Foundation fellow and is supported by Hjart-lungfonden. UL is supported
by the Swedish Research Council (DBRM; Linneus Center in Developmental
Biology and Regenerative Medicine), the Theme Center for Regenerative
Medicine, the Swedish Cancer Society, and Knut och Alice Wallenbergs
Stiftelse (WIRM; the Wallenberg Institute for Regenerative Medicine).
NR 83
TC 12
Z9 13
U1 2
U2 34
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0954-6820
J9 J INTERN MED
JI J. Intern. Med.
PD MAR
PY 2013
VL 273
IS 3
BP 235
EP 245
DI 10.1111/joim.12033
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 092DC
UT WOS:000315098100002
PM 23331408
ER
PT J
AU Bhatia, N
Xiao, TZ
Rosenthal, KA
Siddiqui, IA
Thiyagarajan, S
Smart, B
Meng, Q
Zuleger, CL
Mukhtar, H
Kenney, SC
Albertini, MR
Longley, BJ
AF Bhatia, Neehar
Xiao, Tony Z.
Rosenthal, Kimberly A.
Siddiqui, Imtiaz A.
Thiyagarajan, Saravanan
Smart, Brendan
Meng, Qiao
Zuleger, Cindy L.
Mukhtar, Hasan
Kenney, Shannon C.
Albertini, Mark R.
Longley, B. Jack
TI MAGE-C2 Promotes Growth and Tumorigenicity of Melanoma Cells,
Phosphorylation of KAP1, and DNA Damage Repair
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID DOUBLE-STRAND BREAKS; METASTATIC MELANOMA; ANTIGEN-EXPRESSION;
MULTIPLE-MYELOMA; GENE-EXPRESSION; GERM-CELLS; CANCER; TESTIS;
APOPTOSIS; PROGRESSION
AB Melanoma-associated antigen-encoding (MAGE) genes are expressed in melanoma and other cancers but not in normal somatic cells. MAGE expression is associated with aggressive tumor growth, poor clinical outcome, and resistance to chemotherapy, but the mechanisms have not been completely elucidated. In this study, we show that downregulation of MAGE-C2 in A375 melanoma cells and low-passage cultures from human metastatic melanomas (MRA cells) results in increased apoptosis and decreased growth of tumor xenografts in athymic nude mice. Previously, we showed that MAGE-C2 binds KAP1, a scaffolding protein that regulates DNA repair. Phosphorylation of KAP1-Serine 824 (Ser824) by ataxia-telangiectasia mutated (ATM) kinase is necessary for repair of DNA double-strand breaks (DSBs); now we show that MAGE-C2 knockdown reduces, whereas MAGE-C2 overexpression increases, ATM kinase dependent phosphorylation of KAP1-Ser824. We demonstrate that MAGE-C2 increases co-precipitation of KAP1 with ATM and that binding of MAGE-C2 to KAP1 is necessary for increased KAP1-Ser824 phosphorylation. Furthermore, ectopic expression of MAGE-C2 enhances repair of I-Scel endonuclease induced DSBs in U-2OS cells. As phosphorylation of KAP1-Ser824 facilitates relaxation of heterochromatin, which is necessary for DNA repair and cellular proliferation, our results suggest that MAGE-C2 can promote tumor growth by phosphorylation of KAP1-Ser824 and by enhancement of DNA damage repair. Journal of Investigative Dermatology (2013) 133, 759-767; doi:10.1038/jid.2012.355; published online 25 October 2012
C1 [Bhatia, Neehar; Zuleger, Cindy L.; Albertini, Mark R.] Univ Wisconsin, Carbone Canc Ctr, Dept Med, Madison, WI 53705 USA.
[Xiao, Tony Z.; Rosenthal, Kimberly A.; Siddiqui, Imtiaz A.; Smart, Brendan; Mukhtar, Hasan; Longley, B. Jack] Univ Wisconsin, Dept Dermatol, Madison, WI 53705 USA.
[Thiyagarajan, Saravanan] Mazumdar Shaw Canc Ctr, Bangalore, Karnataka, India.
[Meng, Qiao; Kenney, Shannon C.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA.
[Albertini, Mark R.] William S Middleton Mem Vet Adm Med Ctr, Med Serv, Madison, WI USA.
RP Bhatia, N (reprint author), Univ Wisconsin, Carbone Canc Ctr, Dept Med, WI Inst Med Res 4040, 1111 Highland Ave, Madison, WI 53705 USA.
EM bneehar@medicine.wisc.edu; bjlongley@dermatology.wisc.edu
FU University of Wisconsin Carbone Cancer Center, the Office of Research
and Development, Biomedical Laboratory Research and Development Service,
Department of Veterans Affairs; National Cancer Institute [P30
CA014520]; Gretchen and Andrew Dawes Melanoma Research Fund; Ann's Hope
Foundation; Jay Van Sloan Memorial from the Steve Leuthold Family; Tim
Eagle Memorial
FX We acknowledge Dr Maria Jasin for providing us modified U2-OS cells for
DNA repair assay, and Dr Andrew Simpson and Dr Otavia Caballero for
reagents. We also thank Dr V.S. Setaluri for critical suggestions and
support. We are grateful to Tisha Kawahara for support with the IRB
protocol. This work was supported by the University of Wisconsin Carbone
Cancer Center, the Office of Research and Development, Biomedical
Laboratory Research and Development Service, Department of Veterans
Affairs; by Grant P30 CA014520 from the National Cancer Institute; the
Gretchen and Andrew Dawes Melanoma Research Fund; Ann's Hope Foundation;
the Jay Van Sloan Memorial from the Steve Leuthold Family; and the Tim
Eagle Memorial. The contents do not represent the views of the
Department of Veterans Affairs or of the United States Government.
Melanoma patient samples were used under UW-Madison Health Sciences IRB
protocol number M-2009-1157.
NR 38
TC 16
Z9 17
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD MAR
PY 2013
VL 133
IS 3
BP 759
EP 767
DI 10.1038/jid.2012.355
PG 9
WC Dermatology
SC Dermatology
GA 090VQ
UT WOS:000315008500024
PM 23096706
ER
PT J
AU Gordon, CT
Vuillot, A
Marlin, S
Gerkes, E
Henderson, A
AlKindy, A
Holder-Espinasse, M
Park, SS
Omarjee, A
Sanchis-Borja, M
Ben Bdira, E
Oufadem, M
Sikkema-Raddatz, B
Stewart, A
Palmer, R
McGowan, R
Petit, F
Delobel, B
Speicher, MR
Aurora, P
Kilner, D
Pellerin, P
Simon, M
Bonnefont, JP
Tobias, ES
Garcia-Minaur, S
Bitner-Glindzicz, M
Lindholm, P
Meijer, BA
Abadie, V
Denoyelle, F
Vazquez, MP
Rotky-Fast, C
Couloigner, V
Pierrot, S
Manach, Y
Breton, S
Hendriks, YMC
Munnich, A
Jakobsen, L
Kroisel, P
Lin, A
Kaban, LB
Basel-Vanagaite, L
Wilson, L
Cunningham, ML
Lyonnet, S
Amiel, J
AF Gordon, Christopher T.
Vuillot, Alice
Marlin, Sandrine
Gerkes, Erica
Henderson, Alex
AlKindy, Adila
Holder-Espinasse, Muriel
Park, Sarah S.
Omarjee, Asma
Sanchis-Borja, Mateo
Ben Bdira, Eya
Oufadem, Myriam
Sikkema-Raddatz, Birgit
Stewart, Alison
Palmer, Rodger
McGowan, Ruth
Petit, Florence
Delobel, Bruno
Speicher, Michael R.
Aurora, Paul
Kilner, David
Pellerin, Philippe
Simon, Marie
Bonnefont, Jean-Paul
Tobias, Edward S.
Garcia-Minaur, Sixto
Bitner-Glindzicz, Maria
Lindholm, Pernille
Meijer, Brigitte A.
Abadie, Veronique
Denoyelle, Francoise
Vazquez, Marie-Paule
Rotky-Fast, Christa
Couloigner, Vincent
Pierrot, Sebastien
Manach, Yves
Breton, Sylvain
Hendriks, Yvonne M. C.
Munnich, Arnold
Jakobsen, Linda
Kroisel, Peter
Lin, Angela
Kaban, Leonard B.
Basel-Vanagaite, Lina
Wilson, Louise
Cunningham, Michael L.
Lyonnet, Stanislas
Amiel, Jeanne
TI Heterogeneity of mutational mechanisms and modes of inheritance in
auriculocondylar syndrome
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID QUESTION MARK EAR; CONGENITAL AURICULAR CLEFT; PARKINSON-WHITE-SYNDROME;
PROTEIN ALPHA-SUBUNITS; PHOSPHOLIPASE-C-BETA; CONDYLAR SYNDROME;
ALAGILLE SYNDROME; DYSGNATHIA COMPLEX; DELETION; MICE
AB Background Auriculocondylar syndrome (ACS) is a rare craniofacial disorder consisting of micrognathia, mandibular condyle hypoplasia and a specific malformation of the ear at the junction between the lobe and helix. Missense heterozygous mutations in the phospholipase C, beta 4 (PLCB4) and guanine nucleotide binding protein (G protein), a inhibiting activity polypeptide 3 (GNAI3) genes have recently been identified in ACS patients by exome sequencing. These genes are predicted to function within the G protein-coupled endothelin receptor pathway during craniofacial development.
Results We report eight additional cases ascribed to PLCB4 or GNAI3 gene lesions, comprising six heterozygous PLCB4 missense mutations, one heterozygous GNAI3 missense mutation and one homozygous PLCB4 intragenic deletion. Certain residues represent mutational hotspots; of the total of 11 ACS PLCB4 missense mutations now described, five disrupt Arg621 and two disrupt Asp360. The narrow distribution of mutations within protein space suggests that the mutations may result in dominantly interfering proteins, rather than haploinsufficiency. The consanguineous parents of the patient with a homozygous PLCB4 deletion each harboured the heterozygous deletion, but did not present the ACS phenotype, further suggesting that ACS is not caused by PLCB4 haploinsufficiency. In addition to ACS, the patient harbouring a homozygous deletion presented with central apnoea, a phenotype that has not been previously reported in ACS patients.
Conclusions These findings indicate that ACS is not only genetically heterogeneous but also an autosomal dominant or recessive condition according to the nature of the PLCB4 gene lesion.
C1 [Gordon, Christopher T.; Vuillot, Alice; Omarjee, Asma; Sanchis-Borja, Mateo; Ben Bdira, Eya; Oufadem, Myriam; Munnich, Arnold; Lyonnet, Stanislas; Amiel, Jeanne] Hop Necker Enfants Malad, INSERM, U781, F-75015 Paris, France.
[Gordon, Christopher T.; Vuillot, Alice; Omarjee, Asma; Sanchis-Borja, Mateo; Ben Bdira, Eya; Oufadem, Myriam; Munnich, Arnold; Lyonnet, Stanislas; Amiel, Jeanne] Univ Paris 05, Sorbonne Paris Cite, Inst Imagine, Paris, France.
[Marlin, Sandrine] Hop Enfants Armand Trousseau, AP HP, Serv Genet Med, Ctr Reference Surdites Genet, Paris, France.
[Gerkes, Erica; Sikkema-Raddatz, Birgit] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands.
[Henderson, Alex] Newcastle Upon Tyne Hosp NHS Fdn Trust, No Genet Serv, Newcastle Upon Tyne, Tyne & Wear, England.
[AlKindy, Adila] Sultan Qaboos Univ Hosp, Dept Genet, Muscat, Oman.
[Holder-Espinasse, Muriel; Petit, Florence] CHRU Lille, Hop Jeanne de Flandre, Serv Genet Clin, Lille, France.
[Park, Sarah S.; Cunningham, Michael L.] Seattle Childrens Res Inst, Ctr Tissue & Cell Sci, Seattle, WA USA.
[Stewart, Alison] W Midlands Reg Genet Serv, Birmingham, W Midlands, England.
[Palmer, Rodger; Wilson, Louise] Great Ormond St Hosp Sick Children, NE Thames Reg Genet Serv, London, England.
[McGowan, Ruth] N Scotland Reg Genet Serv, Aberdeen, Scotland.
[Delobel, Bruno] Hop St Vincent de Paul, Lab Genet Chromosom, Lille, France.
[Speicher, Michael R.; Kroisel, Peter] Med Univ Graz, Inst Human Genet, Graz, Austria.
[Aurora, Paul; Kilner, David] Great Ormond St Hosp Sick Children, London, England.
[Pellerin, Philippe] CHRU Lille, Ctr Reference Malformat Craniomaxillofaciales Rar, Lille, France.
[Simon, Marie; Bonnefont, Jean-Paul; Munnich, Arnold; Lyonnet, Stanislas; Amiel, Jeanne] Hop Necker Enfants Malad, AP HP, Dept Genet, F-75015 Paris, France.
[Tobias, Edward S.] Univ Glasgow, Yorkhill Hosp, Sch Med, Glasgow, Lanark, Scotland.
[Garcia-Minaur, Sixto] La Paz Univ Hosp, Inst Med & Mol Genet, Madrid, Spain.
[Bitner-Glindzicz, Maria] UCL, Inst Child Hlth, London, England.
[Lindholm, Pernille; Jakobsen, Linda] Rigshosp, Copenhagen Univ Hosp, Dept Plast & Reconstruct Surg, Copenhagen, Denmark.
[Meijer, Brigitte A.] Kennemer Gasthuis, Dept Oral & Maxillofacial Surg, Haarlem, Netherlands.
[Abadie, Veronique] Univ Paris 05, Hop Necker Enfants Malad, Serv Pediat Gen, Paris, France.
[Denoyelle, Francoise] Univ Paris 06, Armand Trousseau Childrens Hosp, AP HP, INSERM,UMR S587, Paris, France.
[Denoyelle, Francoise] Univ Paris 06, Armand Trousseau Childrens Hosp, AP HP, Dept Pediat Otolaryngol, Paris, France.
[Vazquez, Marie-Paule] Hop Necker Enfants Malad, AP HP, CRMR Malformat Face & Cavite Buccale, Serv Chirurg Maxillofaciale & Plast, F-75015 Paris, France.
[Vazquez, Marie-Paule] Univ Paris 05, UFR Med Paris Descartes, Paris, France.
[Vazquez, Marie-Paule] Ctr Rech Cordeliers, UMR S 872, Paris, France.
[Rotky-Fast, Christa] Med Univ Graz, Dept Pediat & Adolescence Med, Graz, Austria.
[Couloigner, Vincent; Pierrot, Sebastien; Manach, Yves] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Serv ORL Pediat, Paris, France.
[Breton, Sylvain] Hop Necker Enfants Malad, AP HP, Serv Imagerie Pediat, F-75015 Paris, France.
[Breton, Sylvain] Univ Paris 05, Anat Lab, Paris, France.
[Hendriks, Yvonne M. C.] Free Univ Amsterdam, Med Ctr, Dept Clin Genet, Amsterdam, Netherlands.
[Lin, Angela] MassGen Hosp Children, Genet Unit, Boston, MA USA.
[Kaban, Leonard B.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
[Basel-Vanagaite, Lina] Schneider Childrens Med Ctr Israel, Petah Tiqwa, Israel.
[Basel-Vanagaite, Lina] Rabin Med Ctr, Raphael Recanati Genet Inst, Petah Tiqwa, Israel.
[Basel-Vanagaite, Lina] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel.
[Basel-Vanagaite, Lina] Rabin Med Ctr, Felsenstein Med Res Ctr, Petah Tiqwa, Israel.
[Cunningham, Michael L.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA.
[Cunningham, Michael L.] Seattle Childrens Hosp, Craniofacial Ctr, Seattle, WA USA.
RP Gordon, CT (reprint author), Hop Necker Enfants Malad, INSERM, U781, Tour Lavoisier 2Eme Etage,149 Rue Sevres, F-75015 Paris, France.
EM chris.gordon@inserm.fr; jeanne.amiel@inserm.fr
RI Speicher, Michael/B-5362-2013; Bitner-Glindzicz, Maria/A-4231-2009;
Gordon, Christopher/F-1267-2017;
OI Speicher, Michael/0000-0003-0105-955X; Gordon,
Christopher/0000-0002-9300-8399; petit, florence/0000-0002-1368-1023
FU Ecole de l'Inserm Liliane Bettencourt; Jean Renny Endowment for
Craniofacial Research; E-Rare CRANIRARE; Fondation pour la Recherche
Medicale
FX This work was supported by funding from the Ecole de l'Inserm Liliane
Bettencourt (AV), the Jean Renny Endowment for Craniofacial Research
(MLC), E-Rare CRANIRARE (SL) and the Fondation pour la Recherche
Medicale (JA).
NR 65
TC 16
Z9 16
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD MAR
PY 2013
VL 50
IS 3
BP 174
EP 186
DI 10.1136/jmedgenet-2012-101331
PG 13
WC Genetics & Heredity
SC Genetics & Heredity
GA 088ZR
UT WOS:000314877600007
PM 23315542
ER
PT J
AU Cougle, JR
Bernstein, A
Zvolensky, MJ
Vujanovic, AA
Macatee, RJ
AF Cougle, Jesse R.
Bernstein, Amit
Zvolensky, Michael J.
Vujanovic, Anka A.
Macatee, Richard J.
TI Validation of Self-Report Measures of Emotional and Physical Distress
Tolerance
SO JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT
LA English
DT Article
DE Distress tolerance; Discomfort tolerance; Construct validity;
Assessment; Anxiety sensitivity
ID ANXIETY SENSITIVITY; INTOLERANCE; DISORDERS
AB The Distress Tolerance Scale (DTS) and Discomfort Intolerance Scale (DIS) are self-report measures developed for the assessment of emotional and physical distress tolerance, respectively. However, little evidence exists for their construct and specifically criterion-related validity. The current study examined the associations of these self-report measures with lab-based assessments of perceived emotional tolerance and physical discomfort tolerance. Undergraduate participants (N = 166) were administered four film clips intended to induce sadness, disgust, fear, and anger, and a handgrip persistence task intended to elicit physical discomfort. The DTS, but not the DIS, was significantly associated with self-reported emotional tolerance and perceived threat associated with each film after controlling for emotional intensity. Among DTS subscales, the absorption subscale was the only subscale incrementally predictive of negative perceptions of the sad film, the appraisal subscale was incrementally predictive of negative perceptions of the other three films, and little support for the incremental validity of the tolerance and regulation subscales was found. The DTS also incrementally predicted tolerance and perceived threat of film-elicited emotions across films after controlling for anxiety sensitivity. The DIS was only marginally predictive of handgrip task persistence and was unrelated to emotional film perceptions. Overall, these findings uniquely add to the empirical literature on the construct and criterion-related validity of the DTS and DIS.
C1 [Cougle, Jesse R.; Macatee, Richard J.] Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA.
[Bernstein, Amit] Univ Haifa, Dept Psychol, IL-31999 Haifa, Israel.
[Zvolensky, Michael J.] Univ Houston, Dept Psychol, Houston, TX USA.
[Vujanovic, Anka A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Behav Sci Div, Boston, MA USA.
[Vujanovic, Anka A.] Boston Univ, Sch Med, Boston, MA 02118 USA.
RP Cougle, JR (reprint author), Florida State Univ, Dept Psychol, 1107 W Call St, Tallahassee, FL 32306 USA.
EM cougle@psy.fsu.edu
NR 26
TC 3
Z9 3
U1 4
U2 9
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0882-2689
J9 J PSYCHOPATHOL BEHAV
JI J. Psychopathol. Behav. Assess.
PD MAR
PY 2013
VL 35
IS 1
BP 76
EP 84
DI 10.1007/s10862-012-9317-2
PG 9
WC Psychology, Clinical
SC Psychology
GA 087QD
UT WOS:000314776100008
ER
PT J
AU Schmidt, B
Yoon, SS
AF Schmidt, Benjamin
Yoon, Sam S.
TI D1 versus D2 lymphadenectomy for gastric cancer
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Review
DE gastric adenocarcinoma; lymphadenectomy; surgery; stage; survival
ID LYMPH-NODE DISSECTION; PRESERVING TOTAL GASTRECTOMY; RANDOMIZED
CONTROLLED-TRIAL; DISEASE-SPECIFIC SURVIVAL; UNITED-STATES; SURGICAL
TRIAL; HELICOBACTER-PYLORI; D-2 RESECTIONS; STAGING SYSTEM;
CLINICAL-TRIAL
AB Significant variability exists throughout the world in the extent of lymphadenectomy that is performed for gastric adenocarcinoma. D2 lymphadenectomy is the standard lymphadenectomy performed in high incidence countries such as Japan and South Korea, and less extensive lymphadenectomies are often performed in lower incidence countries such as the Unites States. This article reviews the evidence on the extent of lymphadenectomy that should be performed for gastric adenocarcinoma. J. Surg. Oncol. 2013;107:259264. (c) 2012 Wiley Periodicals, Inc.
C1 [Yoon, Sam S.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Yoon, SS (reprint author), Massachusetts Gen Hosp, Dept Surg, Yawkey 7B,55 Fruit St, Boston, MA 02114 USA.
EM syoon@partners.org
FU NCI NIH HHS [T32 CA071345]
NR 60
TC 24
Z9 26
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD MAR
PY 2013
VL 107
IS 3
BP 259
EP 264
DI 10.1002/jso.23127
PG 6
WC Oncology; Surgery
SC Oncology; Surgery
GA 088WZ
UT WOS:000314869900006
PM 22513454
ER
PT J
AU Kougias, P
Tiwari, V
Barshes, NR
Bechara, CF
Lowery, B
Pisimisis, G
Berger, DH
AF Kougias, Panagiotis
Tiwari, Vikram
Barshes, Neal R.
Bechara, Carlos F.
Lowery, Briauna
Pisimisis, George
Berger, David H.
TI Modeling anesthetic times. Predictors and implications for short-term
outcomes
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE Modeling; Regression; Anesthetic length; Precision
ID SURGERY; EXPENDITURES; VARIABILITY; DURATION; THEATER
AB Background: Little is known about the predictors of anesthetic times and impact of anesthetic and operative times on patient outcomes.
Methods: We documented operative case length, anesthetic induction time length, and anesthetic recovery time length in 1713 consecutive patients who underwent elective vascular surgical interventions. We recorded patient and procedure-related characteristics that might influence the anesthetic time length, including a variable for possible July effect. Multivariate linear regression was used to model the length of anesthetic times. Multivariate logistic regression was used to model the impact of anesthetic and operative time lengths on a composite outcome of perioperative (30-d postoperative) death, myocardial infarction, cardiac arrhythmias, stroke, and congestive heart failure.
Results: Statistically significant predictors of anesthetic induction time included body mass index, anesthesia type, and procedure type. Statistically significant predictors of anesthetic recovery time included operative case length, procedure type, and anesthesia type. After adjusting for the statistically significant covariates of total blood transfusion, history of coronary artery disease, and procedure type, there was a trend for increased likelihood of the composite end point as a function of operative time (odds ratio, 1.14; 95% confidence interval, 0.97-1.33; P = 0.09), which did not reach statistical significance. Multivariate analysis showed no association between the anesthetic time and composite end point.
Conclusions: Modeling individually anesthetic induction and recovery time on the basis of operative and anesthetic procedure characteristics is feasible. Anesthetic and operative times do not impact perioperative morbidity and mortality. Published by Elsevier Inc.
C1 [Kougias, Panagiotis; Barshes, Neal R.; Bechara, Carlos F.; Lowery, Briauna; Pisimisis, George; Berger, David H.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
[Tiwari, Vikram] Vanderbilt Univ, Med Ctr, Director Perioperat Serv, Nashville, TN USA.
RP Kougias, P (reprint author), Houston VAMC, Michael E DeBakey Dept Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA.
EM pkougias@bcm.edu
NR 14
TC 5
Z9 5
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD MAR
PY 2013
VL 180
IS 1
BP 1
EP 7
DI 10.1016/j.jss.2012.10.007
PG 7
WC Surgery
SC Surgery
GA 089LQ
UT WOS:000314912400008
PM 23158406
ER
PT J
AU Di Eusanio, M
Patel, HJ
Nienaber, CA
Montgomery, DM
Korach, A
Sundt, TM
DeVincentiis, C
Voehringer, M
Peterson, MD
Myrmel, T
Folesani, G
Larsen, M
Desai, ND
Bavaria, JE
Appoo, JJ
Kieser, TM
Fattori, R
Eagle, K
Di Bartolomeo, R
Trimarchi, S
AF Di Eusanio, Marco
Patel, Himanshu J.
Nienaber, Christoph A.
Montgomery, Daniel M.
Korach, Amit
Sundt, Thoralf M.
DeVincentiis, Carlo
Voehringer, Matthias
Peterson, Mark D.
Myrmel, Truls
Folesani, Gianluca
Larsen, Magnus
Desai, Nimesh D.
Bavaria, Joseph E.
Appoo, Jehangir J.
Kieser, Teresa M.
Fattori, Rossella
Eagle, Kim
Di Bartolomeo, Roberto
Trimarchi, Santi
TI Patients with type A acute aortic dissection presenting with major brain
injury: Should we operate on them?
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article; Proceedings Paper
CT Aortic Surgery Symposium of the
American-Association-for-Thoracic-Surgery
CY APR 26-27, 2012
CL New York, NY
SP Amer Assoc Thorac Surg
ID INTERNATIONAL REGISTRY; NEUROLOGICAL DYSFUNCTION; DISEASE; REPAIR;
INSIGHTS; SURGERY; STROKE; IRAD; COMA
AB Objectives: The management strategy remains controversial for patients presenting with type A acute aortic dissection with cerebrovascular accident or coma. The present study aimed to help guide surgeons treating these high-risk patients.
Methods: Of 1873 patients with type A acute aortic dissection enrolled in the International Registry for Acute Dissection, 87 (4.7%) presented with cerebrovascular accident and 54 (2.9%) with coma. The hospital and 5-year results were stratified by the presence and type of brain injury (no injury vs stroke vs coma) and management type (medical vs surgical). Independent predictors of short-and mid-term survival were identified.
Results: Presentation with shock, hypotension, or tamponade (46.8% vs 25.2%; P < .001) and arch vessel involvement (55.0% vs 36.1%; P < .001) was more likely in patients with brain injury. Surgical management was avoided more often in patients with coma (33.3%) or cerebrovascular accident (24.1%) than in those without brain injury (11.1%; P < .001). The overall hospital mortality was 22.7% without brain injury, 40.2% with cerebrovascular accident, and 63.0% with coma (P < .001). Mortality varied among the management types for both cerebrovascular accident (76.2% medical vs 27.0% surgical; P < .001) and coma (100% medical vs 44.4% surgical; P < .001). Postoperatively, cerebrovascular accident and coma resolved in 84.3% and 78.8% of cases, respectively. On logistic regression analysis, surgery was protective against mortality in patients presenting with brain injury (odds ratio 0.058; P < .001). The 5-year survival of patients presenting with cerebrovascular accident and comawas 23.8% and 0% after medical management versus 67.1% and 57.1% after surgery (log rank, P < .001), respectively.
Conclusions: Brain injury at presentation adversely affects hospital survival of patients with type A acute aortic dissection. In the present observational study, the patients selected to undergo surgery demonstrated improved late survival and frequent reversal of neurologic deficits. (J Thorac Cardiovasc Surg 2013;145:S213-21)
C1 [Di Eusanio, Marco; Folesani, Gianluca; Fattori, Rossella; Di Bartolomeo, Roberto] St Orsola Marcello Malpighi Hosp, Dept Cardiac Surg, Bologna, Italy.
[Patel, Himanshu J.; Montgomery, Daniel M.; Eagle, Kim] Univ Michigan, Dept Cardiac Surg, Ann Arbor, MI 48109 USA.
[Nienaber, Christoph A.] Univ Hosp Eppendorf Rostock, Dept Internal Med, Rostock, Germany.
[Korach, Amit] Hadassah Hebrew Univ Med Ctr, Dept Cardiothorac Surg, Jerusalem, Israel.
[Sundt, Thoralf M.] Massachusetts Gen Hosp, Thorac Aort Ctr, Boston, MA 02114 USA.
[DeVincentiis, Carlo; Trimarchi, Santi] IRCCS Policlin San Donato, Thorac Aort Res Ctr, San Donato Milanese, Italy.
[Voehringer, Matthias] Robert Bosch Krankenhaus, Dept Cardiol, Stuttgart, Germany.
[Peterson, Mark D.] St Michaels Hosp, Div Cardiac Surg, Toronto, ON M5B 1W8, Canada.
[Myrmel, Truls; Larsen, Magnus] Univ Tromso Hosp, Dept Cardiothorac & Vasc Surg, N-9012 Tromso, Norway.
[Desai, Nimesh D.; Bavaria, Joseph E.] Univ Penn, Sch Med, Dept Cardiovasc Surg, Philadelphia, PA 19104 USA.
[Appoo, Jehangir J.; Kieser, Teresa M.] Univ Calgary, Med Ctr, Dept Cardiac Surg, Calgary, AB, Canada.
RP Di Eusanio, M (reprint author), Univ Bologna, Dept Cardiac Surg, Policlin St Orsola Malpighi, Pad 25,Via Massarenti 9, I-40128 Bologna, Italy.
EM marco.dieusanio2@unibo.it
RI Trimarchi, Santi/J-7361-2016;
OI Trimarchi, Santi/0000-0001-5996-3264; di bartolomeo,
roberto/0000-0003-3965-5779
NR 16
TC 15
Z9 15
U1 1
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD MAR
PY 2013
VL 145
IS 3
SU S
BP S213
EP +
DI 10.1016/j.jtcvs.2012.11.054
PG 10
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 089BQ
UT WOS:000314884000040
PM 23410778
ER
PT J
AU Sundt, TM
AF Sundt, Thoralf M.
TI Indications for aortic aneurysmectomy: Too many variables and not enough
equations?
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article
ID HUMAN ASCENDING AORTA; THORACIC AORTA; DISSECTION; GUIDELINES; BEHAVIOR;
RUPTURE; EVENTS; RATES; SIZE
AB Endografting for treatment of thoracic aortic pathology continues to gain popularity; in some countries, endovascular aortic repair numbers now exceed open surgery cases. The skills and understanding of open surgical teams are not always translated into endovascular interventions, which may be led by a cardiologist or vascular surgeon with little knowledge of thoracic pathology. The indications for intervention on the dilated aorta continue to be debated despite volumes of literature and multisocietal guidelines. The challenge of making a binary decision in the face of competing continuous risks depends on a best guess as to when the risk of the natural history of the disease exceeds that of the operation. Unfortunately, we have more information about average risk than actual (patient-specific) risk, and only for some of the variables determining those risks. Individual patient-specific operative risk can be calculated for some procedures by means of the Society of Thoracic Surgeons database, although surgeon-specific risk models are really required. On the other side of the balance, aortic dissection and rupture represent material failure of the aortic wall when tensile stress exceeds tensile strength. When framed in this way, it is not surprising that diameter is imprecise, as this is only one of the variables in the law of Laplace. The circumferential (hoop) stress is the product of radius and intraluminal pressure, divided by wall thickness. We also have no good measures of the material properties of the wall that determine strength, although a great deal of attention has been paid to the genetic markers for aortic wall abnormalities. Other factors, such as smoking or poorly controlled hypertension, likely should enter into our clinical assessment because they impact wall strength as well. For now, discussions with patients should be framed with all these elements in mind. (J Thorac Cardiovasc Surg 2013;145:S126-9)
C1 [Sundt, Thoralf M.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Sundt, Thoralf M.] Massachusetts Gen Hosp, Div Cardiac Surg, Boston, MA 02114 USA.
RP Sundt, TM (reprint author), Harvard Univ, Sch Med, Cox 652,55 Fruit St, Boston, MA 02114 USA.
EM tsundt@partners.org
NR 27
TC 3
Z9 3
U1 0
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD MAR
PY 2013
VL 145
IS 3
SU S
BP S126
EP S129
DI 10.1016/j.jtcvs.2012.11.067
PG 4
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 089BQ
UT WOS:000314884000024
PM 23410769
ER
PT J
AU Trimarchi, S
Tolenaar, JL
Jonker, FHW
Murray, B
Tsai, TT
Eagle, KA
Rampoldi, V
Verhagen, HJM
van Herwaarden, JA
Moll, FL
Muhs, BE
Elefteriades, JA
AF Trimarchi, Santi
Tolenaar, Jip L.
Jonker, Frederik H. W.
Murray, Brian
Tsai, Thomas T.
Eagle, Kim A.
Rampoldi, Vincenzo
Verhagen, Hence J. M.
van Herwaarden, Joost A.
Moll, Frans L.
Muhs, Bart E.
Elefteriades, John A.
TI Importance of false lumen thrombosis in type B aortic dissection
prognosis
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Article
ID INTERNATIONAL REGISTRY; ECHOCARDIOGRAPHY; PATENCY; REPAIR
AB Background: Partial thrombosis of the false lumen has been reported as a significant predictor of mortality during follow-up in patients with acute type B aortic dissection. The purpose of this study was to investigate the correlation of false lumen thrombosis and aortic expansion during follow-up in patients with acute type B aortic dissection.
Methods: All medically treated patients with acute type B aortic dissection observed in 4 cardiovascular referral centers between 1998 and 2011, with admission and follow-up computed tomography or magnetic resonance imaging scans, were included. Aortic diameters of the dissected aortas were measured at 4 levels on the baseline and follow-up scans, and annual growth rates were calculated. Univariate and multivariate regression analyses were used to investigate the effect of false lumen thrombosis on aortic growth rate.
Results: A total of 84 patients were included, of whom 40 (47.6%) had a partially thrombosed false lumen, 7 (8.3%) had a completely thrombosed false lumen, and 37 (44.0%) had a patent false lumen. A total of 273 of the 336 (81.3%) evaluated aortic levels were dissected segments. Overall, the mean aortic diameter increased significantly at all evaluated levels (P <. 001). Univariate analysis showed that annual aortic growth rates were significantly higher in those segments having a false lumen with partial thrombosis (mean, 4.25 +/- 10.2) when compared with the patent group (mean, 2.10 +/- 5.56; P = .035). In multivariate analysis, partial lumen thrombosis was an independent predictor of higher aortic growth (adjusted mean difference, 2.05 mm/year; 95% confidence interval, 0.10-4.01; P = .040).
Conclusions: In patients with acute type B aortic dissection, aortic segments with a partially thrombosed false lumen have a significantly higher annual aortic growth rate when compared with those presenting with patent or complete thrombosis of the false lumen. Therefore, patients with partial thrombosis require more intensive follow-up and may benefit from prophylactic intervention. (J Thorac Cardiovasc Surg 2013;145:S208-12)
C1 [Trimarchi, Santi; Tolenaar, Jip L.; Rampoldi, Vincenzo] Policlin San Donato IRCCS, Thorac Aort Res Ctr, Milan, Italy.
[Jonker, Frederik H. W.] Maasstad Hosp, Dept Surg, Rotterdam, Netherlands.
[Murray, Brian; Elefteriades, John A.] Yale Univ, Sch Med, Sect Cardiac Surg, New Haven, CT USA.
[Tsai, Thomas T.] Denver VA Med Ctr, Div Cardiol & Intervent Cardiol, Denver, CO USA.
[Eagle, Kim A.] Univ Michigan Hlth Syst, Ctr Cardiovasc, Ann Arbor, MI USA.
[Verhagen, Hence J. M.] Erasmus MC, Dept Vasc Surg, Rotterdam, Netherlands.
[van Herwaarden, Joost A.; Moll, Frans L.] Univ Med Ctr Utrecht, Dept Vasc Surg, Utrecht, Netherlands.
[Muhs, Bart E.] Yale Univ, Sch Med, Vasc Surg Sect, New Haven, CT USA.
RP Trimarchi, S (reprint author), Univ Milan, Thorac Aort Res Ctr, Policlin San Donato IRCCS, Piazza Malan 2, I-20097 San Donato Milanese, MI, Italy.
EM santi.trimarchi@unimi.it
RI Trimarchi, Santi/J-7361-2016
OI Trimarchi, Santi/0000-0001-5996-3264
NR 15
TC 34
Z9 34
U1 0
U2 9
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD MAR
PY 2013
VL 145
IS 3
SU S
BP S208
EP S212
DI 10.1016/j.jtcvs.2012.11.048
PG 5
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA 089BQ
UT WOS:000314884000039
PM 23260434
ER
PT J
AU Desormeaux, A
Coutu, M
Medjahed, H
Pacheco, B
Herschhorn, A
Gu, C
Xiang, SH
Mao, YD
Sodroski, J
Finzi, A
AF Desormeaux, Anik
Coutu, Mathieu
Medjahed, Halima
Pacheco, Beatriz
Herschhorn, Alon
Gu, Christopher
Xiang, Shi-Hua
Mao, Youdong
Sodroski, Joseph
Finzi, Andres
TI The Highly Conserved Layer-3 Component of the HIV-1 gp120 Inner Domain
Is Critical for CD4-Required Conformational Transitions
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN TRIMER; CD4
RECEPTOR; SOLUBLE CD4; HTLV-III; TRANSMEMBRANE GLYCOPROTEIN;
NEUTRALIZING ANTIBODIES; CD4-BOUND CONFORMATION; MOLECULAR CLONE; AIDS
PATIENTS
AB The trimeric envelope glycoprotein (Env) of human immunodeficiency virus type 1 (HIV-1) mediates virus entry into host cells. CD4 engagement with the gp120 exterior envelope glycoprotein subunit represents the first step during HIV-1 entry. CD4-induced conformational changes in the gp120 inner domain involve three potentially flexible topological layers (layers 1, 2, and 3). Structural rearrangements between layer 1 and layer 2 have been shown to facilitate the transition of the envelope glycoprotein trimer from the unliganded to the CD4-bound state and to stabilize gp120-CD4 interaction. However, our understanding of CD4-induced conformational changes in the gp120 inner domain remains incomplete. Here, we report that a highly conserved element of the gp120 inner domain, layer 3, plays a pivot-like role in these allosteric changes. In the unliganded state, layer 3 modulates the association of gp120 with the Env trimer, probably by influencing the relationship of the gp120 inner and outer domains. Importantly, layer 3 governs the efficiency of the initial gp120 interaction with CD4, a function that can also be fulfilled by filling the Phe43 cavity. This work defines the functional importance of layer 3 and completes a picture detailing the role of the gp120 inner domain in CD4-induced conformational transitions in the HIV-1 Env trimer.
C1 [Desormeaux, Anik; Coutu, Mathieu; Medjahed, Halima; Finzi, Andres] Univ Montreal, CHUM, Ctr Rech, Montreal, PQ, Canada.
[Desormeaux, Anik; Coutu, Mathieu; Medjahed, Halima; Finzi, Andres] Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada.
[Finzi, Andres] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada.
[Xiang, Shi-Hua] Univ Nebraska, Sch Vet Med & Biomed Sci, Nebraska Ctr Virol, Lincoln, NE USA.
[Pacheco, Beatriz; Herschhorn, Alon; Gu, Christopher; Mao, Youdong; Sodroski, Joseph] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
[Pacheco, Beatriz; Herschhorn, Alon; Gu, Christopher; Mao, Youdong; Sodroski, Joseph] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Div Aids, Boston, MA 02115 USA.
[Sodroski, Joseph] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Sodroski, Joseph] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Boston, MA USA.
RP Finzi, A (reprint author), Univ Montreal, CHUM, Ctr Rech, Montreal, PQ, Canada.
EM andres.finzi@umontreal.ca
FU amfAR Mathilde Krim Fellowship in Basic Biomedical Research
[108092-50-RKVA]; Canada Foundation for Innovation [29866]; CIHR
[257792]; FRQS [24639]; National Institutes of Health [AI24755,
AI67854]; International AIDS Vaccine Initiative
FX This work was supported by an amfAR Mathilde Krim Fellowship in Basic
Biomedical Research (Phase II, no. 108092-50-RKVA), by a Canada
Foundation for Innovation Program Leader grant (no. 29866), by a CIHR
operating grant (no. 257792), and by an FRQS Establishment of Young
Scientist grant (no. 24639) to A.F. A.F. is the recipient of an FRSQ
Chercheur Boursier Junior 1 Fellowship (no. 24639). This work was also
supported by grants from the National Institutes of Health (AI24755 and
AI67854), by the International AIDS Vaccine Initiative, and by the late
William F. McCarty-Cooper.
NR 72
TC 25
Z9 25
U1 0
U2 20
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD MAR
PY 2013
VL 87
IS 5
BP 2549
EP 2562
DI 10.1128/JVI.03104-12
PG 14
WC Virology
SC Virology
GA 088ZL
UT WOS:000314876900017
PM 23255784
ER
PT J
AU Csiszar, A
Sosnowska, D
Tucsek, Z
Gautam, T
Toth, P
Losonczy, G
Colman, RJ
Weindruch, R
Anderson, RM
Sonntag, WE
Ungvari, Z
AF Csiszar, Anna
Sosnowska, Danuta
Tucsek, Zsuzsanna
Gautam, Tripti
Toth, Peter
Losonczy, Gyorgy
Colman, Ricki J.
Weindruch, Richard
Anderson, Rozalyn M.
Sonntag, William E.
Ungvari, Zoltan
TI Circulating Factors Induced by Caloric Restriction in the Nonhuman
Primate Macaca Mulatta Activate Angiogenic Processes in Endothelial
Cells
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
SCIENCES
LA English
DT Article
DE Dietary restriction; Vascular aging; Angiogenesis; Microcirculation;
Cardiovascular system
ID VASCULAR OXIDATIVE STRESS; LEWIS DWARF RATS; MEMBRANE REDOX SYSTEM;
SMOOTH-MUSCLE-CELLS; KAPPA-B ACTIVATION; RHESUS-MONKEYS; DIETARY
RESTRICTION; LIFE-SPAN; MITOCHONDRIAL BIOGENESIS; BODY-COMPOSITION
AB Moderate caloric restriction (CR) without malnutrition increases healthspan in virtually every species studied, including nonhuman primates. In mice, CR exerts significant microvascular protective effects resulting in increased microvascular density in the heart and the brain, which likely contribute to enhanced tolerance to ischemia and improved cardiac performance and cognitive function. Yet, the underlying mechanisms by which CR confer microvascular protection remain elusive. To test the hypothesis that circulating factors triggered by CR regulate endothelial angiogenic capacity, we treated cultured human endothelial cells with sera derived from Macaca mulatta on long-term (over 10 years) CR. Cells treated with sera derived from ad-libitum-fed control monkeys served as controls. We found that factors present in CR sera upregulate vascular endothelial growth factor (VEGF) signaling and stimulate angiogenic processes, including endothelial cell proliferation and formation of capillary-like structures. Treatment with CR sera also tended to increase cellular migration (measured by a wound-healing assay using electric cellsubstrate impedance sensing [ECIS] technology) and adhesion to collagen. Collectively, we find that circulating factors induced by CR promote endothelial angiogenic processes, suggesting that increased angiogenesis may be a potential mechanism by which CR improves cardiac function and prevents vascular cognitive impairment.
C1 [Csiszar, Anna; Sosnowska, Danuta; Tucsek, Zsuzsanna; Gautam, Tripti; Toth, Peter; Sonntag, William E.; Ungvari, Zoltan] Univ Oklahoma, Hlth Sci Ctr, Dept Geriatr Med, Reynolds Oklahoma Ctr Aging, Norman, OK 73019 USA.
[Csiszar, Anna; Sonntag, William E.; Ungvari, Zoltan] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Norman, OK 73019 USA.
[Losonczy, Gyorgy] Semmelweis Univ, Dept Pulmonol, H-1085 Budapest, Hungary.
[Colman, Ricki J.] Univ Wisconsin, William S Middleton Mem Vet Hosp, Wisconsin Natl Primate Res Center, Madison, WI 53706 USA.
[Weindruch, Richard; Anderson, Rozalyn M.] Univ Wisconsin, William S Middleton Mem Vet Hosp, Sch Med & Publ Hlth, Dept Med, Madison, WI 53706 USA.
[Weindruch, Richard; Anderson, Rozalyn M.] Univ Wisconsin, William S Middleton Mem Vet Hosp, Geriatr Res Educ & Clin Ctr, Madison, WI 53706 USA.
RP Csiszar, A (reprint author), Univ Oklahoma HSC, Reynolds Oklahoma Ctr Aging, Dept Geriatr Med, 975 NE 10th St,BRC 1303, Oklahoma City, OK 73104 USA.
EM anna-csiszar@ouhsc.edu; zoltan-ungvari@ouhsc.edu
FU American Federation for Aging Research; Oklahoma Center for the
Advancement of Science and Technology; University of Oklahoma College of
Medicine Alumni Association; American Heart Association; National
Institutes of Health (NIH) [AG031085, AT006526, P01 AG011915, P51
RR000167, AG038747, NS056218, P01 AG11370]; Ellison Medical Foundation;
Arkansas Claude Pepper Older Americans Independence Center at University
of Arkansas Medical Center; NCRR [RR15459-01, RR020141-01]; Donald W.
Reynolds Foundation
FX This work was supported by grants from the American Federation for Aging
Research (to A. C.), the Oklahoma Center for the Advancement of Science
and Technology (to A. C., Z.U., and W. E. S.), the University of
Oklahoma College of Medicine Alumni Association (to A. C.), the American
Heart Association (to A. C., P. T., and Z.U.), the National Institutes
of Health (NIH) (AG031085 to A. C., AT006526 to Z.U., P01 AG011915 to R.
W., P51 RR000167 to W.N.P.R.C., and AG038747, NS056218, and P01 AG11370
to W. E. S.), the Ellison Medical Foundation (to W. E. S.), and the
Arkansas Claude Pepper Older Americans Independence Center at University
of Arkansas Medical Center (to A. C.). This research was conducted in
part at a facility constructed with support from Research Facilities
Improvement Program grant numbers RR15459-01 and RR020141-01 from NCRR.;
The authors would like to express their gratitude for the support of the
Donald W. Reynolds Foundation, which funds aging research at the
University of Oklahoma Health Sciences Center under its Aging and
Quality of Life Program.
NR 124
TC 19
Z9 20
U1 3
U2 15
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD MAR
PY 2013
VL 68
IS 3
BP 235
EP 249
DI 10.1093/gerona/gls158
PG 15
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA 088PM
UT WOS:000314847600003
PM 22904098
ER
PT J
AU Duong, VH
Jaglal, MV
Zhang, L
Kale, V
Lancet, JE
Komrokji, RS
List, AF
AF Duong, Vu H.
Jaglal, Michael V.
Zhang, Ling
Kale, Vishakha
Lancet, Jeffrey E.
Komrokji, Rami S.
List, Alan F.
TI Phase II pilot study of oral dasatinib in patients with higher-risk
myelodysplastic syndrome (MDS) who failed conventional therapy
SO LEUKEMIA RESEARCH
LA English
DT Article
DE Myelodysplastic syndromes; Myelodysplastic-myeloproliferative diseases;
Dasatinib; Azacitidine; Decitabine
ID ACUTE MYELOID-LEUKEMIA; SRC FAMILY KINASES; SCORING SYSTEM;
ONCOLOGY-GROUP; TRISOMY-8; EXPRESSION; INHIBITOR; SURVIVAL; IMPACT; LYN
AB Given evidence for the role of Src family kinases, especially Lyn kinase, in myeloblast proliferation and the in vitro inhibitory activity of dasatinib on Src and Lyn, we conducted a phase II study to assess overall response to 100 mg/day dasatinib in patients with higher-risk myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia arising from MDS and who had failed prior treatment with azanucleoside analogs. Among 18 patients treated, 3 responded, 4 had stable disease, and 10 experienced disease progression. Toxicities were limited and consistent with previous reports. Dasatinib appears to be safe but with limited efficacy. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Duong, Vu H.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
[Jaglal, Michael V.; Zhang, Ling; Lancet, Jeffrey E.; Komrokji, Rami S.; List, Alan F.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Kale, Vishakha] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Komrokji, RS (reprint author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr,FOB 3,Room 3117, Tampa, FL 33612 USA.
EM rami.komrokji@moffitt.org
OI Jaglal, Michael/0000-0002-4305-2535
FU Bristol-Myers Squibb
FX We thank Rasa Hamilton (Moffitt Cancer Center) for editorial assistance.
This study was funded by Bristol-Myers Squibb.
NR 26
TC 8
Z9 8
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0145-2126
J9 LEUKEMIA RES
JI Leuk. Res.
PD MAR
PY 2013
VL 37
IS 3
BP 300
EP 304
DI 10.1016/j.leukres.2012.11.001
PG 5
WC Oncology; Hematology
SC Oncology; Hematology
GA 088XP
UT WOS:000314871500014
PM 23273539
ER
PT J
AU Goulet, JL
Brandt, C
Crystal, S
Fiellin, DA
Gibert, C
Gordon, AJ
Kerns, RD
Maisto, S
Justice, AC
AF Goulet, Joseph L.
Brandt, Cynthia
Crystal, Stephen
Fiellin, David A.
Gibert, Cynthia
Gordon, Adam J.
Kerns, Robert D.
Maisto, Stephen
Justice, Amy C.
TI Agreement Between Electronic Medical Record-based and Self-administered
Pain Numeric Rating Scale Clinical and Research Implications
SO MEDICAL CARE
LA English
DT Article
DE veterans; pain screening; electronic medical records
ID 5TH VITAL SIGN; COGNITIVE IMPAIRMENT; DIABETES PATIENTS; VETERANS;
MANAGEMENT; DEPRESSION; PREVALENCE; QUALITY; SYSTEM; CARE
AB Background: Pain screening may improve the quality of care by identifying patients in need of further assessment and management. Many health care systems use the numeric rating scale (NRS) for pain screening, and record the score in the patients' electronic medical record (EMR).
Objective: Determine the level of agreement between EMR and patient survey NRS, and whether discrepancies vary by demographic and clinical characteristics.
Methods: We linked survey data from a sample of veterans receiving care in 8 Veterans Affairs medical facilities, to EMR data including an NRS collected on the day of the survey to compare responses to the NRS question from these 2 sources. We assessed correlation, agreement on clinical cut-points (eg, severe), and, using the survey as the gold standard, whether patient characteristics were associated with a discrepancy on moderate-severe pain.
Results: A total of 1643 participants had a survey and EMR NRS score on the same day. The correlation was 0.56 (95% confidence interval, 0.52-0.59), but the mean EMR score was significantly lower than the survey score (1.72 vs. 2.79; P < 0.0001). Agreement was moderate (kappa = 0.35). Characteristics associated with an increased odds of a discrepancy included: diabetes [adjusted odds ratio (AOR) = 1.48], posttraumatic stress disorder (AOR = 1.59), major depressive disorder (AOR = 1.81), other race versus white (AOR = 2.29), and facility in which care was received.
Conclusions: The underestimation of pain using EMR data, especially clinically actionable levels of pain, has important clinical and research implications. Improving the quality of pain care may require better screening.
C1 [Goulet, Joseph L.; Brandt, Cynthia; Kerns, Robert D.; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA.
[Goulet, Joseph L.; Kerns, Robert D.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Brandt, Cynthia] Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06510 USA.
[Crystal, Stephen] Rutgers State Univ, Inst Hlth, Ctr Hlth Serv Res Pharmacotherapy Chron Dis Manag, New Brunswick, NJ 08903 USA.
[Fiellin, David A.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
[Gibert, Cynthia] VA Med Ctr, Washington, DC USA.
[Gibert, Cynthia] George Washington Univ, Med Ctr, Washington, DC 20037 USA.
[Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Gordon, Adam J.] Univ Pittsburgh, Ctr Res Hlth Care, Pittsburgh, PA USA.
[Kerns, Robert D.] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA.
[Kerns, Robert D.] Yale Univ, Sch Med, Dept Psychol, New Haven, CT 06510 USA.
[Maisto, Stephen] VA Syracuse, Syracuse, NY USA.
[Maisto, Stephen] Syracuse Univ, Dept Psychol, Syracuse, NY USA.
[Justice, Amy C.] Yale Univ, Sch Med, Sch Med & Publ Hlth, New Haven, CT USA.
RP Goulet, JL (reprint author), VA Connecticut Healthcare Syst, 950 Campbell Ave,Bldg 35A,Room 2-207, West Haven, CT 06516 USA.
EM joseph.goulet@va.gov
OI Fiellin, David/0000-0002-4006-010X; Goulet, Joseph/0000-0002-0842-804X
FU National Institute on Alcohol and Alcohol Abuse [U01 AA 13566, U10 AA
13566]; VA HSR&D Research Enhancement Award Program [REAP 08-266]; AHRQ
[U18-HS016097]
FX Supported by National Institute on Alcohol and Alcohol Abuse (U01 AA
13566 and U10 AA 13566), and VA HSR&D Research Enhancement Award Program
(REAP 08-266). S. C.'s work is supported in part by AHRQ U18-HS016097.
NR 41
TC 18
Z9 19
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
J9 MED CARE
JI Med. Care
PD MAR
PY 2013
VL 51
IS 3
BP 245
EP 250
DI 10.1097/MLR.0b013e318277f1ad
PG 6
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 090NE
UT WOS:000314985100007
PM 23222528
ER
PT J
AU Walensky, LD
AF Walensky, Loren D.
TI PROTEIN-PROTEIN INTERACTIONS A PUMA mechanism unfolds
SO NATURE CHEMICAL BIOLOGY
LA English
DT News Item
ID P53; ACTIVATION; APOPTOSIS; BAX
C1 [Walensky, Loren D.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Walensky, Loren D.] Dana Farber Canc Inst, Linde Program Canc Chem Biol, Boston, MA 02115 USA.
RP Walensky, LD (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
EM loren_walensky@dfci.harvard.edu
FU NCI NIH HHS [R01 CA050239]; NIGMS NIH HHS [R01 GM090299]
NR 10
TC 0
Z9 0
U1 0
U2 20
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1552-4450
J9 NAT CHEM BIOL
JI Nat. Chem. Biol.
PD MAR
PY 2013
VL 9
IS 3
BP 141
EP 143
PG 3
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 092OW
UT WOS:000315132900005
PM 23416398
ER
PT J
AU Mroz, EA
Rocco, JW
AF Mroz, Edmund A.
Rocco, James W.
TI MATH, a novel measure of intratumor genetic heterogeneity, is high in
poor-outcome classes of head and neck squamous cell carcinoma
SO ORAL ONCOLOGY
LA English
DT Article
DE Head and neck cancer; Intratumor heterogeneity; Tumor biomarkers;
Next-generation DNA sequencing; Somatic mutations; TP53; Human
papillomavirus; Cigarette smoking
ID HUMAN-PAPILLOMAVIRUS; OROPHARYNGEAL CANCER; EVOLUTION; PROGRESSION;
DIVERSITY; SURVIVAL; MUTATIONS
AB Objectives: Differences among cancer cells within a tumor are important in tumorigenesis and treatment resistance, yet no measure of intratumor heterogeneity is suitable for routine application. We developed a quantitative measure of intratumor genetic heterogeneity, based on differences among mutated loci in the mutant-allele fractions determined by next-generation sequencing (NGS) of tumor DNA. We then evaluated the application of this measure to head and neck squamous cell carcinoma (HNSCC).
Materials and methods: We analyzed published electronically available NGS results for 74 HNSCC. For each tumor we calculated mutant-allele tumor heterogeneity (MATH) as the ratio of the width to the center of its distribution of mutant-allele fractions among tumor-specific mutated loci.
Results: Intratumor heterogeneity assessed by MATH was higher in three poor-outcome classes of HNSCC: tumors with disruptive mutations in the TP53 gene (versus wild-type TP53 or non-disruptive mutations), tumors negative versus positive for human papillomavirus (even when restricted to tumors having wild-type TP53), and HPV-negative tumors from smokers with more pack-years of cigarette exposure (with TP53 status taken into account).
Conclusion: The relation of this type of intratumor heterogeneity to HNSCC outcome classes supports its further evaluation as a prognostic biomarker. As NGS of tumor DNA becomes widespread in clinical research and practice, MATH should provide a simple, quantitative, and clinically practical biomarker to help evaluate relations of intratumor genetic heterogeneity to outcome in any type of cancer. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Mroz, Edmund A.; Rocco, James W.] Massachusetts Gen Hosp, Ctr Canc Res, Boston, MA 02114 USA.
[Mroz, Edmund A.; Rocco, James W.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Rocco, James W.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Rocco, James W.] Harvard Univ, Sch Med, Boston, MA USA.
RP Rocco, JW (reprint author), Massachusetts Gen Hosp, Jackson 904G,55 Fruit St, Boston, MA 02114 USA.
EM jrocco@partners.org
FU Norman Knight Fund; Flight Attendant Medical Research Institute;
National Institute of Dental and Craniofacial Research [R01 DE022087];
National Cancer Institute [R21 CA119591]
FX The Norman Knight Fund, the Flight Attendant Medical Research Institute,
the National Institute of Dental and Craniofacial Research (R01
DE022087), and the National Cancer Institute (R21 CA119591).
NR 22
TC 28
Z9 28
U1 1
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1368-8375
J9 ORAL ONCOL
JI Oral Oncol.
PD MAR
PY 2013
VL 49
IS 3
BP 211
EP 215
DI 10.1016/j.oraloncology.2012.09.007
PG 5
WC Oncology; Dentistry, Oral Surgery & Medicine
SC Oncology; Dentistry, Oral Surgery & Medicine
GA 088XT
UT WOS:000314871900010
PM 23079694
ER
PT J
AU Morse, LR
Sudhakar, S
Lazzari, AA
Tun, C
Garshick, E
Zafonte, R
Battaglino, RA
AF Morse, L. R.
Sudhakar, S.
Lazzari, A. A.
Tun, C.
Garshick, E.
Zafonte, R.
Battaglino, R. A.
TI Sclerostin: a candidate biomarker of SCI-induced osteoporosis
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bone biomarker; Osteoporosis; Rehabilitation medicine; Sclerostin;
Spinal cord injury
ID SPINAL-CORD-INJURY; X-RAY ABSORPTIOMETRY; REDUCES OSTEOCYTE EXPRESSION;
BONE-MINERAL DENSITY; MECHANICAL STIMULATION; ASSOCIATION; PROTEINS;
MARKERS; MICE
AB We assessed several circulating proteins as candidate biomarkers of bone status in men with chronic spinal cord injury. We report that sclerostin is significantly associated with bone mineral content and bone density at all skeletal sites tested. We found no association between bone and any other tested biomarker.
Spinal cord injury results in severe osteoporosis. To date, no circulating biomarker of spinal cord injury (SCI)-induced osteoporosis has been identified. We recently reported that circulating sclerostin is associated with bone density in chronic SCI. In this study, we assessed several circulating proteins as candidate biomarkers of bone in men with chronic SCI.
We assessed the relationship between bone mineral content or bone density and the following circulating bone-related proteins: sclerostin, DKK-1, soluble receptor activator of nuclear factor kappa B ligand, osteoprotegerin, osteocalcin, and c-telopeptide in 39 men with chronic SCI and 10 men with no SCI.
After adjusting for age, lower sclerostin levels were significantly associated with lower bone mineral content and bone density at all skeletal sites tested (p = 0.0002-0.03). No other circulating protein was associated with bone mineral content or bone mineral density (p = 0.18-0.99).
These findings suggest that circulating sclerostin reflects the severity of bone loss and is a candidate biomarker of osteoporosis severity in chronic SCI.
C1 [Morse, L. R.; Zafonte, R.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
[Morse, L. R.; Sudhakar, S.; Zafonte, R.] Spaulding Rehabil Hosp, Spaulding Harvard SCI Model Syst, Boston, MA USA.
[Morse, L. R.; Battaglino, R. A.] Forsyth Inst, Cambridge, MA 02142 USA.
[Morse, L. R.] VA Boston Healthcare Syst, Spinal Cord Injury Serv, Boston, MA USA.
[Lazzari, A. A.] VA Boston Healthcare Syst, Primary Care & Rehabil Sect, Boston, MA USA.
[Lazzari, A. A.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Tun, C.] VA Boston Healthcare Syst, Rehabil Med Serv, Boston, MA USA.
[Garshick, E.] VA Boston Healthcare Syst, Pulm & Crit Care Med Sect, Med Serv, Boston, MA USA.
[Garshick, E.] Harvard Univ, Brigham & Womens Hosp, Channing Lab, Dept Med,Med Sch, Boston, MA 02115 USA.
[Battaglino, R. A.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Battaglino, R. A.] Forsyth Inst, Skeletal Biol Dept, Cambridge, MA 02142 USA.
RP Battaglino, RA (reprint author), Forsyth Inst, Skeletal Biol Dept, 245 1st St, Cambridge, MA 02142 USA.
EM rbattaglino@forsyth.org
RI battaglino, ricardo/D-2892-2015; Morse, Leslie/C-9442-2015
OI Morse, Leslie/0000-0002-7426-6341
FU National Institute of Child Health and Human Development [R21HD057030,
R21HD057030-02S1]; National Institute of Arthritis and Musculoskeletal
and Skin Diseases [1R01AR059270]; Office of Research and Development,
Rehabilitation Research and Development [B6618R]
FX This study received support from: the National Institute of Child Health
and Human Development [R21HD057030 and R21HD057030-02S1], the National
Institute of Arthritis and Musculoskeletal and Skin Diseases
[1R01AR059270], and the Office of Research and Development,
Rehabilitation Research and Development [Merit Review Grant B6618R].
NR 27
TC 13
Z9 14
U1 0
U2 16
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937-941X
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAR
PY 2013
VL 24
IS 3
BP 961
EP 968
DI 10.1007/s00198-012-2072-0
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 089DH
UT WOS:000314889100022
PM 22801952
ER
PT J
AU Parikh, H
Jia, JP
Zhang, XJ
Chung, CC
Jacobs, KB
Yeager, M
Boland, J
Hutchinson, A
Burdett, L
Hoskins, J
Risch, HA
Stolzenberg-Solomon, RZ
Chanock, SJ
Wolpin, BM
Petersen, GM
Fuchs, CS
Hartge, P
Amundadottir, L
AF Parikh, Hemang
Jia, Jinping
Zhang, Xijun
Chung, Charles C.
Jacobs, Kevin B.
Yeager, Meredith
Boland, Joseph
Hutchinson, Amy
Burdett, Laura
Hoskins, Jason
Risch, Harvey A.
Stolzenberg-Solomon, Rachael Z.
Chanock, Stephen J.
Wolpin, Brian M.
Petersen, Gloria M.
Fuchs, Charles S.
Hartge, Patricia
Amundadottir, Laufey
TI A Resequence Analysis of Genomic Loci on Chromosomes 1q32.1, 5p15.33,
and 13q22.1 Associated With Pancreatic Cancer Risk
SO PANCREAS
LA English
DT Article
DE pancreatic cancer; targeted resequencing; GWAS; susceptibility loci;
SNP; 1000G
ID COHORT-CONSORTIUM PANSCAN; SUSCEPTIBILITY LOCI; WIDE ASSOCIATION;
POOLED-ANALYSIS; TERT-CLPTM1L LOCUS; VARIANTS; LUNG; PROSTATE; HISTORY
AB Objective: The objective of this study was to fine-map common pancreatic cancer susceptibility regions.
Methods: We conducted targeted Roche-454 resequencing across 428 kb in 3 genomic regions identified in genome-wide association studies (GWAS) of pancreatic cancer, on chromosomes 1q32.1, 5p15.33, and 13q22.1.
Results: An analytical pipeline for calling genotypes was developed using HapMap samples sequenced on chr5p15.33. Concordance to 1000 Genomes data for chr5p15.33 was greater than 96%. The concordance for chr1q32.1 and chr13q22.1 with pancreatic cancer GWAS data was greater than 99%. Between 9.2% and 19.0% of variants detected were not present in 1000 Genomes for the respective continental population. The majority of completely novel single-nucleotide polymorphisms (SNPs) were less common (minor allele frequency [MAF], <= 5%) or rare (MAF, <= 2%), illustrating the value of enlarging test sets for discovery of less common variants. Using the data set, we examined haplotype blocks across each region using a tag SNP analysis (r(2) > 0.8 for MAF of >= 5%) and determined that at least 196, 243, and 63 SNPs are required for fine-mapping chr1q32.1, chr5p15.33, and chr13q22.1, respectively, in European populations.
Conclusions: We have characterized germline variation in 3 regions associated with pancreatic cancer risk and show that targeted resequencing leads to the discovery of novel variants and improves the completeness of germline sequence variants for fine-mapping GWAS susceptibility loci.
C1 [Parikh, Hemang; Jia, Jinping; Chung, Charles C.; Hoskins, Jason; Chanock, Stephen J.; Amundadottir, Laufey] NCI, Lab Translat Genom, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Parikh, Hemang; Jia, Jinping; Zhang, Xijun; Chung, Charles C.; Jacobs, Kevin B.; Yeager, Meredith; Boland, Joseph; Hutchinson, Amy; Burdett, Laura; Hoskins, Jason; Stolzenberg-Solomon, Rachael Z.; Chanock, Stephen J.; Hartge, Patricia; Amundadottir, Laufey] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Zhang, Xijun; Jacobs, Kevin B.; Yeager, Meredith; Boland, Joseph; Hutchinson, Amy; Burdett, Laura] NCI, Core Genotyping Facil, SAIC Frederick Inc, Frederick, MD 21701 USA.
[Risch, Harvey A.] Yale Univ, Sch Med, Sch Publ Hlth, New Haven, CT USA.
[Wolpin, Brian M.; Fuchs, Charles S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Wolpin, Brian M.; Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
[Wolpin, Brian M.; Fuchs, Charles S.] Harvard Univ, Sch Med, Boston, MA USA.
[Petersen, Gloria M.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
RP Amundadottir, L (reprint author), NIH, Lab Translat Genom, Div Canc Epidemiol & Genet, 8717 Grovemont Circle, Gaithersburg, MD 20877 USA.
EM amundadottirl@mail.nih.gov
RI Hoskins, Jason/F-5672-2012; Amundadottir, Laufey/L-7656-2016
OI Hoskins, Jason/0000-0001-6944-1996; Amundadottir,
Laufey/0000-0003-1859-8971
FU Intramural Research Program of the Division of Cancer Epidemiology and
Genetics, National Cancer Institute, National Institutes of Health (NIH)
[HHSN261200800001E]
FX This work was supported in part by the Intramural Research Program of
the Division of Cancer Epidemiology and Genetics, National Cancer
Institute, National Institutes of Health (NIH) under contract no.
HHSN261200800001E.
NR 37
TC 4
Z9 4
U1 1
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
EI 1536-4828
J9 PANCREAS
JI Pancreas
PD MAR
PY 2013
VL 42
IS 2
BP 209
EP 215
DI 10.1097/MPA.0b013e318264cea5
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 090JL
UT WOS:000314975200005
PM 23295781
ER
PT J
AU Chen, MC
Go, VLW
Wu, SV
AF Chen, Monica C.
Go, Vay Liang W.
Wu, S. Vincent
TI Identification and Characterization of Corticotropin Releasing Hormone
(CRH) Type 1 System in Human Pancreatic Neuroendocrine Tumors
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Chen, Monica C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Go, Vay Liang W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Wu, S. Vincent] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
J9 PANCREAS
JI Pancreas
PD MAR
PY 2013
VL 42
IS 2
BP 371
EP 371
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 090JL
UT WOS:000314975200045
ER
PT J
AU Chen, MC
Go, VLW
Pham, H
Mulugeta, M
Solorzano, S
Martin, MG
Tache, Y
Wu, SV
AF Chen, Monica C.
Go, Vay Liang W.
Hung Pham
Mulugeta, Million
Solorzano, Sergio
Martin, Martin G.
Tache, Yvette
Wu, S. Vincent
TI Regulation of Corticotropin Releasing Hormone (CRH) and Urocortin Family
Peptide Expression in Human Carcinoid BON Cells
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Chen, Monica C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Go, Vay Liang W.; Hung Pham; Mulugeta, Million; Tache, Yvette] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Solorzano, Sergio; Martin, Martin G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA.
[Tache, Yvette; Wu, S. Vincent] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90095 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
J9 PANCREAS
JI Pancreas
PD MAR
PY 2013
VL 42
IS 2
BP 371
EP 372
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 090JL
UT WOS:000314975200046
ER
PT J
AU Choti, MA
Bobiak, S
Strosberg, JR
Benson, AB
Bloomston, PM
Yao, JC
Zornosa, CC
Bergsland, EK
Kulke, MH
Nakakura, EK
Shah, MH
AF Choti, Michael A.
Bobiak, Sarah
Strosberg, Jonathan R.
Benson, Al B., III
Bloomston, P. Mark
Yao, James C.
Zornosa, Carrie C.
Bergsland, Emily K.
Kulke, Matthew H.
Nakakura, Eric K.
Shah, Manisha H.
TI Prevalence of Functional Tumors in Neuroendocrine Carcinoma: An Analysis
from the NCCN NET Database
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Choti, Michael A.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA.
[Bobiak, Sarah; Zornosa, Carrie C.] Natl Comprehens Canc Network, Ft Washington, PA 19034 USA.
[Strosberg, Jonathan R.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Benson, Al B., III] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
[Bloomston, P. Mark; Shah, Manisha H.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Bloomston, P. Mark; Shah, Manisha H.] Solove Res Inst, Columbus, OH 43210 USA.
[Yao, James C.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Bergsland, Emily K.; Nakakura, Eric K.] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Kulke, Matthew H.] Dana Farber Canc Inst, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
J9 PANCREAS
JI Pancreas
PD MAR
PY 2013
VL 42
IS 2
BP 372
EP 372
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 090JL
UT WOS:000314975200047
ER
PT J
AU Kulke, MH
Chan, JA
Ryan, DP
Meyerhardt, JA
Fuchs, CS
Abrams, T
Regan, E
Brady, R
Weber, J
Campos, T
Kvols, LK
Strosberg, JR
AF Kulke, Matthew H.
Chan, Jennifer A.
Ryan, David P.
Meyerhardt, Jeffrey A.
Fuchs, Charles S.
Abrams, Thomas
Regan, Eileen
Brady, Rachel
Weber, Jill
Campos, Tiffany
Kvols, Larry K.
Strosberg, Jonathan R.
TI A Multi-Institutional Phase II Open-Label Study of AMG 479 in Advanced
Carcinoid and Pancreatic Neuroendocrine Tumors
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Kulke, Matthew H.; Chan, Jennifer A.; Meyerhardt, Jeffrey A.; Fuchs, Charles S.; Abrams, Thomas; Regan, Eileen; Brady, Rachel] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Ryan, David P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Weber, Jill; Campos, Tiffany; Kvols, Larry K.; Strosberg, Jonathan R.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
J9 PANCREAS
JI Pancreas
PD MAR
PY 2013
VL 42
IS 2
BP 377
EP 377
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 090JL
UT WOS:000314975200064
ER
PT J
AU Qian, ZR
Ter-Minassian, M
Chan, JA
Imamura, Y
Hooshmand, SM
Kuchiba, A
Morikawa, T
Brais, LK
Daskalova, A
Heafield, R
Lin, XH
Christiani, DC
Fuchs, CS
Ogino, S
Kulke, MH
AF Qian, Zhi Rong
Ter-Minassian, Monica
Chan, Jennifer A.
Imamura, Yu
Hooshmand, Susanne M.
Kuchiba, Aya
Morikawa, Teppei
Brais, Lauren K.
Daskalova, Anastassia
Heafield, Rachel
Lin, Xihong
Christiani, David C.
Fuchs, Charles S.
Ogino, Shuji
Kulke, Matthew H.
TI Expression of MTOR Pathway Components and Association With Clinical
Outcomes in Neuroendocrine Tumors
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Qian, Zhi Rong; Ter-Minassian, Monica; Chan, Jennifer A.; Imamura, Yu; Hooshmand, Susanne M.; Kuchiba, Aya; Morikawa, Teppei; Brais, Lauren K.; Daskalova, Anastassia; Heafield, Rachel; Fuchs, Charles S.; Ogino, Shuji; Kulke, Matthew H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Qian, Zhi Rong; Ter-Minassian, Monica; Chan, Jennifer A.; Imamura, Yu; Hooshmand, Susanne M.; Kuchiba, Aya; Morikawa, Teppei; Brais, Lauren K.; Daskalova, Anastassia; Heafield, Rachel; Fuchs, Charles S.; Ogino, Shuji; Kulke, Matthew H.] Harvard Univ, Sch Med, Boston, MA USA.
[Lin, Xihong] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Ter-Minassian, Monica; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Christiani, David C.; Ogino, Shuji] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Christiani, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Fuchs, Charles S.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
[Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
J9 PANCREAS
JI Pancreas
PD MAR
PY 2013
VL 42
IS 2
BP 379
EP 379
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 090JL
UT WOS:000314975200073
ER
PT J
AU Schnabel, CA
Kerr, SE
Sullivan, P
Zhang, Y
Singh, V
Carey, B
Erlander, MG
Highsmith, WE
Brachtel, EF
Dry, SM
AF Schnabel, Catherine A.
Kerr, Sarah E.
Sullivan, Peggy
Zhang, Yi
Singh, Veena
Carey, Brittany
Erlander, Mark G.
Highsmith, W. Edward
Brachtel, Elena F.
Dry, Sarah M.
TI Use of a 92-gene Molecular Classifier to Predict the Site of Origin for
Primary and Metastatic Tumors with Neuroendocrine Differentiation
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Schnabel, Catherine A.; Zhang, Yi; Singh, Veena; Erlander, Mark G.] BioTheranostics Inc, San Diego, CA USA.
[Kerr, Sarah E.; Highsmith, W. Edward] Mayo Clin, Rochester, MN USA.
[Sullivan, Peggy; Dry, Sarah M.] Univ Calif Los Angeles, Los Angeles, CA USA.
[Carey, Brittany; Brachtel, Elena F.] Massachussetts Gen Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
J9 PANCREAS
JI Pancreas
PD MAR
PY 2013
VL 42
IS 2
BP 380
EP 380
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 090JL
UT WOS:000314975200074
ER
PT J
AU Ter-Minassian, M
Chan, JA
Hooshmand, SM
Brais, LK
Daskalova, A
Heafield, R
Buchanan, L
Qian, ZR
Lin, XH
Christiani, DC
Kulke, MH
AF Ter-Minassian, Monica
Chan, Jennifer A.
Hooshmand, Susanne M.
Brais, Lauren K.
Daskalova, Anastassia
Heafield, Rachel
Buchanan, Laurie
Qian, Zhi Rong
Lin, Xihong
Christiani, David C.
Kulke, Matthew H.
TI Duration and Type of Presenting Symptoms in Patients with Neuroendocrine
Tumor (NET)
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Ter-Minassian, Monica; Chan, Jennifer A.; Hooshmand, Susanne M.; Brais, Lauren K.; Daskalova, Anastassia; Heafield, Rachel; Buchanan, Laurie; Qian, Zhi Rong; Kulke, Matthew H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Ter-Minassian, Monica; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Lin, Xihong] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
J9 PANCREAS
JI Pancreas
PD MAR
PY 2013
VL 42
IS 2
BP 384
EP 384
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 090JL
UT WOS:000314975200088
ER
PT J
AU Yao, JC
Pavel, ME
Fazio, N
Kulke, M
Singh, S
Shah, G
Klimovsky, J
Strosberg, J
AF Yao, James C.
Pavel, Marianne E.
Fazio, Nicola
Kulke, Matthew
Singh, Simron
Shah, Gaurav
Klimovsky, Judith
Strosberg, Jonathan
TI RADIANT-4: A Randomized, Double-blind, Multicenter, Phase III Study of
Everolimus Versus Placebo in the Treatment of Patients With Advanced
Non-functional NET of GI or Lung Origin
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Yao, James C.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Pavel, Marianne E.] Charite, Campus Virchow Klinikum, D-10117 Berlin, Germany.
[Fazio, Nicola] European Inst Oncol, I-20141 Milan, Italy.
[Kulke, Matthew] Dana Farber Canc Inst, Boston, MA 02215 USA.
Sunnybrook Odette Canc Ctr, Toronto, ON M4N 3M5, Canada.
[Singh, Simron; Shah, Gaurav; Klimovsky, Judith] Novartis, Florham Pk, NJ 07932 USA.
[Strosberg, Jonathan] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
J9 PANCREAS
JI Pancreas
PD MAR
PY 2013
VL 42
IS 2
BP 386
EP 386
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 090JL
UT WOS:000314975200096
ER
PT J
AU Zornosa, CC
Choti, MA
Bobiak, S
Kulke, MH
Yao, JC
Bergsland, EK
Nakakura, EK
Bloomston, PM
Benson, AB
Shah, MH
Strosberg, JR
AF Zornosa, Carrie C.
Choti, Michael A.
Bobiak, Sarah
Kulke, Matthew H.
Yao, James C.
Bergsland, Emily K.
Nakakura, Eric K.
Bloomston, P. Mark
Benson, Al B., III
Shah, Manisha H.
Strosberg, Jonathan R.
TI Baseline Demographics of Neuroendocrine Tumor Patients Presenting to
Seven National Comprehensive Cancer Network (NCCN) Institutions:
Development of a Multi-Institutional Outcomes Database
SO PANCREAS
LA English
DT Meeting Abstract
C1 [Zornosa, Carrie C.; Bobiak, Sarah] Natl Comprehens Canc Network, Ft Washington, PA 19034 USA.
[Choti, Michael A.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA.
[Kulke, Matthew H.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Yao, James C.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Bergsland, Emily K.; Nakakura, Eric K.] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Bloomston, P. Mark; Shah, Manisha H.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Bloomston, P. Mark; Shah, Manisha H.] Solove Res Inst, Columbus, OH 43210 USA.
[Benson, Al B., III] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
[Strosberg, Jonathan R.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0885-3177
J9 PANCREAS
JI Pancreas
PD MAR
PY 2013
VL 42
IS 2
BP 387
EP 387
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 090JL
UT WOS:000314975200099
ER
PT J
AU Schendan, HE
Ganis, G
AF Schendan, Haline E.
Ganis, Giorgio
TI Face-specificity is robust across diverse stimuli and individual people,
even when interstimulus variance is zero
SO PSYCHOPHYSIOLOGY
LA English
DT Article
DE Sensation; Perception; EEG; ERP; Cognition; Individual differences;
Learning; Memory; Normal volunteers
ID PERCEPTUAL VARIANCE; HUMAN BRAIN; N170; ACCOUNT; CORTEX
AB The N170 is a brain electrical potential proposed to index the earliest time of categorical perception of faces in occipitotemporal visual areas implicated in face cognition, being more negative for faces than nonface objects between 120 and 200ms. The interstimulus variance (ISV) account instead explained N170 face-specificity as an artifact due to objects varying more visually than faces. Ganis, Smith, and Schendan (2012) tested this account directly, finding that N170 face-specificity remains even when ISV is eliminated. Here, N170 peak amplitude and face-specificity is quantified for individual stimuli and participants, revealing that the right hemisphere N170 is especially sensitive to stimulus variability. Further, ISV contributes 0 to 37% to N170 face-specificity. These findings provide evidence for optimizing face processing science. The paradigm can apply to any research in which ISV may be uncontrolled (e.g., category comparisons).
C1 [Schendan, Haline E.; Ganis, Giorgio] Univ Plymouth, Sch Psychol, Cognit Inst, Plymouth PL4 8AA, Devon, England.
[Schendan, Haline E.; Ganis, Giorgio] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Ganis, Giorgio] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
RP Schendan, HE (reprint author), Univ Plymouth, Sch Psychol, Plymouth PL4 8AA, Devon, England.
EM haline.schendan@plymouth.ac.uk
RI sebastianovitsch, stepan/G-8507-2013;
OI Ganis, Giorgio/0000-0001-6175-2618; Schendan, Haline/0000-0001-8925-5605
FU Plymouth University
FX Research was supported by Plymouth University.
NR 15
TC 2
Z9 4
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0048-5772
J9 PSYCHOPHYSIOLOGY
JI Psychophysiology
PD MAR
PY 2013
VL 50
IS 3
BP 287
EP 291
DI 10.1111/psyp.12013
PG 5
WC Psychology, Biological; Neurosciences; Physiology; Psychology;
Psychology, Experimental
SC Psychology; Neurosciences & Neurology; Physiology
GA 087JL
UT WOS:000314757500007
PM 23350993
ER
PT J
AU Fan, X
Borba, CPC
Copeland, P
Hayden, D
Freudenreich, O
Goff, DC
Henderson, DC
AF Fan, X.
Borba, C. P. C.
Copeland, P.
Hayden, D.
Freudenreich, O.
Goff, D. C.
Henderson, D. C.
TI Metabolic effects of adjunctive aripiprazole in clozapine-treated
patients with schizophrenia
SO ACTA PSYCHIATRICA SCANDINAVICA
LA English
DT Article
DE antipsychotics; schizophrenia; metabolic syndrome
ID ATYPICAL ANTIPSYCHOTIC-DRUGS; PLACEBO-CONTROLLED TRIAL;
GLUCOSE-TOLERANCE TEST; INSULIN-RESISTANCE; DOUBLE-BLIND; WEIGHT-GAIN;
POSTMENOPAUSAL WOMEN; DIABETES-MELLITUS; SKELETAL-MUSCLE; PARTICLE-SIZE
AB Fan X, Borba CPC, Copeland P, Hayden D, Freudenreich O, Goff DC, Henderson DC. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Objective: This study examined the effects of adjunctive aripiprazole therapy on metabolism in clozapine-treated patients with schizophrenia. Method: In an 8-week randomized, double-blind, placebo-controlled study, subjects received either aripiprazole (15mg/day) or placebo. At baseline and week 8, metabolic parameters were assessed by the frequently sampled intravenous glucose tolerance test, nuclear magnetic resonance spectroscopy and whole-body dual-energy X-ray absorptiometry (DXA). Results: Thirty subjects completed the study (16 in the aripiprazole group and 14 in the placebo group). Glucose effectiveness measured by the frequently sampled intravenous glucose tolerance test improved significantly in the aripiprazole group (0.003 +/- 0.006 vs. 0.005 +/- 0.007/min, P=0.010). The aripiprazole group showed significant reductions in both plasma low-density lipoprotein (LDL) levels (15.1 +/- 19.8 vs. 4.4 +/- 22.5mg/dl, P=0.019) and LDL particle numbers (376 +/- 632 vs. 36 +/- 301nm, P=0.035). Further, there was a significant reduction in the lean mass (1125 +/- 1620 vs. 607 +/- 1578g, P=0.011) measured by whole-body DXA scan in the aripiprazole group. All values were expressed as mean +/- standard deviation, aripiprazole vs. placebo. Conclusion: Adjunctive therapy with aripiprazole may have some metabolic benefits in clozapine-treated patients with schizophrenia.
C1 [Fan, X.; Borba, C. P. C.; Freudenreich, O.; Goff, D. C.; Henderson, D. C.] Massachusetts Gen Hosp, Dept Psychiat, Schizophrenia Program, Boston, MA 02114 USA.
[Fan, X.; Borba, C. P. C.; Copeland, P.; Freudenreich, O.; Goff, D. C.; Henderson, D. C.] Harvard Univ, Sch Med, Boston, MA USA.
[Copeland, P.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Hayden, D.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
RP Fan, X (reprint author), Freedom Trail Clin, 25 Staniford St, Boston, MA 02114 USA.
EM xiaoduo.fan@umassmed.edu
FU National Institutes of Health [5R01MH072635]; National Institutes of
Health, National Center for Research Resources General Clinical Research
Centers Program (MGH Clinical research Center) [M01-RR-01066, UL1
RR025758-01]; Eli Lilly; AstraZeneca; Bristol-Myer-Squibb; Janssen;
Pfizer; Cephalon; Bristol-Myers Squibb; Indevus Pharmaceuticals; H.
Lundbeck; Schering-Plough; Takeda; Biovail; Sovay; Hoffman-La Roche;
Cypress; Dainippon Sumitomo; Abbott Laboratories; Genentech; Novartis;
PamLab; GlaxoSmithKline; Endo Pharmaceuticals; Solvay; Covance; Alkermis
FX This study was supported by Grant 5R01MH072635 from the National
Institutes of Health (Dr. Henderson), Grant M01-RR-01066 and Grant UL1
RR025758-01 from the National Institutes of Health, National Center for
Research Resources General Clinical Research Centers Program (MGH
Clinical research Center).; Dr. Fan has received research support or
honoraria from Eli Lilly, AstraZeneca, Bristol-Myer-Squibb, Janssen and
Pfizer. Dr. Freudenreich has received research support or honoraria from
AstraZeneca, Bristol-Myer-Squibb, Janssen, Eli Lilly, Cephalon and
Pfizer. Dr. Goff has received research support or honoraria from
Bristol-Myers Squibb, Indevus Pharmaceuticals, H. Lundbeck,
Schering-Plough, Eli Lilly, Takeda, Biovail, Sovay, Hoffman-La Roche,
Cypress, Dainippon Sumitomo, Abbott Laboratories, Genentech, Pfizer,
Janssen, Novartis, PamLab and GlaxoSmithKline and Endo Pharmaceuticals.
He served on a DSMB for Otsuka. Dr. Henderson has received research
support or honoraria from Takeda, Janssen, Solvay, Novartis, Covance,
Alkermis and Pfizer. Dr. Borba, Dr. Copeland and Mr. Hayden report no
competing interests.
NR 55
TC 26
Z9 27
U1 2
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-690X
J9 ACTA PSYCHIAT SCAND
JI Acta Psychiatr. Scand.
PD MAR
PY 2013
VL 127
IS 3
BP 217
EP 226
DI 10.1111/acps.12009
PG 10
WC Psychiatry
SC Psychiatry
GA 088RH
UT WOS:000314853200007
PM 22943577
ER
PT J
AU Gandy, S
Haroutunian, V
DeKosky, ST
Sano, M
Schadt, EE
AF Gandy, Sam
Haroutunian, Vahram
DeKosky, Steven T.
Sano, Mary
Schadt, Eric E.
TI CR1 and the "Vanishing Amyloid" Hypothesis of Alzheimer's Disease
SO BIOLOGICAL PSYCHIATRY
LA English
DT Editorial Material
ID OLDEST-OLD; DEMENTIA; GENE
C1 [Gandy, Sam; Haroutunian, Vahram; Sano, Mary] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Gandy, Sam; Haroutunian, Vahram; Sano, Mary] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA.
[Gandy, Sam] Icahn Sch Med Mt Sinai, Ctr Cognit Hlth, New York, NY 10029 USA.
[Gandy, Sam] Icahn Sch Med Mt Sinai, NFL Neurol Ctr, New York, NY 10029 USA.
[Schadt, Eric E.] Icahn Sch Med Mt Sinai, Inst Genom & Multiscale Biol, New York, NY 10029 USA.
[Schadt, Eric E.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA.
[Gandy, Sam; Haroutunian, Vahram; Sano, Mary] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[DeKosky, Steven T.] Univ Virginia, Charlottesville, VA USA.
RP Gandy, S (reprint author), Icahn Sch Med Mt Sinai, 1 Gustave L Levy Pl,Box 1137, New York, NY 10029 USA.
EM samuel.gandy@mssm.edu
FU BLRD VA [I01 BX000348]; NIA NIH HHS [AG02219, AG025204, AG042965,
AG05133, AG05138, AG14449, P01 AG002219, P01 AG014449, P01 AG025204, P50
AG005133, P50 AG005138, RF1 AG042965]; NINDS NIH HHS [NS075685, R01
NS075685]
NR 15
TC 8
Z9 9
U1 2
U2 25
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAR 1
PY 2013
VL 73
IS 5
BP 393
EP 395
DI 10.1016/j.biopsych.2013.01.013
PG 3
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 085SP
UT WOS:000314634900002
PM 23399469
ER
PT J
AU McCormick, AV
Wheeler, JM
Guthrie, CR
Liachko, NF
Kraemer, BC
AF McCormick, Allyson V.
Wheeler, Jeanna M.
Guthrie, Chris R.
Liachko, Nicole F.
Kraemer, Brian C.
TI Dopamine D2 Receptor Antagonism Suppresses Tau Aggregation and
Neurotoxicity
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Alzheimer's disease; antipsychotics; dopamine; drug screen; protein
aggregation; tau
ID PLACEBO-CONTROLLED TRIALS; CAENORHABDITIS-ELEGANS; ALZHEIMERS-DISEASE;
C-ELEGANS; TAUOPATHY; DEMENTIA; METAANALYSIS; PLAQUES; TANGLES; PROTEIN
AB Background: Tauopathies, including Alzheimer's disease and frontotemporal dementia, are diseases characterized by the formation of pathological tau protein aggregates in the brain and progressive neurodegeneration. Presently no effective disease-modifying treatments exist for tauopathies.
Methods: To identify drugs targeting tau neurotoxicity, we have used a Caenorhabditis elegans model of tauopathy to screen a drug library containing 1120 compounds approved for human use for the ability to suppress tau-induced behavioral effects.
Results: One compound, the typical antipsychotic azaperone, improved the motility of tau transgenic worms, reduced levels of insoluble tau, and was protective against neurodegeneration. We found that azaperone reduces insoluble tau in a human cell culture model of tau aggregation and that other antipsychotic drugs (flupenthixol, perphenazine, and zotepine) also ameliorate the effects of tau expression in both models.
Conclusions: Reduction of dopamine signaling through the dopamine D2 receptor with the use of gene knockouts in Caenorhabditis elegans or RNA interference knockdown in human cell culture has similar protective effects against tau toxicity. These results suggest dopamine D2 receptor antagonism holds promise as a potential neuroprotective strategy for targeting tau aggregation and neurotoxicity.
C1 [McCormick, Allyson V.; Wheeler, Jeanna M.; Guthrie, Chris R.; Liachko, Nicole F.; Kraemer, Brian C.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Kraemer, Brian C.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA USA.
RP Kraemer, BC (reprint author), Univ Washington Med, Seattle Vet Affairs Puget Sound Hlth Care Syst, Div Gerontol, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM kraemerb@u.washington.edu
FU Alzheimer's Association [IIRG-08-90627]; Department of Veterans Affairs;
National Institutes of Health [R01NS064131]
FX This work was supported by a grant from the Alzheimer's Association
(IIRG-08-90627, made possible in part by a generous gift from Sherrill
Miller). Support was also provided by the Department of Veterans Affairs
and a National Institutes of Health grant [R01NS064131] to BK.
NR 24
TC 14
Z9 17
U1 0
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD MAR 1
PY 2013
VL 73
IS 5
BP 464
EP 471
DI 10.1016/j.biopsych.2012.08.027
PG 8
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 085SP
UT WOS:000314634900012
PM 23140663
ER
PT J
AU Kobayashi, E
Iyer, AK
Hornicek, FJ
Amiji, MM
Duan, ZF
AF Kobayashi, Eisuke
Iyer, Arun K.
Hornicek, Francis J.
Amiji, Mansoor M.
Duan, Zhenfeng
TI Lipid-functionalized Dextran Nanosystems to Overcome Multidrug
Resistance in Cancer: A Pilot Study
SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
LA English
DT Article
ID MESOPOROUS SILICA NANOPARTICLES; P-GLYCOPROTEIN EXPRESSION; CARCINOMA
CELL-LINE; DRUG-RESISTANCE; OVARIAN-CANCER; POLYMERIC NANOPARTICLES;
ENHANCED PERMEABILITY; PACLITAXEL RESISTANCE; PROGNOSTIC-FACTORS; RNA
INTERFERENCE
AB The toxicity of anticancer agents and the difficulty in delivering drugs selectively to tumor cells pose a challenge in overcoming multidrug resistance (MDR). Recently, nanotechnology has emerged as a powerful tool in addressing some of the barriers to drug delivery, including MDR in cancer, by utilizing alternate routes of cellular entry and targeted delivery of drugs and genes. However, it is unclear whether doxorubicin (Dox) can be delivered by nanotechnologic approaches.
We asked whether (1) Dox-loaded lipid-functionalized dextran-based biocompatible nanoparticles (Dox/NP) can reverse MDR, (2) Dox/NP has more potent cytotoxic effect on MDR tumors than poly(ethylene glycol)-modified liposomal Dox (PLD), and (3) multidrug resistance protein 1 (MDR1) small interfering RNA loaded in these nanoparticles (siMDR1/NP) can modulate MDR.
To create stable Dox/NP and siMDR1/NP, we used two different lipid-modified dextran derivatives. The effect of Dox or Dox/NP was tested on drug-sensitive osteosarcoma (KHOS) and ovarian cancer (SKOV-3) cell cultures in triplicate and their respective MDR counterparts KHOSR2 and SKOV-3(TR) in triplicate. We determined the effects on drug retention, transfection efficacy of siMDR1/NP, and P-glycoprotein expression and the antiproliferative effect between Dox/NP and PLD in MDR tumor cells.
Fluorescence microscopy revealed efficient uptake of the Dox/NP and fluorescently tagged siMDR1/NP. Dox/NP showed five- to 10-fold higher antiproliferative activity at the 50% inhibitory concentration than free Dox in tumor cells. Dox/NP showed twofold higher activity than PLD in MDR tumor cells. siMDR1/NP (100 nM) suppressed P-glycoprotein expression in KHOSR2.
Dextran-lipid nanoparticles are a promising platform for delivering Dox and siRNAs.
Biocompatible dextran-based nanoparticles that are directly translatable to clinical medicine may lead to new potential therapeutics for reversing MDR in patients with cancer.
C1 [Kobayashi, Eisuke; Hornicek, Francis J.; Duan, Zhenfeng] Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA 02114 USA.
[Kobayashi, Eisuke; Hornicek, Francis J.; Duan, Zhenfeng] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
[Kobayashi, Eisuke; Hornicek, Francis J.; Duan, Zhenfeng] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Iyer, Arun K.; Amiji, Mansoor M.] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Boston, MA 02115 USA.
RP Duan, ZF (reprint author), Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, 100 Blossom St,Jackson 1115, Boston, MA 02114 USA.
EM zduan@partners.org
RI Amiji, Mansoor/A-4365-2014;
OI Amiji, Mansoor/0000-0001-6170-881X; Iyer, Arun/0000-0002-4428-0222
FU National Cancer Institute/NIH [UO1-CA 151452]; Gattegno Fund; Wechsler
Fund; Kenneth Stanton Fund for Sarcoma (Nashua, NH, USA); Sarcoma
Foundation of America (Damascus, MD, USA); Chordoma Foundation (Durham,
NC, USA)
FX The institution of one or more of the authors certifies that they have
received during the study period funding from grants from the National
Cancer Institute/NIH (UO1-CA 151452) (MMA, ZD), Gattegno and Wechsler
Funds (FJH, ZD), Kenneth Stanton Fund for Sarcoma (Nashua, NH, USA)
(FJH, ZD), Sarcoma Foundation of America (Damascus, MD, USA) (ZD), and
The Chordoma Foundation (Durham, NC, USA) (ZD). Each author certifies
that he or she, or a member of his or her immediate family, has no
commercial associations (eg, consultancies, stock ownership, equity
interest, patent/licensing arrangements, etc) that might pose a conflict
of interest in connection with the submitted article.
NR 59
TC 23
Z9 23
U1 0
U2 44
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0009-921X
J9 CLIN ORTHOP RELAT R
JI Clin. Orthop. Rel. Res.
PD MAR
PY 2013
VL 471
IS 3
BP 915
EP 925
DI 10.1007/s11999-012-2610-2
PG 11
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 084EC
UT WOS:000314518500030
PM 23011844
ER
PT J
AU Palioura, S
Chodosh, J
Pineda, R
AF Palioura, Sotiria
Chodosh, James
Pineda, Roberto
TI A Novel Approach to the Management of a Progressive Descemet Membrane
Tear in a Patient With Keratoglobus and Acute Hydrops
SO CORNEA
LA English
DT Article
DE keratoglobus; corneal hydrops; DSAEK; corneal ectasia; keratoconus
ID ACUTE CORNEAL HYDROPS; INTRACAMERAL INJECTION; KERATOCONUS;
DEGENERATION; SECONDARY; C3F8
AB Purpose: To report a case of corneal hydrops in a patient with keratoglobus that was managed with endothelial keratoplasty to achieve corneal stability and prevent a limbus-to-limbus tear in Descemet membrane.
Methods: A 30-year-old man with keratoglobus presented with corneal hydrops in his left eye resulting from a central vertical tear in Descemet membrane. His other eye had been previously treated with penetrating keratoplasty using a large graft (an 11-mm donor graft to a 10-mm recipient bed) because of a limbus-to-limbus tear in Descemet membrane without resolution of his edema. An attempt to approximate the edges of the Descemet tear in the left eye by an intracameral air injection failed, and the tear continued to progress peripherally. An endothelial keratoplasty button with anchoring sutures was placed over the Descemet tear because of excessive localized edema.
Results: One month after insertion of the sutured endothelial keratoplasty button, the edema had resolved, and 1 year later, the tear remains sealed. The patient's visual acuity improved from counting fingers at 1 foot to 20/100.
Conclusions: Reconstitution of the posterior corneal surface in keratoglobus-induced hydrops can be achieved with endothelial keratoplasty over the Descemet tear. Preventing progression of a central Descemet tear is essential to bypass the need for a large-diameter penetrating keratoplasty graft and its complications in a young patient with a history of bilateral corneal hydrops.
C1 [Palioura, Sotiria; Chodosh, James; Pineda, Roberto] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Cornea Serv,Dept Ophthalmol, Boston, MA 02114 USA.
RP Pineda, R (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA.
EM roberto_pineda@meei.har-vard.edu
FU Research to Prevent Blindness Inc, New York
FX Supported in part by an unrestricted grant to the Department of
Ophthalmology, Harvard Medical School, from Research to Prevent
Blindness Inc, New York.
NR 9
TC 0
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-3740
J9 CORNEA
JI Cornea
PD MAR
PY 2013
VL 32
IS 3
BP 355
EP 358
DI 10.1097/ICO.0b013e31825cea80
PG 4
WC Ophthalmology
SC Ophthalmology
GA 088FH
UT WOS:000314818700022
PM 22893098
ER
PT J
AU Tamez, H
Kalim, S
Thadhani, RI
AF Tamez, Hector
Kalim, Sahir
Thadhani, Ravi I.
TI Does vitamin D modulate blood pressure?
SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
LA English
DT Review
DE active vitamin D analogs; blood pressure and hypertension;
renin-angiotensin-aldosterone axis; vitamin D
ID RENIN-ANGIOTENSIN SYSTEM; 25-HYDROXYVITAMIN D LEVELS; NUTRITION
EXAMINATION SURVEY; RANDOMIZED CONTROLLED-TRIAL; 3RD NATIONAL-HEALTH;
INCIDENT HYPERTENSION; 1,25-DIHYDROXYVITAMIN D-3;
CARDIOVASCULAR-DISEASE; PARATHYROID-HORMONE; D SUPPLEMENTATION
AB Purpose of review
Both vitamin D deficiency and hypertension are highly prevalent. It is unclear whether vitamin D modulates blood pressure and therefore whether vitamin D testing and therapy should become part of routine hypertension prevention and management. This article provides an overview of the data, with special emphasis on the work published in the last 2 years.
Recent findings
Several animal studies corroborate the strong effect of vitamin D on the renin-angiotensin-aldosterone axis. Small and large observational studies have found associations between vitamin D, increased blood pressure, and the risk of developing hypertension. In contrast, recent data from randomized trials are mixed. Two randomized trials with approximately 1 year of follow-up detected no association between vitamin D treatment and blood pressure, whereas another study of active vitamin D reported a 9-mmHg decrease in systolic blood pressure. Meta-analyses have linked vitamin D levels with blood pressure, but the effect of vitamin D administration on blood pressure remains controversial.
Summary
Vitamin D deficiency is asociated with high blood pressure in observational studies. This effect is thought to be partly mediated through regulation of the renin-angiotensin-aldosterone axis. However, randomized clinical trials and their meta-analyses have yielded inconclusive results. Large randomized trials focusing on patients with severe vitamin D deficiency and hypertension are needed before vitamin D can be recommended for the prevention or treatment of hypertension.
C1 [Tamez, Hector; Kalim, Sahir; Thadhani, Ravi I.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.
RP Tamez, H (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Bulfinch 127, Boston, MA 02114 USA.
EM htamez@partners.org
FU Abbott Laboratories; National Institutes of Health [K24 DK094872, R01
DK094486]
FX R.I.T. has a research grant from Abbott Laboratories and is supported by
grants K24 DK094872 and R01 DK094486 from the National Institutes of
Health. H.T. and S.K. have no conflicts of interest.
NR 44
TC 22
Z9 27
U1 1
U2 25
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1062-4821
J9 CURR OPIN NEPHROL HY
JI Curr. Opin. Nephrol. Hypertens.
PD MAR
PY 2013
VL 22
IS 2
BP 204
EP 209
DI 10.1097/MNH.0b013e32835d919b
PG 6
WC Urology & Nephrology; Peripheral Vascular Disease
SC Urology & Nephrology; Cardiovascular System & Cardiology
GA 086PC
UT WOS:000314696900011
PM 23299053
ER
PT J
AU Christov, M
Pereira, R
Wesseling-Perry, K
AF Christov, Marta
Pereira, Renata
Wesseling-Perry, Kate
TI Bone biopsy in renal osteodystrophy: continued insights into a complex
disease
SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
LA English
DT Review
DE African-American; chronic kidney disease mineral and bone disorder;
fibroblast growth factor 23; osteocyte; pediatric
ID CHRONIC KIDNEY-DISEASE; GROWTH-FACTOR 23; ADYNAMIC BONE;
HEMODIALYSIS-PATIENTS; SECONDARY HYPERPARATHYROIDISM; CORONARY
CALCIFICATION; PARATHYROID-HORMONE; MINERAL METABOLISM; TURNOVER;
CALCIUM
AB Purpose of review
The pathogenesis and optimal therapy of renal bone disease remains poorly understood in chronic kidney disease (CKD) and dialysis patients. Bone biopsy is thus far the only window into cellular and molecular events in bone. This review will focus on recent insights into the pathophysiology of renal bone disease, as highlighted by bone biopsy, and discuss implications for treatment.
Recent findings
Abnormalities in bone physiology start very early in children and adults with CKD, when most clinically measurable mineral metabolism parameters are normal. In addition, racial differences, known to exist in serum markers such as parathyroid hormone, also appear prominent in the bone, suggesting that clinical treatment guidelines may not address the needs of all patient populations. The effects of treatments for secondary hyperparathyroidism on bone may be unexpected.
Summary
With the help of bone biopsy studies, molecular insights into the pathogenesis of renal osteodystrophy are beginning to emerge. Current therapies may have unexpected effects on bone physiology.
C1 [Christov, Marta] Beth Israel Deaconess Med Ctr, Div Nephrol, Boston, MA 02214 USA.
[Christov, Marta] Massachusetts Gen Hosp, Div Endocrinol, Boston, MA 02114 USA.
[Pereira, Renata; Wesseling-Perry, Kate] UCLA Sch Med, Los Angeles, CA USA.
RP Christov, M (reprint author), Beth Israel Deaconess Med Ctr, 185 Pilgrim Rd,Farr8 Renal Unit, Boston, MA 02214 USA.
EM mchrist3@bidmc.harvard.edu
FU NIDDK NIH HHS [K08 DK093608]
NR 33
TC 3
Z9 6
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1062-4821
J9 CURR OPIN NEPHROL HY
JI Curr. Opin. Nephrol. Hypertens.
PD MAR
PY 2013
VL 22
IS 2
BP 210
EP 215
DI 10.1097/MNH.0b013e32835dda01
PG 6
WC Urology & Nephrology; Peripheral Vascular Disease
SC Urology & Nephrology; Cardiovascular System & Cardiology
GA 086PC
UT WOS:000314696900012
PM 23318700
ER
PT J
AU Mount, DB
AF Mount, David B.
TI The kidney in hyperuricemia and gout
SO CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
LA English
DT Review
DE allopurinol; colchicine; febuxostat; gout; transporter; uric acid
ID SERUM URIC-ACID; NUTRITION EXAMINATION SURVEY; OF-RHEUMATOLOGY
GUIDELINES; US GENERAL-POPULATION; URATE TRANSPORTER;
ESSENTIAL-HYPERTENSION; METABOLIC SYNDROME; RENAL EXCRETION;
NATIONAL-HEALTH; ADVERSE EVENTS
AB Purpose of review
Gout is a painful inflammatory arthritis associated with hyperuricemia, with a prevalence of almost 10 million in the USA. Reduced renal excretion of urate is the underlying hyperuricemic mechanism in the vast majority of gout patients; most of the genes that affect serum urate level (SUA) encode urate transporters or associated regulatory proteins. Acquired influences can also modulate SUA and renal urate excretion, sometimes precipitating acute gout. Coincidentally, the prevalence of renal comorbidities in gout - hypertension, chronic kidney disease (CKD), and nephrolithiasis - is very high.
Recent findings
Recent advances in genetics and molecular physiology have greatly enhanced the understanding of renal reabsorption and secretion of filtered urate. Moreover, baseline SUA appears to be set by the net balance of absorption and secretion across epithelial cells in the kidney and intestine. There have also been substantial advances in the management of gout in patients with CKD.
Summary
The stage is set for an increasingly molecular understanding of baseline and regulated urate transport by the kidney and intestine. The increasing prevalence of gout with CKD will be balanced by an expanding spectrum of therapeutic options for this important disease.
C1 [Mount, David B.] VA Boston Healthcare Syst, Brigham & Womens Hosp, Div Renal, Boston, MA USA.
RP Mount, DB (reprint author), R Oom 540,4 Blackfan Circle, Boston, MA 02115 USA.
EM david.mount2@va.gov
FU NIH [DK070756]; Veterans Administration; Takeda
FX The author's research in this area has been supported by the NIH
(DK070756) and the Veterans Administration. He is the recipient of an
investigator-initiated research grant from Takeda.
NR 74
TC 15
Z9 16
U1 2
U2 25
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1062-4821
J9 CURR OPIN NEPHROL HY
JI Curr. Opin. Nephrol. Hypertens.
PD MAR
PY 2013
VL 22
IS 2
BP 216
EP 223
DI 10.1097/MNH.0b013e32835ddad2
PG 8
WC Urology & Nephrology; Peripheral Vascular Disease
SC Urology & Nephrology; Cardiovascular System & Cardiology
GA 086PC
UT WOS:000314696900013
PM 23318701
ER
PT J
AU Lai, PS
Christiani, DC
AF Lai, Peggy S.
Christiani, David C.
TI Long-term respiratory health effects in textile workers
SO CURRENT OPINION IN PULMONARY MEDICINE
LA English
DT Review
DE byssinosis; chronic obstructive pulmonary disease; endotoxin; lung;
textile; vegetable dust
ID OBSTRUCTIVE PULMONARY-DISEASE; CHRONIC LUNG-DISEASE; AIR-FLOW
OBSTRUCTION; COTTON DUST; VENTILATORY CAPACITY; ENDOTOXIN EXPOSURE;
BYSSINOSIS; EPIDEMIOLOGY; PREDICTORS; REACTIVITY
AB Purpose of review
Over 60 million people worldwide work in the textile or clothing industry. Recent studies have recognized the contribution of workplace exposures to chronic lung diseases, in particular chronic obstructive pulmonary disease (COPD). Early studies in textile workers have focused on the relationship between hemp or cotton dust exposure and the development of a syndrome termed byssinosis. The purpose of this review is to evaluate the effect of long-term exposure to organic dust in textile workers on chronic respiratory disease in the broader context of disease classifications, such as reversible or irreversible obstructive lung disease (i.e. asthma or COPD), and restrictive lung disease.
Recent findings
Cessation of exposure to cotton dust leads to improvement in lung function. Recent animal models have suggested a shift in the lung macrophage: dendritic cell population ratio as a potential mechanistic explanation for persistent inflammation in the lung due to repeated cotton dust-related endotoxin exposure. Other types of textile dust, such as silk, may contribute to COPD in textile workers.
Summary
Textile dust-related obstructive lung disease has characteristics of both asthma and COPD. Significant progress has been made in the understanding of chronic lung disease due to organic dust exposure in textile workers.
C1 [Lai, Peggy S.; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth Environm & Occupat Med & Epide, Boston, MA 02115 USA.
[Lai, Peggy S.; Christiani, David C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit,Dept Med, Boston, MA USA.
RP Lai, PS (reprint author), Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Bulfinch 148,55 Fruit St, Boston, MA 02114 USA.
EM pslai@hsph.harvard.edu
OI Lai, Peggy/0000-0001-9501-8606
FU NIOSH [RO1OH02421]; NIH [ES000002, F32 ES020082]
FX Funded by grants RO1OH02421 from NIOSH, ES000002 and F32 ES020082 from
NIH.
NR 47
TC 19
Z9 19
U1 0
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1070-5287
EI 1531-6971
J9 CURR OPIN PULM MED
JI Curr. Opin. Pulm. Med.
PD MAR
PY 2013
VL 19
IS 2
BP 152
EP 157
DI 10.1097/MCP.0b013e32835cee9a
PG 6
WC Respiratory System
SC Respiratory System
GA 081UX
UT WOS:000314349000010
PM 23361196
ER
PT J
AU Moon, HS
Dincer, F
Mantzoros, CS
AF Moon, H. -S.
Dincer, F.
Mantzoros, C. S.
TI Amylin-induced downregulation of hippocampal neurogenesis is attenuated
by leptin in a STAT3/AMPK/ERK-dependent manner in mice
SO DIABETOLOGIA
LA English
DT Article
DE Adiponectin; Amylin; Hippocampal neurogenesis; Leptin; STAT3 signalling
ID LONG-TERM POTENTIATION; IN-VITRO; ADIPONECTIN RECEPTORS; ADULT
NEUROGENESIS; ALZHEIMERS-DISEASE; INSULIN-RESISTANCE; EX-VIVO; OBESITY;
MEMORY; NEUROENDOCRINE
AB Both leptin and insulin sensitivity have been linked with pathophysiological processes involving the central nervous system in general, and the hippocampus in particular, but the role of leptin in hippocampal neurogenesis has not yet been elucidated. Also, no previous studies have evaluated whether amylin or the endogenous insulin sensitiser adiponectin interact with leptin to alter hippocampal neurogenesis in mouse hippocampal neuronal (HN) cells or investigated the role of leptin, amylin or adiponectin signalling in mouse HN cells.
Hippocampal neurogenesis and leptin, amylin and adiponectin signalling were studied in vitro using mouse H19-7 HN cell lines.
Amylin decreased cell proliferation in a dose-dependent manner. This effect was diminished by leptin administration and was dependent on signal transducer and activator of transcription 3 (STAT3)/AMP-activated protein kinase (AMPK)/extracellular signal-regulated kinase (ERK). Adiponectin effects were null. We also observed, using immunocytochemical analysis, that amylin decreased activation of microtubule-associated protein 2, a specific neurite outgrowth marker, and synapsin, a specific synaptogenesis marker. By contrast, both effects were attenuated by co-administration of leptin. Finally, we observed that these effects were blocked by pre-treatment with AG490, a STAT3 inhibitor, and STAT3 small interfering RNA administration.
Our data suggest that amylin in pharmacological concentrations may have a neurotoxic effect whereas leptin in physiological and pharmacological concentrations has a protective effect counteracting amylin-decreased hippocampal neurogenesis via STAT3/AMPK/ERK signalling in mouse H19-7 HN cell lines. Overall, our data support a novel role for leptin and amylin in the processes of mouse hippocampal neurogenesis and provide new insights into the mechanisms of neurogenic regulation.
C1 [Moon, H. -S.; Dincer, F.; Mantzoros, C. S.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02130 USA.
[Mantzoros, C. S.] Harvard Univ, Sch Med, Boston VA Healthcare Syst, Endocrinol Sect, Boston, MA 02130 USA.
RP Mantzoros, CS (reprint author), Harvard Univ, Sch Med, Boston VA Healthcare Syst, Endocrinol Sect, JP9B52A,150S Huntington Ave, Boston, MA 02130 USA.
EM cmantzor@bidmc.harvard.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases [58785,
79929, 81913]; Clinical Science Research and Development Service of the
Veterans Affairs (VA) Office of Research and Development
[1I01CX000422-01A1]
FX The Mantzoros Laboratory was supported by the National Institute of
Diabetes and Digestive and Kidney Diseases grants 58785, 79929 and
81913, and by Award No. 1I01CX000422-01A1 from the Clinical Science
Research and Development Service of the Veterans Affairs (VA) Office of
Research and Development.
NR 43
TC 10
Z9 10
U1 0
U2 19
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD MAR
PY 2013
VL 56
IS 3
BP 627
EP 634
DI 10.1007/s00125-012-2799-3
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 084IH
UT WOS:000314531700022
PM 23224631
ER
PT J
AU Hong, NJL
Hornicek, FJ
Harmon, DC
Choy, E
Chen, YL
Yoon, SS
Nielsen, GP
Szymonifka, J
Yeap, BY
DeLaney, TF
Mullen, JT
AF Hong, Nicole J. Look
Hornicek, Francis J.
Harmon, David C.
Choy, Edwin
Chen, Yen-Lin
Yoon, Sam S.
Nielsen, G. Petur
Szymonifka, Jackie
Yeap, Beow Y.
DeLaney, Thomas F.
Mullen, John T.
TI Neoadjuvant chemoradiotherapy for patients with high-risk extremity and
truncal sarcomas: A 10-year single institution retrospective study
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Sarcoma; Neoadjuvant; Chemoradiotherapy; Chemotherapy; Survival;
Toxicity; Recurrence; Radiation
ID SOFT-TISSUE SARCOMAS; RADIATION-THERAPY; POSTOPERATIVE RADIOTHERAPY;
PREOPERATIVE RADIATION; ADJUVANT CHEMOTHERAPY; SURGICAL MARGINS;
HIGH-GRADE; POSITIVE MARGINS; RANDOMIZED-TRIAL; LOCAL-CONTROL
AB Background: Patients with large, high-grade extremity and truncal soft tissue sarcomas (STS) are at considerable risk for recurrence. A regimen of pre-operative chemotherapy consisting of mesna, adriamycin, ifosfamide and dacarbazine (MAID), interdigitated with radiotherapy (RT), followed by resection and post-operative chemotherapy with or without RT, has demonstrated high rates of local and distant control. The goal of this study is to assess outcomes in a recent cohort of patients treated on this regimen.
Methods: We retrospectively reviewed records of 66 consecutive patients with STS of the extremity or trunk who were treated with the aforementioned regimen from May 2000 to April 2011. Clinicopathologic characteristics and patient outcomes were analysed.
Results: Sixty-six patients were analysed and were equally divided between grade 2 and 3 tumours. Margins were negative in 57 (89%) patients and positive in seven (11%) patients. At a median follow-up of 46 months, there were six (9%) locoregional and 20 (30%) distant recurrences. The locoregional and distant 5-year recurrence-free survival (RFS) rates were 91% and 64%, respectively. The 5-year overall (OS) and disease-specific survival rates were 86% and 89%, respectively. There were no treatment-related deaths or secondary myelodysplasias. Thirty-four (52%) patients had grade 3 or 4 acute haematologic chemotherapy-related toxicity. There were no statistically significant predictors of OS or RFS.
Conclusions: For a contemporary cohort of patients with high-risk extremity and truncal STS, a regimen of neoadjuvant chemoradiotherapy and surgery continues to result in high rates of survival with tolerable short- and long-term toxicity. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Hong, Nicole J. Look; Yoon, Sam S.; Mullen, John T.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hornicek, Francis J.] Harvard Univ, Sch Med, Dept Orthoped Oncol, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Harmon, David C.; Choy, Edwin] Harvard Univ, Sch Med, Dept Med Oncol, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Chen, Yen-Lin; DeLaney, Thomas F.] Harvard Univ, Sch Med, Dept Radiat Oncol, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Nielsen, G. Petur] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Szymonifka, Jackie; Yeap, Beow Y.] Harvard Univ, Sch Med, Dept Biostat, Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Mullen, JT (reprint author), Massachusetts Gen Hosp, Div Surg Oncol, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA.
EM jmullen@partners.org
OI Choy, Edwin/0000-0001-9896-8084
FU NCI Cancer Center [NIH 5 P30 CA06516]
FX Biostatistics Core of Dana-Farber/Harvard Cancer Center supported by NCI
Cancer Center Support Grant # NIH 5 P30 CA06516.
NR 29
TC 19
Z9 19
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
J9 EUR J CANCER
JI Eur. J. Cancer
PD MAR
PY 2013
VL 49
IS 4
BP 875
EP 883
DI 10.1016/j.ejca.2012.10.002
PG 9
WC Oncology
SC Oncology
GA 088QB
UT WOS:000314849300014
ER
PT J
AU Chaudhuri, SE
Merfeld, DM
AF Chaudhuri, Shomesh E.
Merfeld, Daniel M.
TI Signal detection theory and vestibular perception: III. Estimating
unbiased fit parameters for psychometric functions
SO EXPERIMENTAL BRAIN RESEARCH
LA English
DT Article
DE Maximum likelihood estimation; Generalized linear models; GLM;
Psychophysics; Threshold; Vestibular
ID BIAS; THRESHOLDS; BOOTSTRAP
AB Psychophysics generally relies on estimating a subject's ability to perform a specific task as a function of an observed stimulus. For threshold studies, the fitted functions are called psychometric functions. While fitting psychometric functions to data acquired using adaptive sampling procedures (e.g., "staircase" procedures), investigators have encountered a bias in the spread ("slope" or "threshold") parameter that has been attributed to the serial dependency of the adaptive data. Using simulations, we confirm this bias for cumulative Gaussian parametric maximum likelihood fits on data collected via adaptive sampling procedures, and then present a bias-reduced maximum likelihood fit that substantially reduces the bias without reducing the precision of the spread parameter estimate and without reducing the accuracy or precision of the other fit parameters. As a separate topic, we explain how to implement this bias reduction technique using generalized linear model fits as well as other numeric maximum likelihood techniques such as the Nelder-Mead simplex. We then provide a comparison of the iterative bootstrap and observed information matrix techniques for estimating parameter fit variance from adaptive sampling procedure data sets. The iterative bootstrap technique is shown to be slightly more accurate; however, the observed information technique executes in a small fraction (0.005 %) of the time required by the iterative bootstrap technique, which is an advantage when a real-time estimate of parameter fit variance is required.
C1 [Chaudhuri, Shomesh E.; Merfeld, Daniel M.] Massachusetts Eye & Ear Infirm, Jenks Vestibular Physiol Lab, Boston, MA 02114 USA.
[Merfeld, Daniel M.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Merfeld, DM (reprint author), Harvard Univ, Sch Med, Boston, MA 02114 USA.
EM shomesh_chaudhuri@meei.harvard.edu; dan_merfeld@meei.harvard.edu
FU National Institutes of Health/National Institute of Deafness and Other
Communication Disorders [DC04158]; National Institutes of Health
[1S10RR028832]
FX We thank Faisal Karmali, Wei Wang, Torin Clark, and Luzia Grabherr for
reviewing a draft of this manuscript. This research was supported by the
National Institutes of Health/National Institute of Deafness and Other
Communication Disorders grant DC04158. The Orchestra computational
cluster is supported by the National Institutes of Health shared
equipment grant 1S10RR028832.
NR 30
TC 6
Z9 6
U1 2
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0014-4819
J9 EXP BRAIN RES
JI Exp. Brain Res.
PD MAR
PY 2013
VL 225
IS 1
BP 133
EP 146
DI 10.1007/s00221-012-3354-7
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 087OW
UT WOS:000314772600011
PM 23250442
ER
PT J
AU Pichler, I
Schwienbacher, C
Zanon, A
Fuchsberger, C
Serafin, A
Facheris, MF
Marroni, F
Pattaro, C
Shen, YP
Tellgren-Roth, C
Gyllensten, U
Gusella, JF
Hicks, AA
Pramstaller, PP
AF Pichler, Irene
Schwienbacher, Christine
Zanon, Alessandra
Fuchsberger, Christian
Serafin, Alice
Facheris, Maurizio F.
Marroni, Fabio
Pattaro, Cristian
Shen, Yiping
Tellgren-Roth, Christian
Gyllensten, Ulf
Gusella, James F.
Hicks, Andrew A.
Pramstaller, Peter P.
TI Fine-Mapping of Restless Legs Locus 4 (RLS4) Identifies a Haplotype over
the SPATS2L and KCTD18 Genes
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article
DE Restless legs syndrome; Familial form; Genetics; Isolated population;
RLS4
ID TYROLEAN POPULATION ISOLATE; SUSCEPTIBILITY LOCUS; LINKAGE ANALYSIS;
MAPS; EPIDEMIOLOGY
AB Restless legs syndrome (RLS) is a sleep-related movement disorder that affects up to 15 % of the population. Linkage studies have identified several genomic loci in single families (12q, 14q, 9p, 2q, 20p and 16p, respectively). However, confirmation of these loci has not always been achieved, and causative mutations have not yet been identified. The locus on chromosome 2q33 (RLS4) was identified in two South Tyrolean families who shared a haplotype of microsatellite marker alleles across an 8.2-cM region. To pinpoint the gene localisation within RLS4, additional families from the same geographic region were evaluated, and linkage was replicated in one family. Within the candidate region, we initially found a haplotype of 23 single nucleotide polymorphism markers spanning 131.6 Kb shared by all affected members of the three linked families. Using a next generation sequencing approach, we further restricted the shared candidate region to 46.9 Kb over the potassium channel-related gene KCTD18 and exons 10-13 of SPATS2L.
C1 [Pichler, Irene; Schwienbacher, Christine; Zanon, Alessandra; Serafin, Alice; Facheris, Maurizio F.; Pattaro, Cristian; Hicks, Andrew A.; Pramstaller, Peter P.] Univ Lubeck, Ctr Biomed, European Acad Bozen Bolzano EURAC, Affiliated Inst, I-39100 Bozen Bolzano, Italy.
[Schwienbacher, Christine] Univ Ferrara, Dept Expt & Diagnost Med, I-44100 Ferrara, Italy.
[Fuchsberger, Christian] Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
[Marroni, Fabio] Inst Appl Genom, Udine, Italy.
[Shen, Yiping; Gusella, James F.] Massachusetts Gen Hosp, Mol Neurogenet Unit, Ctr Human Genet Res, Boston, MA 02114 USA.
[Shen, Yiping] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA.
[Shen, Yiping] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Shen, Yiping] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Shanghai 200030, Peoples R China.
[Tellgren-Roth, Christian; Gyllensten, Ulf] Uppsala Univ, Dept Immunol Genet & Pathol, Rudbeck Lab, SciLifeLab Uppsala, Uppsala, Sweden.
[Gusella, James F.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Pramstaller, Peter P.] Gen Cent Hosp, Dept Neurol, Bolzano, Italy.
[Pramstaller, Peter P.] Med Univ Lubeck, Dept Neurol, D-23538 Lubeck, Germany.
RP Pramstaller, PP (reprint author), Univ Lubeck, Ctr Biomed, European Acad Bozen Bolzano EURAC, Affiliated Inst, Drususallee 1, I-39100 Bozen Bolzano, Italy.
EM peter.pramstaller@eurac.edu
RI Pramstaller, Peter/C-2357-2008; Hicks, Andrew/E-9518-2017;
OI Hicks, Andrew/0000-0001-6320-0411; Tellgren-Roth,
Christian/0000-0003-0502-3693; Marroni, Fabio/0000-0002-1556-5907;
Pichler, Irene/0000-0001-8251-0757; Fuchsberger,
Christian/0000-0002-5918-8947
FU Ministry of Health and Department of Educational Assistance; University
and Research of the Autonomous Province of Bolzano; South Tyrolean
Sparkasse Foundation
FX The authors are grateful to the study participants and the primary care
physicians of the villages for their participation and collaboration in
this research project. We thank Martin Gogele and Daniel Taliun for
their technical support. The study was supported by the Ministry of
Health and Department of Educational Assistance, University and Research
of the Autonomous Province of Bolzano and the South Tyrolean Sparkasse
Foundation.
NR 16
TC 3
Z9 3
U1 0
U2 4
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD MAR
PY 2013
VL 49
IS 3
BP 600
EP 605
DI 10.1007/s12031-012-9891-5
PG 6
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 086QN
UT WOS:000314701300022
PM 23054586
ER
PT J
AU Lim, SN
Gladman, SJ
Dyall, SC
Patel, U
Virani, N
Kang, JX
Priestley, JV
Michael-Titus, AT
AF Lim, Siew-Na
Gladman, Stacy J.
Dyall, Simon C.
Patel, Urva
Virani, Nabeel
Kang, Jing X.
Priestley, John V.
Michael-Titus, Adina T.
TI Transgenic mice with high endogenous omega-3 fatty acids are protected
from spinal cord injury
SO NEUROBIOLOGY OF DISEASE
LA English
DT Article
DE Transgenic fat-1 mice; Spinal cord injury; Omega-3 fatty acids;
Neuroprotection
ID TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; FATTY-ACIDS;
DOCOSAHEXAENOIC ACID; LEUKOCYTE MOBILIZATION; FUNCTIONAL RECOVERY; FAT-1
MICE; RAT; NEUROTOXICITY; METABOLISM
AB Omega-3 polyunsaturated fatty acids have been shown to have therapeutic potential in a variety of neurological disorders, including acute traumatic injury of the spinal cord. We addressed the question whether the neuroprotective effect of these compounds after spinal cord injury could also be seen when their level is raised in tissues prophylactically, prior to injury. In this study we used transgenic fat-1 mice to examine whether enriching spinal cord tissue in endogenous omega-3 polyunsaturated fatty acids has an effect on the outcome after compression spinal cord injury. The results demonstrate that after thoracic compression spinal cord injury, fat-1 mice display better locomotor recovery compared with the wild-type mice on a high omega-6 diet (high omega-6 polyunsaturated fatty acids in tissues), and wild-type mice on a normal diet (controls). This is associated with a significant increase in neuronal and oligodendrocyte survival and a decrease in non-phosphorylated neurofilament loss. The protection from spinal cord injury in fat-1 mice was also correlated with a reduction in microglia/macrophage activation and in pro-inflammatory mediators. In vitro experiments in dorsal root ganglia primary sensory neurons further demonstrated that a fat-1 tissue background confers robust neuroprotection against a combined mechanical stretch and hypoxic injury. In conclusion, our studies support the hypothesis that a raised omega-3 polyunsaturated fatty acid level and an altered tissue omega-6/omega-3 ratio prior to injury leads to a much improved outcome after spinal cord injury. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Lim, Siew-Na; Gladman, Stacy J.; Dyall, Simon C.; Patel, Urva; Virani, Nabeel; Priestley, John V.; Michael-Titus, Adina T.] Barts & London Queen Marys Sch Med & Dent, Blizard Inst, Ctr Neurosci & Trauma, London, England.
[Lim, Siew-Na] Chang Gung Mem Hosp, Dept Neurol, Taipei 10591, Taiwan.
[Lim, Siew-Na] Chang Gung Univ, Coll Med, Taipei, Taiwan.
[Dyall, Simon C.] Roehampton Univ, Whitelands Coll, Dept Life Sci, London, England.
[Kang, Jing X.] Massachusetts Gen Hosp, Dept Med, Lab Lipid Med & Technol, Boston, MA 02114 USA.
[Kang, Jing X.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Michael-Titus, AT (reprint author), Barts & London Queen Marys Sch Med & Dent, Blizard Inst Cell & Mol Sci, Ctr Neurosci & Trauma, 4 Newark St, London, England.
EM a.t.michael-titus@qmul.ac.uk
OI Gladman, Stacy/0000-0002-7112-4516; Dyall, Simon/0000-0001-7591-4219
FU Chang Gung Memorial Hospital, Taiwan [CMRPG360622]
FX This work was supported by Chang Gung Memorial Hospital, Taiwan
(CMRPG360622). We gratefully acknowledge the assistance of Patrick
Pallier, Laura Poddighe and Rasall Choudhury with preparatory staining
for the Abercrombie correction.
NR 46
TC 17
Z9 17
U1 2
U2 20
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0969-9961
J9 NEUROBIOL DIS
JI Neurobiol. Dis.
PD MAR
PY 2013
VL 51
SI SI
BP 104
EP 112
DI 10.1016/j.nbd.2012.10.021
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 085PQ
UT WOS:000314627100012
PM 23123586
ER
PT J
AU Holt, CL
Wang, MQ
Clark, EM
Williams, BR
Schulz, E
AF Holt, Cheryl L.
Wang, Min Qi
Clark, Eddie M.
Williams, Beverly Rosa
Schulz, Emily
TI Religious involvement and physical and emotional functioning among
African Americans: The mediating role of religious support
SO PSYCHOLOGY & HEALTH
LA English
DT Article
DE religion; religious support; African Americans; functioning; depression
ID SOCIAL SUPPORT; HEALTH CONNECTION; DEPRESSION; MODEL; SPIRITUALITY;
PERCEPTIONS; MORTALITY; SAMPLE; ADULTS; SCALES
AB Objectives: Religious social support may in part account for the relationship between religious involvement and health-related outcomes. African Americans, on average, tend to have relatively high levels of religious involvement, and suffer a higher burden of health conditions than other groups. This study aimed to examine whether religious social support played a mediating role between religious involvement and physical and emotional functioning, and depressive symptoms. Design: The study used a cross sectional telephone survey among a national probability sample of African Americans (n=803). Study participants completed telephone interviews and data were analysed using structural equation modelling. Main outcome measures: Physical and emotional functioning and depressive symptoms served as study outcomes. Results: In both the emotional functioning and depressive symptoms models, the indirect effect test from religious behaviours to emotional religious support indicated evidence for mediation. There was no mediation for the physical functioning model. Conclusion: Implications for faith-based health promotion interventions are discussed.
C1 [Holt, Cheryl L.; Wang, Min Qi] Univ Maryland, Sch Publ Hlth, Dept Behav & Community Hlth, College Pk, MD 20742 USA.
[Clark, Eddie M.] St Louis Univ, Dept Psychol, St Louis, MO 63103 USA.
[Williams, Beverly Rosa] Birmingham VA Med Ctr, Div Gerontol Geriatr Palliat Care, Dept Med, Birmingham, AL USA.
[Williams, Beverly Rosa] Univ Alabama Birmingham, Birmingham, AL USA.
[Schulz, Emily] Arizona Sch Hlth Sci, Dept Occupat Therapy, Mesa, AZ USA.
RP Holt, CL (reprint author), Univ Maryland, Sch Publ Hlth, Dept Behav & Community Hlth, College Pk, MD 20742 USA.
EM cholt14@umd.edu
NR 45
TC 12
Z9 12
U1 2
U2 18
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0887-0446
J9 PSYCHOL HEALTH
JI Psychol. Health
PD MAR 1
PY 2013
VL 28
IS 3
BP 267
EP 283
DI 10.1080/08870446.2012.717624
PG 17
WC Public, Environmental & Occupational Health; Psychology,
Multidisciplinary
SC Public, Environmental & Occupational Health; Psychology
GA 089LH
UT WOS:000314911500003
PM 22928653
ER
PT J
AU Scala, S
Pousada, A
Stone, WS
Thermenos, HW
Manschreck, TC
Tsuang, MT
Faraone, SV
Seidman, LJ
AF Scala, Silvia
Pousada, Andrea
Stone, William S.
Thermenos, Heidi W.
Manschreck, Theo C.
Tsuang, Ming T.
Faraone, Stephen V.
Seidman, Larry J.
TI Verbal and visual-spatial memory impairment in youth at familial risk
for schizophrenia or affective psychosis: A pilot study
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Family high-risk; Psychosis; Memory; Psychopathology; Vulnerability
ID UNAFFECTED 1ST-DEGREE RELATIVES; BIPOLAR DISORDER; NEUROCOGNITIVE
ENDOPHENOTYPES; MULTIGENERATIONAL FAMILIES; COGNITIVE DEFICITS; EUTHYMIC
PATIENTS; GENETIC RISK; YOUNG-ADULTS; METAANALYSIS; DYSFUNCTION
AB Background: Schizophrenia and affective psychoses share several common biological origins, particularly genetic susceptibility. Kraepelin posited that differing clinical expressions in these disorders reflect different etiopathologies. We tested a neuropsychological component of this hypothesis by evaluating verbal memory and visual memory performance in nonpsychotic youth at familial risk for psychosis, taking into account contributions to memory dysfunction including executive processing and psychopathology.
Methods: Teenage and young adults (ages 13-25) at familial high-risk (FHR) for schizophrenia (HR-SCZ, n=41) or affective psychosis (HR-AFF, n=24) were compared to community controls (CC, n=54) on verbal (Miller-Selfridge Context Memory) and visual (Rey-Osterrieth Complex Figure) memory tests in which the roles of strategy and contextual processing on distinct recall domains could be assessed. Effects of psychopathology, vigilance and working memory were investigated to determine their influence on memory performance.
Results: HR-AFF and HR-SCZ exhibited similarly impaired memory profiles and elevated levels of psychopathology compared to CC. HR-SCZ were significantly impaired on both verbal memory and visual-spatial memory, while HR-AFF in verbal memory only. However, effect sizes, in the medium range, were largely comparable between the two HR groups. Deficits in verbal recall and in visual memory organization remained significant after adjustment for confounders.
Conclusions: Youth at FHR for psychosis present relatively common memory deficits across both visual-spatial and verbal modalities that are not explained by current psychopathology, vigilance or working memory deficits. Deficits in organizing information to be recalled represent a promising trait of psychosis vulnerability. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Scala, Silvia] Univ Verona, Dept Publ Hlth & Community Med, Sect Psychiat & Clin Psychol, I-37134 Verona, Italy.
[Scala, Silvia; Pousada, Andrea; Stone, William S.; Thermenos, Heidi W.; Tsuang, Ming T.; Seidman, Larry J.] Harvard Univ, Sch Med, Dept Psychiat,Beth Israel Deaconess Med Ctr, Massachusetts Mental Hlth Ctr,Div Publ Psychiat, Boston, MA 02115 USA.
[Thermenos, Heidi W.; Seidman, Larry J.] Harvard Univ, Sch Med, MIT, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Thermenos, Heidi W.; Seidman, Larry J.] Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
[Manschreck, Theo C.] Harvard Univ, Commonwealth Massachusetts Res Ctr, Sch Med, Dept Psychiat,John C Corrigan Mental Hlth Ctr, Fall River, MA 02720 USA.
[Tsuang, Ming T.] Univ Calif San Diego, Dept Psychiat, Ctr Behav Genom, La Jolla, CA 92093 USA.
[Tsuang, Ming T.] Inst Genom Med, La Jolla, CA 92093 USA.
[Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA.
[Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci, Syracuse, NY 13210 USA.
[Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Physiol, Syracuse, NY 13210 USA.
RP Seidman, LJ (reprint author), Massachusetts Mental Hlth Ctr, Commonwealth Res Ctr, 5th Floor,75 Fenwood Rd, Boston, MA 02115 USA.
EM lseidman@bidmc.harvard.edu
OI Faraone, Stephen/0000-0002-9217-3982
FU Stanley Medical Research Institute; National Association for Research on
Schizophrenia and Depression (NARSAD); Commonwealth Research Center of
the Massachusetts Department of Mental Health [SCDMH82101008006];
[MH43518]; [MH65562]; [MH63951]; [MH46318]
FX Stanley Medical Research Institute (LJS); National Association for
Research on Schizophrenia and Depression (NARSAD; MTT, LJS); MH43518 and
MH65562 (MTT, LJS); MH63951 (LJS); MH46318 (MTT); The Commonwealth
Research Center of the Massachusetts Department of Mental Health
(SCDMH82101008006; LJS).
NR 71
TC 7
Z9 7
U1 2
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD MAR
PY 2013
VL 144
IS 1-3
BP 122
EP 128
DI 10.1016/j.schres.2012.11.027
PG 7
WC Psychiatry
SC Psychiatry
GA 088GI
UT WOS:000314821400018
PM 23312552
ER
PT J
AU McClure, MM
Harvey, PD
Bowie, CR
Iacoviello, B
Siever, LJ
AF McClure, Margaret M.
Harvey, Philip D.
Bowie, Christopher R.
Iacoviello, Brian
Siever, Larry J.
TI Functional outcomes, functional capacity, and cognitive impairment in
schizotypal personality disorder
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia spectrum; Cognition; Functional outcome; Performance-based
assessments; Schizotypal personality disorder
ID WORKING-MEMORY; NEUROPSYCHOLOGICAL DYSFUNCTION; SKILLS ASSESSMENT;
SCHIZOPHRENIA; PERFORMANCE; SPECIFICITY; SENSITIVITY; DISABILITY;
DETERMINANTS; RELIABILITY
AB Background: Individuals with schizotypal personality disorder (SPD) exhibit impaired cognitive functioning in a pattern similar to that found in schizophrenia; less clear is the extent to which these individuals also share schizophrenia patients' impairments in functional capacity and real-world functioning.
Method: We evaluated 46 SPD patients, as well as 38 individuals with avoidant personality disorder (AvPD) and 55 healthy controls (HC) on: cognitive functioning, real-world functioning (employment and residential status), and functional capacity (indexed by the UPSA, a performance-based skills assessment).
Results: We found that individuals with SPD exhibited worse performance on both the cognitive battery and the UPSA than the other groups; they were also less likely to be employed and to be living independently. Additionally, cognitive and UPSA performance in the SPD group was intercorrelated to a degree comparable to what has been found in schizophrenia, and this relationship was not present in the AvPD group. Finally, real-world functioning was related to UPSA performance for both patient groups.
Conclusions: SPD patients exhibit impaired real-world functioning suggesting that these deficits extend across the schizophrenia spectrum. In addition, there is supportive evidence for the validity and importance of performance-based measures such as the UPSA to predict everyday outcomes across the schizophrenia spectrum. Published by Elsevier B.V.
C1 [McClure, Margaret M.; Iacoviello, Brian; Siever, Larry J.] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[McClure, Margaret M.; Siever, Larry J.] VA VISN3 Mental Illness Res Educ & Clin Ctr, Bronx, NY USA.
[McClure, Margaret M.] Fairfield Univ, Dept Psychol, Fairfield, CT 06430 USA.
[Harvey, Philip D.] Univ Miami, Miller Sch Med, Dept Psychiat, Miami, FL 33136 USA.
[Harvey, Philip D.] Miami VA Med Ctr, Res Serv, Miami, FL USA.
[Bowie, Christopher R.] Queens Univ, Kingston, ON, Canada.
RP McClure, MM (reprint author), James J Peters VAMC, VA VISN MIRECC 3, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.
EM Margaret.McNamara@mssm.edu
FU NIMH [MH 56140, MH 78775]; VA VISN-3 MIRECC; National Center for
Research Resources (NCRR), a component of the National Institutes of
Health (NIH) [MO1-RR-00071]
FX This research was supported by NIMH Grant Number MH 56140 to Dr. Siever,
NIMH Grant Number MH 78775 to Dr. Harvey, and by the VA VISN-3 MIRECC.
This research was also supported by Grant Number MO1-RR-00071 from the
National Center for Research Resources (NCRR), a component of the
National Institutes of Health (NIH). Its contents are solely the
responsibility of the authors and do not necessarily represent the
official views of NCRR or NIH.
NR 38
TC 13
Z9 13
U1 2
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD MAR
PY 2013
VL 144
IS 1-3
BP 146
EP 150
DI 10.1016/j.schres.2012.12.012
PG 5
WC Psychiatry
SC Psychiatry
GA 088GI
UT WOS:000314821400022
PM 23375943
ER
PT J
AU Schorge, JO
AF Schorge, John O.
TI Cervical Cancer Screening
SO CLINICAL OBSTETRICS AND GYNECOLOGY
LA English
DT Editorial Material
C1 Massachusetts Gen Hosp, Div Gynecol Oncol, Boston, MA 02114 USA.
RP Schorge, JO (reprint author), Massachusetts Gen Hosp, Div Gynecol Oncol, Boston, MA 02114 USA.
EM jschorge@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-9201
J9 CLIN OBSTET GYNECOL
JI Clin. Obstet. Gynecol.
PD MAR
PY 2013
VL 56
IS 1
BP 1
EP 2
DI 10.1097/GRF.0b013e31828365f4
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 082ML
UT WOS:000314396000001
PM 23318572
ER
PT J
AU Tambouret, RH
AF Tambouret, Rosemary H.
TI The Evolution of the Papanicolaou Smear
SO CLINICAL OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE Papanicolaou smear; cervicovaginal cytology; cancer screening
ID LABORATORY IMPROVEMENT AMENDMENTS; CERVICAL-CANCER; CLINICAL
LABORATORIES; FEDERAL-REGULATION; BETHESDA SYSTEM; CYTOLOGY; MORTALITY;
CARCINOMA; PATHOLOGY; ICELAND
AB The Papanicolaou smear or cervicovaginal cytology has been the mainstay of screening for cervical cancer in women of over 60 years. In this article, the origins of the Pap smear as a screening method and the many changes associated with the use of the Pap smear are detailed.
C1 Massachusetts Gen Hosp, Cytopathol Fellowship Program, Boston, MA 02114 USA.
RP Tambouret, RH (reprint author), Massachusetts Gen Hosp, Cytopathol Fellowship Program, Boston, MA 02114 USA.
EM rtambouret@partners.org
NR 40
TC 2
Z9 2
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-9201
J9 CLIN OBSTET GYNECOL
JI Clin. Obstet. Gynecol.
PD MAR
PY 2013
VL 56
IS 1
BP 3
EP 9
DI 10.1097/GRF.0b013e318282b982
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 082ML
UT WOS:000314396000002
PM 23314726
ER
PT J
AU Lui, R
AF Lui, Raymond
TI Clinical Utility of HPV Testing
SO CLINICAL OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE cervical cancer screening; HPV testing; human papilloma virus; Pap smear
ID INVASIVE CERVICAL-CANCER; ATYPICAL SQUAMOUS-CELLS; HUMAN-PAPILLOMAVIRUS
INFECTION; INTERNATIONAL INCIDENCE RATES; UNDETERMINED SIGNIFICANCE;
UNITED-STATES; RANDOMIZED-TRIAL; ABSOLUTE RISK; CYTOLOGY; WOMEN
AB Testing for human papilloma virus (HPV) has been shown to be more sensitive than cervical cytology in detecting both high-grade and low-grade dysplasia. When screening for cervical cancer, unfortunately, the HPV test lacks specificity and has limited its usefulness as a primary screening modality for cervical cancer. In this chapter, we will review HPV and its role in cervical cancer, the utilization of HPV testing in current practice, and the possible future utilization of HPV and its role in screening
C1 Massachusetts Gen Hosp, Colposcopy Clin, Vincent Obstet & Gynecol, Boston, MA 02114 USA.
RP Lui, R (reprint author), Massachusetts Gen Hosp, Colposcopy Clin, Vincent Obstet & Gynecol, Boston, MA 02114 USA.
EM rlui@partners.org
NR 48
TC 4
Z9 4
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-9201
J9 CLIN OBSTET GYNECOL
JI Clin. Obstet. Gynecol.
PD MAR
PY 2013
VL 56
IS 1
BP 17
EP 24
DI 10.1097/GRF.0b013e31827af708
PG 8
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 082ML
UT WOS:000314396000004
PM 23314715
ER
PT J
AU Schorge, JO
Rauh-Hain, JA
AF Schorge, John O.
Rauh-Hain, Jose Alejandro
TI Atypical Glandular Cells
SO CLINICAL OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE atypical glandular cells; adenocarcinoma in situ; cervical
adenocarcinoma
ID UNDETERMINED SIGNIFICANCE AGUS; CERVICAL CYTOLOGY; INCIDENCE TRENDS;
BETHESDA SYSTEM; UNITED-STATES; PAP TESTS; ADENOCARCINOMA; WOMEN;
TERMINOLOGY; GUIDELINES
AB Less than 1% of Pap smears are interpreted as having atypical glandular cells. Because of the rarity of diagnosis, providers are frequently unfamiliar with both the workup and the potential ramifications. Comprehensive evaluation is required in all cases to exclude a spectrum of possible diagnoses. Although colposcopy, human papillomavirus DNA testing, endocervical curettage, and endometrial sampling should be the initial part of the evaluation, these procedures may not identify any specific etiology. The aim of this review is to provide the most current strategy for management of this rare, but suspicious Pap test result.
C1 [Schorge, John O.; Rauh-Hain, Jose Alejandro] Massachusetts Gen Hosp, Div Gynecol Oncol, Boston, MA 02114 USA.
RP Schorge, JO (reprint author), Massachusetts Gen Hosp, Div Gynecol Oncol, Yawkey 9E, Boston, MA 02114 USA.
EM jschorge@partners.org
NR 30
TC 3
Z9 3
U1 3
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-9201
J9 CLIN OBSTET GYNECOL
JI Clin. Obstet. Gynecol.
PD MAR
PY 2013
VL 56
IS 1
BP 35
EP 43
DI 10.1097/GRF.0b013e3182823849
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 082ML
UT WOS:000314396000006
PM 23314725
ER
PT J
AU Coleman, CA
AF Coleman, Carrie A.
TI Evaluation and Management of Abnormal Cervical Cytology During Pregnancy
SO CLINICAL OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE abnormal pap smear; pregnancy; colposcopy
ID 2006 CONSENSUS GUIDELINES; WOMEN
AB Pregnancy is a particularly motivating time for a woman to access the health care system and seek out preventative services. Papanicolaou screening is a routine part of the initial examination. Although the vast majority of smears will have a normal result, it is important for providers to be aware of the appropriate evaluation of abnormal cervical cytology in this unique population because the standard management algorithms do not always apply. For example, colposcopy during pregnancy is a safe and effective tool, but endocervical curettage is contraindicated. In addition, for most diagnoses, more aggressive intervention is often best delayed.
C1 Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Boston, MA 02114 USA.
RP Coleman, CA (reprint author), Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Boston, MA 02114 USA.
EM cacoleman@partners.org
NR 14
TC 4
Z9 5
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-9201
EI 1532-5520
J9 CLIN OBSTET GYNECOL
JI Clin. Obstet. Gynecol.
PD MAR
PY 2013
VL 56
IS 1
BP 51
EP 54
DI 10.1097/GRF.0b013e31828365b8
PG 4
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 082ML
UT WOS:000314396000008
PM 23318571
ER
PT J
AU del Carmen, MG
Avila-Wallace, M
AF del Carmen, Marcela G.
Avila-Wallace, Maria
TI Effect of Health Care Disparities on Screening
SO CLINICAL OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE cervical cancer; disparities; prevention; screening
ID SPECIAL POPULATIONS NETWORKS; AFRICAN-AMERICAN WOMEN; CERVICAL-CANCER;
UNITED-STATES; HISPANIC WOMEN; BREAST; PROGRAM; US; STAGE; INTERVENTION
AB Significant declines in the incidence and mortality rates of cervical cancer have occurred in the United States since the introduction of the Papanicolaou (Pap) test. Unfortunately, a reduction in the burden of cervical cancer is not equal across all ethnic and racial groups; significant disparities exist. Disparities are reflected not only in mortality and incidence rates, but also in screening rates. We review barriers to screening and effective approaches towards overcoming them. As minority populations increase over the next few decades, it becomes ever more urgent to employ interventions that will reduce the burden of cervical cancer among diverse groups.
C1 [del Carmen, Marcela G.; Avila-Wallace, Maria] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gynecol Oncol, Boston, MA USA.
RP del Carmen, MG (reprint author), Massachusetts Gen Hosp, Div Gynecol Oncol, Yawkey 9E, Boston, MA 02114 USA.
EM mdelcarmen@partners.org
NR 46
TC 7
Z9 7
U1 1
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-9201
EI 1532-5520
J9 CLIN OBSTET GYNECOL
JI Clin. Obstet. Gynecol.
PD MAR
PY 2013
VL 56
IS 1
BP 65
EP 75
DI 10.1097/GRF.0b013e31827af75a
PG 11
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 082ML
UT WOS:000314396000010
PM 23314716
ER
PT J
AU Bradford, L
Goodman, A
AF Bradford, Leslie
Goodman, Annekathryn
TI Cervical Cancer Screening and Prevention in Low-resource Settings
SO CLINICAL OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE cervical cancer; low-resource setting; developing countries; screening;
VIA; HPV-DNA testing
ID RANDOMIZED CONTROLLED-TRIAL; VISUAL INSPECTION METHODS;
HUMAN-PAPILLOMAVIRUS; ACETIC-ACID; DEVELOPING-COUNTRIES;
COST-EFFECTIVENESS; INTRAEPITHELIAL NEOPLASIA; POOLED ANALYSIS; POOR
SETTINGS; SINGLE-VISIT
AB Cervical cancer is both preventable and curable, yet it remains one of the leading causes of mortality in women worldwide. Approximately 88% of cervical cancer cases are diagnosed in low-resource countries, yet very few resources are allocated to prevention and treatment programs. In fact, it is estimated that only 5% of women in low-resources countries are screened appropriately for cervical cancer. Cytology-based programs are not feasible because of lack of healthcare infrastructure and cost, thus alternative methods of cancer screening, such as visual inspection with acetic acid and HPV-DNA testing, have been intensively studied and are reviewed in this article.
C1 [Bradford, Leslie; Goodman, Annekathryn] Massachusetts Gen Hosp, Div Gynecol Oncol, Dept Obstet & Gynecol, Boston, MA 02114 USA.
RP Goodman, A (reprint author), Massachusetts Gen Hosp, Div Gynecol Oncol, Boston, MA 02114 USA.
EM jschorge@partners.org
NR 73
TC 16
Z9 16
U1 3
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-9201
J9 CLIN OBSTET GYNECOL
JI Clin. Obstet. Gynecol.
PD MAR
PY 2013
VL 56
IS 1
BP 76
EP 87
DI 10.1097/GRF.0b013e31828237ac
PG 12
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 082ML
UT WOS:000314396000011
PM 23337844
ER
PT J
AU Fitzsimmons, J
Kubicki, M
Shenton, ME
AF Fitzsimmons, Jennifer
Kubicki, Marek
Shenton, Martha E.
TI Review of functional and anatomical brain connectivity findings in
schizophrenia
SO CURRENT OPINION IN PSYCHIATRY
LA English
DT Review
DE diffusion tensor imaging; fractional anisotropy; functional magnetic
resonance; schizophrenia; white matter
ID WHITE-MATTER ABNORMALITIES; FRACTIONAL ANISOTROPY; 1ST-EPISODE
PSYCHOSIS; RADIAL DIFFUSIVITY; GENETIC LIABILITY; INTERNAL CAPSULE;
CORPUS-CALLOSUM; ANTERIOR LIMB; DEFAULT MODE; INTEGRITY
AB Purpose of review
We review diffusion tensor imaging (DTI) studies that investigate white matter abnormalities in patients with chronic schizophrenia, first episode schizophrenia, and those who are at genetic risk for developing schizophrenia. Additionally, we include studies that combine DTI and functional MRI (fMRI) to investigate brain connectivity abnormalities.
Recent findings
Schizophrenia is a complex mental disorder with a peak age of onset in early adulthood. Abnormalities in white matter tracts, which connect brain regions into functional networks, are most likely relevant for understanding structural and functional brain abnormalities in schizophrenia. Dysconnectivity between brain regions, in fact, is thought to underlie cognitive abnormalities in schizophrenia but little is known about how alterations at the functional level relate to abnormalities in anatomical connectivity. DTI has become one of the most popular tools in brain research to address such questions. Here we review white matter abnormalities using DTI with the aim of understanding dysconnectivity of brain regions and their implications in schizophrenia.
Summary
Advances in DTI and in combining DTI with fMRI provide new insight into anatomical and functional connections in the brain, and for studying dysconnectivity in schizophrenia.
C1 [Fitzsimmons, Jennifer; Kubicki, Marek; Shenton, Martha E.] Harvard Univ, Sch Med, Dept Psychiat, Psychiat Neuroimaging Lab,Brigham & Womens Hosp, Boston, MA 02115 USA.
[Kubicki, Marek; Shenton, Martha E.] Harvard Univ, Sch Med, Dept Radiol, Surg Planning Lab,MRI Div,Brigham & Womens Hosp, Boston, MA 02115 USA.
[Shenton, Martha E.] VA Boston Healthcare Syst, Boston, MA USA.
RP Fitzsimmons, J (reprint author), Psychiat Neuroimaging Lab, 1249 Boylston St,2nd Floor, Boston, MA 02215 USA.
EM jfitzsimmons@bwh.harvard.edu
FU Department of Veterans Affairs Merit Awards; National Institute of
Mental Health [R01 MH 50740]
FX The present research was supported by the Department of Veterans Affairs
Merit Awards (MES) and by the grant from the National Institute of
Mental Health (R01 MH 50740 to MES).
NR 67
TC 97
Z9 102
U1 6
U2 86
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0951-7367
J9 CURR OPIN PSYCHIATR
JI Curr. Opin. Psychiatr.
PD MAR
PY 2013
VL 26
IS 2
BP 172
EP 187
DI 10.1097/YCO.0b013e32835d9e6a
PG 16
WC Psychiatry
SC Psychiatry
GA 082MZ
UT WOS:000314397400007
PM 23324948
ER
PT J
AU Mohammad, OM
DeLisi, LE
AF Mohammad, Othman M.
DeLisi, Lynn E.
TI N400 in schizophrenia patients
SO CURRENT OPINION IN PSYCHIATRY
LA English
DT Review
DE event related potentials; language; N400; priming; schizophrenia
ID EVENT-RELATED POTENTIALS; FORMAL THOUGHT-DISORDER; BRAIN POTENTIALS;
SEMANTIC MEMORY; ELECTROPHYSIOLOGICAL EVIDENCE; LEXICAL DECISION; WORD
REPETITION; LANGUAGE; ERP; ABNORMALITIES
AB Purpose of review
The purpose of this article is to review major findings in event related potential (ERP) research in schizophrenia patients, specifically focusing on the N400 component.
Recent findings
Patients with chronic schizophrenia have difficulty using 'context' (understanding the meaning of the word relative to the sentence) in sentence processing studies and often show differences from control populations in language experiments using word priming. Both of these observations are associated with an abnormal N400 ERP component when compared with nonpsychotic individuals. Many studies of language function rely on priming paradigms that use pairs of words such that the first word in a pair is a 'prime' and a second word in a pair is a 'target', separated from the prime by a period of time known as the Stimulus Onset Asynchrony (SOA). If the SOA is short (i.e., below 400 ms) then it is believed that a priming study examines primarily processes of initial activation within semantic networks; if it is long (i.e., more than 400 ms) then it is believed that a priming study examines primarily processes of context use, generating predictions and matching these predictions against upcoming semantic information. Priming paradigms that use long SOAs are consistently associated with a more negative N400 (hence lack of priming) in schizophrenia, whereas priming paradigms using a short SOA produce either a normal N400 priming response or hyperpriming as shown by a reduced N400 and related to a hypothesized too rapid automatic spread of activation within the semantic memory pathway. Apparent differences among reported study results are likely due to paradigm differences that tap into different aspects of language processing. Although the presence of both hyperactivation within semantic networks and difficulties with the use of context is well known in schizophrenia, it is unclear whether these abnormalities are also present prior to illness onset in people who are at risk for development of schizophrenia or even present at the onset of illness.
Summary
In order to clarify the findings reviewed here, future studies will be needed that focus on examining the N400 response in young people at high risk for developing the illness using multiple paradigms that probe different aspects of language function.
C1 [Mohammad, Othman M.] Boston Childrens Hosp, Boston, MA USA.
[Mohammad, Othman M.; DeLisi, Lynn E.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[DeLisi, Lynn E.] VA Boston Healthcare Syst, Boston, MA USA.
RP DeLisi, LE (reprint author), 940 Belmont Ave, Brockton, MA 02301 USA.
EM DeLisi76@AOL.com
NR 56
TC 12
Z9 13
U1 4
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0951-7367
J9 CURR OPIN PSYCHIATR
JI Curr. Opin. Psychiatr.
PD MAR
PY 2013
VL 26
IS 2
BP 196
EP 207
DI 10.1097/YCO.0b013e32835d9e56
PG 12
WC Psychiatry
SC Psychiatry
GA 082MZ
UT WOS:000314397400009
PM 23340116
ER
PT J
AU Bogoch, II
Andrews, JR
Nagami, EH
Rivera, AM
Gandhi, RT
Stone, D
AF Bogoch, I. I.
Andrews, J. R.
Nagami, E. H.
Rivera, A. M.
Gandhi, R. T.
Stone, D.
TI Clinical predictors for the aetiology of peripheral lymphadenopathy in
HIV-infected adults
SO HIV MEDICINE
LA English
DT Article
DE biopsy; HIV; lymphadenopathy; opportunistic infection; tuberculosis
ID NEEDLE-ASPIRATION-CYTOLOGY; HUMAN-IMMUNODEFICIENCY-VIRUS; BIOPSY; INDIA
AB Objectives The aim of the study was to determine the aetiology and clinical predictors of peripheral lymphadenopathy in HIV-infected individuals during the antiretroviral (ARV) era in a nontuberculosis endemic setting. Methods A multicentred, retrospective cohort study of peripheral lymph node biopsies in HIV-positive adults was carried out. A total of 107 charts were identified and reviewed for clinical features, lymphadenopathy size, and ARV use and duration. Biopsy results were categorized, and multivariate logistic regression determined independent predictors of lymphadenopathy aetiology. Results Evaluation of 107 peripheral lymph node biopsies revealed that 42.9% of peripheral lymphadenopathy was attributable to malignancy, 49.5% to reactive changes, and 7.5% to infections, with only 2.8% of all cases secondary to tuberculosis. Fevers, weight loss, ARV use, and lower viral loads are significantly associated with nonreactive lymphadenopathy. Conclusions Lymphadenopathy is likely to be reactive or malignant in nontuberculosis endemic regions. Readily available clinical features can aid clinicians in predicting the underlying aetiology, those at risk for malignancy, and who to biopsy.
C1 [Bogoch, I. I.; Andrews, J. R.; Gandhi, R. T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Bogoch, I. I.; Andrews, J. R.; Gandhi, R. T.] Harvard Univ, Sch Med, Boston, MA USA.
[Nagami, E. H.; Gandhi, R. T.] Ragon Inst MGH MIT & Harvard, Boston, MA USA.
[Rivera, A. M.; Stone, D.] Tufts Med Ctr, Div Infect Dis, Boston, MA USA.
[Nagami, E. H.; Stone, D.] Lemuel Shattuck Hosp, Boston, MA USA.
RP Bogoch, II (reprint author), Massachusetts Gen Hosp, COX 5,55 Fruit St, Boston, MA 02114 USA.
EM ibogoch@partners.org
OI Andrews, Jason/0000-0002-5967-251X
FU National Institute of Allergy and Infectious Diseases [T32 AI007433-20];
NIH [R01 AI066992-04A1, G08LM008830-01, U01 AI 694722, 2P30 AI060354-06]
FX This study was unfunded. JRA is supported by the National Institute of
Allergy and Infectious Diseases (T32 AI007433-20). RTG is supported by
NIH R01 AI066992-04A1 and NIH G08LM008830-01 and by a grant to the AIDS
Clinical Trials Group (NIH U01 AI 694722). RTG and EHN are supported by
a grant to the Harvard University Center for AIDS Research (NIH 2P30
AI060354-06). The content is solely the responsibility of the authors
and does not necessarily represent the official views of the National
Institutes of Health, which played no role in the study design, methods,
interpretation of results, the content of this manuscript, or the
decision to submit it for publication.
NR 13
TC 3
Z9 4
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-2662
J9 HIV MED
JI HIV Med.
PD MAR
PY 2013
VL 14
IS 3
BP 182
EP 186
DI 10.1111/j.1468-1293.2012.01035.x
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 083MW
UT WOS:000314469500008
PM 22805116
ER
PT J
AU Merritt, MA
Cramer, DW
Vitonis, AF
Titus, LJ
Terry, KL
AF Merritt, Melissa A.
Cramer, Daniel W.
Vitonis, Allison F.
Titus, Linda J.
Terry, Kathryn L.
TI Dairy foods and nutrients in relation to risk of ovarian cancer and
major histological subtypes
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE dairy foods; calcium; vitamin D; lactose; ovarian cancer
ID DIETARY-FAT INTAKE; GALACTOSE CONSUMPTION; POOLED ANALYSIS; VITAMIN-D;
FREQUENCY QUESTIONNAIRE; MILK CONSUMPTION; LACTOSE INTAKE;
UNITED-STATES; 12 COHORT; METABOLISM
AB Inconsistent results for the role of dairy food intake in relation to ovarian cancer risk may reflect the potential adverse effects of lactose, which has been hypothesized to increase gonadotropin levels, and the beneficial antiproliferative effects of calcium and vitamin D. Using data from the New England case-control study (1,909 cases and 1,989 controls), we examined dairy foods and nutrients in relation to risk of ovarian cancer overall, histological subtypes and rapidly fatal versus less aggressive disease. We used logistic regression and polytomous logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs). In models that were simultaneously adjusted for total (dietary plus supplements) calcium, total vitamin D and lactose, we observed a decreased overall risk of ovarian cancer with high intake of total calcium [Quartile 4 (Q4, >1,319 mg/day) vs. Quartile 1 (Q1, <655 mg/day), OR = 0.62, 95% CI = 0.49-0.79]; the inverse association was strongest for serous borderline and mucinous tumors. High intake of total vitamin D was not associated overall with ovarian cancer risk, but was inversely associated with risk of serous borderline (Q4, >559 IU/day vs. Q1, <164 IU/day, OR = 0.51, 95% CI = 0.34-0.76) and endometrioid tumors (Q4 vs. Q1, OR = 0.55, 95% CI = 0.39-0.80). We found no evidence that lactose intake influenced ovarian cancer risk or that risk varied by tumor aggressiveness in the analyses of intake of dairy foods and nutrients. The overall inverse association with high intake of calcium and the inverse associations of calcium and vitamin D with specific histological subtypes warrant further investigation.
C1 [Merritt, Melissa A.; Cramer, Daniel W.; Terry, Kathryn L.] Harvard Univ, Dept Epidemiol, Sch Publ Hlth, Boston, MA 02115 USA.
[Merritt, Melissa A.; Cramer, Daniel W.; Vitonis, Allison F.; Terry, Kathryn L.] Harvard Univ, OB GYN Epidemiol Ctr, Brigham & Womens Hosp, Dept Obstet & Gynecol,Med Sch, Boston, MA 02115 USA.
[Merritt, Melissa A.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Titus, Linda J.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA.
RP Merritt, MA (reprint author), Harvard Univ, OB GYN Epidemiol Ctr, Brigham & Womens Hosp, Dept Obstet & Gynecol,Med Sch, 221 Longwood Ave, Boston, MA 02115 USA.
EM merritt@jimmy.harvard.edu
FU National Cancer Institute, NIH [R01CA54419, P50CA105009, R25CA098566];
Department of Defense [W81XWH-10-1-0280]; Ovarian Cancer Research Fund
Liz Tilberis Scholar Award
FX Grant sponsor: National Cancer Institute, NIH; Grant numbers:
R01CA54419, P50CA105009, R25CA098566; Grant sponsor: Department of
Defense; Grant number: W81XWH-10-1-0280; Grant sponsor: Ovarian Cancer
Research Fund Liz Tilberis Scholar Award
NR 49
TC 12
Z9 14
U1 1
U2 30
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD MAR 1
PY 2013
VL 132
IS 5
BP 1114
EP 1124
DI 10.1002/ijc.27701
PG 11
WC Oncology
SC Oncology
GA 078AU
UT WOS:000314071300014
PM 22740148
ER
PT J
AU Lau, EF
Holcomb, PJ
Kuperberg, GR
AF Lau, Ellen F.
Holcomb, Phillip J.
Kuperberg, Gina R.
TI Dissociating N400 Effects of Prediction from Association in Single-word
Contexts
SO JOURNAL OF COGNITIVE NEUROSCIENCE
LA English
DT Article
ID LEXICAL-DECISION TASK; EVENT-RELATED POTENTIALS; SENTENCE-LEVEL CONTEXT;
LANGUAGE COMPREHENSION; SPREADING ACTIVATION; WORKING-MEMORY; BRAIN
POTENTIALS; SEMANTIC INTEGRATION; RIGHT-HEMISPHERE; UPCOMING WORDS
AB When a word is preceded by a supportive context such as a semantically associated word or a strongly constraining sentence frame, the N400 component of the ERP is reduced in amplitude. An ongoing debate is the degree to which this reduction reflects a passive spread of activation across long-term semantic memory representations as opposed to specific predictions about upcoming input. We addressed this question by embedding semantically associated prime-target pairs within an experimental context that encouraged prediction to a greater or lesser degree. The proportion of related items was used to manipulate the predictive validity of the prime for the target while holding semantic association constant. A semantic category probe detection task was used to encourage semantic processing and to preclude the need for a motor response on the trials of interest. A larger N400 reduction to associated targets was observed in the high than the low relatedness proportion condition, consistent with the hypothesis that predictions about upcoming stimuli make a substantial contribution to the N400 effect. We also observed an earlier priming effect (205-240 msec) in the high-proportion condition, which may reflect facilitation because of form-based prediction. In summary, the results suggest that predictability modulates N400 amplitude to a greater degree than the semantic content of the context.
C1 [Lau, Ellen F.; Kuperberg, Gina R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lau, Ellen F.; Holcomb, Phillip J.; Kuperberg, Gina R.] Tufts Univ, Medford, MA USA.
[Lau, Ellen F.] Univ Maryland, College Pk, MD 20742 USA.
RP Lau, EF (reprint author), Univ Maryland, Dept Linguist, 1401 Marie Mount Hall, College Pk, MD 20742 USA.
EM ellenlau@umd.edu
FU National Institute of Mental Health [R01MH071635]; National Institute of
Child Health and Human Development [F32HD063221]
FX The authors thank Eric Fields and Sorabh Kothari for their assistance
with this project. This work was funded by the National Institute of
Mental Health (R01MH071635 to G. R. K.) and the National Institute of
Child Health and Human Development (F32HD063221 to E. F. L.).
NR 94
TC 44
Z9 45
U1 3
U2 38
PU MIT PRESS
PI CAMBRIDGE
PA 55 HAYWARD STREET, CAMBRIDGE, MA 02142 USA
SN 0898-929X
J9 J COGNITIVE NEUROSCI
JI J. Cogn. Neurosci.
PD MAR
PY 2013
VL 25
IS 3
BP 484
EP 502
PG 19
WC Neurosciences; Psychology, Experimental
SC Neurosciences & Neurology; Psychology
GA 082AD
UT WOS:000314363200012
PM 23163410
ER
PT J
AU Samagh, SP
Kramer, EJ
Melkus, G
Laron, D
Bodendorfer, BM
Natsuhara, K
Kim, HT
Liu, XH
Feeley, BT
AF Samagh, Sanjum P.
Kramer, Erik J.
Melkus, Gerd
Laron, Dominique
Bodendorfer, Blake M.
Natsuhara, Kyle
Kim, Hubert T.
Liu, Xuhui
Feeley, Brian T.
TI MRI quantification of fatty infiltration and muscle atrophy in a mouse
model of rotator cuff tears
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE rotator cuff; muscle atrophy; fatty infiltration; MRI; mouse
ID SUPRASCAPULAR NEUROPATHY; REPAIR; SHEEP; SUPRASPINATUS; DEGENERATION;
VOLUME; WATER
AB Rotator cuff pathology is the most common shoulder problem seen by orthopedic surgeons. Rotator cuff muscle fatty infiltration and muscle atrophy are common in larger tears and are considered predicting factors for the prognosis of cuff repair. Clinically, MRI is the gold standard in determining fatty infiltration and muscle atrophy; however, analysis for MRI imaging is primarily qualitative in nature with the results lacking further validation. We have recently developed a mouse model of rotator cuff tears. The goal of this study is to quantify and verify rotator cuff muscle atrophy and fatty infiltration using high-resolution MRI in our mouse model. The rotator cuff muscles were analyzed for fat using a triglyceride quantification assay (TQA), muscle volume was measured through water displacement (WD), and histology. The study revealed that MRI had a high correlation with fat as measured with histology and TQA (R2?=?098). MRI also correlated well with atrophy measured with WD and wet weight. This suggests that MRI is a reliable modality in evaluating the progression of fatty infiltration and muscle atrophy following rotator cuff tears in a small animal model. (C) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 31: 421426, 2013
C1 [Samagh, Sanjum P.; Kramer, Erik J.; Natsuhara, Kyle; Kim, Hubert T.; Liu, Xuhui] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA.
[Samagh, Sanjum P.; Laron, Dominique; Bodendorfer, Blake M.; Kim, Hubert T.; Liu, Xuhui; Feeley, Brian T.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA.
[Melkus, Gerd] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA.
RP Feeley, BT (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA USA.
EM feeleyb@orthosurg.ucsf.edu
OI Melkus, Gerd/0000-0001-5387-8958
FU Orthopaedic Research Education Foundation (OREF)
FX Grant sponsor: Orthopaedic Research Education Foundation (OREF).
NR 33
TC 15
Z9 15
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-0266
J9 J ORTHOP RES
JI J. Orthop. Res.
PD MAR
PY 2013
VL 31
IS 3
BP 421
EP 426
DI 10.1002/jor.22233
PG 6
WC Orthopedics
SC Orthopedics
GA 076TJ
UT WOS:000313980600012
PM 22991068
ER
PT J
AU Yang, W
Liu, XZ
Choy, E
Mankin, H
Hornicek, FJ
Duan, ZF
AF Yang, Wen
Liu, Xianzhe
Choy, Edwin
Mankin, Henry
Hornicek, Francis J.
Duan, Zhenfeng
TI Targeting hedgehog-GLI-2 pathway in osteosarcoma
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE osteosarcoma; hedgehog; GLI-2
ID SIGNAL TRANSDUCER; CELL-GROWTH; CANCER; INHIBITION; APOPTOSIS; STAT3;
GLI2
AB Osteosarcoma is the most common primary malignant tumor of bone. Patients with localized osteosarcoma are routinely treated with chemotherapy and surgery. However, many of these patients eventually relapse after these treatments. In such cases, there are limited treatment options for these patients and most will eventually die with metastatic disease. Therefore, it is imperative to identify better therapeutic strategies. Hedgehog-GLI is responsible for the development of vertebrate embryonic and tumorigenesis. Specifically, the transcription factor, GLI-2, plays a key role in development of normal prostate. Aberrant activation of GLI-2 is correlated with various malignancies. We observe that GLI-2 is highly expressed in osteosarcoma cell lines, and this correlates with poor clinical outcomes in patients. Knockdown of GLI-2 by siRNA decreases osteosarcoma cell proliferation and viability, which eventually induces cell death as revealed in both in 2D and 3D cultures. In addition, we notice that administration of GLI-2 siRNA can increase the sensitivity of osteosarcoma cells to chemotherapeutic drugs. These findings suggest GLI-2 is required for osteosarcoma cell proliferation and survival. GLI-2 may be exploited as a therapeutic target for the treatment of osteosarcoma patients. (C) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 31: 502509, 2013
C1 [Yang, Wen; Liu, Xianzhe; Choy, Edwin; Mankin, Henry; Hornicek, Francis J.; Duan, Zhenfeng] Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA 02114 USA.
[Yang, Wen; Liu, Xianzhe; Choy, Edwin; Mankin, Henry; Hornicek, Francis J.; Duan, Zhenfeng] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Yang, Wen] Huazhong Univ Sci & Technol, Union Hosp, Dept Anesthesiol, Tongji Med Coll, Wuhan 430022, Peoples R China.
[Liu, Xianzhe] Huazhong Univ Sci & Technol, Union Hosp, Dept Orthopaed Surg, Tongji Med Coll, Wuhan 430022, Peoples R China.
[Mankin, Henry; Hornicek, Francis J.; Duan, Zhenfeng] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
RP Duan, ZF (reprint author), Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA 02114 USA.
EM zduan@partners.org
OI Choy, Edwin/0000-0001-9896-8084
FU Sarcoma Foundation of America; Gattegno and Wechsler Funds; Kenneth
Stanton Fund; Jennifer Hunter Yates Foundation
FX Dr. Duan is supported, in part, through a grant from Sarcoma Foundation
of America.; Grant sponsor: Gattegno and Wechsler Funds (partial
support); Grant sponsor: Kenneth Stanton Fund; Grant sponsor: Jennifer
Hunter Yates Foundation; Grant sponsor: Sarcoma Foundation of America
(partial support).
NR 22
TC 14
Z9 17
U1 1
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-0266
J9 J ORTHOP RES
JI J. Orthop. Res.
PD MAR
PY 2013
VL 31
IS 3
BP 502
EP 509
DI 10.1002/jor.22230
PG 8
WC Orthopedics
SC Orthopedics
GA 076TJ
UT WOS:000313980600023
PM 22968906
ER
PT J
AU Suganuma, R
Wang, LL
Sano, H
Naranjo, A
London, WB
Seeger, RC
Hogarty, MD
Gastier-Foster, JM
Look, AT
Park, JR
Maris, JM
Cohn, SL
Amann, G
Beiske, K
Cullinane, CJ
d'Amore, ESG
Gambini, C
Jarzembowski, JA
Joshi, VV
Navarro, S
Peuchmaur, M
Shimada, H
AF Suganuma, Rie
Wang, Larry L.
Sano, Hideki
Naranjo, Arlene
London, Wendy B.
Seeger, Robert C.
Hogarty, Michael D.
Gastier-Foster, Julie M.
Look, A. Thomas
Park, Julie R.
Maris, John M.
Cohn, Susan L.
Amann, Gabriele
Beiske, Klaus
Cullinane, Catherine J.
d'Amore, Emanuele S. G.
Gambini, Claudio
Jarzembowski, Jason A.
Joshi, Vijay V.
Navarro, Samuel
Peuchmaur, Michel
Shimada, Hiroyuki
TI Peripheral neuroblastic tumors with genotype-phenotype discordance: A
report from the Children's Oncology Group and the International
Neuroblastoma Pathology Committee
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article
DE genotype-phenotype correlation; immunohistochemistry; International
Neuroblastoma Pathology Classification; MYCN; neuroblastoma; prognosis
ID MYC GENE AMPLIFICATION; SCHWANNIAN STROMA-POOR; N-MYC; CANCER; BIOLOGY;
STAGE; GANGLIONEUROBLASTOMA; CLASSIFICATION; PROGNOSIS; DIAGNOSIS
AB Background Of 4,706 peripheral neuroblastic tumors (pNTs) registered on the Children's Cancer Group and Children's Oncology Group Neuroblastoma Study between 1989 and 2010, 51 cases (1.1%) had genotypephenotype discordance characterized by MYCN amplification (indicating poor prognosis) and Favorable Histology (indicating better prognosis). Procedure To distinguish prognostic subgroups in the genotypephenotype discordant pNTs, two subgroups, conventional and bull's eye, were identified based on the nuclear morphology. The conventional tumors (35 cases) included: Neuroblastoma, poorly differentiated subtype (NB-PD, 26 cases) with salt-and-pepper nuclei; neuroblastoma, differentiating subtype (4 cases); ganglioneuroblastoma, intermixed (3 cases); and ganglioneuroma, maturing subtype (2 cases). The bull's eye tumors included NB-PD with prominent nucleoli (16 cases). Clinicopathologic characteristics of these two subgroups were analyzed. N-myc protein expression was tested immunohistochemically on available tumors. Results No significant difference was found between these two subgroups in the distribution of prognostic factors such as age at diagnosis, clinical stage, histopathology category/subtype, mitosis-karyorrhexis index, ploidy, 1p LOH, and unbalanced 11q LOH. However, prognosis of the patients with conventional tumors (5-year EFS 85.7 +/- 12.2%;OS 89.3 +/- 10.3%) was significantly better than those with bull's eye tumors (EFS 31.3 +/- 13.0%; OS 42.9 +/- 16.2%; P = 0.0010 and 0.0008, respectively). Immunohistochemically all (11/11) tested conventional tumors were negative, and 10/11 tested bull's eye tumors were positive for N-myc protein expression. Conclusions Based on the presence or absence of prominent nucleoli (the putative site of RNA synthesis/accumulation leading to N-myc protein expression), two prognostic subgroups, conventional with a better prognosis and bull's eye with a poor prognosis, were distinguished among the genotypephenotype discordant pNTs. Pediatr Blood Cancer 2013; 60: 363370. (C) 2012 Wiley Periodicals, Inc.
C1 [Suganuma, Rie; Wang, Larry L.; Shimada, Hiroyuki] Childrens Hosp Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90027 USA.
[Suganuma, Rie; Wang, Larry L.; Seeger, Robert C.; Shimada, Hiroyuki] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Sano, Hideki] Fukushima Med Univ, Sch Med, Dept Pediat, Fukushima, Japan.
[Naranjo, Arlene] Univ Florida, Coll Med, Dept Biostat, Gainesville, FL USA.
[Naranjo, Arlene] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Biostat, Gainesville, FL USA.
[London, Wendy B.] Childrens Hosp Boston, Boston, MA USA.
[London, Wendy B.] Harvard Univ, Sch Med, Dana Farber Harvard Canc Ctr, Boston, MA USA.
[Seeger, Robert C.] Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA.
[Hogarty, Michael D.; Maris, John M.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Oncol, Philadelphia, PA 19104 USA.
[Gastier-Foster, Julie M.] Ohio Univ, Coll Med, Nationwide Childrens Hosp, Dept Pathol & Lab Med, Columbus, OH USA.
[Look, A. Thomas] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Park, Julie R.] Seattle Childrens Hosp, Dept Pediat, Seattle, WA USA.
[Park, Julie R.] Univ Washington, Sch Med, Seattle, WA USA.
[Cohn, Susan L.] Univ Chicago, Dept Pediat, Div Hematol Oncol, Chicago, IL 60637 USA.
[Amann, Gabriele] Med Univ Vienna, AKH, Clin Inst Pathol, Vienna, Austria.
[Beiske, Klaus] Univ Oslo, Rikshosp, Oslo Univ Hosp, Dept Pathol, N-0027 Oslo, Norway.
[Cullinane, Catherine J.] Leeds Teaching Hosp Trust, St Jamess Univ Hosp, Dept Histopathol, Leeds, W Yorkshire, England.
[d'Amore, Emanuele S. G.] Osped S Bortolo, Dept Anat Pathol, Vicenza, Italy.
[Gambini, Claudio] IRCCS Ist G Gaslini, Dept Res & Diagnost, Genoa, Italy.
[Jarzembowski, Jason A.] Childrens Hosp Wisconsin, Dept Pathol, Milwaukee, WI 53201 USA.
[Joshi, Vijay V.] Virginia Commonwealth Univ, Med Coll Virginia, Dept Pathol, Richmond, VA 23298 USA.
[Navarro, Samuel] Univ Valencia, Sch Med, Dept Pathol, Valencia, Spain.
[Peuchmaur, Michel] Univ Paris Diderot, Hop R Debre, APHP, Serv Pathol, Paris, France.
RP Shimada, H (reprint author), Childrens Hosp Los Angeles, Dept Pathol & Lab Med, 4650 Sunset Blvd,MS 43, Los Angeles, CA 90027 USA.
EM hshimada@chla.usc.edu
OI Jarzembowski, Jason/0000-0002-9027-5686; Cohn, Susan/0000-0001-5749-7650
FU National Institutes of Health [U10 CA98413, U10 CA98543]; CHLA Research
Institute; Showa University
FX Grant sponsor: National Institutes of Health; Grant numbers: U10
CA98413, U10 CA98543.; We thank Xingchao Wang, BS, HT (ASCP) at
Children's Hospital Los Angeles for his technical support in
immunohistochemistry. We also thank Akira Toki, MD, PhD (Division of
Pediatric Surgery, Department of Surgery, Showa University School of
Medicine, Tokyo, Japan) for his encouragement and discussion during the
project. Many thanks also goes to Dr. Nilsa Ramirez and Ms. Wanda Smith
at Nationwide Children's Hospital for their continuous support in this
project. This study was supported by the NIH grants U10 CA98413 (COG SDC
grant) and U10 CA98543 (COG Chair's grant), the Merit Award to Hiroyuki
Shimada from the CHLA Research Institute and the Showa University
Research Grant for Young Researchers.
NR 36
TC 3
Z9 4
U1 2
U2 9
PU WILEY PERIODICALS, INC
PI SAN FRANCISCO
PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD MAR
PY 2013
VL 60
IS 3
BP 363
EP 370
DI 10.1002/pbc.24238
PG 8
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 073ET
UT WOS:000313727000004
PM 22744966
ER
PT J
AU Raney, B
Huh, W
Hawkins, D
Hayes-Jordan, A
Million, L
Rodeberg, D
Teot, L
Anderson, J
AF Raney, Beverly
Huh, Winston
Hawkins, Douglas
Hayes-Jordan, Andrea
Million, Lynn
Rodeberg, David
Teot, Lisa
Anderson, James
CA Children's Oncology Grp
TI Outcome of patients with localized orbital sarcoma who relapsed
following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG)
Protocols-III and -IV, 1984-1997: A report from the Children's Oncology
Group
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article
DE outcome after recurrence; pediatric; adolescent orbital sarcoma
ID OF-PEDIATRIC-ONCOLOGY; NONMETASTATIC RHABDOMYOSARCOMA; 3RD; ADOLESCENTS;
RECURRENCE; CHILDHOOD; SURVIVAL; THERAPY; PATTERN; TUMORS
AB Background We wanted to ascertain patterns of recurrence, re-treatment, and outcome among 188 eligible patients treated for localized orbital sarcoma on IRSG Protocols III/IV, 1984-1997. Procedure Retrospective chart review. Results Twenty-four of 188 patients (12.8%) developed local (n = 22) or distant relapse (n = 2) at 0.057-7.05 years (median, 1.58) after enrollment. Ages at study entry were 0.14-17 years (median, 5 years). Initial tumor operations included biopsy (n = 20) or gross resection with microscopic residual (n = 4). Initial tumor diameters were 0.57 cm (median, 3). Pathologic subtypes were embryonal rhabdomyosarcoma (ERMS, n = 19), sarcoma not otherwise specified (n = 2), and alveolar RMS, botryoid ERMS, or undifferentiated sarcoma (n = 1 each). Initial treatment included vincristine/dactinomycin (n = 24) including an alkylator (n = 4) and radiotherapy (RT, n = 21). Twenty patients responded, 14 completely, 6 partially. After recurrence, patients underwent orbital exenteration (n = 10), enucleation (2), tumor excision (3), or biopsy (1); 7 had no operation, and 1 had no data. Post-relapse chemotherapy included combinations of etoposide (n = 14 patients), doxorubicin (14), ifosfamide (12), cyclophosphamide (7), and dacarbazine (n = 1). Six patients received RT, including four previously treated and two not irradiated initially. Two patients died; one at 1.79 years after contralateral brain metastasis followed by local recurrence, and another at 2.49 years after multiple local recurrences. Twenty-two patients (91.7%) survived sarcoma-free for 0.04-17 years (median, 6.9) after relapse, and 18 of 22 (82%) were alive >= 5 years after relapse. Conclusion Survival following recurrent localized orbital sarcoma appears likely after vigorous re-treatment given with curative intent. Pediatr Blood Cancer 2013; 60: 371-376. (C) 2012 Wiley Periodicals, Inc.
C1 [Raney, Beverly; Huh, Winston; Hayes-Jordan, Andrea] UT MD Anderson Canc Ctr, Div Pediat, Houston, TX USA.
[Raney, Beverly; Huh, Winston; Hayes-Jordan, Andrea] UT MD Anderson Canc Ctr, Childrens Canc Hosp, Houston, TX USA.
[Hawkins, Douglas] Univ Washington, Sch Med, Seattle Childrens Hosp, Seattle, WA USA.
[Hawkins, Douglas] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Million, Lynn] Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
[Rodeberg, David] Univ Pittsburgh, Pittsburgh, PA USA.
[Teot, Lisa] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Anderson, James] Univ Nebraska Med Ctr, Omaha, NE USA.
RP Raney, B (reprint author), 2903 White Rock Dr, Austin, TX 78757 USA.
EM rbraney@austin.rr.com
FU National Cancer Institute [CA-24507, CA-29511, CA-72989, CA-98543];
National Cancer Institute, Bethesda, MD [CA-24507, CA-29511, CA-72989,
CA-98543]
FX Grant sponsor: National Cancer Institute; Grant numbers: CA-24507,
CA-29511, CA-72989, CA-98543.; This work was supported in part by Grants
CA-24507, CA-29511, CA-72989, and CA-98543 from the National Cancer
Institute, Bethesda, MD. A complete listing of grant support for
research conducted by CCG and POG before initiation of the COG grant in
2003 is available online at
http://www.childrensoncologygroup.org/admin/grantinfo.htm
NR 22
TC 6
Z9 7
U1 0
U2 9
PU WILEY PERIODICALS, INC
PI SAN FRANCISCO
PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD MAR
PY 2013
VL 60
IS 3
BP 371
EP 376
DI 10.1002/pbc.24289
PG 6
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 073ET
UT WOS:000313727000005
PM 22961750
ER
PT J
AU Han, CNN
Xie, WL
Yang, M
Hsieh, CL
Drouin, S
Lee, GSM
Kantoff, PW
AF Han Christine Ngoc Nguyen
Xie, Wanling
Yang, Ming
Hsieh, Chen-Lin
Drouin, Sarah
Lee, Gwo-Shu Mary
Kantoff, Philip W.
TI Expression differences of circulating microRNAs in metastatic castration
resistant prostate cancer and low-risk, localized prostate cancer
SO PROSTATE
LA English
DT Article
DE circulating microRNAs; prostate cancer; castration resistant prostate
cancer
ID BIOMARKERS; CARCINOMA; THERAPY; CELLS
AB BACKGROUND Recent studies show that microRNAs (miRNAs), small non-coding RNAs that negatively regulate gene expression, may have potential for monitoring cancer status. We investigated circulating miRNAs in prostate cancer that may be associated with the progression of hormone-sensitive primary tumors to metastatic castration resistant prostate cancer (CRPC) after androgen deprivation therapy. METHODS Using genome-wide expression profiling by TaqMan Human MicroRNA Arrays (Applied Biosystems) and/or quantitative real-time polymerase chain reaction, we compared the expression levels of miRNAs in serum samples from 28 patients of low-risk localized disease, 30 of high-risk localized disease and 26 of metastatic CRPC. RESULTS We demonstrated that serum samples from patients of low risk, localized prostate cancer and metastatic CRPC patients exhibit distinct circulating miRNA signatures. MiR-375, miR-378*, and miR-141 were significantly over-expressed in serum from CRPC patients compared with serum from low-risk localized patients, while miR-409-3p was significantly under-expressed. In prostate primary tumor samples, miR-375 and miR-141 also had significantly higher expression levels compared with those in normal prostate tissue. CONCLUSIONS Circulating miRNAs, particularly miR-375, miR-141, miR-378*, and miR-409-3p, are differentially expressed in serum samples from prostate cancer patients. In the search for improved minimally invasive methods to follow cancer pathogenesis, the correlation of disease status with the expression patterns of circulating miRNAs may indicate the potential importance of circulating miRNAs as prognostic markers for prostate cancer progression. Prostate 73: 346354, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Han Christine Ngoc Nguyen; Yang, Ming; Hsieh, Chen-Lin; Drouin, Sarah; Lee, Gwo-Shu Mary; Kantoff, Philip W.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Han Christine Ngoc Nguyen; Xie, Wanling; Yang, Ming; Hsieh, Chen-Lin; Drouin, Sarah; Lee, Gwo-Shu Mary; Kantoff, Philip W.] Harvard Univ, Sch Med, Boston, MA USA.
[Xie, Wanling] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
RP Lee, GSM (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM gwo-shu_lee@dfci.harvard.edu; philip_kantoff@dfci.harvard.edu
RI Yang, Ming/G-4705-2012
OI Yang, Ming/0000-0002-7722-7487
FU SPORE in Prostate Cancer (PWK) [2 P50 CA090381-06]
FX Grant sponsor: SPORE in Prostate Cancer (PWK); Grant number: 2 P50
CA090381-06.
NR 24
TC 1
Z9 1
U1 3
U2 19
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-4137
J9 PROSTATE
JI Prostate
PD MAR
PY 2013
VL 73
IS 4
BP 346
EP 354
DI 10.1002/pros.22572
PG 9
WC Endocrinology & Metabolism; Urology & Nephrology
SC Endocrinology & Metabolism; Urology & Nephrology
GA 076WZ
UT WOS:000313991200002
ER
PT J
AU Abern, MR
Aronson, WJ
Terris, MK
Kane, CJ
Presti, JC
Amling, CL
Freedland, SJ
AF Abern, Michael R.
Aronson, William J.
Terris, Martha K.
Kane, Christopher J.
Presti, Joseph C., Jr.
Amling, Christopher L.
Freedland, Stephen J.
TI Delayed radical prostatectomy for intermediate-risk prostate cancer is
associated with biochemical recurrence: Possible implications for active
surveillance from the SEARCH database
SO PROSTATE
LA English
DT Article
DE prostatic neoplasms; prostatectomy; retropubic; treatment outcome;
active surveillance
ID DISEASE RECURRENCE; MEN; BIOPSY; DEATH; DIAGNOSIS; MORTALITY; OUTCOMES;
THERAPY; IMPACT; TIME
AB INTRODUCTION Active surveillance (AS) is increasingly accepted as appropriate management for low-risk prostate cancer (PC) patients. It is unknown whether delaying radical prostatectomy (RP) is associated with increased risk of biochemical recurrence (BCR) for men with intermediate-risk PC. METHODS We performed a retrospective analysis of 1,561 low and intermediate-risk men from the Shared Equal Access Regional Cancer Hospital (SEARCH) database treated with RP between 1988 and 2011. Patients were stratified by interval between diagnosis and RP (=3, 36, 69, or >9 months) and by risk using the D'Amico classification. Cox proportional hazard models were used to analyze BCR. Logistic regression was used to analyze positive surgical margins (PSM), extracapsular extension (ECE), and pathologic upgrading. RESULTS Overall, 813 (52%) men were low-risk, and 748 (48%) intermediate-risk. Median follow-up among men without recurrence was 52.9 months, during which 437 men (38.9%) recurred. For low-risk men, RP delays were unrelated to BCR, ECE, PSM, or upgrading (all P?>?0.05). For intermediate-risk men, however, delays >9 months were significantly related to BCR (HR: 2.10, P?=?0.01) and PSM (OR: 4.08, P?0.01). Delays >9 months were associated with BCR in subsets of intermediate-risk men with biopsy Gleason score =3?+?4 (HR: 2.51, P?0.01), PSA?=?6 (HR: 2.82, P?=?0.06), and low tumor volume (HR: 2.59, P?=?0.06). CONCLUSIONS For low-risk men, delayed RP did not significantly affect outcome. For men with intermediate-risk disease, delays >9 months predicted greater BCR and PSM risk. If confirmed in future studies, this suggests delayed RP for intermediate-risk PC may compromise outcomes. Prostate 73: 409417, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Abern, Michael R.; Freedland, Stephen J.] Duke Univ, Sch Med, Dept Surg, Div Urol Surg, Durham, NC 27705 USA.
[Aronson, William J.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Urol Sect, Los Angeles, CA USA.
[Aronson, William J.] Univ Calif Los Angeles, Sch Med, Dept Urol, Los Angeles, CA USA.
[Terris, Martha K.] VAMC, Urol Sect, Augusta, GA USA.
[Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA.
[Kane, Christopher J.] Univ Calif San Diego, Div Urol, San Diego, CA USA.
[Presti, Joseph C., Jr.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA.
[Presti, Joseph C., Jr.] VAMC, Urol Sect, Palo Alto, CA USA.
[Amling, Christopher L.] Oregon Hlth & Sci Univ, Dept Urol, Portland, OR USA.
[Freedland, Stephen J.] VAMC, Urol Sect, Durham, NC USA.
RP Abern, MR (reprint author), Duke Univ, Sch Med, Dept Surg, Div Urol Surg, 200 Trent Dr,DUMC Box 2804, Durham, NC 27705 USA.
EM michael.abern@duke.edu
OI Terris, Martha/0000-0002-3843-7270
NR 33
TC 26
Z9 26
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-4137
J9 PROSTATE
JI Prostate
PD MAR
PY 2013
VL 73
IS 4
BP 409
EP 417
DI 10.1002/pros.22582
PG 9
WC Endocrinology & Metabolism; Urology & Nephrology
SC Endocrinology & Metabolism; Urology & Nephrology
GA 076WZ
UT WOS:000313991200009
PM 22996686
ER
PT J
AU Terrin, N
Rodday, AM
Tighiouart, H
Chang, G
Parsons, SK
AF Terrin, Norma
Rodday, Angie Mae
Tighiouart, Hocine
Chang, Grace
Parsons, Susan K.
CA Journeys Recovery Study
TI Parental emotional functioning declines with occurrence of clinical
complications in pediatric hematopoietic stem cell transplant
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Pediatric hematopoietic stem cell transplant; Parental emotional
functioning; Parental distress; Transplant-related toxicity
ID BONE-MARROW-TRANSPLANTATION; CHILDREN; DISTRESS; MOTHERS; DEPRESSION;
DISEASE; ANXIETY; STRESS; GRAFT
AB Parents' stress levels are high prior to their child's hematopoietic stem cell transplant (HSCT) and during transplant hospitalization, usually abating after discharge. Nevertheless, a subgroup of parents continues to experience frequent anxiety and mood disruption, the causes of which are not well understood. The purpose of this study was to assess whether clinical complications of HSCT could explain variation in parents' recovery of emotional functioning.
Pediatric HSCT recipients (n = 165) aged 5-18 and their parents were followed over the first year post-transplant. Health-related quality of life assessments and medical chart reviews were performed at each time period (baseline, 45 days, 3, 6, and 12 months). We tested the association between clinical complications [acute and chronic graft versus host disease (aGVHD and cGVHD), organ toxicity, and infection] and longitudinally measured parental emotional functioning, as assessed by the Child Health-Ratings Inventories. The models used maximum likelihood estimation with repeated measures.
In adjusted analyses covering the early time period (45 days and 3 months), aGVHD grade a parts per thousand yen2, intermediate or poor organ toxicity, and systemic infection were associated with decreases in mean parental emotional functioning of 5.2 (p = 0.086), 5.8 (p = 0.052), and 5.1 (p = 0.023) points, respectively. In the later time period (6 and 12 months), systemic infection was associated with a decrease of 20 points (p < 0.0001). cGVHD was not significantly associated.
When children experience clinical complications after HSCT, parental emotional functioning can be impacted. Intervening at critical junctures could mitigate potential negative consequences for parents and their children.
C1 [Terrin, Norma; Rodday, Angie Mae; Tighiouart, Hocine; Parsons, Susan K.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA.
[Terrin, Norma; Parsons, Susan K.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Chang, Grace] VA Boston Healthcare Syst, Brockton, MA 02301 USA.
RP Terrin, N (reprint author), Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, 800 Washington St,Box 063, Boston, MA 02111 USA.
EM nterrin@tuftsmedicalcenter.org
FU American Cancer Society [RSGPB-02-186-01-PBP]; NIH [R01 CA119196]
FX This study was supported by American Cancer Society grant
RSGPB-02-186-01-PBP (Parsons, PI) and NIH grant R01 CA119196 (Parsons,
PI).
NR 24
TC 10
Z9 10
U1 1
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD MAR
PY 2013
VL 21
IS 3
BP 687
EP 695
DI 10.1007/s00520-012-1566-9
PG 9
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 081FD
UT WOS:000314301900004
PM 22936494
ER
PT J
AU Mosher, CE
Champion, VL
Azzoli, CG
Hanna, N
Jalal, SI
Fakiris, AJ
Birdas, TJ
Okereke, IC
Kesler, KA
Einhorn, LH
Monahan, PO
Ostroff, JS
AF Mosher, Catherine E.
Champion, Victoria L.
Azzoli, Christopher G.
Hanna, Nasser
Jalal, Shadia I.
Fakiris, Achilles J.
Birdas, Thomas J.
Okereke, Ikenna C.
Kesler, Kenneth A.
Einhorn, Lawrence H.
Monahan, Patrick O.
Ostroff, Jamie S.
TI Economic and social changes among distressed family caregivers of lung
cancer patients
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Lung cancer; Family caregiving; Economic; Financial; Employment;
Psychological distress
ID QUALITY-OF-LIFE; INFORMAL CAREGIVERS; HOSPITAL ANXIETY; DEPRESSION
SCALE; MENTAL-HEALTH; BURDEN; CARE; SUPPORT; STRESS; IMPACT
AB Although costs of lung cancer care have been documented, economic and social changes among lung cancer patients' family caregivers have yet to be fully examined. In addition, research has not focused on caregivers with greater need for support services. This study examined various economic and social changes among distressed family caregivers of lung cancer patients during the initial months of cancer care in the USA.
Lung cancer patients' primary family caregivers with significant anxiety or depressive symptoms were recruited from three medical centers within 12 weeks of the patient's new oncology visit. Caregivers (N = 83) reported demographic and medical information and caregiving burden at baseline. Seventy-four caregivers reported anxiety and depressive symptoms and economic and social changes 3 months later.
Seventy-four percent of distressed caregivers experienced one or more adverse economic or social changes since the patient's illness. Common changes included caregivers' disengagement from most social and leisure activities (56 %) and, among employed caregivers (n = 49), reduced hours of work (45 %). In 18 % of cases, a family member quit work or made another major lifestyle change due to caregiving. Additionally, 28 % of caregivers reported losing the main source of family income, and 18 % reported losing most or all of the family savings. Loss of the main source of family income and disengagement from most social and leisure activities predicted greater caregiver distress.
Findings suggest that distressed caregivers of lung cancer patients experience high rates of adverse economic and social changes that warrant clinical and research attention.
C1 [Mosher, Catherine E.] Indiana Univ Purdue Univ Indianapolis, Dept Psychol, Indianapolis, IN 46202 USA.
[Champion, Victoria L.] Indiana Univ, Sch Nursing, Indianapolis, IN 46202 USA.
[Azzoli, Christopher G.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Hanna, Nasser; Jalal, Shadia I.; Einhorn, Lawrence H.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
[Fakiris, Achilles J.] Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27514 USA.
[Birdas, Thomas J.; Okereke, Ikenna C.; Kesler, Kenneth A.] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.
[Monahan, Patrick O.] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA.
[Ostroff, Jamie S.] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, New York, NY 10022 USA.
RP Mosher, CE (reprint author), Indiana Univ Purdue Univ Indianapolis, Dept Psychol, 402 N Blackford St,LD 124, Indianapolis, IN 46202 USA.
EM cemosher@iupui.edu
OI Ostroff, Jamie/0000-0003-2671-5680
FU National Cancer Institute [R03CA139862, F32CA130600]; National Center
for Research Resources [KL2 RR025760]
FX This study was supported by Grant No. R03CA139862 from the National
Cancer Institute. CM was supported by F32CA130600 from the National
Cancer Institute and KL2 RR025760 (A. Shekhar, PI) from the National
Center for Research Resources. The authors would like to thank the study
participants, the thoracic oncology teams at Memorial Sloan-Kettering
Cancer Center, Indiana University Simon Cancer Center, and the Roudebush
VA Medical Center, Scarlett Ho, Aigul Amankeldi, Shannon M. Christy, and
undergraduate students for their assistance.
NR 33
TC 10
Z9 10
U1 2
U2 25
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD MAR
PY 2013
VL 21
IS 3
BP 819
EP 826
DI 10.1007/s00520-012-1585-6
PG 8
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 081FD
UT WOS:000314301900018
PM 22945881
ER
PT J
AU Wang, ZH
Sagotsky, J
Taylor, T
Shironoshita, P
Deisboeck, TS
AF Wang, Zhihui
Sagotsky, Jonathan
Taylor, Thomas
Shironoshita, Patrick
Deisboeck, Thomas S.
TI Accelerating cancer systems biology research through Semantic Web
technology
SO WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE
LA English
DT Review
ID CELL LUNG-CANCER; MATHEMATICAL-MODEL; LIFE SCIENCES; TUMOR-GROWTH;
ONTOLOGIES; FUTURE; IMPLEMENTATION; REPRESENTATION; EVOLUTION; DISCOVERY
AB Cancer systems biology is an interdisciplinary, rapidly expanding research field in which collaborations are a critical means to advance the field. Yet the prevalent database technologies often isolate data rather than making it easily accessible. The Semantic Web has the potential to help facilitate web-based collaborative cancer research by presenting data in a manner that is self-descriptive, human and machine readable, and easily sharable. We have created a semantically linked online Digital Model Repository (DMR) for storing, managing, executing, annotating, and sharing computational cancer models. Within the DMR, distributed, multidisciplinary, and inter-organizational teams can collaborate on projects, without forfeiting intellectual property. This is achieved by the introduction of a new stakeholder to the collaboration workflow, the institutional licensing officer, part of the Technology Transfer Office. Furthermore, the DMR has achieved silver level compatibility with the National Cancer Institute's caBIG, so users can interact with the DMR not only through a web browser but also through a semantically annotated and secure web service. We also discuss the technology behind the DMR leveraging the Semantic Web, ontologies, and grid computing to provide secure inter-institutional collaboration on cancer modeling projects, online grid-based execution of shared models, and the collaboration workflow protecting researchers' intellectual property. WIREs Syst Biol Med 2013, 5:135151. doi: 10.1002/wsbm.1200 For further resources related to this article, please visit the WIREs website.
C1 [Wang, Zhihui] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA.
[Sagotsky, Jonathan; Deisboeck, Thomas S.] Massachusetts Gen Hosp, Harvard MIT HST Athinoula A Martinos Ctr Biomed I, Charlestown, MA USA.
[Taylor, Thomas; Shironoshita, Patrick] INFOTECH Soft Inc, Miami, FL USA.
RP Deisboeck, TS (reprint author), Massachusetts Gen Hosp, Harvard MIT HST Athinoula A Martinos Ctr Biomed I, Charlestown, MA USA.
EM deisboec@helix.mgh.harvard.edu
FU NIH [CA 113004]; Harvard-MIT (HST) Athinoula A. Martinos Center for
Biomedical Imaging; Department of Radiology at Massachusetts General
Hospital
FX This work has been supported in part by NIH grant CA 113004 and by the
Harvard-MIT (HST) Athinoula A. Martinos Center for Biomedical Imaging
and the Department of Radiology at Massachusetts General Hospital. Both
CViT.org and DMR/CMEF are currently hosted at INFOTECH SOFT Inc.
NR 69
TC 7
Z9 7
U1 0
U2 30
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1939-5094
J9 WIRES SYST BIOL MED
JI Wiley Interdiscip. Rev.-Syst. Biol
PD MAR-APR
PY 2013
VL 5
IS 2
BP 135
EP 151
DI 10.1002/wsbm.1200
PG 17
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 079MZ
UT WOS:000314176000002
PM 23188758
ER
PT J
AU Bedoya, CA
Traeger, L
Trinh, NH
Chang, T
Brill, C
Hails, K
Hagan, P
Flaherty, K
Yeung, A
AF Bedoya, C. Andres
Traeger, Lara
Nhi-Ha Trinh
Chang, Trina
Brill, Charlotte
Hails, Katherine
Hagan, Patrick
Flaherty, Katherine
Yeung, Albert
TI IMPACT OF A CULTURALLY-FOCUSED PSYCHIATRIC CONSULTATION INTERVENTION ON
DEPRESSIVE SYMPTOMS AMONG LATINO PRIMARY CARE PATIENTS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Bedoya, C. Andres; Traeger, Lara; Nhi-Ha Trinh; Chang, Trina; Yeung, Albert] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Bedoya, C. Andres; Traeger, Lara; Nhi-Ha Trinh; Chang, Trina; Yeung, Albert] Harvard Med Sch, Boston, MA USA.
[Flaherty, Katherine] ABT Associates Inc, Cambridge, MA USA.
[Brill, Charlotte] Univ Washington, Seattle, WA 98195 USA.
[Hails, Katherine] Childrens Hosp, Boston, MA 02115 USA.
[Hagan, Patrick] Smith Coll, Northampton, MA 01063 USA.
EM abedoya@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 3113
BP S179
EP S179
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928001274
ER
PT J
AU Benedict, C
Traeger, L
Rasheed, M
Zhou, E
Bustillo, NE
Kava, B
Soloway, M
Antoni, M
Penedo, FJ
AF Benedict, Catherine
Traeger, Lara
Rasheed, Mikal
Zhou, Eric
Bustillo, Natalie E.
Kava, Bruce
Soloway, Mark
Antoni, Michael
Penedo, Frank J.
TI QUALITY OF LIFE IN MEN WITH PROSTATE CANCER: LONG-TERM EFFECTS OF A
PSYCHOSOCIAL INTERVENTION
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Benedict, Catherine; Rasheed, Mikal; Zhou, Eric; Bustillo, Natalie E.; Antoni, Michael] Univ Miami, Psychol, Coral Gables, FL 33124 USA.
[Antoni, Michael] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA.
[Kava, Bruce; Soloway, Mark] Miller Sch Med, Urol, Miami, FL USA.
[Traeger, Lara] Massachusetts Gen Hosp, Psychiat, Boston, MA 02114 USA.
[Penedo, Frank J.] Northwestern Univ, Feinberg Sch Med, Med Social Sci, Boston, MA USA.
EM cbenedict@psy.miami.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA D-003
BP S258
EP S258
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928001588
ER
PT J
AU Chandwani, K
Zhao, FM
Morrow, GR
Deshields, T
Manola, J
Fisch, MJ
AF Chandwani, Kavita
Zhao, Fengmin
Morrow, Gary R.
Deshields, Teresa
Manola, Judith
Fisch, Michael J.
TI PATIENT-CLINICIAN DISCORDANCE (PCD), DISTRESS, AND QUALITY OF LIFE (QOL)
IN CANCER
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Chandwani, Kavita; Morrow, Gary R.] Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY 14623 USA.
[Fisch, Michael J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Zhao, Fengmin; Manola, Judith] Dana Farber Canc Ctr, Boston, MA USA.
[Deshields, Teresa] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO 63110 USA.
EM kavita_chandwani@urmc.rochester.edu
FU PHS [CA37604, CA17145]; NCI, NIH; DHHS
FX PHS Grants CA37604, CA17145, and NCI, NIH, and DHHS grants
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA B-013
BP S100
EP S100
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000392
ER
PT J
AU Chiu, CJ
Lu, FH
Hsu, YC
Lee, SL
Wray, LA
Beverly, EA
AF Chiu, Ching-Ju
Lu, Feng-Hwa
Hsu, Yu-Ching
Lee, Siao-Ling
Wray, Linda A.
Beverly, Elizabeth A.
TI IDENTIFICATION OF RISK GROUPS DEVELOPING DEPRESSION AFTER DIABETES
DIAGNOSIS: GROUP-BASED TRAJECTORY MODELING APPROACH
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Chiu, Ching-Ju; Lu, Feng-Hwa; Hsu, Yu-Ching; Lee, Siao-Ling] Natl Cheng Kung Univ, Inst Gerontol, Tainan, Taiwan.
[Lu, Feng-Hwa] Natl Cheng Kung Univ Hosp, Family Med, Tainan, Taiwan.
[Wray, Linda A.] Penn State Univ, Biobehav Hlth, State Coll, PA USA.
[Hsu, Yu-Ching] Tainan Hosp, Chinese Med, Tainan, Taiwan.
[Beverly, Elizabeth A.] Joslin Diabet Med Ctr, Boston, MA USA.
EM cjchiu@mail.ncku.edu.tw
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA C-057
BP S205
EP S205
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928001375
ER
PT J
AU Cohen, L
Wolpert, H
Ritholz, M
Kaufman, F
AF Cohen, Larry
Wolpert, Howard
Ritholz, Marilyn
Kaufman, Francine
TI FACING DIABETES AS A NATION: MAXIMIZING HEALTH THROUGH TECHNOLOGY AND
COMMUNITY
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Cohen, Larry] Prevent Inst, Oakland, CA 94607 USA.
[Wolpert, Howard] Joslin Diabet Ctr, Sect Adult Diabet, Boston, MA 02215 USA.
[Ritholz, Marilyn] Harvard Med Sch, Joslin Diabet Ctr, Mental Hlth Psychiat, Boston, MA USA.
[Kaufman, Francine] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA.
[Kaufman, Francine] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 2103
BP S81
EP S81
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000316
ER
PT J
AU Cooley, ME
Lobach, DF
Abrahm, JL
Braun, I
Rabin, MS
Berry, DL
AF Cooley, Mary E.
Lobach, David F.
Abrahm, Janet L.
Braun, Illana
Rabin, Michael S.
Berry, Donna L.
TI DECISION SUPPORT FOR SYMPTOM AND QUALITY OF LIFE MANAGEMENT
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Cooley, Mary E.; Abrahm, Janet L.; Braun, Illana; Rabin, Michael S.; Berry, Donna L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Lobach, David F.] Religent Hlth Inc, Raleigh, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 2003
BP S55
EP S55
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000216
ER
PT J
AU Deguchi, M
Oropeza, ME
Nigg, C
Niederman, R
Efird, J
Valente, T
AF Deguchi, Mikako
Oropeza, Martha E.
Nigg, Claudio
Niederman, Richard
Efird, Jimmy
Valente, Tom
TI THE MINO'AKA (SMILE) PROJECT: LESSONS LEARNED FROM PILOTING AN EVIDENCE
BASED ORAL HEALTH PROGRAM FOR CHILDREN
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Deguchi, Mikako; Oropeza, Martha E.; Nigg, Claudio] Univ Hawaii Manoa, Dept Publ Hlth Sci, Honolulu, HI 96826 USA.
[Niederman, Richard] Forsyth Inst, Dept Appl Oral Hlth Sci, Cambridge, MA USA.
[Efird, Jimmy] East Carolina Univ, Publ Hlth, Greenville, NC USA.
[Valente, Tom] Univ Southern Calif, Prevent Med, Los Angeles, CA USA.
EM meo3@hawaii.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 3093
BP S174
EP S174
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928001254
ER
PT J
AU Gonzalez, JS
Cagliero, E
Psaros, C
Wexler, D
Delahanty, L
Perry, N
Blashill, A
Safren, S
AF Gonzalez, Jeffrey S.
Cagliero, Enrico
Psaros, Christina
Wexler, Deborah
Delahanty, Linda
Perry, Nicholas
Blashill, Aaron
Safren, Steven
TI COGNITIVE BEHAVIORAL THERAPY FOR ADHERENCE AND DEPRESSION IN ADULTS WITH
TYPE 2 DIABETES: ACUTE AND MAINTENANCE OUTCOMES FROM A RANDOMIZED
CONTROLLED TRIAL
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Gonzalez, Jeffrey S.] Yeshiva Univ, Albert Einstein Coll Med, Bronx, NY 10461 USA.
[Cagliero, Enrico; Psaros, Christina; Wexler, Deborah; Delahanty, Linda; Perry, Nicholas; Blashill, Aaron; Safren, Steven] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA.
EM jeffrey.gonzalez@einstein.yu.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 3114
BP S179
EP S179
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928001275
ER
PT J
AU Goodrich, DE
Kilbourne, AM
Chermack, S
Bauer, MS
AF Goodrich, David E.
Kilbourne, Amy M.
Chermack, Steve
Bauer, Mark S.
TI TWO-YEAR OUTCOMES FROM THE SMAHRT TRIAL TO REDUCE CVD RISK IN VETERANS
WITH BIPOLAR DISORDER
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Goodrich, David E.; Kilbourne, Amy M.; Chermack, Steve] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI 48105 USA.
[Goodrich, David E.; Kilbourne, Amy M.; Chermack, Steve] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA.
[Bauer, Mark S.] VA Boston Healthcare Syst, Boston, MA USA.
EM david.goodrich2@va.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA B-078
BP S115
EP S115
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928001023
ER
PT J
AU Hartigan, DB
Viswanath, K
AF Hartigan, Danielle Blanch
Viswanath, Kasisomayajula
TI CANCER SURVIVORS' USE OF MULTIPLE INFORMATION SOURCES FOR CANCER-RELATED
INFORMATION: THE MORE THE MERRIER?
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Hartigan, Danielle Blanch] NCI, Off Canc Survivorship, Rockville, MD 20892 USA.
[Viswanath, Kasisomayajula] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Viswanath, Kasisomayajula] Harvard Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA USA.
EM danielleblanch@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA B-017
BP S101
EP S101
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000396
ER
PT J
AU Hartigan, DB
Viswanath, K
AF Hartigan, Danielle Blanch
Viswanath, Kasisomayajula
TI SOCIOECONOMIC AND SOCIODEMOGRAPHIC PREDICTORS OF SOURCES OF
CANCER-RELATED INFORMATION USED BY CANCER SURVIVORS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Hartigan, Danielle Blanch] NCI, Off Canc Survivorship, Rockville, MD 20892 USA.
[Viswanath, Kasisomayajula] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Viswanath, Kasisomayajula] Harvard Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA USA.
EM danielleblanch@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA B-016
BP S101
EP S101
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000395
ER
PT J
AU Hooker, SA
Ross, K
Masters, KS
Park, C
Allen, LA
Bekelman, DB
Grigsby, M
AF Hooker, Stephanie A.
Ross, Kaile
Masters, Kevin S.
Park, Crystal
Allen, Larry A.
Bekelman, David B.
Grigsby, Megan
TI EFFECTS OF A SPIRITUAL INTERVENTION FOR HEART FAILURE PATIENTS: THE
DENVER SPIRITED HEART PILOT STUDY
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Hooker, Stephanie A.; Ross, Kaile; Masters, Kevin S.; Grigsby, Megan] Univ Colorado, Denver, CO 80220 USA.
[Park, Crystal] Univ Connecticut, Storrs, CT USA.
[Allen, Larry A.; Bekelman, David B.] Univ Colorado, Sch Med, Aurora, CO USA.
[Hooker, Stephanie A.; Bekelman, David B.] Denver Vet Affairs Med Ctr, Denver, CO USA.
EM stephanie.hooker@ucdenver.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA C-039
BP S201
EP S201
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928001358
ER
PT J
AU Hooker, SA
Ross, K
Masters, KS
Park, C
Allen, LA
Bekelman, DB
Grigsby, M
AF Hooker, Stephanie A.
Ross, Kaile
Masters, Kevin S.
Park, Crystal
Allen, Larry A.
Bekelman, David B.
Grigsby, Megan
TI QUALITATIVE EVALUATION OF A PSYCHOSPIRITUAL INTERVENTION FOR CHRONIC
HEART FAILURE (HF) PATIENTS: THE DENVER SPIRITED HEART PILOT STUDY
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Hooker, Stephanie A.; Ross, Kaile; Masters, Kevin S.; Grigsby, Megan] Univ Colorado, Denver, CO 80220 USA.
[Allen, Larry A.; Bekelman, David B.] Univ Colorado, Sch Med, Aurora, CO USA.
[Hooker, Stephanie A.; Bekelman, David B.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Park, Crystal] Univ Connecticut, Storrs, CT USA.
EM stephanie.hooker@ucdenver.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 2037
BP S64
EP S64
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000250
ER
PT J
AU Koblitz, AR
Kaufman, A
Park, E
Klein, W
Ferrer, R
AF Koblitz, Amber R.
Kaufman, Annette
Park, Elyse
Klein, William
Ferrer, Rebecca
TI LUNG CANCER-RELATED RISK PERCEPTIONS IN THE NATIONAL LUNG SCREENING
TRIAL: RELIABILITY AND PREDICTION ACROSS TIME
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Koblitz, Amber R.; Kaufman, Annette; Klein, William; Ferrer, Rebecca] NCI, Behav Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Park, Elyse] Massachusetts Gen Hosp, Dept Psychiat, Ctr Canc, Boston, MA 02114 USA.
EM amber.koblitz@nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 3084
BP S171
EP S171
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928001245
ER
PT J
AU Kobrin, S
Tanaka, M
Han, P
Sepucha, K
Naveed, S
Moser, R
AF Kobrin, Sarah
Tanaka, Miho
Han, Paul
Sepucha, Karen
Naveed, Sana
Moser, Richard
TI SHARED DECISION MAKING MEASURES: PROMOTING HARMONIZED DATA USING THE
NATIONAL CANCER INSTITUTE'S GRID-ENABLED MEASURES (GEM) PORTAL
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Kobrin, Sarah; Tanaka, Miho; Naveed, Sana; Moser, Richard] NCI, Rockville, MD 20852 USA.
[Han, Paul] Maine Med Ctr, Scarborough, ME USA.
[Sepucha, Karen] Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM miho.tanaka@nih.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 3047
BP S161
EP S161
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928001203
ER
PT J
AU Lewis, M
Bann, C
Sterba, K
Thorpe, CT
Carpenter, D
DeVellis, R
AF Lewis, Megan
Bann, Carla
Sterba, Katherine
Thorpe, Carolyn T.
Carpenter, Delesha
DeVellis, Robert
TI ADHERENCE MEDIATES THE LINK BETWEEN DYADIC EFFICACY AND WELL-BEING AMONG
COUPLES MANAGING CHRONIC ILLNESS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Lewis, Megan; Bann, Carla] Res Triangle Inst, Res Triangle Pk, NC 27709 USA.
[Sterba, Katherine] Med Univ South Carolina, Charleston, SC USA.
[Thorpe, Carolyn T.] Univ Pittsburgh, Pittsburgh, PA USA.
[Thorpe, Carolyn T.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Carpenter, Delesha; DeVellis, Robert] Univ North Carolina Chapel Hill, Chapel Hill, NC USA.
EM melewis@rti.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA C-125
BP S220
EP S220
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928001435
ER
PT J
AU Littman, AJ
Boyko, EJ
Arterburn, DE
Haselkorn, JK
Sangeorzan, BJ
AF Littman, Alyson J.
Boyko, Edward J.
Arterburn, David E.
Haselkorn, Jodie K.
Sangeorzan, Bruce J.
TI PHYSICAL ACTIVITIES, BARRIERS, AND FACILITATORS IN VETERANS WITH
AMPUTATIONS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Littman, Alyson J.; Boyko, Edward J.] VA Puget Sound, Epidemiol, Seattle, WA USA.
[Littman, Alyson J.] UW, Epidemiol, Seattle, WA USA.
[Arterburn, David E.] Grp Hlth Res Inst, Seattle, WA USA.
[Arterburn, David E.; Haselkorn, Jodie K.] VA Puget Sound, Multiple Sclerosis Ctr Excellence West, Seattle, WA USA.
[Haselkorn, Jodie K.] UW, Rehabil Med, Seattle, WA USA.
[Sangeorzan, Bruce J.] VA Puget Sound, Rehabil R&D Ctr Excellence Limb Loss Prevent & Pr, Seattle, WA USA.
EM alyson@u.washington.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA B-166
BP S136
EP S136
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928001106
ER
PT J
AU Lovejoy, TI
AF Lovejoy, Travis I.
TI GENDER AND SEXUAL ORIENTATION MODERATE THE EFFECTS OF MOTIVATIONAL
INTERVIEWING IN REDUCING SEXUAL RISK BEHAVIOR IN HIV plus OLDER ADULTS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Lovejoy, Travis I.] Portland VA Med Ctr, Mental Hlth & Clin Neurosci Div, Portland, OR 97239 USA.
EM travis.lovejoy@va.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA D-066
BP S273
EP S273
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928002047
ER
PT J
AU Michalek, AK
Prochaska, J
Kan, D
Banys, P
Batki, S
Clift, W
Lane, P
Young, R
AF Michalek, Anne K.
Prochaska, Judith
Kan, David
Banys, Peter
Batki, Steven
Clift, William
Lane, Patricia
Young, Rebecca
TI EFFECTIVE INTERVENTION RECRUITMENT & RETENTION STRATEGIES: WE BUILT IT
AND THEY CAME ... AND RETURNED!
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Michalek, Anne K.; Prochaska, Judith; Kan, David; Banys, Peter; Batki, Steven] Univ Calif San Francisco, San Francisco, CA 94109 USA.
[Kan, David; Banys, Peter; Batki, Steven; Clift, William; Lane, Patricia; Young, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA.
[Prochaska, Judith] Stanford Univ, Stanford, CA 94305 USA.
EM anne.michalek@ucsf.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA A-220
BP S54
EP S54
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000212
ER
PT J
AU O'Cleirigh, C
Lerner, J
Gordan, J
Safren, S
AF O'Cleirigh, Conall
Lerner, Jonathan
Gordan, Janna
Safren, Steven
TI THE IMPACT ON ANXIETY SYMPTOMS OF A CBT INTERVENTION TO TREAT MOOD
DISORDERS AMONG PATIENTS WITH HIV IN TREATMENT FOR SUBSTANCE DEPENDENCE:
A SECONDARY ANALYSIS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [O'Cleirigh, Conall; Lerner, Jonathan; Gordan, Janna; Safren, Steven] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[O'Cleirigh, Conall; Lerner, Jonathan; Gordan, Janna; Safren, Steven] Harvard Med Sch, Boston, MA USA.
EM COCLEIRIGH@PARTNERS.ORG
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 2041
BP S65
EP S65
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000254
ER
PT J
AU O'Cleirigh, C
Carrico, AW
Taylor, W
Pantalone, D
AF O'Cleirigh, Conall
Carrico, Adam W.
Taylor, Wade
Pantalone, David
TI ADAPTING CBT INTERVENTIONS FOR USE WITH MARGINALIZED PATIENT GROUPS
MANAGING THE CHALLENGES OF HIV, MENTAL HEALTH, AND SUBSTANCE USE
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [O'Cleirigh, Conall] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Carrico, Adam W.] Univ San Francisco, Sch Nursing, San Francisco, CA 94117 USA.
[Taylor, Wade] Fenway Hlth, Fenway Inst, Boston, MA USA.
[Pantalone, David] Univ Massachusetts, Dept Psychol, Boston, MA 02125 USA.
EM COCLEIRIGH@PARTNERS.ORG
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 2038
BP S64
EP S64
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000251
ER
PT J
AU O'Neill, S
Selby, JV
Houston, TK
Cooley, ME
Knight, SJ
AF O'Neill, Suzanne
Selby, Joe V.
Houston, Thomas K.
Cooley, Mary E.
Knight, Sara J.
TI PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE AND PARTNERS: IMPROVING
PATIENT OUTCOMES THROUGH BEHAVIORAL MEDICINE RESEARCH
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [O'Neill, Suzanne] Georgetown Univ, Washington, DC USA.
[Cooley, Mary E.] Patient Ctr Outcomes Res Inst, Washington, DC USA.
[Houston, Thomas K.] Univ Massachusetts, Sch Med, Worcester, MA USA.
[Selby, Joe V.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Knight, Sara J.] VA Off Res & Dev UCSF, San Francisco, CA USA.
EM sco4@georgetown.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 2001
BP S55
EP S55
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000214
ER
PT J
AU Oropeza, ME
Valente, T
Nigg, C
Efird, J
Deguchi, M
Niederman, R
AF Oropeza, Martha E.
Valente, Tom
Nigg, Claudio
Efird, Jimmy
Deguchi, Mikako
Niederman, Richard
TI EXPLORING THE RELATIONSHIP BETWEEN ORAL HEALTH SOCIAL NETWORKS, ATTITUDE
AND STAGE OF CHANGE IN AFTERSCHOOL STAFF
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Oropeza, Martha E.; Nigg, Claudio; Deguchi, Mikako] Univ Hawaii Manoa, Publ Hlth Sci, Honolulu, HI 96826 USA.
[Valente, Tom] Univ Southern Calif, Prevent Med, Los Angeles, CA USA.
[Efird, Jimmy] East Carolina Univ, Publ Hlth, Greenville, NC USA.
[Niederman, Richard] Forsyth Inst, Dept Appl Oral Hlth Sci, Cambridge, MA USA.
EM meo3@hawaii.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 3094
BP S174
EP S174
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928001255
ER
PT J
AU Ramanadhan, S
Rao, M
Mendez, S
Viswanath, K
AF Ramanadhan, Shoba
Rao, Meg
Mendez, Samuel
Viswanath, Kasisomayajula
TI SOCIAL MEDIA USE BY COMMUNITY-BASED ORGANIZATIONS IN THREE MASSACHUSETTS
COMMUNITIES: A CONTENT ANALYSIS HIGHLIGHTING PATTERNS AND OPPORTUNITIES
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Ramanadhan, Shoba; Mendez, Samuel; Viswanath, Kasisomayajula] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02215 USA.
[Rao, Meg] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA.
[Viswanath, Kasisomayajula] Harvard Sch Publ Hlth, Boston, MA USA.
EM shoba_ramanadhan@dfci.harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA A-132
BP S34
EP S34
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000131
ER
PT J
AU Richard, N
Tavares, M
Goodson, M
AF Richard, Niederman
Tavares, Mary
Goodson, Max
TI FORSYTHKIDS SCHOOL-BASED COMPREHENSIVE CARIES PREVENTION PROGRAM
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Richard, Niederman; Tavares, Mary; Goodson, Max] Forsyth Inst, Boston, MA USA.
FU NIH-NIMHD [U24 MD006964]; NIH-NIDCR [R34 DE022272]
FX Supported by NIH-NIMHD / U24 MD006964 and NIH-NIDCR / R34 DE022272
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 3092
BP S173
EP S173
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928001253
ER
PT J
AU Ritholz, M
AF Ritholz, Marilyn
TI LIVING WITH DIABETES IN RELATIONSHIPS: HOW PARENTS AND PARTNERS CAN
SUPPORT CHRONIC DISEASE MANAGEMENT
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Ritholz, Marilyn] Joslin Diabet Ctr, Behav & Mental Hlth Res, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 2033
BP S63
EP S63
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000246
ER
PT J
AU Ritholz, MD
AF Ritholz, Marilyn D.
TI CONSIDERING THE HUMAN SIDE OF DIABETES TECHNOLOGY
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Ritholz, Marilyn D.] Harvard Med Sch, Joslin Diabet Ctr, Mental Hlth Psychiat, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 2105
BP S81
EP S81
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000318
ER
PT J
AU Ruddy, K
Greaney, M
Sprunck, K
Meyer, M
Emmons, K
Partridge, A
AF Ruddy, Kathryn
Greaney, Mary
Sprunck, Kim
Meyer, Meghan
Emmons, Karen
Partridge, Ann
TI YOUNG WOMEN WITH BREAST CANCER: NEEDS AND POTENTIAL INTERVENTIONS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Ruddy, Kathryn; Meyer, Meghan; Partridge, Ann] Dana Farber Canc Inst, Med Breast Oncol, Boston, MA 02215 USA.
[Greaney, Mary; Sprunck, Kim; Emmons, Karen] DFCI, Populat Sci, Boston, MA 02215 USA.
EM kim_sprunckharrild@dfci.harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA D-029
BP S265
EP S265
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928002014
ER
PT J
AU Sanford, S
Zhao, F
Salsman, M
Chang, V
Wagner, I
Fisch, M
AF Sanford, Stacy
Zhao, F.
Salsman, M.
Chang, V.
Wagner, I.
Fisch, M.
TI SYMPTOM BURDEN AMONG YOUNG ADULTS WITH BREAST OR COLORECTAL CANCER (ECOG
E2Z02)
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Sanford, Stacy; Salsman, M.; Wagner, I.] Northwestern Univ, Chicago, IL 60611 USA.
[Zhao, F.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Chang, V.] UMDNJ, VA New Jersey Hlth Care Syst, East Orange, NJ USA.
[Fisch, M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
EM ssanford@nmff.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 2015
BP S58
EP S58
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000228
ER
PT J
AU Schneider, K
Magidson, J
Whited, MC
Pagoto, SL
AF Schneider, Kristin
Magidson, Jessica
Whited, Matthew C.
Pagoto, Sherry L.
TI CLINICAL SEMINAR IN BEHAVIORAL ACTIVATION TREATMENT FOR DEPRESSION WITH
COMORBID HEALTH CONDITIONS
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Schneider, Kristin] Rosalind Franklin Univ, Psychol, N Chicago, IL USA.
[Magidson, Jessica] Univ Maryland, College Pk, MD 20742 USA.
[Magidson, Jessica] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA.
[Whited, Matthew C.] East Carolina Univ, Greenville, NC USA.
[Pagoto, Sherry L.] Univ Massachusetts, Sch Med, Worcester, MA USA.
EM kristin.schneider@rosalindfranklin.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 1007
BP S3
EP S3
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000008
ER
PT J
AU Taylor, W
Safren, S
Mayer, K
O'Cleirigh, C
AF Taylor, Wade
Safren, Steven
Mayer, Kenneth
O'Cleirigh, Conall
TI PILOT OUTCOMES FOR A CBT INTERVENTION TO ADDRESS SEXUAL RISK AND
ENGAGEMENT IN CARE AMONG HIV-INFECTED AFRICAN-AMERICAN MEN WHO HAVE SEX
WITH MEN
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Taylor, Wade; Mayer, Kenneth] Fenway Hlth, Fenway Inst, Boston, MA 02118 USA.
[Safren, Steven; O'Cleirigh, Conall] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
EM wtaylor@fenwayhealth.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 2039
BP S64
EP S64
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000252
ER
PT J
AU Trivedi, R
Beaver, K
Zeliadt, SB
Nelson, K
Eugenio, E
Rosland, AM
Grimesey, J
Bouldin, E
Piette, JD
AF Trivedi, Ranak
Beaver, Kristine
Zeliadt, Steven B.
Nelson, Karin
Eugenio, Evercita
Rosland, Ann-Marie
Grimesey, Jackie
Bouldin, Erin
Piette, John D.
TI WHO ARE INFORMAL CAREGIVERS? RESULTS FROM A NATIONALLY-REPRESENTATIVE US
SURVEY
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Trivedi, Ranak; Zeliadt, Steven B.; Nelson, Karin] Univ Washington, VA Puget Sound, Seattle, WA 98101 USA.
[Beaver, Kristine; Eugenio, Evercita; Grimesey, Jackie; Bouldin, Erin] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Rosland, Ann-Marie; Piette, John D.] Univ Michigan, VA Ann Arbor Hlth Care Syst, Ann Arbor, MI 48109 USA.
EM ranak.trivedi@va.gov
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA B-124
BP S126
EP S126
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928001066
ER
PT J
AU Tucker-Seeley, RD
Allen, J
Yang, M
Anne, S
Sorensen, G
AF Tucker-Seeley, Reginald D.
Allen, Jennifer
Yang, May
Anne, Stoddard
Sorensen, Glorian
TI AMONG LOW-INCOME HOUSING RESIDENTS WHO SMOKE IS MATERIAL HARDSHIP
ASSOCIATED WITH THE DECISION TO QUIT?
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Tucker-Seeley, Reginald D.; Allen, Jennifer; Sorensen, Glorian] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02215 USA.
[Yang, May; Anne, Stoddard] NERI, Watertown, MA USA.
EM reginald_tucker-seeley@dfci.harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA D-196
BP S303
EP S303
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928002168
ER
PT J
AU Valentine, SE
Pantalone, DW
Woodward, EN
O'Cleirigh, C
AF Valentine, Sarah E.
Pantalone, David W.
Woodward, Eva N.
O'Cleirigh, Conall
TI SYNDEMIC INDICATORS PREDICT POOR MEDICATION ADHERENCE AND INCREASED
HEALTH CARE UTILIZATION FOR URBAN HIV-POSITIVE SEXUAL MINORITY MEN
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Valentine, Sarah E.; Woodward, Eva N.] Suffolk Univ, Dept Psychol, Boston, MA 02114 USA.
[Pantalone, David W.] Univ Massachusetts, Dept Psychol, Boston, MA 02125 USA.
[O'Cleirigh, Conall] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA USA.
EM sevalentine@suffolk.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA C-064
BP S206
EP S206
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928001380
ER
PT J
AU Wolpert, H
AF Wolpert, Howard
TI CLINICAL BENEFITS AND PRACTICAL BARRIERS TO ADOPTION OF DIABETES
TECHNOLOGIES
SO ANNALS OF BEHAVIORAL MEDICINE
LA English
DT Meeting Abstract
C1 [Wolpert, Howard] Joslin Diabet Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0883-6612
EI 1532-4796
J9 ANN BEHAV MED
JI Ann. Behav. Med.
PD MAR
PY 2013
VL 45
SU 2
MA 2104
BP S81
EP S81
PG 1
WC Psychology, Multidisciplinary
SC Psychology
GA V47BT
UT WOS:000209928000317
ER
PT J
AU Light-McGroary, K
Goodlin, SJ
AF Light-McGroary, KellyAnn
Goodlin, Sarah J.
TI The challenges of understanding and managing pain in the heart failure
patient
SO CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE
LA English
DT Review
DE heart failure; opioids; pain
AB Purpose of review
Heart failure is a leading cause of significant disability and death throughout the world. The assessment and management of pain syndromes in heart failure require specialized knowledge of the pathophysiology of pain and of heart failure. Effective treatment entails an understanding of the physical, psychological, spiritual and social aspects of the pain experience and how pharmacological interventions need to be carefully tailored in this patient population. As we intensify technology to manage the challenges of heart failure it is critical that we review as a profession this critical issue.
Recent findings
We will review the various aspects of the pain experience for the heart failure patient, disease-specific treatment modalities and ways to incorporate existing expertise in pain management in to the care of these complex patients. Most recently the Pain Assessment, Incidence & Nature in Heart Failure trial has been completed and is currently in publication. This study was the first attempt at trying to understand the complexity of pain in the heart failure patients and will be the foundation for future work.
Summary
In closing, as palliative care and hospice move further in to the care of patients with complex, chronic illnesses, it is essential that we take this foundational work and expand upon it. Recognizing that pain and suffering in the heart failure patient is multidimensional and that the physical experience of pain is multifactorial is the beginning of developing expertise and improving the quality of care delivered to these patients.
C1 [Light-McGroary, KellyAnn] Univ Iowa Hosp & Clin, Dept Med, Iowa City, IA 52242 USA.
[Goodlin, Sarah J.] Portland VA Med Ctr, Portland, OR USA.
RP Light-McGroary, K (reprint author), Univ Iowa Hosp & Clin, 200 Hawkins Dr,T402-GH, Iowa City, IA 52242 USA.
EM Kellyann-light-mcgroary@uiowa.edu
NR 12
TC 5
Z9 5
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1751-4258
EI 1751-4266
J9 CURR OPIN SUPPORT PA
JI Curr. Opin Support Palliat. Car.
PD MAR
PY 2013
VL 7
IS 1
BP 14
EP 20
DI 10.1097/SPC.0b013e32835c1f2f
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA AJ2IC
UT WOS:000337478100004
PM 23254859
ER
PT J
AU Hartmann, AS
Rief, W
Hilbert, A
AF Hartmann, Andrea Sabrina
Rief, Winfried
Hilbert, Anja
TI Impulsivity and negative mood in adolescents with loss of control eating
and ADHD symptoms: an experimental study
SO EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY
LA English
DT Article
DE Impulsivity; Negative mood; Stop signal task; Loss of control eating;
Attention deficit hyperactivity disorder; Adolescents
ID DEFICIT HYPERACTIVITY DISORDER; TEST MEAL INTAKE; BEHAVIORAL-INHIBITION;
SOCIAL EXCLUSION; BULIMIA-NERVOSA; CHILDREN; OBESE; ATTENTION; SAMPLE;
WOMEN
AB The aim of the study was to experimentally examine the reactivity of mood and impulsivity to negative mood induction in adolescents with loss of control (LOC) eating and adolescents with attention deficit hyperactivity disorder (ADHD) symptoms. The study included eighty-eight adolescents with LOC eating, ADHD symptoms, and control. Participants self-reported on mood and participated in a stop signal task before and after negative mood induction with Cyberball. Groups did not differ in impulsivity at baseline (p > .05). The LOC group presented with greater increase of negative mood than the ADHD group, and with greater increase of impulsivity than both other groups from pre- to post-Cyberball (p < .05). Stronger reactivity of negative mood and impulsivity in LOC eating corroborates findings in adults that the concepts' association might be specific to binge eating disorder. Additionally, findings add to previous results showing emotion regulation deficits in LOC eating. Future research should examine the concepts' impact on actual eating behavior including binge eating.
C1 [Hartmann, Andrea Sabrina] Massachusetts Gen Hosp, Boston, MA 02214 USA.
[Hartmann, Andrea Sabrina] Harvard Univ, Sch Med, Boston, MA 02214 USA.
[Rief, Winfried] Univ Marburg, Dept Psychol, D-35032 Marburg, Germany.
[Hilbert, Anja] Univ Hosp Leipzig, Leipzig, Germany.
RP Hartmann, AS (reprint author), Massachusetts Gen Hosp, Simches Res Bldg,2nd Floor,185 Cambridge St, Boston, MA 02214 USA.
EM ahartmann1@partners.org; rief@staff.uni-marburg.de;
Anja.Hilbert@medizin.uni-leipzig.de
FU German Research Foundation [HI 1111/1-2, HI 1111/1-3]
FX This research was supported by Grant HI 1111/1-2, 3 from the German
Research Foundation awarded to Anja Hilbert.
NR 51
TC 6
Z9 6
U1 3
U2 32
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1124-4909
EI 1590-1262
J9 EAT WEIGHT DISORD-ST
JI Eat. Weight Disord.-Stud. Anorex.
PD MAR
PY 2013
VL 18
IS 1
BP 53
EP 60
DI 10.1007/s40519-013-0004-4
PG 8
WC Psychiatry
SC Psychiatry
GA AA0PL
UT WOS:000330797600008
PM 23757251
ER
PT J
AU O'Day, DH
Huber, RJ
AF O'Day, Danton H.
Huber, Robert J.
TI Matricellular Signal Transduction Involving Calmodulin in the Social
Amoebozoan Dictyostelium
SO GENES
LA English
DT Review
DE matricellular; signal transduction; EGF-like repeats; extracellular
matrix; calmodulin; morphogenesis; cell differentiation; development
AB The social amoebozoan Dictyostelium discoideum undergoes a developmental sequence wherein an extracellular matrix (ECM) sheath surrounds a group of differentiating cells. This sheath is comprised of proteins and carbohydrates, like the ECM of mammalian tissues. One of the characterized ECM proteins is the cysteine-rich, EGF-like (EGFL) repeat-containing, calmodulin (CaM)-binding protein (CaMBP) CyrA. The first EGFL repeat of CyrA increases the rate of random cell motility and cyclic AMP-mediated chemotaxis. Processing of full-length CyrA (similar to 63 kDa) releases two major EGFL repeat-containing fragments (similar to 45 kDa and similar to 40 kDa) in an event that is developmentally regulated. Evidence for an EGFL repeat receptor also exists and downstream intracellular signaling pathways involving CaM, Ras, protein kinase A and vinculin B phosphorylation have been characterized. In total, these results identify CyrA as a true matricellular protein comparable in function to tenascin C and other matricellular proteins from mammalian cells. Insight into the regulation and processing of CyrA has also been revealed. CyrA is the first identified extracellular CaMBP in this eukaryotic microbe. In keeping with this, extracellular CaM (extCaM) has been shown to be present in the ECM sheath where it binds to CyrA and inhibits its cleavage to release the 45 kDa and 40 kDa EGFL repeat-containing fragments. The presence of extCaM and its role in regulating a matricellular protein during morphogenesis extends our understanding of CaM-mediated signal transduction in eukaryotes.
C1 [O'Day, Danton H.] Univ Toronto, Dept Biol, Mississauga, ON L5L 1C6, Canada.
[O'Day, Danton H.] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON M5S 3G5, Canada.
[Huber, Robert J.] Harvard Univ, Massachusetts Gen Hosp, Ctr Human Genet Res, Med Sch,Richard B Simches Res Ctr, Boston, MA 02114 USA.
RP O'Day, DH (reprint author), Univ Toronto, Dept Biol, 3359 Mississauga Rd North, Mississauga, ON L5L 1C6, Canada.
EM rhuber@chgr.mgh.harvard.edu; rhuber@chgr.mgh.harvard.edu
FU Canada Graduate Scholarship from the Natural Sciences and Engineering
Research Council of Canada; [A6807]
FX This review was supported by a Discovery Grant (D.H.O'D.; A6807) and a
Canada Graduate Scholarship (R.J.H.) from the Natural Sciences and
Engineering Research Council of Canada.
NR 48
TC 0
Z9 0
U1 0
U2 0
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2073-4425
J9 GENES-BASEL
JI Genes
PD MAR
PY 2013
VL 4
IS 1
BP 33
EP 45
DI 10.3390/genes4010033
PG 13
WC Genetics & Heredity
SC Genetics & Heredity
GA V36YE
UT WOS:000209242700002
PM 24705101
ER
PT J
AU Lesselroth, BJ
Adams, K
Tallett, S
Wood, SD
Keeling, A
Cheng, K
Church, VL
Felder, R
Tran, H
AF Lesselroth, Blake J.
Adams, Kathleen
Tallett, Stephanie
Wood, Scott D.
Keeling, Amy
Cheng, Karen
Church, Victoria L.
Felder, Robert
Hanna Tran
TI Design of Admission Medication Reconciliation Technology: A Human
Factors Approach to Requirements and Prototyping
SO HERD-HEALTH ENVIRONMENTS RESEARCH & DESIGN JOURNAL
LA English
DT Article
DE Evidence-based design; human factors; patient-centered care; safety;
technology
ID CARE INFORMATION-SYSTEMS; ADVERSE DRUG EVENTS; HEALTH-CARE; HOSPITAL
ADMISSION; PATIENT SAFETY; TIME; PHARMACISTS; PHYSICIANS; EFFICIENCY;
IMPLEMENTATION
AB OBJECTIVE: Our objectives were to (1) develop an in-depth understanding of the workflow and information flow in medication reconciliation, and (2) design medication reconciliation support technology using a combination of rapid-cycle prototyping and human-centered design.
BACKGROUND: Although medication reconciliation is a national patient safety goal, limitations both of physical environment and in workflow can make it challenging to implement durable systems. We used several human factors techniques to gather requirements and develop a new process to collect a medication history at hospital admission.
METHODS: We completed an ethnography and time and motion analysis of pharmacists in order to illustrate the processes used to reconcile medications. We then used the requirements to design prototype multimedia software for collecting a bedside medication history. We observed how pharmacists incorporated the technology into their physical environment and documented usability issues.
RESULTS: Admissions occurred in three phases: (1) list compilation, (2) order processing, and (3) team coordination. Current medication reconciliation processes at the hospital average 19 minutes to complete and do not include a bedside interview. Use of our technology during a bedside interview required an average of 29 minutes. The software represents a viable proof-of-concept to automate parts of history collection and enhance patient communication. However, we discovered several usability issues that require attention.
CONCLUSIONS: We designed a patient-centered technology to enhance how clinicians collect a patient's medication history. By using multiple human factors methods, our research team identified system themes and design constraints that influence the quality of the medication reconciliation process and implementation effectiveness of new technology.
C1 [Lesselroth, Blake J.; Church, Victoria L.] Portland VA Med Ctr, Portland Patient Safety Ctr Inquiry, Portland, OR USA.
[Lesselroth, Blake J.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
[Adams, Kathleen; Tallett, Stephanie; Felder, Robert; Hanna Tran] Portland VA Med Ctr, Portland, OR USA.
[Wood, Scott D.] VHA Off Informat & Analyt Informat Patient Safety, Ann Arbor, MI USA.
[Keeling, Amy] Univ Washington, Sch Art, Div Design, Seattle, WA 98195 USA.
[Cheng, Karen] Univ Washington, Sch Art, Div Design, Visual Commun Design Program, Seattle, WA 98195 USA.
RP Lesselroth, BJ (reprint author), Portland VA Med Ctr, Portland Patient Safety Ctr Inquiry, Dept Med, Mail Code P3 MED,3720 SW US Vet Hosp Dr, Portland, OR 97239 USA.
EM blake.lesselroth@va.gov
NR 62
TC 0
Z9 0
U1 2
U2 4
PU VENDOME GROUP LLC
PI NEW YORK
PA 6 EAST 32 ST, 8 FLOOR, NEW YORK, NY 10016 USA
SN 1937-5867
EI 2167-5112
J9 HERD-HEALTH ENV RES
JI Herd-Health Env. Res. Des. J.
PD SPR
PY 2013
VL 6
IS 3
BP 30
EP 48
PG 19
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AN9LY
UT WOS:000340929500004
PM 23817905
ER
PT J
AU Tyc, VL
Puleo, E
Emmons, K
de Moor, JS
Ford, JS
AF Tyc, Vida L.
Puleo, Elaine
Emmons, Karen
de Moor, Janet S.
Ford, Jennifer S.
TI Smoking Restrictions Among Households of Childhood and Young Adult
Cancer Survivors: Implications for Tobacco Control Efforts
SO JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY
LA English
DT Article
DE survivors; smoking; restrictions; tobacco
AB Purpose: This study assessed the prevalence of smoking restrictions among households of survivors of childhood and young adult cancer who smoke. It also examined the relationship between home smoking restrictions and motivation to quit smoking, as well as other smoking, psychosocial, and environmental factors.
Methods: Participants included 374 smokers who were childhood or young adult cancer survivors (between the ages of 18 and 55 years) recruited from five cancer centers to participate in a randomized smoking cessation trial. Survivors completed baseline measures about the smoking restrictions in their households, their smoking behavior, and related psychological and environmental factors, which are the focus of the current manuscript.
Results: Almost 54% of survivors reported that smoking was prohibited in their households. Living with a nonsmoking partner, having a strict smoking policy at work, and not being nicotine dependent all increased the likelihood of having a total home smoking ban. Participants who were older, smoked more cigarettes per day over the prior week, and received prior chemotherapy were less likely to reside in households that adopted total bans.
Conclusion: Findings suggest that socio-environmental factors and current smoking behaviors are associated with complete smoking restrictions in the homes of survivors. These factors should be considered when communicating with survivors about the importance of establishing strict smoking policies in their private residences.
C1 [Tyc, Vida L.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
[Puleo, Elaine] Univ Massachusetts, Amherst, MA 01003 USA.
[Emmons, Karen] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA.
[de Moor, Janet S.] Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USA.
[Ford, Jennifer S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
RP Tyc, VL (reprint author), St Jude Childrens Res Hosp, Dept Psychol, 262 Danny Thomas Pl,Mail Stop 740, Memphis, TN 38105 USA.
EM vida.tyc@stjude.org
FU National Cancer Institute [5R01CA106914-05, 1K05CA124415]
FX This study was funded by the National Cancer Institute grants
5R01CA106914-05 and 1K05CA124415.
NR 48
TC 1
Z9 1
U1 2
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2156-5333
EI 2156-535X
J9 J ADOLESC YOUNG ADUL
JI J. Adolesc. Young Adult Oncol.
PD MAR
PY 2013
VL 2
IS 1
BP 17
EP 24
DI 10.1089/jayao.2012.0019
PG 8
WC Oncology
SC Oncology
GA V39II
UT WOS:000209404300004
ER
PT J
AU Antshel, KM
Kaul, P
Biederman, J
Spencer, TJ
Hier, BO
Hendricks, K
Faraone, SV
AF Antshel, Kevin M.
Kaul, Prashant
Biederman, Joseph
Spencer, Thomas J.
Hier, Bridget O.
Hendricks, Kaitlin
Faraone, Stephen V.
TI Posttraumatic Stress Disorder in Adult Attention-Deficit/Hyperactivity
Disorder: Clinical Features and Familial Transmission
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID DEFICIT HYPERACTIVITY DISORDER; EMOTIONAL SELF-REGULATION;
QUALITY-OF-LIFE; SUBTHRESHOLD DIAGNOSES; LATE-ONSET; NICOTINE EXPOSURE;
RISK ANALYSIS; CHILDREN; ADHD; COMORBIDITY
AB Objective: Attention-deficit/hyperactivity disorder (ADHD) is characterized by clinically significant functional impairment due to symptoms of inattention and/or hyperactivity and impulsivity. Previous research suggests a link, in child samples, between ADHD and posttraumatic stress disorder (PTSD), which is characterized by (1) chronically reexperiencing a traumatic event, (2) hyperarousal, and (3) avoiding stimuli associated with the trauma while exhibiting numbed responsiveness. This study sought to address the link between ADHD and PTSD in adults by providing a comprehensive comparison of ADHD patients with and without PTSD across multiple variables including demographics, patterns of psychiatric comorbidities, functional impairments, quality of life, social adjustment, and familial transmission.
Method: Participants in our controlled family study conducted between 1998 and 2003 were 190 adults with DSM-IV ADHD who were attending an outpatient mental health clinic in Boston, Massachusetts; 16 adults with DSM-IV ADHD who were recruited by advertisement from the greater Boston area; and 123 adult controls without ADHD who were recruited by advertisement from the greater Boston area. All available first-degree relatives also participated. Subjects completed a large battery of self-report measures (the Quality of Life Enjoyment and Satisfaction Questionnaire, items from the Current Behavior Scale, the Social Adjustment Scale Self-Report, and the Four Factor Index of Social Status) designed to assess various psychiatric and functional parameters. Diagnoses were made using data obtained from structured psychiatric interviews (Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version, and the Schedule for Affective Disorders and Schizophrenia for School-Aged Children-Epidemiologic Version).
Results: The lifetime prevalence of PTSD was significantly higher among adults with ADHD compared with controls (10.0% vs 1.6%; P = .004). Participants with ADHD and those with ADHD + PTSD did not differ in core symptoms of ADHD nor in age at onset, but those with ADHD + PTSD had higher rates of psychiatric comorbidity than those with ADHD only (including higher lifetime rates of major depressive disorder, oppositional defiant disorder, social phobia, agoraphobia, and generalized anxiety disorder) and worse quality of life ratings for all domains. Familial risk analysis revealed that relatives of ADHD probands without PTSD had elevated rates of both ADHD (51%) and PTSD (12%) that significantly differed from rates among relatives of controls (7% [P <= .001] and 0% [P <= .05], respectively). A similar pattern of elevated risk for ADHD and PTSD (80% and 40%) was observed in relatives of probands with ADHD + PTSD (P <= .001 for both conditions).
Conclusions: The comorbidity of PTSD and ADHD in adults leads to greater clinical severity in terms of psychiatric comorbidity and psychosocial functioning. The familial coaggregation of the 2 disorders suggests that these disorders share familial risk factors and that their co-occurrence is not due to diagnostic errors. (C) Copyright 2013 Physicians Postgraduate Press, Inc.
C1 [Antshel, Kevin M.; Kaul, Prashant; Hier, Bridget O.; Hendricks, Kaitlin; Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat & Behav Sci, Syracuse, NY 13210 USA.
[Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA.
[Antshel, Kevin M.] Syracuse Univ, Dept Psychol, Syracuse, NY USA.
[Kaul, Prashant] Vet Affairs Med Ctr, Dept Mental Hlth, Syracuse, NY USA.
[Biederman, Joseph; Spencer, Thomas J.] Massachusetts Gen Hosp, Dept Psychiat, Clin & Res Programs Pediat Psychopharmacol & Adul, Boston, MA 02114 USA.
[Biederman, Joseph; Spencer, Thomas J.] Harvard Univ, Sch Med, Boston, MA USA.
RP Faraone, SV (reprint author), SUNY Upstate Med Univ, Dept Psychiat & Behav Sci, 750 E Adams St, Syracuse, NY 13210 USA.
EM sfaraone@childpsychresearch.org
OI Faraone, Stephen/0000-0002-9217-3982
FU NIH [R01MH57934]
FX This work was supported by NIH grant R01MH57934 to Dr Faraone.
NR 40
TC 13
Z9 13
U1 3
U2 15
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD MAR
PY 2013
VL 74
IS 3
BP E197
EP E204
DI 10.4088/JCP.12m07698
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AA4VH
UT WOS:000331094000002
PM 23561240
ER
PT J
AU Chuang, SK
AF Chuang, Sung-Kiang
TI There Is Modest Evidence That Systemic Acyclovir or Valacyclovir
Prevents Recurrent Herpes Labialis
SO JOURNAL OF EVIDENCE-BASED DENTAL PRACTICE
LA English
DT Editorial Material
C1 [Chuang, Sung-Kiang] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
[Chuang, Sung-Kiang] Harvard Univ, Sch Dent Med, Boston, MA 02115 USA.
RP Chuang, SK (reprint author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
EM sungkiangchuang@gmail.com
NR 3
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1532-3382
J9 J EVID-BASED DENT PR
JI J. Evid.-Based Dent. Pract.
PD MAR
PY 2013
VL 13
IS 1
BP 16
EP 17
DI 10.1016/j.jebdp.2013.01.004
PG 2
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA V37RW
UT WOS:000209293900005
PM 23481008
ER
PT J
AU Friedlander, AH
AF Friedlander, Arthur H.
TI Carotid Artery Calcifications are a Risk Indicator for Both Stroke and
Myocardial Infarction
SO JOURNAL OF EVIDENCE-BASED DENTAL PRACTICE
LA English
DT Letter
C1 [Friedlander, Arthur H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Los Angeles, CA 90024 USA.
Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA.
RP Friedlander, AH (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM arthur.friedlander@va.gov
NR 5
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1532-3382
J9 J EVID-BASED DENT PR
JI J. Evid.-Based Dent. Pract.
PD MAR
PY 2013
VL 13
IS 1
BP 37
EP 37
DI 10.1016/j.jebdp.2012.12.002
PG 1
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA V37RW
UT WOS:000209293900015
PM 23481018
ER
PT J
AU Wolfe, BE
Kelly-Weeder, S
Malcom, AW
McKenery, M
AF Wolfe, Barbara E.
Kelly-Weeder, Susan
Malcom, Alexis W.
McKenery, Michael
TI Accuracy of Self-Reported Body Weight and Height in Remitted Anorexia
Nervosa
SO JOURNAL OF THE AMERICAN PSYCHIATRIC NURSES ASSOCIATION
LA English
DT Article
DE anorexia nervosa; eating disorders; body weight; body mass index;
remission
ID EATING-DISORDERS; YOUNG-WOMEN; REPLICATION
AB BACKGROUND: The literature reflects contradictory evidence on the ability of persons with anorexia nervosa (AN) to accurately report body weight and height. Furthermore, it is currently unknown if individuals are able to correctly report their weight and height following weight recovery from AN. OBJECTIVE: This study examined the accuracy of self-reported body weight and height following remission from anorexia nervosa (RAN). DESIGN: Individuals included women with RAN (n = 45), anorexia nervosa (AN; n = 23), and controls (CON; n = 71). Subjective body mass index (BMI; kg/m(2)) was calculated from self-reported weight and height; objective BMI was calculated using values obtained with standard measures. RESULTS: Subjective weights were significantly less than objective weights for the RAN and CON groups (p < .005). These groups reported being taller resulting in lower subjective BMIs (p < .001). The AN group did not significantly differ on subjective and objective weight, height, or BMI. CONCLUSIONS: Results highlight the importance of objective measures for early identification/relapse prevention.
C1 [Wolfe, Barbara E.; Kelly-Weeder, Susan] Boston Coll, Connell Sch Nursing, Chestnut Hill, MA 02467 USA.
[Malcom, Alexis W.] Mill City Med Grp, Lowell, MA USA.
[McKenery, Michael] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Wolfe, BE (reprint author), Boston Coll, Connell Sch Nursing, Cushing Hall,Rm 433A,140 Commonwealth Ave, Chestnut Hill, MA 02467 USA.
EM barbara.wolfe.1@bc.edu
FU U.S. Public Health Service, National Institutes of Health [R01 MH057395,
K23 NR011175, M01 RR0132]
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: Supported
in part by Grants R01 MH057395, K23 NR011175, and M01 RR0132 from the
U.S. Public Health Service, National Institutes of Health.
NR 14
TC 2
Z9 2
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1078-3903
EI 1532-5725
J9 J AM PSYCHIAT NURSES
JI J. Am. Psych. Nurses Assoc.
PD MAR-APR
PY 2013
VL 19
IS 2
BP 66
EP 70
DI 10.1177/1078390313481062
PG 5
WC Nursing; Psychiatry
SC Nursing; Psychiatry
GA AJ2RB
UT WOS:000337506100004
PM 23514932
ER
PT J
AU Mifflin, J
Pomeroy, E
AF Mifflin, Jeffrey
Stepenoff, Bonnie
TI FROM MISSOURI: An American Farmer Looks Back
SO JOURNAL OF THE WEST
LA English
DT Book Review
C1 [Mifflin, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Mifflin, J (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ABC-CLIO
PI SANTA BARBARA
PA 130 CREMONA DR, SANTA BARBARA, CA 93117 USA
SN 0022-5169
EI 1930-0115
J9 J WEST
JI J. West
PD SPR
PY 2013
VL 52
IS 2
BP 90
EP 90
PG 1
WC History
SC History
GA V39AM
UT WOS:000209383900021
ER
PT J
AU Atmanli, A
Domian, IJ
AF Atmanli, Ayhan
Domian, Ibrahim J.
TI Generation of Aligned Functional Myocardial Tissue Through Microcontact
Printing
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Stem Cell Biology; Issue 73; Bioengineering; Biomedical Engineering;
Medicine; Molecular Biology; Cellular Biology; Anatomy; Physiology;
Tissue Engineering; Cardiology; Cell Biology; Embryonic Stem Cells;
ESCs; Micropatterning; Microcontact Printing; Cell Alignment; Heart
Progenitors; in vitro Differentiation; Transgenic Mice; Mouse Embryonic
Stem Cells; stem cells; myocardial tissue; PDMS; FACS; flow cytometry;
animal model
AB Advanced heart failure represents a major unmet clinical challenge, arising from the loss of viable and/or fully functional cardiac muscle cells. Despite optimum drug therapy, heart failure represents a leading cause of mortality and morbidity in the developed world. A major challenge in drug development is the identification of cellular assays that accurately recapitulate normal and diseased human myocardial physiology in vitro. Likewise, the major challenges in regenerative cardiac biology revolve around the identification and isolation of patient-specific cardiac progenitors in clinically relevant quantities. These cells have to then be assembled into functional tissue that resembles the native heart tissue architecture. Microcontact printing allows for the creation of precise micropatterned protein shapes that resemble structural organization of the heart, thus providing geometric cues to control cell adhesion spatially. Herein we describe our approach for the isolation of highly purified myocardial cells from pluripotent stem cells differentiating in vitro, the generation of cell growth surfaces micropatterned with extracellular matrix proteins, and the assembly of the stem cell-derived cardiac muscle cells into anisotropic myocardial tissue.
C1 [Atmanli, Ayhan; Domian, Ibrahim J.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Atmanli, Ayhan; Domian, Ibrahim J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Domian, Ibrahim J.] Harvard Stem Cell Inst, Cambridge, MA USA.
RP Domian, IJ (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
EM idomian@partners.org
FU National Science Foundation [ECS-0335765]
FX This work was performed in part at the Center for Nanoscale Systems
(CNS), a member of the National Nanotechnology Infrastructure Network
(NNIN), which is supported by the National Science Foundation under NSF
award no. ECS-0335765. CNS is part of Harvard University.
NR 21
TC 2
Z9 2
U1 1
U2 6
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD MAR
PY 2013
IS 73
AR UNSP e50288
DI 10.3791/50288
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V36QW
UT WOS:000209226900041
PM 23542789
ER
PT J
AU Connors, EC
Yazzolino, LA
Sanchez, J
Merabet, LB
AF Connors, Erin C.
Yazzolino, Lindsay A.
Sanchez, Jaime
Merabet, Lotfi B.
TI Development of an Audio-based Virtual Gaming Environment to Assist with
Navigation Skills in the Blind
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 73; Behavior; Neuroscience; Anatomy; Physiology;
Neurobiology; Ophthalmology; Psychology; Behavior and Behavior
Mechanisms; Technology; Industry; virtual environments; action video
games; blind; audio; rehabilitation; indoor navigation; spatial
cognitive map; Audio-based Environment Simulator; virtual reality;
cognitive psychology; clinical techniques
AB Audio-based Environment Simulator (AbES) is virtual environment software designed to improve real world navigation skills in the blind. Using only audio based cues and set within the context of a video game metaphor, users gather relevant spatial information regarding a building's layout. This allows the user to develop an accurate spatial cognitive map of a large-scale three-dimensional space that can be manipulated for the purposes of a real indoor navigation task. After game play, participants are then assessed on their ability to navigate within the target physical building represented in the game. Preliminary results suggest that early blind users were able to acquire relevant information regarding the spatial layout of a previously unfamiliar building as indexed by their performance on a series of navigation tasks. These tasks included path finding through the virtual and physical building, as well as a series of drop off tasks. We find that the immersive and highly interactive nature of the AbES software appears to greatly engage the blind user to actively explore the virtual environment. Applications of this approach may extend to larger populations of visually impaired individuals.
C1 [Connors, Erin C.; Yazzolino, Lindsay A.; Merabet, Lotfi B.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Lab Visual Neuroplast,Dept Ophthalmol, Cambridge, MA 02138 USA.
[Sanchez, Jaime] Univ Chile, Dept Comp Sci, Santiago, Chile.
[Sanchez, Jaime] Univ Chile, CARE, Santiago, Chile.
RP Merabet, LB (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Lab Visual Neuroplast,Dept Ophthalmol, Cambridge, MA 02138 USA.
EM lotfi_merabet@meei.harvard.edu
FU NIH/NEI [RO1 EY019924]
FX The authors would like to thank Rabih Dow, Padma Rajagopal, Molly
Connors and the staff of the Carroll Center for the Blind (Newton MA,
USA) for their support in carrying out this research. This work was
supported by the NIH/NEI grant: RO1 EY019924.
NR 13
TC 5
Z9 5
U1 4
U2 8
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD MAR
PY 2013
IS 73
AR UNSP e50272
DI 10.3791/50272
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V36QW
UT WOS:000209226900039
ER
PT J
AU Lin, PY
Roche-Labarbe, N
Dehaes, M
Carp, S
Fenoglio, A
Barbieri, B
Hagan, K
Grant, PE
Franceschini, MA
AF Lin, Pei-Yi
Roche-Labarbe, Nadege
Dehaes, Mathieu
Carp, Stefan
Fenoglio, Angela
Barbieri, Beniamino
Hagan, Katherine
Grant, P. Ellen
Franceschini, Maria Angela
TI Non-invasive Optical Measurement of Cerebral Metabolism and Hemodynamics
in Infants
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Medicine; Issue 73; Developmental Biology; Neurobiology; Neuroscience;
Biomedical Engineering; Anatomy; Physiology; Near infrared spectroscopy;
diffuse correlation spectroscopy; cerebral hemodynamic; cerebral
metabolism; brain injury screening; brain health; brain development;
newborns; neonates; imaging; clinical techniques
AB Perinatal brain injury remains a significant cause of infant mortality and morbidity, but there is not yet an effective bedside tool that can accurately screen for brain injury, monitor injury evolution, or assess response to therapy. The energy used by neurons is derived largely from tissue oxidative metabolism, and neural hyperactivity and cell death are reflected by corresponding changes in cerebral oxygen metabolism (CMRO2). Thus, measures of CMRO2 are reflective of neuronal viability and provide critical diagnostic information, making CMRO2 an ideal target for bedside measurement of brain health.
Brain-imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) yield measures of cerebral glucose and oxygen metabolism, but these techniques require the administration of radionucleotides, so they are used in only the most acute cases.
Continuous-wave near-infrared spectroscopy (CWNIRS) provides non-invasive and non-ionizing radiation measures of hemoglobin oxygen saturation (SO2) as a surrogate for cerebral oxygen consumption. However, SO2 is less than ideal as a surrogate for cerebral oxygen metabolism as it is influenced by both oxygen delivery and consumption. Furthermore, measurements of SO2 are not sensitive enough to detect brain injury hours after the insult (1,2), because oxygen consumption and delivery reach equilibrium after acute transients (3). We investigated the possibility of using more sophisticated NIRS optical methods to quantify cerebral oxygen metabolism at the bedside in healthy and brain-injured newborns. More specifically, we combined the frequency-domain NIRS (FDNIRS) measure of SO2 with the diffuse correlation spectroscopy (DCS) measure of blood flow index (CBFi) to yield an index of CMRO2 (CMRO2i) (4,5).
With the combined FDNIRS/DCS system we are able to quantify cerebral metabolism and hemodynamics. This represents an improvement over CWNIRS for detecting brain health, brain development, and response to therapy in neonates. Moreover, this method adheres to all neonatal intensive care unit (NICU) policies on infection control and institutional policies on laser safety. Future work will seek to integrate the two instruments to reduce acquisition time at the bedside and to implement real-time feedback on data quality to reduce the rate of data rejection.
C1 [Lin, Pei-Yi; Roche-Labarbe, Nadege; Carp, Stefan; Hagan, Katherine; Franceschini, Maria Angela] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Cambridge, MA 02138 USA.
[Roche-Labarbe, Nadege] Univ Caen Basse Normandie, Lab PALM, Caen, France.
[Dehaes, Mathieu; Fenoglio, Angela; Grant, P. Ellen] Harvard Univ, Sch Med, Boston Childrens Hosp, Fetal Neonatal Neuroimaging & Dev Sci Ctr, Cambridge, MA 02138 USA.
[Barbieri, Beniamino] ISS INC, Colorado Springs, CO USA.
RP Lin, PY (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Cambridge, MA 02138 USA.
EM ivylin@nmr.mgh.harvard.edu
RI Roche-Labarbe, Nadege/N-9101-2015
OI Roche-Labarbe, Nadege/0000-0002-5010-0400
FU NIH [R01-HD042908, R21- HD058725, P41- RR14075, R43-HD071761]; Clinical
Translational Science Award [UL1RR025758]; Brigham and Women's Hospital
from the National Center for Research Resources
FX The authors thank all the families for their participation in this study
and the nurses, physicians, and staff in the Neonatal ICU, the Special
Care Nursery, Pediatric Neurology, and the maternity units at
Massachusetts General Hospital, Brigham and Women's Hospital and Boston
Children's Hospital for their help and support. In particular we thank
Linda J. Van Marter, Robert M. Insoft, Jonathan H. Cronin, Julianne
Mazzawi, and Steven A. Ringer. The authors also thank Marcia
Kocienski-Filip, Yvonne Sheldon, Alpna Aggarwall, Maddy Artunguada and
Genevieve Nave for their assistance during measurements. This project is
supported by NIH R01-HD042908, R21- HD058725, P41- RR14075 and
R43-HD071761. Marcia Kocienski-Filip and Yvonne Sheldon are supported by
the Clinical Translational Science Award UL1RR025758 to Harvard
University and Brigham and Women's Hospital from the National Center for
Research Resources. The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
National Center for Research Resources or the National Institutes of
Health.
NR 24
TC 5
Z9 5
U1 2
U2 8
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD MAR
PY 2013
IS 73
AR UNSP e4379
DI 10.3791/4379
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V36QW
UT WOS:000209226900009
PM 23524854
ER
PT J
AU Pino, EC
Webster, CM
Carr, CE
Soukas, AA
AF Pino, Elizabeth C.
Webster, Christopher M.
Carr, Christopher E.
Soukas, Alexander A.
TI Biochemical and High Throughput Microscopic Assessment of Fat Mass in
Caenorhabditis Elegans
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Genetics; Issue 73; Biochemistry; Cellular Biology; Molecular Biology;
Developmental Biology; Physiology; Anatomy; Caenorhabditis elegans;
Obesity; Energy Metabolism; Lipid Metabolism; C. elegans; fluorescent
lipid staining; lipids; Nile red; fat; high throughput screening;
obesity; gas chromatography; mass spectrometry; GC/MS; animal model
AB The nematode C. elegans has emerged as an important model for the study of conserved genetic pathways regulating fat metabolism as it relates to human obesity and its associated pathologies. Several previous methodologies developed for the visualization of C. elegans triglyceride-rich fat stores have proven to be erroneous, highlighting cellular compartments other than lipid droplets. Other methods require specialized equipment, are time-consuming, or yield inconsistent results. We introduce a rapid, reproducible, fixative-based Nile red staining method for the accurate and rapid detection of neutral lipid droplets in C. elegans. A short fixation step in 40% isopropanol makes animals completely permeable to Nile red, which is then used to stain animals. Spectral properties of this lipophilic dye allow it to strongly and selectively fluoresce in the yellow-green spectrum only when in a lipid-rich environment, but not in more polar environments. Thus, lipid droplets can be visualized on a fluorescent microscope equipped with simple GFP imaging capability after only a brief Nile red staining step in isopropanol. The speed, affordability, and reproducibility of this protocol make it ideally suited for high throughput screens. We also demonstrate a paired method for the biochemical determination of triglycerides and phospholipids using gas chromatography mass-spectrometry. This more rigorous protocol should be used as confirmation of results obtained from the Nile red microscopic lipid determination. We anticipate that these techniques will become new standards in the field of C. elegans metabolic research.
C1 [Pino, Elizabeth C.; Webster, Christopher M.; Soukas, Alexander A.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Pino, Elizabeth C.; Webster, Christopher M.; Soukas, Alexander A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Pino, Elizabeth C.; Webster, Christopher M.; Soukas, Alexander A.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Carr, Christopher E.] MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA.
RP Soukas, AA (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
EM asoukas@chgr.mgh.harvard.edu
OI Carr, Christopher/0000-0002-7946-5622
FU NIH/NIDDK [K08DK087941, 5T32DK007028]; Ellison Medical Foundation;
Charles H. Hood Foundation
FX We would like to thank Michael Kacergis for technical assistance and
Lianfeng Wu for discussions and reading the manuscript. This work was
supported by a career development award from the NIH/NIDDK (K08DK087941
to A.A.S.), a NIH/NIDDK training grant (5T32DK007028 to E.C.P.), the
Ellison Medical Foundation New Scholar in Aging Award (to A.A.S), and
the Charles H. Hood Foundation Child Health Research Award (to A.A.S.).
NR 39
TC 1
Z9 1
U1 2
U2 8
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD MAR
PY 2013
IS 73
AR UNSP e50180
DI 10.3791/50180
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V36QW
UT WOS:000209226900026
ER
PT J
AU Zappaterra, MW
LaMantia, AS
Walsh, CA
Lehtinen, MK
AF Zappaterra, Mauro W.
LaMantia, Anthony S.
Walsh, Christopher A.
Lehtinen, Maria K.
TI Isolation of Cerebrospinal Fluid from Rodent Embryos for use with
Dissected Cerebral Cortical Explants
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Neuroscience; Issue 73; Neurobiology; Developmental Biology; Anatomy;
Physiology; Stem Cell Biology; Cellular Biology; Biomedical Engineering;
Medicine; Surgery; Neural Stem Cells (NSCs); stem cells; Cerebral
Cortex; Cerebrospinal Fluid; CSF; ventricular embryonic CSF; Isolation;
Brain; Cerebral Cortical Explant; tissue; culture; mouse; animal model
AB The CSF is a complex fluid with a dynamically varying proteome throughout development and in adulthood. During embryonic development, the nascent CSF differentiates from the amniotic fluid upon closure of the anterior neural tube. CSF volume then increases over subsequent days as the neuroepithelial progenitor cells lining the ventricles and the choroid plexus generate CSF. The embryonic CSF contacts the apical, ventricular surface of the neural stem cells of the developing brain and spinal cord. CSF provides crucial fluid pressure for the expansion of the developing brain and distributes important growth promoting factors to neural progenitor cells in a temporally-specific manner. To investigate the function of the CSF, it is important to isolate pure samples of embryonic CSF without contamination from blood or the developing telencephalic tissue. Here, we describe a technique to isolate relatively pure samples of ventricular embryonic CSF that can be used for a wide range of experimental assays including mass spectrometry, protein electrophoresis, and cell and primary explant culture. We demonstrate how to dissect and culture cortical explants on porous polycarbonate membranes in order to grow developing cortical tissue with reduced volumes of media or CSF. With this method, experiments can be performed using CSF from varying ages or conditions to investigate the biological activity of the CSF proteome on target cells.
C1 [Zappaterra, Mauro W.] VA Greater Los Angeles Healthcare Syst, Dept Phys Med & Rehabil, Los Angeles, CA USA.
[LaMantia, Anthony S.] George Washington Univ, Sch Med & Hlth Sci, Inst Neurosci, Dept Pharmacol & Physiol, Washington, DC 20052 USA.
[Walsh, Christopher A.] Boston Childrens Hosp, Div Genet, Dept Med, Boston, MA USA.
[Walsh, Christopher A.] Boston Childrens Hosp, Howard Hughes Med Inst, Boston, MA USA.
[Lehtinen, Maria K.] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Pathol, Cambridge, MA 02138 USA.
RP Lehtinen, MK (reprint author), Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Pathol, Cambridge, MA 02138 USA.
EM Maria.Lehtinen@childrens.harvard.edu
FU NIH [R00 NS072192, HD029178, 2 RO1NS032457]; Children's Hospital Boston
Career Development Fellowship/Harvard Medical School Shore Fellowship;
Alfred P. Sloan Foundation
FX We are grateful for support from the NIH (Award numbers R00 NS072192 to
M.K.L., HD029178 to A-S.L., and 2 RO1NS032457 to C.A.W.). M.K.L. is the
recipient of the Children's Hospital Boston Career Development
Fellowship/Harvard Medical School Shore Fellowship and a Fellow of the
Alfred P. Sloan Foundation. C.A.W. is an Investigator of the Howard
Hughes Medical Institute.
NR 12
TC 0
Z9 0
U1 0
U2 1
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD MAR
PY 2013
IS 73
AR UNSP e50333
DI 10.3791/50333
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V36QW
UT WOS:000209226900050
PM 23524481
ER
PT J
AU Osser, DN
Patterson, RD
AF Osser, David N.
Patterson, Robert D.
TI On the Value of Evidence-Based Psychopharmacology Algorithms
SO KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY
LA English
DT Editorial Material
ID SOUTH SHORE PROGRAM; PRACTICE GUIDELINE; PROJECT; UPDATE; SCHIZOPHRENIA;
DEPRESSION; DISORDER; MEDICINE; BIASES; CARE
C1 [Osser, David N.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Brockton Div, Brockton, MA 02301 USA.
[Patterson, Robert D.] Harvard Univ, Sch Med, McLean Hosp, Belmont, MA 02478 USA.
RP Osser, DN (reprint author), Harvard Univ, Sch Med, VA Boston Healthcare Syst, Brockton Div, 940 Belmont St, Brockton, MA 02301 USA.
EM david.osser@va.gov; bpatterson5961@gmail.com
NR 33
TC 2
Z9 2
U1 0
U2 1
PU KURE ILETISIM GRUBU A S
PI ISTANBUL
PA SIRACEVIZLER CAD 43/3 SISLI, ISTANBUL, 34381, TURKEY
SN 1017-7833
J9 KLIN PSIKOFARMAKOL B
JI Klin. Psikofarmakol. Bul.
PD MAR
PY 2013
VL 23
IS 1
BP 1
EP 5
DI 10.5455/bcp.19691231040000
PG 5
WC Pharmacology & Pharmacy; Psychiatry
SC Pharmacology & Pharmacy; Psychiatry
GA AM6NT
UT WOS:000339982600001
ER
PT J
AU Erlendsson, AM
Taudorf, EH
Eriksson, AH
Zibert, JR
Paasch, U
Anderson, RR
Haedersdal, M
AF Erlendsson, Andres M.
Taudorf, Elisabeth H.
Eriksson, Andre H.
Zibert, John R.
Paasch, Uwe
Anderson, R. Rox
Haedersdal, Merete
TI FRACTIONAL LASER-MEDIATED DELIVERY OF INGENOL MEBUTATE - PRELIMINARY
RESULTS FROM AN IN VITRO FRANZ CELL STUDY
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark.
LEO Pharma AS, Ballerup, Denmark.
Univ Leipzig, D-04109 Leipzig, Germany.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 1
BP 1
EP 1
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800002
ER
PT J
AU Chuang, G
Farinelli, W
Avram, M
Anderson, RR
AF Chuang, Gary
Farinelli, William
Avram, Mathew
Anderson, R. Rox
TI SMOKE PLUME FROM LASER HAIR REMOVAL: GAS-CHROMATOGRAPHY ANALYSIS
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 [Chuang, Gary; Farinelli, William; Avram, Mathew; Anderson, R. Rox] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 35
BP 13
EP 13
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800036
ER
PT J
AU Jalian, HR
Avram, M
Stankiewicz, K
Shofner, J
Tannous, Z
AF Jalian, H. Ray
Avram, Mathew
Stankiewicz, Kelly
Shofner, Joshua
Tannous, Zeina
TI COMBINED PULSED DYE LASER AND Nd:YAG LASER FOR THE TREATMENT OF BASAL
CELL CARCINOMA
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Lebanese Amer Univ, Beirut, Lebanon.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 47
BP 17
EP 17
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800048
ER
PT J
AU Yin, R
Lin, L
Xiao, Y
Hao, F
Hamblin, M
AF Yin, Rui
Lin, Lin
Xiao, Yan
Hao, Fei
Hamblin, Michael
TI COMBINATION ALA-PDT AND ABLATIVE FRACTIONAL ERBIUM LASER (2940 nm) ON
THE TREATMENT OF SEVERE ACNE
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Third Mil Med Univ, Southwest Hosp, Chongqing, Peoples R China.
Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 49
BP 18
EP 18
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800050
ER
PT J
AU Jalian, HR
Avram, M
Anderson, RR
AF Jalian, H. Ray
Avram, Mathew
Anderson, R. Rox
TI RARE SIDE EFFECTS ASSOCIATED WITH CRYOLIPOLYSIS
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 [Jalian, H. Ray; Avram, Mathew; Anderson, R. Rox] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 53
BP 19
EP 19
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800054
ER
PT J
AU Ortiz, A
Truong, S
Serowka, K
Kelly, K
AF Ortiz, Arisa
Truong, Samuel
Serowka, Kathryn
Kelly, Kristen
TI 1320 nm Nd:YAG LASER FOR IMPROVING THE APPEARANCE OF ONYCHOMYCOSIS
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
Univ Calif Irvine, Irvine, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 54
BP 19
EP 20
PG 2
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800055
ER
PT J
AU Shek, SY
Yeung, CK
Chan, JCY
Chan, HHL
AF Shek, Samantha Y.
Yeung, C. K.
Chan, Johnny C. Y.
Chan, Henry H. L.
TI EFFICACY OF A HIGH-INTENSITY FOCUSED ULTRASOUND DEVICE FOR NON-INVASIVE
BODY CONTOURING
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 60
BP 22
EP 22
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800061
ER
PT J
AU Salinas, H
Lin, A
Cooper, R
Cooper, J
AF Salinas, Harry
Lin, Alex
Cooper, Robert
Cooper, Jason
TI NOVEL TREATMENT OF PERIORAL RHYTIDES BY SUBCISION COMBINED WITH Er:YAG
LASER RESURFACING
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Waters Edge Surg Ctr, Stuart, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 64
BP 23
EP 23
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800065
ER
PT J
AU Gutierrez-Herrera, E
Vacas-Jacques, P
Zapol, W
Anderson, RR
Franco, W
AF Gutierrez-Herrera, Enoch
Vacas-Jacques, Paulino
Zapol, Warren
Anderson, R. Rox
Franco, Walfre
TI MINIMALLY INVASIVE OXYGEN SENSOR TO MONITOR MYO AND HEMOGLOBIN
SATURATION IN MUSCLE OF MARINE MAMMALS
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 [Gutierrez-Herrera, Enoch; Vacas-Jacques, Paulino; Zapol, Warren; Anderson, R. Rox; Franco, Walfre] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 75
BP 26
EP 27
PG 2
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800074
ER
PT J
AU Haak, CS
Farinelli, WA
Tam, J
Doukas, AG
Anderson, RR
Haedersdal, M
AF Haak, Christina S.
Farinelli, William A.
Tam, Joshua
Doukas, Apostolos G.
Anderson, R. Rox
Haedersdal, Merete
TI FRACTIONAL LASER-ASSISTED DELIVERY OF METHYL AMINOLEVULINATE: IMPACT OF
LASER CHANNEL DEPTH AND INCUBATION TIME
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 78
BP 27
EP 28
PG 2
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800077
ER
PT J
AU Lewis, WF
Farinelli, WA
Doukas, AG
Franco, W
Anderson, RR
Sakamoto, FH
AF Lewis, William F.
Farinelli, William A.
Doukas, Apostolos G.
Franco, Walfre
Anderson, R. Rox
Sakamoto, Fernanda H.
TI FLUORESCENCE IMAGING OF SEBACEOUS GLAND PORPHYRINS IN VIVO INDUCED BY
ALA, USING LONG WAVELENGTH EXCITATION
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 [Lewis, William F.; Farinelli, William A.; Doukas, Apostolos G.; Franco, Walfre; Anderson, R. Rox; Sakamoto, Fernanda H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 77
BP 27
EP 27
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800076
ER
PT J
AU Purschke, M
Wang, Y
Taghados, SJ
Farinelli, WA
Franco, W
Anderson, RR
Doukas, A
AF Purschke, Martin
Wang, Ying
Taghados, Seyed Javid
Farinelli, William A.
Franco, Walfre
Anderson, R. Rox
Doukas, Apostolos
TI A NOVEL ULTRAVIOLET FLUORESCENCE IMAGING TECHNIQUE AS A NON-INVASIVE AND
RAPID METHOD TO MONITOR EPIDERMAL GROWTH
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 [Purschke, Martin; Wang, Ying; Taghados, Seyed Javid; Farinelli, William A.; Franco, Walfre; Anderson, R. Rox; Doukas, Apostolos] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 76
BP 27
EP 27
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800075
ER
PT J
AU Haedersdal, M
Sakamoto, FH
Farinelli, WA
Doukas, AG
Tam, J
Anderson, RR
AF Haedersdal, Merete
Sakamoto, Fernanda H.
Farinelli, William A.
Doukas, Apostolos G.
Tam, Joshua
Anderson, R. Rox
TI PRETREATMENT WITH ABLATIVE FRACTIONAL LASER CHANGES KINETICS AND
BIODISTRIBUTION OF TOPICAL 5-AMINOLEVULINIC ACID AND METHYL
AMINOLEVULINATE
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 79
BP 28
EP 28
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800078
ER
PT J
AU Tan, WB
Jia, WC
Sun, V
Mihm, M
Nelson, JS
AF Tan, Wenbin
Jia, Wangcun
Sun, Victor
Mihm, Martin
Nelson, J. Stuart
TI TOPICAL RAPAMYCIN SUPPRESSES THE ANGIOGENESIS PATHWAYS INDUCED BY PULSED
DYE LASER
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Univ Calif Irvine, Beckman Laser Inst & Med Clin, Irvine, CA 92715 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 85
BP 30
EP 30
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800084
ER
PT J
AU Franco, W
Taghados, SJ
Ortiz, A
Farinelli, WA
Anderson, RR
Doukas, AG
AF Franco, Walfre
Taghados, Seyed Javid
Ortiz, Arisa
Farinelli, William A.
Anderson, R. Rox
Doukas, Apostolos G.
TI ULTRAVIOLET FLUORESCENCE IMAGING OF THE SKIN RESPONSE TO IRRITANT
CONTACT DERMATITIS AND TAPE STRIPPING
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 [Franco, Walfre; Taghados, Seyed Javid; Ortiz, Arisa; Farinelli, William A.; Anderson, R. Rox; Doukas, Apostolos G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 109
BP 37
EP 38
PG 2
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800106
ER
PT J
AU Dai, TH
Gupta, A
Huang, YY
Yin, R
Murray, C
Vrahas, M
Kielian, T
Hamblin, M
AF Dai, Tianhong
Gupta, Asheesh
Huang, Yingying
Yin, Rui
Murray, Clinton
Vrahas, Mark
Kielian, Tammy
Hamblin, Michael
TI BLUE LIGHT ELIMINATES COMMUNITY-ACQUIRED METHICILLIN-RESISTANT
STAPHYLOCOCCUS AUREUS IN INFECTED MOUSE SKIN ABRASIONS
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
Brooke Army Med Ctr, Infect Dis Serv, Houston, TX USA.
Univ Nebraska Med Ctr, Omaha, NE USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 121
BP 41
EP 41
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800116
ER
PT J
AU Echague, AV
Casas, G
Rivera, FP
Nieto, S
Schomacker, K
Anderson, RR
AF Vila Echague, Agustina
Casas, Gabriel
Perez Rivera, Fabian
Nieto, Silvana
Schomacker, Kevin
Anderson, R. Rox
TI OVER TIME HISTOLOGICAL TISSUE CHANGES AFTER NON-INVASIVE TREATMENT WITH
A 1210 nm LASER
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Hosp Alemaan Deutsch, Inst Pathol, Buenos Aires, DF, Argentina.
Consejo Nacl Invest Cient & Tecn, CEMIC, Buenos Aires, DF, Argentina.
Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 129
BP 44
EP 44
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800123
ER
PT J
AU Taudorf, EH
Haak, CS
Erlendsson, AM
Philipsen, PA
Paasch, U
Anderson, RR
Haedersdal, M
AF Taudorf, Elisabeth Hjardem
Haak, Christina Skovboelling
Erlendsson, Andres Maar
Philipsen, Peter Alshede
Paasch, Uwe
Anderson, R. Rox
Haedersdal, Merete
TI SPECIFIC MICROPORE DIMENSIONS FROM VARYING SETTINGS WITH A PORTABLE
FRACTIONAL ERBIUM LASER-HISTOLOGICAL DATA FROM EX VIVO PORCINE SKIN
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark.
Univ Leipzig, D-04109 Leipzig, Germany.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 140
BP 47
EP 48
PG 2
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800134
ER
PT J
AU Hamblin, M
Xuan, WJ
Huang, LY
Huang, SF
AF Hamblin, Michael
Xuan, Weijun
Huang, Liyi
Huang, Shih-Fong
TI TRANSCRANIAL LOW-LEVEL LASER (LIGHT) THERAPY IN MICE: TRAMAUTIC BRAIN
INJURY AND BEYOND
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 [Hamblin, Michael; Xuan, Weijun; Huang, Liyi; Huang, Shih-Fong] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 154
BP 50
EP 51
PG 2
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800143
ER
PT J
AU Haak, CS
Togsverd-Bo, K
Thaysen-Petersen, D
Wulf, HC
Paasch, U
Anderson, RR
Haedersdal, M
AF Haak, Christina S.
Togsverd-Bo, Katrine
Thaysen-Petersen, Daniel
Wulf, Hans Christian
Paasch, Uwe
Anderson, R. Rox
Haedersdal, Merete
TI CONVENTIONAL vs FRACTIONAL LASER-MEDIATED PHOTODYNAMIC THERAPY OF
DIFFICULT TO TREAT BASAL CELL CARCINOMAS - A RANDOMIZED CLINICAL TRIAL
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark.
Univ Leipzig, D-04109 Leipzig, Germany.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 178
BP 58
EP 58
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800166
ER
PT J
AU Ribeiro, M
Kato, I
Sabino, C
Yoshimura, T
Hamblin, M
Prates, R
AF Ribeiro, Martha
Kato, Ilka
Sabino, Caetano
Yoshimura, Tania
Hamblin, Michael
Prates, Renato
TI EVALUATION OF VARIABLES INVOLVED IN ANTIFUNGAL PHOTODYNAMIC THERAPY
SO LASERS IN SURGERY AND MEDICINE
LA English
DT Meeting Abstract
C1 IPEN CNEN SP, Ctr Lasers & Applicat, Sao Paulo, Brazil.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RI Sabino, Caetano/K-8356-2013; Sabino, Caetano/D-4196-2016
OI Sabino, Caetano/0000-0002-2048-2823
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0196-8092
EI 1096-9101
J9 LASER SURG MED
JI Lasers Surg. Med.
PD MAR
PY 2013
VL 45
SU 25
MA 217
BP 62
EP 62
PG 1
WC Dermatology; Surgery
SC Dermatology; Surgery
GA V38YX
UT WOS:000209379800179
ER
PT J
AU Cohen, AN
Chinman, MJ
Hamilton, AB
Whelan, F
Young, AS
AF Cohen, Amy N.
Chinman, Matthew J.
Hamilton, Alison B.
Whelan, Fiona
Young, Alexander S.
TI Using Patient-facing Kiosks to Support Quality Improvement at Mental
Health Clinics
SO MEDICAL CARE
LA English
DT Article
DE health information technology; quality improvement; mental health
ID RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE; SELF-ASSESSMENT;
SCHIZOPHRENIA; ILLNESS; IMPLEMENTATION; DEPRESSION; OUTCOMES; PROGRAM;
INTERVENTION
AB Objectives: Evidence-based services improve outcomes in schizophrenia, but most patients at mental health clinics do not receive such services. This gap in care has been perpetuated by a lack of routinely collected data on patients' clinical status and the treatments they receive. However, routine data collection can be completed by patients themselves, especially when aided by health information technology. It is not known whether these data can be used to improve care quality.
Methods: In a controlled trial, 8 medical centers of the Veterans Health Administration were assigned to implementation or usual care. A total of 571 patients with schizophrenia were overweight and had not used evidence-based weight services. The implementation strategy included data from patient-facing kiosks, continuous data feedback, clinical champions, education, social marketing, and evidence-based quality improvement teams. Mixed methods evaluated the impact of the kiosks on utilization of and retention in weight services.
Results: Compared with usual care, implementation resulted in individuals being more likely to use weight services, availing services >5 weeks sooner, and continuing to use the services 3 times more. When compared with the year before implementation, patients at implementation sites saw a 3-fold increase in treatment visits. Usual care resulted in no change.
Conclusions: Mental health clinics have been slow to adopt health information technology. This study is among the first to implement and evaluate automated collection of data from patients at these clinics. Patient-facing kiosks are feasible in routine care and provide data that can be used to substantially improve the quality of care.
C1 [Cohen, Amy N.; Hamilton, Alison B.; Young, Alexander S.] VA Desert Pacific Mental Illness Res Educ & Clin, Los Angeles, CA USA.
[Cohen, Amy N.; Hamilton, Alison B.; Young, Alexander S.] VA Hlth Serv Res & Dev Ctr Excellence Study Healt, Palo Alto, CA USA.
[Cohen, Amy N.; Hamilton, Alison B.; Whelan, Fiona; Young, Alexander S.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Chinman, Matthew J.] VA VISN 4 Mental Illness Res Educ & Clin Ctr MIRE, Philadelphia, PA USA.
[Chinman, Matthew J.] RAND, Pittsburgh, PA USA.
RP Cohen, AN (reprint author), Greater Los Angeles VA Healthcare Ctr, 11301 Wilshire Blvd 210A, Los Angeles, CA 90073 USA.
EM amy.cohen@va.gov
FU Department of Veterans Affairs, Veterans Health Administration, Health
Services Research and Development Service Quality Enhancement Research
Initiative (QUERI) [MNT 03-213]; VA Desert Pacific Mental Illness
Research, Education and Clinical Center (MIRECC); UCLA-RAND NIMH
Partnered Research Center for Quality Care [P30 MH082760]
FX Supported by the Department of Veterans Affairs, Veterans Health
Administration, Health Services Research and Development Service Quality
Enhancement Research Initiative (QUERI; MNT 03-213), and VA Desert
Pacific Mental Illness Research, Education and Clinical Center (MIRECC)
and by the UCLA-RAND NIMH Partnered Research Center for Quality Care
(P30 MH082760). The views expressed in this article are those of the
authors and do not necessarily represent the views of the affiliated
institutions.
NR 40
TC 7
Z9 7
U1 2
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD MAR
PY 2013
VL 51
IS 3
SU 1
BP S13
EP S20
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA AJ7YH
UT WOS:000337917300004
PM 23407006
ER
PT J
AU Gabrielian, S
Yuan, A
Andersen, RM
McGuire, J
Rubenstein, L
Sapir, N
Gelberg, L
AF Gabrielian, Sonya
Yuan, Anita
Andersen, Ronald M.
McGuire, James
Rubenstein, Lisa
Sapir, Negar
Gelberg, Lillian
TI Chronic Disease Management for Recently Homeless Veterans A Clinical
Practice Improvement Program to Apply Home Telehealth Technology to a
Vulnerable Population
SO MEDICAL CARE
LA English
DT Article
DE homeless; disease management; peer support
ID MENTALLY-ILL; PEER SUPPORT; HEALTH-CARE; SYSTEMS; ACCESS
AB Background: Although vulnerable populations may benefit from in-home health information technologies (HIT) that promote disease self-management, there is a "digital divide" in which these groups are often unlikely to use such programs. We describe the early phases of applying and testing an existing Veterans Affairs (VA) HIT-care management program, Care Coordination Home Telehealth (CCHT), to recently homeless Veterans in the US Department of Housing and Urban Development-VA Supportive Housing (HUD-VASH) program. Peers were used to support patient participation.
Methods: CCHT uses in-home messaging devices to provide health education and daily questions about clinical indicators from chronic illness care guidelines, with patient responses reviewed by VHA nurses. Patients could also receive adjunctive peer support. We used medical record review, Veteran interviews, and staff surveys to "diagnose" barriers to CCHT use, assess program acceptability, explore the role of peer support, and inform future quality improvement.
Subjects: Fourteen eligible Veterans in HUD-VASH agreed to CCHT participation. Ten of these Veterans opted to have adjunctive peer support and the other 4 enrolled in CCHT usual care.
Results: Although barriers to enrollment/engagement must be addressed, this subset of Veterans in HUD-VASH was satisfied with CCHT. Most Veterans did not require support from peers to engage in CCHT but valued peer social assistance amidst the isolation felt in their scattered-site homes.
Conclusions: HIT tools hold promise for in-home care management for recently housed Veterans. Patient-level barriers to enrollment must be addressed in the next steps of quality improvement, testing and evaluating peer-driven CCHT recruitment.
C1 [Gabrielian, Sonya] Vet Adm Greater Los Angeles, Mental Illness Res Educ & Clin Ctr, Los Angeles, CA 90073 USA.
[Yuan, Anita; Gelberg, Lillian] Vet Adm Greater Los Angeles, Dept Primary Care, Los Angeles, CA 90073 USA.
[Andersen, Ronald M.; Gelberg, Lillian] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[McGuire, James] Vet Hlth Adm Justice Programs, Washington, DC USA.
[Rubenstein, Lisa; Sapir, Negar] Vet Adm Greater Los Angeles, Hlth Serv Res & Dev Ctr Excellence Study Healthca, Los Angeles, CA USA.
[Rubenstein, Lisa] RAND Corp, Santa Monica, CA USA.
[Gelberg, Lillian] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA USA.
RP Gabrielian, S (reprint author), Vet Adm Greater Los Angeles, Mental Illness Res Educ & Clin Ctr, VA Healthcare Ctr, 11301 Wilshire Blvd,210A Los Angeles, Los Angeles, CA 90073 USA.
EM sonya.gabrielian@va.gov
FU PACT Demonstration Laboratory initiative is provided by the VA Office of
Patient Care Services; VISN 22 VA Assessment and Improvement Lab for
Patient Centered Care (VAIL-PCC) [XVA 65-018]; Office of Academic
Affiliations, Advanced Fellowship Program in Mental Illness Research and
Treatment, Department of Veterans Affairs; Office of Academic
Affiliations, Advanced Fellowship Program in Health Services Research,
Department of Veterans Affairs [TPP 65-013]; NIDA [DA 022445]; UCLA/DREW
Project EXPORT, National Center on Minority Health and Health
Disparities [P20MD000148/P20MD000182]; VAIL-PCC [XVA 650-18]
FX This work was undertaken as part of the Veterans Administration's PACT
Demonstration Laboratory initiative, supporting and evaluating VA's
transition to a patient-centered medical home. Funding for the PACT
Demonstration Laboratory initiative is provided by the VA Office of
Patient Care Services. In particular, this project was supported by the
VISN 22 VA Assessment and Improvement Lab for Patient Centered Care
(VAIL-PCC) (XVA 65-018; PI: Rubenstein). S. G. was supported by the
Office of Academic Affiliations, Advanced Fellowship Program in Mental
Illness Research and Treatment, Department of Veterans Affairs. A.Y. was
supported by the Office of Academic Affiliations, Advanced Fellowship
Program in Health Services Research, Department of Veterans Affairs (TPP
65-013). L. G. and R. M. A. were supported in part by NIDA DA 022445. R.
M. A. received additional support from the UCLA/DREW Project EXPORT,
National Center on Minority Health and Health Disparities,
P20MD000148/P20MD000182. L. R. and N.S. were supported in part by
VAIL-PCC (XVA 650-18).
NR 21
TC 6
Z9 6
U1 2
U2 17
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD MAR
PY 2013
VL 51
IS 3
SU 1
BP S44
EP S51
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA AJ7YH
UT WOS:000337917300008
PM 23407011
ER
PT J
AU Hynes, DM
Whittier, ER
Owens, A
AF Hynes, Denise M.
Whittier, Erika R.
Owens, Arika
TI Health Information Technology and Implementation Science Partners in
Progress in the VHA INTRODUCTION
SO MEDICAL CARE
LA English
DT Editorial Material
DE Veterans; health information technology; electronic health record;
quality improvement; implementation research; qualitative analysis
ID SELF-ASSESSMENT; QUERI; CARE; SCHIZOPHRENIA; QUALITY; ILLNESS
AB Background: The Veterans Health Administration (VHA) Quality Enhancement Research Initiative (QUERI) has demonstrated how implementation science can enhance the quality of health care. During this time an increasing number of implementation research projects have developed or utilized health information technology (HIT) innovations to leverage the VHA's electronic health record and information systems.
Objective: To describe the HIT approaches used and to characterize the facilitators and barriers to progress within implementation research projects in the VHA QUERI program.
Participants: Nine case studies were selected from among 88 projects and represented 8 of 14 HIT categories identified. Each case study included key informants whose roles on the project were principal investigator, implementation science and informatics development.
Approach: We conducted documentation analysis and semi-structured in-person interviews with key informants for each of the 9 case studies. We used qualitative analysis software to identify and thematically code information and interview responses.
Results: Thematic analyses revealed 3 domains or pathways critical to progression through the QUERI steps. These pathways addressed: (1) compliance and collaboration with information technology policies and procedures; (2) operating within organizational policies and building collaborations with end users, clinicians, and administrators; and (3) obtaining and maintaining research resources and approvals.
Conclusion: Sustained efforts in HIT innovation and in implementation science in the Veterans Health Administration demonstrates the interdependencies of these initiatives and the critical pathways that can contribute to progress. Other health care quality improvement efforts that rely on HIT can learn from the Veterans Health Administration experience.
C1 [Hynes, Denise M.; Whittier, Erika R.; Owens, Arika] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, VA Informat Resource Ctr, Hines, IL 60141 USA.
[Hynes, Denise M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, CMC3, Hines, IL 60141 USA.
[Hynes, Denise M.] Univ Illinois, Dept Med, Chicago, IL USA.
[Hynes, Denise M.] Univ Illinois, Ctr Clin & Translat Sci, Chicago, IL USA.
RP Hynes, DM (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, VA Informat Resource Ctr, 5th & Roosevelt Rd,Bldg 18,Room 206 151-V, Hines, IL 60141 USA.
EM denise.hynes@va.gov
NR 23
TC 3
Z9 3
U1 3
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD MAR
PY 2013
VL 51
IS 3
SU 1
BP S6
EP S12
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA AJ7YH
UT WOS:000337917300003
PM 23407014
ER
PT J
AU Hynes, DM
AF Hynes, Denise M.
TI Health Information Technology in VHA Quality Improvement Research
Overview INTRODUCTION
SO MEDICAL CARE
LA English
DT Editorial Material
DE administrative data; database; health information technology; personal
health record; electronic health record; health services research;
quality improvement; telehealth; Veterans; secure messaging
C1 [Hynes, Denise M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, VA Informat Resource Ctr VIReC, Hines, IL 60141 USA.
[Hynes, Denise M.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, CMC3, Hines, IL 60141 USA.
[Hynes, Denise M.] Univ Illinois, Dept Med, Chicago, IL USA.
[Hynes, Denise M.] Univ Illinois, Ctr Clin & Translat Sci, Chicago, IL USA.
RP Hynes, DM (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Informat Resource Ctr, 5th & Roosevelt Rd,Bldg 18,Room 206 151-V, Hines, IL 60141 USA.
EM denise.hynes@va.gov
NR 10
TC 0
Z9 0
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD MAR
PY 2013
VL 51
IS 3
SU 1
BP S4
EP S5
PG 2
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA AJ7YH
UT WOS:000337917300002
PM 23407010
ER
PT J
AU McInnes, DK
Solomon, JL
Shimada, SL
Petrakis, BA
Bokhour, BG
Asch, SM
Nazi, KM
Houston, TK
Gifford, AL
AF McInnes, D. Keith
Solomon, Jeffrey L.
Shimada, Stephanie L.
Petrakis, Beth A.
Bokhour, Barbara G.
Asch, Steven M.
Nazi, Kim M.
Houston, Thomas K.
Gifford, Allen L.
TI Development and Evaluation of an Internet and Personal Health Record
Training Program for Low-income Patients With HIV or Hepatitis C
SO MEDICAL CARE
LA English
DT Article
DE vulnerable populations; health informatics; HIV; hepatitis C; veterans
ID BEHAVIORAL SKILLS MODEL; ANTIRETROVIRAL THERAPY; CARE UTILIZATION;
DIGITAL DIVIDE; DEEP SOUTH; INFORMATION; ACTIVATION; ADHERENCE;
INTERVENTION; MOTIVATION
AB Background: Vulnerable populations face difficulties accessing and using the internet and personal health record (PHR) systems for health-related purposes. Populations disconnected from the internet also tend to be disconnected from health care services.
Objectives: To develop and evaluate an intervention to increase skills in health-related internet and PHR use for vulnerable populations with limited computer and internet experience.
Research Design: Preevaluation and postevaluation using quantitative surveys, semistructured interviews, focus groups, and ethnographic observation.
Subjects: Fourteen low-income Veterans receiving care at Veterans Affairs medical centers for human immunodeficiency virus or hepatitis C.
Measures: Internet and PHR use, self-efficacy, patient activation, disease knowledge, predictors of medication adherence.
Results: At follow-up one (FU1), mean number of internet for health features used increased from 1.57 to 4.07 (P < 0.001) as did number of PHR features, from 0.36 to 2.00 (P < 0.001). Mean self-efficacy increased at FU1, from 7.12 to 8.60, (P = 0.009) and was maintained at follow-up two (FU2). Patient activation increased only at FU2, from 3.42 to 3.61 (P = 0.03). Disease specific knowledge showed borderline increase at FU1, from 67.9% to 72.2% (P = 0.05), whereas there were no changes in predictors of medication adherence. Qualitative findings underscored the interest in using internet and PHRs and their contribution to increased engagement in care. Training cost per participant was $287.
Conclusions: Group training of vulnerable patients represents a cost-effective method to increase internet and PHR skills, and improve patient confidence in finding health-related information, making online health-related transactions, and interacting with health care providers.
C1 [McInnes, D. Keith; Solomon, Jeffrey L.; Shimada, Stephanie L.; Petrakis, Beth A.; Bokhour, Barbara G.; Houston, Thomas K.; Gifford, Allen L.] ENRM VA Med Ctr, VA QUERI Program, Bedford, MA 01730 USA.
[McInnes, D. Keith; Solomon, Jeffrey L.; Shimada, Stephanie L.; Petrakis, Beth A.; Bokhour, Barbara G.; Houston, Thomas K.; Gifford, Allen L.] ENRM VA Med Ctr, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA 01730 USA.
[McInnes, D. Keith; Shimada, Stephanie L.; Bokhour, Barbara G.; Gifford, Allen L.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
[Asch, Steven M.] VA Palo Alto Healthcare Syst, VA QUERI Program, Palo Alto, CA USA.
[Asch, Steven M.] VA Palo Alto Healthcare Syst, Ctr Hlth Care Evaluat, Palo Alto, CA USA.
[Asch, Steven M.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA.
[Nazi, Kim M.] US Dept Vet Affairs, Vet & Consumers Hlth Informat Off, Off Informat & Analyt, Vet Hlth Adm, Washington, DC USA.
[Houston, Thomas K.] Univ Massachusetts, Dept Quantitat Hlth Sci, Sch Med, Worcester, MA 01605 USA.
[Gifford, Allen L.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
RP McInnes, DK (reprint author), ENRM VA Med Ctr, VA QUERI Program, Bldg 70,200 Springs Rd, Bedford, MA 01730 USA.
EM keith.mcinnes@va.gov
FU Department of Veterans Affairs (VA) Quality Enhancement Research
Initiatives (QUERI) HIV/Hepatitis and eHealth (RRP) [09-192]; VA Health
Services Research and Development Career Development Award (CDA)
[09-016]
FX Supported by the Department of Veterans Affairs (VA) Quality Enhancement
Research Initiatives (QUERI) HIV/Hepatitis and eHealth (RRP#09-192). In
addition, D. K. M. was supported by a VA Health Services Research and
Development Career Development Award (CDA#09-016).
NR 41
TC 12
Z9 12
U1 3
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD MAR
PY 2013
VL 51
IS 3
SU 1
BP S62
EP S66
PG 5
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA AJ7YH
UT WOS:000337917300011
PM 23407015
ER
PT J
AU Nazi, KM
Hogan, TP
McInnes, DK
Woods, SS
Graham, G
AF Nazi, Kim M.
Hogan, Timothy P.
McInnes, D. Keith
Woods, Susan S.
Graham, Gail
TI Evaluating Patient Access to Electronic Health Records Results From a
Survey of Veterans
SO MEDICAL CARE
LA English
DT Article
DE PHR; personal health record; EHR; eHealth; access; portal
ID MEDICAL-RECORDS; MEANINGFUL USE; TECHNOLOGIES; CARE
AB Objective: Personal Health Records (PHRs) tethered to an Electronic Health Record (EHR) offer patients unprecedented access to their personal health information. At the Department of Veteran Affairs (VA), the My HealtheVet Pilot Program was an early PHR prototype enabling patients to import 18 types of information, including clinical notes and laboratory test results, from the VA EHR into a secure PHR portal. The goal of this study was to explore Veteran perceptions about this access to their medical records, including perceived value and effect on satisfaction, self-care, and communication.
Methods: Patients enrolled in the pilot program were invited to participate in a web-based survey.
Results: Among 688 Veteran respondents, there was a high degree of satisfaction with the pilot program, with 84% agreeing that the information and services were helpful. The most highly ranked feature was access to personal health information from the VA EHR. The majority of respondents (72%) indicated that the pilot Web site made it easy for them to locate relevant information. Most participants (66%) agreed that the pilot program helped improve their care, with 90% indicating that they would recommend it to another Veteran.
Conclusions: Veterans' primary motivation for use of the pilot Web site was the ability to access their own personal health information from the EHR. With patients viewing such access as beneficial to their health and care, PHRs with access to EHR data are positioned to improve health care quality. Making additional information accessible to patients is crucial to meet their needs and preferences.
C1 [Nazi, Kim M.] US Dept Vet Affairs, Vet & Consumers Hlth Informat Off, Off Informat & Analyt, Vet Hlth Adm, Washington, DC USA.
[Hogan, Timothy P.; McInnes, D. Keith] Edith Nourse Rogers Mem Vet Hosp, Ctr Hlth Qual Outcomes & Econ Res, Natl eHlth QUERI Coordinating Ctr, Bedford, MA USA.
[Hogan, Timothy P.] Edith Nourse Rogers Mem Vet Hosp, eHlth Qual Enhancement Res Initiat QUERI, Natl eHlth QUERI Coordinating Ctr, Bedford, MA USA.
[Hogan, Timothy P.] Univ Massachusetts, Sch Med, Div Hlth Informat & Implementat Sci, Worcester, MA USA.
[McInnes, D. Keith] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
[Woods, Susan S.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
[Woods, Susan S.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Woods, Susan S.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
[Graham, Gail] US Dept Vet Affairs, Off Informat & Analyt, Vet Hlth Adm, Washington, DC USA.
RP Nazi, KM (reprint author), Stratton VA Med Ctr, 113 Holland Ave, Albany, NY 12208 USA.
EM kim.nazi@va.gov
NR 28
TC 21
Z9 21
U1 1
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD MAR
PY 2013
VL 51
IS 3
SU 1
BP S52
EP S56
PG 5
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA AJ7YH
UT WOS:000337917300009
PM 23407012
ER
PT J
AU Shimada, SL
Hogan, TP
Rao, SR
Allison, JJ
Quill, AL
Feng, H
Phillips, BD
Nazi, KM
Haidary, ST
Houston, TK
AF Shimada, Stephanie L.
Hogan, Timothy P.
Rao, Sowmya R.
Allison, Jeroan J.
Quill, Ann L.
Feng, Hua
Phillips, Barrett D.
Nazi, Kim M.
Haidary, Susan T.
Houston, Thomas K.
TI Patient-Provider Secure Messaging in VA Variations in Adoption and
Association With Urgent Care Utilization
SO MEDICAL CARE
LA English
DT Article
DE veterans; urgent care; ambulatory care; continuity; implementation;
secure messaging; Internet
ID KAISER PERMANENTE; MEDICAL HOME; IMPLEMENTATION; FRAMEWORK; QUALITY;
ACCESS; IMPACT
AB Background: The Veterans Health Administration has implemented patient to clinical team electronic asynchronous secure messaging (SM). This disruptive technology has the potential to support continuous, coordinated quality care, but limited evidence supports this connection.
Objectives: The objective of this paper is to (1) measure SM implementation and identify facility characteristics associated with higher rates of adoption and (2) understand the association of SM use and noncontinuity care [ie, urgent care (UC)] utilization rates.
Measures: We conducted a retrospective cohort study of 132 VA facilities implementing SM in primary care. We used a combination of cross-sectional survey data on predictors of SM implementation and longitudinal data (July 2010-June 2012) on use of SM and UC.
Results: Human resources (coordinator and staff/volunteer availability to directly assist Veterans), computer resources (computers and computer rooms for Veterans), and leadership support for coordinators were associated with increased SM adoption rates. Higher SM use was associated with lower UC rates; early adopters of SM achieved a greater decrease in UC utilization over time than later adopters.
Conclusions: In this exploratory analysis of early SM implementation in VA, we found a path of associations linking SM and reductions in UC utilization. These results suggest a need for further examination of the relationship between SM and its effects on health care utilization patterns.
C1 [Shimada, Stephanie L.; Hogan, Timothy P.; Rao, Sowmya R.; Allison, Jeroan J.; Quill, Ann L.; Feng, Hua; Phillips, Barrett D.; Houston, Thomas K.] Edith Nourse Rogers Mem Vet Hosp, CHQOER, Bedford, MA 01730 USA.
[Shimada, Stephanie L.; Hogan, Timothy P.; Rao, Sowmya R.; Allison, Jeroan J.; Quill, Ann L.; Feng, Hua; Phillips, Barrett D.; Houston, Thomas K.] eHlth Qual Enhancement Res Initiat QUERI, Amherst, MA USA.
[Shimada, Stephanie L.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA.
[Hogan, Timothy P.; Rao, Sowmya R.; Allison, Jeroan J.; Feng, Hua; Phillips, Barrett D.; Houston, Thomas K.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA.
[Nazi, Kim M.; Haidary, Susan T.] US Dept Vet Affairs, Vet & Consumers Hlth Informat Off, Off Informat & Analyt, Vet Hlth Adm, Washington, DC USA.
RP Shimada, SL (reprint author), Edith Nourse Rogers Mem Vet Hosp, 200 Springs Rd 152, Bedford, MA 01730 USA.
EM stephanie.shimada@va.gov
FU eHealth Quality Enhancement Research Initiative [EHQ 10-190]; VA Career
Development Award [CDA 10-210]; University of Massachusetts Center for
Clinical and Translational Research; NIH Clinical and Translational
Sciences Award [1UL1RR031982-01]
FX The authors acknowledge the eHealth Quality Enhancement Research
Initiative (EHQ 10-190) for funding to support this paper. Dr Shimada's
efforts were covered by a VA Career Development Award (CDA 10-210). Drs
Allison and Houston were supported by the University of Massachusetts
Center for Clinical and Translational Research, funding by NIH Clinical
and Translational Sciences Award (1UL1RR031982-01). Theresa Hancock and
Alex Hersh of the Veterans/Consumers Health Informatics Office, D. Keith
McInnes and Beth Ann Petrakis of the eHealth QUERI, Tracey Martin and
other My HealtheVet coordinators were also instrumental to data
collection.
NR 20
TC 12
Z9 12
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD MAR
PY 2013
VL 51
IS 3
SU 1
BP S21
EP S28
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA AJ7YH
UT WOS:000337917300005
PM 23407007
ER
PT J
AU Spears, GV
Roth, CP
Miake-Lye, IM
Saliba, D
Shekelle, PG
Ganz, DA
AF Spears, Gwendolyn V.
Roth, Carol P.
Miake-Lye, Isomi M.
Saliba, Debra
Shekelle, Paul G.
Ganz, David A.
TI Redesign of an Electronic Clinical Reminder to Prevent Falls in Older
Adults
SO MEDICAL CARE
LA English
DT Article
DE quality improvement; fall prevention; primary care; clinical reminder
ID PRIMARY-CARE PRACTICES; URINARY-INCONTINENCE; GERIATRIC SYNDROMES;
QUALITY INDICATORS; MOBILITY PROBLEMS; INTERVENTION; FACILITATORS;
PERCEPTIONS; MANAGEMENT; PHYSICIANS
AB Background: Falls are the leading cause of unintentional injury among US older adults. Guidelines recommend screening patients for fall risk, and providing exercise for patients with gait and balance problems. We redesigned an electronic clinical reminder to improve identification and management of Veterans at high risk for falls, and piloted the reminder in 3 Veterans Health Administration community-based outpatient clinics.
Methods: This project had 5 key elements: (1) case finding, (2) efficient collection of condition-specific clinical data, (3) clinical reminders to prompt appropriate care, (4) patient and family education materials, and (5) primary care provider (PCP) decision support/PCP and staff education. We reviewed clinical reminder reports, interviewed nurses and PCPs, directly observed clinic operations, and watched nurses and PCPs use the clinical reminder with a dummy patient record to determine areas in need of improvement.
Results: Over a 1-year period, 2943 Veterans aged 75 years and older visited the 3 clinics, with 2264 screened for fall risk by the intake nurse, yielding 472 positive screens. PCPs completed gait, balance, and strength evaluations on 231 screen-positive Veterans. Among the 162 Veterans who had a gait, balance, or strength problem on evaluation and were free of advanced dementia or poor prognosis, 39 were offered physical therapy or exercise. PCPs and nurses held divergent opinions about the clinical reminder and the project, with PCPs more negative and nurses more positive.
Conclusions: A fall prevention clinical reminder can be incorporated into routine care, but low referral rates to exercise programs suggest that further quality improvement cycles are needed.
C1 [Spears, Gwendolyn V.; Miake-Lye, Isomi M.; Saliba, Debra; Shekelle, Paul G.; Ganz, David A.] VA Greater Los Angeles HSR&D Ctr Excellence, Sepulveda, CA USA.
[Roth, Carol P.] RAND Corp, Santa Monica, CA USA.
[Saliba, Debra; Ganz, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
[Saliba, Debra; Shekelle, Paul G.; Ganz, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Saliba, Debra] Univ Calif Los Angeles, Borun Ctr Gerontol Res, Los Angeles, CA USA.
[Saliba, Debra] Los Angeles Jewish Home, Los Angeles, CA USA.
RP Ganz, DA (reprint author), VA Greater Los Angeles Healthcare Syst 11G, 11301 Wilshire Blvd,Bldg 220,Room 313, Los Angeles, CA 90073 USA.
EM dganz@mednet.ucla.edu
FU US Department of Veterans Affairs, Veterans Health Administration
Quality Enhancement Research Initiative [RRP 09-202]; VA Career
Development Award from the VA Health Services Research & Development
(HSR&D) Service through the VA Greater Los Angeles HSR&D Center of
Excellence [VA CD2 08-012-1]; John A. Hartford Foundation; American
Federation for Aging Research through the UCLA Geriatrics Center of
Excellence; VA Greater Los Angeles HSR&D Center of Excellence [LIP
65-127]; Robert Wood Johnson Foundation Physician Faculty Scholars
Program
FX Supported by the US Department of Veterans Affairs, Veterans Health
Administration Quality Enhancement Research Initiative (Project # RRP
09-202). David Ganz was supported by a VA Career Development Award from
the VA Health Services Research & Development (HSR&D) Service (Project #
VA CD2 08-012-1) through the VA Greater Los Angeles HSR&D Center of
Excellence. Additional support was provided by the John A. Hartford
Foundation and the American Federation for Aging Research through the
UCLA Geriatrics Center of Excellence, a locally initiated project
through the VA Greater Los Angeles HSR&D Center of Excellence (LIP
65-127), and the Robert Wood Johnson Foundation Physician Faculty
Scholars Program.
NR 19
TC 3
Z9 3
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD MAR
PY 2013
VL 51
IS 3
SU 1
BP S37
EP S43
PG 7
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA AJ7YH
UT WOS:000337917300007
PM 23407009
ER
PT J
AU Tsai, TT
Box, TL
Gethoffer, H
Noonan, G
Varosy, PD
Maddox, TM
Fihn, SD
Gross, TP
Jesse, RL
Rumsfeld, JS
AF Tsai, Thomas T.
Box, Tamara L.
Gethoffer, Hans
Noonan, Gregory
Varosy, Paul D.
Maddox, Thomas M.
Fihn, Stephan D.
Gross, Thomas P.
Jesse, Robert L.
Rumsfeld, John S.
TI Feasibility of Proactive Medical Device Surveillance The VA Clinical
Assessment Reporting and Tracking (CART) Program
SO MEDICAL CARE
LA English
DT Article
DE patient safety; device safety; cardiovascular
ID COMPREHENSIVE APPROACH; SAFETY NET; STENTS; HOLES
AB Background: Timely identification and reporting of medical device problems is critical to postmarket device surveillance programs to maximize patient safety. Cardiac catheterization laboratories are high-device utilization areas well suited for device surveillance.
Objective: To demonstrate the feasibility of the national VA Clinical Assessment, Reporting, and Tracking (CART) system, embedded in the electronic health record of all 76 VA cardiac catheterization laboratories, to document unexpected problems with medical devices at the point of care.
Methods: We evaluated 260,258 consecutive cardiac catheterization and/or percutaneous coronary intervention procedures on 175,098 Veterans between August 2006 and February 2012. Unexpected device problems (UDPs) encountered for any equipment used during a procedure were entered by clinicians at the point of care as part of regular care documentation. All UDPs were reviewed in collaboration with the FDA to ascertain the likelihood of a device defect (eg, in manufacture or design) and/or contributing to a procedural complication (level I, unlikely; level II, possibly; level III, likely).
Results: Of the 260,258 procedure reports, 974 (0.37%) UDP's were reported by 71 (92.2%) of the 76 VA hospitals. After triage, 739 (75.9%) were deemed level I, 196 (20.1%) level II, and 39 (4.0%) level III. Of the 39 level III reports, 12 (30.7%) are in the submission phase as a FDA MedWatch report. The number of monthly UDP reports increased significantly from 2006 to 2012 (P < 0.001).
Conclusions: Leveraging a clinical application embedded in the electronic health record and in collaboration with FDA, a proactive national cardiac device surveillance program has been successfully implemented in the VA.
C1 [Tsai, Thomas T.; Box, Tamara L.; Gethoffer, Hans; Noonan, Gregory; Varosy, Paul D.; Maddox, Thomas M.; Rumsfeld, John S.] Univ Colorado, VA Eastern Colorado Hlth Care Syst, Dept Med, CART Coordinating Ctr, Denver, CO 80220 USA.
[Fihn, Stephan D.] VA Hlth Serv R&D, Off Analyt & Business Intelligence, Seattle, WA USA.
[Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Gross, Thomas P.] US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD USA.
[Jesse, Robert L.; Rumsfeld, John S.] VA Cent Off, Washington, DC USA.
[Jesse, Robert L.] Richmond VA Med Ctr, Richmond, VA USA.
RP Tsai, TT (reprint author), Univ Colorado, VA Eastern Colorado Hlth Care Syst, Dept Med, CART Coordinating Ctr,Cardiol Sect 111B, 1055 Clermont St, Denver, CO 80220 USA.
EM thomas.tsai@va.gov
NR 18
TC 11
Z9 11
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD MAR
PY 2013
VL 51
IS 3
SU 1
BP S57
EP S61
PG 5
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA AJ7YH
UT WOS:000337917300010
PM 23407013
ER
PT J
AU Guinan, E
Boudreau, KJ
Lakhani, KR
AF Guinan, Eva
Boudreau, Kevin J.
Lakhani, Karim R.
TI Experiments in Open Innovation at Harvard Medical School
SO MIT SLOAN MANAGEMENT REVIEW
LA English
DT Article
AB This article examines an experiment in open innovation applied to scientific research on Type 1 diabetes at Harvard Medical School. In the traditional research process, a single research team typically carries through each stage of the process-from generating the idea to raising money to carrying out the research and publishing the results. Harvard Catalyst, a pan-Harvard agency with a mission to speed biomedical research from the lab to patients' bedsides, modified the traditional grant proposal process as an experiment in bringing greater openness into every stage of research.
Participation was successfully extended to nontraditional actors. In the end, 150 new hypotheses and research pathways were proposed. Teams were invited to propose projects on the 12 most promising of these; today, seven teams are carrying out the research. The Harvard Catalyst experience suggests that open-innovation principles can be adopted even within a well-established and experienced innovation-driven organization.
C1 [Guinan, Eva] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Guinan, Eva] Dana Farber Canc Inst, Boston, MA USA.
[Guinan, Eva] Harvard Catalyst, Innovat & Implementat Program, Boston, MA USA.
[Boudreau, Kevin J.] London Business Sch, London, England.
[Boudreau, Kevin J.] Harvard Univ, Inst Quantitat Social Sci, Harvard NASA Tournament Lab, Cambridge, MA 02138 USA.
[Lakhani, Karim R.] Harvard Univ, Sch Business, Cambridge, MA 02138 USA.
RP Guinan, E (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
NR 20
TC 5
Z9 5
U1 3
U2 8
PU SLOAN MANAGEMENT REVIEW ASSOC, MIT SLOAN SCHOOL MANAGEMENT
PI CAMBRIDGE
PA 77 MASSACHUSETTS AVE, E60-100, CAMBRIDGE, MA 02139-4307 USA
SN 1532-9194
J9 MIT SLOAN MANAGE REV
JI MIT Sloan Manage. Rev.
PD SPR
PY 2013
VL 54
IS 3
BP 45
EP +
PG 10
WC Business; Management
SC Business & Economics
GA V37MN
UT WOS:000209280000010
ER
PT J
AU Gaudet, MM
Kuchenbaecker, KB
Vijai, J
Klein, RJ
Kirchhoff, T
McGuffog, L
Barrowdale, D
Dunning, AM
Lee, A
Dennis, J
Healey, S
Dicks, E
Soucy, P
Sinilnikova, O
Pankratz, VS
Wang, XS
Eldridge, RC
Tessier, DC
Vincent, D
Bacot, F
Hogervorst, FBL
Peock, S
Stoppa-Lyonnet, D
Peterlongo, P
Schmutzler, RK
Nathanson, KL
Piedmonte, M
Singer, CF
Thomassen, M
Hansen, TVO
Neuhausen, SL
Blanco, I
Greene, MH
Garber, J
Weitzel, JN
Andrulis, IL
Goldgar, DE
D'Andrea, E
Caldes, T
Nevanlinna, H
Osorio, A
van Rensburg, EJ
Arason, A
Rennert, G
van den Ouweland, AMW
van der Hout, AH
Kets, CM
Aalfs, CM
Wijnen, JT
Ausems, MGEM
Frost, D
Ellis, S
Fineberg, E
Platte, R
Evans, DG
Jacobs, C
Adlard, J
Tischkowitz, M
Porteous, ME
Damiola, F
Golmard, L
Barjhoux, L
Longy, M
Belotti, M
Ferrer, SF
Mazoyer, S
Spurdle, AB
Manoukian, S
Barile, M
Genuardi, M
Arnold, N
Meindl, A
Sutter, C
Wappenschmidt, B
Domchek, SM
Pfeiler, G
Friedman, E
Jensen, UB
Robson, M
Shah, S
Lazaro, C
Mai, PL
Benitez, J
Southey, MC
Schmidt, MK
Fasching, PA
Peto, J
Humphreys, MK
Wang, Q
Michailidou, K
Sawyer, EJ
Burwinkel, B
Guenel, P
Bojesen, SE
Milne, RL
Brenner, H
Lochmann, M
Aittomaki, K
Dork, T
Margolin, S
Mannermaa, A
Lambrechts, D
Chang-Claude, J
Radice, P
Giles, GG
Haiman, CA
Winqvist, R
Devillee, P
Garcia-Closas, M
Schoof, N
Hooning, MJ
Cox, A
Pharoah, PDP
Jakubowska, A
Orr, N
Gonzalez-Neira, A
Pita, G
Alonso, MR
Hall, P
Couch, FJ
Simard, J
Altshuler, D
Easton, DF
Chenevix-Trench, G
Antoniou, AC
Offit, K
AF Gaudet, Mia M.
Kuchenbaecker, Karoline B.
Vijai, Joseph
Klein, Robert J.
Kirchhoff, Tomas
McGuffog, Lesley
Barrowdale, Daniel
Dunning, Alison M.
Lee, Andrew
Dennis, Joe
Healey, Sue
Dicks, Ed
Soucy, Penny
Sinilnikova, Olgam.
Pankratz, Vernon S.
Wang, Xianshu
Eldridge, Ronald C.
Tessier, Daniel C.
Vincent, Daniel
Bacot, Francois
Hogervorst, Frans B. L.
Peock, Susan
Stoppa-Lyonnet, Dominique
Peterlongo, Paolo
Schmutzler, Rita K.
Nathanson, Katherine L.
Piedmonte, Marion
Singer, Christian F.
Thomassen, Mads
Hansen, Thomas V. O.
Neuhausen, Susan L.
Blanco, Ignacio
Greene, Mark H.
Garber, Judith
Weitzel, Jeffrey N.
Andrulis, Irene L.
Goldgar, David E.
D'Andrea, Emma
Caldes, Trinidad
Nevanlinna, Heli
Osorio, Ana
van Rensburg, Elizabeth J.
Arason, Adalgeir
Rennert, Gad
van den Ouweland, Ans M. W.
van der Hout, Annemarie H.
Kets, Carolien M.
Aalfs, Cora M.
Wijnen, Juul T.
Ausems, Margreet G. E. M.
Frost, Debra
Ellis, Steve
Fineberg, Elena
Platte, Radka
Evans, D. Gareth
Jacobs, Chris
Adlard, Julian
Tischkowitz, Marc
Porteous, Mary E.
Damiola, Francesca
Golmard, Lisa
Barjhoux, Laure
Longy, Michel
Belotti, Muriel
Ferrer, Sandra Fert
Mazoyer, Sylvie
Spurdle, Amanda B.
Manoukian, Siranoush
Barile, Monica
Genuardi, Maurizio
Arnold, Norbert
Meindl, Alfons
Sutter, Christian
Wappenschmidt, Barbara
Domchek, Susan M.
Pfeiler, Georg
Friedman, Eitan
Jensen, Uffe Birk
Robson, Mark
Shah, Sohela
Lazaro, Conxi
Mai, Phuong L.
Benitez, Javier
Southey, Melissa C.
Schmidt, Marjanka K.
Fasching, Peter A.
Peto, Julian
Humphreys, Manjeet K.
Wang, Qin
Michailidou, Kyriaki
Sawyer, Elinor J.
Burwinkel, Barbara
Guenel, Pascal
Bojesen, Stig E.
Milne, Roger L.
Brenner, Hermann
Lochmann, Magdalena
Aittomaki, Kristiina
Doerk, Thilo
Margolin, Sara
Mannermaa, Arto
Lambrechts, Diether
Chang-Claude, Jenny
Radice, Paolo
Giles, Graham G.
Haiman, Christopher A.
Winqvist, Robert
Devillee, Peter
Garcia-Closas, Montserrat
Schoof, Nils
Hooning, Maartje J.
Cox, Angela
Pharoah, Paul D. P.
Jakubowska, Anna
Orr, Nick
Gonzalez-Neira, Anna
Pita, Guillermo
Rosario Alonso, M.
Hall, Per
Couch, Fergus J.
Simard, Jacques
Altshuler, David
Easton, Douglas F.
Chenevix-Trench, Georgia
Antoniou, Antonis C.
Offit, Kenneth
CA KConFab Investigators
Ontario Canc Genetics Network
HEBON
EMBRACE
GEMO Study Collaborators
GENICA Network
TI Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to
Breast Cancer Risk
SO PLOS GENETICS
LA English
DT Article
ID BRCA2 MUTATION CARRIERS; TRANSCRIPTION FACTOR AP-2; GENOME-WIDE
ASSOCIATION; COMMON VARIANTS; SUSCEPTIBILITY ALLELES; OVARIAN-CANCER;
ZNF365; POPULATION; CONSORTIUM; SUBTYPES
AB Common genetic variants contribute to the observed variation in breast cancer risk for BRCA2 mutation carriers; those known to date have all been found through population-based genome-wide association studies (GWAS). To comprehensively identify breast cancer risk modifying loci for BRCA2 mutation carriers, we conducted a deep replication of an ongoing GWAS discovery study. Using the ranked P-values of the breast cancer associations with the imputed genotype of 1.4 M SNPs, 19,029 SNPs were selected and designed for inclusion on a custom Illumina array that included a total of 211,155 SNPs as part of a multi-consortial project. DNA samples from 3,881 breast cancer affected and 4,330 unaffected BRCA2 mutation carriers from 47 studies belonging to the Consortium of Investigators of Modifiers of BRCA1/2 were genotyped and available for analysis. We replicated previously reported breast cancer susceptibility alleles in these BRCA2 mutation carriers and for several regions (including FGFR2, MAP3K1, CDKN2A/B, and PTHLH) identified SNPs that have stronger evidence of association than those previously published. We also identified a novel susceptibility allele at 6p24 that was inversely associated with risk in BRCA2 mutation carriers (rs9348512; per allele HR = 0.85, 95% CI 0.80-0.90, P = 3.9 x 10(-8)). This SNP was not associated with breast cancer risk either in the general population or in BRCA1 mutation carriers. The locus lies within a region containing TFAP2A, which encodes a transcriptional activation protein that interacts with several tumor suppressor genes. This report identifies the first breast cancer risk locus specific to a BRCA2 mutation background. This comprehensive update of novel and previously reported breast cancer susceptibility loci contributes to the establishment of a panel of SNPs that modify breast cancer risk in BRCA2 mutation carriers. This panel may have clinical utility for women with BRCA2 mutations weighing options for medical prevention of breast cancer.
C1 [Gaudet, Mia M.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.
[Kuchenbaecker, Karoline B.; McGuffog, Lesley; Barrowdale, Daniel; Lee, Andrew; Dennis, Joe; Dicks, Ed; Peock, Susan; Frost, Debra; Ellis, Steve; Fineberg, Elena; Platte, Radka; Evans, D. Gareth; Humphreys, Manjeet K.; Wang, Qin; Michailidou, Kyriaki; Pharoah, Paul D. P.; Easton, Douglas F.; Antoniou, Antonis C.; EMBRACE] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Publ Hlth & Primary Care, Cambridge, England.
[Vijai, Joseph; Robson, Mark; Shah, Sohela; Offit, Kenneth] Mem Sloan Kettering Canc Ctr, Clin Genet Serv, New York, NY 10021 USA.
[Klein, Robert J.] Mem Sloan Kettering Canc Ctr, Program Canc Biol & Genet, New York, NY 10021 USA.
[Kirchhoff, Tomas] NYU, Dept Environm Med, Div Epidemiol, Sch Med, New York, NY 10016 USA.
[Dunning, Alison M.; Pharoah, Paul D. P.; Easton, Douglas F.] Univ Cambridge, Ctr Canc Genet Epidemiol, Dept Oncol, Cambridge, England.
[Healey, Sue; Spurdle, Amanda B.; Chenevix-Trench, Georgia] Queensland Inst Med Res, Genet & Populat Hlth Div, Brisbane, Qld 4006, Australia.
[Soucy, Penny; Simard, Jacques] Ctr Hosp Univ Quebec, Canc Genom Lab, Quebec City, PQ, Canada.
[Soucy, Penny; Simard, Jacques] Univ Laval, Quebec City, PQ, Canada.
[Sinilnikova, Olgam.] Hosp Civils Lyon, Unite Mixte Genet Constitut Canc Frequents, Ctr Leon Berard, Lyon, France.
[Pankratz, Vernon S.; Damiola, Francesca; Barjhoux, Laure; Mazoyer, Sylvie] Univ Lyon 1, INSERM U1052, CNRS UMR5286, Ctr Rech Cancerol Lyon, F-69365 Lyon, France.
[Wang, Xianshu; Couch, Fergus J.] Mayo Clin, Dept Hlth Sci, Rochester, MN USA.
[Eldridge, Ronald C.; Couch, Fergus J.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
[Tessier, Daniel C.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
[Vincent, Daniel; Bacot, Francois] Ctr Innovat Genome Quebec, Montreal, PQ, Canada.
[Vincent, Daniel; Bacot, Francois] McGill Univ, Montreal, PQ, Canada.
[Hogervorst, Frans B. L.] Netherlands Canc Inst, Family Canc Clin, Amsterdam, Netherlands.
[Stoppa-Lyonnet, Dominique; Golmard, Lisa; Belotti, Muriel] Inst Curie, Dept Tumour Biol, Paris, France.
[Stoppa-Lyonnet, Dominique] Inst Curie, INSERM U830, Paris, France.
[Stoppa-Lyonnet, Dominique] Univ Paris 05, Sorbonne Paris Cite, Paris, France.
[KConFab Investigators] Peter MacCallum Canc Ctr, Kathleen Cuningham Consortium Res Familial Breast, Melbourne, Vic, Australia.
[Peterlongo, Paolo; Radice, Paolo] Fdn IRCCS Ist Nazl Tumori, Unit Mol Bases Genet Risk & Genet Testing, Dept Prevent & Predict Med, Milan, Italy.
[Radice, Paolo] Fdn Ist FIRC Oncol Mol, IFOM, Milan, Italy.
[Schmutzler, Rita K.; Wappenschmidt, Barbara] Univ Hosp Cologne, Cologne, Germany.
[Nathanson, Katherine L.; Domchek, Susan M.] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Nathanson, Katherine L.] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Piedmonte, Marion] Roswell Pk Canc Inst, Gynecol Oncol Grp, Stat & Data Ctr, Buffalo, NY 14263 USA.
[Singer, Christian F.; Pfeiler, Georg] Med Univ Vienna, Dept Obstet & Gyncol, Vienna, Austria.
[Singer, Christian F.; Pfeiler, Georg] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria.
[Thomassen, Mads] Odense Univ Hosp, Dept Clin Genet, DK-5000 Odense, Denmark.
[Andrulis, Irene L.; Ontario Canc Genetics Network] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
[Hansen, Thomas V. O.] Copenhagen Univ Hosp, Ctr Genom Med, Rigshosp, Copenhagen, Denmark.
[Neuhausen, Susan L.] City Hope Natl Med Ctr, Dept Populat Sci, Beckman Res Inst, Duarte, CA USA.
[Blanco, Ignacio] IDIBELL Catalan Inst Oncol, Genet Counseling Unit, Hereditary Canc Program, Barcelona, Spain.
[Greene, Mark H.; Mai, Phuong L.] NCI, Clin Genet Branch, Div Canc Epidemiol & Genet, NIH, Rockville, MD USA.
[Garber, Judith] Dana Farber Partners CancerCare, Dept Med Oncol, Boston, MA USA.
[Weitzel, Jeffrey N.] City Hope Natl Med Ctr, Clin Canc Genet, City Hope Clin Canc Genet Community Res Network, Duarte, CA USA.
[Andrulis, Irene L.] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A1, Canada.
[Andrulis, Irene L.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A1, Canada.
[Goldgar, David E.] Univ Utah, Sch Med, Dept Dermatol, Salt Lake City, UT USA.
[D'Andrea, Emma] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy.
[D'Andrea, Emma] Ist Oncolog Veneto IOV IRCCS, Immunol & Mol Oncol Unit, Padua, Italy.
[Caldes, Trinidad] Hosp Clin San Carlos, Mol Oncol Lab, IdISSC, Madrid, Spain.
[Nevanlinna, Heli] Univ Helsinki, Dept Obstet & Gynecol, Helsinki, Finland.
[Nevanlinna, Heli] Univ Helsinki, Cent Hosp, Helsinki, Finland.
[Osorio, Ana; Benitez, Javier; Milne, Roger L.] Spanish Natl Canc Ctr CNIO, Human Genet Grp, Madrid, Spain.
[Osorio, Ana; Benitez, Javier] Biomed Network Rare Dis CIBERER, Madrid, Spain.
[van Rensburg, Elizabeth J.] Univ Pretoria, Dept Genet, ZA-0002 Pretoria, South Africa.
[Arason, Adalgeir] Landspitali Univ Hosp, Dept Pathol, Reykjavik, Iceland.
[Arason, Adalgeir] Univ Iceland, BMC, Fac Med, Reykjavik, Iceland.
[Rennert, Gad] Clalit Natl Israeli Canc Control Ctr, Haifa, Israel.
[Rennert, Gad] Carmel Hosp, Dept Community Med & Epidemiol, Haifa, Israel.
[Rennert, Gad] B Rappaport Fac Med, Haifa, Israel.
[van den Ouweland, Ans M. W.] Erasmus Univ, Dept Clin Genet, Family Canc Clin, Med Ctr, NL-3000 DR Rotterdam, Netherlands.
[van der Hout, Annemarie H.] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands.
[Kets, Carolien M.] Radboud Univ Nijmegen, Dept Human Genet, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
[Aalfs, Cora M.] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.
[Wijnen, Juul T.; Devillee, Peter] Leiden Univ, Dept Human Genet, Med Ctr, NL-2300 RA Leiden, Netherlands.
[Wijnen, Juul T.] Leiden Univ, Dept Clin Genet, Med Ctr, NL-2300 RA Leiden, Netherlands.
[Ausems, Margreet G. E. M.] Univ Med Ctr Utrecht, Dept Med Genet, Utrecht, Netherlands.
[HEBON] Netherlands Canc Inst, Dept Epidemiol, Amsterdam, Netherlands.
[Jacobs, Chris] Guys & St Thomas NHS Fdn Trust, London, England.
[Adlard, Julian] Yorkshire Reg Genet Serv, Leeds, W Yorkshire, England.
[Tischkowitz, Marc] Univ Cambridge, Dept Med Genet, Cambridge, England.
[Porteous, Mary E.] Western Gen Hosp, South East Scotland Reg Genet Serv, Edinburgh EH4 2XU, Midlothian, Scotland.
[Longy, Michel] Univ Bordeaux, Canc Genet Unit, INSERM U916, Inst Bergonie, Bordeaux, France.
[Ferrer, Sandra Fert] Hotel Dieu Ctr Hosp, Lab Genet Chromosom, Chambery, France.
[Manoukian, Siranoush] Fdn IRCCS Ist Nazl Tumori INT, Unit Med Genet, Dept Prevent & Predict Med, Milan, Italy.
[Barile, Monica] Ist Europeo Oncol, Div Canc Prevent & Genet, Milan, Italy.
[Genuardi, Maurizio] Univ Florence, Fiorgen Fdn Pharmacogenom, Florence, Italy.
[Genuardi, Maurizio] Univ Florence, Unit Med Genet, Dept Clin Physiopathol, Florence, Italy.
[Arnold, Norbert] Univ Kiel, Univ Hosp Schleswig Holstein, Kiel, Germany.
[Meindl, Alfons; Lochmann, Magdalena] Tech Univ Munich, Klinikum Rechts Isar, Dept Obstet & Gynaecol, Div Tumor Genet, D-80290 Munich, Germany.
[Sutter, Christian] Heidelberg Univ, Heidelberg, Germany.
[Friedman, Eitan] Chaim Sheba Med Ctr, Tel Aviv, Israel.
[Jensen, Uffe Birk] Aarhus Univ Hosp, Dept Clin Genet, DK-8000 Aarhus, Denmark.
[Lazaro, Conxi] IDIBELL Catalan Inst Oncol, Hereditary Canc Program, Mol Diagnost Unit, Barcelona, Spain.
[Southey, Melissa C.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia.
[Schmidt, Marjanka K.] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands.
[Fasching, Peter A.] Univ Hosp Erlangen, Univ Breast Ctr Franconia, Dept Gynecol & Obstet, Erlangen, Germany.
[Fasching, Peter A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.
[Peto, Julian] London Sch Hyg & Trop Med, London WC1, England.
[Sawyer, Elinor J.] Guys St Thomas NHS Fdn Trust Partnership Kings Co, Div Canc Studies, NIHR Comprehens Biomed Res Ctr, London, England.
[Burwinkel, Barbara] Heidelberg Univ, Dept Obstet & Gynecol, Heidelberg, Germany.
[Burwinkel, Barbara] German Canc Res Ctr, Mol Epidemiol Grp, Heidelberg, Germany.
[Guenel, Pascal] INSERM, CESP Ctr Res Epidemiol & Populat Health, Environm Epidemiol Canc U1018, Villejuif, France.
[Guenel, Pascal] Univ Paris 11, UMR S 1018, Villejuif, France.
[Bojesen, Stig E.] Copenhagen Gen Populat Study, Copenhagen, Denmark.
[Bojesen, Stig E.] Univ Copenhagen, Dept Clin Biochem, Herlev Hosp, Copenhagen Univ Hosp, Copenhagen, Denmark.
[Brenner, Hermann] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany.
Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany.
Univ Tubingen, Tubingen, Germany.
Deutsch Krebsforschungszentrum DKFZ, Heidelberg, Germany.
German Social Accid Insurance IPA, Inst Prevent & Occupat Med, Bochum, Germany.
Univ Saarland, Inst & Outpatient Clin Occupat Med, Med Ctr, Homburg, Germany.
Univ Saarland, Fac Med, Homburg, Germany.
Univ Bonn, Inst Pathol, Fac Med, Bonn, Germany.
[GENICA Network] Johanniter Krankenhaus, Dept Internal Med, Evangel Kliniken Bonn gGmbH, Bonn, Germany.
[Aittomaki, Kristiina] Univ Helsinki, Cent Hosp, Dept Clin Genet, Helsinki, Finland.
[Doerk, Thilo] Hannover Med Sch, Dept Obstet & Gynecol, Hannover, Germany.
[Margolin, Sara] Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden.
[Mannermaa, Arto] Univ Eastern Finland, Inst Clin Med Pathol & Forens Med, Bioctr Kuopio, Sch Med,Canc Ctr Eastern Finland, Kuopio, Finland.
[Mannermaa, Arto] Kuopio Univ Hosp, Imaging Ctr, Dept Clin Pathol, SF-70210 Kuopio, Finland.
[Lambrechts, Diether] Katholieke Univ Leuven VIB, Vesalius Res Ctr, Louvain, Belgium.
[Lambrechts, Diether] Katholieke Univ Leuven, Lab Translat Genet, Dept Oncol, Louvain, Belgium.
[Chang-Claude, Jenny] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany.
[Giles, Graham G.] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia.
[Giles, Graham G.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia.
[Haiman, Christopher A.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
[Winqvist, Robert] Univ Oulu, Oulu Univ Hosp, Lab Canc Genet & Tumor Biol, Dept Clin Genet, Oulu, Finland.
[Winqvist, Robert] Univ Oulu, Oulu Univ Hosp, Bioctr Oulu, Oulu, Finland.
[Devillee, Peter] Leiden Univ, Dept Pathol, Med Ctr, Leiden, Netherlands.
[Garcia-Closas, Montserrat] Inst Canc Res, Div Genet & Epidemiol, Sutton, Surrey, England.
[Garcia-Closas, Montserrat] Inst Canc Res, Div Breast Canc Res, Sutton, Surrey, England.
[Garcia-Closas, Montserrat; Orr, Nick; Hall, Per] Inst Canc Res, Div Breast Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England.
[Schoof, Nils] Karolinska Inst, Stockholm, Sweden.
[Hooning, Maartje J.] Erasmus Univ, Dept Med Oncol, Med Ctr, Rotterdam, Netherlands.
[Cox, Angela] Univ Sheffield, CRUK YCR Sheffield Canc Res Ctr, Dept Oncol, Sheffield, S Yorkshire, England.
[Jakubowska, Anna] Pomeranian Med Univ, Dept Genet & Pathol, Szczecin, Poland.
[Gonzalez-Neira, Anna; Pita, Guillermo; Rosario Alonso, M.] Spanish Natl Canc Res Ctr CNIO, Human Genotyping CEGEN Unit, Human Canc Genet Program, Madrid, Spain.
[Altshuler, David] Massachusetts Gen Hosp, Dept Mol Biol & Med, Boston, MA 02114 USA.
[Altshuler, David] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA.
[Altshuler, David] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Altshuler, David] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Gaudet, MM (reprint author), Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA.
EM offitk@mskcc.org
RI Klein, Robert/K-1888-2013; Dork, Thilo/J-8620-2012; Brenner,
Hermann/B-4627-2017; manoukian, siranoush/E-7132-2017; Spurdle,
Amanda/A-4978-2011; Jakubowska, Anna/O-8050-2014; Altshuler,
David/A-4476-2009; Verdrengh, Evelien/H-4571-2012; Blanco,
Ignacio/D-2565-2013; Gonzalez-Neira, Anna/C-5791-2015; Garcia-Closas,
Montserrat /F-3871-2015; Osorio, Ana/I-4324-2014; Joseph,
Vijai/J-9158-2013; Radice, Paolo/O-3119-2013; Jansen van Rensburg,
Elizabeth (Lizette)/B-9104-2011; Arnold, Norbert/E-3012-2010; Andrulis,
Irene/E-7267-2013
OI Dennis, Joe/0000-0003-4591-1214; Dunning, Alison
Margaret/0000-0001-6651-7166; Nevanlinna, Heli/0000-0002-0916-2976; Cox,
Angela/0000-0002-5138-1099; Kirchhoff, Tomas/0000-0002-9055-2364;
Jacobs, Chris/0000-0002-9557-9080; Giles, Graham/0000-0003-4946-9099;
VENAT-BOUVET, Laurence/0000-0002-0716-2550; Evans,
Gareth/0000-0002-8482-5784; Klein, Robert/0000-0003-3539-5391; Brenner,
Hermann/0000-0002-6129-1572; manoukian, siranoush/0000-0002-6034-7562;
Barton, David E/0000-0002-2031-9719; Robson, Mark/0000-0002-3109-1692;
Nathanson, Katherine/0000-0002-6740-0901; Spurdle,
Amanda/0000-0003-1337-7897; Barrowdale, Daniel/0000-0003-1661-3939;
Altshuler, David/0000-0002-7250-4107; Blanco,
Ignacio/0000-0002-7414-7481; Garcia-Closas, Montserrat
/0000-0003-1033-2650; Osorio, Ana/0000-0001-8124-3984; Joseph,
Vijai/0000-0002-7933-151X; Arnold, Norbert/0000-0003-4523-8808;
FU University of Eastern Finland; Cancer Fund of North Savo; National
Breast Cancer Foundation; National Health and Medical Research Council
(NHMRC); Queensland Cancer Fund; Cancer Councils of New South Wales,
Victoria; Cancer Councils of New South Wales, Tasmania; Cancer Councils
of New South Wales, South Australia; Cancer Foundation of Western
Australia; United States Army Medical Research and Materiel Command
[DAMD17-01-1-0729]; Cancer Council of Tasmania; NHMRC [199600]; NHMRC;
Cancer Australia [628333]; National R&D Program for Cancer Control,
Ministry for Health, Welfare and Family Affairs, Republic of Korea
[1020350]; Stichting tegen Kanker [232-2008, 196-2010]; FWO;
KULPFV/10/016-SymBioSysII; Deutsche Krebshilfe e.V. [70-2892-BR I];
Hamburg Cancer Society; German Cancer Research Center; Federal Ministry
of Education and Research (BMBF) [01KH0402]; NIH [CA128978, CA63464,
CA54281, CA098758, CA132839]; NCI Specialized Program of Research
Excellence (SPORE) in Breast Cancer [CA116201]; U.S. Department of
Defence Ovarian Cancer Idea award [W81XWH-10-1-0341]; Breast Cancer
Research Foundation; Komen Foundation for the Cure; Fondazione Italiana
per la Ricerca sul Cancro; Italian Association for Cancer Research
(AIRC) [IG 8713]; Italian Ministry of Health ("Progetto Tumori
Femminili"); Italian citizens; Fondazione IRCCS Istituto Nazionale
Tumori; VicHealth and Cancer Council Victoria; Australian NHMRC [209057,
251553, 504711]; Jewish General Hospital; Niehaus Clinical Cancer
Genetics Initiative; Andrew Sabin Family Foundation; Lymphoma
Foundation; Quebec Breast Cancer Foundation; Canadian Institutes of
Health Research [CRN-87521]; Ministry of Economic Development,
Innovation and Export Trade [PSR-SIIRI-701]; Intramural Research Program
of the US National Cancer Institute, NIH; Westat, Rockville, MD
[NO2-CP-11019-50, N02-CP-65504]; Clalit Health Services in Israel;
Israel Cancer Association; Breast Cancer Research Foundation (BCRF);
Russian Federation for Basic Research [11-04-00227, 12-04-00928,
12-04-01490]; Federal Agency for Science and Innovations, Russia
[02.740.11.0780]; Finnish Cancer Foundation; Academy of Finland;
University of Oulu; Oulu University Hospital; Dutch Cancer Society [RUL
1997-1505, DDHK 2004-3124, DDHK 2009-4318]; Biobanking and Biomolecular
Resources Research Infrastructure [BBMRI-NL CP16]; Ohio State University
Comprehensive Cancer Center; Ministry of Science, Technology and
Innovation, Ministry of Higher Education [UM.C/HlR/MOHE/06]; Cancer
Research Initiatives Foundation; National Cancer Institute, Department
of Health and Human Services, USA; Marit and Hans Rausings Initiative
Against Breast Cancer; Agency for Science, Technology and Research of
Singapore (A*STAR); U.S. National Institute of Health (NIH); Susan G.
Komen Breast Cancer Foundation; Yorkshire Cancer Research [S295, S299,
S305PA]; Malaysian Ministry of Science, Technology and Innovation;
Ministry of Higher Education [UM.C/HIR/MOHE/06]; Cancer Research UK
[[C490/A10124][C8197/A10123]; Swedish Cancer Society; U.S. National
Cancer Institute (NIH/NCI); Ralph and Marion Falk Medical Research
Trust; Entertainment Industry Fund National Women's Cancer Research
Alliance,; Jonsson Comprehensive Cancer Center Foundation; UCSF Cancer
Risk Program; Helen Diller Family Comprehensive Cancer Center;
Breakthrough Breast Cancer; Institute of Cancer Research (ICR); NHS;
CRUK; National Institutes of Health (NIH) [R01-CA102776, R01-CA083855];
Rooney Family Foundation; Susan G. Komen Foundation for the Cure;
Facdonald Family Foundation; Victorian Cancer Agency; Cancer Australia;
American Cancer Society [SIOP-06-258-01-COUN]; Ligue National Contre le
Cancer; Association "Le cancer du sein, parlons-en!" Award; Canadian
Institutes of Health Research for the "CIHR Team in Familial Risks of
Breast Cancer" program; [C8197/A10865]; [PBZ_KBN_122/P05/2004]
FX Hospital grants, Cancer Fund of North Savo, the Finnish Cancer
Organizations, the Academy of Finland, and by the strategic funding of
the University of Eastern Finland. Kathleen Cuningham Consortium for
Research into Familial Breast Cancer: kConFab is supported by grants
from the National Breast Cancer Foundation and the National Health and
Medical Research Council (NHMRC) and by the Queensland Cancer Fund; the
Cancer Councils of New South Wales, Victoria, Tasmania, and South
Australia; and the Cancer Foundation of Western Australia. G
Chenevix-Trench and AB Spurdle are NHMRC Senior Research Fellows.
Financial support for the AOCS was provided by the United States Army
Medical Research and Materiel Command [DAMD17-01-1-0729], the Cancer
Council of Tasmania and Cancer Foundation of Western Australia, and the
NHMRC [199600]. G Chenevix-Trench is supported by the NHMRC. The
Clinical Follow Up Study (funded 2001-2009 by NHMRC and currently by the
National Breast Cancer Foundation and Cancer Australia #628333) Korean
Hereditary Breast Cancer Study: KOHBRA is supported by a grant from the
National R&D Program for Cancer Control, Ministry for Health, Welfare
and Family Affairs, Republic of Korea (1020350). Leuven
Multidisciplinary Breast Centre: LMBC is supported by the 'Stichting
tegen Kanker' (232-2008 and 196-2010). D Lambrechts is supported by the
FWO and the KULPFV/10/016-SymBioSysII. Mammary Carcinoma Risk Factor
Investigation: The MARIE study was supported by the Deutsche Krebshilfe
e.V. [70-2892-BR I], the Hamburg Cancer Society, the German Cancer
Research Center, and the genotype work in part by the Federal Ministry
of Education and Research (BMBF) Germany [01KH0402]. Mayo Clinic: MAYO
is supported by NIH grant CA128978, an NCI Specialized Program of
Research Excellence (SPORE) in Breast Cancer (CA116201), a U.S.
Department of Defence Ovarian Cancer Idea award (W81XWH-10-1-0341), and
grants from the Breast Cancer Research Foundation and the Komen
Foundation for the Cure. Milan Breast Cancer Study Group: MBCSG was
funded by grants from Fondazione Italiana per la Ricerca sul Cancro
(Special Project "Hereditary tumors"), Italian Association for Cancer
Research (AIRC, IG 8713), Italian Ministry of Health ("Progetto Tumori
Femminili"), and by Italian citizens who allocated the 561000 share of
their tax payment in support of the Fondazione IRCCS Istituto Nazionale
Tumori, according to Italian laws (INT-Institutional strategic projects
"5 x 1000"). Melbourne Collaborative Cohort Study: MCCS cohort
recruitment was funded by VicHealth and Cancer Council Victoria. The
MCCS was further supported by Australian NHMRC grants 209057, 251553 and
504711 and by infrastructure provided by Cancer Council Victoria. McGill
University: The McGill Study was supported by Jewish General Hospital
Weekend to End Breast Cancer, Quebec Ministry of Economic Development,
Innovation and Export Trade. Multi-Ethnic Cohort: The MEC was supported
by NIH grants CA63464, CA54281, CA098758, and CA132839. Memorial
Sloan-Kettering Cancer Center: The MSKCC was supported by Breast Cancer
Research Foundation, Niehaus Clinical Cancer Genetics Initiative, Andrew
Sabin Family Foundation, and Lymphoma Foundation. Montreal
Gene-Environment Breast Cancer Study: The work of MTLGEBCS was supported
by the Quebec Breast Cancer Foundation, the Canadian Institutes of
Health Research for the "CIHR Team in Familial Risks of Breast Cancer"
program grant CRN-87521 and the Ministry of Economic Development,
Innovation and Export Trade grant PSR-SIIRI-701.; J Simard is
Chairholder of the Canada Research Chair in Oncogenetics. National
Cancer Institute: The research of MH Greene and PL Mai was supported by
the Intramural Research Program of the US National Cancer Institute,
NIH, and by support services contracts NO2-CP-11019-50 and N02-CP-65504
with Westat, Rockville, MD. National Israeli Cancer Control Center:
NICCC is supported by Clalit Health Services in Israel. Some of its
activities are supported by the Israel Cancer Association and the Breast
Cancer Research Foundation (BCRF), New York. N. N. Petrov Institute of
Oncology: The NNPIO study has been supported by the Russian Federation
for Basic Research (grants 11-04-00227, 12-04-00928, and 12-04-01490)
and the Federal Agency for Science and Innovations, Russia (contract
02.740.11.0780). Oulu Breast Cancer Study: The OBCS was supported by
research grants from the Finnish Cancer Foundation, the Academy of
Finland, the University of Oulu, and the Oulu University Hospital.
Leiden University Medical Centre Breast Cancer Study: The ORIGO study
was supported by the Dutch Cancer Society (RUL 1997-1505) and the
Biobanking and Biomolecular Resources Research Infrastructure (BBMRI-NL
CP16). The Ohio State University Comprehensive Cancer Center: OSUCCG is
supported by the Ohio State University Comprehensive Cancer Center.
SEABASS is supported by the Ministry of Science, Technology and
Innovation, Ministry of Higher Education (UM.C/HlR/MOHE/06) and Cancer
Research Initiatives Foundation. The U. S. National Cancer Institute
Polish Breast Cancer Study: The PBCS was funded by Intramural Research
Funds of the National Cancer Institute, Department of Health and Human
Services, USA. Karolinska Mammography Project for Risk Prediction of
Breast Cancer - prevalent cases: The pKARMA study was supported by Marit
and Hans Rausings Initiative Against Breast Cancer. Rotterdam Breast
Cancer Study: The RBCS was funded by the Dutch Cancer Society (DDHK
2004-3124, DDHK 2009-4318). Singapore and Sweden Breast Cancer Study:
The SASBAC study was supported by funding from the Agency for Science,
Technology and Research of Singapore (A*STAR), the U.S. National
Institute of Health (NIH), and the Susan G. Komen Breast Cancer
Foundation. Sheffield Breast Cancer Study: The SBCS was supported by
Yorkshire Cancer Research S295, S299, and S305PA. South East Asian
Breast Cancer Association Study: SEABASS is supported by the Ministry of
Science, Technology and Innovation, Ministry of Higher Education
(UM.C/HlR/MOHE/06) and Cancer Research Initiatives Foundation. The
Malaysian Breast Cancer Genetic Study is funded by research grants from
the Malaysian Ministry of Science, Technology and Innovation; Ministry
of Higher Education (UM.C/HIR/MOHE/06);and charitable funding from
Cancer Research Initiatives Foundation. Study of Epidemiology and Risk
Factors in Cancer Heredity: SEARCH is funded by programmegrants from
Cancer Research UK [C490/A10124][C8197/A10123]. AM Dunning was funded by
[C8197/A10865]. Sheba Medical Centre: The SMC study was partially funded
through a grant by the Israel Cancer Association and the funding for the
Israeli Inherited Breast Cancer Consortium. Swedish Breast Cancer Study:
SWE-BRCA collaborators are supported by the Swedish Cancer Society.
IHCC-Szczecin Breast Cancer Study: The SZBCS was supported by Grant
PBZ_KBN_122/P05/2004. The University of Chicago Center for Clinical
Cancer Genetics and Global Health: UCHICAGO is supported by grants from
the U.S.; National Cancer Institute (NIH/NCI) and by the Ralph and
Marion Falk Medical Research Trust, the Entertainment Industry Fund
National Women's Cancer Research Alliance, and the Breast Cancer
Research Foundation. University of California Los Angeles: The UCLA
study was supported by the Jonsson Comprehensive Cancer Center
Foundation and the Breast Cancer Research Foundation. University of
California San Francisco: The UCSF study was supported by the UCSF
Cancer Risk Program and the Helen Diller Family Comprehensive Cancer
Center. United Kingdom Breakthrough Generations Study: The UKBGS is
funded by Breakthrough Breast Cancer and the Institute of Cancer
Research (ICR). ICR acknowledges NHS funding to the NIHR Biomedical
Research Centre. United Kingdom Familial Ovarian Cancer Registries:
UKFOCR was supported by a project grant from CRUK to PDP Pharoah.
University of Pennsylvania: The UPENN study was supported by the
National Institutes of Health (NIH) (R01-CA102776 and R01-CA083855),
Breast Cancer Research Foundation, Rooney Family Foundation, Susan G.
Komen Foundation for the Cure, and the Facdonald Family Foundation.
Victorian Familial Cancer Trials Group: The VFCTG study was supported by
the Victorian Cancer Agency, Cancer Australia, and National Breast
Cancer Foundation. Women's Cancer Program: The WCP at the Samuel Oschin
Comprehensive Cancer Institute is funded by the American Cancer Society
Early Detection Professorship (SIOP-06-258-01-COUN). Genetic Modifiers
of Cancer Risk in BRCA1/2 Mutation Carriers (GEMO) study: The study was
supported by the Ligue National Contre le Cancer, the Association "Le
cancer du sein, parlons-en!" Award, and the Canadian Institutes of
Health Research for the "CIHR Team in Familial Risks of Breast Cancer"
program. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 34
TC 51
Z9 51
U1 3
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7390
EI 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD MAR
PY 2013
VL 9
IS 3
AR e1003173
DI 10.1371/journal.pgen.1003173
PG 15
WC Genetics & Heredity
SC Genetics & Heredity
GA 116EY
UT WOS:000316866700001
PM 23544012
ER
PT J
AU Baruch, L
AF Baruch, Lawrence
TI Laboratory Monitoring of Anticoagulant Medications: Focus on Novel Oral
Anticoagulants
SO POSTGRADUATE MEDICINE
LA English
DT Article
DE apixaban; coagulation assays; dabigatran; edoxaban; rivaroxaban
ID INDUCED CLOTTING TIME; FACTOR-XA INHIBITOR; DIRECT THROMBIN INHIBITORS;
PATHOLOGISTS CONFERENCE XXXI; ECARIN CHROMOGENIC ASSAY; NONVALVULAR
ATRIAL-FIBRILLATION; PARTIAL THROMBOPLASTIN TIME; DIRECT FXA-INHIBITORS;
HEALTHY MALE-SUBJECTS; DABIGATRAN ETEXILATE
AB Novel oral anticoagulants, direct thrombin inhibitors, and factor Xa inhibitors are being introduced into clinical practice. In contrast to vitamin K antagonists, such as warfarin, these novel agents, because of their relatively wide therapeutic range and predictable pharmacokinetics, have been evaluated in clinical trials and approved for clinical use without the need for routine coagulation monitoring. On occasion, it will be important to assess the anticoagulant status of patients treated with these agents. As a result of their targeted mechanisms of action, they affect standard coagulation assays differently than vitamin K antagonists and heparins, and such assay results may not provide clinically useful information. Thus, less commonly used coagulation assays (eg, chromogenic anti-factor Xa activity assays, diluted thrombin time, and ecarin-based clotting tests) may be introduced into clinical practice. These assays are currently limited by the absence of validated therapeutic targets and lack of standardization across laboratories, vendors, and medication classes. This article provides an overview of the coagulation assays and their potential role in determining the anticoagulant status of patients treated with the emerging anticoagulants.
C1 James J Peters VA Med Ctr, Program Med, Bronx, NY 10468 USA.
RP Baruch, L (reprint author), James J Peters VA Med Ctr, Program Med, Bronx, NY 10468 USA.
FU Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)
FX This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc.
(BIPI). Editorial assistance was provided by Annie Rowe, PhD, CMPP, of
UBC-Envision Group, which was contracted by BIPI for these services. The
author meets criteria for authorship as recommended by the International
Committee of Medical Journal Editors (ICMJE), was fully responsible for
all content and editorial decisions, and was involved at all stages of
manuscript development. The author received no compensation related to
the development of the manuscript.
NR 70
TC 2
Z9 2
U1 0
U2 4
PU JTE MULTIMEDIA
PI WEST CONSHOHOCKEN
PA 18 ELIZABETH ST, STE 110, WEST CONSHOHOCKEN, PA 19428 USA
SN 0032-5481
EI 1941-9260
J9 POSTGRAD MED
JI Postgrad. Med.
PD MAR
PY 2013
VL 125
IS 2
DI 10.3810/pgm.2013.03.2647
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA AX2SJ
UT WOS:000346794200013
PM 23816779
ER
PT J
AU Schunemann, HJ
Tugwell, P
Reeves, BC
Akl, EA
Santesso, N
Spencer, FA
Shea, B
Wells, G
Helfand, M
AF Schuenemann, Holger J.
Tugwell, Peter
Reeves, Barnaby C.
Akl, Elie A.
Santesso, Nancy
Spencer, Frederick A.
Shea, Beverley
Wells, George
Helfand, Mark
TI Non-randomized studies as a source of complementary, sequential or
replacement evidence for randomized controlled trials in systematic
reviews on the effects of interventions
SO RESEARCH SYNTHESIS METHODS
LA English
DT Review
DE GRADE; observational studies; non randomized studies; decision making;
systematic reviews
AB The terms applicability, generalizability, external validity and transferability are related, sometimes used interchangeably and have in common that they lack a clear and consistent definition in the classic epidemiological literature. However, all of these terms generally describe one overarching theme: whether or not available research evidence can be directly utilized to answer the healthcare questions at hand, ideally supported by a judgment about the degree of confidence for this utilization. This concept has been called directness. The objectives of this paper were to delineate how non-randomized studies (NRS) inform judgments in relation to directness and the concepts that it encompasses in the context of systematic reviews. We will briefly review what is known and describe the theoretical and practical issues as well as offer guidance to those tackling the challenges of judging directness and using research evidence to answer healthcare questions with evidence from NRS.
In particular, we suggest a framework in which authors can use NRS as a complement, sequence or replacement for randomized controlled trials (RCTs) by focusing on judgments about the population, intervention, comparison and outcomes. Authors of systematic reviews will use NRS to complement judgments about the inconsistencies, the rationale and credibility of subgroup analysis, the baseline risk estimates for the determination of absolute benefits and downsides, and the directness of surrogate outcomes. This evidence includes contextual or supplementary evidence. Authors of systematic review and other summaries of the evidence use NRS as sequential evidence to provide evidence when insufficient evidence is available for an outcome from RCTs, but NRS evidence is available (e.g., long-term harms). Use of evidence from NRS may also serve to replace RCT evidence when NRS provide equivalent (or potentially higher) confidence in the evidence (i.e. quality) compared to indirect evidence from RCTs. These judgments will be made in the context of other domains that influence the overall quality of the body of evidence, including the risk of bias, publication bias (i.e. limitations in the detailed study design and execution), inconsistency, imprecision and factors that increase our confidence in effects.
This article will support systematic reviewers in their interaction with decision makers, that is, those who use the systematic review to develop guidelines, address health policy makers, and make clinical decisions, by making these judgments transparent. Copyright (C) 2013 John Wiley & Sons, Ltd.
C1 [Schuenemann, Holger J.; Akl, Elie A.; Santesso, Nancy] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4K1, Canada.
[Schuenemann, Holger J.; Spencer, Frederick A.] McMaster Univ, Dept Med, Hamilton, ON L8S 4K1, Canada.
[Tugwell, Peter; Shea, Beverley; Wells, George] Ottawa Hosp, Res Inst, Clin Epidemiol Unit, Ottawa, ON, Canada.
[Reeves, Barnaby C.] Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol, Avon, England.
[Akl, Elie A.] Amer Univ Beirut, Dept Internal Med, Beirut, Lebanon.
[Helfand, Mark] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97201 USA.
[Helfand, Mark] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
RP Schunemann, HJ (reprint author), McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Room 2C10B,1280 Main St W, Hamilton, ON L8S 4K1, Canada.
EM schuneh@mcmaster.ca
FU Agency for Healthcare Quality and Research (through the Ottawa
Collaborating Centre of the Agency for Healthcare Quality and Research);
Cochrane Collaboration Discretionary Fund; UK National Institute for
Health Research Bristol Cardiovascular Biomedical Research Unit
FX The Workshop was supported financially by the Agency for Healthcare
Quality and Research (through the Ottawa Collaborating Centre of the
Agency for Healthcare Quality and Research) and by a grant from the
Cochrane Collaboration Discretionary Fund. BCR is supported in part by
the UK National Institute for Health Research Bristol Cardiovascular
Biomedical Research Unit. The views expressed in this article are those
of the authors and not necessarily those of the funding bodies, The
Cochrane Collaboration or its registered entities, committees or working
groups, The Campbell Collaboration or the Patient Centered Outcomes
Research Institute.
NR 20
TC 22
Z9 22
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1759-2879
EI 1759-2887
J9 RES SYNTH METHODS
JI Res. Synth. Methods
PD MAR
PY 2013
VL 4
IS 1
SI SI
BP 49
EP 62
DI 10.1002/jrsm.1078
PG 14
WC Mathematical & Computational Biology; Multidisciplinary Sciences
SC Mathematical & Computational Biology; Science & Technology - Other
Topics
GA V38ZN
UT WOS:000209381400006
PM 26053539
ER
PT J
AU McDermott, S
Gervais, DA
AF McDermott, Shaunagh
Gervais, Debra A.
TI Radiofrequency Ablation of Liver Tumors
SO SEMINARS IN INTERVENTIONAL RADIOLOGY
LA English
DT Article
DE radiofrequency ablation; liver; hepatocellular carcinoma; metastases;
technique
AB Radiofrequency ablation (RFA) is an alternative therapy for hepatocellular carcinoma and liver metastases when resection cannot be performed or, in the case of hepatocellular carcinoma, when transplant cannot be performed in a timely enough manner to avoid the risk of dropping off the transplant list. RFA has the advantage of being a relatively low-risk minimally invasive procedure used in the treatment of focal liver tumors. This review article discusses the current evidence supporting RFA of liver tumors, as well as the indications, complications, and follow-up algorithms used after RFA.
C1 [McDermott, Shaunagh; Gervais, Debra A.] Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent Radiol, Dept Radiol, Boston, MA 02114 USA.
[Gervais, Debra A.] Massachusetts Gen Hosp, Dept Radiol, Div Pediat Imaging, Boston, MA 02114 USA.
RP McDermott, S (reprint author), Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent Radiol, Dept Radiol, 55 Fruit St,White 270, Boston, MA 02114 USA.
EM smcdermott1@partners.org
NR 51
TC 10
Z9 11
U1 0
U2 0
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0739-9529
J9 SEMIN INTERVENT RAD
JI Semin. Interv. Radiol.
PD MAR
PY 2013
VL 30
IS 1
BP 49
EP 55
DI 10.1055/s-0033-1333653
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA V40YD
UT WOS:000209513000007
PM 24436517
ER
PT J
AU Liu, SY
Buka, SL
Kubzansky, LD
Kawachi, I
Gilman, SE
Loucks, EB
AF Liu, Sze Yan
Buka, Stephen L.
Kubzansky, Laura D.
Kawachi, Ichiro
Gilman, Stephen E.
Loucks, Eric B.
TI Sheepskin effects of education in the 10-year Framingham risk of
coronary heart disease
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Article
DE CHD risk; Education; Sheepskin effect
AB While the association between education and adult health is well documented, it is unclear whether quantity (i.e. years of schooling) or credentials (i.e. degrees) drive this association. Individuals with degrees may have better health than their non-credentialed counterparts given similar years of schooling, the so-called "sheepskin" effect. This paper contributes to this line of inquiry by examining associations of educational degree and years of schooling with the Framingham Risk Score, a measure of 10-year risk of coronary heart disease (CHD), using data from a unique birth cohort (the New England Family Study; participants mean age 42 years) with prospective information on childhood health and intelligence quotient (IQ). According to our results, years of schooling were inversely associated with 10-year CHD risk in the unadjusted model but not in the fully adjusted models that included degree attainment. By contrast, associations between degree attainment and 10-year CHD risk remained significant in the fully adjusted models that included years of schooling. College degree holders had 10-year CHD risk 19% (95% CI: -33%, -2%) lower than individuals with HS degrees or less in the fully adjusted models. Subanalyses evaluating sheepskin effects on the individual components of the 10-year CHD risk algorithm showed the expected education gradient was generally noted for each of the individual components, with decreasing prevalence of "high risk" values associated with higher degree credentials. Our results suggest educational credentials provide an additional benefit to risk of coronary heart disease beyond schooling. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Liu, Sze Yan; Buka, Stephen L.; Kubzansky, Laura D.; Kawachi, Ichiro; Gilman, Stephen E.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
[Buka, Stephen L.; Loucks, Eric B.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA.
[Gilman, Stephen E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Gilman, Stephen E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
RP Liu, SY (reprint author), Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, 677 Huntington Ave, Boston, MA 02115 USA.
EM szeliu@harvard.hsph.edu
RI Buka, Stephen/H-7335-2014; Gilman, Stephen/E-7632-2010; Loucks,
Eric/I-1272-2014
OI Buka, Stephen/0000-0002-8578-9308; Gilman, Stephen/0000-0002-8331-6419;
Loucks, Eric/0000-0002-9962-0386
FU NIA NIH HHS [R01 AG023397]; NICHD NIH HHS [R24 HD041020]
NR 36
TC 3
Z9 3
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD MAR
PY 2013
VL 80
BP 31
EP 36
DI 10.1016/j.socscimed.2012.12.026
PG 6
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA V39YW
UT WOS:000209447300005
PM 23415589
ER
PT J
AU Caspi, CE
Kawachi, I
Subramanian, SV
Tucker-Seeley, R
Sorensen, G
AF Caspi, Caitlin E.
Kawachi, Ichiro
Subramanian, S. V.
Tucker-Seeley, Reginald
Sorensen, Glorian
TI The social environment and walking behavior among low-income housing
residents
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Article
DE USA; Environment; Social capital; Safety; Social disorder; Physical
activity; Low-income housing
AB Walking, both for leisure and for travel/errands, counts toward meeting physical activity recommendations. Both social and physical neighborhood environmental features may encourage or inhibit walking. This study examined social capital, perceived safety, and disorder in relation to walking behavior among a population of low-income housing residents. Social and physical disorder were assessed by systematic social observation in the area surrounding 20 low-income housing sites in greater Boston. A cross-sectional survey of 828 residents of these housing sites provided data on walking behavior, socio-demographics, and individual-level social capital and perceived safety of the areas in and around the housing site. Community social capital and safety were calculated by aggregating individual scores to the level of the housing site. Generalized estimating equations were used to estimate prevalence rate ratios for walking less than 10 min per day for a) travel/errands, b) leisure and c) both travel/errands and leisure. 21.8% of participants walked for travel/errands less than 10 min per day, 34.8% for leisure, and 16.8% for both kinds of walking. In fully adjusted models, those who reported low individual-level social capital and safety also reported less overall walking and less walking for travel/errands. Unexpectedly, those who reported low social disorder also reported less walking for leisure, and those who reported high community social capital also walked less for all outcomes. Physical disorder and community safety were not associated with walking behavior. For low-income housing residents, neighborhood social environmental variables are unlikely the most important factors in determining walking behavior. Researchers should carefully weigh the respective limitations of subjective and objective measures of the social environment when linking them to health outcomes. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Caspi, Caitlin E.; Kawachi, Ichiro; Subramanian, S. V.; Tucker-Seeley, Reginald; Sorensen, Glorian] Harvard Univ, Sch Publ Hlth, Boston, MA 02114 USA.
[Tucker-Seeley, Reginald; Sorensen, Glorian] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA.
RP Caspi, CE (reprint author), Harvard Univ, Sch Publ Hlth, 677 Huntingon Ave, Boston, MA 02114 USA.
EM caitlincaspi@gmail.com
FU National Cancer Institute [5R01CA111310-04]; National Cancer Institute
by the Harvard Education Program in Cancer Prevention and Control
[5R25CA057711-17, 2R25CA057711-16]
FX We gratefully acknowledge the efforts of the Health in Common Research
Team: Anne Stoddard, Jennifer Allen, Amy Harley, Marty Alvarez-Reeves,
Brianna Wadler, Brittany Bricen, Suze Jean-Felix, May Yang, David
Wilson, and Ruth Lederman. The authors also thank the Cambridge Housing
Authority, the Somerville Housing Authority, and the Chelsea Housing
Authority, the resident participants and resident service coordinators
at collaborating housing site. This research was supported by Grant
5R01CA111310-04 from the National Cancer Institute. Funding support for
the lead author (CC) was also provided through the National Cancer
Institute by the Harvard Education Program in Cancer Prevention and
Control 5R25CA057711-17 and 2R25CA057711-16. Funding agencies played no
role in this study and the contents of this manuscript are solely the
responsibility of the authors.
NR 62
TC 7
Z9 7
U1 2
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD MAR
PY 2013
VL 80
BP 76
EP 84
DI 10.1016/j.socscimed.2012.11.030
PG 9
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA V39YW
UT WOS:000209447300010
PM 23312303
ER
PT J
AU Guanci, MM
AF Guanci, Mary McKenna
TI Olympic Cooling Cap for Neonatal Hypoxic Arrest
SO THERAPEUTIC HYPOTHERMIA AND TEMPERATURE MANAGEMENT
LA English
DT Letter
C1 Massachusetts Gen Hosp, Neurosci ICU, Boston, MA 02114 USA.
RP Guanci, MM (reprint author), Massachusetts Gen Hosp, Neurosci ICU, Boston, MA 02114 USA.
NR 6
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2153-7658
EI 2153-7933
J9 THER HYPOTHERMIA TEM
JI Ther. Hypothermia Temp. Manag.
PD MAR 1
PY 2013
VL 3
IS 1
BP 34
EP 35
PG 2
WC Critical Care Medicine
SC General & Internal Medicine
GA V38PZ
UT WOS:000209356600014
ER
PT J
AU Sweeney, AC
Weitlauf, JC
Manning, EA
Sze, JA
Waldrop, AE
Hasser, C
AF Sweeney, Alison C.
Weitlauf, Julie C.
Manning, Elizabeth A.
Sze, Jocelyn A.
Waldrop, Angela E.
Hasser, Caitlin
TI Intimate Partner Violence: Perspectives on Universal Screening for Women
in VHA Primary Care
SO WOMENS HEALTH ISSUES
LA English
DT Editorial Material
ID POSTTRAUMATIC-STRESS-DISORDER; MILITARY SEXUAL TRAUMA; MENTAL-HEALTH;
UNINTENDED PREGNANCY; DOMESTIC VIOLENCE; FEMALE-PATIENTS; VETERANS;
PREVALENCE; DEPRESSION; SYMPTOMS
C1 [Sweeney, Alison C.] Michael E DeBakey VA Med Ctr, Dept Vet Affairs, Houston, TX 77030 USA.
[Weitlauf, Julie C.; Manning, Elizabeth A.] VA Palo Alto Hlth Care Syst, Dept Vet Affairs, Palo Alto, CA USA.
[Weitlauf, Julie C.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
[Sze, Jocelyn A.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA.
[Waldrop, Angela E.; Hasser, Caitlin] Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA USA.
RP Sweeney, AC (reprint author), Michael E DeBakey VA Med Ctr, Dept Vet Affairs, 2002 Holcombe Blvd 116B, Houston, TX 77030 USA.
EM alison.sweeney@va.gov
NR 61
TC 5
Z9 5
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD MAR-APR
PY 2013
VL 23
IS 2
BP E73
EP E76
DI 10.1016/j.whi.2012.12.004
PG 4
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA AO1WD
UT WOS:000341105300002
PM 23415320
ER
PT J
AU Yuen, EK
Herbert, JD
Forman, EM
Goetter, EM
Comer, R
Bradley, JC
AF Yuen, Erica K.
Herbert, James D.
Forman, Evan M.
Goetter, Elizabeth M.
Comer, Ronald
Bradley, Jean-Claude
TI Treatment of Social Anxiety Disorder Using Online Virtual Environments
in Second Life
SO BEHAVIOR THERAPY
LA English
DT Article
DE social anxiety; virtual reality; Second Life; telehealth; telepsychology
ID COGNITIVE-BEHAVIORAL THERAPY; CONTROLLED EFFECTIVENESS TRIAL; NEGATIVE
EVALUATION SCALE; SHEEHAN DISABILITY SCALE; REALITY EXPOSURE THERAPY;
DEPRESSION INVENTORY-II; COMMITMENT THERAPY; UNITED-STATES; CONCURRENT
VALIDITY; PANIC DISORDER
AB Over 80% of people with social anxiety disorder (SAD) do not receive any type of treatment, despite the existence of effective evidence-based treatments. Barriers to treatment include lack of trained therapists (particularly in non-metropolitan areas), logistical difficulties (e.g., cost, time, transportation), concerns regarding social stigma, and fear of negative evaluation from health care providers. Interventions conducted through electronic communication media, such as the Internet, have the potential to reach individuals who otherwise would not have access to evidence-based treatments. Second Life is an online virtual world that holds great promise in the widespread delivery of evidence-based treatments. We assessed the feasibility, acceptability, and initial efficacy of an acceptance-based behavior therapy in Second Life to treat adults with generalized SAD. Participants (n=14) received 12 sessions of weekly therapy and were assessed at pretreatment, midtreatment, post-treatment, and follow-up. Participants and therapists rated the treatment program as acceptable and feasible, despite frequently encountered technical difficulties. Analyses showed significant pretreatment to follow-up improvements in social anxiety symptoms, depression, disability, and quality of life, with effect sizes comparable to previously published results of studies delivering in-person cognitive behavior therapy for SAD. Implications and future directions are discussed.
C1 [Yuen, Erica K.] Med Univ S Carolina, Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA.
[Herbert, James D.] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA.
RP Herbert, JD (reprint author), Univ Penn, Dept Psychol, 119 Stratton,1341 Chestnut St, Philadelphia, PA 19104 USA.
EM james.herbert@drexel.edu
RI Forman, Evan/I-1042-2012;
OI Bradley, Jean-Claude/0000-0001-7144-4846
NR 68
TC 19
Z9 19
U1 10
U2 85
PU ASSOC ADV BEHAVIOR THERAPY
PI NEW YORK
PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA
SN 0005-7894
J9 BEHAV THER
JI Behav. Therapy
PD MAR
PY 2013
VL 44
IS 1
BP 51
EP 61
PG 11
WC Psychology, Clinical
SC Psychology
GA 074XW
UT WOS:000313849400005
PM 23312426
ER
PT J
AU Shenhav, A
Barrett, LF
Bar, M
AF Shenhav, Amitai
Barrett, Lisa Feldman
Bar, Moshe
TI Affective value and associative processing share a cortical substrate
SO COGNITIVE AFFECTIVE & BEHAVIORAL NEUROSCIENCE
LA English
DT Article
DE Valence; Context; Prefrontal cortex; Object recognition
ID VENTROMEDIAL PREFRONTAL CORTEX; MEDIAL ORBITOFRONTAL CORTEX; BRAINS
DEFAULT NETWORK; HUMAN CEREBRAL-CORTEX; DECISION-MAKING; SELECTIVE
ATTENTION; MACAQUE MONKEYS; MEMORY; EMOTION; CONTEXT
AB The brain stores information in an associative manner so that contextually related entities are connected in memory. Such associative representations mediate the brain's ability to generate predictions about which other objects and events to expect in a given context. Likewise, the brain encodes and is able to rapidly retrieve the affective value of stimuli in our environment. That both contextual associations and affect serve as building blocks of numerous mental functions often makes interpretation of brain activation ambiguous. A critical brain region where such activation has often resulted in equivocal interpretation is the medial orbitofrontal cortex (mOFC), which has been implicated separately in both affective and associative processing. To characterize its role more unequivocally, we tested whether activity in the mOFC was most directly attributable to affective processing, associative processing, or a combination of both. Subjects performed an object recognition task while undergoing fMRI scans. Objects varied independently in their affective valence and in their degree of association with other objects (associativity). Analyses revealed an overlapping sensitivity whereby the left mOFC responded both to increasingly positive affective value and to stronger associativity. These two properties individually accounted for mOFC response, even after controlling for their interrelationship. The role of the mOFC is either general enough to encompass associations that link stimuli both with reinforcing outcomes and with other stimuli or abstract enough to use both valence and associativity in conjunction to inform downstream processes related to perception and action. These results may further point to a fundamental relationship between associativity and positive affect.
C1 [Shenhav, Amitai] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA.
[Shenhav, Amitai; Barrett, Lisa Feldman; Bar, Moshe] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Boston, MA 02129 USA.
[Barrett, Lisa Feldman; Bar, Moshe] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02129 USA.
[Barrett, Lisa Feldman] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA.
[Bar, Moshe] Bar Ilan Univ, Gonda Ctr Multidisciplinary Brain Res, IL-52900 Ramat Gan, Israel.
[Shenhav, Amitai] Princeton Univ, Princeton Neurosci Inst, Princeton, NJ 08540 USA.
RP Shenhav, A (reprint author), Princeton Univ, Princeton Neurosci Inst, Green Hall 3-N-12, Princeton, NJ 08540 USA.
EM ashenhav@princeton.edu
FU NSF [0842947]; National Institutes of Health [DP1OD003312]; NIH
[R01EY019477]
FX Note We are grateful to J. Boshyan, M. Rosen, and K. Shepherd for
assistance in data collection, T. Benner for technical guidance, E.
Aminoff for assistance in stimulus collection, and S. Gagnon for
assistance with analysis and helpful comments on the manuscript. This
work was supported by an NSF Graduate Research Fellowship awarded to
A.S., National Institutes of Health Director's Pioneer Award
(DP1OD003312) to L.F.B., and NIH R01EY019477 and NSF 0842947 to M.B.
NR 98
TC 15
Z9 15
U1 5
U2 35
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-7026
J9 COGN AFFECT BEHAV NE
JI Cogn. Affect. Behav. Neurosci.
PD MAR
PY 2013
VL 13
IS 1
BP 46
EP 59
DI 10.3758/s13415-012-0128-4
PG 14
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 077VW
UT WOS:000314058400004
PM 23090717
ER
PT J
AU Psutka, SP
Feldman, AS
McDougal, WS
McGovern, FJ
Mueller, P
Gervais, DA
AF Psutka, Sarah P.
Feldman, Adam S.
McDougal, W. Scott
McGovern, Francis J.
Mueller, Peter
Gervais, Debra A.
TI Long-Term Oncologic Outcomes After Radiofrequency Ablation for T1 Renal
Cell Carcinoma
SO EUROPEAN UROLOGY
LA English
DT Article
DE Radiofrequency ablation; Renal cell carcinoma; Small renal masses; Renal
mass biopsy; Disease-specific survival
ID RADIO-FREQUENCY ABLATION; PARTIAL NEPHRECTOMY; THERMAL ABLATION;
FOLLOW-UP; MASSES; METAANALYSIS; EXPERIENCE; TUMORS; CRYOABLATION;
SURVEILLANCE
AB Background: Radiofrequency ablation(RFA) of renal cell carcinoma(RCC) is used to obtain local control of small renal masses. However, available long-term oncologic outcomes for RFA of RCC are limited by small numbers, short follow-up, and lack of pathologic diagnoses.
Objective: To assess the oncologic effectiveness of RFA for the treatment of biopsy-proven RCC.
Design, setting, and participants: Exclusion criteria included prior RCC or metastatic RCC, familial syndromes, or T2 RCC. We retrospectively reviewed long-term oncologic outcomes for 185 patients with sporadic T1 RCC. Median follow-up was 6.43 yr (interquartile range [IQR]: 5.3-7.7).
Outcome measurements and statistical analysis: The chi-square test and Wilcoxon rank-sum tests were used to compare proportions and medians, respectively. Disease-specific survival and overall survival (OS) were calculated using Kaplan-Meier analysis, then stratified by tumor stage, and comparisons were made using log-rank analysis. The 5-yr disease-free survival (DFS) and OS rates are reported. A p value <0.05 was considered statistically significant.
Results and limitations: Median tumor size was 3 cm (IQR: 2.1-3.9 cm). Tumor stage was T1a: 143 (77.3%) or T1b: 42 (22.7%). Twenty-four patients (13%) were retreated for residual disease. There were 12 local recurrences (6.5%), 6 recurrences in T1a disease (4.2%) and 6 in T1b disease (14.3%) (p = 0.0196). Median time to recurrence was 2.5 yr. Local salvage RFA was performed in six patients, of whom five remain disease free at 3.8-yr median follow-up. Tumor stage was the only significant predictor of DFS on multivariate analysis. At last follow-up, 164 patients (88.6%) were disease free (T1a: n = 132 [92.3%]; T1b: n = 32 [76.2%]; p = 0.0038). OS was similar regardless of stage (p = 0.06). Five patients developed metachronous renal tumors (2.7%). Four patients developed extrarenal metastases (2.2%), three of whom died of metastatic RCC (1.6%).
Conclusions: In poor surgical candidates, RFA results in durable local control and low risk of recurrence in T1a RCC. Higher stage correlates with a decreased disease-free survival. Long-term surveillance is necessary following RFA. Patient selection based on tumor characteristics, comorbid disease, and life expectancy is of paramount importance. (C) 2012 European Association of Urology. Published by Elsevier B. V. All rights reserved.
C1 [Psutka, Sarah P.; Feldman, Adam S.; McDougal, W. Scott; McGovern, Francis J.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
[Mueller, Peter; Gervais, Debra A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP McDougal, WS (reprint author), Massachusetts Gen Hosp, Dept Urol, GRB 1102,55 Fruit St, Boston, MA 02114 USA.
EM wmcdougal@partners.org
NR 37
TC 101
Z9 106
U1 3
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302-2838
J9 EUR UROL
JI Eur. Urol.
PD MAR
PY 2013
VL 63
IS 3
BP 486
EP 492
DI 10.1016/j.eururo.2012.08.062
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 078NZ
UT WOS:000314107100019
PM 22959191
ER
PT J
AU Halfond, R
Corona, R
Moon, A
AF Halfond, Raquel
Corona, Rosalie
Moon, Anya
TI Latino Parent and Adolescent Perceptions of Hoped-for and Feared
Possible Selves for Adolescents
SO JOURNAL OF ADOLESCENT RESEARCH
LA English
DT Article
DE possible selves; Latino; adolescents; parents; school achievement; teen
pregnancy
ID SEXUAL RISK; INTERVENTION; COMMUNICATION; MOTHERS; AMERICAN;
ACHIEVEMENT; PSYCHOLOGY; ETHNICITY; IDENTITY; BEHAVIOR
AB The authors examined Latino parent and adolescent reports of hoped-for and feared possible selves for adolescents. Twenty-nine Latino parents (18 mothers, 11 fathers) and their 18 adolescents participated in semistructured individual interviews. Interviews were digitally recorded, transcribed, and coded for themes via content analysis. Themes that emerged included achievement, interpersonal, personal characteristics, financial-material, cultural roots, and risk behaviors. More parents than adolescents mentioned feared interpersonal selves such as being a teenage parent. Findings suggest that Latino parents and adolescents express hopes and fears for future outcomes that are not consistent with the high rates of school dropout and teen pregnancy among Latino adolescents. Results shed light on strategies for program and policy prevention efforts.
C1 [Halfond, Raquel] Harbor UCLA Med Ctr, Child & Adolescent Psychiat Div, Torrance, CA 90509 USA.
[Halfond, Raquel; Corona, Rosalie; Moon, Anya] Virginia Commonwealth Univ, Richmond, VA USA.
[Moon, Anya] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Halfond, R (reprint author), Harbor UCLA Med Ctr, Child & Adolescent Psychiat Div, 1000 W Carson St,Box 498, Torrance, CA 90509 USA.
EM halfondrw@vcu.edu
NR 66
TC 1
Z9 1
U1 4
U2 24
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0743-5584
J9 J ADOLESCENT RES
JI J. Adolesc. Res.
PD MAR
PY 2013
VL 28
IS 2
BP 209
EP 240
DI 10.1177/0743558412457818
PG 32
WC Psychology, Developmental
SC Psychology
GA 077YM
UT WOS:000314065300004
ER
PT J
AU Vanderburg, CR
Clarke, MSF
AF Vanderburg, Charles R.
Clarke, Mark S. F.
TI Laser capture microdissection of metachromatically stained skeletal
muscle allows quantification of fiber type specific gene expression
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Skeletal muscle; Fiber type; Laser capture microdissection (LCM);
Atrophy; Expression profiling
ID CALCIUM-PUMP GENE; SIGNALING PATHWAYS; SOLEUS MUSCLE; ATROPHY; MASS;
IDENTIFICATION; HYPERTROPHY; MODEL; RATS
AB Skeletal muscle contains various myofiber types closely associated with satellite stem cells, vasculature, and neurons, thus making it difficult to perform genetic or proteomic expression analysis with sufficient cellular specificity to resolve differences at the individual cell or myofiber type level. Here, we describe the combination of a simple histochemical method capable of simultaneously identifying Type I, IIA, IIB, and IIC myofibers followed by laser capture micro-dissection (LCM) to compare the expression profiles of individual fiber types, myonuclear domains, and satellite cells in frozen muscle sections of control and atrophied muscle. Quantitative RT-PCR (qPCR) was used to verify the integrity of the cell-specific RNAs harvested after histologic staining, while qPCR for specific genes of interest was used to quantify atrophy-associated changes in mRNA. Our data demonstrate that the differential myofiber atrophy previously described by histologic means is related to differential expression of atrophy-related genes, such as MuRF1 and MAFbx (a.k.a. Atrogin-1), within different myofiber type populations. This spatially resolved molecular pathology (SRMP) technique allowed quantitation of atrophy-related gene products within individual fiber types that could not be resolved by expression analysis of the whole muscle. The present study demonstrates the importance of fiber type specific expression profiling in understanding skeletal muscle biology especially during muscle atrophy and provides a practical method of performing such research.
C1 [Vanderburg, Charles R.] Massachusetts Gen Hosp, Harvard NeuroDiscovery Ctr, Boston, MA 02114 USA.
[Clarke, Mark S. F.] Univ Houston, Dept Hlth & Human Performance, Houston, TX 77204 USA.
[Clarke, Mark S. F.] Dept Hlth & Human Performance, Lab Integrated Physiol, Houston, TX 77204 USA.
RP Clarke, MSF (reprint author), Dept Hlth & Human Performance, Lab Integrated Physiol, 3855 Holman St,Room 104D, Houston, TX 77204 USA.
EM mclarke@central.uh.edu
NR 29
TC 7
Z9 7
U1 2
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD MAR
PY 2013
VL 375
IS 1-2
BP 159
EP 170
DI 10.1007/s11010-012-1538-x
PG 12
WC Cell Biology
SC Cell Biology
GA 077MR
UT WOS:000314032300017
PM 23196635
ER
PT J
AU Yun, SM
Cho, SJ
Song, JC
Song, SY
Jo, SA
Jo, C
Yoon, K
Tanzi, RE
Choi, EJ
Koh, YH
AF Yun, Sang-Moon
Cho, Sun-Jung
Song, Jae Chun
Song, Sung Yeon
Jo, Sangmee Ahn
Jo, Chulman
Yoon, Keejung
Tanzi, Rudolph E.
Choi, Eui-Ju
Koh, Young Ho
TI SUMO1 modulates A beta generation via BACE1 accumulation
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Alzheimer's disease; BACE1; SUMO1; Amyloid peptide
ID AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; TRANSGENIC MICE;
ENZYMATIC-ACTIVITY; SECRETASE ACTIVITY; TARGET PROTEINS; MODIFIER SUMO;
UBIQUITIN; SUMOYLATION; EXPRESSION
AB Accumulation of disease-related proteins is a characteristic event observed in the pathogenesis of neurodegenerative diseases. beta-secretase (BACE)-1, which initiates generation of beta-amyloid (A beta), is increased in the Alzheimer's diseased brain. However, the mechanisms of BACE1 accumulation in Alzheimer's disease are largely unknown. In this report, we found that small ubiquitin-like modifier (SUMO)-1 interacts with the dileucine motif of BACE1 and regulates the level of BACE1 protein. This was proved by the coimmunoprecipitation, and gain or loss of function experiments. Altering 3 SUMO isoforms affects BACE1 protein levels, and consequently results in altered amyloid precursor protein processing and A beta generation. BACE1 levels were increased in response to A beta or apoptosis, but not in cells lacking SUMO1. A beta increased SUMO1 protein levels in rat cortical neurons. Moreover, SUMO1 immunoreactivity was increased in the amyloid precursor protein transgenic mice. Furthermore, the C-terminus fragments of BACE1 containing dileucine motif reduced A beta generation by SUMO1 overexpression. Our study indicates SUMO1 is not only a novel and potent regulator of BACE1 accumulation and A beta generation but also a potential therapeutic target for Alzheimer's disease. (c) 2013 Elsevier Inc. All rights reserved.
C1 [Yun, Sang-Moon; Cho, Sun-Jung; Song, Jae Chun; Song, Sung Yeon; Jo, Chulman; Koh, Young Ho] Korea Natl Inst Hlth, Ctr Biomed Sci, Div Brain Dis, Chungcheongbuk Do, South Korea.
[Yun, Sang-Moon; Choi, Eui-Ju] Korea Univ, Sch Life Sci & Biotechnol, Seoul, South Korea.
[Jo, Sangmee Ahn] Dankook Univ, Coll Pharm, Dept Pharm, Chungnam, South Korea.
[Yoon, Keejung] Sungkyunkwan Univ, Sch Life ScienceandBiotechnol, Suwon, South Korea.
[Tanzi, Rudolph E.] Massachusetts Gen Hosp, Genet & Aging Res Unit, Charlestown, MA USA.
RP Koh, YH (reprint author), Korea Natl Inst Hlth, Ctr Biomed Sci, Div Brain Dis, Chungcheongbuk Do, South Korea.
EM kohyoungho122@gmail.com
FU Ministry of Health and Welfare; Korea National Institute of Health
Intramural Research Grant [091-4845-300-210-13]
FX We are deeply indebted to Drs. Olli A. Janne for providing
SUMO1-knockout and wild type primary MEFs. We also thank Dr. Seongman
Kang for providing the GFP-A beta1-42 plasmid cDNA. This
study was supported by a grant of the Ministry of Health and Welfare and
Korea National Institute of Health Intramural Research Grant
(091-4845-300-210-13).
NR 42
TC 18
Z9 18
U1 1
U2 41
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD MAR
PY 2013
VL 34
IS 3
BP 650
EP 662
DI 10.1016/j.neurobiolaging.2012.08.005
PG 13
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 065AF
UT WOS:000313117900002
PM 22975420
ER
PT J
AU Sperling, RA
Johnson, KA
Doraiswamy, PM
Reiman, EM
Fleisher, AS
Sabbagh, MN
Sadowsky, CH
Carpenter, A
Davis, MD
Lu, M
Flitter, M
Joshi, AD
Clark, CM
Grundman, M
Mintun, MA
Skovronsky, DM
Pontecorvo, MJ
AF Sperling, Reisa A.
Johnson, Keith A.
Doraiswamy, P. Murali
Reiman, Eric M.
Fleisher, Adam S.
Sabbagh, Marwan N.
Sadowsky, Carl H.
Carpenter, Alan
Davis, Mat D.
Lu, Ming
Flitter, Matthew
Joshi, Abhinay D.
Clark, Christopher M.
Grundman, Michael
Mintun, Mark A.
Skovronsky, Daniel M.
Pontecorvo, Michael J.
CA AV45-A05 Study Grp
TI Amyloid deposition detected with florbetapir F 18 (F-18-AV-45) is
related to lower episodic memory performance in clinically normal older
individuals
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Memory; Amyloid; Aging
ID PRECLINICAL ALZHEIMERS-DISEASE; MILD COGNITIVE IMPAIRMENT; A-BETA;
FUNCTIONAL CONNECTIVITY; NONDEMENTED INDIVIDUALS; IN-VIVO; DEMENTIA;
DECLINE; ADULTS; PREDICTION
AB The objective of this study was to evaluate the relationship of amyloid burden, as assessed by florbetapir F 18 (F-18-AV-45) amyloid positron emission tomography, and cognition in healthy older control (HC) subjects. Seventy-eight HC subjects were assessed with a brief cognitive test battery and positron emission tomography (PET) imaging with 18F-AV-45. A standard uptake value ratio was computed for mean data from 6 cortical regions using a whole cerebellum reference region. Scans were also visually rated as amyloid positive or amyloid negative by 3 readers. Higher standard uptake value ratio correlated with lower immediate memory (r = -0.33; p = 0.003) and delayed recall scores (r = -0.25; p = 0.027). Performance on immediate recall was also lower in the visually rated amyloid positive compared with amyloid negative HC (p = 0.04), with a similar trend observed in delayed recall (p = 0.06). These findings support the hypothesis that higher amyloid burden is associated with lower memory performance among clinically normal older subjects. Longitudinal follow-up is ongoing to determine whether 18F-AV-45 may also predict subsequent cognitive decline. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Sperling, Reisa A.; Johnson, Keith A.] Harvard Univ, Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, Dept Neurol, Boston, MA 02115 USA.
[Sperling, Reisa A.; Johnson, Keith A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Johnson, Keith A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Doraiswamy, P. Murali] Duke Univ, Med Ctr, Durham, NC USA.
[Reiman, Eric M.; Fleisher, Adam S.] Banner Alzheimers Inst, San Diego, CA USA.
[Fleisher, Adam S.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Sabbagh, Marwan N.] Banner Sun Hlth Res Inst, Phoenix, AZ USA.
[Sadowsky, Carl H.] Nova SE Univ, Ft Lauderdale, FL 33314 USA.
[Lu, Ming; Flitter, Matthew; Joshi, Abhinay D.; Clark, Christopher M.; Mintun, Mark A.; Skovronsky, Daniel M.; Pontecorvo, Michael J.] Avid Radiopharmaceut, Philadelphia, PA USA.
[Davis, Mat D.] Univ Penn, Philadelphia, PA 19104 USA.
[Grundman, Michael] Global R&D Partners LLC, San Diego, CA USA.
RP Sperling, RA (reprint author), 221 Longwood Ave, Boston, MA 02115 USA.
EM reisa@rics.bwh.harvard.edu
FU Harvard Aging Brain Study [P01AG036694]; Avid Pharmaceuticals;
Avid/Lilly
FX Drs. Sperling and Johnson's efforts were supported by; P01AG036694-the
Harvard Aging Brain Study. The authors wish to acknowledge the clinical
research staff at all of the A05 study centers, and the dedication of
research participants in this study. This report is dedicated to Dr.
Chris Clark, who sadly passed away during the preparation of this
manuscript, but contributed greatly to this work and the field of
Alzheimer's disease.; The phase II study was funded by Avid
Pharmaceuticals.; Dr. Sperling has served as a site investigator for
Avid, Bristol-Myers-Squibb, Elan, Janssen, Pfizer, and Wyeth, a
consultant to Bayer, Bristol-Myers-Squibb, Elan, Eisai, Janssen, Pfizer,
and Wyeth, and an unpaid consultant to Avid. She has received speaking
honoraria from Pfizer, Janssen, Eli Lilly, and Bayer. Dr. Johnson has
served as a site investigator for Avid, Pfizer, Janssen,
Bristol-Myers-Squibb, and as a consultant to Bristol-Myers-Squibb and
Bayer. Dr. Doraiswamy has served as a paid advisor/speaker and/or
received research grants from Avid/Lilly and several pharmaceutical
companies. He owns stock in Sonexa and Clarimedix. Dr. Reiman has served
as a paid consultant to Eli Lilly for its amyloid-modifying drug
development programs, but has not served as a paid consultant to Eli
Lilly or Avid for the development of florbetapir F18, and has served as
a site investigator for Eli Lilly and Avid. Dr. Fleisher is a consultant
for Lilly SAB and has received grant funding from Avid. Dr. Sabbagh has
served as a site investigator for Avid, BMS, Elan, Janssen, Pfizer,
Wyeth, Baxter, Bayer, GE, Lilly, Genentech, Eisai, Ceregene, and
Celgene, and a consultant to BMS, Bayer, Lilly, Avid, Amerisciences,
Eisai, and Takeda. Dr. Sadowsky is on the speaker's bureau for Novartis,
Forest and Axona, and is a site investigator for Avid. Dr. Davis
performed statistical analysis under a consulting contract from Avid.
Dr. Grundman is a paid consultant to Avid, Eli Lilly, and other
pharmaceutical companies. Drs. Carpenter, Davis, Flitter, Joshi, Mintun,
Skovronsky, and Pontecorvo are all employees of Avid
Radiopharmaceuticals.
NR 47
TC 49
Z9 49
U1 2
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD MAR
PY 2013
VL 34
IS 3
BP 822
EP 831
DI 10.1016/j.neurobiolaging.2012.06.014
PG 10
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 065AF
UT WOS:000313117900015
PM 22878163
ER
PT J
AU McGill, LA
Ismail, T
Nielles-Vallespin, S
Ferreira, P
Scott, AD
Roughton, M
Kilner, PJ
Ho, SY
McCarthy, KP
Gatehouse, PD
de Silva, R
Speier, P
Feiweier, T
Mekkaoui, C
Sosnovik, DE
Prasad, SK
Firmin, DN
Pennell, DJ
AF McGill, Laura-Ann
Ismail, Tevfik
Nielles-Vallespin, Sonia
Ferreira, Pedro
Scott, Andrew D.
Roughton, Michael
Kilner, Philip J.
Ho, S. Yen
McCarthy, Karen P.
Gatehouse, Peter D.
de Silva, Ranil
Speier, Peter
Feiweier, Thorsten
Mekkaoui, Choukkri
Sosnovik, David E.
Prasad, Sanjay K.
Firmin, David N.
Pennell, Dudley J.
TI reproducibility of in-vivo diffusion tensor cardiovascular magnetic
resonance in hypertrophic cardiomyopathy (vol 14, pg 86, 2012)
SO JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE
LA English
DT Correction
C1 [McGill, Laura-Ann; Ismail, Tevfik; Nielles-Vallespin, Sonia; Ferreira, Pedro; Scott, Andrew D.; Roughton, Michael; Kilner, Philip J.; Ho, S. Yen; McCarthy, Karen P.; Gatehouse, Peter D.; de Silva, Ranil; Prasad, Sanjay K.; Firmin, David N.; Pennell, Dudley J.] Royal Brompton Hosp, Cardiovasc Magnet Resonance Unit, London SW3 6LY, England.
[McGill, Laura-Ann; Nielles-Vallespin, Sonia; Ferreira, Pedro; Scott, Andrew D.; Kilner, Philip J.; Ho, S. Yen; McCarthy, Karen P.; de Silva, Ranil; Prasad, Sanjay K.; Firmin, David N.; Pennell, Dudley J.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England.
[Nielles-Vallespin, Sonia] NHLBI, NIH, DHHS, Bethesda, MD 20892 USA.
[Speier, Peter; Feiweier, Thorsten] Siemens AG Med Solut, MR R&D, Erlangen, Germany.
[Mekkaoui, Choukkri; Sosnovik, David E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Martinos Ctr Biomed Imaging, Boston, MA USA.
RP Firmin, DN (reprint author), Royal Brompton Hosp, Cardiovasc Magnet Resonance Unit, London SW3 6LY, England.
EM d.firmin@imperial.ac.uk
NR 1
TC 2
Z9 2
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1097-6647
J9 J CARDIOVASC MAGN R
JI J. Cardiov. Magn. Reson.
PD FEB 28
PY 2013
VL 15
AR 22
DI 10.1186/1532-429X-15-22
PG 1
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 128AI
UT WOS:000317739900001
ER
PT J
AU Kufe, DW
AF Kufe, D. W.
TI MUC1-C oncoprotein as a target in breast cancer: activation of signaling
pathways and therapeutic approaches
SO ONCOGENE
LA English
DT Review
DE MUC1; breast cancer; oncoprotein; signaling pathways; targeted agents
ID GROWTH-FACTOR RECEPTOR; CARCINOMA-ASSOCIATED ANTIGEN; MUCIN 1
ONCOPROTEIN; BETA-CATENIN; CYCLIN D1; GENE-EXPRESSION; LUNG-CANCER;
C-SRC; PHOSPHOINOSITIDE 3-KINASE; PROGNOSTIC-SIGNIFICANCE
AB Mucin 1 (MUC1) is a heterodimeric protein formed by two subunits that is aberrantly overexpressed in human breast cancer and other cancers. Historically, much of the early work on MUC1 focused on the shed mucin subunit. However, more recent studies have been directed at the transmembrane MUC1-C-terminal subunit (MUC1-C) that functions as an oncoprotein. MUC1-C interacts with EGFR (epidermal growth factor receptor), ErbB2 and other receptor tyrosine kinases at the cell membrane and contributes to activation of the PI3K -> AKT and mitogen-activated protein kinase kinase (MEK)-> extracellular signal-regulated kinase (ERK) pathways. MUC1-C also localizes to the nucleus where it activates the Wnt/beta-catenin, signal transducer and activator of transcription (STAT) and NF (nuclear factor)-kappa B RelA pathways. These findings and the demonstration that MUC1-C is a druggable target have provided the experimental basis for designing agents that block MUC1-C function. Notably, inhibitors of the MUC1-C subunit have been developed that directly block its oncogenic function and induce death of breast cancer cells in vitro and in xenograft models. On the basis of these findings, a first-in-class MUC1-C inhibitor has entered phase I evaluation as a potential agent for the treatment of patients with breast cancers who express this oncoprotein. Oncogene (2013) 32, 1073-1081; doi:10.1038/onc.2012.158; published online 14 May 2012
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Kufe, DW (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,Dana 830, Boston, MA 02215 USA.
EM donald_kufe@dfci.harvard.edu
FU National Cancer Institute [CA97098]
FX This work has been supported by Grant CA97098 awarded by the National
Cancer Institute.
NR 103
TC 90
Z9 94
U1 5
U2 28
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
J9 ONCOGENE
JI Oncogene
PD FEB 28
PY 2013
VL 32
IS 9
BP 1073
EP 1081
DI 10.1038/onc.2012.158
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 110FU
UT WOS:000316428800001
PM 22580612
ER
PT J
AU Zheng, HX
Cai, YD
Wang, YD
Cui, XB
Xie, TT
Li, WJ
Peng, L
Zhang, Y
Wang, ZQ
Wang, J
Jiang, B
AF Zheng, H. X.
Cai, Y. D.
Wang, Y. D.
Cui, X. B.
Xie, T. T.
Li, W. J.
Peng, L.
Zhang, Y.
Wang, Z. Q.
Wang, J.
Jiang, B.
TI Fas signaling promotes motility and metastasis through
epithelial-mesenchymal transition in gastrointestinal cancer
SO ONCOGENE
LA English
DT Article
DE Fas signaling; metastasis; motility; epithelial-mesenchymal transition
ID TUMOR PROGRESSION; COLORECTAL CANCER.; GLIOMA-CELLS; CD95; EXPRESSION;
COLON; GROWTH; LIVER; ACTIVATION; MECHANISMS
AB Fas signaling was reported to participate in cell apoptosis. However, this pathway has also been shown to promote tumor cell motility, leading to the hypothesis that Fas signaling may induce epithelial mesenchymal transition (EMT) to promote metastasis. The effects of Fas-ligand (FasL) treatment and inhibition of Fas signaling on colorectal and gastric cancer cells were tested using motility assay, immunofluorescence, RT-PCR and immunoblot analyses. Fas signaling downregulated epithelial markers, upregulated mesenchymal markers and promoted motility in gastrointestinal (GI) cancer cells. FasL treatment also increased the expression of EMT transcriptional factors in the nucleus and induced a spindle shape cell morphology in these cells. Knockdown of Snail or Twist expression significantly decreased FasL-induced motility. The ERK1/2 pathway was activated by Fas signaling and is required for FasL-induced EMT and motility. Moreover, oxaliplatin, a chemotherapeutic agent, induced EMT partly through Fas signaling. Evaluation of human GI clinical specimens showed that FasL expression increased whereas E-cadherin expression decreased during GI cancer progression. Both markers were significantly inversely correlated. Tissue samples with a non-EMT phenotype were mainly distributed in patients with early cancer stages, whereas samples with an EMT phenotype were mostly distributed in patients with advanced cancer stages. A non-EMT phenotype significantly correlated with better prognosis. Altogether, these data indicate that Fas signaling may induce EMT to promote tumor motility and metastasis in GI cancer in vivo and in vitro. Oncogene (2013) 32, 1183-1192; doi:0.1038/onc.2012.126; published online 16 April 2012
C1 [Zheng, H. X.; Cai, Y. D.; Wang, Y. D.; Cui, X. B.; Xie, T. T.; Li, W. J.; Peng, L.; Zhang, Y.; Wang, Z. Q.; Wang, J.; Jiang, B.] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Guangdong, Peoples R China.
[Cai, Y. D.] China Acad Chinese Med Sci, Xiyuan Hosp, Dept Gastroenterol, Beijing, Peoples R China.
[Peng, L.] Mt Sinai Sch Med, Dept Med, Inst Immunol, New York, NY USA.
[Zhang, Y.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Wang, Z. Q.] Mt Sinai Sch Med, Dept Pathol, New York, NY USA.
RP Jiang, B (reprint author), Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guanzhoudabaobei 1838, Guangzhou 510515, Guangdong, Peoples R China.
EM prof.jiang@yahoo.com.cn
RI Cui, XiaoBing/K-8159-2012
OI Cui, XiaoBing/0000-0002-5460-0357
FU Science and Technology Project of Guangzhou [2009Z1-E051]; Nanfang
Hospital President Foundation [2011C015]
FX This study was supported by Science and Technology Project of Guangzhou
(2009Z1-E051) and Nanfang Hospital President Foundation(2011C015).
NR 33
TC 26
Z9 26
U1 2
U2 22
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD FEB 28
PY 2013
VL 32
IS 9
BP 1183
EP 1192
DI 10.1038/onc.2012.126
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
Heredity
GA 110FU
UT WOS:000316428800012
PM 22508480
ER
PT J
AU Hollon, JR
Cureton, PA
Martin, ML
Puppa, ELL
Fasano, A
AF Hollon, Justin R.
Cureton, Pamela A.
Martin, Margaret L.
Puppa, Elaine L. Leonard
Fasano, Alessio
TI Trace gluten contamination may play a role in mucosal and clinical
recovery in a subgroup of diet-adherent non-responsive celiac disease
patients
SO BMC GASTROENTEROLOGY
LA English
DT Article
DE Celiac disease; Refractory celiac disease; Refractory sprue;
Non-responsive celiac disease; Gluten-free diet
ID ADULT PATIENTS; UNITED-STATES; DIAGNOSIS; MANAGEMENT; CHILDREN;
PREVALENCE; SYMPTOMS; SPECTRUM; SPRUE
AB Background: Patients with persistent symptoms and/or villous atrophy despite strict adherence to a gluten-free diet (GFD) have non-responsive celiac disease (NRCD). A subset of these patients has refractory celiac disease (RCD), yet some NRCD patients may simply be reacting to gluten cross-contamination. Here we describe the effects of a 3-6 month diet of whole, unprocessed foods, termed the Gluten Contamination Elimination Diet (GCED), on NRCD. We aim to demonstrate that this diet reclassifies the majority of patients thought to have RCD type 1 (RCD1).
Methods: We reviewed the records of all GFD-adherent NRCD patients cared for in our celiac center from 2005-2011 who were documented to have started the GCED. Response to the GCED was defined as being asymptomatic after the diet, with normal villous architecture on repeat biopsy, if performed.
Results: Prior to the GCED, all patients were interviewed by an experienced dietitian and no sources of hidden gluten ingestion were identified. 17 patients completed the GCED; 15 were female (88%). Median age at start of the GCED was 42 years (range 6-73). Fourteen patients (82%) responded to the GCED. Six patients met criteria for RCD prior to the GCED; 5 (83%) were asymptomatic after the GCED and no longer meet RCD criteria. Of the 14 patients who responded to the GCED, 11 (79%) successfully returned to a traditional GFD without resurgence of symptoms.
Conclusions: The GCED may be an effective therapeutic option for GFD-adherent NRCD patients. Response to this diet identifies a subgroup of patients, previously classified as RCD1, that is not truly refractory to dietary treatment. Preventing an inaccurate diagnosis of RCD1 avoids immunotherapy. Most patients are able to return to a traditional GFD without return of symptoms.
C1 [Hollon, Justin R.] Johns Hopkins Univ, Sch Med, Div Pediat Gastroenterol, Baltimore, MD 21218 USA.
[Cureton, Pamela A.; Martin, Margaret L.; Puppa, Elaine L. Leonard] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Cureton, Pamela A.; Fasano, Alessio] Massachusetts Gen Hosp, Ctr Celiac Res, Boston, MA 02114 USA.
[Cureton, Pamela A.; Fasano, Alessio] Massachusetts Gen Hosp Children, Div Pediat Gastroenterol & Nutr, Boston, MA USA.
RP Hollon, JR (reprint author), Johns Hopkins Univ, Sch Med, Div Pediat Gastroenterol, 600 North Wolfe St,Brady 320, Baltimore, MD 21218 USA.
EM jhollon1@jhmi.edu
NR 35
TC 19
Z9 21
U1 2
U2 20
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-230X
J9 BMC GASTROENTEROL
JI BMC Gastroenterol.
PD FEB 28
PY 2013
VL 13
AR 40
DI 10.1186/1471-230X-13-40
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 103WS
UT WOS:000315950800001
PM 23448408
ER
PT J
AU Snuderl, M
Batista, A
Kirkpatrick, ND
de Almodovar, CR
Riedemann, L
Walsh, EC
Anolik, R
Huang, YH
Martin, JD
Kamoun, W
Knevels, E
Schmidt, T
Farrar, CT
Vakoc, BJ
Mohan, N
Chung, EH
Roberge, S
Peterson, T
Bais, C
Zhelyazkova, BH
Yip, S
Hasselblatt, M
Rossig, C
Niemeyer, E
Ferrara, N
Klagsbrun, M
Duda, DG
Fukumura, D
Xu, L
Carmeliet, P
Jain, RK
AF Snuderl, Matija
Batista, Ana
Kirkpatrick, Nathaniel D.
de Almodovar, Carmen Ruiz
Riedemann, Lars
Walsh, Elisa C.
Anolik, Rachel
Huang, Yuhui
Martin, John D.
Kamoun, Walid
Knevels, Ellen
Schmidt, Thomas
Farrar, Christian T.
Vakoc, Benjamin J.
Mohan, Nishant
Chung, Euiheon
Roberge, Sylvie
Peterson, Teresa
Bais, Carlos
Zhelyazkova, Boryana H.
Yip, Stephen
Hasselblatt, Martin
Rossig, Claudia
Niemeyer, Elisabeth
Ferrara, Napoleone
Klagsbrun, Michael
Duda, Dan G.
Fukumura, Dai
Xu, Lei
Carmeliet, Peter
Jain, Rakesh K.
TI Targeting Placental Growth Factor/Neuropilin 1 Pathway Inhibits Growth
and Spread of Medulloblastoma
SO CELL
LA English
DT Article
ID TUMOR-GROWTH; DOSE-ESCALATION; CELL-LINE; PHASE-I; ANGIOGENESIS; CANCER;
PLGF; METASTASIS; RESISTANCE; TB-403
AB Medulloblastoma is the most common pediatric malignant brain tumor. Although current therapies improve survival, these regimens are highly toxic and are associated with significant morbidity. Here, we report that placental growth factor (PlGF) is expressed in the majority of medulloblastomas, independent of their subtype. Moreover, high expression of PlGF receptor neuropilin 1 (Nrp1) correlates with poor overall survival in patients. We demonstrate that PlGF and Nrp1 are required for the growth and spread of medulloblastoma: PlGF/Nrp1 blockade results in direct antitumor effects in vivo, resulting in medulloblastoma regression, decreased metastasis, and increased mouse survival. We reveal that PlGF is produced in the cerebellar stroma via tumor-derived Sonic hedgehog (Shh) and show that PlGF acts through Nrp1-and not vascular endothelial growth factor receptor 1-to promote tumor cell survival. This critical tumor-stroma interaction-mediated by Shh, PlGF, and Nrp1 across medulloblastoma subtypes-supports the development of therapies targeting PlGF/Nrp1 pathway.
C1 [Snuderl, Matija; Zhelyazkova, Boryana H.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Batista, Ana; Kirkpatrick, Nathaniel D.; Riedemann, Lars; Walsh, Elisa C.; Anolik, Rachel; Huang, Yuhui; Martin, John D.; Kamoun, Walid; Chung, Euiheon; Roberge, Sylvie; Peterson, Teresa; Niemeyer, Elisabeth; Duda, Dan G.; Fukumura, Dai; Xu, Lei; Jain, Rakesh K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA.
[Vakoc, Benjamin J.; Mohan, Nishant] Massachusetts Gen Hosp, Dept Dermatol, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Snuderl, Matija; Batista, Ana; Kirkpatrick, Nathaniel D.; Riedemann, Lars; Walsh, Elisa C.; Anolik, Rachel; Huang, Yuhui; Martin, John D.; Kamoun, Walid; Farrar, Christian T.; Vakoc, Benjamin J.; Mohan, Nishant; Chung, Euiheon; Roberge, Sylvie; Peterson, Teresa; Niemeyer, Elisabeth; Klagsbrun, Michael; Duda, Dan G.; Fukumura, Dai; Xu, Lei; Jain, Rakesh K.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[de Almodovar, Carmen Ruiz] Katholieke Univ Leuven, Vesalius Res Ctr, Lab Angiogenesis & Neurovasc Link, B-3000 Louvain, Belgium.
[de Almodovar, Carmen Ruiz; Knevels, Ellen; Schmidt, Thomas; Carmeliet, Peter] VIB, Vesalius Res Ctr, Lab Angiogenesis & Neurovasc Link, B-3000 Louvain, Belgium.
[Farrar, Christian T.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Vakoc, Benjamin J.; Mohan, Nishant] Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Bais, Carlos; Ferrara, Napoleone] Genentech Inc, San Francisco, CA 94080 USA.
[Yip, Stephen] Univ British Columbia, Vancouver Gen Hosp, Dept Pathol & Lab Med, Vancouver, BC V5Z 4E6, Canada.
[Hasselblatt, Martin] Univ Hosp Munster, Inst Neuropathol, D-48149 Munster, Germany.
[Rossig, Claudia] Univ Hosp Munster, Dept Pediat Hematol & Oncol, D-48149 Munster, Germany.
[Klagsbrun, Michael] Childrens Hosp Boston, Vasc Biol Program, Dept Surg, Boston, MA 02115 USA.
RP Jain, RK (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA.
EM jain@steele.mgh.harvard.edu
RI Riedemann, Lars/J-5725-2014; Martin, John/L-6892-2016;
OI Riedemann, Lars/0000-0002-9510-1845; Martin, John/0000-0002-9828-8203;
Huang, Yuhui/0000-0003-1985-3575; Hasselblatt,
Martin/0000-0003-2707-8484; Snuderl, Matija/0000-0003-0752-0917;
Schmidt, Thomas/0000-0002-7166-3675
FU Hoffmann-La Roche; NIH [R01CA163815, P01CA080124, R01CA096915,
S10RR027070, R01CA126642, R01CA159258, K25AG029415, R21CA155862,
CA37392, CA45548, R01CA163528, P41-EB015903]; Department of Defense
(DoD) [W81XWH-10-1-0016]; Belgian Government [IUAP06/30]; Flemish
Government; Concerted Research Activities, Stichting Emmanuel van der
Schueren (Belgium) [GOA2006/11]; American Cancer Society
[120733-RSG-11-073-01-TBG, RSG-12-199-01-TBG]; BrainCare BC; DoD
[W81XWH-11-1-0619]; Calabresi Career Development Award [2K12CA090354];
Mildred-Scheel-Fellowship (Deutsche Krebshilfe); Rolf Dierichs Stiftung;
[T32-CA073479]
FX We would like to thank Drs. J. M. Olson, M. Dewerchin, A. J. Iafrate, E.
di Tomaso, M. Ancukiewicz, S. Goel, D. Kodack, K. Munro, B. Seed, R.
Wechsler-Reya, and M. Weidner for invaluable suggestions and
experimental assistance and Ms. C. J. Smith, A. Khachatryan, K. Kinzel,
and B. Riesmeier for technical assistance. This study was supported by a
grant from Hoffmann-La Roche and NIH grant R01CA163815 (to R. K. J.).
The study was partially supported by NIH grants P01CA080124 (to R. K.
J., D. G. D., D. F., and L. X.), R01CA096915 and S10RR027070 (to D. F.),
R01CA126642 (to R. K. J.), and R01CA159258 (to D. G. D.); Department of
Defense (DoD) Breast Cancer Research Innovator Award W81XWH-10-1-0016
(to R. K. J.); Belgian Government grant IUAP06/30 (to P. C.); Flemish
Government long-term structural funding Methusalem (to P. C.); the
Concerted Research Activities, Stichting Emmanuel van der Schueren
(Belgium), GOA2006/11 (to P. C.); and American Cancer Society grants
120733-RSG-11-073-01-TBG (to D. G. D.) and RSG-12-199-01-TBG (to L. X.).
C. T. F. is supported by NIH grants K25AG029415 and R21CA155862. M. K.'s
work is supported by NIH grants CA37392 and CA45548. B. J. V.'s work is
supported by NIH grants R01CA163528 and P41-EB015903. S. Y.'s work is
supported by BrainCare BC. Y. H. is supported by DoD Research Fellowship
W81XWH-11-1-0619. N. D. K. was supported by T32-CA073479. M. S. was
supported by the Calabresi Career Development Award 2K12CA090354. L. R.
received funding from Mildred-Scheel-Fellowship (Deutsche Krebshilfe)
and from Rolf Dierichs Stiftung. P. C. has patent applications claiming
subject matter related to this report, which may result in royalty
payments. R. K. J. is a member of Board of Trustees of H& Q Healthcare
Investors and H&Q Life Sciences Investors.
NR 39
TC 70
Z9 72
U1 2
U2 57
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD FEB 28
PY 2013
VL 152
IS 5
BP 1065
EP 1076
DI 10.1016/j.cell.2013.01.036
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 100OK
UT WOS:000315710300014
PM 23452854
ER
PT J
AU Boros, E
Caravan, P
AF Boros, Eszter
Caravan, Peter
TI Structure-Relaxivity Relationships of Serum Albumin Targeted MRI Probes
Based on a Single Amino Acid Gd Complex
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID CONTRAST AGENTS; PHYSICOCHEMICAL CHARACTERIZATION; GADOLINIUM; BINDING;
ENHANCEMENT; MS-325; MEDIA
AB The Gd(III) complex of DO3A-N-alpha-aminopropionate, Gd(DOTAla), was used to generate a small library of putative MRI probes targeted to human serum albumin (HSA). Ten compounds were synthesized via multistep organic synthesis, and the corresponding Gd complexes were investigated for their affinity to HSA, lipophilicity, and relaxivity in the absence and presence of HSA. Negative charge and moderate lipophilicity correlate with increased HSA affinity and relaxivity
C1 [Boros, Eszter; Caravan, Peter] Harvard Univ, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol,Med Sch, Charlestown, MA 02129 USA.
RP Caravan, P (reprint author), Harvard Univ, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol,Med Sch, 149 13th St,Suite 2301, Charlestown, MA 02129 USA.
EM caravan@nmr.mgh.harvard.edu
FU Swiss National Science Foundation; National Institute of Biomedical
Imaging and Bioengineering (NIBIB) [R01EB009062]; National Center for
Research Resources (NCRR) [P41RR14075]
FX E.B. acknowledges the Swiss National Science Foundation for a fellowship
for prospective researchers. Nathaniel Kenton is acknowledged for
synthesis of DOTAla and Fmoc-DOTAla according to ref 19. This work was
supported in part by Award R01EB009062 from the National Institute of
Biomedical Imaging and Bioengineering (NIBIB) and Award P41RR14075 from
the National Center for Research Resources (NCRR).
NR 23
TC 12
Z9 12
U1 0
U2 33
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD FEB 28
PY 2013
VL 56
IS 4
BP 1782
EP 1786
DI 10.1021/jm4000177
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 100NG
UT WOS:000315707300036
PM 23391162
ER
PT J
AU Adair, BD
Xiong, JP
Alonso, JL
Hyman, BT
Arnaout, MA
AF Adair, Brian D.
Xiong, Jian-Ping
Alonso, Jose Luis
Hyman, Bradley T.
Arnaout, M. Amin
TI EM Structure of the Ectodomain of Integrin CD11b/CD18 and Localization
of Its Ligand-Binding Site Relative to the Plasma Membrane
SO PLOS ONE
LA English
DT Article
ID DEPENDENT ADHESION SITE; CRYSTAL-STRUCTURE; A-DOMAIN;
CONFORMATIONAL-CHANGES; EXTRACELLULAR SEGMENT; I-DOMAIN; ACTIVATION;
ALPHA(IIB)BETA(3); ALPHA-V-BETA-3; RECEPTOR
AB One-half of the integrin alpha-subunit Propeller domains contain and extra vWFA domain (alpha A domain), which mediates integrin binding to extracellular physiologic ligands via its metal-ion-dependent adhesion site (MIDAS). We used electron microscopy to determine the 3D structure of the alpha A-containing ectodomain of the leukocyte integrin CD11b/CD18 (alpha M beta 2) in its inactive state. A well defined density for alpha A was observed within a bent ectodomain conformation, while the structure of the ectodomain in complex with the Fab fragment of mAb107, which binds at the MIDAS face of CD11b and stabilizes the inactive state, further revealed that alpha A is restricted to a relatively small range of orientations relative to the Propeller domain. Using Fab 107 as probe in fluorescent lifetime imaging microscopy (FLIM) revealed that alpha A is positioned relatively far from the membrane surface in the inactive state, and a systematic orientation search revealed that the MIDAS face would be accessible to extracellular ligand in the inactive state of the full-length cellular integrin. These studies are the first to define the 3D EM structure of an alpha A-containing integrin ectodomain and to position the ligand-binding face of alpha A domain in relation to the plasma membrane, providing new insights into current models of integrin activation.
C1 [Adair, Brian D.; Xiong, Jian-Ping; Arnaout, M. Amin] Massachusetts Gen Hosp, Struct Biol Program, Charlestown, MA USA.
[Adair, Brian D.; Xiong, Jian-Ping; Alonso, Jose Luis; Hyman, Bradley T.; Arnaout, M. Amin] Harvard Univ, Sch Med, Charlestown, MA USA.
[Alonso, Jose Luis; Arnaout, M. Amin] Massachusetts Gen Hosp, Leukocyte Biol & Inflammat Program, Charlestown, MA USA.
[Hyman, Bradley T.] Massachusetts Gen Hosp, Div Nephrol, Charlestown, MA USA.
[Hyman, Bradley T.] Massachusetts Gen Hosp, Inst Neurodegenerat Dis, Charlestown, MA USA.
RP Arnaout, MA (reprint author), Massachusetts Gen Hosp, Struct Biol Program, Charlestown, MA USA.
EM aarnaout1@partners.org
FU National Institutes of Health [DK48549, DK50305, DK068253]
FX This research was supported by grants DK48549, DK50305 and DK068253 from
the National Institutes of Health. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 46
TC 1
Z9 1
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 28
PY 2013
VL 8
IS 2
AR e57951
DI 10.1371/journal.pone.0057951
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 098DA
UT WOS:000315524900209
PM 23469114
ER
PT J
AU Seed, KD
Lazinski, DW
Calderwood, SB
Camilli, A
AF Seed, Kimberley D.
Lazinski, David W.
Calderwood, Stephen B.
Camilli, Andrew
TI A bacteriophage encodes its own CRISPR/Cas adaptive response to evade
host innate immunity
SO NATURE
LA English
DT Article
ID CAS SYSTEMS; PHAGE; INTERFERENCE; ARCHAEA; DEFENSE; RNA; DNA;
RESISTANCE; EVOLUTION; PATHOGEN
AB Bacteriophages (or phages) are the most abundant biological entities on earth, and are estimated to outnumber their bacterial prey by tenfold(1). The constant threat of phage predation has led to the evolution of a broad range of bacterial immunity mechanisms that in turn result in the evolution of diverse phage immune evasion strategies, leading to a dynamic co-evolutionary arms race(2,3). Although bacterial innate immune mechanisms against phage abound, the only documented bacterial adaptive immune system is the CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR-associated proteins) system, which provides sequence-specific protection from invading nudeic acids, including phage(4-11). Here we show a remarkable turn of events, in which a phage-encoded CRISPR/Cas system is used to counteract a phage inhibitory chromosomal island of the bacterial host. A successful lytic infection by the phage is dependent on sequence identity between CRISPR spacers and the target chromosomal island. In the absence of such targeting, the phage-encoded CRISPR/Cas system can acquire new spacers to evolve rapidly and ensure effective targeting of the chromosomal island to restore phage replication.
C1 [Seed, Kimberley D.; Lazinski, David W.; Camilli, Andrew] Tufts Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02111 USA.
[Seed, Kimberley D.; Lazinski, David W.; Camilli, Andrew] Tufts Univ, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.
[Calderwood, Stephen B.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Calderwood, Stephen B.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Camilli, A (reprint author), Tufts Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02111 USA.
EM andrew.camilli@tufts.edu
FU US National Institutes of Health [AI055058, AI045746, AI058935]
FX The authors thank the Tufts University Core Facility for sequencing and
computational support. This work was supported by US National Institutes
of Health grants AI055058 (A.C.), AI045746 (A.C.) and AI058935 (S.B.C.).
A.C. is a Howard Hughes Medical Institute Investigator.
NR 30
TC 85
Z9 91
U1 18
U2 152
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD FEB 28
PY 2013
VL 494
IS 7438
BP 489
EP 491
DI 10.1038/nature11927
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 099YI
UT WOS:000315661500041
PM 23446421
ER
PT J
AU Uihlein, A
Greenwald, J
Russell, SJ
AF Uihlein, Alexander
Greenwald, Jeffrey
Russell, Steven J.
TI Case 35-2012: A Man with Weakness, Anorexia, and Diffuse Pain Reply
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
ID HYPOGONADISM; DISEASE
C1 [Uihlein, Alexander; Greenwald, Jeffrey; Russell, Steven J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Uihlein, A (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 5
TC 0
Z9 0
U1 0
U2 1
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD FEB 28
PY 2013
VL 368
IS 9
BP 874
EP 875
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 096ET
UT WOS:000315387700028
PM 23445105
ER
PT J
AU Cote, GM
Sawyer, DB
Chabner, BA
AF Cote, Gregory M.
Sawyer, Douglas B.
Chabner, Bruce A.
TI ERBB2 Inhibition and Heart Failure Reply
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
ID CARDIOMYOCYTE PROLIFERATION
C1 [Cote, Gregory M.; Chabner, Bruce A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Sawyer, Douglas B.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
RP Cote, GM (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
EM gcote@partners.org
NR 2
TC 0
Z9 0
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD FEB 28
PY 2013
VL 368
IS 9
BP 876
EP 876
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 096ET
UT WOS:000315387700030
PM 23445109
ER
PT J
AU Oaklander, AL
Long, DM
Larvie, M
Davidson, CJ
AF Oaklander, Anne Louise
Long, Donlin M.
Larvie, Mykol
Davidson, Christian J.
TI Case 7-2013: A 77-Year-Old Woman with Long-Standing Unilateral Thoracic
Pain and Incontinence
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID SACRAL PERINEURIAL CYSTS; TARLOV CYSTS; MENINGEAL CYSTS; MICROSURGICAL
TREATMENT; PREVALENCE
C1 [Oaklander, Anne Louise] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Larvie, Mykol] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Oaklander, Anne Louise; Davidson, Christian J.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Oaklander, Anne Louise] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
[Larvie, Mykol] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Davidson, Christian J.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Long, Donlin M.] Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD USA.
RP Oaklander, AL (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
FU Aptiv Solutions; Seikagaku
FX Dr. Long reports receiving consulting fees from Aptiv Solutions and
Seikagaku. No other potential conflict of interest relevant to this
article was reported.
NR 26
TC 5
Z9 5
U1 0
U2 4
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD FEB 28
PY 2013
VL 368
IS 9
BP 853
EP 861
DI 10.1056/NEJMcpc1114034
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 096ET
UT WOS:000315387700013
PM 23445097
ER
PT J
AU Chen, L
Stuart, L
Ohsumi, TK
Burgess, S
Varshney, GK
Dastur, A
Borowsky, M
Benes, C
Lacy-Hulbert, A
Schmidt, EV
AF Chen, Li
Stuart, Lynda
Ohsumi, Toshiro K.
Burgess, Shawn
Varshney, Gaurav K.
Dastur, Anahita
Borowsky, Mark
Benes, Cyril
Lacy-Hulbert, Adam
Schmidt, Emmett V.
TI Transposon activation mutagenesis as a screening tool for identifying
resistance to cancer therapeutics
SO BMC CANCER
LA English
DT Article
DE Transposon mutagenesis; Chemotherapy; Resistance; Gene activation
ID PDZ DOMAIN PROTEINS; INSERTIONAL MUTAGENESIS; STEM-CELLS; SIGNALING
COMPLEXES; DRUG-SENSITIVITY; SLEEPING-BEAUTY; ION CHANNELS; GENOME;
PIGGYBAC; EXPRESSION
AB Background: The development of resistance to chemotherapies represents a significant barrier to successful cancer treatment. Resistance mechanisms are complex, can involve diverse and often unexpected cellular processes, and can vary with both the underlying genetic lesion and the origin or type of tumor. For these reasons developing experimental strategies that could be used to understand, identify and predict mechanisms of resistance in different malignant cells would be a major advance.
Methods: Here we describe a gain-of-function forward genetic approach for identifying mechanisms of resistance. This approach uses a modified piggyBac transposon to generate libraries of mutagenized cells, each containing transposon insertions that randomly activate nearby gene expression. Genes of interest are identified using next-gen high-throughput sequencing and barcode multiplexing is used to reduce experimental cost.
Results: Using this approach we successfully identify genes involved in paclitaxel resistance in a variety of cancer cell lines, including the multidrug transporter ABCB1, a previously identified major paclitaxel resistance gene. Analysis of co-occurring transposons integration sites in single cell clone allows for the identification of genes that might act cooperatively to produce drug resistance a level of information not accessible using RNAi or ORF expression screening approaches.
Conclusion: We have developed a powerful pipeline to systematically discover drug resistance in mammalian cells in vitro. This cost-effective approach can be readily applied to different cell lines, to identify canonical or context specific resistance mechanisms. Its ability to probe complex genetic context and non-coding genomic elements as well as cooperative resistance events makes it a good complement to RNAi or ORF expression based screens.
C1 [Chen, Li; Dastur, Anahita; Benes, Cyril] Massachusetts Gen Hosp, Ctr Canc Res, Ctr Mol Therapeut, Charlestown, MA 02129 USA.
[Chen, Li; Dastur, Anahita; Benes, Cyril] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Chen, Li; Stuart, Lynda; Lacy-Hulbert, Adam; Schmidt, Emmett V.] Massachusetts Gen Hosp, Program Dev Immunol, Boston, MA 02115 USA.
[Chen, Li; Stuart, Lynda; Lacy-Hulbert, Adam; Schmidt, Emmett V.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Ohsumi, Toshiro K.; Borowsky, Mark] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02115 USA.
[Ohsumi, Toshiro K.; Borowsky, Mark] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Burgess, Shawn; Varshney, Gaurav K.] NHGRI, Dev Genom Sect, Genome Technol Branch, Bethesda, MD 20892 USA.
RP Chen, L (reprint author), Massachusetts Gen Hosp, Ctr Canc Res, Ctr Mol Therapeut, CNY 149 Rm7308,13th St, Charlestown, MA 02129 USA.
EM lchen13@partners.org
RI Varshney, Gaurav/L-5261-2014;
OI Burgess, Shawn/0000-0003-1147-0596; Lacy-Hulbert,
Adam/0000-0003-2162-0156; Varshney, Gaurav K./0000-0002-0429-1904
FU National Institutes of Health [U01-AI070330]; Wellcome Trust [086357]
FX This work was supported by National Institutes of Health grant
(U01-AI070330). LC, AD, and CB received additional funding from the
Wellcome Trust (086357).
NR 50
TC 10
Z9 10
U1 0
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD FEB 27
PY 2013
VL 13
AR 93
DI 10.1186/1471-2407-13-93
PG 15
WC Oncology
SC Oncology
GA 103NA
UT WOS:000315922700001
PM 23442791
ER
PT J
AU Loftis, JM
Wilhelm, CJ
Vandenbark, AA
Huckans, M
AF Loftis, Jennifer M.
Wilhelm, Clare J.
Vandenbark, Arthur A.
Huckans, Marilyn
TI Partial MHC/Neuroantigen Peptide Constructs: A Potential
Neuroimmune-Based Treatment for Methamphetamine Addiction
SO PLOS ONE
LA English
DT Article
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; BLOOD-BRAIN-BARRIER;
MIGRATION INHIBITORY FACTOR; CELL-RECEPTOR LIGAND; WHITE-MATTER;
DEPENDENT INDIVIDUALS; MICROGLIAL ACTIVATION; COGNITIVE ENHANCEMENT;
PSYCHIATRIC-SYMPTOMS; STIMULANT ADDICTION
AB Relapse rates following current methamphetamine abuse treatments are very high (similar to 40-60%), and the neuropsychiatric impairments (e. g., cognitive deficits, mood disorders) that arise and persist during remission from methamphetamine addiction likely contribute to these high relapse rates. Pharmacotherapeutic development of medications to treat addiction has focused on neurotransmitter systems with only limited success, and there are no Food and Drug Administration approved pharmacotherapies for methamphetamine addiction. A growing literature shows that methamphetamine alters peripheral and central immune functions and that immune factors such as cytokines, chemokines, and adhesion molecules play a role in the development and persistence of methamphetamine induced neuronal injury and neuropsychiatric impairments. The objective of this study was to evaluate the efficacy of a new immunotherapy, partial MHC/neuroantigen peptide construct (RTL551; pI-A(b)/mMOG-35-55), in treating learning and memory impairments induced by repeated methamphetamine exposure. C57BL/6J mice were exposed to two different methamphetamine treatment regimens (using repeated doses of 4 mg/kg or 10 mg/kg, s.c.). Cognitive performance was assessed using the Morris water maze and CNS cytokine levels were measured by multiplex assay. Immunotherapy with RTL551 improved the memory impairments induced by repeated methamphetamine exposure in both mouse models of chronic methamphetamine addiction. Treatment with RTL551 also attenuated the methamphetamine induced increases in hypothalamic interleukin-2 (IL-2) levels. Collectively, these initial results indicate that neuroimmune targeted therapies, and specifically RTL551, may have potential as treatments for methamphetamine-induced neuropsychiatric impairments.
C1 [Loftis, Jennifer M.; Wilhelm, Clare J.; Vandenbark, Arthur A.; Huckans, Marilyn] Portland VA Med Ctr, Portland, OR USA.
[Huckans, Marilyn] Portland VA Med Ctr, Behav Hlth & Clin Neurosci Div, Portland, OR USA.
[Loftis, Jennifer M.; Wilhelm, Clare J.; Huckans, Marilyn] Oregon Hlth & Sci Univ, Dept Psychiat, Sch Med, Portland, OR 97201 USA.
[Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Portland, OR 97201 USA.
[Vandenbark, Arthur A.] Oregon Hlth & Sci Univ, Sch Med, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
RP Loftis, JM (reprint author), Portland VA Med Ctr, Portland, OR USA.
EM loftisj@ohsu.edu
FU National Institutes of Health [RC1DA028537, R41DA029345]; Department of
Veterans Affairs, Veterans Health Administration, Office of Research and
Development, Clinical Sciences Research and Development; Methamphetamine
Abuse Research Center, Portland, OR [NIDA P50DA018165]
FX This work was supported by National Institutes of Health grants
RC1DA028537 and R41DA029345 to JML and MH. JML (Research Scientist) and
MH (Staff Psychologist and Neuropsychologist) are supported by career
development awards from the Department of Veterans Affairs, Veterans
Health Administration, Office of Research and Development, Clinical
Sciences Research and Development. This research was supported, in part,
by the Methamphetamine Abuse Research Center, Portland, OR (NIDA
P50DA018165). The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 61
TC 5
Z9 5
U1 2
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 27
PY 2013
VL 8
IS 2
AR e56306
DI 10.1371/journal.pone.0056306
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 098BN
UT WOS:000315519000021
PM 23460798
ER
PT J
AU Srinivasan, L
Asaad, WF
Ginat, DT
Gale, JT
Dougherty, DD
Williams, ZM
Sejnowski, TJ
Eskandar, EN
AF Srinivasan, Lakshminarayan
Asaad, Wael F.
Ginat, Daniel T.
Gale, John T.
Dougherty, Darin D.
Williams, Ziv M.
Sejnowski, Terrence J.
Eskandar, Emad N.
TI Action Initiation in the Human Dorsal Anterior Cingulate Cortex
SO PLOS ONE
LA English
DT Article
ID MEDIAL FRONTAL-CORTEX; SUPPLEMENTARY MOTOR AREA; PREFRONTAL CORTEX;
NEURAL ACTIVITY; SELECTIVE ATTENTION; RESPONSE-INHIBITION;
NEURONAL-ACTIVITY; ARM MOVEMENTS; MONKEY; CINGULOTOMY
AB The dorsal anterior cingulate cortex (dACC) has previously been implicated in processes that influence action initiation. In humans however, there has been little direct evidence connecting dACC to the temporal onset of actions. We studied reactive behavior in patients undergoing therapeutic bilateral cingulotomy to determine the immediate effects of dACC ablation on action initiation. In a simple reaction task, three patients were instructed to respond to a specific visual cue with the movement of a joystick. Within minutes of dACC ablation, the frequency of false starts increased, where movements occurred prior to presentation of the visual cue. In a decision making task with three separate patients, the ablation effect on action initiation persisted even when action selection was intact. These findings suggest that human dACC influences action initiation, apart from its role in action selection.
C1 [Srinivasan, Lakshminarayan] Univ Calif Los Angeles, Neural Signal Proc Lab, Dept Radiol, Los Angeles, CA 90024 USA.
[Asaad, Wael F.] Brown Univ, Dept Neurosurg, Alpert Med Sch, Providence, RI 02912 USA.
[Asaad, Wael F.] Rhode Isl Hosp, Brown Inst Brain Sci, Providence, RI 02912 USA.
[Asaad, Wael F.] Norman Prince Neurosci Inst, Providence, RI 02912 USA.
[Ginat, Daniel T.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Gale, John T.; Dougherty, Darin D.; Williams, Ziv M.; Eskandar, Emad N.] Harvard Univ, Sch Med, Boston, MA USA.
[Gale, John T.] Cleveland Clin, Dept Neurosci, Cleveland, OH 44106 USA.
[Gale, John T.] Cleveland Clin, Ctr Neurol Restorat, Cleveland, OH 44106 USA.
[Dougherty, Darin D.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Williams, Ziv M.; Eskandar, Emad N.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Sejnowski, Terrence J.] Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA.
[Sejnowski, Terrence J.] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA.
RP Srinivasan, L (reprint author), Univ Calif Los Angeles, Neural Signal Proc Lab, Dept Radiol, Los Angeles, CA 90024 USA.
EM ls2@nsplab.org
RI Asaad, Wael/I-8485-2012
OI Asaad, Wael/0000-0003-4406-9096
FU American Heart Association Scientist Development Grant [11SDG7550015];
DARPA Reliable Neural-Interface Technology (RE-NET) Program; UCLA
Radiology Exploratory Development Grant; Massachusetts Biomedical
Research Corporation; Howard Hughes Medical Institute; National Science
Foundation [IOB 0645886]; National Institutes of Health [NEI
R01EY017658, NIDA R01DA026297, NIMH MH086400]; Klingenstein Foundation
FX LS is supported by the American Heart Association Scientist Development
Grant (11SDG7550015), the DARPA Reliable Neural-Interface Technology
(RE-NET) Program, and the UCLA Radiology Exploratory Development Grant.
WFA is supported by a Tosteson award from the Massachusetts Biomedical
Research Corporation. TJS is supported by the Howard Hughes Medical
Institute. EE is supported by grants from the National Science
Foundation (IOB 0645886), the National Institutes of Health (NEI
R01EY017658, NIDA R01DA026297, NIMH MH086400), the Howard Hughes Medical
Institute, and the Klingenstein Foundation. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 61
TC 9
Z9 9
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 27
PY 2013
VL 8
IS 2
AR e55247
DI 10.1371/journal.pone.0055247
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 098BN
UT WOS:000315519000006
PM 23460783
ER
PT J
AU Tao, WC
Higgs, MH
Spain, WJ
Ransom, CB
AF Tao, Wucheng
Higgs, Matthew H.
Spain, William J.
Ransom, Christopher B.
TI Postsynaptic GABA(B) Receptors Enhance Extrasynaptic GABA(A) Receptor
Function in Dentate Gyrus Granule Cells
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID LONG-TERM POTENTIATION; TONIC INHIBITION; RAT HIPPOCAMPUS;
MOLECULAR-BASIS; B RECEPTORS; ACTIVATION; NEURONS; MODULATION;
LOCALIZATION; EXCITABILITY
AB Ambient GABA in the brain tonically activates extrasynaptic GABA(A) receptors, and activity-dependent changes in ambient GABA concentration can also activate GABA(B) receptors. To investigate an interaction between postsynaptic GABA(B) and GABA(A) receptors, we recorded GABA(A) currents elicited by exogenous GABA (10 mu M) from dentate gyrus granule cells (DGGCs) in adult rat hippocampal slices. The GABA(B) receptor agonist baclofen (20 mu M) enhanced GABA(A) currents. This enhancement was blocked by the GABA(B) receptor antagonist CGP 55845 and intracellular solutions containing the GTP analog GDP-beta-s, indicating that baclofen was acting on postsynaptic GABA(B) receptors. Modulation of GABA(A) currents by postsynaptic GABA(B) receptors was not observed in CA1 pyramidal cells or layer 2/3 cortical pyramidal neurons. Baclofen reduced the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) but did not alter sIPSC amplitude or kinetics. Thus, GABA(A) receptors activated at synapses were not modulated by postsynaptic GABA(B) receptors. In contrast, tonic GAB(A) currents and currents activated by the GABA(A) receptor delta subunit-selective agonist THIP (10 mu M) were potentiated by baclofen. Our data indicate that postsynaptic GABA(B) receptors enhance the function of extrasynaptic GABA(A) receptors, including delta subunit-containing receptors that mediate tonic inhibition in DGGCs. The modulation of GABA(A) receptor function by postsynaptic GABA(B) receptors is a newly identified mechanism that will influence the inhibitory tone of DGGCs when GABA(B) and GABA(A) receptors are both activated.
C1 [Higgs, Matthew H.; Spain, William J.; Ransom, Christopher B.] Vet Affairs Puget Sound Hlth Care Syst, Epilepsy Ctr Excellence, Seattle, WA 98108 USA.
[Tao, Wucheng; Higgs, Matthew H.; Spain, William J.] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA.
[Spain, William J.; Ransom, Christopher B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
RP Ransom, CB (reprint author), Univ Washington, Dept Neurol, Epilepsy Ctr Excellence, VA Puget Sound, 1600 South Columbian Way, Seattle, WA 98108 USA.
EM cbr5@uw.edu
FU Veterans Affairs (VA) Merit Review Award; VA Career Development Award;
VA Epilepsy Centers of Excellence
FX This work was supported by a Veterans Affairs (VA) Merit Review Award
(W.J.S.), a VA Career Development Award (C.B.R.), and the VA Epilepsy
Centers of Excellence (C.B.R., W.J.S., M.H.H.). The authors appreciate
the expert technical assistance of Sue Usher and discussions with
Professor Bertil Hille during the course of experiments.
NR 36
TC 28
Z9 31
U1 0
U2 9
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD FEB 27
PY 2013
VL 33
IS 9
BP 3738
EP 3743
DI 10.1523/JNEUROSCI.4829-12.2013
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 098ZO
UT WOS:000315588000002
PM 23447585
ER
PT J
AU Kokel, D
Dunn, TW
Ahrens, MB
Alshut, R
Cheung, CYJ
Saint-Amant, L
Bruni, G
Mateus, R
van Ham, TJ
Shiraki, T
Fukada, Y
Kojima, D
Yeh, JRJ
Mikut, R
von Lintig, J
Engert, F
Peterson, RT
AF Kokel, David
Dunn, Timothy W.
Ahrens, Misha B.
Alshut, Ruediger
Cheung, Chung Yan J.
Saint-Amant, Louis
Bruni, Giancarlo
Mateus, Rita
van Ham, Tjakko J.
Shiraki, Tomoya
Fukada, Yoshitaka
Kojima, Daisuke
Yeh, Jing-Ruey J.
Mikut, Ralf
von Lintig, Johannes
Engert, Florian
Peterson, Randall T.
TI Identification of Nonvisual Photomotor Response Cells in the Vertebrate
Hindbrain
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID ZEBRAFISH DANIO-RERIO; DEEP BRAIN; IN-VIVO; PHOTORECEPTIVE MOLECULE;
LARVAL ZEBRAFISH; LOCOMOTOR NETWORK; GANGLION-CELLS; LIGHT; PINEAL;
OPSIN
AB Nonvisual photosensation enables animals to sense light without sight. However, the cellular and molecular mechanisms of nonvisual photobehaviors are poorly understood, especially in vertebrate animals. Here, we describe the photomotor response (PMR), a robust and reproducible series of motor behaviors in zebrafish that is elicited by visual wavelengths of light but does not require the eyes, pineal gland, or other canonical deep-brain photoreceptive organs. Unlike the relatively slow effects of canonical nonvisual pathways, motor circuits are strongly and quickly (seconds) recruited during the PMR behavior. We find that the hindbrain is both necessary and sufficient to drive these behaviors. Using in vivo calcium imaging, we identify a discrete set of neurons within the hindbrain whose responses to light mirror the PMR behavior. Pharmacological inhibition of the visual cycle blocks PMR behaviors, suggesting that opsin-based photoreceptors control this behavior. These data represent the first known light-sensing circuit in the vertebrate hindbrain.
C1 [Kokel, David; Cheung, Chung Yan J.; Bruni, Giancarlo; Mateus, Rita; van Ham, Tjakko J.; Yeh, Jing-Ruey J.; Peterson, Randall T.] Harvard Univ, Cardiovasc Res Ctr, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA.
[Kokel, David; Cheung, Chung Yan J.; Bruni, Giancarlo; Mateus, Rita; van Ham, Tjakko J.; Yeh, Jing-Ruey J.; Peterson, Randall T.] Harvard Univ, Div Cardiol, Massachusetts Gen Hosp, Sch Med,Dept Med, Charlestown, MA 02129 USA.
[Kokel, David; Cheung, Chung Yan J.; Bruni, Giancarlo; Mateus, Rita; van Ham, Tjakko J.; Peterson, Randall T.] Broad Inst, Cambridge, MA 02142 USA.
[Dunn, Timothy W.; Ahrens, Misha B.; Engert, Florian] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
[Shiraki, Tomoya; Fukada, Yoshitaka; Kojima, Daisuke] Univ Tokyo, Dept Biophys & Biochem, Grad Sch Sci, Tokyo 1130033, Japan.
[Alshut, Ruediger; Mikut, Ralf] Karlsruhe Inst Technol, Inst Appl Comp Sci, D-76128 Karlsruhe, Germany.
[Saint-Amant, Louis] Univ Montreal, Montreal, PQ H3C 3J7, Canada.
[von Lintig, Johannes] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA.
RP Kokel, D (reprint author), Harvard Univ, Cardiovasc Res Ctr, Massachusetts Gen Hosp, Sch Med, 149 13th St, Charlestown, MA 02129 USA.
EM dkokel@cvrc.mgh.harvard.edu; peterson@cvrc.mgh.harvard.edu
RI van Ham, Tjakko/I-2382-2013; Kojima, Daisuke/G-4958-2014; Mikut, Ralf
/A-5949-2013; van Ham, Tjakko/A-1989-2015;
OI Kojima, Daisuke/0000-0003-2658-780X; Mikut, Ralf /0000-0001-9100-5496;
van Ham, Tjakko/0000-0002-2175-8713; Shiraki,
Tomoya/0000-0003-0447-007X; Bruni, Giancarlo/0000-0003-2850-4633
FU National Institutes of Health [K01MH091449, R01MH086867, R21MH085205,
DP1 NS082121, R01DA030304]; Japan Society for the Promotion of Science;
National Science Foundation Graduate Research Fellowship; Sir Henry
Wellcome Postdoctoral Fellowship from the Wellcome Trust; Charles and
Ann Sanders MGH Research Scholar award
FX This work was supported by National Institutes of Health Grants
K01MH091449 to D. Kokel, R01MH086867 and R21MH085205 to R.T.P., and DP1
NS082121 and R01DA030304 to T.W.D. and F.E. This work was supported in
part by Grants-in-Aid for Scientific Research from Japan Society for the
Promotion of Science to Y.F. and D. Kojima, T.W.D. was supported by the
National Science Foundation Graduate Research Fellowship. M.B.A. was
supported by a Sir Henry Wellcome Postdoctoral Fellowship from the
Wellcome Trust. R.T.P. was supported by the Charles and Ann Sanders MGH
Research Scholar award. We thank John Dowling and members of our
research groups for encouragement and advice.
NR 62
TC 27
Z9 27
U1 3
U2 21
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD FEB 27
PY 2013
VL 33
IS 9
BP 3834
EP 3843
DI 10.1523/JNEUROSCI.3689-12.2013
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA 098ZO
UT WOS:000315588000012
PM 23447595
ER
PT J
AU Cruz, RJ
Dew, MA
Myaskovsky, L
Goodpaster, B
Fox, K
Fontes, P
DiMartini, A
AF Cruz, Ruy J., Jr.
Dew, Mary Amanda
Myaskovsky, Larissa
Goodpaster, Bret
Fox, Kristen
Fontes, Paulo
DiMartini, Andrea
TI Objective Radiologic Assessment of Body Composition in Patients with
End-Stage Liver Disease: Going Beyond the BMI
SO TRANSPLANTATION
LA English
DT Article
DE Radiologic assessment; Assessment liver transplant candidates; Body
composition; Cachexia
ID COMPUTED-TOMOGRAPHY; MASS INDEX; INSULIN SENSITIVITY; SARCOPENIC
OBESITY; ADIPOSE-TISSUE; MUSCLE MASS; MORTALITY; CIRRHOSIS;
HEMODIALYSIS; SURVIVAL
AB Background. Body mass index (BMI) is a commonly used but likely inexact measure of body composition for patients with end-stage liver disease. For this reason, we examined whether body composition measurements from direct visualization on computed tomography (CT) scans provide new insights in both the degree of malnutrition and the discordant combinations such as obesity with muscle mass loss. This technology is widely used in other medically ill populations but not yet in liver transplantation.
Methods. We examined actual body composition using abdominal CT scan data and software designed to measure fat and muscle compartments.
Results. In 234 liver transplant candidates, we found that BMI was highly and significantly correlated to subcutaneous and visceral fat. However, we additionally found that, even among obese patients, cachexia, as defined by muscle mass, was common, with 56% of those with BMI above 30 being cachexic. We also found that patients with nonalcoholic steatohepatitis, compared with other types of liver diseases, were significantly more likely to have larger amounts of visceral fat while also having less muscle. In an exploratory analysis, muscle mass corrected for height was a significant predictor of posttransplantation survival.
Conclusions. Body composition by CT scan data provides a specific method to identify obesity and muscle wasting for end-stage liver disease patients. Whether these data can aid in the prognostication of outcomes and survival requires further investigation.
C1 [Cruz, Ruy J., Jr.; Fontes, Paulo; DiMartini, Andrea] Univ Pittsburgh, Dept Transplantat Surg, Med Ctr, Pittsburgh, PA USA.
[Dew, Mary Amanda; Myaskovsky, Larissa; Fox, Kristen; DiMartini, Andrea] Univ Pittsburgh, Dept Psychiat, Med Ctr, Pittsburgh, PA USA.
[Dew, Mary Amanda] Univ Pittsburgh, Dept Psychol, Med Ctr, Pittsburgh, PA 15260 USA.
[Dew, Mary Amanda] Univ Pittsburgh, Dept Epidemiol, Med Ctr, Pittsburgh, PA 15261 USA.
[Myaskovsky, Larissa; Goodpaster, Bret] Univ Pittsburgh, Dept Med, Med Ctr, Pittsburgh, PA USA.
[Goodpaster, Bret] Univ Pittsburgh, Med Ctr, Dept Hlth & Phys Educ, Pittsburgh, PA USA.
[Dew, Mary Amanda] Univ Pittsburgh, Dept Biostat, Med Ctr, Pittsburgh, PA 15261 USA.
[Fontes, Paulo; DiMartini, Andrea] Univ Pittsburgh, Starzl Transplant Inst, Med Ctr, Pittsburgh, PA USA.
[Myaskovsky, Larissa] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[DiMartini, Andrea] Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA.
RP DiMartini, A (reprint author), Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA.
EM dimartiniaf@upmc.edu
FU National Institute of Digestive Disorders and Kidney Diseases
(Rockville, MD) [R01 DK066266]; National Center for Research Resources,
a component of the National Institutes of Health [5UL1 RR024153-04];
National Institutes of Health Roadmap for Medical Research; Starzl
Transplant Institute Junior Investigator Award
FX R.J.C.J. received the Starzl Transplant Institute Junior Investigator
Award to conduct this research. This research is also funded by grant
R01 DK066266 from the National Institute of Digestive Disorders and
Kidney Diseases (Rockville, MD) and grant 5UL1 RR024153-04 from the
National Center for Research Resources, a component of the National
Institutes of Health, and National Institutes of Health Roadmap for
Medical Research. Its contents are solely the responsibility of the
authors and do not necessarily represent the official view of the
National Institute of Digestive Disorders and Kidney Diseases, National
Center for Research Resources or National Institutes of Health.
Information on National Center for Research Resources is available at
http://www.ncrr.nih.gov/.
NR 24
TC 20
Z9 20
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD FEB 27
PY 2013
VL 95
IS 4
BP 617
EP 622
DI 10.1097/TP.0b013e31827a0f27
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 093NS
UT WOS:000315199200017
PM 23348896
ER
PT J
AU Walling, AM
Asch, SM
Lorenz, KA
Wenger, NS
AF Walling, Anne M.
Asch, Steven M.
Lorenz, Karl A.
Wenger, Neil S.
TI Impact of Consideration of Transplantation on End-of-Life Care for
Patients During a Terminal Hospitalization
SO TRANSPLANTATION
LA English
DT Article
DE Transplant; End-of-life care; Palliative care; Quality of care
ID LIVER-TRANSPLANTATION; SUSTAINING TREATMENTS; PALLIATIVE CARE; ADVANCED
CANCER; PREFERENCES; OUTCOMES
AB Background. Many patients considered for transplantation die before receiving the organ, underlining the importance of providing high-quality symptomatic relief and communication for all transplant patients.
Methods. To study how consideration of transplantation affects the end-of-life care received by patients, care was evaluated by abstracting medical records for 496 adults who died in one high-volume transplant medical center between April 2005 and April 2006. Sixteen quality indicators from the Assessing Care of Vulnerable Elders set that focused on communication and symptom management were measured to calculate an overall patient-level quality score. We evaluated the predictors of quality of end-of-life care, with the main independent variable being whether the patient was being considered for transplantation. Restricting to patients who died an "expected death," we also evaluated the end-of-life treatments received.
Results. Twenty-five percent of decedent patients were considered for transplantation. In adjusted models, patients considered for transplantation received lower-quality end-of-life care, had longer hospital stays before death, and were more likely to receive aggressive life-sustaining treatments.
Conclusions. Care models should incorporate an emphasis on symptom relief and communication along with transplant preparation.
C1 [Walling, Anne M.; Wenger, Neil S.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Wenger, Neil S.] Univ Calif Los Angeles, Hlth Syst Eth Ctr, Los Angeles, CA 90024 USA.
[Lorenz, Karl A.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
[Walling, Anne M.; Wenger, Neil S.] RAND Hlth, Santa Monica, CA USA.
[Asch, Steven M.] VA Palo Alto Healthcare Syst, Menlo Pk, CA USA.
[Asch, Steven M.] Stanford Sch Med, Palo Alto, CA USA.
[Walling, Anne M.] Univ Calif Los Angeles, Div Gen Internal Med, Los Angeles, CA 90024 USA.
RP Walling, AM (reprint author), Univ Calif Los Angeles, Div Gen Internal Med, 911 Broxton Plaza, Los Angeles, CA 90024 USA.
EM awalling@mednet.ucla.edu
FU National Palliative Care Research Center Career Development Award
FX This project was supported by a donation from Mary Kay Farley to RAND
Health. A.M.W. was supported by a National Palliative Care Research
Center Career Development Award.
NR 20
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD FEB 27
PY 2013
VL 95
IS 4
BP 641
EP 646
DI 10.1097/TP.0b013e318277f238
PG 6
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 093NS
UT WOS:000315199200021
PM 23197177
ER
PT J
AU Matarese, G
La Rocca, C
Moon, HS
Huh, JY
Brinkoetter, MT
Chou, SR
Perna, F
Greco, D
Kilim, HP
Gao, CY
Arampatzi, K
Wang, ZX
Mantzoros, CS
AF Matarese, Giuseppe
La Rocca, Claudia
Moon, Hyun-Seuk
Huh, Joo Young
Brinkoetter, Mary T.
Chou, Sharon
Perna, Francesco
Greco, Dario
Kilim, Holly P.
Gao, Chuanyun
Arampatzi, Kalliope
Wang, Zhaoxi
Mantzoros, Christos S.
TI Selective capacity of metreleptin administration to reconstitute CD4(+)
T-cell number in females with acquired hypoleptinemia
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Editorial Material
ID HUMAN PHYSIOLOGY; LEPTIN
C1 [Matarese, Giuseppe; La Rocca, Claudia] Univ Salerno, Dipartimento Med & Chirurg, I-84081 Baronissi, Italy.
[Matarese, Giuseppe; La Rocca, Claudia] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Consiglio Nazl Ric, Lab Immunol,Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy.
[Perna, Francesco] Univ Naples Federico II, Dipartimento Med Clin & Sperimentale, I-80131 Naples, Italy.
[Moon, Hyun-Seuk; Huh, Joo Young; Brinkoetter, Mary T.; Chou, Sharon; Kilim, Holly P.; Gao, Chuanyun; Arampatzi, Kalliope; Mantzoros, Christos S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA.
[Greco, Dario] Karolinska Inst, Dept Biosci & Nutr, S-14183 Stockholm, Sweden.
[Wang, Zhaoxi] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Mantzoros, Christos S.] Harvard Univ, Sch Med, Boston VA Healthcare Syst, Sect Endocrinol, Boston, MA 02130 USA.
RP Mantzoros, CS (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA.
EM cmantzor@bidmc.harvard.edu
NR 4
TC 0
Z9 0
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 26
PY 2013
VL 110
IS 9
BP 3225
EP 3226
DI 10.1073/pnas.1214554110
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 102JW
UT WOS:000315841900014
ER
PT J
AU Matarese, G
La Rocca, C
Moon, HS
Huh, JY
Brinkoetter, MT
Chou, S
Perna, F
Greco, D
Kilim, HP
Gao, CY
Arampatzi, K
Wang, ZX
Mantzoros, CS
AF Matarese, Giuseppe
La Rocca, Claudia
Moon, Hyun-Seuk
Huh, Joo Young
Brinkoetter, Mary T.
Chou, Sharon
Perna, Francesco
Greco, Dario
Kilim, Holly P.
Gao, Chuanyun
Arampatzi, Kalliope
Wang, Zhaoxi
Mantzoros, Christos S.
TI Selective capacity of metreleptin administration to reconstitute CD4(+)
T-cell number in females with acquired hypoleptinemia
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE CD4 cells; metabolism; nutritional status
ID ACTIVE ANTIRETROVIRAL THERAPY; INSULIN-RESISTANCE; IMMUNE-RESPONSE;
METABOLIC SYNDROME; HUMAN LEPTIN; PROBE LEVEL; RECEPTOR;
IMMUNODEFICIENCY; SURVIVAL; LYMPHOCYTES
AB Edited by Philippa Marrack, Howard Hughes Medical Institute, National Jewish Health, Denver, CO, and approved December 19, 2012 (received for review August 24, 2012) Leptin is an adipocyte-derived hormone that controls food intake and reproductive and immune functions in rodents. In uncontrolled human studies, low leptin levels are associated with impaired immune responses and reduced T-cell counts; however, the effects of leptin replacement on the adaptive immune system have not yet been reported in the context of randomized, controlled studies and/or in conditions of chronic acquired leptin deficiency. To address these questions, we performed a randomized, double-blinded, placebo-controlled trial of recombinant methionyl-human leptin (metreleptin) administration in replacement doses in women experiencing the female triad (hypothalamic amenorrhea) with acquired chronic hypoleptinemia induced by negative energy balance. Metreleptin restored both CD4(+) T-cell counts and their in vitro proliferative responses in these women. These changes were accompanied by a transcriptional signature in which genes relevant to cell survival and hormonal response were up-regulated, and apoptosis genes were down-regulated in circulating immune cells. We also observed that signaling pathways involved in cell growth/survival/proliferation, such as the STAT3, AMPK, mTOR, ERK1/2, and Akt pathways, were activated directly by acute in vivo metreleptin administration in peripheral blood mononuclear cells and CD4(+) T-cells both from subjects with chronic hypoleptinemia and from normoleptinemic, lean female subjects. Our data show that metreleptin administration, in doses that normalize circulating leptin levels, induces transcriptional changes, activates intracellular signaling pathways, and restores CD4(+) T-cell counts. Thus, metreleptin may prove to be a safe and effective therapy for selective CD4(+) T-cell immune reconstitution in hypoleptinemic states such as tuberculosis and HIV infection in which CD4(+) T cells are reduced.
C1 [Matarese, Giuseppe; La Rocca, Claudia] Univ Salerno, Dipartimento Med & Chirurg, I-84081 Baronissi, Italy.
[Matarese, Giuseppe; La Rocca, Claudia] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Consiglio Nazl Ric, Ist Endocrinol & Oncol Sperimentale,Lab Immunol, I-80131 Naples, Italy.
[Perna, Francesco] Univ Naples Federico II, Dipartimento Med Clin & Sperimentale, I-80131 Naples, Italy.
[Moon, Hyun-Seuk; Huh, Joo Young; Brinkoetter, Mary T.; Chou, Sharon; Kilim, Holly P.; Gao, Chuanyun; Arampatzi, Kalliope; Mantzoros, Christos S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA.
[Greco, Dario] Karolinska Inst, Dept Biosci & Nutr, S-14183 Stockholm, Sweden.
[Wang, Zhaoxi] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Mantzoros, Christos S.] Harvard Univ, Sch Med, Boston VA Healthcare Syst, Endocrinol Sect, Boston, MA 02130 USA.
RP Mantzoros, CS (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA.
EM cmantzor@bidmc.harvard.edu
RI Moon, Hyun-Seuk/G-8576-2015
OI Moon, Hyun-Seuk/0000-0002-5216-2090
FU National Institute of Diabetes and Digestive and Kidney Diseases
[DK58785, DK79929, DK81913, AG032030]; National Institutes of
Health-National Center for Research [UL1 RR025758, M01-RR-01032];
Harvard Clinical and Translational Science Center; National Center for
Research Resources; European Union Ideas Programme; European Research
Council Starting Grant "menTORingTregs" [310496]; Telethon-Juvenal
Diabetes Research Foundation [GJT08004]; Fondi per la Ricerca di Base
Medical Research in Italy [RBNE08HWLZ]
FX We thank Claudio Procaccini, Fortunate Carbone, and Mario Galgani for
critical reading of the manuscript; Jean Chan, MD, for contributions
during initial phases of the study; and the nurses, technicians, and
nutritionists at the Beth Israel Deaconess Medical Center General
Clinical Research Center and Core Laboratory for their assistance in the
conduct of the study. Amylin Pharmaceuticals supplied recombinant human
leptin for this study and approved the design of the study but had no
role in study design; conduct of the study; collection, management,
analysis, or interpretation of the data; or the preparation, review, or
approval of the manuscript. The C.S.M. laboratory is supported by
National Institute of Diabetes and Digestive and Kidney Diseases Grants
DK58785, DK79929, DK81913, and AG032030. Funding also was received from
the National Institutes of Health-National Center for Research Grants
UL1 RR025758 and M01-RR-01032; the Harvard Clinical and Translational
Science Center; and the National Center for Research Resources. G.M. is
supported by grants from the European Union Ideas Programme, European
Research Council Starting Grant "menTORingTregs" 310496,
Telethon-Juvenal Diabetes Research Foundation Grant GJT08004, and Fondi
per la Ricerca di Base Medical Research in Italy Grant RBNE08HWLZ.
NR 47
TC 22
Z9 23
U1 0
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 26
PY 2013
VL 110
IS 9
BP E818
EP E827
DI 10.1073/pnas.1214554110
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 130VH
UT WOS:000317947700006
PM 23382191
ER
PT J
AU Emerling, BM
Benes, CH
Poulogiannis, G
Bell, EL
Courtney, K
Liu, H
Choo-Wing, R
Bellinger, G
Tsukazawa, KS
Brown, V
Signoretti, S
Soltoff, SP
Cantley, LC
AF Emerling, Brooke M.
Benes, Cyril H.
Poulogiannis, George
Bell, Eric L.
Courtney, Kevin
Liu, Hui
Choo-Wing, Rayman
Bellinger, Gary
Tsukazawa, Kazumi S.
Brown, Victoria
Signoretti, Sabina
Soltoff, Stephen P.
Cantley, Lewis C.
TI Identification of CDCP1 as a hypoxia-inducible factor 2 alpha (HIF-2
alpha) target gene that is associated with survival in clear cell renal
cell carcinoma patients
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE kidney cancer; oxygen deprivation
ID DOMAIN-CONTAINING PROTEIN-1; CUB-DOMAIN; PKC-DELTA; PROLYL
HYDROXYLATION; TUMOR-CELLS; HIF-ALPHA; VHL LOSS; CANCER; SRC; INHIBITION
AB CUB domain-containing protein 1 (CDCP1) is a transmembrane protein that is highly expressed in stem cells and frequently overexpressed,and tyrosine-phosphorylated in cancer. CDCP1 promotes cancer cell metastasis. However, the mechanisms that regulate CDCP1 are not well-defined. Here we show that hypoxia induces CDCP1 expression and tyrosine phosphorylation in hypoxia-inducible factor (HIF)-2 alpha-, but not HIF-l alpha-, dependent fashion. shRNA knockdown of CDCP1 impairs cancer cell migration under hypoxic conditions, whereas overexpression of HIF-2 alpha promotes the growth of tumor xenografts in association with enhanced CDCP1 expression and tyrosine phosphorylation. Immunohistochemistry analysis of tissue microarray samples from tumors of patients with clear cell renal cell carcinoma shows that increased CDCP1 expression correlates with decreased overall survival. Together, these data support a critical role for CDCP1 as a unique HIF-2 alpha target gene involved in the regulation of cancer metastasis, and suggest that CDCP1 is a biomarker and potential therapeutic target for metastatic cancers.
C1 [Emerling, Brooke M.; Poulogiannis, George; Liu, Hui; Choo-Wing, Rayman; Bellinger, Gary; Tsukazawa, Kazumi S.; Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
[Emerling, Brooke M.; Poulogiannis, George; Liu, Hui; Choo-Wing, Rayman; Bellinger, Gary; Tsukazawa, Kazumi S.; Soltoff, Stephen P.; Cantley, Lewis C.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA.
[Benes, Cyril H.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.
[Benes, Cyril H.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Bell, Eric L.] MIT, Dept Biol, Paul F Glenn Lab, Cambridge, MA 02139 USA.
[Courtney, Kevin; Brown, Victoria; Signoretti, Sabina] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Courtney, Kevin] Univ Texas SW Med Ctr Dallas, Div Hematol Oncol, Dallas, TX 75390 USA.
[Brown, Victoria; Signoretti, Sabina] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Cantley, LC (reprint author), Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
EM lewis_cantley@hms.harvard.edu
RI Cantley, Lewis/D-1800-2014
OI Cantley, Lewis/0000-0002-1298-7653
FU National Institutes of Health [5R01GM056203-15]; American Cancer Society
(ACS) [PF-08215-01-TBE]; DF/HCC Career Development Award
FX We thank William G. Kaelin for the HIF-2 alpha antibody and for the RCC
cell lines, Victoria Petkova for the qRT-PCR analysis (Real Time PCR
Core, BIDMC), and the entire DF/HCC Kidney Cancer Specialized Programs
of Research Excellence (SPORE) team. This work was supported by National
Institutes of Health Grant 5R01GM056203-15 (to L.C.C.), American Cancer
Society (ACS) Grant PF-08215-01-TBE, and a DF/HCC Career Development
Award (to B.M.E.). G.P. is a Pfizer Fellow of the Life Sciences Research
Foundation.
NR 34
TC 16
Z9 17
U1 0
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 26
PY 2013
VL 110
IS 9
BP 3483
EP 3488
DI 10.1073/pnas.1222435110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 102JW
UT WOS:000315841900059
PM 23378636
ER
PT J
AU Seok, J
Warren, HS
Cuenca, AG
Mindrinos, MN
Baker, HV
Xu, WH
Richards, DR
McDonald-Smith, GP
Gao, H
Hennessy, L
Finnerty, CC
Lopez, CM
Honari, S
Moore, EE
Minei, JP
Cuschieri, J
Bankey, PE
Johnson, JL
Sperry, J
Nathens, AB
Billiar, TR
West, MA
Jeschke, MG
Klein, MB
Gamelli, RL
Gibran, NS
Brownstein, BH
Miller-Graziano, C
Calvano, SE
Mason, PH
Cobb, JP
Rahme, LG
Lowry, SF
Maier, RV
Moldawer, LL
Herndon, DN
Davis, RW
Xiao, WZ
Tompkins, RG
AF Seok, Junhee
Warren, H. Shaw
Cuenca, Alex G.
Mindrinos, Michael N.
Baker, Henry V.
Xu, Weihong
Richards, Daniel R.
McDonald-Smith, Grace P.
Gao, Hong
Hennessy, Laura
Finnerty, Celeste C.
Lopez, Cecilia M.
Honari, Shari
Moore, Ernest E.
Minei, Joseph P.
Cuschieri, Joseph
Bankey, Paul E.
Johnson, Jeffrey L.
Sperry, Jason
Nathens, Avery B.
Billiar, Timothy R.
West, Michael A.
Jeschke, Marc G.
Klein, Matthew B.
Gamelli, Richard L.
Gibran, Nicole S.
Brownstein, Bernard H.
Miller-Graziano, Carol
Calvano, Steve E.
Mason, Philip H.
Cobb, J. Perren
Rahme, Laurence G.
Lowry, Stephen F.
Maier, Ronald V.
Moldawer, Lyle L.
Herndon, David N.
Davis, Ronald W.
Xiao, Wenzhong
Tompkins, Ronald G.
CA Inflammation Host Response Injury
TI Genomic responses in mouse models poorly mimic human inflammatory
diseases
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE human disease; translational medicine; inflammation; immune response;
injury
ID LEUKOCYTE GENE-EXPRESSION; HUMAN IMMUNOLOGY; INFECTIOUS-DISEASES;
SEPSIS; MICE; RESISTANCE; TOLERANCE; ENDOTOXIN; ANIMALS; INJURY
AB A cornerstone of modern biomedical research is the use of mouse models to explore basic pathophysiological mechanisms, evaluate new therapeutic approaches, and make go or no-go decisions to carry new drug candidates forward into clinical trials. Systematic studies evaluating how well murine models mimic human inflammatory diseases are nonexistent. Here, we show that, although acute inflammatory stresses from different etiologies result in highly similar genomic responses in humans, the responses in corresponding mouse models correlate poorly with the human conditions and also, one another. Among genes changed significantly in humans, the murine orthologs are close to random in matching their human counterparts (e.g., R-2 between 0.0 and 0.1). In addition to improvements in the current animal model systems, our study supports higher priority for translational medical research to focus on the more complex human conditions rather than relying on mouse models to study human inflammatory diseases.
C1 [Seok, Junhee; Mindrinos, Michael N.; Xu, Weihong; Gao, Hong; Davis, Ronald W.; Xiao, Wenzhong] Stanford Univ, Stanford Genome Technol Ctr, Stanford, CA 94305 USA.
[Warren, H. Shaw] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat & Med, Boston, MA 02114 USA.
[Cobb, J. Perren] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesiol & Crit Care Med, Boston, MA 02114 USA.
[Rahme, Laurence G.; Xiao, Wenzhong; Tompkins, Ronald G.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA 02114 USA.
[Cuenca, Alex G.; Baker, Henry V.; Lopez, Cecilia M.; Moldawer, Lyle L.] Univ Florida, Coll Med, Dept Surg, Gainesville, FL 32610 USA.
[Richards, Daniel R.] Ingenuity Inc, Redwood City, CA 94063 USA.
[McDonald-Smith, Grace P.; Mason, Philip H.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Hennessy, Laura; Honari, Shari] Harborview Med Ctr, Dept Surg, Seattle, WA 98195 USA.
[Finnerty, Celeste C.; Herndon, David N.] Univ Texas Med Branch, Shriners Hosp Children, Galveston, TX 77550 USA.
[Finnerty, Celeste C.; Herndon, David N.] Univ Texas Med Branch, Dept Surg, Galveston, TX 77550 USA.
[Moore, Ernest E.; Johnson, Jeffrey L.] Univ Colorado, Dept Surg, Denver, CO 80045 USA.
[Minei, Joseph P.] Univ Texas SW Med Ctr Dallas, Dept Surg, Parkland Mem Hosp, Dallas, TX 75390 USA.
[Cuschieri, Joseph; Klein, Matthew B.; Gibran, Nicole S.; Maier, Ronald V.] Univ Washington, Sch Med, Dept Surg, Harborview Med Ctr, Seattle, WA 98195 USA.
[Bankey, Paul E.; Miller-Graziano, Carol] Univ Rochester, Sch Med, Dept Surg, Rochester, NY 14642 USA.
[Sperry, Jason; Billiar, Timothy R.] Univ Pittsburgh, Dept Surg, Med Ctr, Presbyterian Univ Hosp, Pittsburgh, PA 15213 USA.
[Nathens, Avery B.] Univ Toronto, St Michaels Hosp, Dept Surg, Toronto, ON M5B 1W8, Canada.
[West, Michael A.] Univ Calif San Francisco, Dept Surg, San Francisco Gen Hosp, San Francisco, CA 94143 USA.
[Jeschke, Marc G.] Univ Toronto, Div Plast & Reconstruct Surg, Dept Surg, Toronto, ON M4N 3M5, Canada.
[Gamelli, Richard L.] Loyola Univ, Stritch Sch Med, Dept Surg, Chicago, IL 60153 USA.
[Brownstein, Bernard H.] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA.
[Calvano, Steve E.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA.
RP Davis, RW (reprint author), Stanford Univ, Stanford Genome Technol Ctr, Stanford, CA 94305 USA.
EM dbowe@stanford.edu; wxiao1@partners.org; rtompkins@partners.org
OI xiao, wenzhong/0000-0003-4944-6380
FU Defense Advanced Research Projects Agency [W9111NF-10-1-0271]; National
Institute on Disability and Rehabilitation Research [H133A070026];
National Institute of General Medical Sciences [5P50GM060338,
5R01GM056687, R24GM102656, 5U54GM062119]; National Human Genome Research
Institute [P01HG000205]
FX The datasets reported in the paper are available on GEO with accession
numbers listed in SI Appendix. This work was supported by Defense
Advanced Research Projects Agency Grant W9111NF-10-1-0271 (to H.S.W.),
National Institute on Disability and Rehabilitation Research Grant
H133A070026 (to D.N.H.), National Institute of General Medical Sciences
Grants 5P50GM060338 (to D.N.H.), 5R01GM056687 (to D.N.H.), R24GM102656
(to W. Xiao), and 5U54GM062119 (to R.G.T.), and National Human Genome
Research Institute Grant P01HG000205 (to R.W.D.).
NR 34
TC 1009
Z9 1014
U1 15
U2 177
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 26
PY 2013
VL 110
IS 9
BP 3507
EP 3512
DI 10.1073/pnas.1222878110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 102JW
UT WOS:000315841900063
PM 23401516
ER
PT J
AU Bohr, S
Patel, SJ
Shen, KY
Vitalo, AG
Brines, M
Cerami, A
Berthiaume, F
Yarmush, ML
AF Bohr, Stefan
Patel, Suraj J.
Shen, Keyue
Vitalo, Antonia G.
Brines, Michael
Cerami, Anthony
Berthiaume, Francois
Yarmush, Martin L.
TI Alternative erythropoietin-mediated signaling prevents secondary
microvascular thrombosis and inflammation within cutaneous burns
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE thermal injury; hypoxia; oxidative stress; leukocyte infiltration; cell
adhesion molecules
ID KERATINOCYTE GROWTH-FACTOR; BETA-COMMON-RECEPTOR; TNF-ALPHA; BARRIER
FUNCTION; TERTIARY STRUCTURE; CELLS; INJURY; ANGIOGENESIS; REGENERATION;
EXPRESSION
AB Alternate erythropoietin (EPO)-mediated signaling via the heteromeric receptor composed of the EPO receptor and the beta-common receptor (CD131) exerts the tissue-protective actions of EPO in various types of injuries. Herein we investigated the effects of the EPO derivative helix beta surface peptide (synonym: ARA290), which specifically triggers alternate EPO-mediated signaling, but does not bind the erythropoietic EPO receptor homodimer, on the progression of secondary tissue damage following cutaneous burns. For this purpose, a deep partial thickness cutaneous burn injury was applied on the back of mice, followed by systemic administration of vehicle or ARA290 at 1, 12, and 24 h postburn. With vehicle-only treatment, wounds exhibited secondary microvascular thrombosis within 24 h postburn, and subsequent necrosis of the surrounding tissue, thus converting to a full-thickness injury within 48 h. On the other hand, when ARA290 was systemically administered, patency of the microvasculature was maintained. Furthermore, ARA290 mitigated the innate inflammatory response, most notably tumor necrosis factor-alpha mediated signaling. These findings correlated with long-term recovery of initially injured yet viable tissue cornponents. In conclusion, ARA290 may be a promising therapeutic approach to prevent the conversion of partial- to full-thickness burn injuries. In a clinical setting, the decrease in burn depth and area would likely reduce the necessity for extensive surgical debridement as well as secondary wound closure by means of skin grafting. This use of ARA290 is consistent with its tissue-protective properties previously reported in other models of injury, such as myocardial infarction and hemorrhagic shock.
C1 [Bohr, Stefan; Patel, Suraj J.; Shen, Keyue; Vitalo, Antonia G.; Yarmush, Martin L.] Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA.
[Bohr, Stefan; Patel, Suraj J.; Shen, Keyue; Vitalo, Antonia G.; Yarmush, Martin L.] Shriners Hosp Children, Boston, MA 02114 USA.
[Brines, Michael; Cerami, Anthony] Araim Pharmaceut, Ossining, NY 10562 USA.
[Berthiaume, Francois; Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA.
RP Yarmush, ML (reprint author), Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA.
EM ireis@sbi.org
OI Brines, Michael/0000-0003-4151-4449
FU Shriners Hospital for Children; Deutsche Forschungsgemeinschaft
(Germany) [GZ: BO3468/2-1]
FX The peptides ARA290 and ARA297 were kindly provided by Araim
Pharmaceuticals, Inc. (Ossining, NY). This work was funded by the
Shriners Hospital for Children. S.B. is a recipient of Deutsche
Forschungsgemeinschaft (Germany) postdoctoral fellowship Award GZ:
BO3468/2-1. S.J.P. was supported by a Shriners Hospital for Children
postdoctoral fellowship award.
NR 39
TC 21
Z9 22
U1 0
U2 14
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 26
PY 2013
VL 110
IS 9
BP 3513
EP 3518
DI 10.1073/pnas.1214099110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 102JW
UT WOS:000315841900064
PM 23401545
ER
PT J
AU Mebazaa, A
Gayat, E
Lassus, J
Meas, T
Mueller, C
Maggioni, A
Peacock, F
Spinar, J
Harjola, VP
van Kimmenade, R
Pathak, A
Mueller, T
Tavazzi, L
Disomma, S
Metra, M
Pascual-Figal, D
Laribi, S
Logeart, D
Nouira, S
Sato, N
Parenica, J
Deye, N
Boukef, R
Collet, C
Van den Berghe, G
Cohen-Solal, A
Januzzi, JL
AF Mebazaa, Alexandre
Gayat, Etienne
Lassus, Johan
Meas, Taly
Mueller, Christian
Maggioni, Aldo
Peacock, Frank
Spinar, Jindrich
Harjola, Veli-Pekka
van Kimmenade, Roland
Pathak, Atul
Mueller, Thomas
Tavazzi, Luigi
diSomma, Salvatore
Metra, Marco
Pascual-Figal, Domingo
Laribi, Said
Logeart, Damien
Nouira, Semir
Sato, Naoki
Parenica, Jiri
Deye, Nicolas
Boukef, Riadh
Collet, Corinne
Van den Berghe, Greet
Cohen-Solal, Alain
Januzzi, James L., Jr.
CA GREAT Network
TI Association Between Elevated Blood Glucose and Outcome in Acute Heart
Failure Results From an International Observational Cohort
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE acute heart failure; blood glucose; 30-day mortality; hyperglycemia
ID ACUTE MYOCARDIAL-INFARCTION; STRESS HYPERGLYCEMIA; NATRIURETIC PEPTIDE;
DIABETES-MELLITUS; ADMISSION GLUCOSE; ROC CURVE; MORTALITY; DISEASE;
RECLASSIFICATION; NORMALIZATION
AB Objective The aim of this analysis was to assess the association between elevated blood glucose level and mortality in acute heart failure (AHF).
Background Elevated blood glucose has been reported to be prognostically meaningful in patients with cardiac diagnoses, such as coronary artery disease. The short-term prognostic impact of hyperglycemia in AHF is unknown, however.
Methods In a multinational cohort of AHF, we examined the ability of blood glucose concentrations at presentation to predict all-cause mortality by 30 days. Fully adjusted models for prognosis included a previous diagnosis of diabetes mellitus as a covariate.
Results A total of 6,212 subjects with AHF (mean age, 72 years; 52.5% male) were studied; the median blood glucose concentration on arrival at the hospital was 7.5 mmol/l (135 mg/dl), and 41% had a previous diagnosis of diabetes mellitus (DM). After 30 days, 618 patients (10%) had died. Compared with survivors, decedents had significantly higher median blood glucose concentrations (8.9 mmol/l vs. 7.4 mmol/l; p < 0.0001). In the fully adjusted model, an elevated blood glucose level was an independent predictor of 30-day mortality in AHF (odds ratio: 2.19; 95% confidence interval: 1.69 to 2.83; p < 0.001). The risk associated with an elevated blood glucose level appeared consistent across all subgroups of patients, including patients with preserved (hazard ratio: 5.41; 95% confidence interval: 2.44 to 12.0; p < 0.0001) and impaired systolic function (hazard ratio: 2.37; 95% confidence interval: 1.57 to 3.59; p < 0.0001). Furthermore, in reclassification analyses, elevated blood glucose added significant prognostic information to clinical parameters alone (4.4% net reclassification improvement; p = 0.01).
Conclusions Among patients with AHF, blood glucose concentrations at presentation are powerfully prognostic for 30-day mortality, independent of a diagnosis of diabetes mellitus or other clinical variables. Because blood glucose is easily modifiable, it may represent a valid target for therapeutic intervention. (J Am Coll Cardiol 2013;61:820-9) (C) 2013 by the American College of Cardiology Foundation
C1 [Mebazaa, Alexandre; Gayat, Etienne] Univ Paris Diderot, AP HP, Lariboisiere Univ Hosp, Dept Anesthesiol & Intens Care, Paris, France.
[Mebazaa, Alexandre; Gayat, Etienne; Meas, Taly; Logeart, Damien; Deye, Nicolas; Collet, Corinne; Cohen-Solal, Alain] INSERM, UMR 942, Paris, France.
[Lassus, Johan] Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland.
[Meas, Taly] Univ Paris Diderot, AP HP, Lariboisiere Univ Hosp, Dept Endocrinol, Paris, France.
[Mueller, Christian] Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland.
[Maggioni, Aldo] ANMCO Res Ctr, Florence, Italy.
[Peacock, Frank] Cleveland Clin, Emergency Med Inst, Cleveland, OH 44106 USA.
[Spinar, Jindrich; Parenica, Jiri] Masaryk Univ, Fac Med, Univ Hosp Brno, Dept Internal Med & Cardiol, Brno, Czech Republic.
[Harjola, Veli-Pekka] Univ Helsinki, Cent Hosp, Div Emergency Care, Helsinki, Finland.
[van Kimmenade, Roland] Univ Med Ctr, Utrecht, Netherlands.
[Pathak, Atul] Toulouse Univ Hosp, Dept Cardiol, Toulouse, France.
[Mueller, Thomas] Konventhosp Barmherzige Brueder, Dept Lab Med, Linz, Austria.
[Tavazzi, Luigi] Maria Cecilia Hosp, Ettore Sansavini Hlth Sci Fdn, GVM Care & Res, Cotignola, Italy.
[diSomma, Salvatore] Univ Roma La Sapienza, SantAndrea Hosp, Emergency Dept, Rome, Italy.
[Metra, Marco] Univ Brescia, Dept Expt & Appl Med, Brescia, Italy.
[Pascual-Figal, Domingo] Univ Murcia, Fac Med, Dept Med, Virgen de la Arrixaca Hosp,Cardiol Serv, Murcia, Spain.
[Laribi, Said; Cohen-Solal, Alain] Univ Paris Diderot, AP HP, Lariboisiere Univ Hosp, Dept Emergency Med, Paris, France.
[Logeart, Damien; Boukef, Riadh] Univ Paris Diderot, AP HP, Lariboisiere Univ Hosp, Dept Cardiol, Paris, France.
[Nouira, Semir] Fattouma Bourguiba Univ Hosp, Emergency Dept, Monastir, Tunisia.
[Nouira, Semir] Fattouma Bourguiba Univ Hosp, Res Unit UR06SP21, Monastir, Tunisia.
[Sato, Naoki] Musashi Kosugi Hosp, Nippon Med Sch, Tokyo, Japan.
[Deye, Nicolas] Univ Paris Diderot, AP HP, Lariboisiere Univ Hosp, Paris, France.
[Van den Berghe, Greet] Univ Leuven, Univ Hosp Leuven, Dept Intens Care Med, Louvain, Belgium.
[Januzzi, James L., Jr.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Mebazaa, A (reprint author), Lariboisiere Univ Hosp, Dept Anesthesiol & Intens Care, 2 Rue Ambroise Pare, F-75010 Paris, France.
EM alexandre.mebazaa@lrb.aphp.fr
RI Pascual Figal, Domingo /B-3794-2008; Laribi, Said/D-5229-2014; Harjola,
Veli-Pekka/G-9229-2015; Kimmenade, R.R.J./L-4432-2015; Laribi,
said/S-3693-2016;
OI Maggioni, Aldo Pietro/0000-0003-2764-6779; Pascual Figal, Domingo
/0000-0002-4993-9540; boukef, riadh/0000-0001-7469-930X; Metra,
Marco/0000-0001-6691-8568; Nouira, Semir/0000-0002-0137-5491
FU INSERM [AAP2009/AM]; Roche Diagnostics; Siemens; Critical Diagnostics;
Brahms; Sphingotec; Bayer HealthCare AG; Pronota; Otsuka;
Daiichi-Sankyo; Astellas; Mochida; Chugai; Servier; Medtronic; St. Jude
Medical; Vifor Pharma; Boston Scientific; Lone Star Heart Inc.;
Bristol-Myers Squibb; Cardiorentis; Quintiles
FX This work was supported by a grant from INSERM (AAP2009/AM). Dr. Januzzi
has received support from Roche Diagnostics, Siemens, Critical
Diagnostics, Brahms, and Sphingotec. Dr. Mebazaa has received consultant
fees from Bayer HealthCare AG; honoraria from Alere, Cardiorentis,
Edwards, Thermofisher, and Orion; and a research grant from Pronota. Dr.
Metra receives honoraria for speeches and is a member of the advisory
board and/or steering committee of Corthera, Bayer, Novartis, Servier,
and Abbott Vascular. Dr. Sato receives research support and honoraria
from Otsuka, Daiichi-Sankyo, Astellas, and Mochida; honoraria from Eisai
and Boston Scientific; and consulting fees from Chugai. Dr. Tavazzi
receives consulting fees from Servier and research grants from
Medtronic, St. Jude Medical, Vifor Pharma, Boston Scientific, Lone Star
Heart Inc., Bristol-Myers Squibb, Cardiorentis, and Quintiles. The first
2 authors contributed equally to this work.
NR 47
TC 41
Z9 43
U1 1
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD FEB 26
PY 2013
VL 61
IS 8
BP 820
EP 829
DI 10.1016/j.jacc.2012.11.054
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 093NU
UT WOS:000315199400005
PM 23333145
ER
PT J
AU Frelinger, AL
Bhatt, DL
Lee, RD
Mulford, DJ
Wu, JT
Nudurupati, S
Nigam, A
Lampa, M
Brooks, JK
Barnard, MR
Michelson, AD
AF Frelinger, Andrew L., III
Bhatt, Deepak L.
Lee, Ronald D.
Mulford, Darcy J.
Wu, Jingtao
Nudurupati, Sai
Nigam, Anu
Lampa, Michael
Brooks, Julie K.
Barnard, Marc R.
Michelson, Alan D.
TI Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite
Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1),
Noncompliance, Diet, Smoking, Co-Medications (Including Proton Pump
Inhibitors), and Pre-Existent Variability in Platelet Function
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE drugs; pharmacokinetics; platelets; receptors; risk factors
ID CIGARETTE-SMOKING; ASSOCIATION; REACTIVITY; EFFICACY; TRIAL;
PARAOXONASE-1; ABSORPTION; RESISTANCE; PRASUGREL; GENOTYPE
AB Objectives This study sought to determine whether known genetic, drug, dietary, compliance, and lifestyle factors affecting clopidogrel absorption and metabolism fully account for the variability in clopidogrel pharmacokinetics and pharmacodynamics.
Background Platelet inhibition by clopidogrel is highly variable. Patients with reduced inhibition have increased risk for major adverse cardiovascular events. Identification of factors contributing to clopidogrel's variable response is needed to improve platelet inhibition and reduce risk for cardiovascular events.
Methods Healthy subjects (n = 160; ages 20 to 53 years; homozygous CYP2C19 extensive metabolizer genotype; no nicotine for 6 weeks, prescription drugs for 4 weeks, over-the-counter drugs for 2 weeks, and no caffeine or alcohol for 72 h; confined; restricted diet) received clopidogrel 75 mg/day for 9 days, at which time clopidogrel pharmacokinetic and pharmacodynamic endpoints were measured.
Results At steady-state, clopidogrel active metabolite (clopidogrel(AM)) pharmacokinetics varied widely between subjects (coefficients of variation [CVs] 33.8% and 40.2% for clopidogrel(AM) area under the time-concentration curve and peak plasma concentration, respectively). On-treatment vasodilator stimulated phosphoprotein P2Y(12) platelet reactivity index (PRI), maximal platelet aggregation (MPA) to adenosine phosphate, and VerifyNow P2Y12 platelet response units (PRU) also varied widely (CVs 32% to 53%). All identified factors together accounted for only 18% of intersubject variation in pharmacokinetic parameters and 32% to 64% of intersubject variation in PRI, MPA, and PRU. High on-treatment platelet reactivity was present in 45% of subjects.
Conclusions: Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite rigorous exclusion or control of known disease, polymorphisms (CYP2C19, CYP3A5, ABCB1, PON1), noncompliance, co-medications, diet, smoking, alcohol, demographics, and pre-treatment platelet hyperreactivity. Thus, as yet unidentified factors contribute to high on-treatment platelet reactivity with its known increased risk of major adverse cardiovascular events. (A Study of the Effects of Multiple Doses of Dexiansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants: NCT00942175) (J Am Coll Cardiol 2013;61:872-9) (c) 2013 by the American College of Cardiology Foundation
C1 [Frelinger, Andrew L., III; Nigam, Anu; Lampa, Michael; Brooks, Julie K.; Barnard, Marc R.; Michelson, Alan D.] Boston Childrens Hosp, Div Hematol Oncol, Ctr Platelet Res Studies, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Frelinger, Andrew L., III; Bhatt, Deepak L.; Michelson, Alan D.] Harvard Univ, Sch Med, Boston, MA USA.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Lee, Ronald D.; Mulford, Darcy J.; Wu, Jingtao; Nudurupati, Sai] Takeda Global Res & Dev Ctr Inc, Deerfield, IL USA.
RP Frelinger, AL (reprint author), Boston Childrens Hosp, Div Hematol Oncol, Ctr Platelet Res Studies, Karp 07212,300 Longwood Ave, Boston, MA 02115 USA.
EM Andrew.Frelinger@childrens.harvard.edu
FU Takeda Global Research & Development Center, Inc., Deerfield, Illinois;
GLSynthesis; Lilly; Amarin; AstraZeneca; Bristol-Myers Squibb; Eisai;
Ethicon; Medtronic; Sanofi Aventis; The Medicines Company
FX From the *Center for Platelet Research Studies, Division of
Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer
Institute, Boston, Massachusetts; dagger Harvard Medical School, Boston,
Massachusetts; double dagger VA Boston Healthcare System, Brigham and
Women's Hospital, Boston, Massachusetts; and the Takeda Global Research
& Development Center, Inc., Deerfield, Illinois. This study was
supported in part by a research grant from Takeda Global Research &
Development Center, Inc., Deerfield, Illinois to Children's Hospital
Boston (Alan D. Michelson, principal investigator). Drs. Frelinger and
Michelson have received research grants from GLSynthesis and Lilly. Dr.
Michelson has been a member of the Data Monitoring Committee of a
clinical trial sponsored by Lilly. Dr. Bhatt is a member of the Advisory
Board for Medscape Cardiology; a member of the Board of Directors for
the Boston VA Research Institute and the Society of Chest Pain Centers;
and is the Chair of the American Heart Association Get With The
Guidelines Science Subcommittee; he has received honoraria from the
American College of Cardiology (Editor, Clinical Trials, Cardiosource),
Duke Clinical Research Institute (clinical trial steering committees),
Slack Publications (Chief Medical Editor, Cardiology Today
Intervention), WebMD (CME steering committees); and is Senior Associate
Editor, Journal of Invasive Cardiology. Dr. Bhatt has also received
research grants from Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai,
Ethicon, Medtronic, Sanofi Aventis, and The Medicines Company; and he
has performed unfunded research with FlowCo, PLx Pharma, and Takeda. Drs
Lee, Mulford, Wu, and Nudurupati are employees of Takeda Global Research
& Development Center, Inc. All other authors have reported that they
have no relationships relevant to the contents of this paper to
disclose.
NR 28
TC 84
Z9 87
U1 3
U2 42
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD FEB 26
PY 2013
VL 61
IS 8
BP 872
EP 879
DI 10.1016/j.jacc.2012.11.040
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 093NU
UT WOS:000315199400013
PM 23333143
ER
PT J
AU Fukuzawa, T
Fukazawa, M
Ueda, O
Shimada, H
Kito, A
Kakefuda, M
Kawase, Y
Wada, NA
Goto, C
Fukushima, N
Jishage, K
Honda, K
King, GL
Kawabe, Y
AF Fukuzawa, Taku
Fukazawa, Masanori
Ueda, Otoya
Shimada, Hideaki
Kito, Aki
Kakefuda, Mami
Kawase, Yosuke
Wada, Naoko A.
Goto, Chisato
Fukushima, Naoshi
Jishage, Kou-ichi
Honda, Kiyofumi
King, George L.
Kawabe, Yoshiki
TI SGLT5 Reabsorbs Fructose in the Kidney but Its Deficiency Paradoxically
Exacerbates Hepatic Steatosis Induced by Fructose
SO PLOS ONE
LA English
DT Article
ID INSULIN-RESISTANCE; GLUCOSE-TRANSPORTER; METABOLIC SYNDROME; RAT-KIDNEY;
GLUT2; EXPRESSION; DISEASE; CONSUMPTION; INTESTINE; MANNOSE
AB Although excessive fructose intake is epidemiologically linked with dyslipidemia, obesity, and diabetes, the mechanisms regulating plasma fructose are not well known. Cells transfected with sodium/glucose cotransporter 5 (SGLT5), which is expressed exclusively in the kidney, transport fructose in vitro; however, the physiological role of this transporter in fructose metabolism remains unclear. To determine whether SGLT5 functions as a fructose transporter in vivo, we established a line of mice lacking the gene encoding SGLT5. Sodium-dependent fructose uptake disappeared in renal brush border membrane vesicles from SGLT5-deficient mice, and the increased urinary fructose in SGLT5-deficient mice indicated that SGLT5 was the major fructose reabsorption transporter in the kidney. From this, we hypothesized that urinary fructose excretion induced by SGLT5 deficiency would ameliorate fructose-induced hepatic steatosis. To test this hypothesis we compared SGLT5-deficient mice with wild-type mice under conditions of long-term fructose consumption. Paradoxically, however, fructose-induced hepatic steatosis was exacerbated in the SGLT5-deficient mice, and the massive urinary fructose excretion was accompanied by reduced levels of plasma triglycerides and epididymal fat but fasting hyperinsulinemia compared with fructose-fed wild-type mice. There was no difference in food consumption, water intake, or plasma fructose between the two types of mice. No compensatory effect by other transporters reportedly involved in fructose uptake in the liver and kidney were indicated at the mRNA level. These surprising findings indicated a previously unrecognized link through SGLT5 between renal fructose reabsorption and hepatic lipid metabolism.
C1 [Fukuzawa, Taku; Fukazawa, Masanori; Ueda, Otoya; Shimada, Hideaki; Kito, Aki; Wada, Naoko A.; Fukushima, Naoshi; Jishage, Kou-ichi; Honda, Kiyofumi; Kawabe, Yoshiki] Chugai Pharmaceut Co Ltd, Div Res, Shizuoka, Japan.
[Kakefuda, Mami; Kawase, Yosuke; Goto, Chisato] Chugai Res Inst Med Sci Inc, Shizuoka, Japan.
[King, George L.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02115 USA.
RP Fukazawa, M (reprint author), Chugai Pharmaceut Co Ltd, Div Res, Shizuoka, Japan.
EM fukazawamsn@chugai-pharm.co.jp
FU Chugai Pharmaceutical Co., Ltd.; Sanofi Aventis
FX No sources of funding outside Chugai Pharmaceutical Co., Ltd. supported
this work, and there are no current external funding sources for this
study.; T. Fukuzawa, M. Fukazawa, O. Ueda, H. Shimada, A. Kito, N.A.
Wada, N. Fukushima, K. Jishage, K. Honda, and Y. Kawabe are employees of
Chugai Pharmaceutical Co., Ltd. M. Kakefuda, Y. Kawase, and C. Goto are
employees of Chugai Research Institute for Medical Science, Inc. These
employments do not alter the authors' adherence to all the PLOS ONE
policies on sharing data and materials. George L. King has received a
grant from Sanofi Aventis for research unrelated to the current study.
This does not alter the authors' adherence to all the PLOS ONE policies
on sharing data and materials.
NR 40
TC 4
Z9 5
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 25
PY 2013
VL 8
IS 2
AR e56681
DI 10.1371/journal.pone.0056681
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 115ZB
UT WOS:000316849500022
PM 23451068
ER
PT J
AU Yoong, J
Park, ER
Greer, JA
Jackson, VA
Gallagher, ER
Pirl, WF
Back, AL
Temel, JS
AF Yoong, Jaclyn
Park, Elyse R.
Greer, Joseph A.
Jackson, Vicki A.
Gallagher, Emily R.
Pirl, William F.
Back, Anthony L.
Temel, Jennifer S.
TI Early Palliative Care in Advanced Lung Cancer A Qualitative Study
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID OF-LIFE CARE; TEAMS IMPROVE OUTCOMES; MEDICINE CONSULTATION; CLINICAL
ONCOLOGY; AMERICAN SOCIETY; CONTROLLED-TRIAL; OUTPATIENT; END;
RECOMMENDATIONS; COMMUNICATION
AB Background: Early ambulatory palliative care (PC) is an emerging practice, and its key elements have not been defined. We conducted a qualitative analysis of data from a randomized controlled trial that demonstrated improved quality of life, mood, and survival in patients with newly diagnosed metastatic non-small cell lung cancer who received early PC integrated with standard oncologic care vs standard oncologic care alone. Our objectives were to (1) identify key elements of early PC clinic visits, (2) explore the timing of key elements, and (3) compare the content of PC and oncologic visit notes at the critical time points of clinical deterioration and radiographic disease progression.
Methods: We randomly selected 20 patients who received early PC and survived within 4 periods: less than 3 months (n=5), 3 to 6 months (n=5), 6 to 12 months (n=5), and 12 to 24 months (n=5). We performed content analysis on PC and oncologic visit notes from the electronic health records of these patients.
Results: Addressing symptoms and coping were the most prevalent components of the PC clinic visits. Initial vis-its focused on building relationships and rapport with patients and their families and on illness understanding, including prognostic awareness. Discussions about resuscitation preferences and hospice predominantly occurred during later visits. Comparing PC and oncologic care visits around critical time points, both included discussions about symptoms and illness status; however, PC visits emphasized psychosocial elements, such as coping, whereas oncologic care visits focused on cancer treatment and management of medical complications.
Conclusions: Early PC clinic visits emphasize managing symptoms, strengthening coping, and cultivating illness understanding and prognostic awareness in a responsive and time-sensitive model. During critical clinical time points, PC and oncologic care visits have distinct features that suggest a key role for PC involvement and enable oncologists to focus on cancer treatment and managing medical complications.
C1 [Yoong, Jaclyn; Park, Elyse R.; Greer, Joseph A.; Jackson, Vicki A.; Gallagher, Emily R.; Pirl, William F.; Temel, Jennifer S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Back, Anthony L.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
RP Temel, JS (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Yawkey 7E, Boston, MA 02114 USA.
EM jtemel@partners.org
FU American Society of Clinical Oncology Conquer Cancer Foundation Career
Development Award
FX This study was funded by an American Society of Clinical Oncology
Conquer Cancer Foundation Career Development Award.
NR 44
TC 62
Z9 62
U1 3
U2 28
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD FEB 25
PY 2013
VL 173
IS 4
BP 283
EP 290
DI 10.1001/jamainternmed.2013.1874
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 153NZ
UT WOS:000319610400007
PM 23358690
ER
PT J
AU Smith, AK
AF Smith, Alexander K.
TI Palliative Care An Approach for All Internists
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID CONTROLLED-TRIAL; CANCER; OUTCOMES
C1 [Smith, Alexander K.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94941 USA.
[Smith, Alexander K.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Smith, AK (reprint author), Univ Calif San Francisco, Dept Med, 4150 Clement St,181G, San Francisco, CA 94941 USA.
EM aksmith@ucsf.edu
FU NIA NIH HHS [K23 AG040772]
NR 7
TC 1
Z9 1
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD FEB 25
PY 2013
VL 173
IS 4
BP 291
EP 292
DI 10.1001/jamainternmed.2013.1888
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 153NZ
UT WOS:000319610400008
PM 23358724
ER
PT J
AU Gross, R
Bellamy, SL
Chapman, J
Han, XY
O'Duor, J
Palmer, SC
Houts, PS
Coyne, JC
Strom, BL
AF Gross, Robert
Bellamy, Scarlett L.
Chapman, Jennifer
Han, Xiaoyan
O'Duor, Jacqueline
Palmer, Steven C.
Houts, Peter S.
Coyne, James C.
Strom, Brian L.
TI Managed Problem Solving for Antiretroviral Therapy Adherence A
Randomized Trial
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID SELF-ADMINISTERED THERAPY; HIV-INFECTED PATIENTS; MEDICATION ADHERENCE;
HEALTH LITERACY; VIRAL LOAD; PROTEASE; FAILURE; INTERVENTIONS;
SUPPRESSION; RESISTANCE
AB Background: Adherence to antiretroviral therapy is critical to successful treatment of human immunodeficiency virus (HIV). Few interventions have been demonstrated to improve both adherence and virologic outcomes. We sought to determine whether an intervention derived from problem solving theory, Managed Problem Solving (MAPS), would improve antiretroviral outcomes.
Methods: We conducted a randomized investigator blind trial of MAPS compared with usual care in HIV-1 infected individuals at 3 HIV clinics in Philadelphia, Pennsylvania. Eligible patients had plasma HIV-1 viral loads greater than 1000 copies/mL and were initiating or changing therapy. Managed Problem Solving consists of 4 in-person and 12 telephone-based meetings with a trained interventionist, then monthly follow-up calls for a year. Primary outcome was medication adherence measured using electronic monitors, summarized as fraction of doses taken quarterly over 1 year. Secondary outcome was undetectable HIV viral load over 1 year. We assessed 218 for eligibility, with 190 eligible and 180 enrolled, 91 randomized to MAPS and 89 to usual care. Fifty-six participants were lost to follow-up: 33 in the MAPS group and 23 in usual care group.
Results: In primary intention-to-treat analyses, the odds of being in a higher adherence category was 1.78 (95% CI, 1.07-2.96) times greater for MAPS than usual care. In secondary analyses, the odds of an undetectable viral load was 1.48 (95% CI, 0.94-2.31) times greater for MAPS than usual care. In as-treated analyses, the effect of MAPS was stronger for both outcomes. There was neither a difference by prior treatment status nor change in effect over time.
Conclusions: Managed Problem Solving is an effective antiretroviral adherence intervention over the first year with a new regimen. It was equally effective at improving adherence in treatment experienced and naive patients and did not lose effect over time. Implementation of MAPS should be strongly considered where resources are available.
Trial Registration: clinicaltrials.gov Identifier: NCT00130273
C1 [Gross, Robert; Bellamy, Scarlett L.; Chapman, Jennifer; Han, Xiaoyan; Strom, Brian L.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Palmer, Steven C.; Coyne, James C.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Gross, Robert; O'Duor, Jacqueline] Univ Penn, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA.
[Gross, Robert; Bellamy, Scarlett L.; Chapman, Jennifer; Han, Xiaoyan; Strom, Brian L.] Univ Penn, Perelman Sch Med, Dept Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Gross, Robert; O'Duor, Jacqueline] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
[Gross, Robert] Vet Affairs Med Ctr, Philadelphia, PA USA.
[Houts, Peter S.] Penn State Univ, Coll Med, Hershey, PA USA.
[Coyne, James C.] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Hlth Psychol Sect, Groningen, Netherlands.
RP Gross, R (reprint author), Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Div Infect Dis,Dept Med, 804 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM grossr@mail.med.upenn.edu
FU National Institute of Mental Health [R01 MH067498]; National Center for
Research Resources [UL1 RR024134]; Penn Center for AIDS Research [P30 AI
045008]
FX The study was supported by R01 MH067498 from the National Institute of
Mental Health, UL1 RR024134 from the National Center for Research
Resources, core services and support from the Penn Center for AIDS
Research (P30 AI 045008), and career support from the Philadelphia
Veterans Affairs Medical Center (Dr Gross).
NR 40
TC 23
Z9 23
U1 0
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD FEB 25
PY 2013
VL 173
IS 4
BP 300
EP 306
DI 10.1001/jamainternmed.2013.2152
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 153NZ
UT WOS:000319610400011
PM 23358784
ER
PT J
AU Bangsberg, DR
Haberer, JE
AF Bangsberg, David R.
Haberer, Jessica E.
TI Lifetime HIV Antiretroviral Therapy Adherence Intervention Timing Is
Everything
SO JAMA INTERNAL MEDICINE
LA English
DT Editorial Material
ID EXPECTANCY; RESISTANCE; TRIALS; UGANDA; TIME
C1 [Bangsberg, David R.; Haberer, Jessica E.] Massachusetts Gen Hosp MGH Ctr Global Hlth, Dept Med, Boston, MA USA.
[Bangsberg, David R.; Haberer, Jessica E.] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA.
[Bangsberg, David R.] Ragon Inst MGH Massachusetts Inst Technol & Harva, Charlestown, MA USA.
[Bangsberg, David R.] Mbarara Univ Sci & Technol, Fac Med, Mbarara, Uganda.
RP Bangsberg, DR (reprint author), MGH Ctr Global Hlth, 100 Cambridge St,15th Floor, Boston, MA 02114 USA.
EM dbangsberg@partners.org
FU NIMH NIH HHS [K24 MH087227, K23 MH087228, K-24 MH 087227, K-23 MH
087228, MH 54807]
NR 11
TC 1
Z9 1
U1 1
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD FEB 25
PY 2013
VL 173
IS 4
BP 306
EP 307
DI 10.1001/jamainternmed.2013.2858
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 153NZ
UT WOS:000319610400012
PM 23358810
ER
PT J
AU Udell, JA
Steg, PG
Bhatt, DL
AF Udell, Jacob A.
Steg, Philippe Gabriel
Bhatt, Deepak L.
TI Impact of Loneliness and Living Alone Reply
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Udell, Jacob A.] Univ Toronto, Womens Coll Hosp, Dept Med, Div Cardiovasc, Toronto, ON, Canada.
[Steg, Philippe Gabriel] Univ Paris Diderot, Sorbonne Paris Cite, INSERM U698, Paris, France.
[Steg, Philippe Gabriel] Hop Bichat Claude Bernard, AP HP, Dept Cardiol, F-75877 Paris, France.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Bhatt, DL (reprint author), VA Boston Healthcare Syst, 1400 VFW Pkwy, Boston, MA 02132 USA.
EM dlbhattmd@post.harvard.edu
NR 1
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD FEB 25
PY 2013
VL 173
IS 4
BP 322
EP 323
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 153NZ
UT WOS:000319610400023
PM 23440235
ER
PT J
AU Odden, MC
Peralta, CA
Covinsky, KE
AF Odden, Michelle C.
Peralta, Carmen A.
Covinsky, Kenneth E.
TI Walking Speed Is a Useful Marker of Frailty in Older Persons Reply
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Odden, Michelle C.] Oregon State Univ, Sch Biol & Populat Hlth Sci, Corvallis, OR 97330 USA.
[Peralta, Carmen A.; Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Peralta, Carmen A.; Covinsky, Kenneth E.] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA.
RP Odden, MC (reprint author), Oregon State Univ, Sch Biol & Populat Hlth Sci, 321 Milam Hall, Corvallis, OR 97330 USA.
EM Michelle.Odden@oregonstate.edu
NR 2
TC 1
Z9 1
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD FEB 25
PY 2013
VL 173
IS 4
BP 326
EP 326
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 153NZ
UT WOS:000319610400029
ER
PT J
AU Yang, YF
Cao, ZH
Tian, L
Garvey, WT
Cheng, GJ
AF Yang, Youfeng
Cao, Zehong
Tian, Ling
Garvey, W. Timothy
Cheng, Guangjie
TI VPO1 Mediates ApoE Oxidation and Impairs the Clearance of Plasma Lipids
SO PLOS ONE
LA English
DT Article
ID LOW-DENSITY-LIPOPROTEIN; VASCULAR PEROXIDASE 1; HEME-CONTAINING
PEROXIDASE; APOLIPOPROTEIN-E; DEFICIENT MICE; CHOLESTEROL TRANSPORT;
TNF-ALPHA; OX-LDL; ATHEROSCLEROSIS; MYELOPEROXIDASE
AB Objective: ApoE is an abundant component of chylomicron, VLDL, IDL, and HDL. It binds to multiple types of lipids and is implicated in cholesterol and triglyceride homeostasis. Oxidation of ApoE plays a crucial role in the genesis of atherosclerosis. It is proposed that heme-containing peroxidases (hPx) are major mediators of lipoprotein oxidization. Vascular peroxidase 1 (VPO1) is a recently-discovered hPx, which is expressed in cardiovascular system, lung, liver etc. and secreted into plasma. Its plasma concentration is three orders of magnitude of that of myeloperoxidase. If VPO1 mediates ApoE oxidation and affects the lipid metabolism remains to be elucidated.
Methods: Recombinant ApoE and VPO1 were expressed and purified from stably-expressing cell lines deriving from HEK293 cells. ApoE oxidation was carried out by VPO1 in the presence of H2O2 and chloride. ApoE oxidation was verified by a variety of approaches including immunoblot and amino acid analyses. To evaluate the functional changes in VPO1-oxidized ApoE, lipid emulsion particle binding assays were employed.
Results: Oxidized ApoE binds weaker to lipid emulsion particles, which mimic the large lipid complexes in vivo. In lipid efflux assay, oxidized ApoE showed reduced capability in efflux of lipids from foam cells. Mice administrated with oxidized ApoE via blood exhibited weaker clearance ability of plasma lipids.
Conclusions: Our data suggest that VPO1 is a new mediator regulating lipid homeostasis, implying a role in genesis and development of atherosclerosis.
C1 [Yang, Youfeng; Cao, Zehong; Cheng, Guangjie] Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA.
[Tian, Ling; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL USA.
[Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Cheng, GJ (reprint author), Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL USA.
EM gjcheng@uab.edu
OI Cheng, Guangjie/0000-0002-9368-379X
FU National Heart, Blood, and Lung Institute; National Institute of Allergy
and Infectious Diseases, National Institutes of Health [R01 HL086836,
R21AI101642]; National Institutes of Health [DK-083562, DK-038764];
Merit Review program of the Department of Veterans Affairs; UAB Diabetes
Research and Training Center [P60-DK079626]
FX This work was supported by the National Heart, Blood, and Lung
Institute, and National Institute of Allergy and Infectious Diseases,
National Institutes of Health under Award Number R01 HL086836 and
R21AI101642 (to GC). WTG was supported by the National Institutes of
Health (Award Number DK-083562 and DK-038764), the Merit Review program
of the Department of Veterans Affairs, and the UAB Diabetes Research and
Training Center (P60-DK079626). The content is solely the responsibility
of the authors and does not necessarily represent the official views of
the National Institutes of Health. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 55
TC 6
Z9 6
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 25
PY 2013
VL 8
IS 2
AR e57571
DI 10.1371/journal.pone.0057571
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 115ZB
UT WOS:000316849500115
PM 23451244
ER
PT J
AU Jordaan, G
Liao, W
Sharma, S
AF Jordaan, Gwen
Liao, Wei
Sharma, Sanjai
TI E-cadherin gene re-expression in chronic lymphocytic leukemia cells by
HDAC inhibitors
SO BMC CANCER
LA English
DT Article
DE CLL; E-cadherin; Aberrant splicing; Nonsense mediated decay; Chromatin
modeling; HDAC inhibitors; Wnt pathway
ID WNT SIGNALING PATHWAY; BETA-CATENIN; HISTONE DEACETYLASE; CANCER;
EXPRESSION; EPIGENETICS; ACTIVATION; CHROMATIN; TRANSACTIVATION;
IDENTIFICATION
AB Background: The tumor suppressor gene E-cadherin gene is frequently silenced in chronic lymphocytic leukemia (CLL) cells and results in wnt-pathway activation. We analyzed the role of histone epigenetic modifications in E-cadherin gene silencing.
Methods: CLL specimens were treated with histone deacetylase inhibitor (HDACi) MS-275 and analyzed for E-cadherin expression with western blot and RT-PCR analysis. The downstream effects of HDACi treated leukemic cells were studied by analyzing the effect on wnt-pathway signaling. HDACi induced alterations in E-cadherin splicing were investigated by transcript specific real time PCR analysis.
Results: Treatment of CLL specimens with histone deacetylase inhibitors (HDACi) treatment resulted in an increase of the E-cadherin RNA transcript (5 to 119 fold increase, n=10) in eight out of ten CLL specimens indicating that this gene is down regulated by histone hypoacetylation in a majority of CLL specimens. The E-cadherin re-expression in CLL specimens was noted by western blot analysis as well. Besides epigenetic silencing another mechanism of E-cadherin inactivation is aberrant exon 11 splicing resulting in an alternatively spliced transcript that lacks exon 11 and is degraded by the non-sense mediated decay (NMD) pathway. Our chromatin immunoprecipitation experiments show that HDACi increased the acetylation of histones H3 and H4 in the E-cadherin promoter region. This also affected the E-cadherin exon 11 splicing pattern as HDACi treated CLL specimens preferentially expressed the correctly spliced transcript and not the exon 11 skipped aberrant transcript. The re-expressed E-cadherin binds to beta-catenin with inhibition of the active wnt-beta-catenin pathway in these cells. This resulted in a down regulation of two wnt target genes, LEF and cyclinD1 and the wnt pathway reporter.
Conclusion: The E-cadherin gene is epigenetically modified and hypoacetylated in CLL leukemic cells. Treatment of CLL specimens with HDACi MS-275 activates transcription from this silent gene with expression of more correctly spliced E-cadherin transcripts as compared to the aberrant exon11 skipped transcripts that in turn inhibits the wnt signaling pathway. The data highlights the role of epigenetic modifications in altering gene splicing patterns.
C1 [Jordaan, Gwen; Liao, Wei; Sharma, Sanjai] Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA 90073 USA.
RP Sharma, S (reprint author), Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Greater Los Angeles VA Healthcare Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM sasharma@mednet.ucla.edu
FU Flight Attendant Medical Research Institute Fund (FAMRI); Veterans
Administration Merit Review Grant
FX The authors thank Dr. Alan Lichtenstein for clinical samples and useful
discussions. This work was supported by a grant from Flight Attendant
Medical Research Institute Fund (FAMRI) and Veterans Administration
Merit Review Grant to SS.
NR 55
TC 9
Z9 11
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD FEB 25
PY 2013
VL 13
AR 88
DI 10.1186/1471-2407-13-88
PG 11
WC Oncology
SC Oncology
GA 099RD
UT WOS:000315638000001
PM 23432814
ER
PT J
AU Pereira, MJN
Ouyang, B
Sundback, CA
Lang, N
Friehs, I
Mureli, S
Pomerantseva, I
McFadden, J
Mochel, MC
Mwizerwa, O
del Nido, P
Sarkar, D
Masiakos, PT
Langer, R
Ferreira, LS
Karp, JM
AF Pereira, Maria Jose Nunes
Ouyang, Ben
Sundback, Cathryn A.
Lang, Nora
Friehs, Ingeborg
Mureli, Shwetha
Pomerantseva, Irina
McFadden, Jacob
Mochel, Mark C.
Mwizerwa, Olive
del Nido, Pedro
Sarkar, Debanjan
Masiakos, Peter T.
Langer, Robert
Ferreira, Lino S.
Karp, Jeffrey M.
TI A Highly Tunable Biocompatible and Multifunctional Biodegradable
Elastomer
SO ADVANCED MATERIALS
LA English
DT Article
DE elastomers; biodegradable polymers; biocompatible materials; drug
delivery; biomacromolecules
ID POLY(GLYCEROL SEBACATE); MYOCARDIAL-INFARCTION; TISSUE; DEGRADATION;
POLYURETHANE; DELIVERY; BEHAVIOR; PATCH
C1 [Pereira, Maria Jose Nunes; Ouyang, Ben; Mureli, Shwetha; Sarkar, Debanjan; Karp, Jeffrey M.] Harvard Univ, Harvard MIT Div Hlth Sci & Technol, Brigham & Womens Hosp,Sch Med, Div Biomed Engn,Ctr Regenerat Therapeut,Dept Med, Cambridge, MA 02139 USA.
[Pereira, Maria Jose Nunes; Ferreira, Lino S.] Univ Coimbra, CNC Ctr Neurosci & Cell Biol, Biocant Biotechnol Innovat Ctr, P-3004517 Coimbra, Portugal.
[Sundback, Cathryn A.; Pomerantseva, Irina; McFadden, Jacob; Mwizerwa, Olive; Masiakos, Peter T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, Boston, MA 02114 USA.
[Lang, Nora; Friehs, Ingeborg; del Nido, Pedro] Harvard Univ, Childrens Hosp Boston, Sch Med, Dept Cardiac Surg, Boston, MA 02115 USA.
[Mochel, Mark C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Sarkar, Debanjan] SUNY Buffalo, Dept Biomed Engn, Buffalo, NY 14260 USA.
[Langer, Robert] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
[Langer, Robert] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
RP Ferreira, LS (reprint author), Univ Coimbra, CNC Ctr Neurosci & Cell Biol, Biocant Biotechnol Innovat Ctr, P-3004517 Coimbra, Portugal.
EM lino@biocant.pt; jkarp@rics.bwh.harvard.edu
RI Sarkar, Debanjan/C-6093-2017;
OI Sarkar, Debanjan/0000-0002-6666-3152; ferreira, lino/0000-0001-8985-9302
FU National Institutes of Health [GM086433, DE013023]; Portuguese
Foundation for Science and Technology [SFR/BD/43013/2008]; MIT-Portugal
program (bioengineering focus area)
FX We would like to thank Admet Inc. for generously providing an eXpert
7601 mechanical tester that was instrumental for this work. This work
was supported by National Institutes of Health grant GM086433 to J.M.K.
and National Institutes of Health grant DE013023 to R. L. M.J.P.
acknowledges the Portuguese Foundation for Science and Technology
(fellowship SFR/BD/43013/2008) and the MIT-Portugal program
(bioengineering focus area).
NR 27
TC 29
Z9 29
U1 13
U2 147
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 0935-9648
J9 ADV MATER
JI Adv. Mater.
PD FEB 25
PY 2013
VL 25
IS 8
BP 1209
EP 1215
DI 10.1002/adma.201203824
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
Physics
GA 092ES
UT WOS:000315102600020
PM 23239051
ER
PT J
AU Friebely, J
Rigotti, NA
Chang, YC
Hall, N
Weiley, V
Dempsey, J
Hipple, B
Nabi-Burza, E
Murphy, S
Woo, H
Winickoff, JP
AF Friebely, Joan
Rigotti, Nancy A.
Chang, Yuchiao
Hall, Nicole
Weiley, Victoria
Dempsey, Janelle
Hipple, Bethany
Nabi-Burza, Emara
Murphy, Sybil
Woo, Heide
Winickoff, Jonathan P.
TI Parent smoker role conflict and planning to quit smoking: a
cross-sectional study
SO BMC PUBLIC HEALTH
LA English
DT Article
DE Parent smoker identity; Parent smoker role conflict; Tobacco smoke
exposure; Readiness to quit; Stages of change; Tobacco control;
Pediatrics; Smoking cessation; Parent child dyad
ID ENVIRONMENTAL TOBACCO-SMOKE; CHILDREN; IDENTITY; INTERVENTION;
ASSOCIATION; CESSATION; EXPOSURE; STAGE
AB Background: Role conflict can motivate behavior change. No prior studies have explored the association between parent/smoker role conflict and readiness to quit. The objective of the study is to assess the association of a measure of parent/smoker role conflict with other parent and child characteristics and to test the hypothesis that parent/smoker role conflict is associated with a parent's intention to quit smoking in the next 30 days. As part of a cluster randomized controlled trial to address parental smoking (Clinical Effort Against Secondhand Smoke Exposure-CEASE), research assistants completed exit interviews with 1980 parents whose children had been seen in 20 Pediatric Research in Office Settings (PROS) practices and asked a novel identity-conflict question about "how strongly you agree or disagree" with the statement, "My being a smoker gets in the way of my being a parent." Response choices were dichotomized as "Strongly Agree" or "Agree" versus "Disagree" or "Strongly Disagree" for the analysis. Parents were also asked whether they were "seriously planning to quit smoking in 30 days." Chi-square and logistic regression were performed to assess the association between role conflict and other parent/children characteristics. A similar strategy was used to determine whether role conflict was independently associated with intention to quit in the next 30 days.
Methods: As part of a RTC in 20 pediatric practices, exit interviews were held with smoking parents after their child's exam. Parents who smoked were asked questions about smoking behavior, smoke-free home and car rules, and role conflict. Role conflict was assessed with the question, "Please tell me how strongly you agree or disagree with the statement: 'My being a smoker gets in the way of my being a parent.' (Answer choices were: "Strongly agree, Agree, Disagree, Strongly Disagree.")
Results: Of 1980 eligible smokers identified, 1935 (97%) responded to the role-conflict question, and of those, 563 (29%) reported experiencing conflict. Factors that were significantly associated with parent/smoker role conflict in the multivariable model included: being non-Hispanic white, allowing home smoking, the child being seen that day for a sick visit, parents receiving any assistance for their smoking, and planning to quit in the next 30 days. In a separate multivariable logistic regression model, parent/smoker role conflict was independently associated with intention to quit in the next 30 days [AOR 2.25 (95% CI 1.80-2.18)].
Conclusion: This study demonstrated an association between parent/smoker role conflict and readiness to quit. Interventions that increase parent/smoker role conflict might act to increase readiness to quit among parents who smoke.
C1 [Friebely, Joan; Hall, Nicole; Dempsey, Janelle; Hipple, Bethany; Nabi-Burza, Emara; Murphy, Sybil; Winickoff, Jonathan P.] Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Res & Policy, Boston, MA 02114 USA.
[Weiley, Victoria; Woo, Heide] Amer Acad Pediat, Pediat Res Off Settings, Elk Grove Village, IL USA.
[Rigotti, Nancy A.; Chang, Yuchiao] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Winickoff, Jonathan P.] Amer Acad Pediat, AAP Richmond Ctr Excellence, Elk Grove Village, IL USA.
[Friebely, Joan; Rigotti, Nancy A.; Hall, Nicole; Hipple, Bethany; Nabi-Burza, Emara; Murphy, Sybil; Winickoff, Jonathan P.] Massachusetts Gen Hosp, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA.
RP Winickoff, JP (reprint author), Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Res & Policy, Boston, MA 02114 USA.
EM jwinickoff@partners.org
FU National Institutes of Health NCI [R01CA127127]; National Institute on
Drug Abuse; Agency for Healthcare Research and Quality; American Academy
of Pediatrics (AAP); Flight Attendant Medical Research Institute;
Pediatric Research in Office Settings (PROS) Network from the HRSA MCHB
[HRSA 5-UA6-10-001]
FX This study was supported by the National Institutes of Health NCI grant
R01CA127127 (to Dr. Winickoff), the National Institute on Drug Abuse,
the Agency for Healthcare Research and Quality, and the American Academy
of Pediatrics (AAP). This study was also partially supported by a grant
from the Flight Attendant Medical Research Institute to the AAP Julius
B. Richmond Center. In addition, the Pediatric Research in Office
Settings (PROS) Network receives core funding from the HRSA MCHB (HRSA
5-UA6-10-001) and the AAP. The funders had no role in the design or
conduct of the study; collection, management, analysis and
interpretation of the data; or preparation, review and approval of the
manuscript. We especially appreciate the efforts of the PROS practices
and practitioners. The pediatric practices or individual practitioners
who enrolled participants in the larger study are listed here by AAP
Chapter: Alaska: Anchorage Pediatric Group, LLC (Anchorage);
Connecticut: Hospital of Saint Raphaels (New Haven); Illinois: Community
Health Improvement Center (Decatur); Maryland: Cambridge Pediatrics LLC
(Waldorf); Massachusetts: Quabbins Pediatrics (Ware), RiverBend Medical
Group - Springfield Office (Springfield); Missouri: Priority Care
Pediatrics LLC (Kansas City); New Mexico: Las Vegas Clinic for Children
and Youth; PA (Las Vegas); Ohio: Bryan Medical Group (Bryan), The
Cleveland Clinic Wooster (Wooster); Oklahoma: Shawnee Medical Center
Clinic (Shawnee); Oregon: Siskiyou Pediatric Clinic LLP (Grants Pass);
Pennsylvania: Pennridge Pediatric Associates (Sellersville); South
Carolina: Inlet Pediatrics (Murrells Inlet); South Dakota: Avera
McGreevy Clinic (Sioux Falls); Tennessee: Raleigh Group PC (Memphis);
Virginia: Pediatrics of Kempsville PC (Virginia Beach), Riverside
Pediatric Center (Newport News), The Clinic (Richlands); West Virginia:
Shenandoah Community Health Center (Martinsburg).
NR 23
TC 7
Z9 7
U1 0
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2458
J9 BMC PUBLIC HEALTH
JI BMC Public Health
PD FEB 22
PY 2013
VL 13
AR 164
DI 10.1186/1471-2458-13-164
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 119TQ
UT WOS:000317121000001
PM 23433098
ER
PT J
AU Teo, AKK
Windmueller, R
Johansson, BB
Dirice, E
Njolstad, PR
Tjora, E
Raeder, H
Kulkarni, RN
AF Teo, Adrian K. K.
Windmueller, Rebecca
Johansson, Bente B.
Dirice, Ercument
Njolstad, Pal R.
Tjora, Erling
Raeder, Helge
Kulkarni, Rohit N.
TI Derivation of Human Induced Pluripotent Stem Cells from Patients with
Maturity Onset Diabetes of the Young
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DEFINED FACTORS
AB Maturity onset diabetes of the young (MODY) is an autosomal dominant disease. Despite extensive research, the mechanism by which a mutant MODY gene results in monogenic diabetes is not yet clear due to the inaccessibility of patient samples. Induced pluripotency and directed differentiation toward the pancreatic lineage are now viable and attractive methods to uncover the molecular mechanisms underlying MODY. Here we report, for the first time, the derivation of human induced pluripotent stem cells (hiPSCs) from patients with five types of MODY: MODY1 (HNF4A), MODY2 (GCK), MODY3 (HNF1A), MODY5 (HNF1B), and MODY8 (CEL) with a polycistronic lentiviral vector expressing a Cre-excisable human "stem cell cassette" containing the four reprogramming factors OCT4, KLF4, SOX2, and CMYC. These MODY-hiPSCs morphologically resemble human pluripotent stem cells (hPSCs), express pluripotency markers OCT4, SOX2, NANOG, SSEA-4, and TRA-1-60, give rise to derivatives of the three germ layers in a teratoma assay, and are karyotypically normal. Overall, our MODYhiPSCs serve as invaluable tools to dissect the role of MODY genes in the development of pancreas and islet cells and to evaluate their significance in regulating beta cell function. This knowledge will aid future attempts aimed at deriving functional mature beta cells from hPSCs.
C1 [Teo, Adrian K. K.; Windmueller, Rebecca; Dirice, Ercument; Kulkarni, Rohit N.] Brigham & Womens Hosp, Dept Med, Joslin Diabet Ctr, Sect Islet Cell & Regenerat Biol, Boston, MA 02215 USA.
[Teo, Adrian K. K.; Windmueller, Rebecca; Dirice, Ercument; Kulkarni, Rohit N.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Njolstad, Pal R.; Tjora, Erling; Raeder, Helge] Haukeland Hosp, Dept Pediat, N-5021 Bergen, Norway.
[Johansson, Bente B.] Haukeland Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway.
[Johansson, Bente B.; Njolstad, Pal R.; Raeder, Helge] Univ Bergen, Dept Med 2, KG Jebsen Ctr Diabet Res, N-5021 Bergen, Norway.
RP Kulkarni, RN (reprint author), Brigham & Womens Hosp, Dept Med, Joslin Diabet Ctr, Sect Islet Cell & Regenerat Biol, 1 Joslin Pl, Boston, MA 02215 USA.
EM rohit.kulkarni@joslin.harvard.edu
RI Teo, Adrian/A-4009-2013; Dirice, Ercument/B-2825-2017;
OI Teo, Adrian/0000-0001-5901-7075; Johansson, Bente
Berg/0000-0001-8893-1915
FU Harvard Stem Cell Institute [SG-0078-12-00]; National Institutes of
Health [RO1 DK 67536]
FX This work was supported in part by a grant from the Harvard Stem Cell
Institute Agreement SG-0078-12-00 (to R.N.K.) and in part by National
Institutes of Health Grant RO1 DK 67536 (to R.N.K.).
NR 11
TC 31
Z9 33
U1 5
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 22
PY 2013
VL 288
IS 8
BP 5353
EP 5356
DI 10.1074/jbc.C112.428979
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 095NY
UT WOS:000315342500009
PM 23306198
ER
PT J
AU Hosokawa, H
Dip, PV
Merkulova, M
Bakulina, A
Zhuang, ZJ
Khatri, A
Jian, XY
Keating, SM
Bueler, SA
Rubinstein, JL
Randazzo, PA
Ausiello, DA
Gruber, G
Marshansky, V
AF Hosokawa, Hiroyuki
Dip, Phat Vinh
Merkulova, Maria
Bakulina, Anastasia
Zhuang, Zhenjie
Khatri, Ashok
Jian, Xiaoying
Keating, Shawn M.
Bueler, Stephanie A.
Rubinstein, John L.
Randazzo, Paul A.
Ausiello, Dennis A.
Grueber, Gerhard
Marshansky, Vladimir
TI The N Termini of a-Subunit Isoforms Are Involved in Signaling between
Vacuolar H+-ATPase (V-ATPase) and Cytohesin-2
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NUCLEOTIDE EXCHANGE FACTOR; CIRCULAR-DICHROISM SPECTRA; PROTEIN
SECONDARY STRUCTURE; VESICULAR TRAFFICKING; ARF ACTIVATION; PROTON
PUMPS; FACTOR ARNO; PH-SENSOR; RECEPTOR; A2-SUBUNIT
AB Previously, we reported an acidification-dependent interaction of the endosomal vacuolar H+-ATPase (V-ATPase) with cytohesin-2, a GDP/GTP exchange factor (GEF), suggesting that it functions as a pH-sensing receptor. Here, we have studied the molecular mechanism of signaling between the V-ATPase, cytohesin-2, and Arf GTP-binding proteins. We found that part of the N-terminal cytosolic tail of the V-ATPase a2-subunit (a2N), corresponding to its first 17 amino acids (a2N(1-17)), potently modulates the enzymatic GDP/GTP exchange activity of cytohesin-2. Moreover, this peptide strongly inhibits GEF activity via direct interaction with the Sec7 domain of cytohesin-2. The structure of a2N(1-17) and its amino acids Phe(5), Met(10), and Gln(14) involved in interaction with Sec7 domain were determined by NMR spectroscopy analysis. In silico docking experiments revealed that part of the V-ATPase formed by its a2N(1-17) epitope competes with the switch 2 region of Arf1 and Arf6 for binding to the Sec7 domain of cytohesin-2. The amino acid sequence alignment and GEF activity studies also uncovered the conserved character of signaling between all four (a1-a4) a-subunit isoforms of mammalian V-ATPase and cytohesin-2. Moreover, the conserved character of this phenomenon was also confirmed in experiments showing binding of mammalian cytohesin-2 to the intact yeast V-ATPase holo-complex. Thus, here we have uncovered an evolutionarily conserved function of the V-ATPase as a novel cytohesin-signaling receptor.
C1 [Hosokawa, Hiroyuki; Merkulova, Maria; Zhuang, Zhenjie; Ausiello, Dennis A.; Marshansky, Vladimir] Massachusetts Gen Hosp, Simches Res Ctr, Ctr Syst Biol, Program Membrane Biol, Boston, MA 02114 USA.
[Hosokawa, Hiroyuki; Merkulova, Maria; Zhuang, Zhenjie; Ausiello, Dennis A.; Marshansky, Vladimir] Massachusetts Gen Hosp, Simches Res Ctr, Div Nephrol, Boston, MA 02114 USA.
[Ausiello, Dennis A.; Marshansky, Vladimir] Harvard Univ, Sch Med, Dept Med, Boston, MA 02114 USA.
[Dip, Phat Vinh; Grueber, Gerhard] Nanyang Technol Univ, Sch Biol Sci, Div Struct Biol & Biochem, Singapore 637551, Singapore.
[Bakulina, Anastasia] State Res Ctr Virol & Biotechnol VECTOR, Koltsov 630559, Novosibirsk Reg, Russia.
[Khatri, Ashok] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
[Khatri, Ashok] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Jian, Xiaoying; Randazzo, Paul A.] NCI, Lab Cellular & Mol Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Keating, Shawn M.; Bueler, Stephanie A.; Rubinstein, John L.] Hosp Sick Children, Res Inst, Mol Struct & Funct Program, Toronto, ON M5G 1X8, Canada.
[Keating, Shawn M.; Rubinstein, John L.] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1X8, Canada.
RP Marshansky, V (reprint author), Massachusetts Gen Hosp, Simches Res Ctr, Ctr Syst Biol, Program Membrane Biol, Boston, MA 02114 USA.
EM Marshansky.Vladimir@mgh.harvard.edu
RI Bakulina, Anastasia/A-6215-2014;
OI Dip, Phat Vinh/0000-0002-1535-9644; Rubinstein, John/0000-0003-0566-2209
FU National Institutes of Health Grant [DK038452, DK57521]; Boston Area
Diabetes Endocrinology Research Center Grant [DK057521-08]; National
Institutes of Health Intramural Program of NCI; Canadian Institutes of
Health Research Grant [MOP 81294]; A*STAR Biomedical Research Council
Grant [09/1/22/19/609]; Center for the Study of Inflammatory Bowel
Disease [DK43351]; Singapore International Graduate Award (SINGA)
[20092010S10303]
FX This work was supported, in whole or in part, by National Institutes of
Health Grant DK038452. This work was also supported by Boston Area
Diabetes Endocrinology Research Center Grant DK057521-08 (to V. M.).;
Recipient of a Singapore International Graduate Award (SINGA,
20092010S10303).; Supported by the National Institutes of Health
Intramural Program of NCI.; Supported by Canadian Institutes of Health
Research Grant MOP 81294.; Supported by A*STAR Biomedical Research
Council Grant 09/1/22/19/609.; We thank Dr. Dennis Brown for critical
reading and constructive suggestions during the preparation of this
manuscript. We are grateful to Dr. Masamitsu Futai and Dr. James
Casanova for providing cDNA encoding V-ATPase a2-isoform and
cytohesin-2, respectively. We are also grateful to Dr. Sylvain Bourgoin
for the generous gift of SecinH3 inhibitor. The Microscopy Core Facility
of the Program in Membrane Biology received additional support from
National Institutes of Health Grant DK57521 to BADERC and Grant DK43351
to Center for the Study of Inflammatory Bowel Disease.
NR 68
TC 21
Z9 21
U1 1
U2 15
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 22
PY 2013
VL 288
IS 8
BP 5896
EP 5913
DI 10.1074/jbc.M112.409169
PG 18
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 095NY
UT WOS:000315342500059
PM 23288846
ER
PT J
AU Aukrust, I
Bjorkhaug, L
Negahdar, M
Molnes, J
Johansson, BB
Muller, Y
Haas, W
Gygi, SP
Sovik, O
Flatmark, T
Kulkarni, RN
Njolstad, PR
AF Aukrust, Ingvild
Bjorkhaug, Lise
Negahdar, Maria
Molnes, Janne
Johansson, Bente B.
Muller, Yvonne
Haas, Wilhelm
Gygi, Steven P.
Sovik, Oddmund
Flatmark, Torgeir
Kulkarni, Rohit N.
Njolstad, Pal R.
TI SUMOylation of Pancreatic Glucokinase Regulates Its Cellular Stability
and Activity
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DIABETES-MELLITUS; ISLET GLUCOKINASE; PROTEIN STABILITY; ENZYME UBC9;
BETA-CELLS; GLUCOSE; GENE; SUMO; IDENTIFICATION; ACTIVATION
AB Glucokinase is the predominant hexokinase expressed in hepatocytes and pancreatic beta-cells, with a pivotal role in regulating glucose-stimulated insulin secretion, illustrated by glucokinase gene mutations causing monogenic diabetes and congenital hyperinsulinemic hypoglycemia. A complex tissue-specific network of mechanisms regulates this enzyme, and a major unanswered question in glucokinase biology is how post-translational modifications control the function of the enzyme. Here, we show that the pancreatic isoform of human glucokinase is SUMOylated in vitro, using recombinant enzymes, and in insulin-secreting model cells. Three N-terminal lysines unique for the pancreatic isoform (Lys-12/Lys-13 and/or Lys-15) may represent one SUMOylation site, with an additional site (Lys-346) common for the pancreatic and the liver isoform. SUMO-1 and E2 overexpression stabilized preferentially the wild-type human pancreatic enzyme in MIN6 beta-cells, and SUMOylation increased the catalytic activity of recombinant human glucokinase in vitro and also of glucokinase in target cells. Small ubiquitin-like modifier conjugation represents a novel form of post-translational modification of the enzyme, and it may have an important regulatory function in pancreatic beta-cells.
C1 [Aukrust, Ingvild; Bjorkhaug, Lise; Negahdar, Maria; Molnes, Janne; Johansson, Bente B.; Muller, Yvonne; Sovik, Oddmund; Njolstad, Pal R.] KG Jebsen Ctr Diabet Res, Dept Clin Med, N-5020 Bergen, Norway.
[Aukrust, Ingvild; Bjorkhaug, Lise; Molnes, Janne; Muller, Yvonne; Flatmark, Torgeir] Univ Bergen, Dept Biomed, N-5020 Bergen, Norway.
[Aukrust, Ingvild; Bjorkhaug, Lise; Negahdar, Maria; Johansson, Bente B.; Muller, Yvonne] Haukeland Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway.
[Aukrust, Ingvild; Kulkarni, Rohit N.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Joslin Diabet Ctr, Boston, MA 02215 USA.
[Molnes, Janne; Johansson, Bente B.; Njolstad, Pal R.] Haukeland Hosp, Dept Pediat, N-5021 Bergen, Norway.
[Haas, Wilhelm; Gygi, Steven P.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
RP Bjorkhaug, L (reprint author), Univ Bergen, Dept Clin Med, N-5020 Bergen, Norway.
EM lise.gundersen@pedi.uib.no; pal.njolstad@uib.no
OI Johansson, Bente Berg/0000-0001-8893-1915; Gundersen, Lise
Bjorkhaug/0000-0002-9695-4559
FU National Institutes of Health [RO1 DK067536]; Helse Vest, Innovest; Novo
Nordisk Foundation; Bergen Medical Research Foundation; University of
Bergen; Nils Norman Foundation; Norwegian Diabetes Association; Meltzer
Foundation; KG Jebsen Foundation; European Research Council
FX This work was supported, in whole or in part, by National Institutes of
Health Grant RO1 DK067536 (to R.N.K.). This work was also supported by
Helse Vest, Innovest, the Novo Nordisk Foundation, the Bergen Medical
Research Foundation, the University of Bergen, the Nils Norman
Foundation, the Norwegian Diabetes Association, the Meltzer Foundation,
the KG Jebsen Foundation, and the European Research Council (to P.R.N.).
NR 57
TC 14
Z9 14
U1 0
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 22
PY 2013
VL 288
IS 8
BP 5951
EP 5962
DI 10.1074/jbc.M112.393769
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 095NY
UT WOS:000315342500063
PM 23297408
ER
PT J
AU Biju, KC
Santacruz, RA
Chen, C
Zhou, Q
Yao, JM
Rohrabaugh, SL
Clark, RA
Roberts, JL
Phillips, KA
Imam, SZ
Li, SL
AF Biju, K. C.
Santacruz, Rene A.
Chen, Cang
Zhou, Qing
Yao, Jiemin
Rohrabaugh, Sara L.
Clark, Robert A.
Roberts, James L.
Phillips, Kimberley A.
Imam, Syed Z.
Li, Senlin
TI Bone marrow-derived microglia-based neurturin delivery protects against
dopaminergic neurodegeneration in a mouse model of Parkinson's disease
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Parkinson's disease; Gene therapy; Neurodegenerative disease;
Neurotrophic factors; Dopamine
ID GENE-THERAPY; NEUROTROPHIC FACTOR; TRANSPLANTATION; GDNF; CNS
AB Although neurotrophic factors have long been recognized as potent agents for protecting against neuronal degeneration, clinical success in treating Parkinson's disease and other neurodegenerative disorders has been hindered by difficulties in delivery of trophic factors across the blood brain barrier (BBB). Bone marrow hematopoietic stem cell-based gene therapy is emerging as a promising tool for overcoming drug delivery problems, as myeloid cells can cross the BBB and are recruited in large numbers to sites of neurodegeneration, where they become activated microglia that can secrete trophic factors. We tested the efficacy of bone marrow-derived microglial delivery of neurturin (NTN) in protecting dopaminergic neurons against neurotoxin-induced death in mice. Bone marrow cells were transduced ex vivo with lentivirus expressing the NTN gene driven by a synthetic macrophage-specific promoter. Infected bone marrow cells were then collected and transplanted into recipient animals. Eight weeks after transplantation, the mice were injected with the neurotoxin1-methyl-4-phenyl-1,2,3,6-tetrahydropuridine (MPTP) for seven days to induce dopaminergic neurodegeneration. Microglia-mediated NTN delivery dramatically ameliorated MPTP-induced degeneration of tyrosine hydroxylase (TH)-positive neurons of the substantia nigra and their terminals in the striatum. Microglia-mediated NTN delivery also induced significant recovery of synaptic marker staining in the striatum of MPTP-treated animals. Functionally, NTN treatment restored MPTP-induced decline in general activity, rearing behavior, and food intake. Thus, bone marrow-derived microglia can serve as cellular vehicles for sustained delivery of neurotrophic factors capable of mitigating dopaminergic injury. Published by Elsevier Ireland Ltd.
C1 [Biju, K. C.; Santacruz, Rene A.; Chen, Cang; Zhou, Qing; Yao, Jiemin; Rohrabaugh, Sara L.; Clark, Robert A.; Li, Senlin] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Santacruz, Rene A.; Li, Senlin] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
[Roberts, James L.; Li, Senlin] Sam & Ann Barshop Inst Longev & Aging Studies, San Antonio, TX 78245 USA.
[Clark, Robert A.; Roberts, James L.; Li, Senlin] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Roberts, James L.] Trinity Univ, Dept Biol, San Antonio, TX 78212 USA.
[Phillips, Kimberley A.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA.
[Imam, Syed Z.] US FDA, Div Neurotoxicol, NCTR, Jefferson, AR USA.
RP Li, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM lis1@uthscsa.edu
OI Phillips, Kimberley/0000-0002-5517-3596
FU NIH [NS046004, AG024579]; Veterans Health Administration; NIH Clinical
and Translational Science Award [UL1 TR0000149]
FX This work was supported by NIH grants (NS046004 and AG024579), a Merit
Review Grant from the Veterans Health Administration, and a NIH Clinical
and Translational Science Award (UL1 TR0000149) Pilot Project grant
awarded to S.L.
NR 23
TC 11
Z9 11
U1 0
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3940
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD FEB 22
PY 2013
VL 535
BP 24
EP 29
DI 10.1016/j.neulet.2012.12.034
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 095XK
UT WOS:000315368100005
PM 23295906
ER
PT J
AU Huang, FW
Hodis, E
Xu, MJ
Kryukov, GV
Chin, L
Garraway, LA
AF Huang, Franklin W.
Hodis, Eran
Xu, Mary Jue
Kryukov, Gregory V.
Chin, Lynda
Garraway, Levi A.
TI Highly Recurrent TERT Promoter Mutations in Human Melanoma
SO SCIENCE
LA English
DT Article
AB Systematic sequencing of human cancer genomes has identified many recurrent mutations in the protein-coding regions of genes but rarely in gene regulatory regions. Here, we describe two independent mutations within the core promoter of telomerase reverse transcriptase (TERT), the gene coding for the catalytic subunit of telomerase, which collectively occur in 50 of 70 (71%) melanomas examined. These mutations generate de novo consensus binding motifs for E-twenty-six (ETS) transcription factors, and in reporter assays, the mutations increased transcriptional activity from the TERT promoter by two-to fourfold. Examination of 150 cancer cell lines derived from diverse tumor types revealed the same mutations in 24 cases (16%), with preliminary evidence of elevated frequency in bladder and hepatocellular cancer cells. Thus, somatic mutations in regulatory regions of the genome may represent an important tumorigenic mechanism.
C1 [Huang, Franklin W.; Hodis, Eran; Xu, Mary Jue; Kryukov, Gregory V.; Garraway, Levi A.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Huang, Franklin W.; Garraway, Levi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Huang, Franklin W.; Hodis, Eran; Xu, Mary Jue; Garraway, Levi A.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Hodis, Eran; Xu, Mary Jue] MIT, Harvard Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Chin, Lynda] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.
[Chin, Lynda] Univ Texas MD Anderson Canc Ctr, Inst Appl Canc Sci, Houston, TX 77030 USA.
RP Garraway, LA (reprint author), Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
EM levi_garraway@dfci.harvard.edu
RI Kryukov, Gregory/A-9592-2008; Waha, Andreas/J-2950-2014
FU NIH [T32 CA009172]; Mittelman Family Fellowship; National Institute of
General Medical Sciences [T32GM07753]; American Cancer Society; NIH New
Innovator Award [DP2OD002750]; National Cancer Institute [R33CA126674];
Novartis Institutes for Biomedical Research; Melanoma Research Alliance;
Starr Cancer Consortium
FX We thank S. N. Wagner, D. Schadendorf, J. A. Wargo, and D. S. B. Hoon
for contribution of samples; K. Cibulskis for assistance with
whole-genome sequence data analysis; and E. Nickerson for coordination
of validation/extension studies. This work was supported by NIH grant
T32 CA009172 (F. W. H.), the Mittelman Family Fellowship (F. W. H.),
National Institute of General Medical Sciences grant T32GM07753 (E. H.),
the American Cancer Society (M. J. X.), NIH New Innovator Award
DP2OD002750 (L. A. G.), National Cancer Institute grant R33CA126674 (L.
A. G.), the Novartis Institutes for Biomedical Research (G. V. K. and L.
A. G.), the Melanoma Research Alliance (L. A. G.), and the Starr Cancer
Consortium (L. C. and L. A. G.). L. A. G. is on the Scientific Advisory
Board of Millennium Pharmaceuticals, is a paid consultant for and holds
equity in Foundation Medicine, and is a paid consultant for and
sponsored research recipient from Novartis. The BAM files for the CCLE
Whole Genome Sequencing data corresponding to the TERT locus can be
accessed at ftp://tertguest:broad@ftp.broadinstitute.org.
NR 10
TC 523
Z9 533
U1 6
U2 81
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD FEB 22
PY 2013
VL 339
IS 6122
BP 957
EP 959
DI 10.1126/science.1229259
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 092UX
UT WOS:000315149600049
PM 23348506
ER
PT J
AU Amabile, G
Welner, RS
Nombela-Arrieta, C
D'Alise, AM
Di Ruscio, A
Ebralidze, AK
Kraytsberg, Y
Ye, M
Kocher, O
Neuberg, DS
Khrapko, K
Silberstein, LE
Tenen, DG
AF Amabile, Giovanni
Welner, Robert S.
Nombela-Arrieta, Cesar
D'Alise, Anna Morena
Di Ruscio, Annalisa
Ebralidze, Alexander K.
Kraytsberg, Yevgenya
Ye, Min
Kocher, Olivier
Neuberg, Donna S.
Khrapko, Konstantin
Silberstein, Leslie E.
Tenen, Daniel G.
TI In vivo generation of transplantable human hematopoietic cells from
induced pluripotent stem cells
SO BLOOD
LA English
DT Article
ID HUMAN FIBROBLASTS; DIFFERENTIATION; PROGENITORS; BLOOD; VITRO;
INDUCTION; EFFICIENT; MOUSE; MYC
AB Lineage-restricted cells can be reprogrammed to a pluripotent state known as induced pluripotent stem (iPS) cells through overexpression of 4 transcription factors. iPS cells are similar to human embryonic stem (hES) cells and have the same ability to generate all the cells of the human body, including blood cells. However, this process is extremely inefficient and to date has been unsuccessful at differentiating iPS into hematopoietic stem cells (HSCs). We hypothesized that iPS cells, injected into NOD. Cg-Prkdc(scid) Il2rg(tm1Wjl)/SzJ immunocompromised (NSG) mice could give rise to hematopoietic stem/progenitor cells (HSPCs) during teratoma formation. Here, we report a novel in vivo system in which human iPS cells differentiate within teratomas to derive functional myeloid and lymphoid cells. Similarly, HSPCs can be isolated from teratoma parenchyma and reconstitute a human immune system when transplanted into immunodeficient mice. Our data provide evidence that in vivo generation of patient customized cells is feasible, providing materials that could be useful for transplantation, human antibody generation, and drug screening applications.
C1 [Amabile, Giovanni; Welner, Robert S.; D'Alise, Anna Morena; Di Ruscio, Annalisa; Ebralidze, Alexander K.; Kraytsberg, Yevgenya; Ye, Min; Kocher, Olivier; Khrapko, Konstantin; Tenen, Daniel G.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Amabile, Giovanni; Welner, Robert S.; Nombela-Arrieta, Cesar; D'Alise, Anna Morena; Di Ruscio, Annalisa; Ebralidze, Alexander K.; Kraytsberg, Yevgenya; Ye, Min; Silberstein, Leslie E.; Tenen, Daniel G.] Harvard Stem Cell Inst, Boston, MA USA.
[Amabile, Giovanni; Welner, Robert S.; Di Ruscio, Annalisa; Ebralidze, Alexander K.; Kraytsberg, Yevgenya; Ye, Min; Khrapko, Konstantin] Beth Israel Deaconess Med Ctr, Dept Hematol Oncol, Boston, MA 02215 USA.
[Nombela-Arrieta, Cesar; Silberstein, Leslie E.] Childrens Hosp, Dept Lab Med, Joint Program Transfus Med, Boston, MA 02115 USA.
[Neuberg, Donna S.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Tenen, Daniel G.] Natl Univ Singapore, Canc Sci Inst, Singapore 117548, Singapore.
RP Tenen, DG (reprint author), Harvard Univ, Sch Med, Harvard Stem Cell Inst, Ctr Life Sci, 3 Blackfan Circle, Boston, MA 02115 USA.
EM dtenen@bidmc.harvard.edu
OI Nombela-Arrieta, Cesar/0000-0003-0415-259X; Tenen,
Daniel/0000-0002-6423-3888
FU Collegio Ghislieri fellowship program; Jose Carreras fellowship program;
long-term Human Frontier fellowship; Harvard Stem Cell Institute; Amelia
Peabody Foundation
FX The authors are grateful to Paul Kincade (OMRF) for providing the OP9,
OP9-GFP, OP9W3a, and OP9D cell lines and for critical reading of the
paper. The authors thank Riccardo Cortese and Alfredo Nicosia (CEINGE)
for sharing protocols and suggestions during immunizations experiments.
The authors are grateful to Linda Clayton (Dana-Farber Cancer Institute)
for suggestions regarding the T-cell experiments. G. A. was supported by
the Collegio Ghislieri fellowship program. R. S. W. was supported by the
Jose Carreras fellowship program. C.N.A. was supported by the long-term
Human Frontier fellowship.; This work was supported by the Harvard Stem
Cell Institute and a grant from the Amelia Peabody Foundation.
NR 38
TC 71
Z9 73
U1 6
U2 38
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD FEB 21
PY 2013
VL 121
IS 8
BP 1255
EP 1264
DI 10.1182/blood-2012-06-434407
PG 10
WC Hematology
SC Hematology
GA 182NK
UT WOS:000321750000010
PM 23212524
ER
PT J
AU Ghobrial, IM
Campigotto, F
Murphy, TJ
Boswell, EN
Banwait, R
Azab, F
Chuma, S
Kunsman, J
Donovan, A
Masood, F
Warren, D
Rodig, S
Anderson, KC
Richardson, PG
Weller, E
Matous, J
AF Ghobrial, Irene M.
Campigotto, Federico
Murphy, Timothy J.
Boswell, Erica N.
Banwait, Ranjit
Azab, Feda
Chuma, Stacey
Kunsman, Janet
Donovan, Amanda
Masood, Farzana
Warren, Diane
Rodig, Scott
Anderson, Kenneth C.
Richardson, Paul G.
Weller, Edie
Matous, Jeffrey
TI Results of a phase 2 trial of the single-agent histone deacetylase
inhibitor panobinostat in patients with relapsed/refractory Waldenstrom
macroglobulinemia
SO BLOOD
LA English
DT Review
ID CONSENSUS PANEL RECOMMENDATIONS; 2ND INTERNATIONAL WORKSHOP;
MULTIPLE-MYELOMA; HUMAN CANCER; II TRIAL; LBH589; MANAGEMENT; LYMPHOMA;
UPDATE
AB The present study aimed to determine the safety and activity of the histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM). Eligibility criteria included patients with relapsed/refractory WM with any number of prior therapies. Patients received panobinostat at 30 mg 3 times a week; 12 of 36 (33%) patients were enrolled at 25 mg dose. A total of 36 patients received therapy. The median age was 62 years (range, 47-80) and the median number of prior therapies was 3 (range, 1-8). All of the patients had received prior rituximab. Minimal response (MR) or better was achieved in 47% of patients (90% confidence interval [CI], 33-62), with 22% partial remissions and 25% MR. In addition, 18 (50%) patients achieved stable disease and none showed progression while on therapy. The median time to first response was 1.8 months (range, 1.7-3.2). The median progression-free survival was 6.6 months(90% CI, 5.5-14.8). Grade 3 and 4 toxicities included thrombocytopenia (67%), neutropenia (36%), anemia (28%), leukopenia (22%), and fatigue (11%). We conclude that panobinostat is an active therapeutic agent in patients with relapsed/refractory WM. This study (www.clinicaltrials.gov identifier: NCT00936611) establishes a role for histone deacetylase inhibitors as an active class of therapeutic agents in WM.
C1 [Ghobrial, Irene M.; Boswell, Erica N.; Banwait, Ranjit; Azab, Feda; Chuma, Stacey; Kunsman, Janet; Donovan, Amanda; Masood, Farzana; Warren, Diane; Anderson, Kenneth C.; Richardson, Paul G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Campigotto, Federico; Weller, Edie] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Murphy, Timothy J.; Matous, Jeffrey] Rocky Mt Canc Ctr, Colorado Springs, CO USA.
[Rodig, Scott] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Ghobrial, IM (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM irene_ghobrial@dfci.harvard.edu
FU Novartis [1R01F0003743]; International Waldenstrom Macroglobulinemia
Foundation; Michelle and Steven Kirsch Laboratory for Waldenstrom
Macroglobulinemia; Heje Fellowship for Waldenstrom
FX This study was supported in part by a research grant from Novartis
(1R01F0003743), the International Waldenstrom Macroglobulinemia
Foundation, the Michelle and Steven Kirsch Laboratory for Waldenstrom
Macroglobulinemia, and the Heje Fellowship for Waldenstrom.
NR 26
TC 33
Z9 33
U1 1
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD FEB 21
PY 2013
VL 121
IS 8
BP 1296
EP 1303
DI 10.1182/blood-2012-06-439307
PG 8
WC Hematology
SC Hematology
GA 182NK
UT WOS:000321750000014
PM 23287861
ER
PT J
AU Salaverria, I
Royo, C
Carvajal-Cuenca, A
Clot, G
Navarro, A
Valera, A
Song, JY
Woroniecka, R
Rymkiewicz, G
Klapper, W
Hartmann, EM
Sujobert, P
Wlodarska, I
Ferry, JA
Gaulard, P
Ott, G
Rosenwald, A
Lopez-Guillermo, A
Quintanilla-Martinez, L
Harris, NL
Jaffe, ES
Siebert, R
Campo, E
Bea, S
AF Salaverria, Itziar
Royo, Cristina
Carvajal-Cuenca, Alejandra
Clot, Guillem
Navarro, Alba
Valera, Alejandra
Song, Joo Y.
Woroniecka, Renata
Rymkiewicz, Grzegorz
Klapper, Wolfram
Hartmann, Elena M.
Sujobert, Pierre
Wlodarska, Iwona
Ferry, Judith A.
Gaulard, Philippe
Ott, German
Rosenwald, Andreas
Lopez-Guillermo, Armando
Quintanilla-Martinez, Leticia
Harris, Nancy L.
Jaffe, Elaine S.
Siebert, Reiner
Campo, Elias
Bea, Silvia
TI CCND2 rearrangements are the most frequent genetic events in cyclin
D1(-) mantle cell lymphoma
SO BLOOD
LA English
DT Article
ID NUCLEAR EXPRESSION; SOX11 EXPRESSION; GENOME; TARGET; OVEREXPRESSION;
AMPLIFICATIONS; TRANSLOCATION; PATHOGENESIS; NEOPLASMS; DIAGNOSIS
AB Cyclin D1(-) mantle cell lymphomas (MCLs) are not well characterized, in part because of the difficulties in their recognition. SOX11 has been identified recently as a reliable biomarker of MCL that is also expressed in the cyclin D1(-) variant. We investigated 40 lymphomas with MCL morphology and immunophenotype that were negative for cyclin D1 expression/t(11;14)(q13;q32) but positive for SOX11. These tumors presented clinically with generalized lymphadenopathy, advanced stage, and poor outcome (5-year overall survival, 48%). Chromosomal rearrangements of the CCND2 locus were detected in 55% of the cases, with an IG gene as partner in 18 of 22, in particular with light chains (10 IGK@ and 5 IGL@). No mutations in the phosphorylation motifs of CCND1, CCND2, or CCND3 were detected. The global genomic profile and the high complexity of the 32 cyclin D1(-)SOX11(+) MCL patients analyzed by copy number arrays were similar to the conventional cyclin D1(+)/SOX11(+) MCL. 17p deletions and high Ki67 expression conferred a significantly worse outcome for the patients. This comprehensive characterization of a large series of cyclin D1(-) MCL patients indicates that these tumors are clinically and biologically similar to the conventional cyclin D1(+) MCL and provides a basis for the proper identification and clinical management of these patients.
C1 [Salaverria, Itziar; Royo, Cristina; Carvajal-Cuenca, Alejandra; Clot, Guillem; Navarro, Alba; Valera, Alejandra; Campo, Elias; Bea, Silvia] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Dept Pathol, Hematopathol Unit,Hosp Clin, Barcelona, Spain.
[Salaverria, Itziar; Siebert, Reiner] Univ Kiel, Univ Hosp Schleswig Holstein Campus Kiel, Inst Human Genet, Kiel, Germany.
[Song, Joo Y.; Jaffe, Elaine S.] NCI, Pathol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Woroniecka, Renata] Maria Sklodowska Curie Mem Inst & Oncol Ctr, Cytogenet Lab, Warsaw, Poland.
[Rymkiewicz, Grzegorz] Maria Sklodowska Curie Mem Inst & Oncol Ctr, Dept Pathol, Warsaw, Poland.
[Klapper, Wolfram] Univ Kiel, Hematopathol Sect, Dept Pathol, Kiel, Germany.
[Klapper, Wolfram] Univ Kiel, Lymph Node Registry, Kiel, Germany.
[Hartmann, Elena M.; Rosenwald, Andreas] Univ Wurzburg, Inst Pathol, Wurzburg, Germany.
[Sujobert, Pierre; Gaulard, Philippe] Hop Henri Mondor, F-94010 Creteil, France.
[Wlodarska, Iwona] Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium.
[Ferry, Judith A.; Harris, Nancy L.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Ott, German] Robert Bosch Krankenhaus, Dept Clin Pathol, Stuttgart, Germany.
[Ott, German] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany.
[Lopez-Guillermo, Armando] Hosp Clin Barcelona, Hematopathol Unit, Dept Hematol, Barcelona, Spain.
[Quintanilla-Martinez, Leticia] Univ Tubingen, Inst Pathol, Tubingen, Germany.
RP Bea, S (reprint author), Ctr Esther Koplowitz, 2nd Floor,Rossello 153, Barcelona 08036, Spain.
EM sbea@clinic.cat
RI Siebert, Reiner/A-8049-2010; Navarro, Alba/H-2611-2015; Royo,
Cristina/H-3193-2015; SALAVERRIA, ITZIAR/L-2246-2015; Song,
Joo/E-5356-2016; Jaffe, Elaine/G-8984-2014; Klapper,
Wolfram/S-6314-2016; Bea, Silvia/K-7699-2014;
OI Navarro, Alba/0000-0002-4041-0974; Royo, Cristina/0000-0002-1214-4656;
SALAVERRIA, ITZIAR/0000-0002-2427-9822; Song, Joo/0000-0003-3497-2513;
Jaffe, Elaine/0000-0003-4632-0301; Bea, Silvia/0000-0001-7192-2385;
Campo, elias/0000-0001-9850-9793
FU Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias
[PI08/0077, PI11/01177]; Alexander von Humboldt Foundation; Subprograma
Juan de la Cierva Ministerio de Ciencia e Innovacion [JCI-2011-10232];
Instituto de Salud Carlos III, Beca Predoctoral de Formacion en
Investigacion en Salud Comision Interministerial de Ciencia y Tecnologia
Espanola [FI08/00347, SAF08/3630]; Red Tematica de Investigacion
Cooperativa del Cancer [RD06/0020/0039 ISCIII]; Spanish Ministry of
Science and Innovation; European Regional Development Fund (Unio Europea
"Una manera de fer Europa")
FX This study was supported by the Instituto de Salud Carlos III, Fondo de
Investigaciones Sanitarias (PI08/0077; PI11/01177 to S. B.), Alexander
von Humboldt Foundation (to I. S.) and Subprograma Juan de la Cierva
Ministerio de Ciencia e Innovacion (JCI-2011-10232 to I. S.), Instituto
de Salud Carlos III, Beca Predoctoral de Formacion en Investigacion en
Salud (FI08/00347 to C. R.) Comision Interministerial de Ciencia y
Tecnologia Espanola (SAF08/3630 to E. C.), Red Tematica de Investigacion
Cooperativa del Cancer (RD06/0020/0039 ISCIII to E. C.), and the Spanish
Ministry of Science and Innovation and European Regional Development
Fund (Unio Europea "Una manera de fer Europa").
NR 33
TC 36
Z9 39
U1 1
U2 10
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD FEB 21
PY 2013
VL 121
IS 8
BP 1394
EP 1402
DI 10.1182/blood-2012-08-452284
PG 9
WC Hematology
SC Hematology
GA 182NK
UT WOS:000321750000024
PM 23255553
ER
PT J
AU Gao, C
Dimitrov, T
Yong, KJ
Tatetsu, H
Jeong, HW
Luo, HR
Bradner, JE
Tenen, DG
Chai, L
AF Gao, Chong
Dimitrov, Todor
Yong, Kol Jia
Tatetsu, Hiro
Jeong, Ha-won
Luo, Hongbo R.
Bradner, James E.
Tenen, Daniel G.
Chai, Li
TI Targeting transcription factor SALL4 in acute myeloid leukemia by
interrupting its interaction with an epigenetic complex
SO BLOOD
LA English
DT Article
ID GERM-CELL TUMORS; CHRONIC MYELOGENOUS LEUKEMIA; EARLY
EMBRYONIC-DEVELOPMENT; HOMEOTIC GENE SPALT; YOLK-SAC TUMORS; ENDOMETRIAL
CARCINOMA; DEACETYLASE COMPLEX; DIAGNOSTIC UTILITY; REPRESSOR COMPLEX;
NERVOUS-SYSTEM
AB An exciting recent approach to targeting transcription factors in cancer is to block formation of oncogenic complexes. We investigated whether interfering with the interaction of the transcription factor SALL4, which is critical for leukemic cell survival, and its epigenetic partner complex represents a novel therapeutic approach. The mechanism of SALL4 in promoting leukemogenesis is at least in part mediated by its repression of the tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN) through its interaction with a histone deacetylase (HDAC) complex. In this study, we demonstrate that a peptide can compete with SALL4 in interacting with the HDAC complex and reverse its effect on PTEN repression. Treating SALL4-expressing malignant cells with this peptide leads to cell death that can be rescued by a PTEN inhibitor. The antileukemic effect of this peptide can be confirmed on primary human leukemia cells in culture and in vivo, and is identical to that of down-regulation of SALL4 in these cells using an RNAi approach. In summary, our results demonstrate a novel peptide that can block the specific interaction between SALL4 and its epigenetic HDAC complex in regulating its target gene, PTEN. Furthermore, targeting SALL4 with this approach could be an innovative approach in treating leukemia. (Blood. 2013;121(8):1413-1421)
C1 [Gao, Chong; Dimitrov, Todor; Tatetsu, Hiro; Jeong, Ha-won; Chai, Li] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol,Joint Program Transfus Med, Boston, MA 02115 USA.
[Yong, Kol Jia; Tenen, Daniel G.] Natl Univ Singapore, Canc Sci Inst Singapore, Ctr Translat Med, Singapore 117548, Singapore.
[Luo, Hongbo R.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Lab Med, Boston, MA 02115 USA.
[Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Tenen, Daniel G.] Harvard Stem Cell Inst, Boston, MA USA.
RP Chai, L (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol,Joint Program Transfus Med, 75 Francis St, Boston, MA 02115 USA.
EM lchai@partners.org
OI Tenen, Daniel/0000-0002-6423-3888
FU National Institutes of Health [PO1 DK080665, RO1HL092437, PO1HL095489]
FX This work was supported in part by the National Institutes of Health
(grant PO1 DK080665 to D. G. T. and grants RO1HL092437 and PO1HL095489
to L.C.).
NR 48
TC 20
Z9 24
U1 1
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD FEB 21
PY 2013
VL 121
IS 8
BP 1413
EP 1421
DI 10.1182/blood-2012-04-424275
PG 9
WC Hematology
SC Hematology
GA 182NK
UT WOS:000321750000026
PM 23287862
ER
PT J
AU Switzer, GE
Bruce, JG
Myaskovsky, L
DiMartini, A
Shellmer, D
Confer, DL
Abress, LK
King, RJ
Harnaha, AG
Ohngemach, S
Dew, MA
AF Switzer, Galen E.
Bruce, Jessica G.
Myaskovsky, Larissa
DiMartini, Andrea
Shellmer, Diana
Confer, Dennis L.
Abress, Linda K.
King, Roberta J.
Harnaha, Allyson G.
Ohngemach, Sibylle
Dew, Mary Amanda
TI Race and ethnicity in decisions about unrelated hematopoietic stem cell
donation
SO BLOOD
LA English
DT Article
ID BONE-MARROW DONATION; AFRICAN-AMERICANS; ORGAN DONATION; UNITED-STATES;
DONORS; REGISTRY; TRANSPLANTATION; WILLINGNESS; KNOWLEDGE; ATTITUDES
AB Large international registries of potential unrelated hematopoietic stem cell (HSC) donors, including the National Marrow Donor program (NMDP), continue to face difficulties finding matched donors for racial/ethnic minorities. One reason, in addition to the generally less common HLA types among minority patients, is the much higher registry attrition rate of racial/ethnic minorities compared with whites. Reasons for the higher attrition among minority potential donors remain unexplained. The goal of our cross-sectional telephone interview study was to generate a diverse sample of potential HSC donors who have preliminarily matched a patient and to identify factors associated with race/ethnicity and with the decision to continue toward potential donation or to opt out of the registry. Multiple culturally related, psychosocial, and donation-related factors were associated both with race/ethnic group membership and attrition from the registry. The most consistent factor associated with opting out of the registry across all race/ethnic groups was ambivalence about donation: doubts and worries, feeling unsure about donation, wishing someone else would donate in one's place. Our findings suggest that universal donor recruitment and management approaches based on reducing donation-related ambivalence and tailored messages and strategies for each of the individual race/ethnic groups are important. (Blood. 2013;121(8):1469-1476)
C1 [Switzer, Galen E.; Myaskovsky, Larissa] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA.
[Switzer, Galen E.; Myaskovsky, Larissa] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Switzer, Galen E.; Bruce, Jessica G.; Myaskovsky, Larissa; DiMartini, Andrea; Harnaha, Allyson G.; Ohngemach, Sibylle; Dew, Mary Amanda] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Switzer, Galen E.] Univ Pittsburgh, Dept Clin & Translat Sci, Pittsburgh, PA USA.
[DiMartini, Andrea; Shellmer, Diana] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA.
[Confer, Dennis L.; Abress, Linda K.; King, Roberta J.] Natl Marrow Donor Program, Minneapolis, MN USA.
[Dew, Mary Amanda] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA.
[Dew, Mary Amanda] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA.
[Dew, Mary Amanda] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
RP Switzer, GE (reprint author), Div Gen Internal Med, Iroquois Bldg,Ste 502,3600 Forbes Ave, Pittsburgh, PA 15213 USA.
EM switzerge@upmc.edu
FU National Heart, Lung, and Blood Institute, National Institutes of
Health, Bethesda, MD [R01 HL081405]
FX This project was supported by a grant from the National Heart, Lung, and
Blood Institute, National Institutes of Health, Bethesda, MD (R01
HL081405).
NR 37
TC 22
Z9 23
U1 6
U2 9
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD FEB 21
PY 2013
VL 121
IS 8
BP 1469
EP 1476
DI 10.1182/blood-2012-06-437343
PG 8
WC Hematology
SC Hematology
GA 182NK
UT WOS:000321750000033
PM 23258921
ER
PT J
AU Cohen, KS
Cheng, S
Larson, MG
Cupples, LA
McCabe, EL
Wang, YA
Ngwa, JS
Martin, RP
Klein, RJ
Hashmi, B
Ge, Y
O'Donnell, CJ
Vasan, RS
Shaw, SY
Wang, TJ
AF Cohen, Kenneth S.
Cheng, Susan
Larson, Martin G.
Cupples, L. Adrienne
McCabe, Elizabeth L.
Wang, Ying A.
Ngwa, Julius S.
Martin, Roderick P.
Klein, Rachael J.
Hashmi, Basma
Ge, Yin
O'Donnell, Christopher J.
Vasan, Ramachandran S.
Shaw, Stanley Y.
Wang, Thomas J.
TI Circulating CD34(+) progenitor cell frequency is associated with
clinical and genetic factors
SO BLOOD
LA English
DT Article
ID CORONARY-ARTERY-DISEASE; ACUTE MYOCARDIAL-INFARCTION; GENOME-WIDE
ASSOCIATION; CARDIOVASCULAR RISK; ENDOTHELIAL-CELLS; STATIN THERAPY;
HEART-DISEASE; DYSFUNCTION; MOBILIZATION; POPULATION
AB Circulating blood CD34(+) cells consist of hematopoietic stem/progenitor cells, angiogenic cells, and endothelial cells. In addition to their clinical use in hematopoietic stem cell transplantation, CD34(+) cells may also promote therapeutic neovascularization. Therefore, understanding the factors that influence circulating CD34(+) cell frequency has wide implications for vascular biology in addition to stem cell transplantation. In the present study, we examined the clinical and genetic characteristics associated with circulating CD34(+) cell frequency in a large, community-based sample of 1786 Framingham Heart Study participants. Among subjects without cardiovascular disease (n = 1595), CD34(+) frequency was inversely related to older age, female sex, and smoking. CD34(+) frequency was positively related to weight, serum total cholesterol, and statin therapy. Clinical covariates accounted for 6.3% of CD34(+) variability. CD34(+) frequency was highly heritable (h(2) = 54%; P < .0001). Genome-wide association analysis of CD34(+) frequency identified suggestive associations at several loci, including OR4C12 (chromosome 11; P = 6.7 x 10(-7)) and ENO1 and RERE (chromosome 1; P = 8.8 x 10(-7)). CD34(+) cell frequency is reduced in older subjects and is influenced by environmental factors including smoking and statin use. CD34(+) frequency is highly heritable. The results of the present study have implications for therapies that use CD34+ cell populations and support efforts to better understand the genetic mechanisms that underlie CD34(+) frequency.
C1 [Wang, Thomas J.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Cohen, Kenneth S.; Martin, Roderick P.; Klein, Rachael J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, Boston, MA USA.
[Cohen, Kenneth S.] Univ Chicago, Med Ctr, Hematol Oncol Sect, Chicago, IL 60637 USA.
[Cheng, Susan; McCabe, Elizabeth L.; O'Donnell, Christopher J.; Shaw, Stanley Y.; Wang, Thomas J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Cheng, Susan; Larson, Martin G.; O'Donnell, Christopher J.; Vasan, Ramachandran S.; Wang, Thomas J.] Framingham Heart Dis Epidemiol Study, Framingham, MA 90034 USA.
[Cheng, Susan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc Med, Boston, MA 02115 USA.
[Larson, Martin G.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
[Cupples, L. Adrienne; Wang, Ying A.; Ngwa, Julius S.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Martin, Roderick P.] Genzyme Corp, Cambridge, MA USA.
[Hashmi, Basma] Harvard Univ, Dept Bioengn, Boston, MA 02115 USA.
[Ge, Yin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
[O'Donnell, Christopher J.] NHLBI, Ctr Populat Studies, NIH, Bethesda, MD 20892 USA.
[Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Med, Prevent Med Sect, Boston, MA 02118 USA.
[Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Med, Div Cardiol, Boston, MA 02118 USA.
[Shaw, Stanley Y.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA USA.
RP Wang, TJ (reprint author), Massachusetts Gen Hosp, Div Cardiol, GRB 800,55 Fruit St, Boston, MA 02114 USA.
EM kcohen@medicine.bsd.uchicago.edu; shaw.stanley@mgh.harvard.edu;
tjwang@partners.org
OI Larson, Martin/0000-0002-9631-1254; Cupples, L.
Adrienne/0000-0003-0273-7965
FU National Heart, Lung, and Blood Institute's Framingham Heart Study
[N01-HC-25195, R01-HL083197, R01-HL93328]; National Institutes of Health
[K99HL107642]; Ellison Foundation
FX This work was supported in part by the National Heart, Lung, and Blood
Institute's Framingham Heart Study (contract number N01-HC-25195, grant
R01-HL083197 to T.J.W., and grant R01-HL93328 to R. S. V.). S. C. is
supported in part by National Institutes of Health grant K99HL107642 and
the Ellison Foundation.
NR 47
TC 23
Z9 23
U1 0
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD FEB 21
PY 2013
VL 121
IS 8
BP E50
EP E56
DI 10.1182/blood-2012-05-424846
PG 7
WC Hematology
SC Hematology
GA 182NK
UT WOS:000321750000002
PM 23287867
ER
PT J
AU Liu, QS
Sabnis, Y
Zhao, Z
Zhang, TH
Buhrlage, SJ
Jones, LH
Gray, NS
AF Liu, Qingsong
Sabnis, Yogesh
Zhao, Zheng
Zhang, Tinghu
Buhrlage, Sara J.
Jones, Lyn H.
Gray, Nathanael S.
TI Developing Irreversible Inhibitors of the Protein Kinase Cysteinome
SO CHEMISTRY & BIOLOGY
LA English
DT Review
ID KAPPA-B KINASE; GROWTH-FACTOR RECEPTOR; LUNG-CANCER MODELS;
COVALENT-BINDING; IN-VIVO; ACTIVE-SITE; DRUG DESIGN; TYROSINE; EGFR;
SELECTIVITY
AB Protein kinases are a large family of approximately 530 highly conserved enzymes that transfer a gamma-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction. The clinical success of a number of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large number of kinases may represent therapeutically relevant targets. To date, the majority of clinical and preclinical kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases. Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket. Irreversible kinase inhibitors have a number of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacological specificity through mutation of the reactive cysteine residue. Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biological activity profiles. In addition, we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.
C1 [Liu, Qingsong; Zhang, Tinghu; Buhrlage, Sara J.; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Liu, Qingsong; Zhang, Tinghu; Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Sabnis, Yogesh] Pfizer Ltd, World Wide Med Chem, Computat Chem, Sandwich CT13 9NJ, Kent, England.
[Sabnis, Yogesh] UCB NewMed, UCB Pharma, BE-1420 Braine Lalleud, Belgium.
[Zhao, Zheng] Chinese Acad Sci, High Field Magnet Lab, Hefei 230031, Anhui, Peoples R China.
[Jones, Lyn H.] Pfizer, World Wide Med Chem, BioTherapeut Chem, Chem Biol Grp, Cambridge, MA 02140 USA.
RP Jones, LH (reprint author), Pfizer, World Wide Med Chem, BioTherapeut Chem, Chem Biol Grp, Cambridge, MA 02140 USA.
EM lyn.jones@pfizer.com; nathanael_gray@dfci.harvard.edu
OI liu, qing song/0000-0002-7829-2547; Jones, Lyn/0000-0002-8388-5865
FU NCI NIH HHS [R01 CA130876]; NIGMS NIH HHS [P41 GM079575]
NR 74
TC 151
Z9 151
U1 14
U2 129
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-5521
J9 CHEM BIOL
JI Chem. Biol.
PD FEB 21
PY 2013
VL 20
IS 2
BP 146
EP 159
DI 10.1016/j.chembiol.2012.12.006
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 104FZ
UT WOS:000315978600007
PM 23438744
ER
PT J
AU Modjarrad, K
Mohraz, M
Madani, N
AF Modjarrad, Kayvon
Mohraz, Minoo
Madani, Navid
TI Iran needs global support to fight HIV
SO NATURE
LA English
DT Letter
C1 [Modjarrad, Kayvon] NIAID, Bethesda, MD 20892 USA.
[Mohraz, Minoo] Univ Tehran Med Sci, Tehran, Iran.
[Madani, Navid] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Modjarrad, K (reprint author), NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM kayvon.modjarrad@nih.gov
NR 1
TC 1
Z9 1
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD FEB 21
PY 2013
VL 494
IS 7437
BP 314
EP 314
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 095CS
UT WOS:000315312900022
PM 23426315
ER
PT J
AU Chen, JJ
Rosas, HD
Salat, DH
AF Chen, J. Jean
Rosas, H. Diana
Salat, David H.
TI The Relationship between Cortical Blood Flow and Sub-Cortical
White-Matter Health across the Adult Age Span
SO PLOS ONE
LA English
DT Article
ID MILD COGNITIVE IMPAIRMENT; VASCULAR RISK-FACTORS; DIFFUSION TENSOR;
ALZHEIMERS-DISEASE; CORPUS-CALLOSUM; OLDER-ADULTS; NEUROVASCULAR
MECHANISMS; CEREBRAL HYPOPERFUSION; HYPERTENSIVE PATIENTS; SPATIAL
STATISTICS
AB Degeneration of cerebral white matter is commonly observed in aging, and the associated degradation in neural connectivity contributes to cognitive decline in older adults. Vascular dysfunction has been implicated as a potential mechanism for general age-related neural tissue deterioration; however, no prior study has examined the direct relationship between cortical vascular health and subcortical white-matter integrity. In this work, we aimed to determine whether blood supply to the brain is associated with microstructural integrity of connective tissue, and whether such associations are regionally specific and mainly accounted for by aging. We examined the association between cerebral blood flow (CBF) in the cortical mantle, measured using arterial spin labeling (ASL), and subcortical white-matter integrity, measured using diffusion tensor imaging (DTI), in a group of healthy adults spanning early to late adulthood. We found cortical CBF to be significantly associated with white-matter integrity throughout the brain. In addition, these associations were only partially tied to aging, as they remained even when statistically controlling for age, and when restricting the analyses to a young subset of the sample. Furthermore, vascular risk was not a prominent determinant of these effects. These findings suggest that the overall blood supply to the brain is an important indicator of white-matter health in the normal range of variations amongst adults, and that the decline in CBF with advancing age may potentially exacerbate deterioration of the connective anatomy of the brain.
C1 [Chen, J. Jean] Univ Toronto, Rotman Res Inst, Baycrest Ctr Geriatr Care, Toronto, ON, Canada.
[Chen, J. Jean; Rosas, H. Diana; Salat, David H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA USA.
[Chen, J. Jean; Salat, David H.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Rosas, H. Diana] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Salat, David H.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, Boston, MA USA.
RP Chen, JJ (reprint author), Univ Toronto, Rotman Res Inst, Baycrest Ctr Geriatr Care, Toronto, ON, Canada.
EM jchen@rotman-baycrest.on.ca
FU National Institutes of Health [R01NR010827, NS042861, P41RR14075];
Canadian Institutes of Health Research; Athinoula A. Martinos Center for
Biomedical Imaging
FX This research was supported by National Institutes of Health grants
R01NR010827, NS042861, and P41RR14075, as well as by fellowship funding
from the Canadian Institutes of Health Research (to JJC) and the
Athinoula A. Martinos Center for Biomedical Imaging. The funders had no
role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
NR 85
TC 17
Z9 17
U1 3
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 21
PY 2013
VL 8
IS 2
AR e56733
DI 10.1371/journal.pone.0056733
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093IT
UT WOS:000315186000042
PM 23437228
ER
PT J
AU Weisberg, E
Liu, QS
Zhang, X
Nelson, E
Sattler, M
Liu, FY
Nicolais, M
Zhang, JM
Mitsiades, C
Smith, RW
Stone, R
Galinsky, I
Nonami, A
Griffin, JD
Gray, N
AF Weisberg, Ellen
Liu, Qingsong
Zhang, Xin
Nelson, Erik
Sattler, Martin
Liu, Feiyang
Nicolais, Maria
Zhang, Jianming
Mitsiades, Constantine
Smith, Robert W.
Stone, Richard
Galinsky, Ilene
Nonami, Atsushi
Griffin, James D.
Gray, Nathanael
TI Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and
Effectively Override Stroma-Associated Cytoprotection of Mutant
FLT3-Positive AML Cells
SO PLOS ONE
LA English
DT Article
ID LYMPHOBLASTIC-LEUKEMIA CELLS; CONSTITUTIVE ACTIVATION; FLT3 INHIBITORS;
APOPTOSIS; MUTATIONS; SURVIVAL; RESISTANCE; THERAPIES; PATHWAYS; CONTACT
AB Objectives: Tyrosine kinase inhibitor (TKI)-treated acute myeloid leukemia (AML) patients commonly show rapid and significant peripheral blood blast cell reduction, however a marginal decrease in bone marrow blasts. This suggests a protective environment and highlights the demand for a better understanding of stromal: leukemia cell communication. As a strategy to improve clinical efficacy, we searched for novel agents capable of potentiating the stroma-diminished effects of TKI treatment of mutant FLT3-expressing cells.
Methods: We designed a combinatorial high throughput drug screen using well-characterized kinase inhibitor-focused libraries to identify novel kinase inhibitors capable of overriding stromal-mediated resistance to TKIs, such as PKC412 and AC220. Standard liquid culture proliferation assays, cell cycle and apoptosis analysis, and immunoblotting were carried out with cell lines or primary AML to validate putative candidates from the screen and characterize the mechanism(s) underlying observed synergy.
Results and Conclusions: Our study led to the observation of synergy between selective Akt inhibitors and FLT3 inhibitors against mutant FLT3-positive AML in either the absence or presence of stroma. Our findings are consistent with evidence that Akt activation is characteristic of mutant FLT3-transformed cells, as well as observed residual Akt activity following FLT3 inhibitor treatment. In conclusion, our study highlights the potential importance of Akt as a signaling factor in leukemia survival, and supports the use of the co-culture chemical screen to identify agents able to potentiate TKI anti-leukemia activity in a cytoprotective microenvironment.
C1 [Weisberg, Ellen; Nelson, Erik; Sattler, Martin; Nicolais, Maria; Mitsiades, Constantine; Smith, Robert W.; Stone, Richard; Galinsky, Ilene; Nonami, Atsushi; Griffin, James D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Liu, Qingsong; Zhang, Xin; Zhang, Jianming; Gray, Nathanael] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Liu, Feiyang] Chinese Acad Sci, High Field Magnet Lab, Hefei, Anhui, Peoples R China.
RP Weisberg, E (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.
EM ellen_weisberg@dfci.harvard.edu; james_griffin@dfci.harvard.edu
OI liu, qing song/0000-0002-7829-2547
FU National Institutes of Health (NIH) Library of Integrated Network-Based
Cellular Signatures (LINCS) grant [HG006097]; Chinese Academy of Science
High Magnetic Field Laboratory training grant; NIH grant [CA66996]; CAS
FX Grant Support: QL and NG are supported by National Institutes of Health
(NIH) Library of Integrated Network-Based Cellular Signatures (LINCS)
grant HG006097. FL is supported by a Chinese Academy of Science High
Magnetic Field Laboratory training grant. JDG is supported by NIH grant
CA66996. FL is supported by CAS. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 29
TC 14
Z9 15
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 21
PY 2013
VL 8
IS 2
AR e56473
DI 10.1371/journal.pone.0056473
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093IT
UT WOS:000315186000029
PM 23437141
ER
PT J
AU Jang, H
Shin, H
AF Jang, Hyeran
Shin, Hyunjin
TI Current trends in the development and application of molecular
technologies for cancer epigenetics
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Cancer; Epigenetic; Technology; Butyrate; Histone modifications; Diet;
Methyl sources
ID GENOMIC DNA METHYLATION; COVALENT HISTONE MODIFICATIONS; MODEL-BASED
ANALYSIS; LARGE-BOWEL CANCER; CHAIN FATTY-ACIDS; SODIUM-BUTYRATE;
GENE-EXPRESSION; DEFICIENT DIET; COLON-CANCER; GLOBAL DNA
AB Current progress in epigenetic research supports the view that diet and dietary components are important in cancer etiology by enhancing or inhibiting carcinogenesis. Since diet and dietary factors may significantly contribute to the causation and progression of many cancers, it is important to find the molecular mechanisms of action of such dietary factors for cancer prevention and treatment. Recently, the role of epigenetic mechanisms in the cancer development and progression has attracted more attention as additional evidence along with traditional DNA sequence based mechanisms such as mutations and structural re-arrangements. Such an increasing interest in cancer epigenetics has also accelerated the development and application of molecular assays and tools for DNA methylation detection and histone modification enrichment analysis. In this paper, key assays and methods for epigenetic research are reviewed and discussed in terms of their utility and usability. In addition, more advanced methods for genome-wide analysis are introduced as part of upcoming research trends and directions. (C) 2013 Baishideng. All rights reserved.
C1 [Jang, Hyeran] Boston Univ, Sch Med, Endocrinol Sect, Boston, MA 02118 USA.
[Shin, Hyunjin] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
RP Shin, H (reprint author), Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, 665 Huntington Ave, Boston, MA 02215 USA.
EM ulexis.dfci@gmail.com
NR 100
TC 3
Z9 4
U1 0
U2 16
PU BAISHIDENG PUBL GRP CO LTD
PI WANCHAI
PA ROOM 1701, 17-F, HENAN BUILDING, NO. 90, JAFFE RD, WANCHAI, HONG KONG
100025, PEOPLES R CHINA
SN 1007-9327
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD FEB 21
PY 2013
VL 19
IS 7
BP 1030
EP 1039
DI 10.3748/wjg.v19.i7.1030
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 093PI
UT WOS:000315203400008
PM 23467485
ER
PT J
AU Simmons, LH
Guimaraes, AR
Zukerberg, LR
AF Simmons, Leigh H.
Guimaraes, Alexander R.
Zukerberg, Lawrence R.
TI Case 6-2013: A 54-Year-Old Man with Recurrent Diarrhea
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ZOLLINGER-ELLISON-SYNDROME; CELIAC-DISEASE; DIAGNOSIS
C1 [Simmons, Leigh H.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Guimaraes, Alexander R.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Zukerberg, Lawrence R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Simmons, Leigh H.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Guimaraes, Alexander R.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Zukerberg, Lawrence R.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Simmons, LH (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
FU New England Research Institute; Immunogen
FX Dr. Simmons reports receiving consulting fees from New England Research
Institute; and Dr. Zukerberg, receiving consulting fees from Immunogen
and providing expert testimony for law firms and insurance groups on
cases related to leukemia, lymphoma, and gastrointestinal cancers. No
other potential conflict of interest relevant to this article was
reported.
NR 16
TC 2
Z9 2
U1 1
U2 3
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD FEB 21
PY 2013
VL 368
IS 8
BP 757
EP 765
DI 10.1056/NEJMcpc1208149
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 092CG
UT WOS:000315095800012
PM 23425169
ER
PT J
AU Mishra, P
Li, RJ
St James, S
Mak, RH
Williams, CL
Yue, Y
Berbeco, RI
Lewis, JH
AF Mishra, Pankaj
Li, Ruijiang
St James, Sara
Mak, Raymond H.
Williams, Christopher L.
Yue, Yong
Berbeco, Ross I.
Lewis, John H.
TI Evaluation of 3D fluoroscopic image generation from a single planar
treatment image on patient data with a modified XCAT phantom
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID INDEPENDENT COMPONENT ANALYSIS; RESPIRATORY MOTION MODEL; LUNG-TUMOR
TRACKING; COMPUTED-TOMOGRAPHY; RADIOTHERAPY; DEFORMATION; ALGORITHMS;
ARTIFACTS; MARKERS
AB Accurate understanding and modeling of respiration-induced uncertainties is essential in image-guided radiotherapy. Explicit modeling of the overall lung motion and interaction among different organs promises to be a useful approach. Recently, preliminary studies on 3D fluoroscopic treatment imaging and tumor localization based on principal component analysis motion models and cost function optimization have shown encouraging results. However, the performance of this technique for varying breathing parameters and under realistic conditions remains unclear and thus warrants further investigation. In this work, we present a systematic evaluation of a 3D fluoroscopic image generation algorithm via two different approaches. In the first approach, the model's accuracy is tested for changing parameters for sinusoidal breathing. These parameters include changing respiratory motion amplitude, period and baseline shift. The effects of setup error, imaging noise and different tumor sizes are also examined. In the second approach, we test the model for anthropomorphic images obtained from a modified XCAT phantom. This set of experiments is important as all the underlying breathing parameters are simultaneously tested, as in realistic clinical conditions. Based on our simulation results for more than 250 s of breathing data for eight different lung patients, the overall tumor localization accuracies of the model in left-right, anterior-posterior and superior-inferior directions are 0.1 +/- 0.1, 0.5 +/- 0.5 and 0.8 +/- 0.8 mm, respectively. 3D tumor centroid localization accuracy is 1.0 +/- 0.9 mm.
C1 [Mishra, Pankaj; St James, Sara; Mak, Raymond H.; Williams, Christopher L.; Yue, Yong; Berbeco, Ross I.; Lewis, John H.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mishra, Pankaj; St James, Sara; Mak, Raymond H.; Williams, Christopher L.; Yue, Yong; Berbeco, Ross I.; Lewis, John H.] Harvard Univ, Sch Med, Boston, MA USA.
[Li, Ruijiang] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA.
RP Mishra, P (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
EM pmishra@lroc.harvard.edu; jhlewis@lroc.harvard.edu
FU Radiological Society of North America [RSCH1206]; NIH/NCI [1K99CA166186]
FX The authors would like to express their gratitude to Drs Seiko Nishioka
of the Department of Radiology, NTT Hospital, Sapporo, Japan and Hiroki
Shirato of the Department of Radiation Medicine, Hokkaido University
School of Medicine, Sapporo, Japan for sharing the Hokkaido dataset. The
project described was supported by Award Numbers RSCH1206 (JHL) from the
Radiological Society of North America and NIH/NCI 1K99CA166186 (RL).
NR 26
TC 10
Z9 10
U1 0
U2 4
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD FEB 21
PY 2013
VL 58
IS 4
BP 841
EP 858
DI 10.1088/0031-9155/58/4/841
PG 18
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 082MT
UT WOS:000314396800008
PM 23337614
ER
PT J
AU Besemer, A
Paganetti, H
Bednarz, B
AF Besemer, Abigail
Paganetti, Harald
Bednarz, Bryan
TI The clinical impact of uncertainties in the mean excitation energy of
human tissues during proton therapy
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID MONTE-CARLO SIMULATIONS; SCATTERING CROSS-SECTIONS; ELECTRONIC STOPPING
POWER; LIQUID WATER; RANGE UNCERTAINTIES; DOSE DISTRIBUTIONS;
ORGANIC-COMPOUNDS; ALPHA-PARTICLES; BEAM RANGES; IONS
AB Uncertainties in the estimated mean excitation energies (I-values) needed for calculating proton stopping powers can be in the order of 10-15%, which introduces a fundamental limitation in the accuracy of proton range determination. Previous efforts have quantified shifts in proton depth dose distributions due to I-value uncertainties in water and homogenous tissue phantoms. This study is the first to quantify the clinical impact of I-value uncertainties on proton dose distributions within patient geometries. A previously developed Geant4 based Monte Carlo code was used to simulate a proton treatment plan for three patients (prostate, pancreases, and liver) with varying tissue I-values. A uniform variation study was conducted in which the tissue I-values were varied by +/- 5% and +/- 10% of the nominal values as well as a probabilistic variation study in which the I-values were randomly sampled according to a normal distribution with the mean equal to the nominal I-value and a standard deviation of 5 and 10% of the nominal values. Modification of tissue I-values impacted both the proton range and SOBP width. R-90 range shifts up to 7.7 mm (4.4.%) and R-80 range shifts up to 4.8 mm (1.9%) from the nominal range were recorded. Modulating the tissue I-values by 10% the nominal value resulted in up to a 3.5% difference mean dose in the target volumes and organs at risk compared to the nominal case. The range and dose differences were the largest for the deeper-seated prostate and pancreas cases. The treatments that were simulated with randomly sampled I-values resulted in range and dose differences that were generally within the upper and lower bounds set by the 10% uniform variations. This study demonstrated the impact of I-value uncertainties on patient dose distributions. Clearly, sub-millimeter precision in proton therapy would necessitate a reduction in I-value uncertainties to ensure an efficacious clinical outcome.
C1 [Besemer, Abigail; Bednarz, Bryan] Univ Wisconsin, Wisconsin Inst Med Res, Dept Med Phys, Madison, WI 53715 USA.
[Paganetti, Harald] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
RP Besemer, A (reprint author), Univ Wisconsin, Wisconsin Inst Med Res, Dept Med Phys, Madison, WI 53715 USA.
EM bbednarz2@wisc.edu
FU Morgridge Institute for Research; NIH/NCI grant 'Proton Therapy
Research' [P01 CA-21239]
FX Funding for this research was partially supported by the Morgridge
Institute for Research. HP was supported by NIH/NCI grant P01 CA-21239
'Proton Therapy Research'. The authors would like to thank the
UW-Madison Center for High Throughput Computing (CHTC) for providing
computational support and Jan Schuemann for providing relevant data.
NR 41
TC 13
Z9 13
U1 0
U2 13
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD FEB 21
PY 2013
VL 58
IS 4
BP 887
EP 902
DI 10.1088/0031-9155/58/4/887
PG 16
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 082MT
UT WOS:000314396800010
PM 23337713
ER
PT J
AU Ayan, AS
Lin, HB
Yeager, C
Deville, C
McDonough, J
Zhu, TC
Anderson, N
Bar Ad, V
Lu, HM
Both, S
AF Ayan, Ahmet S.
Lin, Haibo
Yeager, Caitlyn
Deville, Curtiland
McDonough, James
Zhu, Timothy C.
Anderson, Nathan
Bar Ad, Voichita
Lu, Hsiao-Ming
Both, Stefan
TI Should image rotation be addressed during routine cone-beam CT quality
assurance?
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID COMPUTED-TOMOGRAPHY; GEOMETRIC CALIBRATION; RADIATION-THERAPY; SYSTEMS
AB The purpose of this study is to investigate whether quality assurance (QA) for cone-beam computed tomography (CBCT) image rotation is necessary in order to ensure the accuracy of CBCT based image-guided radiation therapy (IGRT) and adaptive radiotherapy (ART). Misregistration of angular coordinates during CBCT acquisition may lead to a rotated reconstructed image. If target localization is performed based on this image, an under-or over-dosage of the target volume (TV) and organs at risk (OARs) may occur. Therefore, patient CT image sets were rotated by 1 degrees up to 3 degrees and the treatment plans were recalculated to quantify changes in dose-volume histograms. A computer code in C++ was written to model the TV displacement and overlap area of an ellipse shape at the target and dose prescription levels corresponding to the image rotation. We investigated clinical scenarios in IGRT and ART in order to study the implications of image rotation on dose distributions for: (1) lateral TV and isocenter (SBRT), (2) central TV and isocenter (IMRT), (3) lateral TV and isocenter (IMRT). Mathematical analysis showed the dose coverage of TV depends on its shape, size, location, and orientation relative to the isocenter. Evaluation of three first scenario for theta = 1 degrees showed variations in TV D95 in the context of IGRT and ART when compared to the original plan were within 2.7 +/- 2.6% and 7.7 +/- 6.9% respectively while variations in the second and third scenarios were less significant (<0.5%) for the angular range evaluated. However a larger degree of variation was found in terms of minimum and maximum doses for target and OARs. The rotation of CBCT image data sets may have significant dosimetric consequences in IGRT and ART. The TV's location relative to isocenter and shape determine the extent of alterations in dose indicators. Our findings suggest that a CBCT QA criterion of 1 degrees would be a reasonable action level to ensure accurate dose delivery.
C1 [Ayan, Ahmet S.; Lin, Haibo; Yeager, Caitlyn; Deville, Curtiland; McDonough, James; Zhu, Timothy C.; Anderson, Nathan; Bar Ad, Voichita; Both, Stefan] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
[Lu, Hsiao-Ming] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Ayan, AS (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Radiat Oncol, Columbus, OH 43210 USA.
EM ahmetsedat.ayan@gmail.com
RI Lin, Haibo/D-9589-2011; Deville, Curtiland/B-2819-2013;
OI Lin, Haibo/0000-0001-7476-0967; Deville, Curtiland/0000-0003-4846-6486;
Zhu, Timothy/0000-0003-2842-8984
NR 16
TC 2
Z9 2
U1 0
U2 13
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD FEB 21
PY 2013
VL 58
IS 4
BP 1059
EP 1073
DI 10.1088/0031-9155/58/4/1059
PG 15
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 082MT
UT WOS:000314396800021
PM 23363650
ER
PT J
AU Marangoni, F
Murooka, TT
Manzo, T
Kim, EY
Carrizosa, E
Elpek, NM
Mempel, TR
AF Marangoni, Francesco
Murooka, Thomas T.
Manzo, Teresa
Kim, Edward Y.
Carrizosa, Esteban
Elpek, Natalie M.
Mempel, Thorsten R.
TI The Transcription Factor NFAT Exhibits Signal Memory during Serial T
Cell Interactions with Antigen-Presenting Cells
SO IMMUNITY
LA English
DT Article
ID DENDRITIC CELLS; IN-VIVO; LYMPH-NODES; IMMUNOLOGICAL SYNAPSE; STROMAL
CELLS; CUTTING EDGE; CA2+ SIGNALS; STOP SIGNAL; ACTIVATION; TUMOR
AB Interactions with antigen-presenting cells (APCs) interrupt T cell migration through tissues and trigger signaling pathways that converge on the activation of transcriptional regulators, including nuclear factor of activated T cells (NFAT), which control T cell function and differentiation. Both stable and unstable modes of cognate T cell-APC interactions have been observed in vivo, but the functional significance of unstable, serial contacts has remained unclear. Here we used multiphoton intravital microscopy in lymph nodes and tumors to show that while NFAT nuclear import was fast (t(1/2) (max)similar to 1 min), nuclear export was slow (t(1/2)similar to 20 min) in T cells. During delayed export, nuclear NFAT constituted a short-term imprint of transient TCR signals and remained transcriptionally active for the T cell tolerance gene Egr2, but not for the effector gene Ifng, which required continuous TCR triggering for expression. This provides a potential mechanistic basis for the observation that a predominance of unstable APC interactions correlates with the induction of T cell tolerance.
C1 [Marangoni, Francesco; Murooka, Thomas T.; Manzo, Teresa; Kim, Edward Y.; Carrizosa, Esteban; Elpek, Natalie M.; Mempel, Thorsten R.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.
[Marangoni, Francesco; Murooka, Thomas T.; Kim, Edward Y.; Carrizosa, Esteban; Mempel, Thorsten R.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Mempel, TR (reprint author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.
EM tmempel@mgh.harvard.edu
RI Marangoni, Francesco/I-9087-2012
OI Marangoni, Francesco/0000-0002-2490-849X
FU NIH [AI073457, CA150975, AI0178897, AI097052]; Dana Foundation; MGH Fund
for Medical Discovery Fellowship; MGH ECOR Tosteson Postdoctoral
Fellowship Award
FX We thank Jose Aramburu, Ulrich von Andrian, Shiv Pillai, James Moon, and
Anjana Rao for helpful suggestions and critical reading of the
manuscript, as well as Harald von Boehmer, Jose Aramburu, Vigo
Heissmeyer, Roberto Bonasio, Sean Megason, Paul Allen, and Jason
McCarthy for providing key reagents. We are indebted to Julia Kahn from
the laboratory of Dai Fukumura for technical advice. T. R. M. was
supported by NIH grants AI073457, CA150975, AI0178897, and AI097052 as
well as a grant by the Dana Foundation. F. M. was supported by an MGH
Fund for Medical Discovery Fellowship. T. T. M. was supported by the MGH
ECOR Tosteson Postdoctoral Fellowship Award.
NR 48
TC 48
Z9 48
U1 2
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD FEB 21
PY 2013
VL 38
IS 2
BP 237
EP 249
DI 10.1016/j.immuni.2012.09.012
PG 13
WC Immunology
SC Immunology
GA AA2RC
UT WOS:000330940800007
PM 23313588
ER
PT J
AU Cortez-Retamozo, V
Etzrodt, M
Newton, A
Ryan, R
Pucci, F
Sio, SW
Kuswanto, W
Rauch, PJ
Chudnovskiy, A
Iwamoto, Y
Kohler, R
Marinelli, B
Gorbatov, R
Wojtkiewicz, G
Panizzi, P
Mino-Kenudson, M
Forghani, R
Figueiredo, JL
Chen, JW
Xavier, R
Swirski, FK
Nahrendorf, M
Weissleder, R
Pittet, MJ
AF Cortez-Retamozo, Virna
Etzrodt, Martin
Newton, Andita
Ryan, Russell
Pucci, Ferdinando
Sio, Selena W.
Kuswanto, Wilson
Rauch, Philipp J.
Chudnovskiy, Aleksey
Iwamoto, Yoshiko
Kohler, Rainer
Marinelli, Brett
Gorbatov, Rostic
Wojtkiewicz, Gregory
Panizzi, Peter
Mino-Kenudson, Mari
Forghani, Reza
Figueiredo, Jose-Luiz
Chen, John W.
Xavier, Ramnik
Swirski, Filip K.
Nahrendorf, Matthias
Weissleder, Ralph
Pittet, Mikael J.
TI Angiotensin II Drives the Production of Tumor-Promoting Macrophages
SO IMMUNITY
LA English
DT Article
ID HEMATOPOIETIC STEM-CELLS; MYOCARDIAL-INFARCTION; DENDRITIC CELLS; LUNG
ADENOCARCINOMA; SPLENIC RESERVOIR; LYMPHOID ORGANS; MYELOID CELLS;
CANCER; MONOCYTES; INFLAMMATION
AB Macrophages frequently infiltrate tumors and can enhance cancer growth, yet the origins of the macrophage response are not well understood. Here we address molecular mechanisms of macrophage production in a conditional mouse model of lung adenocarcinoma. We report that overproduction of the peptide hormone Angiotensin II (AngII) in tumor-bearing mice amplifies self-renewing hematopoietic stem cells (HSCs) and macrophage progenitors. The process occurred in the spleen but not the bone marrow, and was independent of hemodynamic changes. The effects of AngII required direct hormone ligation on HSCs, depended on S1P(1) signaling, and allowed the extramedullary tissue to supply new tumor-associated macrophages throughout cancer progression. Conversely, blocking AngII production prevented cancer-induced HSC and macrophage progenitor amplification and thus restrained the macrophage response at its source. These findings indicate that AngII acts upstream of a potent macrophage amplification program and that tumors can remotely exploit the hormone's pathway to stimulate cancer-promoting immunity.
C1 [Cortez-Retamozo, Virna; Etzrodt, Martin; Newton, Andita; Pucci, Ferdinando; Sio, Selena W.; Kuswanto, Wilson; Rauch, Philipp J.; Chudnovskiy, Aleksey; Iwamoto, Yoshiko; Kohler, Rainer; Marinelli, Brett; Gorbatov, Rostic; Wojtkiewicz, Gregory; Panizzi, Peter; Forghani, Reza; Figueiredo, Jose-Luiz; Chen, John W.; Swirski, Filip K.; Nahrendorf, Matthias; Weissleder, Ralph; Pittet, Mikael J.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Xavier, Ramnik] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Xavier, Ramnik] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Xavier, Ramnik] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Ryan, Russell; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
RP Pittet, MJ (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
EM mpittet@mgh.harvard.edu
RI Etzrodt, Martin/P-3325-2015;
OI Etzrodt, Martin/0000-0003-1928-3904; Forghani, Reza/0000-0002-8572-1864;
Panizzi, Peter/0000-0003-0141-8807
FU NIH [P50-CA86355, R01-AI084880, R56-AI084880]; MGH-Center for Systems
Biology [U54-CA126515]; AACR Centennial Predoctoral Fellowship;
Boehringer Ingelheim Fonds
FX The authors thank Jessica Truelove (MGH) for imaging and Michael Waring
and Adam Chicoine (Ragon Institute, MGH) for sorting cells. This work
was supported in part by NIH grants P50-CA86355, R01-AI084880,
R56-AI084880, and MGH-Center for Systems Biology (to M.J.P.) and
U54-CA126515 (to R. W.). M. E. is part of the International PhD program
"Cancer and Immunology" at the University of Lausanne, Switzerland, and
was supported by the AACR Centennial Predoctoral Fellowship and the
Boehringer Ingelheim Fonds.
NR 51
TC 48
Z9 50
U1 2
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD FEB 21
PY 2013
VL 38
IS 2
BP 296
EP 308
DI 10.1016/j.immuni.2012.10.015
PG 13
WC Immunology
SC Immunology
GA AA2RC
UT WOS:000330940800012
PM 23333075
ER
PT J
AU Spector, JM
Reisman, J
Lipsitz, S
Desai, P
Gawande, AA
AF Spector, Jonathan M.
Reisman, Jonathan
Lipsitz, Stuart
Desai, Priya
Gawande, Atul A.
TI Access to essential technologies for safe childbirth: a survey of health
workers in Africa and Asia
SO BMC PREGNANCY AND CHILDBIRTH
LA English
DT Article
DE Neonatal mortality; Maternal mortality; Childbirth; Developing world;
Health technology
ID MATERNAL MORTALITY; NEONATAL DEATHS; SURVIVAL 1; NEWBORN; INTERVENTIONS
AB Background: The reliable availability of health technologies, defined as equipment, medicines, and consumable supplies, is essential to ensure successful childbirth practices proven to prevent avoidable maternal and newborn mortality. The majority of global maternal and newborn deaths take place in Africa and Asia, yet few data exist that describe the availability of childbirth-related health technologies in these regions. We conducted a cross-sectional survey of health workers in Africa and Asia in order to profile the availability of health technologies considered to be essential to providing safe childbirth care.
Methods: Health workers in Africa and Asia were surveyed using a web-based questionnaire. A list of essential childbirth-related health technologies was drawn from World Health Organization guidelines for preventing and managing complications associated with the major causes of maternal and newborn mortality globally. Demographic data describing each birth center were obtained and health workers reported on the availability of essential childbirth-related health technologies at their centers. Comparison analyses were conducted using Rao-Scott chi-square test statistics.
Results: Health workers from 124 birth centers in 26 African and 15 Asian countries participated. All facilities exhibited gaps in the availability of essential childbirth-related health technologies. Availability was significantly reduced in birth centers that had lower birth volumes and those from lower income countries. On average across all centers, health workers reported the availability of 18 of 23 essential childbirth-related health technologies (79%; 95% CI, 74%, 84%). Low-volume facilities suffered severe shortages; on average, these centers reported reliable availability of 13 of 23 technologies (55%; 95% CI, 39%, 71%).
Conclusions: Substantial gaps exist in the availability of essential childbirth-related health technologies across health sector levels in Africa and Asia. Strategies that facilitate reliable access to vital health technologies in these regions are an urgent priority.
C1 [Spector, Jonathan M.; Desai, Priya; Gawande, Atul A.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
[Reisman, Jonathan] Harvard Univ, Massachusetts Gen Hosp, Dept Internal Med Pediat, Boston, MA 02114 USA.
[Lipsitz, Stuart] Brigham & Womens Hosp, Dept Gen Med, Boston, MA 02115 USA.
RP Reisman, J (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Internal Med Pediat, Boston, MA 02114 USA.
EM Reisman.jonathan@gmail.com
OI Gawande, Atul/0000-0002-1824-9176
NR 29
TC 4
Z9 4
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2393
J9 BMC PREGNANCY CHILDB
JI BMC Pregnancy Childbirth
PD FEB 20
PY 2013
VL 13
AR 43
DI 10.1186/1471-2393-13-43
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 140KK
UT WOS:000318652800001
PM 23421767
ER
PT J
AU Malinowska, IA
Lee, N
Kumar, V
Thiele, EA
Franz, DN
Ashwal, S
Sagalowsky, A
DiMario, FJ
Cutler, D
Krueger, D
Camposano, S
Paolini, J
Dabora, SL
AF Malinowska, Izabela A.
Lee, Nancy
Kumar, Vidhya
Thiele, Elizabeth A.
Franz, David Neal
Ashwal, Stephen
Sagalowsky, Arthur
DiMario, Francis J., Jr.
Cutler, Drew
Krueger, Darcy
Camposano, Susana
Paolini, Jan
Dabora, Sandra L.
TI Similar Trends in Serum VEGF-D Levels and Kidney Angiomyolipoma
Responses with Longer Duration Sirolimus Treatment in Adults with
Tuberous Sclerosis
SO PLOS ONE
LA English
DT Article
ID GROWTH FACTOR-D; PULMONARY LYMPHANGIOLEIOMYOMATOSIS; SOLID TUMORS;
COMPLEX; TSC2; WOMEN; HETEROZYGOSITY; MUTATIONS; GENE
AB Context: We have previously shown that serum VEGF-D is elevated at baseline, correlates with kidney angiomyolipoma size at baseline and 12 months, and decreases with sirolimus treatment in adults with tuberous sclerosis complex (TSC). To further investigate the utility of serum VEGF-D for longer term monitoring of TSC kidney disease, we present VEGF-D level results with 24 month follow-up.
Objective: To compare 24 month VEGF-D levels in two subgroups of sirolimus treated patients (OFF SIROLIMUS AFTER 12 MONTHS or ON SIROLIMUS AFTER 12 MONTHS).
Design and Intervention(s): Serum VEGF-D was measured in samples collected from subjects enrolled in a phase 2 multicenter trial evaluating sirolimus for the treatment of kidney angiomyolipomas associated with TSC or TSC/LAM. All participants were treated with sirolimus from 0-12 months. During months 12-24, sirolimus was discontinued in one subgroup. The other subgroup was treated with additional sirolimus.
Setting: Adult TSC participants were recruited from six clinical sites in the United States (comprehensive TSC clinics, 5; urology clinic, 1).
Patients: There were 28 TSC patients who completed all 24 months of the study and serum samples were available at 24 months from 18/28 patients.
Main Outcome Measure(s): We compared the percent change in VEGF-D levels (baseline to 24 months) in patients from the two treatment subgroups.
Results: At 24 months, VEGF-D levels decreased by 67% compared with baseline (to 787+/-426 pg/ml) in the ON SIROLIMUS AFTER 12 MONTHS group versus a 13% decrease (to 2971+/-4014 pg/ml) in the OFF SIROLIMUS AFTER 12 MONTHS group (p = 0.013, Mann-Whitney test). A similar trend was observed in kidney angiomyolipoma size but not in pulmonary function tests. Conclusions Serum VEGF-D may be useful for monitoring response to treatment with sirolimus and kidney angiomyolipoma size in patients with TSC, but confirmation is needed.
C1 [Malinowska, Izabela A.; Lee, Nancy; Kumar, Vidhya; Dabora, Sandra L.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Thiele, Elizabeth A.; Camposano, Susana; Paolini, Jan] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Franz, David Neal; Krueger, Darcy] Childrens Med Ctr, Dept Pediat, Cincinnati, OH USA.
[Ashwal, Stephen] Loma Linda Univ, Dept Neurol, Loma Linda, CA 92350 USA.
[Sagalowsky, Arthur] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA.
[DiMario, Francis J., Jr.] Connecticut Childrens Med Ctr, Dept Pediat Neurol, Hartford, CT USA.
[Cutler, Drew] Loma Linda Univ, Loma Linda, CA 92350 USA.
RP Dabora, SL (reprint author), East Boston Neighborhood Hlth Ctr, Boston, MA USA.
EM sandy.dabora@gmail.com
RI Malinowska, Izabela/A-4816-2013
FU NIH/National Cancer Institute [R01CA107164]; Tuberous Sclerosis Alliance
planning and supplement grants; Brigham and Women's Hospital Research
Institute Bridge Funding award
FX This project was funded by the following grants to S. Dabora:
NIH/National Cancer Institute (R01CA107164), Tuberous Sclerosis Alliance
planning and supplement grants, and the Brigham and Women's Hospital
Research Institute Bridge Funding award. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 29
TC 4
Z9 5
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 20
PY 2013
VL 8
IS 2
AR e56199
DI 10.1371/journal.pone.0056199
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093IE
UT WOS:000315184200045
PM 23437092
ER
PT J
AU Wang, XD
Liu, AP
Wu, YY
Wang, P
AF Wang, Xiao-Dong
Liu, A-Ping
Wu, Yin-Yuan
Wang, Peng
TI Rapid Extraction of Lexical Tone Phonology in Chinese Characters: A
Visual Mismatch Negativity Study
SO PLOS ONE
LA English
DT Article
ID RIGHT CEREBRAL HEMISPHERE; WORD RECOGNITION; CATEGORICAL PERCEPTION;
HUMAN BRAIN; ELECTROPHYSIOLOGICAL EVIDENCE; AUTOMATIC ACTIVATION;
CROSSMODAL BINDING; LINGUISTIC PITCH; MEMORY TRACES; CORTEX
AB Background: In alphabetic languages, emerging evidence from behavioral and neuroimaging studies shows the rapid and automatic activation of phonological information in visual word recognition. In the mapping from orthography to phonology, unlike most alphabetic languages in which there is a natural correspondence between the visual and phonological forms, in logographic Chinese, the mapping between visual and phonological forms is rather arbitrary and depends on learning and experience. The issue of whether the phonological information is rapidly and automatically extracted in Chinese characters by the brain has not yet been thoroughly addressed.
Methodology/Principal Findings: We continuously presented Chinese characters differing in orthography and meaning to adult native Mandarin Chinese speakers to construct a constant varying visual stream. In the stream, most stimuli were homophones of Chinese characters: The phonological features embedded in these visual characters were the same, including consonants, vowels and the lexical tone. Occasionally, the rule of phonology was randomly violated by characters whose phonological features differed in the lexical tone.
Conclusions/Significance: We showed that the violation of the lexical tone phonology evoked an early, robust visual response, as revealed by whole-head electrical recordings of the visual mismatch negativity (vMMN), indicating the rapid extraction of phonological information embedded in Chinese characters. Source analysis revealed that the vMMN was involved in neural activations of the visual cortex, suggesting that the visual sensory memory is sensitive to phonological information embedded in visual words at an early processing stage.
C1 [Wang, Xiao-Dong] Nanyang Technol Univ, Div Psychol, Sch Humanities & Social Sci, Singapore 639798, Singapore.
[Liu, A-Ping] Anhui Univ, Dept Econ, Hefei 230039, Peoples R China.
[Wu, Yin-Yuan] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Wu, Yin-Yuan] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA.
[Liu, A-Ping; Wang, Peng] Chinese Acad Sci, Inst Tech Biol & Agr Engn, CAS Key Lab Ion Beam Bioengn, Hefei, Peoples R China.
RP Wang, XD (reprint author), Nanyang Technol Univ, Div Psychol, Sch Humanities & Social Sci, Singapore 639798, Singapore.
EM XD-Wang@ntu.edu.sg
NR 77
TC 5
Z9 5
U1 2
U2 28
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 20
PY 2013
VL 8
IS 2
AR e56778
DI 10.1371/journal.pone.0056778
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093IE
UT WOS:000315184200159
ER
PT J
AU Koh, Y
Ballana, E
Este, J
Engelman, A
AF Koh, Yasuhiro
Ballana, Ester
Este, Jose
Engelman, Alan
TI Polymorphic LEDGF/p75 variants support efficient HIV-1 infection ex vivo
SO AIDS
LA English
DT Letter
ID DISEASE PROGRESSION; CHROMATIN-BINDING; INTEGRATION; IDENTIFICATION;
PROTEINS; DOMAINS
C1 [Koh, Yasuhiro; Engelman, Alan] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
[Koh, Yasuhiro; Engelman, Alan] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Ballana, Ester; Este, Jose] Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, IrsiCaixa, Badalona, Spain.
RP Engelman, A (reprint author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 450 Brookline Ave,CLS 1010, Boston, MA 02215 USA.
EM alan_engelman@dfci.harvard.edu
RI Este, Jose/B-5509-2008;
OI Este, Jose/0000-0002-1436-5823; Ballana, Ester/0000-0002-5215-7363
FU NIAID NIH HHS [R01 AI039394, R37 AI039394, AI039394]
NR 18
TC 3
Z9 3
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD FEB 20
PY 2013
VL 27
IS 4
BP 665
EP 667
DI 10.1097/QAD.0b013e32835af34c
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 094SM
UT WOS:000315284100022
PM 23364444
ER
PT J
AU Gordon, LI
Hong, FX
Fisher, RI
Bartlett, NL
Connors, JM
Gascoyne, RD
Wagner, H
Stiff, PJ
Cheson, BD
Gospodarowicz, M
Advani, R
Kahl, BS
Friedberg, JW
Blum, KA
Habermann, TM
Tuscano, JM
Hoppe, RT
Horning, SJ
AF Gordon, Leo I.
Hong, Fangxin
Fisher, Richard I.
Bartlett, Nancy L.
Connors, Joseph M.
Gascoyne, Randy D.
Wagner, Henry
Stiff, Patrick J.
Cheson, Bruce D.
Gospodarowicz, Mary
Advani, Ranjana
Kahl, Brad S.
Friedberg, Jonathan W.
Blum, Kristie A.
Habermann, Thomas M.
Tuscano, Joseph M.
Hoppe, Richard T.
Horning, Sandra J.
TI Randomized Phase III Trial of ABVD Versus Stanford V With or Without
Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin
Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative
Oncology Group (E2496)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID INVOLVED-FIELD RADIOTHERAPY; ITALIANO LINFOMI; DISEASE; CHEMOTHERAPY;
CONSOLIDATION; RISK; MOPP
AB Purpose
Although ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) has been established as the standard of care in patients with advanced Hodgkin lymphoma, newer regimens have been investigated, which have appeared superior in early phase II studies. Our aim was to determine if failure-free survival was superior in patients treated with the Stanford V regimen compared with ABVD.
Patients and Methods
The Eastern Cooperative Oncology Group, along with the Cancer and Leukemia Group B, the Southwest Oncology Group, and the Canadian NCIC Clinical Trials Group, conducted this randomized phase III trial in patients with advanced Hodgkin lymphoma. Stratification factors included extent of disease (localized v extensive) and International Prognostic Factors Project Score (0 to 2 v 3 to 7). The primary end point was failure-free survival (FFS), defined as the time from random assignment to progression, relapse, or death, whichever occurred first. Overall survival, a secondary end point, was measured from random assignment to death as a result of any cause. This design provided 87% power to detect a 33% reduction in FFS hazard rate, or a difference in 5-year FFS of 64% versus 74% at two-sided .05 significance level.
Results
There was no significant difference in the overall response rate between the two arms, with complete remission and clinical complete remission rates of 73% for ABVD and 69% for Stanford V. At a median follow-up of 6.4 years, there was no difference in FFS: 74% for ABVD and 71% for Stanford V at 5 years (P = .32).
Conclusion
ABVD remains the standard of care for patients with advanced Hodgkin lymphoma. J Clin Oncol 31:684-691. (c) 2012 by American Society of Clinical Oncology
C1 [Gordon, Leo I.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Gordon, Leo I.] Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA.
[Stiff, Patrick J.] Loyola Univ, Ctr Canc, Maywood, IL 60153 USA.
[Hong, Fangxin] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Fisher, Richard I.; Friedberg, Jonathan W.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA.
[Bartlett, Nancy L.] Washington Univ, Siteman Canc Ctr, St Louis, MO USA.
[Connors, Joseph M.; Gascoyne, Randy D.] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 4E6, Canada.
[Gospodarowicz, Mary] Univ Toronto, Toronto, ON, Canada.
[Wagner, Henry] Penn State Hershey Canc Inst, Hershey, PA USA.
[Cheson, Bruce D.] Georgetown Univ, Ctr Hosp, Washington, DC USA.
[Advani, Ranjana; Hoppe, Richard T.; Horning, Sandra J.] Stanford Univ, Stanford, CA 94305 USA.
[Tuscano, Joseph M.] Univ Calif Davis, Sacramento, CA USA.
[Kahl, Brad S.] Univ Wisconsin, Ctr Canc, Madison, WI USA.
[Blum, Kristie A.] Ohio State Univ, Columbus, OH 43210 USA.
[Habermann, Thomas M.] Mayo Clin, Rochester, MN USA.
RP Gordon, LI (reprint author), 676 N St Clair St, Chicago, IL 60611 USA.
EM l-gordon@northwestern.edu
RI Blum, Kristie/E-2768-2011;
OI Gordon, Leo/0000-0003-1666-7064
FU National Cancer Institute, National Institutes of Health, Department of
Health and Human Services [CA21115, CA23318, CA66636, CA17145, CA77440,
CA11083, CA32102, CA46441, CA46282, CA38926, CA77202, CA21076, CA31946,
CA13650]
FX Supported in part by Public Health Service Grants No. CA21115, CA23318,
CA66636, CA17145, CA77440, CA11083, CA32102, CA46441, CA46282, CA38926,
CA77202, CA21076, CA31946, and CA13650 from the National Cancer
Institute, National Institutes of Health, Department of Health and Human
Services.
NR 28
TC 60
Z9 63
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
BP 684
EP 691
DI 10.1200/JCO.2012.43.4803
PG 8
WC Oncology
SC Oncology
GA 091YT
UT WOS:000315086400016
PM 23182987
ER
PT J
AU Scott, DW
Chan, FC
Hong, FX
Rogic, S
Tan, KL
Meissner, B
Ben-Neriah, S
Boyle, M
Kridel, R
Telenius, A
Woolcock, BW
Farinha, P
Fisher, RI
Rimsza, LM
Bartlett, NL
Cheson, BD
Shepherd, LE
Advani, RH
Connors, JM
Kahl, BS
Gordon, LI
Horning, SJ
Steidl, C
Gascoyne, RD
AF Scott, David W.
Chan, Fong Chun
Hong, Fangxin
Rogic, Sanja
Tan, King L.
Meissner, Barbara
Ben-Neriah, Susana
Boyle, Merrill
Kridel, Robert
Telenius, Adele
Woolcock, Bruce W.
Farinha, Pedro
Fisher, Richard I.
Rimsza, Lisa M.
Bartlett, Nancy L.
Cheson, Bruce D.
Shepherd, Lois E.
Advani, Ranjana H.
Connors, Joseph M.
Kahl, Brad S.
Gordon, Leo I.
Horning, Sandra J.
Steidl, Christian
Gascoyne, Randy D.
TI Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded
Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin
Lymphoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID EPSTEIN-BARR-VIRUS; INTERNATIONAL PROGNOSTIC SCORE; TUMOR
MICROENVIRONMENT; T-CELLS; DISEASE; MACROPHAGES; MARKER; INFECTION;
BEACOPP; SAMPLES
AB Purpose
Our aim was to reliably identify patients with advanced-stage classical Hodgkin lymphoma (cHL) at increased risk of death by developing a robust predictor of overall survival (OS) using gene expression measured in routinely available formalin-fixed paraffin-embedded tissue (FFPET).
Methods
Expression levels of 259 genes, including those previously reported to be associated with outcome in cHL, were determined by digital expression profiling of pretreatment FFPET biopsies from 290 patients enrolled onto the E2496 Intergroup trial comparing doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and Stanford V regimens in locally extensive and advanced-stage cHL. A model for OS separating patients into low- and high-risk groups was produced using penalized Cox regression. The model was tested in an independent cohort of 78 patients enriched for treatment failure but otherwise similar to patients in a population-based registry of patients treated with ABVD. Weighted analysis methods generated unbiased estimates of predictor performance in the population-based registry.
Results
A 23-gene outcome predictor was generated. The model identified a population at increased risk of death in the validation cohort. There was a 29% absolute difference in 5-year OS between the high- and low-risk groups (63% v 92%, respectively; log-rank P < .001; hazard ratio, 6.7; 95% CI, 2.6 to 17.4). The predictor was superior to the International Prognostic Score and CD68 immunohistochemistry in multivariate analyses.
Conclusion
A gene expression-based predictor, developed in and applicable to routinely available FFPET biopsies, identifies patients with advanced-stage cHL at increased risk of death when treated with standard-intensity up-front regimens. J Clin Oncol 31:692-700. (c) 2012 by American Society of Clinical Oncology
C1 [Scott, David W.; Chan, Fong Chun; Tan, King L.; Meissner, Barbara; Ben-Neriah, Susana; Boyle, Merrill; Kridel, Robert; Telenius, Adele; Woolcock, Bruce W.; Connors, Joseph M.; Steidl, Christian; Gascoyne, Randy D.] BC Canc Agency, Ctr Lymphoid Canc, Vancouver, BC V5Z 1L3, Canada.
[Rogic, Sanja] Univ British Columbia, Ctr High Throughput Biol, Vancouver, BC V5Z 1M9, Canada.
[Shepherd, Lois E.] Queens Univ, Natl Canc Inst, Canada Clin Trials Grp, Kingston, ON, Canada.
[Hong, Fangxin] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Fisher, Richard I.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA.
[Rimsza, Lisa M.] Univ Arizona, Tucson, AZ USA.
[Bartlett, Nancy L.] Washington Univ, Sch Med, St Louis, MO USA.
[Woolcock, Bruce W.] Georgetown Univ Hosp, Washington, DC 20007 USA.
[Advani, Ranjana H.] Stanford Univ, Stanford, CA 94305 USA.
[Horning, Sandra J.] Genentech Inc, San Francisco, CA USA.
[Kahl, Brad S.] Univ Wisconsin, Madison, WI USA.
[Gordon, Leo I.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Farinha, Pedro] Ctr Hosp Lisboa Cent, Lisbon, Portugal.
RP Gascoyne, RD (reprint author), BC Canc Agcy, Dept Pathol & Expt Therapeut, 675 W 10th Ave,Room 5-113, Vancouver, BC V5Z 1L3, Canada.
EM rgascoyn@bccancer.bc.ca
OI Gordon, Leo/0000-0003-1666-7064; Farinha, Pedro/0000-0001-9364-9391
FU Roche Canada; Seattle Genetics; Public Health Service from the National
Cancer Institute, National Institutes of Health, and the Department of
Health and Human Services [CA21115, CA23318, CA66636, CA17145, CA11083,
CA32102, CA38926, CA77202, CA21076, CA77470]; Terry Fox Foundation
Strategic Health Research Training Program in Cancer Research at
Canadian Institutes of Health Research [TGT-53912]; Cancer Research
Society; Michael Smith Foundation; Canadian Institutes of Health
Research [178536]
FX Although all authors completed the disclosure declaration, the following
author(s) and/or an author's immediate family member(s) indicated a
financial or other interest that is relevant to the subject matter under
consideration in this article. Certain relationships marked with a "U"
are those for which no compensation was received; those relationships
marked with a "C" were compensated. For a detailed description of the
disclosure categories, or for more information about ASCO's conflict of
interest policy, please refer to the Author Disclosure Declaration and
the Disclosures of Potential Conflicts of Interest section in
Information for Contributors. Employment or Leadership Position: None
Consultant or Advisory Role: Randy D. Gascoyne, Celgene (C), Roche
Canada (C) Stock Ownership: None Honoraria: Randy D. Gascoyne, Roche
Canada Research Funding: Randy D. Gascoyne, Roche Canada, Seattle
Genetics Expert Testimony: None Other Remuneration: None; Supported in
part by Public Health Service Grants No. CA21115, CA23318, CA66636,
CA17145, CA11083, CA32102, CA38926, CA77202, CA21076, and CA77470 from
the National Cancer Institute, National Institutes of Health, and the
Department of Health and Human Services. Biospecimens were provided by
the Eastern Cooperative Oncology Group Pathology Coordinating Office and
Reference Laboratory. D.W.S. and K.L.T. were supported by postdoctoral
fellowships of the Terry Fox Foundation Strategic Health Research
Training Program in Cancer Research at Canadian Institutes of Health
Research (Grant No. TGT-53912). C.S. was supported by postdoctoral
fellowships of the Cancer Research Society (Steven E. Drabin Fellowship)
and the Michael Smith Foundation for Health Research. R.D.G. receives
funding support from the Canadian Institutes of Health Research (Grant
No. 178536).
NR 30
TC 53
Z9 53
U1 0
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
BP 692
EP 700
DI 10.1200/JCO.2012.43.4589
PG 9
WC Oncology
SC Oncology
GA 091YT
UT WOS:000315086400017
PM 23182984
ER
PT J
AU Temel, JS
Greer, JA
Gallagher, ER
Jackson, VA
Lennes, IT
Muzikansky, A
Park, ER
Pirl, WF
AF Temel, Jennifer S.
Greer, Joseph A.
Gallagher, Emily R.
Jackson, Vicki A.
Lennes, Inga T.
Muzikansky, Alona
Park, Elyse R.
Pirl, William F.
TI Electronic Prompt to Improve Outpatient Code Status Documentation for
Patients With Advanced Lung Cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID ILL HOSPITALIZED-PATIENTS; OF-LIFE COMMUNICATION;
CARDIOPULMONARY-RESUSCITATION; PALLIATIVE CARE; DECISION-MAKING;
CARDIAC-ARREST; LAST PHASE; END; PREFERENCES; DEATH
AB Purpose
Rates of documentation of end-of-life care preferences in the medical record remain low, even among patients with incurable malignancies. We therefore conducted a two-phase study to develop and assess the effect of electronic prompts to encourage oncology clinicians to document code status in the outpatient electronic health record (EHR) of patients with advanced lung cancers.
Patients and Methods
To determine the optimal delivery, content, and timing of the electronic prompt, we first facilitated focus groups with oncology clinicians at an affiliated medical center. Given this feedback, we developed e-mail reminders timed to the start of each new chemotherapy regimen. Between July 2009 and January 2011, 102 eligible patients with incurable lung cancer were approached, and 100 agreed to participate. We compared e-mail prompt participants (EPPs) with a cohort of 100 consecutive historical controls who began therapy for incurable lung cancer at least 1 year before the start of this study. The primary outcome measure was clinician documentation of code status in the EHR.
Results
EPPs were similar to historical controls, with no significant differences in demographic or clinical characteristics. At 1-year follow-up, 33.7% (n = 33/98) of EPPs had a code status documented in the outpatient EHR compared with 14.5% (n = 12/83) of historical controls (P = .003). Mean time to code status documentation was significantly shorter in EPPs (8.6 months [95% CI, 7.6 to 9.5]) compared with controls (10.5 months [95% CI, 9.8 to 11.3]; P = .004).
Conclusion
e-mail prompts may improve the rate and timing of code status documentation in the EHR and warrant further investigation. J Clin Oncol 31:710-715. (c) 2013 by American Society of Clinical Oncology
C1 [Temel, Jennifer S.; Greer, Joseph A.; Gallagher, Emily R.; Jackson, Vicki A.; Lennes, Inga T.; Muzikansky, Alona; Park, Elyse R.; Pirl, William F.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Temel, JS (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Yawkey 7E, Boston, MA 02114 USA.
EM jtemel@partners.org
FU American Cancer Society
FX Supported by the American Cancer Society (principal investigator Temel)
and gifts from the Thoracic Oncology Quality of Life Fund.
NR 44
TC 20
Z9 20
U1 0
U2 8
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
BP 710
EP 715
DI 10.1200/JCO.2012.43.2203
PG 6
WC Oncology
SC Oncology
GA 091YT
UT WOS:000315086400019
PM 23284038
ER
PT J
AU Songer, JE
Eatock, RA
AF Songer, Jocelyn E.
Eatock, Ruth Anne
TI Tuning and Timing in Mammalian Type I Hair Cells and Calyceal Synapses
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID VESTIBULAR-NERVE AFFERENTS; PERIPHERAL INNERVATION PATTERNS; ACTIVATED
POTASSIUM CHANNELS; SEMICIRCULAR CANAL AMPULLAE; MOUSE INNER-EAR;
SQUIRREL-MONKEY; DEVELOPMENTAL ACQUISITION; MECHANICAL STIMULATION;
DISCHARGE PROPERTIES; TRANSMITTER RELEASE
AB Afferent nerve fibers in the central zones of vestibular epithelia form calyceal endings around type I hair cells and have phasic response properties that emphasize fast head motions. We investigated how stages from hair-cell transduction to calyceal spiking contribute tuning and timing to central (striolar)-zone afferents of the rat saccular epithelium. In an excised preparation, we deflected individual hair bundles with rigid probes driven with steps and sinusoids (0.5-500 Hz) and recorded whole-cell responses from hair cells and calyces at room temperature and body temperature. In immature hair cells and calyces (postnatal days (P) 1-P4), tuning sharpened at each stage. Transducer adaptation and membrane-charging time produced bandpass filtering of the receptor potential with best frequencies of 10-30 Hz and phase leads below 10 Hz. For small stimuli, electrical resonances sharply tuned the hair-cell membrane in the frequency range of 5-40 Hz. The synaptic delay of quantal transmission added a phase lag at frequencies above 10 Hz. The influence of spike thresholds at the calyceal spike initiation stage sharpened tuning and advanced response phase. Two additional mechanisms strongly advanced response phase above 10 Hz when present: (1) maturing (P7-P9) type I hair cells acquired low-voltage-activated channels that shortened the rise time of the receptor potential and (2) some calyces had nonquantal transmission with little synaptic delay. By reducing response time, the identified inner-ear mechanisms (transducer adaptation, low-voltage-activated channels, nonquantal transmission, and spike triggering) may compensate for transmission delays in vestibular reflex pathways and help stabilize posture and gaze during rapid head motions.
C1 [Songer, Jocelyn E.; Eatock, Ruth Anne] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Eatock, Ruth Anne] Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.
[Songer, Jocelyn E.; Eatock, Ruth Anne] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
RP Eatock, RA (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, 243 Charles St, Boston, MA 02114 USA.
EM eatock@meei.harvard.edu
RI Eatock, Ruth/F-6404-2013;
OI Eatock, Ruth Anne/0000-0001-7547-2051
FU National Institutes of Health [R01 DC002290]; National Space Biomedical
Research Institute through National Aeronautics and Space Administration
[NCC 9-58]
FX This study was supported by National Institutes of Health (R01 DC002290
and American Recovery & Reinvestment Act supplement) and National Space
Biomedical Research Institute through National Aeronautics and Space
Administration NCC 9-58 (J.E.S.). We thank Ben Winterroth, Tilly Kimm,
Alison Casserly, and the Engineering Group at Eaton-Peabody Laboratories
for technical assistance, and Dianna Sands and Jess Cunha for
administrative assistance. We thank Drs. John Guinan, Radha Kalluri, and
Dan Merfeld for helpful comments on an earlier version of this
manuscript.
NR 72
TC 24
Z9 24
U1 0
U2 13
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD FEB 20
PY 2013
VL 33
IS 8
BP 3706
EP 3724
DI 10.1523/JNEUROSCI.4067-12.2013
PG 19
WC Neurosciences
SC Neurosciences & Neurology
GA 093MJ
UT WOS:000315195700045
PM 23426697
ER
PT J
AU Olson, APJ
Tierney, LM
AF Olson, Andrew P. J.
Tierney, Lawrence M., Jr.
TI Remarkably Wise
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
C1 [Olson, Andrew P. J.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA.
[Tierney, Lawrence M., Jr.] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA.
[Tierney, Lawrence M., Jr.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
RP Olson, APJ (reprint author), Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA.
EM olso5714@umn.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD FEB 20
PY 2013
VL 309
IS 7
BP 669
EP 670
DI 10.1001/jama.2013.196
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 091EK
UT WOS:000315032000021
PM 23423412
ER
PT J
AU Bajor, LA
Lai, ZS
Goodrich, DE
Miller, CJ
Penfold, RB
Kim, HM
Bauer, MS
Kilbourne, AM
AF Bajor, Laura A.
Lai, Zongshan
Goodrich, David E.
Miller, Christopher J.
Penfold, Robert B.
Kim, Hyungjin Myra
Bauer, Mark S.
Kilbourne, Amy M.
TI Posttraumatic stress disorder, depression, and health-related quality of
life in patients with bipolar disorder: Review and new data from a
multi-site community clinic sample
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Quality of life; Bipolar disorder; Posttraumatic stress disorders;
Comorbidity
ID TREATMENT ENHANCEMENT PROGRAM; SELF-REPORTED DIAGNOSIS;
COGNITIVE-BEHAVIORAL THERAPY; COMORBID ANXIETY DISORDERS; ALCOHOL-USE
DISORDERS; PUBLIC-SECTOR SAMPLE; I DISORDER; STEP-BD; 2ND-GENERATION
ANTIDEPRESSANTS; PSYCHOSOCIAL INTERVENTIONS
AB Background: Evidence suggests that patients with bipolar disorder have an elevated risk for comorbid posttraumatic stress disorder (PTSD) compared to those without a bipolar diagnosis. Although bipolar disorder is associated with decreased health-related quality of life (HRQOL), it is unclear whether comorbid PTSD interacts to affect HRQOL.
Method: Baseline data from a multi-site study of patients with bipolar disorder were analyzed. Patient surveys ascertained clinical and demographic information, including physical and mental HRQOL based on the SF-12, mood symptoms (PHQ-9, Internal State Scale), and self-reported co-occurring conditions including PTSD.
Results: Overall (N=384), 44.9% of patients self-reported co-occurring PTSD. Patients with PTSD had lower physical and mental HRQOL scores compared to those without PTSD (mean (SD) for those with and without PTSD, respectively): Mental Component Scale score 30.51 (8.22) and 32.86 (8.35); Physical Component Scale score 35.56 (7.77) and 37.21 (7.20). After adjusting for demographic and clinical factors including mood symptoms, multiple linear regression analyses revealed that PTSD was no longer significantly associated with physical or mental HRQOL; however, depressive symptoms were independently associated with mental HRQOL (Beta -0.63, p < 0.01).
Conclusion: Depressive symptoms may explain the association between PTSD and mental HRQOL. Clinicians working with these patients will want to emphasize treatment of depression as important towards improving HRQOL for this group. Published by Elsevier B.V.
C1 [Bajor, Laura A.; Miller, Christopher J.; Bauer, Mark S.] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA.
[Lai, Zongshan; Goodrich, David E.; Kim, Hyungjin Myra; Kilbourne, Amy M.] VA Ann Arbor Ctr Clin Management Res, Ann Arbor, MI USA.
[Bajor, Laura A.; Bauer, Mark S.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Kilbourne, Amy M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA.
[Penfold, Robert B.] Grp Hlth Res Inst, Seattle, WA USA.
[Penfold, Robert B.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
[Kim, Hyungjin Myra] Univ Michigan, Ctr Stat Consultat & Res, Ann Arbor, MI 48109 USA.
RP Bajor, LA (reprint author), VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, 150S Huntington Ave 152M, Boston, MA USA.
EM laura_bajor@hms.harvard.edu
OI Goodrich, David/0000-0003-3232-2189
FU NIMH [R01 MH79994]; Department of Veterans Affairs Research Grant [IIR
10-314]
FX This work was supported by NIMH (R01 MH79994 to AMK) and the Department
of Veterans Affairs Research Grant (IIR 10-314 to MSB). The views
expressed in this article are those of the authors and do not
necessarily represent the views of the Department of Veterans Affairs.
NR 82
TC 8
Z9 8
U1 3
U2 28
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD FEB 20
PY 2013
VL 145
IS 2
BP 232
EP 239
DI 10.1016/j.jad.2012.08.005
PG 8
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 078IN
UT WOS:000314092100013
PM 23021820
ER
PT J
AU Ansari, IUH
Allen, T
Berical, A
Stock, PG
Barin, B
Striker, R
AF Ansari, Israr-ul H.
Allen, Todd
Berical, Andrew
Stock, Peter G.
Barin, Burc
Striker, Rob
TI Phenotypic analysis of NS5A variant from liver transplant patient with
increased cyclosporine susceptibility
SO VIROLOGY
LA English
DT Article
DE Hepatitis C virus; Transplantation; Cyclophilin inhibitor; Cyclosporine;
Antiviral
ID HEPATITIS-C-VIRUS; CYCLOPHILIN INHIBITORS; DOMAIN-II; PROTEIN;
RESISTANCE; INFECTION; NS5A-CYCLOPHILIN; IDENTIFICATION; ALISPORIVIR;
SUBSTRATE
AB Hepatitis C virus (HCV) replication is limited by cyclophilin inhibitors but it remains unclear how viral genetic variations influence susceptibility to cyclosporine (cyclosporine A, CsA), a cyclophilin inhibitor. In this study HCV from liver transplant patients was sequenced before and after CsA exposure. Phenotypic analysis of NS5A sequence was performed by using HCV sub genomic replicon to determine CsA susceptibility. The data indicates an atypical proline at position 328 in NS5A causes increases CsA sensitivity both in the context of genotype 1a and 1b residues. Point mutants mimicking other naturally occurring residues at this position also increased (Ala) or decreased (Arg) replicon sensitivity to CsA relative to the typical threonine (genotype la) or serine (genotype lb) at this position. This work has implications for treatment of HCV by cyclophilin inhibitors. Published by Elsevier Inc.
C1 [Striker, Rob] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53726 USA.
[Ansari, Israr-ul H.; Striker, Rob] Univ Wisconsin, Madison, WI USA.
[Allen, Todd; Berical, Andrew] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Stock, Peter G.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Barin, Burc] EMMES Corp, Rockville, MD USA.
RP Striker, R (reprint author), William S Middleton Mem Vet Adm Med Ctr, 3207 Microbial Sci,1550 Linden Dr, Madison, WI 53726 USA.
EM rtstriker@wisc.edu
RI Allen, Todd/F-5473-2011
FU American Cancer Society [07-077-01]; Office of Research and Development,
Biomedical Laboratory R&D Service, Department of Veterans Affairs;
National Institute of Allergy and Infectious Diseases [AI052748]
FX We gratefully acknowledge the patients and other investigators involved
in the solid organ transplantation in HIV (HIV-TR Study AI052748) and
the Project Manager, Rodney Rogers. This work was supported by the
American Cancer Society Research Scholar Grant (07-077-01) to R.S., by
the Office of Research and Development, Biomedical Laboratory R&D
Service, Department of Veterans Affairs. Patient samples were obtained
via the solid organ transplantation in HIV: Multi-site study (HIV-TR
study AI052748) funded by the National Institute of Allergy and
Infectious Diseases.
NR 28
TC 5
Z9 5
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD FEB 20
PY 2013
VL 436
IS 2
BP 268
EP 273
DI 10.1016/j.virol.2012.11.018
PG 6
WC Virology
SC Virology
GA 083EX
UT WOS:000314446600003
PM 23290631
ER
PT J
AU Aizer, AA
Gu, XM
Choueiri, TK
Martin, NE
Hu, JC
Nguyen, PL
AF Aizer, Ayal A.
Gu, Xiangmei
Choueiri, Toni K.
Martin, Neil E.
Hu, Jim C.
Paul Linh Nguyen
TI Overtreatment of low-risk prostate cancer in the United States:
Incidence, cost, complications, and implications for the screening
debate
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Harvard Radiat Oncol Program, Boston, MA USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol,Med Sch, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
RI Martin, Neil/E-2193-2014
OI Martin, Neil/0000-0002-8164-8516
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 161
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600162
ER
PT J
AU Aizer, AA
Paly, JJ
Zietman, AL
Nguyen, PL
Beard, C
Rao, SK
Kaplan, ID
Niemierko, A
Hirsch, MS
Wu, CL
Olumi, AF
Michaelson, MD
D'Amico, AV
Efstathiou, JA
AF Aizer, Ayal A.
Paly, Jonathan J.
Zietman, Anthony L.
Paul Linh Nguyen
Beard, Clair
Rao, Sandhya K.
Kaplan, Irving D.
Niemierko, Andrzej
Hirsch, Michelle S.
Wu, Chin-Lee
Olumi, Aria F.
Michaelson, M. Dror
D'Amico, Anthony Victor
Efstathiou, Jason Alexander
TI Multidisciplinary care and management of very low-risk prostate cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Harvard Radiat Oncol Program, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 55
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600056
ER
PT J
AU Bambury, RM
Iyer, G
Riester, M
Werner, L
Schultz, N
Stack, EC
Park, R
Loda, M
Ostrovnaya, I
Kantoff, PW
Bajorin, DF
Solit, DB
Michor, F
Bellmunt, J
Rosenberg, JE
AF Bambury, Richard M.
Iyer, Gopa
Riester, Markus
Werner, Lillian
Schultz, Nikolaus
Stack, Edward C.
Park, Rachel
Loda, Massimo
Ostrovnaya, Irina
Kantoff, Philip W.
Bajorin, Dean F.
Solit, David B.
Michor, Franziska
Bellmunt, Joaquim
Rosenberg, Jonathan E.
TI Peroxisome proliferator-activated receptor gamma (PPARG) gene
amplifications in urothelial carcinoma (UC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Weill Cornell Med Coll, New York, NY USA.
Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Hosp Mar IMIM, Barcelona, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 279
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600279
ER
PT J
AU Bambury, RM
Riester, M
Bellmunt, J
Stack, EC
Werner, L
Park, R
Iyer, G
Loda, M
Kantoff, PW
Michor, F
Rosenberg, JE
AF Bambury, Richard M.
Riester, Markus
Bellmunt, Joaquim
Stack, Edward C.
Werner, Lillian
Park, Rachel
Iyer, Gopa
Loda, Massimo
Kantoff, Philip W.
Michor, Franziska
Rosenberg, Jonathan E.
TI Genomic characterization of metastatic urothelial carcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Weill Cornell Med Coll, New York, NY USA.
Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Univ Hosp Mar IMIM, Barcelona, Spain.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 247
PG 2
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600247
ER
PT J
AU Barnett, CM
Heinrich, MC
Nelson, DA
Lim, JY
Beadling, C
Warrick, A
Neff, T
Thomas, G
Garzotto, M
Higano, CS
Beer, TM
Qian, DZ
AF Barnett, Christine M.
Heinrich, Michael C.
Nelson, Dylan A.
Lim, Jeong Youn
Beadling, Carol
Warrick, Andrea
Neff, Tanaya
Thomas, George
Garzotto, Mark
Higano, Celestia S.
Beer, Tomasz M.
Qian, David Z.
TI Genomic analysis of prostate cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Knight Diagnost Labs, Portland, OR 97201 USA.
Univ Washington, Seattle Canc Care Alliance, Puget Sound Oncol Consortium, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 80
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600081
ER
PT J
AU Choueiri, TK
Je, YJ
Sonpavde, G
Galsky, MD
Kaymakcalan, M
Nguyen, PL
Schutz, F
Heng, DYC
Richards, CJ
AF Choueiri, Toni K.
Je, Youjin
Sonpavde, Guru
Galsky, Matt D.
Kaymakcalan, Marina
Nguyen, Paul Linh
Schutz, Fabio
Heng, Daniel Yick Chin
Richards, Christopher J.
TI Incidence and risk of treatment-related mortality in patients with renal
cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin
(mTOR) inhibitors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Kyung Hee Univ, Seoul, South Korea.
Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA 02115 USA.
Hosp St Jose, Sao Paulo, Brazil.
Tom Baker Canc Clin, Calgary, AB, Canada.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 347
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600347
ER
PT J
AU Choueiri, TK
Jacobus, SJ
Qu, AQ
Sweeney, C
Appleman, LJ
Tretter, CPG
Bubley, GJ
Elfiky, A
Park, R
Stack, EC
Signoretti, S
Walsh, MK
Steele, G
Hirsch, MS
Krajewski, KM
Taplin, ME
Rosenberg, JE
Ross, RW
AF Choueiri, Toni K.
Jacobus, Susanna J.
Qu, Angela Q.
Sweeney, Christopher
Appleman, Leonard Joseph
Tretter, Christopher P. G.
Bubley, Glenn J.
Elfiky, Aymen
Park, Rachel
Stack, Edward C.
Signoretti, Sabina
Walsh, Meghara K.
Steele, Graeme
Hirsch, Michelle S.
Krajewski, Katherine Maragaret
Taplin, Mary-Ellen
Rosenberg, Jonathan E.
Ross, Robert W.
TI A phase II multicenter study of neoadjuvant dose-dense methotrexate,
vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with
pegfilgrastim support in patients (pts) muscle-invasive urothelial
cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Lank Ctr Genitourinary Oncol,Dana Farber Canc Ins, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Lahey Clin Fdn, Burlington, MA USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Brigham & Womens Hosp, Div Urol, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 278
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600278
ER
PT J
AU Devlin, PM
AF Devlin, Phillip M.
TI Surface applicator high-dose-rate fractionated brachytherapy for
conservative definitive management of extramammilary Paget's disease of
the penis, scrotum, and mons pubis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 [Devlin, Phillip M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 333
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600333
ER
PT J
AU Fan, AC
Leppert, J
Liliental, JE
Xu, LW
Thong, AE
Yost, C
Yaghi, A
Brooks, JD
Harshman, LC
Sabatti, C
Srinivas, S
Felsher, DW
AF Fan, Alice C.
Leppert, John
Liliental, Joanna E.
Xu, Liwen
Thong, Alan E.
Yost, Christine
Yaghi, Alia
Brooks, James D.
Harshman, Lauren Christine
Sabatti, Chiara
Srinivas, Sandy
Felsher, Dean W.
TI Nanoscale proteomic profiling to define diagnostic signatures and
biomarkers of therapeutic activity in patients with RCC
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Stanford Univ, Sch Med, Stanford, CA 94305 USA.
Stanford Univ, Stanford, CA 94305 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Stanford Med Ctr, Stanford, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 432
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600429
ER
PT J
AU Fleming, MT
Scher, HI
Fizazi, K
Taplin, ME
Forer, D
Hirmand, M
De Bono, JS
AF Fleming, Mark T.
Scher, Howard I.
Fizazi, Karim
Taplin, Mary-Ellen
Forer, David
Hirmand, Mohammad
De Bono, Johann Sebastian
TI Long-term responders to enzalutamide (ENZA) during the phase III AFFIRM
trial: Baseline characteristics and efficacy outcomes
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Virginia Oncol Associates, Norfolk, VA USA.
Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA.
Univ Paris 11, Orsay, France.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Medivation Inc, San Francisco, CA USA.
Inst Canc Res, Sutton, Surrey, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 20
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600023
ER
PT J
AU Galsky, MD
Xie, WL
Nakabayashi, M
Ross, RW
Fennessy, FM
Tempany, CM
Choueiri, TK
Khine, K
Kantoff, PW
Taplin, ME
Oh, WK
AF Galsky, Matt D.
Xie, Wanling
Nakabayashi, Mari
Ross, Robert W.
Fennessy, Fiona M.
Tempany, Clare M.
Choueiri, Toni K.
Khine, Krystal
Kantoff, Philip W.
Taplin, Mary-Ellen
Oh, William K.
TI Paradoxical significance of endorectal MRI (erMRI) response to
neoadjuvant chemotherapy in patients with high-risk localized prostate
cancer (HRLPC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Infin Pharmaceut Inc, Cambridge, MA USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 23
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600026
ER
PT J
AU Gartrell, BA
Ying, J
Sivendran, S
Agarwal, N
Boucher, KM
Choueiri, TK
Sonpavde, G
Oh, WK
Galsky, MD
AF Gartrell, Benjamin Adam
Ying, Jian
Sivendran, Shanthi
Agarwal, Neeraj
Boucher, Kenneth M.
Choueiri, Toni K.
Sonpavde, Guru
Oh, William K.
Galsky, Matt D.
TI Pulmonary complications with the use of mTOR inhibitors in targeted
cancer therapy: A systematic review and meta-analysis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Montefiore Med Ctr, Div Oncol, Bronx, NY 10467 USA.
Univ Utah, Dept Internal Med, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
Lancaster Gen Hlth, Hematol Oncol Med Specialists, Lancaster, PA USA.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol,Sch Med, Boston, MA 02115 USA.
Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 362
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600360
ER
PT J
AU Gray, PJ
Fedewa, SA
Shipley, WU
Lin, CC
Virgo, KS
Kibel, AS
Kamat, AM
Rosenberg, JE
Jemal, A
Zietman, AL
Efstathiou, JA
AF Gray, Phillip J.
Fedewa, Stacey A.
Shipley, William U.
Lin, Chun Chieh
Virgo, Katherine S.
Kibel, Adam Stuart
Kamat, Ashish M.
Rosenberg, Jonathan E.
Jemal, Ahmedin
Zietman, Anthony L.
Efstathiou, Jason Alexander
TI Clinical-pathologic stage discrepancy in patients with bladder cancer
treated with radical cystectomy: Associations with clinical variables
and survival
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Harvard Radiat Oncol Program, Boston, MA USA.
Amer Canc Soc, Atlanta, GA 30329 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 248
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600248
ER
PT J
AU Guancial, EA
Werner, L
Bellmunt, J
Nikitas, N
Stack, EC
Lis, R
Signoretti, S
Loda, M
Regan, MM
Park, RS
O'Brien, R
Berman, DM
Bamias, A
Rosenberg, JE
AF Guancial, Elizabeth A.
Werner, Lillian
Bellmunt, Joaquim
Nikitas, Nikitas
Stack, Edward C.
Lis, Rosina
Signoretti, Sabina
Loda, Massimo
Regan, Meredith M.
Park, Rachel S.
O'Brien, Robert
Berman, David M.
Bamias, Aristotelis
Rosenberg, Jonathan E.
TI Relationship of ERCC1 genotype variant with mRNA expression and ERCC1
protein levels in advanced urothelial carcinoma (UC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Univ Hosp del Mar IMIM, Barcelona, Spain.
Univ Athens, Athens, Greece.
Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
HECOG, Athens, Greece.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 260
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600260
ER
PT J
AU Harshman, LC
Wood, L
Srinivas, S
Heng, DYC
Choueiri, TK
AF Harshman, Lauren Christine
Wood, Lori
Srinivas, Sandy
Heng, Daniel Yick Chin
Choueiri, Toni K.
TI First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An
analysis from the International mRCC Database Consortium
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada.
Stanford Med Ctr, Stanford, CA USA.
Tom Baker Canc Clin, Calgary, AB, Canada.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol,Brigham & Womens Hos, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 430
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600427
ER
PT J
AU Hutson, TE
Dang, LH
Lauer, RC
Starodub, A
Hauke, RJ
Galsky, MD
Bylow, KA
Cowey, CL
Bibby, DC
Kremmidiotis, G
Doolin, EE
Lavranos, TC
Sonpavde, G
Logan, T
Hahn, NM
Sweeney, C
Sarantopoulos, J
AF Hutson, Thomas E.
Dang, Long H.
Lauer, Richard C.
Starodub, Alexander
Hauke, Ralph J.
Galsky, Matt D.
Bylow, Kathryn A.
Cowey, Charles Lance
Bibby, David C.
Kremmidiotis, Gabriel
Doolin, Elizabeth E.
Lavranos, Tina C.
Sonpavde, Guru
Logan, Theodore
Hahn, Noah M.
Sweeney, Christopher
Sarantopoulos, John
CA Hoosier Oncology Grp
TI Updated phase I results of a phase I/II trial of BNC105P with everolimus
in patients with metastatic renal cell carcinoma (mRCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 McKesson Specialty Hlth, US Oncol Res, The Woodlands, TX USA.
Baylor Charles A Sammons Canc Ctr Texas Oncol PA, Dallas, TX USA.
Univ Florida, Gainesville, FL USA.
Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA.
Indiana Univ, Hlth Goshen Ctr Canc Care, Goshen, IN USA.
Nebraska Canc Specialists, Omaha, NE USA.
Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
Baylor Charles A Sammons Canc Ctr, Dallas, TX USA.
Bionomics Ltd, Thebarton, Australia.
Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 397
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600394
ER
PT J
AU Kaymakcalan, M
Je, YJ
Sonpavde, G
Galsky, MD
Nguyen, PL
Schutz, F
Heng, DYC
Richards, CJ
Choueiri, TK
AF Kaymakcalan, Marina
Je, Youjin
Sonpavde, Guru
Galsky, Matt D.
Paul Linh Nguyen
Schutz, Fabio
Heng, Daniel Yick Chin
Richards, Christopher J.
Choueiri, Toni K.
TI Incidence and risk of infections in renal cell cancer (RCC) and non-RCC
patients treated with everolimus and temsirolimus: A meta-analysis of
randomized control trials
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Kyung Hee Univ, Seoul, South Korea.
Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Hosp St Jose, Sao Paulo, Brazil.
Tom Baker Canc Clin, Calgary, AB, Canada.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Lank Ctr Genitourinary Onco, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 353
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600351
ER
PT J
AU Kovtun, K
Wolfsberger, LD
Niedermayr, T
Neubauer, E
Murciano-Goroff, YR
Beard, C
D'Amico, AV
Martin, NE
Orio, PF
Nguyen, PL
AF Kovtun, Konstantin
Wolfsberger, Luciant D.
Niedermayr, Thomas
Neubauer, Emily
Murciano-Goroff, Yonina R.
Beard, Clair
D'Amico, Anthony Victor
Martin, Neil E.
Orio, Peter F.
Nguyen, Paul Linh
TI Dosimetic quality and evolution of edema after prostate brachytherapy
for small prostates: Implications for the use of newer isotopes
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 [Kovtun, Konstantin; Wolfsberger, Luciant D.; Niedermayr, Thomas; Neubauer, Emily; Murciano-Goroff, Yonina R.; Beard, Clair; D'Amico, Anthony Victor; Martin, Neil E.; Orio, Peter F.; Nguyen, Paul Linh] Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA 02115 USA.
RI Martin, Neil/E-2193-2014
OI Martin, Neil/0000-0002-8164-8516
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 232
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600232
ER
PT J
AU Kovtun, K
Penzkofer, T
Agrawal, N
Kapur, T
Fedorov, A
Cormack, RA
D'Amico, AV
Tempany, CM
Nguyen, PL
AF Kovtun, Konstantin
Penzkofer, Tobias
Agrawal, Neha
Kapur, Tina
Fedorov, Andriy
Cormack, Robert A.
D'Amico, Anthony Victor
Tempany, Clare M.
Nguyen, Paul Linh
TI Location of local recurrence after MRI-guided partial prostate
brachytherapy targeting only the peripheral zone: Implications for focal
therapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 149
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600150
ER
PT J
AU Kroeger, N
Xie, WL
Lee, JL
Bjarnason, GA
Knox, JJ
MacKenzie, MJ
Wood, L
Srinivas, S
Vaishamayan, UN
Rha, SY
Pal, SK
Donskov, F
Agarwal, N
Kollmannsberger, CK
Tan, MH
North, SA
Rini, BI
Choueiri, TK
Heng, DYC
AF Kroeger, Nils
Xie, Wanling
Lee, Jae-Lyun
Bjarnason, Georg A.
Knox, Jennifer J.
MacKenzie, Mary J.
Wood, Lori
Srinivas, Sandy
Vaishamayan, Ulka N.
Rha, Sun Young
Pal, Sumanta Kumar
Donskov, Frede
Agarwal, Neeraj
Kollmannsberger, Christian K.
Tan, Min-Han
North, Scott A.
Rini, Brian I.
Choueiri, Toni K.
Heng, Daniel Yick Chin
TI Metastatic non-clear cell renal cell carcinoma (nccRCC) treated with
targeted therapy agents: Applying the International Metastatic Renal
Cell Carcinoma Database Consortium (IMDC) prognostic model to predict
outcomes
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Tom Baker Canc Clin, Calgary, AB, Canada.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea.
Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
London Reg Canc Program, London, ON, Canada.
Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada.
Stanford Med Ctr, Stanford, CA USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea.
City Hope Natl Med Ctr, Duarte, CA USA.
Aarhus Univ Hosp, DK-8000 Aarhus, Denmark.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
Natl Canc Ctr, Singapore, Singapore.
Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Lank Ctr Genitourinary Oncol,Dana Farber Canc Ins, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 396
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600393
ER
PT J
AU Martin, NE
Chen, MH
Beard, C
Nguyen, PL
Loffredo, M
Renshaw, AA
Kantoff, PW
D'Amico, AV
AF Martin, Neil E.
Chen, Ming-Hui
Beard, Clair
Nguyen, Paul Linh
Loffredo, Marian
Renshaw, Andrew A.
Kantoff, Philip W.
D'Amico, Anthony Victor
TI Age, comorbidity, and the risk of death in men with PSA failure
following radiation therapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Connecticut, Storrs, CT USA.
Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA.
Baptist Hosp Miami, Miami, FL USA.
RI Martin, Neil/E-2193-2014
OI Martin, Neil/0000-0002-8164-8516
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 82
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600083
ER
PT J
AU Master, VA
Wang, DSP
Tai, CGL
Sesay, M
Kilbridge, KL
Goodman, M
Jani, AB
AF Master, Viraj A.
Wang, Daniel Shin-Ping
Tai, Caroline Gar-Ling
Sesay, Musu
Kilbridge, Kerry L.
Goodman, Michael
Jani, Ashesh B.
TI Severe lack of comprehension of common prostate health terminology in
underserved populations: External validation
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Emory Univ, Atlanta, GA 30322 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 71
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600072
ER
PT J
AU McDermott, DF
Manola, J
Pins, M
Flaherty, KT
Atkins, MB
Dutcher, JP
George, DJ
Margolin, KA
DiPaola, RS
AF McDermott, David F.
Manola, Judith
Pins, Michael
Flaherty, Keith T.
Atkins, Michael B.
Dutcher, Janice P.
George, Daniel J.
Margolin, Kim Allyson
DiPaola, Robert S.
TI The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase,
and mTOR combination targeted therapy (CTT) with bevacizumab (bev),
sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma
(RCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Illinois, Coll Med, Chicago, IL USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA.
Continuum Canc Ctr New York, St Lukes Roosevelt Hosp Ctr, New York, NY USA.
Duke Univ, Med Ctr, Durham, NC USA.
Univ Washington, Seattle, WA 98195 USA.
Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA.
NR 0
TC 5
Z9 5
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 345
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600345
ER
PT J
AU McDermott, DF
Drake, CG
Sznol, M
Choueiri, TK
Powderly, JD
Smith, DC
Wigginton, JM
Kollia, G
Gupta, AK
Atkins, MB
AF McDermott, David F.
Drake, Charles G.
Sznol, Mario
Choueiri, Toni K.
Powderly, John D.
Smith, David C.
Wigginton, Jon M.
Kollia, Georgia
Gupta, Ashok Kumar
Atkins, Michael B.
TI Clinical activity and safety of antiprogrammed death-1 (PD-1)
(BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously
treated, metastatic renal cell carcinoma (mRCC): An updated analysis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Yale Canc Ctr, New Haven, CT USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Brigham & Womens Hosp,Lank Ctr Genitourinary Onco, Boston, MA 02115 USA.
Carolina BioOncol Inst, Huntersville, NC USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 351
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600349
ER
PT J
AU McKay, RR
Kroeger, N
Xie, WL
Lee, JL
Knox, JJ
Bjarnason, GA
MacKenzie, MJ
Wood, L
Srinivas, S
Vaishampayan, UN
Rha, SY
Pal, SK
Donskov, F
Tantravahi, S
Rini, BI
Heng, DYC
Choueiri, TK
AF McKay, Rana R.
Kroeger, Nils
Xie, Wanling
Lee, Jae-Lyun
Knox, Jennifer J.
Bjarnason, Georg A.
MacKenzie, Mary J.
Wood, Lori
Srinivas, Sandy
Vaishampayan, Ulka N.
Rha, Sun Young
Pal, Sumanta Kumar
Donskov, Frede
Tantravahi, Srinivas
Rini, Brian I.
Heng, Daniel Yick Chin
Choueiri, Toni K.
TI Impact of bone and liver metastases (BM, LM) in patients with metastatic
renal cell carcinoma (mRCC) treated with molecularly targeted agents
(MTAs): Results from the International mRCC Database Consortium (IMDC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Tom Baker Canc Clin, Calgary, AB, Canada.
Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea.
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
London Reg Canc Program, London, ON, Canada.
Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada.
Stanford Med Ctr, Stanford, CA USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea.
City Hope Natl Med Ctr, Duarte, CA USA.
Aarhus Univ Hosp, DK-8000 Aarhus, Denmark.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol,Sch Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 394
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600391
ER
PT J
AU Milowsky, MI
Dittrich, C
Martinez, ID
Jagdev, S
Millard, FE
Sweeney, C
Bajorin, DF
Cerbone, L
Dunn, RM
Sen, P
Shi, M
Kay, ACM
Squires, M
Sternberg, CN
AF Milowsky, Matthew I.
Dittrich, Christian
Martinez, Ignacio Duran
Jagdev, Satinder
Millard, Frederick E.
Sweeney, Christopher
Bajorin, Dean F.
Cerbone, Linda
Dunn, Robert M.
Sen, Paramita
Shi, Michael
Kay, Andrea C. M.
Squires, Matthew
Sternberg, Cora N.
TI Final results of a multicenter, open-label phase II trial of dovitinib
(TKI258) in patients with advanced urothelial carcinoma with either
mutated or nonmutated FGFR3
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 UNC Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
Kaiser Franz Josef Spital, LBI ACR VIEnna, Vienna, Austria.
Kaiser Franz Josef Spital, ACR ITR VIEnna, Vienna, Austria.
CIOCC Grp Hosp Madrid, Madrid, Spain.
St Jamess Inst Oncol, Leeds, W Yorkshire, England.
Univ Calif San Diego, La Jolla, CA 92093 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
San Camillo & Forlanini Hosp, Rome, Italy.
Novartis Pharmaceut, E Hanover, NJ USA.
NR 0
TC 4
Z9 4
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 255
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600255
ER
PT J
AU Mirabeau-Beale, K
Chen, MH
D'Amico, AV
AF Mirabeau-Beale, Kristina
Chen, Ming-Hui
D'Amico, Anthony Victor
TI Prior cancer diagnosis in men with nonmetastatic prostate cancer and the
risk of prostate cancer specific and all-cause mortality
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Harvard Radiat Oncol Program, Boston, MA USA.
Univ Connecticut, Storrs, CT USA.
Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol,Med Sch, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 70
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600071
ER
PT J
AU Molina, AM
Hutson, TE
Larkin, JMG
Gold, A
Andresen, C
Wood, K
Motzer, RJ
Michaelson, MD
AF Molina, Ana M.
Hutson, Thomas E.
Larkin, James M. G.
Gold, Anne
Andresen, Corina
Wood, Karen
Motzer, Robert John
Michaelson, M. Dror
TI A phase Ib clinical trial of the multitargeted kinase inhibitor
lenvatinib (E7080) in combination with everolimus for treatment of
metastatic renal cell carcinoma (RCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Baylor Charles A Sammons Canc Ctr, Dallas, TX USA.
Royal Marsden NHS Fdn Trust, London, England.
Eisai Inc, Woodcliff Lake, NJ USA.
Eisai Ltd, Hatfield, Herts, England.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 358
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600356
ER
PT J
AU Nanda, A
Chen, MH
Moran, BJ
Braccioforte, MH
D'Amico, AV
AF Nanda, Akash
Chen, Ming-Hui
Moran, Brian Joseph
Braccioforte, Michelle H.
D'Amico, Anthony Victor
TI Intermediate versus short-course hormone therapy and mortality in men
with high-risk prostate cancer treated with radiation therapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 MD Anderson Canc Ctr Orlando, Orlando, FL USA.
Univ Connecticut, Storrs, CT USA.
Prostate Canc Fdn Chicago, Westmont, IL USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 83
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600084
ER
PT J
AU O'Donnell, E
Gray, KP
Ravi, P
Sweeney, C
AF O'Donnell, Elizabeth
Gray, Kathryn P.
Ravi, Praful
Sweeney, Christopher
TI A meta-analysis of patient outcomes with subcentimeter disease after
chemotherapy for metastatic nonseminomatous germ cell tumor (NSGCT)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 [O'Donnell, Elizabeth; Gray, Kathryn P.; Ravi, Praful; Sweeney, Christopher] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 324
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600324
ER
PT J
AU O'Donnell, E
Gray, KP
Hirsch, MS
Ravi, P
Beard, C
Sweeney, C
AF O'Donnell, Elizabeth
Gray, Kathryn P.
Hirsch, Michelle S.
Ravi, Praful
Beard, Clair
Sweeney, Christopher
TI A 10-year retrospective review of germ cell tumors not cured with
cisplatin-based chemotherapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 325
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600325
ER
PT J
AU Paly, JJ
Hallemeier, CL
Biggs, PJ
Niemierko, A
Roeder, F
Martinez-Monge, R
Whitson, JM
Calvo, FA
Fastner, G
Wong, W
Ellis, RJ
Efstathiou, JA
AF Paly, Jonathan J.
Hallemeier, Christopher Leigh
Biggs, Peter J.
Niemierko, Andrzej
Roeder, Falk
Martinez-Monge, Rafael
Whitson, Jared Myers
Calvo, Felipe A.
Fastner, Gerd
Wong, William
Ellis, Rodney J.
Efstathiou, Jason Alexander
TI Outcomes for a multi-institutional cohort of patients treated with
intra-operative radiation therapy for advanced or recurrent renal cell
carcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Mayo Clin, Rochester, MN USA.
Univ Clin Heidelberg, Heidelberg, Germany.
Univ Navarra, Navarra, Spain.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Hosp Gen Univ Gregorio Maranon, Madrid, Spain.
Paracelsus Med Univ, Salzburg, Austria.
Mayo Clin, Scottsdale, AZ USA.
Case Western Reserve Univ, Univ Hosp Case Med Ctr, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 442
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600439
ER
PT J
AU Petrylak, DP
Kantoff, PW
Mega, AE
Vogelzang, NJ
Stephenson, J
Fleming, MT
Stambler, N
Petrini, M
Huang, K
Israel, RJ
AF Petrylak, Daniel Peter
Kantoff, Philip W.
Mega, Anthony E.
Vogelzang, Nicholas J.
Stephenson, Joe
Fleming, Mark T.
Stambler, Nancy
Petrini, Michaela
Huang, Kathleen
Israel, Robert Joseph
TI Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A
phase I trial in metastatic castration-resistant prostate cancer (mCRPC)
previously treated with a taxane
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Columbia Univ, Med Ctr, New York, NY USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Brown Univ, Oncol Grp, Providence, RI 02912 USA.
Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
US Oncol Res, Las Vegas, NV USA.
Canc Ctr Carolinas, Greenville, SC USA.
Virginia Oncol Associates, Norfolk, VA USA.
Progen Pharmaceut Inc, Tarrytown, NY USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 119
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600120
ER
PT J
AU Pond, GR
Agarwal, N
Bellmunt, J
Choueiri, TK
Qu, AQ
Fougeray, R
Niegisch, G
Galsky, MD
Wong, YN
Stadler, WM
Sridhar, SS
Sternberg, CN
Sonpavde, G
AF Pond, Gregory Russell
Agarwal, Neeraj
Bellmunt, Joaquim
Choueiri, Toni K.
Qu, Angela Q.
Fougeray, Ronan
Niegisch, Guenter
Galsky, Matt D.
Wong, Yu-Ning
Stadler, Walter Michael
Sridhar, Srikala S.
Sternberg, Cora N.
Sonpavde, Guru
TI Impact of baseline prognostic factors on progression-free survival at 6
months (PFS6) and response in patients receiving second-line therapy for
advanced urothelial carcinoma (UC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 McMaster Univ, Hamilton, ON, Canada.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Univ Hosp Mar, Barcelona, Spain.
Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol,Med Sch, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Inst Rech Pierre Fabre, Boulogne, France.
Univ Dusseldorf, Dept Urol, Dusseldorf, Germany.
Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Univ Chicago, Chicago, IL 60637 USA.
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
San Camillo & Forlanini Hosp, Rome, Italy.
Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 301
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600301
ER
PT J
AU Qu, AQ
Choueiri, TK
Jacobus, SJ
Rosenberg, JE
Ramaiya, NH
Krajewski, KM
AF Qu, Angela Q.
Choueiri, Toni K.
Jacobus, Susanna J.
Rosenberg, Jonathan E.
Ramaiya, Nikhil H.
Krajewski, Katherine Maragaret
TI Radiologic response (RR) by MRI in patients (pts) with muscle-invasive
urothelial cancer (MIUC) undergoing neoadjuvant chemotherapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Lank Ctr Genitourinary Oncol,Dana Farber Canc Ins, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 283
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600283
ER
PT J
AU Rathkopf, DE
Smith, MR
De Bono, JS
Logothetis, C
Shore, ND
De Souza, PL
Fizazi, K
Mulders, P
Mainwaring, PN
Hainsworth, JD
Beer, TM
North, SA
Fradet, Y
Griffin, TW
Park, YC
Kheoh, TS
Small, EJ
Scher, HI
Molina, A
Ryan, CJ
AF Rathkopf, Dana E.
Smith, Matthew Raymond
De Bono, Johann Sebastian
Logothetis, Christopher
Shore, Neal D.
De Souza, Paul L.
Fizazi, Karim
Mulders, Peter
Mainwaring, Paul N.
Hainsworth, John D.
Beer, Tomasz M.
North, Scott A.
Fradet, Yves
Griffin, Thomas W.
Park, Youn Choi
Kheoh, Thian San
Small, Eric Jay
Scher, Howard I.
Molina, Arturo
Ryan, Charles J.
TI Updated interim analysis (IA) of COU-AA-302, a randomized phase III
study of abiraterone acetate (AA) in patients (pts) with metastatic
castration-resistant prostate cancer (mCRPC) without prior chemotherapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Carolina Urol Res Ctr, Myrtle Beach, SC USA.
Univ Western Sydney, Sch Med, Ingham Inst, Liverpool, Australia.
Inst Gustave Roussy, Villejuif, France.
Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
Haematol Clin Australasia, Brisbane, Qld, Australia.
Oncol Clin Australasia, Brisbane, Qld, Australia.
Sarah Cannon Res Inst, Nashville, TN USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
Univ Laval, Quebec City, PQ, Canada.
Janssen Res & Dev, Los Angeles, CA USA.
Janssen Res & Dev, Raritan, NJ USA.
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
RI Mulders, Peter/H-8076-2014
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 5
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600009
ER
PT J
AU Scher, HI
Fizazi, K
Saad, F
Chi, KN
Taplin, ME
Sternberg, CN
Armstrong, AJ
Hirmand, M
Forer, D
De Bono, JS
AF Scher, Howard I.
Fizazi, Karim
Saad, Fred
Chi, Kim N.
Taplin, Mary-Ellen
Sternberg, Cora N.
Armstrong, Andrew J.
Hirmand, Mohammad
Forer, David
De Bono, Johann Sebastian
TI Impact of on-study corticosteroid use on efficacy and safety in the
phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor
inhibitor
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA.
Univ Paris 11, Orsay, France.
Univ Montreal, Ctr Hosp, Montreal, PQ, Canada.
British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC V5Z 4E6, Canada.
Dana Farber Canc Inst, Boston, MA 02115 USA.
San Camillo & Forlanini Hosp, Rome, Italy.
Duke Univ, Med Ctr, Duke Canc Inst, Durham, NC USA.
Medivation Inc, San Francisco, CA USA.
Inst Canc Res, Sutton, Surrey, England.
NR 0
TC 11
Z9 11
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 6
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600010
ER
PT J
AU Schoenfeld, JD
Margalit, DN
Shui, IM
Kasperzyk, JL
Sesso, HD
Martin, NE
Nguyen, PL
Kantoff, PW
Rider, JR
Mucci, LA
AF Schoenfeld, Jonathan D.
Margalit, Danielle Nina
Shui, Irene M.
Kasperzyk, Julie L.
Sesso, Howard D.
Martin, Neil E.
Paul Linh Nguyen
Kantoff, Philip W.
Rider, Jennifer R.
Mucci, Lorelei A.
TI Associations between single nucleotide polymorphisms (SNPs) in
inflammation-related genes and quality of life after radiation therapy
(RT) for prostate cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Harvard Radiat Oncol Program, Boston, MA USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Publ Hlth, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA.
RI Martin, Neil/E-2193-2014
OI Martin, Neil/0000-0002-8164-8516
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 2
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600006
ER
PT J
AU Schweizer, MT
Bardia, A
Blackford, AL
Lin, JQ
Armstrong, AJ
King, S
Rudek, MA
Yegnasubramanian, ST
Carducci, MA
AF Schweizer, Michael Thomas
Bardia, Aditya
Blackford, Amanda L.
Lin, Jianqing
Armstrong, Andrew J.
King, Serina
Rudek, Michelle A.
Yegnasubramanian, Srinivasan Thomas
Carducci, Michael Anthony
TI A prostate cancer clinical trials consortium trial of disulfiram (D) in
men with nonmetastatic recurrent prostate cancer (PCa)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
Harvard Univ, Sch Med, Massachusetts Gen Hosp Canc Ctr, Boston, MA USA.
Thomas Jefferson Univ, Jefferson Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
Duke Univ Med Ctr, Duke Canc Inst, Durham, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 219
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600219
ER
PT J
AU Shah, A
Motiwala, S
O'Dwyer, PJ
Flaherty, KT
Keefe, SM
AF Shah, Amishi
Motiwala, Shweta
O'Dwyer, Peter J.
Flaherty, Keith T.
Keefe, Stephen Michael
TI Increase in blood pressure with sorafenib exposure in renal cell
carcinoma versus other solid tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Univ Penn, Philadelphia, PA 19104 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Hosp Univ Penn, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 384
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600381
ER
PT J
AU Shelton, JB
Skolarus, TA
Ryoo, JJ
Malin, J
Antonio, ALM
He, R
Saigal, C
AF Shelton, Jeremy B.
Skolarus, Ted A.
Ryoo, Joan Joonsun
Malin, Jennifer
Antonio, Anna Liza M.
He, Ren
Saigal, Christopher
TI Specification and validation of prostate cancer quality-of-care
e-measures in the Veterans Health Administration (VHA)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Kaiser Permanente, Los Angeles Med Ctr, Los Angeles, CA USA.
WellPoint Inc, Indianapolis, IN USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 178
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600179
ER
PT J
AU Sivendran, S
Ying, J
Gartrell, BA
Agarwal, N
Boucher, KM
Choueiri, TK
Sonpavde, G
Oh, WK
Galsky, MD
AF Sivendran, Shanthi
Ying, Jian
Gartrell, Benjamin Adam
Agarwal, Neeraj
Boucher, Kenneth M.
Choueiri, Toni K.
Sonpavde, Guru
Oh, William K.
Galsky, Matt D.
TI Metabolic complications with the use of mTOR inhibitors for cancer
therapy: A systematic review and meta-analysis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Lancaster Gen Hlth, Lancaster, PA USA.
Univ Utah, Dept Internal Med, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
Montefiore Med Ctr, Div Oncol, Bronx, NY 10467 USA.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Lank Ctr Genitourinary Oncol,Dana Farber Canc Ins, Boston, MA 02115 USA.
Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA.
Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 398
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600395
ER
PT J
AU Small, EJ
Higano, CS
Kantoff, PW
Whitmore, JB
Frohlich, MW
Petrylak, DP
AF Small, Eric Jay
Higano, Celestia S.
Kantoff, Philip W.
Whitmore, James Boyd
Frohlich, Mark Walter
Petrylak, Daniel Peter
TI Relationship of sipuleucel-T with time to first use of opioid analgesics
(TFOA) in patients (pts) with asymptomatic or minimally symptomatic
metastatic castration-resistant prostate cancer (mCRPC) on the IMPACT
trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
Univ Washington, Sch Med, Seattle, WA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Dendreon Corp, Seattle, WA USA.
Yale Univ, Smilow Canc Hosp, New Haven, CT USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 74
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600075
ER
PT J
AU Smith, MR
Halabi, S
Ryan, CJ
Stadler, WM
Hussain, A
Vogelzang, NJ
Hauke, RJ
Sanford, BL
Small, EJ
AF Smith, Matthew Raymond
Halabi, Susan
Ryan, Charles J.
Stadler, Walter Michael
Hussain, Arif
Vogelzang, Nicholas J.
Hauke, Ralph J.
Sanford, Ben L.
Small, Eric Jay
TI Efficacy and safety of zoledronic acid in men with castration-sensitive
prostate cancer and bone metastases: Results of CALGB 90202 (Alliance)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Duke Univ, Med Ctr, Alliance Stat & Data Ctr, Durham, NC USA.
USCF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
Univ Chicago, Chicago, IL 60637 USA.
Univ Maryland, Baltimore, MD 21201 USA.
Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
Univ Nebraska Med Ctr, Omaha, NE USA.
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 27
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600030
ER
PT J
AU Smith, MR
Antonarakis, ES
Ryan, CJ
Berry, WR
Shore, N
Liu, G
Alumkal, JJ
Higano, CS
Maneval, EC
Rathkopf, DE
AF Smith, Matthew Raymond
Antonarakis, Emmanuel S.
Ryan, Charles J.
Berry, William R.
Shore, Neal
Liu, Glenn
Alumkal, Joshi J.
Higano, Celestia S.
Maneval, Edna Chow
Rathkopf, Dana E.
TI ARN-509 in men with high-risk nonmetastatic castration-resistant
prostate cancer (CRPC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
USCF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
US Oncol, Canc Ctr North Carolina, Raleigh, NC USA.
Grand Strand Urol, Myrtle Beach, SC USA.
Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Univ Washington, Sch Med, Seattle, WA USA.
Aragon Pharmaceut, San Diego, CA USA.
Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA.
RI Antonarakis, Emmanuel/E-4550-2011
NR 0
TC 6
Z9 6
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 7
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600011
ER
PT J
AU Strock, J
Gray, KP
Nakabayashi, M
Evan, C
O'Donnell, E
Pomerantz, M
Kantoff, PW
Sweeney, C
AF Strock, Jessica
Gray, Kathryn P.
Nakabayashi, Mari
Evan, Carolyn
O'Donnell, Elizabeth
Pomerantz, Mark
Kantoff, Philip W.
Sweeney, Christopher
TI Characterization of patients who present with de novo metastatic
prostate cancer: Single-institution database analysis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 [Strock, Jessica; Gray, Kathryn P.; Nakabayashi, Mari; Evan, Carolyn; O'Donnell, Elizabeth; Pomerantz, Mark; Kantoff, Philip W.; Sweeney, Christopher] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 33
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600035
ER
PT J
AU Tombal, B
Borre, M
Rathenborg, P
Werbrouck, P
Heidenreich, A
Iversen, P
Baskin-Bey, ES
Perabo, F
Phung, D
Smith, MR
AF Tombal, Bertrand
Borre, Michael
Rathenborg, Per
Werbrouck, Patrick
Heidenreich, Axel
Iversen, Peter
Baskin-Bey, Edwina S.
Perabo, Frank
Phung, De
Smith, Matthew Raymond
TI Enzalutamide monotherapy: Phase II study results in patients with
hormone-naive prostate cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium.
Arhus Univ Hosp, Dept Urol, Skejby, Denmark.
Herlev Hosp, DK-2730 Herlev, Denmark.
AZ Groeninge Kortrijk, Kortrijk, Belgium.
Klin & Poliklin Urol, North Rhine Westphalia, Germany.
Univ Copenhagen, Rigshosp, DK-2100 Copenhagen, Denmark.
Astellas Pharma Europe Ltd, Staines, England.
Astellas Pharma Inc, Leiderdorp, Netherlands.
Astellas Pharma Europe BV, Leiderdorp, Netherlands.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 18
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600021
ER
PT J
AU Tsao, CK
Gray, KP
Nakabayashi, M
Evan, C
Galsky, MD
Kantoff, PW
Oh, WK
Pomerantz, M
AF Tsao, Che-Kai
Gray, Kathryn P.
Nakabayashi, Mari
Evan, Caroline
Galsky, Matt D.
Kantoff, Philip W.
Oh, William K.
Pomerantz, Mark
TI Association of Gleason 9-10 prostate cancer with worse outcomes compared
to Gleason 8 disease
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Mt Sinai Sch Med, Div Hematol & Med Oncol, Tisch Canc Inst, New York, NY USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Lank Ctr Genitourinary Oncol,Dana Farber Canc Ins, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 157
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600158
ER
PT J
AU Xu, RN
Horick, N
McGovern, FJ
Dahl, DM
Feldman, AS
Blute, ML
Olumi, AF
Michaelson, MD
AF Xu, Rena
Horick, Nora
McGovern, Francis J.
Dahl, Douglas M.
Feldman, Adam S.
Blute, Michael L.
Olumi, Aria F.
Michaelson, M. Dror
TI Prognostic significance of indeterminate lung nodules in renal cell
carcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Genitourinary Cancers Symposium of the Conquer-Cancer-Foundation of
American-Society-of-Clinical-Oncology (ASCO)
CY FEB 14-16, 2013
CL Orlando, FL
SP Amer Soc Clin Oncol, Conquer Canc Fdn
C1 Harvard Univ, Sch Med, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD FEB 20
PY 2013
VL 31
IS 6
SU S
MA 377
PG 1
WC Oncology
SC Oncology
GA AE0TR
UT WOS:000333679600374
ER
PT J
AU Sigova, AA
Mullen, AC
Molinie, B
Gupta, S
Orlando, DA
Guenther, MG
Almada, AE
Lin, C
Sharp, PA
Giallourakis, CC
Young, RA
AF Sigova, Alla A.
Mullen, Alan C.
Molinie, Benoit
Gupta, Sumeet
Orlando, David A.
Guenther, Matthew G.
Almada, Albert E.
Lin, Charles
Sharp, Phillip A.
Giallourakis, Cosmas C.
Young, Richard A.
TI Divergent transcription of long noncoding RNA/mRNA gene pairs in
embryonic stem cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE development; expression
ID ACTIVE GENES; REGULATORY CIRCUITRY; HUMAN PROMOTERS; ANTISENSE RNA;
HISTONE H3; REVEALS; MOUSE; DIFFERENTIATION; EXPRESSION; GENOME
AB Many long noncoding RNA (lncRNA) species have been identified in mammalian cells, but the genomic origin and regulation of these molecules in individual cell types is poorly understood. We have generated catalogs of lncRNA species expressed in human and murine embryonic stem cells and mapped their genomic origin. A surprisingly large fraction of these transcripts (>60%) originate from divergent transcription at promoters of active protein-coding genes. The divergently transcribed lncRNA/mRNA gene pairs exhibit coordinated changes in transcription when embryonic stem cells are differentiated into endoderm. Our results reveal that transcription of most lncRNA genes is coordinated with transcription of protein-coding genes.
C1 [Sigova, Alla A.; Mullen, Alan C.; Gupta, Sumeet; Orlando, David A.; Guenther, Matthew G.; Lin, Charles; Young, Richard A.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Mullen, Alan C.; Molinie, Benoit; Giallourakis, Cosmas C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA.
[Almada, Albert E.; Lin, Charles; Sharp, Phillip A.; Young, Richard A.] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Almada, Albert E.; Sharp, Phillip A.] David H Koch Inst Integrat Canc Res, Cambridge, MA 02140 USA.
[Giallourakis, Cosmas C.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
RP Giallourakis, CC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA.
EM CGIALLOURAKIS@partners.org; young@wi.mit.edu
RI Young, Richard/F-6495-2012
OI Young, Richard/0000-0001-8855-8647
FU National Institutes of Health [HG002668, GM34277, DK090122]; American
Gastroenterological Association; Damon Runyon Cancer Research
Foundation; National Cancer Institute Cancer Center Support (Core) Grant
[P30-CA14051]
FX We thank members of the R.A.Y. laboratory and George Bell (BaRC) for
helpful discussions; Lee Lawton for providing murine H3K4me3 ChIP-seq
data; and the Whitehead Institute Genome Technology Core for help with
high-throughput sequencing. This work was supported by National
Institutes of Health Grants HG002668 (to R.A.Y.), GM34277 (to P. A. S.),
and DK090122 (to A. C. M.); the American Gastroenterological Association
(A. C. M.); the Damon Runyon Cancer Research Foundation (A. A. S.); and
in part by National Cancer Institute Cancer Center Support (Core) Grant
P30-CA14051.
NR 49
TC 149
Z9 152
U1 0
U2 41
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 19
PY 2013
VL 110
IS 8
BP 2876
EP 2881
DI 10.1073/pnas.1221904110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 103YC
UT WOS:000315954400059
PM 23382218
ER
PT J
AU Gostissa, M
Bianco, JM
Malkin, DJ
Kutok, JL
Rodig, SJ
Morse, HC
Bassing, CH
Alt, FW
AF Gostissa, Monica
Bianco, Julia M.
Malkin, Daniel J.
Kutok, Jeffery L.
Rodig, Scott J.
Morse, Herbert C., III
Bassing, Craig H.
Alt, Frederick W.
TI Conditional inactivation of p53 in mature B cells promotes generation of
nongerminal center-derived B-cell lymphomas
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID MARGINAL ZONE LYMPHOMA; CHROMOSOMAL TRANSLOCATIONS; SOMATIC
HYPERMUTATION; ONCOGENIC TRANSLOCATIONS; GENOMIC INSTABILITY;
P53-DEFICIENT MICE; BREAST-CANCER; HISTONE H2AX; MOUSE MODEL; DNA BREAKS
AB The p53 tumor suppressor exerts a central role in protecting cells from oncogenic transformation. Accordingly, the p53 gene is mutated in a large number of human cancers. In mice, germ-line inactivation of p53 confers strong predisposition to development of different types of malignancies, but the early onset of thymic lymphomas in the majority of the animals prevents detailed studies of tumorigenesis in other tissues. Here, we use the Cre/Lox approach to inactivate p53 in mature B cells in mice (referred to as "CP" B cells) and find that such p53 inactivation results in the routine development of IgM-positive CP peripheral B-cell lymphomas. The CP lymphomas generally appear to arise, even in mice subjected to immunization protocols to activate germinal center reaction, from naive B cells that had not undergone immunoglobulin (Ig) heavy chain gene class switching or somatic hypermutation. In contrast to thymic lymphomas that arise in p53-deficient mice, which generally lack clonal translocations, nearly all analyzed CP B-cell tumors carried clonal translocations. However, in contrast to spontaneous translocations in other mouse B-cell tumor models, CP B-cell tumor translocations were not recurrent and did not involve Ig loci. Therefore, CP tumors might provide models for human lymphomas lacking Ig translocations, such as splenic marginal zone B-cell lymphoma or Waldenstrom macroglobulinemia. Our studies indicate that deletion of p53 is sufficient to trigger transformation of mature B cells and support the notion that p53 deficiency may allow accumulation of oncogenic translocations in B cells.
C1 [Gostissa, Monica; Bianco, Julia M.; Malkin, Daniel J.; Alt, Frederick W.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston Childrens Hosp, Boston, MA 02115 USA.
[Gostissa, Monica; Bianco, Julia M.; Malkin, Daniel J.; Alt, Frederick W.] Harvard Univ, Sch Med, Program Cellular & Mol Med, Boston Childrens Hosp, Boston, MA 02115 USA.
[Gostissa, Monica; Bianco, Julia M.; Malkin, Daniel J.; Alt, Frederick W.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Kutok, Jeffery L.; Rodig, Scott J.] Harvard Univ, Sch Med, Dept Pathol, Brigham & Womens Hosp, Boston, MA 02115 USA.
[Morse, Herbert C., III] NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA.
[Bassing, Craig H.] Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
RP Alt, FW (reprint author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston Childrens Hosp, Boston, MA 02115 USA.
EM alt@enders.tch.harvard.edu
OI Morse, Herbert/0000-0002-9331-3705
FU National Institutes of Health [5P01CA92625, CA098285]; Leukemia and
Lymphoma Society of America (LLS) Specialized Center of Research grant;
Intramural Research Program of the National Institutes of Health,
National Institute of Allergy and Infectious Diseases
FX We thank Roberto Chiarle for helpful suggestions. This work was
supported by National Institutes of Health Grants 5P01CA92625 and
CA098285 and a Leukemia and Lymphoma Society of America (LLS)
Specialized Center of Research grant (to F. W. A.). This work was
supported in part by the Intramural Research Program of the National
Institutes of Health, National Institute of Allergy and Infectious
Diseases (to H. C. M.). M. G. was an LLS senior fellow. C. H. B. is an
LLS Scholar. F. W. A. is an investigator of the Howard Hughes Medical
Institute.
NR 48
TC 11
Z9 11
U1 0
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 19
PY 2013
VL 110
IS 8
BP 2934
EP 2939
DI 10.1073/pnas.1222570110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 103YC
UT WOS:000315954400069
PM 23382223
ER
PT J
AU Khan, S
Gramfort, A
Shetty, NR
Kitzbichler, MG
Ganesan, S
Moran, JM
Lee, SM
Gabrieli, JDE
Tager-Flusberg, HB
Joseph, RM
Herbert, MR
Hamalainen, MS
Kenet, T
AF Khan, Sheraz
Gramfort, Alexandre
Shetty, Nandita R.
Kitzbichler, Manfred G.
Ganesan, Santosh
Moran, Joseph M.
Lee, Su Mei
Gabrieli, John D. E.
Tager-Flusberg, Helen B.
Joseph, Robert M.
Herbert, Martha R.
Haemaelaeinen, Matti S.
Kenet, Tal
TI Local and long-range functional connectivity is reduced in concert in
autism spectrum disorders
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE coherence; parvalbumin
ID HIPPOCAMPAL THETA RHYTHM; SPACE SEPARATION METHOD; GAMMA-OSCILLATIONS;
BRAIN CONNECTIVITY; NEURAL SYNCHRONIZATION; MEG; FREQUENCY; CHILDREN;
EEG; INDIVIDUALS
AB Long-range cortical functional connectivity is often reduced in autism spectrum disorders (ASD), but the nature of local cortical functional connectivity in ASD has remained elusive. We used magnetoencephalography to measure task-related local functional connectivity, as manifested by coupling between the phase of alpha oscillations and the amplitude of gamma oscillations, in the fusiform face area (FFA) of individuals diagnosed with ASD and typically developing individuals while they viewed neutral faces, emotional faces, and houses. We also measured task-related long-range functional connectivity between the FFA and the rest of the cortex during the same paradigm. In agreement with earlier studies, long-range functional connectivity between the FFA and three distant cortical regions was reduced in the ASD group. However, contrary to the prevailing hypothesis in the field, we found that local functional connectivity within the FFA was also reduced in individuals with ASD when viewing faces. Furthermore, the strength of long-range functional connectivity was directly correlated to the strength of local functional connectivity in both groups; thus, long-range and local connectivity were reduced proportionally in the ASD group. Finally, the magnitude of local functional connectivity correlated with ASD severity, and statistical classification using local and long-range functional connectivity data identified ASD diagnosis with 90% accuracy. These results suggest that failure to entrain neuronal assemblies fully both within and across cortical regions may be characteristic of ASD.
C1 [Khan, Sheraz; Shetty, Nandita R.; Kitzbichler, Manfred G.; Ganesan, Santosh; Herbert, Martha R.; Kenet, Tal] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02129 USA.
[Gramfort, Alexandre; Haemaelaeinen, Matti S.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02129 USA.
[Khan, Sheraz; Shetty, Nandita R.; Kitzbichler, Manfred G.; Ganesan, Santosh; Herbert, Martha R.; Haemaelaeinen, Matti S.; Kenet, Tal] Harvard Univ, MIT, AA Martinos Ctr Biomed Imaging, Massachusetts Gen Hosp, Boston, MA 02129 USA.
[Moran, Joseph M.; Lee, Su Mei; Gabrieli, John D. E.] MIT, McGovern Inst, Cambridge, MA 02139 USA.
[Moran, Joseph M.; Lee, Su Mei; Gabrieli, John D. E.; Haemaelaeinen, Matti S.] Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Tager-Flusberg, Helen B.] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
[Joseph, Robert M.] Boston Univ, Sch Med, Boston, MA 02118 USA.
RP Kenet, T (reprint author), Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02129 USA.
EM tal@nmr.mgh.harvard.edu
RI Hamalainen, Matti/C-8507-2013;
OI Khan, Sheraz/0000-0002-6792-3577
FU Autism Consortium; Nancy Lurie Marks Family Foundation; Autism Speaks;
National Center for Research Resources [P41RR14075]; National Institute
for Biomedical Imaging and Bioengineering [5R01EB009048]; National
Science Foundation from the Cognitive Rhythms Collaborative: A Discovery
Network [1042134]; John D. and Catherine T. MacArthur Foundation
Research Network on Early Experience and Brain Development
FX We thank Charles A. Nelson for his help and contributions to the
initiation of the project; Elizabeth Redcay, Jasmin Cloutier, and Dan
O'Young for their help in collecting structural MRI scans; and Lee
Mavros for her help with recruitment and assessment of participants.
This work was supported by the Autism Consortium (J.D.E.G., R.M.J.,
H.B.T.-F., and T. K.), the Nancy Lurie Marks Family Foundation (T. K.),
Autism Speaks (T. K.), Grant P41RR14075 from the National Center for
Research Resources (to M. S. H.), Grant 5R01EB009048 from the National
Institute for Biomedical Imaging and Bioengineering (to M. S. H.), and
National Science Foundation Grant 1042134 from the Cognitive Rhythms
Collaborative: A Discovery Network (to M. S. H.). Development of the
MacBrain Face Stimulus Set was overseen by Nim Tottenham and supported
by the John D. and Catherine T. MacArthur Foundation Research Network on
Early Experience and Brain Development. Please contact Nim Tottenham at
tott0006@tc.umn.edu for more information concerning the stimulus set.
NR 62
TC 75
Z9 76
U1 2
U2 53
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 19
PY 2013
VL 110
IS 8
BP 3107
EP 3112
DI 10.1073/pnas.1214533110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 103YC
UT WOS:000315954400098
PM 23319621
ER
PT J
AU Peng, J
Li, QL
Wigglesworth, K
Rangarajan, A
Kattamuri, C
Peterson, RT
Eppig, JJ
Thompson, TB
Matzuk, MM
AF Peng, Jia
Li, Qinglei
Wigglesworth, Karen
Rangarajan, Adithya
Kattamuri, Chandramohan
Peterson, Randall T.
Eppig, John J.
Thompson, Thomas B.
Matzuk, Martin M.
TI Growth differentiation factor 9:bone morphogenetic protein 15
heterodimers are potent regulators of ovarian functions
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE female reproduction; in vitro maturation; TGF-beta signaling
ID OOCYTE DEVELOPMENTAL COMPETENCE; INCREASED OVULATION RATE;
GRANULOSA-CELLS; GENE-EXPRESSION; IN-VITRO; SYNERGISTIC ROLES; CUMULUS
EXPANSION; ACTIVIN RECEPTOR; MAMMALIAN OVARY; BMP15
AB The TGF-beta superfamily is the largest family of secreted proteins in mammals, and members of the TGF-beta family are involved in most developmental and physiological processes. Growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15), oocyte-secreted paralogs of the TGF-beta superfamily, have been shown genetically to control ovarian physiology. Although previous studies found that GDF9 and BMP15 homodimers can modulate ovarian pathways in vitro, the functional species-specific significance of GDF9:BMP15 heterodimers remained unresolved. Therefore, we engineered and produced purified recombinant mouse and human GDF9 and BMP15 homodimers and GDF9:BMP15 heterodimers to compare their molecular characteristics and physiological functions. In mouse granulosa cell and cumulus cell expansion assays, mouse GDF9 and human BMP15 homodimers can up-regulate cumulus expansion-related genes (Ptx3, Has2, and Ptgs2) and promote cumulus expansion in vitro, whereas mouse BMP15 and human GDF9 homodimers are essentially inactive. However, we discovered that mouse GDF9:BMP15 heterodimer is similar to 10- to 30-fold more biopotent than mouse GDF9 homodimer, and human GDF9:BMP15 heterodimer is similar to 1,000- to 3,000-fold more bioactive than human BMP15 homodimer. We also demonstrate that the heterodimers require the kinase activities of ALK4/5/7 and BMPR2 to activate SMAD2/3 but unexpectedly need ALK6 as a coreceptor in the signaling complex in granulosa cells. Our findings that GDF9:BMP15 heterodimers are the most bioactive ligands in mice and humans compared with homodimers explain many puzzling genetic and physiological data generated during the last two decades and have important implications for improving female fertility in mammals.
C1 [Peng, Jia; Matzuk, Martin M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
[Peng, Jia; Matzuk, Martin M.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
[Rangarajan, Adithya; Matzuk, Martin M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
[Matzuk, Martin M.] Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA.
[Matzuk, Martin M.] Baylor Coll Med, Ctr Drug Discovery, Houston, TX 77030 USA.
[Matzuk, Martin M.] Baylor Coll Med, Ctr Reprod Med, Houston, TX 77030 USA.
[Li, Qinglei] Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX 77843 USA.
[Wigglesworth, Karen; Eppig, John J.] Jackson Lab, Bar Harbor, ME 04609 USA.
[Kattamuri, Chandramohan; Thompson, Thomas B.] Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45221 USA.
[Peterson, Randall T.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Peterson, Randall T.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Matzuk, MM (reprint author), Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
EM mmatzuk@bcm.edu
FU Eunice Kennedy Shriver National Institute of Child Health and Human
Development [R01-HD33438, R01-HD23839]
FX We thank Julio Agno and Lang Ma for technical support, Dr. Stephanie
Pangas for the COV434 cells and excellent discussions, Dr. Karen Lyons
for the gift of the Alk6-null mice, Shirley Baker for help with
manuscript formatting, and members of the M. M. M. and Pangas
laboratories for critical comments. These studies were supported by the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development through Grants R01-HD33438 (to M. M. M. and T. B. T.) and
R01-HD23839 (to J.J.E.).
NR 50
TC 69
Z9 75
U1 4
U2 17
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 19
PY 2013
VL 110
IS 8
BP E776
EP E785
DI 10.1073/pnas.1218020110
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 103YC
UT WOS:000315954400020
PM 23382188
ER
PT J
AU Brinkhaus, B
Ortiz, M
Witt, CM
Roll, S
Linde, K
Pfab, F
Niggemann, B
Hummelsberger, J
Treszl, A
Ring, J
Zuberbier, T
Wegscheider, K
Willich, SN
AF Brinkhaus, Benno
Ortiz, Miriam
Witt, Claudia M.
Roll, Stephanie
Linde, Klaus
Pfab, Florian
Niggemann, Bodo
Hummelsberger, Josef
Treszl, Andras
Ring, Johannes
Zuberbier, Torsten
Wegscheider, Karl
Willich, Stefan N.
TI Acupuncture in Patients With Seasonal Allergic Rhinitis A Randomized
Trial
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID CONTROLLED CLINICAL-TRIAL; EXPERIMENTALLY INDUCED ITCH; I
HYPERSENSITIVITY ITCH; QUALITY-OF-LIFE; CROSSOVER TRIAL; ATOPIC ECZEMA;
ALTERNATIVE MEDICINE; RHINOCONJUNCTIVITIS; COMPLEMENTARY; QUESTIONNAIRE
AB Background: Acupuncture is frequently used to treat seasonal allergic rhinitis (SAR) despite limited scientific evidence.
Objective: To evaluate the effects of acupuncture in patients with SAR.
Design: Randomized, controlled multicenter trial. (ClinicalTrials.gov:NCT00610584)
Setting: 46 specialized physicians in 6 hospital clinics and 32 private outpatient clinics.
Patients: 422 persons with SAR and IgE sensitization to birch and grass pollen.
Intervention: Acupuncture plus rescue medication (RM) (cetirizine) (n = 212), sham acupuncture plus RM (n = 102), or RM alone (n = 108). Twelve treatments were provided over 8 weeks in the first year.
Measurements: Changes in the Rhinitis Quality of Life Questionnaire (RQLQ) overall score and the RM score (RMS) from baseline to weeks 7 and 8 and week 16 in the first year and week 8 in the second year after randomization, with predefined noninferiority margins of -0.5 point (RQLQ) and -1.5 points (RMS).
Results: Compared with sham acupuncture and with RM, acupuncture was associated with improvement in RQLQ score (sham vs. acupuncture mean difference, 0.5 point [97.5% CI, 0.2 to 0.8 point; P < 0.001]; RM vs. acupuncture mean difference, 0.7 point [97.5% CI, 0.4 to 1.0 point; P < 0.001]) and RMS (sham vs. acupuncture mean difference, 1.1 points [97.5% CI, 0.4 to 1.9 points; P < 0.001]; RM vs. acupuncture mean difference, 1.5 points [97.5% CI, 0.8 to 2.2 points; P < 0.001]). There were no differences after 16 weeks in the first year. After the 8-week follow-up phase in the second year, small improvements favoring real acupuncture over the sham procedure were noted (RQLQ mean difference, 0.3 point [95% CI, 0.03 to 0.6 point; P = 0.032]; RMS mean difference, 1.0 point [95% CI, 0.2 to 1.9 points; P = 0.018]).
Limitation: The study was not powered to detect rare adverse events, and the RQLQ and RMS values were low at baseline.
Conclusion: Acupuncture led to statistically significant improvements in disease-specific quality of life and antihistamine use measures after 8 weeks of treatment compared with sham acupuncture and with RM alone, but the improvements may not be clinically significant.
C1 [Brinkhaus, Benno; Ortiz, Miriam; Witt, Claudia M.; Roll, Stephanie; Zuberbier, Torsten; Willich, Stefan N.] Charite Univ Med Ctr, D-10098 Berlin, Germany.
[Niggemann, Bodo] German Red Cross Hosp Westend, D-14050 Berlin, Germany.
Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
Tech Univ Munich, Helmholtz Ctr Munich, D-80290 Munich, Germany.
Int Soc Chinese Med, Munich, Germany.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
Univ Med Ctr Eppendorf, Hamburg, Germany.
[Linde, Klaus] Tech Univ Munich, Klinikum Rechts Isar, Inst Gen Practice, D-81667 Munich, Germany.
[Pfab, Florian; Ring, Johannes] Christine Kuhne Ctr Allergy Res & Educ, D-80797 Munich, Germany.
[Treszl, Andras; Wegscheider, Karl] Univ Med Ctr Eppendorf, Dept Med Biometry & Epidemiol, D-20246 Hamburg, Germany.
RP Brinkhaus, B (reprint author), Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, D-10098 Berlin, Germany.
EM stephanie.roll@charite.de
FU German Research Foundation [WI 957/16-1]
FX By grant WI 957/16-1 from the German Research Foundation.
NR 46
TC 36
Z9 40
U1 2
U2 28
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD FEB 19
PY 2013
VL 158
IS 4
BP 225
EP 234
DI 10.7326/0003-4819-158-4-201302190-00002
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 098WR
UT WOS:000315580300013
PM 23420231
ER
PT J
AU Duggal, P
Thio, CL
Wojcik, GL
Goedert, JJ
Mangia, A
Latanich, R
Kim, AY
Lauer, GM
Chung, RT
Peters, MG
Kirk, GD
Mehta, SH
Cox, AL
Khakoo, SI
Alric, L
Cramp, ME
Donfield, SM
Edlin, BR
Tobler, LH
Busch, MP
Alexander, G
Rosen, HR
Gao, XJ
Abdel-Hamid, M
Apps, R
Carrington, M
Thomas, DL
AF Duggal, Priya
Thio, Chloe L.
Wojcik, Genevieve L.
Goedert, James J.
Mangia, Alessandra
Latanich, Rachel
Kim, Arthur Y.
Lauer, Georg M.
Chung, Raymond T.
Peters, Marion G.
Kirk, Gregory D.
Mehta, Shruti H.
Cox, Andrea L.
Khakoo, Salim I.
Alric, Laurent
Cramp, Matthew E.
Donfield, Sharyne M.
Edlin, Brian R.
Tobler, Leslie H.
Busch, Michael P.
Alexander, Graeme
Rosen, Hugo R.
Gao, Xiaojiang
Abdel-Hamid, Mohamed
Apps, Richard
Carrington, Mary
Thomas, David L.
TI Genome-Wide Association Study of Spontaneous Resolution of Hepatitis C
Virus Infection: Data From Multiple Cohorts
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID SPONTANEOUS CLEARANCE; GENETIC-VARIATION; HCV INFECTION; VIRAL LOAD;
HLA; VIREMIA; GENOTYPE; PERSISTENCE; POPULATION; VARIANTS
AB Background: Hepatitis C virus (HCV) infections occur worldwide and either spontaneously resolve or persist and markedly increase the person's lifetime risk for cirrhosis and hepatocellular carcinoma. Although HCV persistence occurs more often in persons of African ancestry and persons with genetic variants near interleukin-28B (IL-28B), the genetic basis is not well-understood.
Objective: To evaluate the host genetic basis for spontaneous resolution of HCV infection.
Design: 2-stage, genome-wide association study.
Setting: 13 international multicenter study sites.
Patients: 919 persons with serum HCV antibodies but no HCV RNA (spontaneous resolution) and 1482 persons with serum HCV antibodies and HCV RNA (persistence).
Measurements: Frequencies of 792 721 single nucleotide polymorphisms (SNPs).
Results: Differences in allele frequencies between persons with spontaneous resolution and persistence were identified on chromosomes 19q13.13 and 6p21.32. On chromosome 19, allele frequency differences localized near IL-28B and included rs12979860 (overall per-allele OR, 0.45; P = 2.17 x 10(-30)) and 10 additional SNPs spanning 55 000 base pairs. On chromosome 6, allele frequency differences localized near genes for HLA class II and included rs4273729 (overall per-allele OR, 0.59; P = 1.71 x 10(-16)) near DQB1*03:01 and an additional 116 SNPs spanning 1 090 000 base pairs. The associations in chromosomes 19 and 6 were independent and additive and explain an estimated 14.9% (95% CI, 8.5% to 22.6%) and 15.8% (CI, 4.4% to 31.0%) of the variation in HCV resolution in persons of European and African ancestry, respectively. Replication of the chromosome 6 SNP, rs4272729, in an additional 745 persons confirmed the findings (P = 0.015).
Limitation: Epigenetic effects were not studied.
Conclusion: IL-28B and HLA class II are independently associated with spontaneous resolution of HCV infection, and SNPs marking IL-28B and DQB1*03:01 may explain approximately 15% of spontaneous resolution of HCV infection.
C1 Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.
NCI, Rockville, MD 20852 USA.
IRCCS Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
Ragon Inst Harvard, Boston, MA USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Blood Syst Res Inst, Viral Reference Lab, San Francisco, CA 94118 USA.
Blood Syst Res Inst, Repository Core, San Francisco, CA 94118 USA.
Univ Southampton, Southampton, Hants, England.
Southampton Gen Hosp, Southampton SO9 4XY, Hants, England.
Univ Toulouse 3, F-31062 Toulouse, France.
Plymouth Hosp NHS Trust, SW Liver Unit, Plymouth, Devon, England.
Rho, Chapel Hill, NC USA.
State Univ New York Downstate Coll Med, Brooklyn, NY USA.
Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England.
Addenbrookes Hosp, Cambridge, England.
Univ Colorado, Denver, CO 80045 USA.
Menia Univ, Al Minya, Egypt.
Natl Hepatol & Trop Dis Res Inst, Viral Hepatitis Res Lab, Cairo, Egypt.
Frederick Natl Lab Canc Res, Canc & Inflammat Program, Expt Immunol Lab, Sci Applicat Int Corp Frederick, Frederick, MD USA.
RP Thomas, DL (reprint author), Johns Hopkins Sch Med, 1830 E Monument St,Suite 437, Baltimore, MD 21287 USA.
EM pduggal@jhsph.edu; dthomas@jhmi.edu
OI Edlin, Brian/0000-0001-8172-8797; Khakoo, Salim/0000-0002-4057-9091
FU Office of AIDS Research, National Institutes of Health; Frederick
National Laboratory for Cancer Research; Office of AIDS Research through
the Center for Inherited Diseases at Johns Hopkins University; National
Institute on Drug Abuse [R01013324, DA033541, DA12568, DA04334];
National Institute of Allergy and Infectious Diseases [U19AI088791,
AI082630]; Frederick National Laboratory for Cancer Research
[HHSN261200800001E]; National Institutes of Health; National Institute
of Allergy and Infectious Diseases; National Cancer Institute
[UO1-AI-35042, UL1-RR025005, UO1-AI-35043, UO1-AI-35039, UO1-AI-35040,
UO1-AI-35041]; National Institute of Allery and Infectious Diseases
[UO1-AI35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI34993,
UO1-AI-42590]; National Institute of Child Health and Human Development
[UO1-HD-32632]; [R01HL076902]; [R01-DA16159]; [R01-DA21550];
[UL1-RR024996]
FX Office of AIDS Research, National Institutes of Health, and Frederick
National Laboratory for Cancer Research.; This project was funded in
whole or in part by the Office of AIDS Research through the Center for
Inherited Diseases at Johns Hopkins University, the National Institute
on Drug Abuse (R01013324, DA033541, DA12568, and DA04334), the National
Institute of Allergy and Infectious Diseases (U19AI088791 and AI082630),
and the Frederick National Laboratory for Cancer Research (contract
HHSN261200800001E). This research was supported in part by the
Intramural Research Programs of the National Institutes of Health and
the Frederick National Laboratory for Cancer Research. The MACS is
funded by the National Institute of Allergy and Infectious Diseases,
with additional supplemental funding from the National Cancer Institute
(UO1-AI-35042, UL1-RR025005, UO1-AI-35043, UO1-AI-35039, UO1-AI-35040,
and UO1-AI-35041). The WIHS is funded by the National Institute of
Allery and Infectious Diseases (UO1-AI35004, UO1-AI-31834, UO1-AI-34994,
UO1-AI-34989, UO1-AI34993, and UO1-AI-42590) and by the National
Institute of Child Health and Human Development (UO1-HD-32632). The
REVELL cohort was funded by R01HL076902. Swann cohort was funded by
R01-DA16159, R01-DA21550, and UL1-RR024996.
NR 38
TC 82
Z9 82
U1 0
U2 8
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD FEB 19
PY 2013
VL 158
IS 4
BP 235
EP 245
DI 10.7326/0003-4819-158-4-201302190-00003
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 098WR
UT WOS:000315580300014
PM 23420232
ER
PT J
AU Jensen, MO
Hagege, AA
Otsuji, Y
Levine, RA
AF Jensen, Morten O.
Hagege, Albert A.
Otsuji, Yutaka
Levine, Robert A.
CA Leducq Transatlantic MITRAL
TI The Unsaddled Annulus Biomechanical Culprit in Mitral Valve Prolapse?
SO CIRCULATION
LA English
DT Editorial Material
DE Editorials; biomechanics; mitral valve; mitral valve prolapse; mitral
valve insufficiency; mitral valve annulus
ID 3-DIMENSIONAL ECHOCARDIOGRAPHIC-ASSESSMENT; ANNULOPLASTY RINGS; SADDLE
SHAPE; IN-VITRO; REGURGITATION; LEAFLET; REPAIR; RECONSTRUCTION;
EXPERIENCE; DYNAMICS
C1 [Jensen, Morten O.] Aarhus Univ Hosp, Dept Cardiothorac & Vasc Surg, DK-8000 Aarhus, Denmark.
[Hagege, Albert A.] Univ Paris 05, Fac Med, Paris, France.
[Hagege, Albert A.] Paris Cardiovasc Res Ctr, INSERM, U633, Paris, France.
[Hagege, Albert A.] Hop Europeen Georges Pompidou, AP HP, Dept Cardiol, Paris, France.
[Otsuji, Yutaka] Univ Occupat & Environm Hlth, Dept Internal Med 2, Kitakyushu, Fukuoka 807, Japan.
[Levine, Robert A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac Ultrasound Lab, Boston, MA USA.
RP Levine, RA (reprint author), Massachusetts Gen Hosp, Cardiac Ultrasound Lab, 55 Fruit St,Yawkey 5068, Boston, MA 02114 USA.
EM rlevine@partners.org
FU NHLBI NIH HHS [HL109506, K24 HL067434, K24 HL67434, R01 HL072265, R01
HL109506, R01 HL72265]
NR 35
TC 13
Z9 13
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD FEB 19
PY 2013
VL 127
IS 7
BP 766
EP 768
DI 10.1161/CIRCULATIONAHA.112.000628
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 094YS
UT WOS:000315302200013
PM 23429895
ER
PT J
AU Johnson, AD
Hwang, SJ
Voorman, A
Morrison, A
Peloso, GM
Hsu, YH
Thanassoulis, G
Newton-Cheh, C
Rogers, IS
Hoffmann, U
Freedman, JE
Fox, CS
Psaty, BM
Boerwinkle, E
Cupples, LA
O'Donnell, CJ
AF Johnson, Andrew D.
Hwang, Shih-Jen
Voorman, Arend
Morrison, Alanna
Peloso, Gina M.
Hsu, Yi-Hsiang
Thanassoulis, George
Newton-Cheh, Christopher
Rogers, Ian S.
Hoffmann, Udo
Freedman, Jane E.
Fox, Caroline S.
Psaty, Bruce M.
Boerwinkle, Eric
Cupples, L. Adrienne
O'Donnell, Christopher J.
TI Resequencing and Clinical Associations of the 9p21.3 Region A
Comprehensive Investigation in the Framingham Heart Study
SO CIRCULATION
LA English
DT Article
DE atherosclerosis; calcium; genetics; myocardial infarction; risk factors
ID GENOME-WIDE ASSOCIATION; CORONARY-ARTERY-DISEASE; SINGLE NUCLEOTIDE
POLYMORPHISMS; ABDOMINAL AORTIC-ANEURYSM; CHROMOSOME 9P21;
MYOCARDIAL-INFARCTION; COMMON SNPS; VARIANTS; LOCUS; ANRIL
AB Background-9p21.3 is among the most strongly replicated regions for cardiovascular disease. There are few reports of sequencing the associated 9p21.3 interval. We set out to sequence the 9p21.3 region followed by a comprehensive study of genetic associations with clinical and subclinical cardiovascular disease and its risk factors, as well as with copy number variation and gene expression, in the Framingham Heart Study (FHS).
Methods and Results-We sequenced 281 individuals (94 with myocardial infarction, 94 with high coronary artery calcium levels, and 93 control subjects free of elevated coronary artery calcium or myocardial infarction), followed by genotyping and association in >7000 additional FHS individuals. We assessed genetic associations with clinical and subclinical cardiovascular disease, risk factor phenotypes, and gene expression levels of the protein-coding genes CDKN2A and CDKN2B and the noncoding gene ANRIL in freshly harvested leukocytes and platelets. Within this large sample, we found strong associations of 9p21.3 variants with increased risk for myocardial infarction, higher coronary artery calcium levels, and larger abdominal aorta diameters and no evidence for association with traditional cardiovascular disease risk factors. No common protein-coding variation, variants in splice donor or acceptor sites, or copy number variation events were observed. By contrast, strong associations were observed between genetic variants and gene expression, particularly for a short isoform of ANRIL and for CDKN2B.
Conclusions-Our thorough genomic characterization of 9p21.3 suggests common variants likely account for observed disease associations and provides further support for the hypothesis that complex regulatory variation affecting ANRIL and CDKN2B gene expression may contribute to increased risk for clinically apparent and subclinical coronary artery disease and aortic disease. (Circulation. 2013;127:799-810.)
C1 [Johnson, Andrew D.; Hwang, Shih-Jen; Peloso, Gina M.; Thanassoulis, George; Fox, Caroline S.; Cupples, L. Adrienne; O'Donnell, Christopher J.] NHLBI, NIH, Framingham Heart Study, Framingham, MA USA.
[Johnson, Andrew D.; Hwang, Shih-Jen; Fox, Caroline S.; O'Donnell, Christopher J.] NHLBI, Div Intramural Res, Bethesda, MD 20892 USA.
[Voorman, Arend] Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Morrison, Alanna; Boerwinkle, Eric] Baylor Coll Med, Texas Med Ctr, Program Human Genet, Houston, TX 77030 USA.
[Peloso, Gina M.; Cupples, L. Adrienne] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Hsu, Yi-Hsiang] Harvard Univ, Sch Med, Hebrew SeniorLife Inst Aging Res, Boston, MA USA.
[Thanassoulis, George] McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
[Newton-Cheh, Christopher] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Newton-Cheh, Christopher] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Rogers, Ian S.; Hoffmann, Udo] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Newton-Cheh, Christopher] Broad Inst Harvard & MIT, Program Med & Populat Genet, Boston, MA USA.
[Rogers, Ian S.] Stanford Univ, Div Cardiovasc Med, Stanford, CA 94305 USA.
[Freedman, Jane E.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA.
[Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Hlth Res Inst, Seattle, WA USA.
[O'Donnell, Christopher J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
RP O'Donnell, CJ (reprint author), 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.
EM odonnellc@nhlbi.nih.gov
RI Johnson, Andrew/G-6520-2013;
OI Cupples, L. Adrienne/0000-0003-0273-7965
FU National Heart, Lung, and Blood Institute (NHLBI) DNA Resequencing and
Genotyping Program [N01-HV-48194]; NHLBI's FHS [N01-HC-25195];
Affymetrix, Inc [N02-HL-6-4278]; Robert Dawson Evans Endowment of the
Department of Medicine at Boston University School of Medicine; Boston
Medical Center; National Institute of Arthritis and Musculoskeletal and
Skin Diseases [R21-AR056405]; NHLBI [RC2-HL02419, N01-HC-55015,
N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021,
N01-HC-55022, R01-HL-087641, R01-HL-59367, R01-HL-086694, N01-HC-85239,
N01-HC-85079, N01-HC-85080]; National Human Genome Research Institute
[U01-HG-004402]; National Institutes of Health [HHSN268200625226C,
UL1-RR-025005]; NIH Roadmap for Medical Research; National Institute on
Aging [AG-023629, AG-15928, AG-20098, AG-027058]; National Center of
Advancing Translational Technologies Clinical & Translational Science
Institute [UL1TR000124]; National Institute of Diabetes and Digestive
and Kidney Diseases [DK063491]; NHLBI. [N01-HC-85081, N01-HC-85082,
N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, N01-HC-35129,
N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133,
HHSN268201200036C, HL080295, HL087652, HL105756, 1T32 HL076136]
FX Resequencing provided via the National Heart, Lung, and Blood Institute
(NHLBI) DNA Resequencing and Genotyping Program by N01-HV-48194. Work on
CNV calling and the FHS LD map was supported by the NHLBI's FHS
(contract No. N01-HC-25195) and its contract with Affymetrix, Inc for
genotyping services (contract No. N02-HL-6-4278). A portion of this
research used the Linux Cluster for Genetic Analysis (LinGA-II), funded
by the Robert Dawson Evans Endowment of the Department of Medicine at
Boston University School of Medicine and Boston Medical Center. CNV
calling was supported by National Institute of Arthritis and
Musculoskeletal and Skin Diseases grant R21-AR056405. Whole genome
sequencing in CHS and ARIC was conducted as part of the CHARGE-S
(Cohorts for Heart and Aging Research in Genome Epidemiology Consortium)
sequencing programming supported by NHLBI Grand Opportunity grant
RC2-HL02419. The ARIC Study is supported by NHLBI contracts
N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020,
N01-HC-55021, and N01-HC-55022 and grants R01-HL-087641, R01-HL-59367,
and R01-HL-086694; National Human Genome Research Institute contract
U01-HG-004402; and National Institutes of Health contract
HHSN268200625226C. The infrastructure was supported in part by grant No.
UL1-RR-025005, a component of the National Institutes of Health and NIH
Roadmap for Medical Research. The CHS research was supported by NHLBI
contracts N01-HC-85239, N01-HC-85079 through N01-HC-85086, N01-HC-35129,
N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, and
HHSN268201200036C and NHLBI grants HL080295, HL087652, and HL105756,
with additional contribution from the National Institute of Neurological
Disorders and Stroke. Additional support was provided through AG-023629,
AG-15928, AG-20098, and AG-027058 from the National Institute on Aging.
See also the CHS Web site (http://www.chsnhlbi.org/pi.htm). DNA handling
and genotyping was supported in part by National Center of Advancing
Translational Technologies Clinical & Translational Science Institute
grant UL1TR000124 and National Institute of Diabetes and Digestive and
Kidney Diseases grant DK063491 to the Southern California Diabetes
Endocrinology Research Center. We thank Daniel Levy and Dr O'Donnell for
genotyping funding. Dr Rogers was supported by NHLBI 1T32 HL076136. Dr
Johnson was supported by an NHLBI Intramural Research Training Award
fellowship.
NR 41
TC 31
Z9 33
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD FEB 19
PY 2013
VL 127
IS 7
BP 799
EP 810
DI 10.1161/CIRCULATIONAHA.112.111559
PG 12
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 094YS
UT WOS:000315302200017
PM 23315372
ER
PT J
AU Schiros, CG
Gladden, JD
Clark, D
Gupta, H
Lloyd, SG
McGiffin, DC
Ahmed, MI
Aban, I
Dell'Italia, LJ
Perry, G
Denney, TS
AF Schiros, Chun G.
Gladden, James D.
Clark, Donald, III
Gupta, Himanshu
Lloyd, Steven G.
McGiffin, David C.
Ahmed, Mustafa I.
Aban, Inmaculada
Dell'Italia, Louis J.
Perry, Gilbert
Denney, Thomas S., Jr.
TI Response to Letter Regarding Article, "Magnetic Resonance Imaging With
3-Dimensional Analysis of Left Ventricular Remodeling in Isolated Mitral
Regurgitation: Implications Beyond Dimensions"
SO CIRCULATION
LA English
DT Letter
C1 [Schiros, Chun G.; Gladden, James D.; Clark, Donald, III; Gupta, Himanshu; Lloyd, Steven G.; McGiffin, David C.; Ahmed, Mustafa I.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
[Aban, Inmaculada] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA.
[Dell'Italia, Louis J.; Perry, Gilbert] Univ Alabama Birmingham, Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
[Denney, Thomas S., Jr.] Auburn Univ, Dept Elect & Comp Engn, Samuel Ginn Coll Engn, Auburn, AL 36849 USA.
RP Schiros, CG (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD FEB 19
PY 2013
VL 127
IS 7
BP E462
EP E462
DI 10.1161/CIRCULATIONAHA.112.134858
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 094YS
UT WOS:000315302200011
PM 23550297
ER
PT J
AU Cesano, A
Putta, S
Rosen, DB
Cohen, AC
Gayko, U
Mathi, K
Woronicz, J
Hawtin, RE
Cripe, L
Sun, ZX
Tallman, MS
Paietta, E
AF Cesano, Alessandra
Putta, Santosh
Rosen, David B.
Cohen, Aileen C.
Gayko, Urte
Mathi, Kavita
Woronicz, John
Hawtin, Rachael E.
Cripe, Larry
Sun, Zhuoxin
Tallman, Martin S.
Paietta, Elisabeth
TI Functional Pathway Analysis Using SCNP of FLT3 Receptor Pathway
Deregulation in AML Provides Prognostic Information Independent from
Mutational Status
SO PLOS ONE
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; ACUTE MYELOGENOUS
LEUKEMIA; SIGNAL TRANSDUCER; NPM1 MUTATIONS; POOR-PROGNOSIS;
HEMATOPOIETIC-CELLS; NORMAL CYTOGENETICS; NORMAL KARYOTYPE; TYROSINE
KINASE
AB FMS-like tyrosine kinase 3 receptor (FLT3) internal tandem duplication (ITD) mutations result in constitutive activation of this receptor and have been shown to increase the risk of relapse in patients with acute myeloid leukemia (AML); however, substantial heterogeneity in clinical outcomes still exists within both the ITD mutated and unmutated AML subgroups, suggesting alternative mechanisms of disease relapse not accounted by FLT3 mutational status. Single cell network profiling (SCNP) is a multiparametric flow cytometry based assay that simultaneously measures, in a quantitative fashion and at the single cell level, both extracellular surface marker levels and changes in intracellular signaling proteins in response to extracellular modulators. We previously reported an initial characterization of FLT3 ITD-mediated signaling using SCNP. Herein SCNP was applied sequentially to two separate cohorts of samples collected from elderly AML patients at diagnosis. In the first (training) study, AML samples carrying unmutated, wild-type FLT3 (FLT3 WT) displayed a wide range of induced signaling, with a fraction having signaling profiles comparable to FLT3 ITD AML samples. Conversely, the FLT3 ITD AML samples displayed more homogeneous induced signaling, with the exception of patients with low (, 40%) mutational load, which had profiles comparable to FLT3 WT AML samples. This observation was then confirmed in an independent (verification) cohort. Data from the second cohort were also used to assess the association between SCNP data and disease-free survival (DFS) in the context of FLT3 and nucleophosmin (NPM1) mutational status among patients who achieved complete remission (CR) to induction chemotherapy. The combination of SCNP read outs together with FLT3 and NPM1 molecular status improved the DFS prediction accuracy of the latter. Taken together, these results emphasize the value of comprehensive functional assessment of biologically relevant signaling pathways in AML as a basis for the development of highly predictive tests for guidance of post-remission therapy.
C1 [Cesano, Alessandra; Putta, Santosh; Rosen, David B.; Cohen, Aileen C.; Gayko, Urte; Mathi, Kavita; Woronicz, John; Hawtin, Rachael E.] Nodality Inc, San Francisco, CA USA.
[Cripe, Larry; Sun, Zhuoxin; Tallman, Martin S.; Paietta, Elisabeth] Eastern Cooperat Oncol Grp ECOG, Boston, MA USA.
[Cripe, Larry] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
[Sun, Zhuoxin] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Paietta, Elisabeth] Montefiore Med Ctr, North Div, Bronx, NY 10467 USA.
RP Cesano, A (reprint author), Nodality Inc, San Francisco, CA USA.
EM Alessandra.Cesano@Nodality.com
FU Nodality, Inc.
FX This study was funded by Nodality, Inc. The funder contributed to study
design, data collection and analysis, decision to publish, and
preparation of the manuscript.
NR 55
TC 3
Z9 3
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 19
PY 2013
VL 8
IS 2
AR e56714
DI 10.1371/journal.pone.0056714
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 093HR
UT WOS:000315182800032
PM 23431389
ER
PT J
AU Gui, DY
Lewis, CA
Vander Heiden, MG
AF Gui, Dan Y.
Lewis, Caroline A.
Vander Heiden, Matthew G.
TI Allosteric Regulation of PKM2 Allows Cellular Adaptation to Different
Physiological States
SO SCIENCE SIGNALING
LA English
DT Article
ID PYRUVATE-KINASE M2; TUMOR-GROWTH; CANCER METABOLISM; ISOFORM;
FRUCTOSE-1,6-BISPHOSPHATE; INHIBITION; ACTIVATORS; BINDING; SERINE;
CONVERSION
AB Pyruvate kinase isoform M2 (PKM2) activity is subject to complex allosteric regulation. Recently, serine and SAICAR (succinylaminoimidazolecarboxamide ribose-5'-phosphate) were identified as previously unrecognized activators of PKM2. These findings add additional complexity to how PKM2 is regulated in cells and support the notion that modulating PKM2 activity enables cells to adapt their metabolic state to specific physiological contexts.
C1 [Gui, Dan Y.; Lewis, Caroline A.; Vander Heiden, Matthew G.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Vander Heiden, Matthew G.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Vander Heiden, MG (reprint author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM mvh@mit.edu
NR 27
TC 22
Z9 22
U1 1
U2 29
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD FEB 19
PY 2013
VL 6
IS 263
AR pe7
DI 10.1126/scisignal.2003925
PG 4
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 094ZA
UT WOS:000315303000001
PM 23423437
ER
PT J
AU Bodur, C
Kutuk, O
Karsli-Uzunbas, G
Isimjan, TT
Harrison, P
Basaga, H
AF Bodur, Cagri
Kutuk, Ozgur
Karsli-Uzunbas, Gizem
Isimjan, Tayirjan T.
Harrison, Paul
Basaga, Huveyda
TI Pramanicin Analog Induces Apoptosis in Human Colon Cancer Cells:
Critical Roles for Bcl-2, Bim, and p38 MAPK Signaling
SO PLOS ONE
LA English
DT Article
ID NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR; DEPENDENT
APOPTOSIS; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; ANTIFUNGAL AGENT;
GENE-EXPRESSION; FAMILY PROTEINS; BREAST-CANCER
AB Pramanicin (PMC) is an antifungal agent that was previously demonstrated to exhibit antiangiogenic and anticancer properties in a few in vitro studies. We initially screened a number of PMC analogs for their cytotoxic effects on HCT116 human colon cancer cells. PMC-A, the analog with the most potent antiproliferative effect was chosen to further interrogate the underlying mechanism of action. PMC-A led to apoptosis through activation of caspase-9 and -3. The apoptotic nature of cell death was confirmed by abrogation of cell death with pretreatment with specific caspase inhibitors. Stress-related MAPKs JNK and p38 were both activated concomittantly with the intrinsic apoptotic pathway. Moreover, pharmacological inhibition of p38 proved to attenuate the cell death induction while pretreatment with JNK inhibitor did not exhibit a protective effect. Resistance of Bax -/- cells and the protective nature of caspase-9 inhibition indicate that mitochondria play a central role in PMC-A induced apoptosis. Early post-exposure elevation of cellular Bim and Bax was followed by a marginal Bcl-2 depletion and Bid cleavage. Further analysis revealed that Bcl-2 downregulation occurs at the mRNA level and is critical to mediate PMC-A induced apoptosis, as ectopic Bcl-2 expression substantially spared the cells from death. Conversely, forced expression of Bim proved to significantly increase cell death. In addition, analyses of p53-/- cells demonstrated that Bcl-2/Bim/Bax modulation and MAPK activations take place independently of p53 expression. Taken together, p53-independent transcriptional Bcl-2 downregulation and p38 signaling appear to be the key modulatory events in PMC-A induced apoptosis.
C1 [Bodur, Cagri; Karsli-Uzunbas, Gizem; Basaga, Huveyda] Sabanci Univ, Biol Sci & Bioengn Program, Istanbul, Turkey.
[Kutuk, Ozgur] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Isimjan, Tayirjan T.; Harrison, Paul] McMaster Univ, Dept Chem & Chem Biol, Hamilton, ON, Canada.
RP Basaga, H (reprint author), Sabanci Univ, Biol Sci & Bioengn Program, Istanbul, Turkey.
EM huveyda@sabanciuniv.edu
FU Sabanci University faculty research funds
FX The funding for the work was provided by Sabanci University faculty
research funds. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 69
TC 6
Z9 10
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 18
PY 2013
VL 8
IS 2
AR e56369
DI 10.1371/journal.pone.0056369
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 092YP
UT WOS:000315159200040
PM 23441183
ER
PT J
AU Crawford, F
Anandan, C
Chappell, FM
Murray, GD
Price, JF
Sheikh, A
Simpson, CR
Maxwell, M
Stansby, GP
Young, MJ
Abbott, CA
Boulton, AJ
Boyko, EJ
Kastenbauer, T
Leese, GP
Monami, M
Monteiro-Soares, M
Rith-Najarian, SJ
Veves, A
Coates, N
Jeffcoate, WJ
Leech, N
Fahey, T
Tierney, J
AF Crawford, Fay
Anandan, Chantelle
Chappell, Francesca M.
Murray, Gordon D.
Price, Jacqueline F.
Sheikh, Aziz
Simpson, Colin R.
Maxwell, Martin
Stansby, Gerard P.
Young, Matthew J.
Abbott, Caroline A.
Boulton, Andrew J. M.
Boyko, Edward J.
Kastenbauer, Thomas
Leese, Graham P.
Monami, Matteo
Monteiro-Soares, Matilde
Rith-Najarian, Stephen J.
Veves, Aristidis
Coates, Nikki
Jeffcoate, William J.
Leech, Nicola
Fahey, Tom
Tierney, Jayne
TI Protocol for a systematic review and individual patient data
meta-analysis of prognostic factors of foot ulceration in people with
diabetes: the international research collaboration for the prediction of
diabetic foot ulcerations (PODUS)
SO BMC MEDICAL RESEARCH METHODOLOGY
LA English
DT Review
ID METHODOLOGICAL STANDARDS; MULTIPLE IMPUTATION; EPIDEMIOLOGY STROBE;
GUIDELINES; STATEMENT; RULES
AB Background: Diabetes-related lower limb amputations are associated with considerable morbidity and mortality and are usually preceded by foot ulceration. The available systematic reviews of aggregate data are compromised because the primary studies report both adjusted and unadjusted estimates. As adjusted meta-analyses of aggregate data can be challenging, the best way to standardise the analytical approach is to conduct a meta-analysis based on individual patient data (IPD).
There are however many challenges and fundamental methodological omissions are common; protocols are rare and the assessment of the risk of bias arising from the conduct of individual studies is frequently not performed, largely because of the absence of widely agreed criteria for assessing the risk of bias in this type of review. In this protocol we propose key methodological approaches to underpin our IPD systematic review of prognostic factors of foot ulceration in diabetes.
Review questions;
1. What are the most highly prognostic factors for foot ulceration (i.e. symptoms, signs, diagnostic tests) in people with diabetes?
2. Can the data from each study be adjusted for a consistent set of adjustment factors?
3. Does the model accuracy change when patient populations are stratified according to demographic and/or clinical characteristics?
Methods: MEDLINE and EMBASE databases from their inception until early 2012 were searched and the corresponding authors of all eligible primary studies invited to contribute their raw data. We developed relevant quality assurance items likely to identify occasions when study validity may have been compromised from several sources. A confidentiality agreement, arrangements for communication and reporting as well as ethical and governance considerations are explained. We have agreement from the corresponding authors of all studies which meet the eligibility criteria and they collectively possess data from more than 17000 patients. We propose, as a provisional analysis plan, to use a multi-level mixed model, using "study" as one of the levels. Such a model can also allow for the within-patient clustering that occurs if a patient contributes data from both feet, although to aid interpretation, we prefer to use patients rather than feet as the unit of analysis. We intend to only attempt this analysis if the results of the investigation of heterogeneity do not rule it out and the model diagnostics are acceptable.
Discussion: This review is central to the development of a global evidence-based strategy for the risk assessment of the foot in patients with diabetes, ensuring future recommendations are valid and can reliably inform international clinical guidelines.
C1 [Crawford, Fay] Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Rd Hosp, Dept Vasc Surg, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.
[Anandan, Chantelle; Chappell, Francesca M.; Murray, Gordon D.; Price, Jacqueline F.; Sheikh, Aziz; Simpson, Colin R.; Maxwell, Martin] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland.
[Stansby, Gerard P.] Fac Med Sci, Sch Surg & Reprod Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
[Young, Matthew J.] Royal Infirm Edinburgh NHS Trust, Dept Diabet, Edinburgh EH16 4SA, Midlothian, Scotland.
[Abbott, Caroline A.] Univ Manchester, Ctr Endocrinol & Diabet, Inst Human Dev, Core Technol Facil, Manchester M13 9NT, Lancs, England.
[Boulton, Andrew J. M.] Manchester Royal Infirm, Div Med, Manchester M13 9WL, Lancs, England.
[Boyko, Edward J.] Univ Washington, Epidemiol Res & Informat Ctr, VA Puget Sound Hlth Care Syst, Seattle, WA 98101 USA.
[Kastenbauer, Thomas] Sci Consulting & Clin Monitoring SCCM, A-1220 Vienna, Austria.
[Leese, Graham P.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Diabet & Endocrinol, Dundee DD1 9SY, Scotland.
[Monami, Matteo] AOU Careggi, Sez Diabetol, Florence, Italy.
[Monteiro-Soares, Matilde] Ctr Hosp Vila Nova de Gaia Espinho EPE, Unidade 1, Serv Endocrinol Pe Diabet, P-4434502 Vila Nova De Gaia, Portugal.
[Rith-Najarian, Stephen J.] Cass Lake Indian Hlth Serv Hosp, Cass Lake, MN 56633 USA.
[Veves, Aristidis] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Coates, Nikki] Newcastle Hosp Community Hlth, Podiatry Dept, Geoffrey Rhodes Clin, Newcastle Upon Tyne NE6 2UZ, Tyne & Wear, England.
[Jeffcoate, William J.] City Hosp Nottingham, Dept Diabet & Endocrinol, Nottingham NG5 1PB, England.
[Leech, Nicola] Royal Victoria Infirm, Ward 31, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
[Fahey, Tom] Royal Coll Surgeons Ireland, Dublin 2, Ireland.
[Tierney, Jayne] MRC, Clin Trials Unit, London WC2B 6NH, England.
RP Crawford, F (reprint author), Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Rd Hosp, Dept Vasc Surg, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.
EM Fay.crawford@ed.ac.uk
RI Sheikh, Aziz /D-2818-2009; Simpson, Colin/L-7180-2014; Monteiro-Soares,
Matilde/F-7192-2013; Fahey, Tom/C-9367-2012; FMUP, CINTESIS/C-6631-2014
OI Sheikh, Aziz /0000-0001-7022-3056; Simpson, Colin/0000-0002-5194-8083;
Monteiro-Soares, Matilde/0000-0002-4586-2910; Murray,
Gordon/0000-0001-9866-4734; Fahey, Tom/0000-0002-5896-5783; FMUP,
CINTESIS/0000-0001-7248-2086
FU National Institute for Health Research Health Technology Assessment
(NIHR HTA) Programme [10/57/08]
FX This project was funded by the National Institute for Health Research
Health Technology Assessment (NIHR HTA) Programme (project number
10/57/08) and will be published in full in Health Technology Assessment.
NR 33
TC 8
Z9 9
U1 1
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2288
J9 BMC MED RES METHODOL
JI BMC Med. Res. Methodol.
PD FEB 15
PY 2013
VL 13
AR 22
DI 10.1186/1471-2288-13-22
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 107OW
UT WOS:000316228700001
PM 23414550
ER
PT J
AU Reichmann, WM
LaValley, MP
Gagnon, DR
Losina, E
AF Reichmann, William M.
LaValley, Michael P.
Gagnon, David R.
Losina, Elena
TI Impact of misspecifying the distribution of a prognostic factor on power
and sample size for testing treatment interactions in clinical trials
SO BMC MEDICAL RESEARCH METHODOLOGY
LA English
DT Article
DE Simulation design; Interaction; Conditional power; Adaptive design;
Sample size re-estimation
ID SUBGROUP ANALYSES; RANDOMIZED-TRIALS
AB Background: Interaction in clinical trials presents challenges for design and appropriate sample size estimation. Here we considered interaction between treatment assignment and a dichotomous prognostic factor with a continuous outcome. Our objectives were to describe differences in power and sample size requirements across alternative distributions of a prognostic factor and magnitudes of the interaction effect, describe the effect of misspecification of the distribution of the prognostic factor on the power to detect an interaction effect, and discuss and compare three methods of handling the misspecification of the prognostic factor distribution.
Methods: We examined the impact of the distribution of the dichotomous prognostic factor on power and sample size for the interaction effect using traditional one-stage sample size calculation. We varied the magnitude of the interaction effect, the distribution of the prognostic factor, and the magnitude and direction of the misspecification of the distribution of the prognostic factor. We compared quota sampling, modified quota sampling, and sample size re-estimation using conditional power as three strategies for ensuring adequate power and type I error in the presence of a misspecification of the prognostic factor distribution.
Results: The sample size required to detect an interaction effect with 80% power increases as the distribution of the prognostic factor becomes less balanced. Misspecification such that the actual distribution of the prognostic factor was more skewed than planned led to a decrease in power with the greatest loss in power seen as the distribution of the prognostic factor became less balanced. Quota sampling was able to maintain the empirical power at 80% and the empirical type I error at 5%. The performance of the modified quota sampling procedure was related to the percentage of trials switching the quota sampling scheme. Sample size re-estimation using conditional power was able to improve the empirical power under negative misspecifications (i.e. skewed distributions) but it was not able to reach the target of 80% in all situations.
Conclusions: Misspecifying the distribution of a dichotomous prognostic factor can greatly impact power to detect an interaction effect. Modified quota sampling and sample size re-estimation using conditional power improve the power when the distribution of the prognostic factor is misspecified. Quota sampling is simple and can prevent misspecification of the prognostic factor, while maintaining power and type I error.
C1 [Reichmann, William M.; Losina, Elena] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
[Reichmann, William M.; LaValley, Michael P.; Gagnon, David R.; Losina, Elena] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Gagnon, David R.] Massachusetts Vet Epidemiol Res & Informat Ctr, VA Cooperat Studies Program, Boston, MA USA.
[Reichmann, William M.] Brigham & Womens Hosp, Orthoped & Arthrit Ctr Outcomes Res, Boston, MA 02115 USA.
RP Reichmann, WM (reprint author), Brigham & Womens Hosp, Dept Orthoped Surg, 75 Francis St, Boston, MA 02115 USA.
EM breich315@gmail.com
OI Gagnon, David/0000-0002-6367-3179; LaValley, Michael/0000-0002-8488-5170
FU National Institutes of Health, National Institute of Arthritis and
Musculoskeletal and Skin Diseases [T32 AR055885, K24 AR057827]
FX This research was supported in part by the National Institutes of
Health, National Institute of Arthritis and Musculoskeletal and Skin
Diseases grants T32 AR055885 and K24 AR057827.
NR 13
TC 0
Z9 0
U1 1
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2288
J9 BMC MED RES METHODOL
JI BMC Med. Res. Methodol.
PD FEB 15
PY 2013
VL 13
AR 21
DI 10.1186/1471-2288-13-21
PG 18
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 111WN
UT WOS:000316552200001
PM 23414513
ER
PT J
AU Niehorster, DC
Peli, E
Haun, A
Li, L
AF Niehorster, Diederick C.
Peli, Eli
Haun, Andrew
Li, Li
TI Influence of Hemianopic Visual Field Loss on Visual Motor Control
SO PLOS ONE
LA English
DT Article
ID LINE BISECTION; HOMONYMOUS HEMIANOPIA; DRIVING PERFORMANCE; STEERING
CONTROL; HUMAN-OPERATOR; ACTIVE CONTROL; NEGLECT; REHABILITATION;
DEFECTS; APHASIA
AB Background: Homonymous hemianopia (HH) is an anisotropic visual impairment characterized by the binocular inability to see one side of the visual field. Patients with HH often misperceive visual space. Here we investigated how HH affects visual motor control.
Methods and Findings: Seven patients with complete HH and no neglect or cognitive decline and seven gender-and age-matched controls viewed displays in which a target moved randomly along the horizontal or the vertical axis. They used a joystick to control the target movement to keep it at the center of the screen. We found that the mean deviation of the target position from the center of the screen along the horizontal axis was biased toward the blind side for five out of seven HH patients. More importantly, while the normal vision controls showed more precise control and larger response amplitudes when the target moved along the horizontal rather than the vertical axis, the control performance of the HH patients was not different between these two target motion experimental conditions.
Conclusions: Compared with normal vision controls, HH affected patients' control performance when the target moved horizontally (i.e., along the axis of their visual impairment) rather than vertically. We conclude that hemianopia affects the use of visual information for online control of a moving target specific to the axis of visual impairment. The implications of the findings for driving in hemianopic patients are discussed.
C1 [Niehorster, Diederick C.; Li, Li] Univ Hong Kong, Dept Psychol, Hong Kong, Hong Kong, Peoples R China.
[Peli, Eli; Haun, Andrew] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst,Dept Ophthalmol, Boston, MA USA.
RP Niehorster, DC (reprint author), Univ Hong Kong, Dept Psychol, Hong Kong, Hong Kong, Peoples R China.
EM dcniehorster@hku.hk; lili@hku.hk
RI Niehorster, Diederick/E-9325-2010; Haun, Andrew/I-4956-2012
OI Niehorster, Diederick/0000-0002-4672-8756; Haun,
Andrew/0000-0001-9458-8957
FU Research Grants Council of Hong Kong [HKU 7478/08H]; NIH [EY12890]
FX This study was supported by a grant from the Research Grants Council of
Hong Kong (HKU 7478/08H) to L. Li, http://www.ugc.edu.hk, and a grant
from the NIH (EY12890) to E. Peli, http://www.nih.gov/. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 64
TC 6
Z9 6
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 15
PY 2013
VL 8
IS 2
AR e56615
DI 10.1371/journal.pone.0056615
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 099EQ
UT WOS:000315603700066
PM 23457594
ER
PT J
AU Lam, D
Fard, AM
Buckley, B
Jalali, B
AF Lam, Daniel
Fard, Ali M.
Buckley, Brandon
Jalali, Bahram
TI Digital broadband linearization of optical links
SO OPTICS LETTERS
LA English
DT Article
ID MICROWAVE PHOTONICS; TRANSMISSION; PERFORMANCE; MODULATOR; RECEIVER
AB We present a digital postprocessing linearization technique to efficiently suppress dynamic distortions added to a wideband signal in an analog optical link. Our technique achieves up to 35 dB suppression of intermodulation distortions over multiple octaves of signal bandwidth. In contrast to conventional linearization methods, it does not require excessive analog bandwidth for performing digital correction. This is made possible by regenerating undesired distortions from the captured output, and subtracting it from the distorted digitized signal. Moreover, we experimentally demonstrate a record spurious-free dynamic range of 120 dB . Hz(2/3) over a 6 GHz electrical signal bandwidth. While our digital broadband linearization technique advances state-of-the-art optical links, it can also be applied to other nonlinear dynamic systems. (c) 2013 Optical Society of America
C1 [Lam, Daniel; Buckley, Brandon; Jalali, Bahram] Univ Calif Los Angeles, Dept Elect Engn, Los Angeles, CA 90095 USA.
[Fard, Ali M.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Fard, Ali M.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Buckley, Brandon] Univ Calif Los Angeles, Dept Phys, Los Angeles, CA 90095 USA.
[Buckley, Brandon; Jalali, Bahram] Calif NanoSyst Inst, Los Angeles, CA 90095 USA.
RP Lam, D (reprint author), Univ Calif Los Angeles, Dept Elect Engn, Los Angeles, CA 90095 USA.
EM dwlam@ucla.edu
FU U.S. Defense Advanced Research Projects Agency (DARPA); National Science
Foundation (NSF) through CIAN ERC [EEC-0812072]
FX This work was partially supported by the U.S. Defense Advanced Research
Projects Agency (DARPA) and the National Science Foundation (NSF)
through CIAN ERC under Grant No. EEC-0812072.
NR 17
TC 22
Z9 22
U1 0
U2 8
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 0146-9592
J9 OPT LETT
JI Opt. Lett.
PD FEB 15
PY 2013
VL 38
IS 4
BP 446
EP 448
PG 3
WC Optics
SC Optics
GA 099EB
UT WOS:000315601700020
PM 23455097
ER
PT J
AU Mathewkutty, S
Sethi, SS
Aneja, A
Shah, K
Iyengar, RL
Hermann, L
Khakimov, S
Razzouk, L
Esquitin, R
Vedanthan, R
Benjamin, TA
Grace, M
Nisenbaum, R
Ramanathan, K
Ramanathan, L
Chesebro, J
Farkouh, ME
AF Mathewkutty, Shiny
Sethi, Sanjum S.
Aneja, Ashish
Shah, Kshitij
Iyengar, Rupa L.
Hermann, Luke
Khakimov, Sayyar
Razzouk, Louai
Esquitin, Ricardo
Vedanthan, Rajesh
Benjamin, Terrie-Ann
Grace, Marie
Nisenbaum, Rosane
Ramanathan, Krishnan
Ramanathan, Lakshmi
Chesebro, James
Farkouh, Michael E.
TI Biomarkers After Risk Stratification in Acute Chest Pain (from the BRIC
Study)
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID ACUTE CORONARY SYNDROMES; NATRIURETIC PEPTIDE; EMERGENCY-DEPARTMENT;
ST-ELEVATION; MYOCARDIAL-INFARCTION; CT ANGIOGRAPHY; CYSTATIN-C;
OUTCOMES; DIAGNOSIS; ISCHEMIA
AB Current models incompletely risk-stratify patients with acute chest pain. In this study, N-terminal pro-B-type natriuretic peptide and cystatin C were incorporated into a contemporary chest pain triage algorithm in a clinically stratified population to improve acute coronary syndrome discrimination. Adult patients with chest pain presenting without myocardial infarction (n = 382) were prospectively enrolled from 2008 to 2009. After clinical risk stratification, N-terminal pro-B-type natriuretic peptide and cystatin C were measured and standard care was performed. The primary end point was the result of a clinical stress test. The secondary end point was any major adverse cardiac event at 6 months. Associations were determined through multivariate stratified analyses. In the low-risk group, 76 of 78 patients with normal levels of the 2 biomarkers had normal stress test results (negative predictive value 97%). Normal biomarkers predicted normal stress test results with an odds ratio of 10.56 (p = 0.006). In contrast, 26 of 33 intermediate-risk patients with normal levels of the 2 biomarkers had normal stress test results (negative predictive value 79%). Biomarkers and stress test results were not associated in the intermediate-risk group (odds ratio 2.48, p = 0.09). There were 42 major adverse cardiac events in the overall cohort. No major adverse cardiac events occurred at 6 months in the low-risk subgroup that underwent stress testing. In conclusion, N-terminal pro-B-type natriuretic peptide and cystatin C levels predict the results of stress tests in low-risk patients with chest pain but should not be substituted for stress testing in intermediate-risk patients. There is potential for their use in the early discharge of low-risk patients after clinical risk stratification. (C) 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111:493-498)
C1 [Mathewkutty, Shiny; Sethi, Sanjum S.; Iyengar, Rupa L.; Khakimov, Sayyar; Vedanthan, Rajesh; Farkouh, Michael E.] Mt Sinai Sch Med, Zena & Michael Wiener Cardiovasc Inst, New York, NY 10029 USA.
[Hermann, Luke] Mt Sinai Sch Med, Dept Emergency Med, New York, NY USA.
[Grace, Marie; Ramanathan, Lakshmi] Mt Sinai Sch Med, Dept Pathol, New York, NY USA.
[Aneja, Ashish] Case Western Reserve Univ, Metrohlth Campus, Heart & Vasc Ctr, Cleveland, OH 44106 USA.
[Shah, Kshitij] James J Peters VA Med Ctr, Dept Med, Bronx, NY USA.
[Razzouk, Louai] NYU, Div Cardiol, New York, NY USA.
[Esquitin, Ricardo] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Cardiol, Boston, MA 02215 USA.
[Benjamin, Terrie-Ann] Cleveland Clin, Dept Med, Cleveland, OH 44106 USA.
[Nisenbaum, Rosane] Univ Toronto, Ctr Res Inner City Hlth, Toronto, ON, Canada.
[Nisenbaum, Rosane] Univ Toronto, Appl Hlth Res Ctr, Toronto, ON, Canada.
[Nisenbaum, Rosane] Univ Toronto, Keenan Res Ctr, Li Ka Shing Knowledge Inst, St Michaels Hosp, Toronto, ON, Canada.
[Nisenbaum, Rosane] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
[Ramanathan, Krishnan] Univ British Columbia, St Pauls Hosp, Div Cardiol, Vancouver, BC V5Z 1M9, Canada.
[Chesebro, James] Univ Massachusetts, Sch Med, Div Cardiovasc Med, Worcester, MA USA.
[Farkouh, Michael E.] Univ Toronto, Peter Munk Cardiac Ctr, Toronto, ON, Canada.
[Farkouh, Michael E.] Univ Toronto, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
RP Farkouh, ME (reprint author), Mt Sinai Sch Med, Zena & Michael Wiener Cardiovasc Inst, New York, NY 10029 USA.
EM michael.farkouh@mssm.edu
OI Razzouk, Louai/0000-0002-0306-6182; Esquitin,
Ricardo/0000-0002-3475-3671
FU Radiometer (Bronshoj, Denmark); Ontario Ministry of Health and Long-Term
Care, Toronto, Ontario, Canada
FX This study was sponsored partly by Radiometer (Bronshoj, Denmark).; Dr.
Nisenbaum gratefully acknowledges the support of the Ontario Ministry of
Health and Long-Term Care, Toronto, Ontario, Canada. The views expressed
in this publication are the views of the investigators and do not
necessarily reflect the views of the Ontario Ministry of Health and
Long-Term Care.
NR 30
TC 4
Z9 6
U1 0
U2 5
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD FEB 15
PY 2013
VL 111
IS 4
BP 493
EP 498
DI 10.1016/j.amjcard.2012.10.032
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 095GN
UT WOS:000315322800006
PM 23218997
ER
PT J
AU Greene, SJ
Vaduganathan, M
Lupi, L
Ambrosy, AP
Mentz, RJ
Konstam, MA
Nodari, S
Subacius, HP
Fonarow, GC
Bonow, RO
Gheorghiade, M
AF Greene, Stephen J.
Vaduganathan, Muthiah
Lupi, Laura
Ambrosy, Andrew P.
Mentz, Robert J.
Konstam, Marvin A.
Nodari, Savina
Subacius, Hans P.
Fonarow, Gregg C.
Bonow, Robert O.
Gheorghiade, Mihai
CA EVEREST Trial Invest
TI Prognostic Significance of Serum Total Cholesterol and Triglyceride
Levels in Patients Hospitalized for Heart Failure With Reduced Ejection
Fraction (from the EVEREST Trial)
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID REVERSE EPIDEMIOLOGY; MORTALITY; RISK; TOLVAPTAN; SURVIVAL; REGISTRY;
PROGRAM; OBESITY; MARKER
AB Lower cholesterol levels are associated with worse outcomes in patients with chronic heart failure (HF) and have been shown to predict in-hospital mortality. The relation between lipid profile and postdischarge outcomes in patients hospitalized for worsening HF is less clear. In this post hoc analysis of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST), 3,957 patients hospitalized for worsening HF with ejection fractions <= 40% were examined. Baseline total cholesterol and triglyceride levels were measured <48 hours after admission and evaluated as continuous variables. The primary end points of all-cause mortality and cardiovascular mortality or hospitalization for HF were compared using Cox regression models. Patient characteristics at randomization were also compared among quartiles of total cholesterol. Patients with lower total cholesterol tended to have lower blood pressure, ejection fractions, serum sodium, and albumin, and were more likely to have worse HF functional class, to have higher natriuretic peptide levels, and to have histories of diabetes mellitus, renal insufficiency, and coronary revascularization (all p values <0.001). After adjustment for baseline clinical risk factors, total cholesterol was predictive of all-cause mortality (hazard ratio 0.73, 95% confidence interval 0.63 to 0.85, p <0.001) and cardiovascular mortality or hospitalization for HF (hazard ratio 0.73, 95% confidence interval 0.66 to 0.82, p <0.001) at median follow-up of 9.9 months. Lower baseline triglyceride level was also associated with worse outcomes. In conclusion, lower baseline total cholesterol is correlated with a high-risk patient profile and is a marker of disease severity in patients hospitalized for worsening HF with reduced ejection fraction. Baseline total cholesterol and triglyceride levels are predictive of mortality and HF rehospitalization beyond traditional risk factors. (C) 2013 Elsevier Inc. All rights reserved. (Am J Cardiol 2013;111:574-581)
C1 [Greene, Stephen J.; Bonow, Robert O.; Gheorghiade, Mihai] Northwestern Univ Feinberg, Sch Med, Ctr Cardiovasc Innovat, Chicago, IL USA.
[Subacius, Hans P.] Northwestern Univ Feinberg, Sch Med, Div Cardiol, Dept Med, Chicago, IL USA.
[Vaduganathan, Muthiah] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med, Boston, MA USA.
[Lupi, Laura; Nodari, Savina] Univ Brescia, Dept Cardiol, Brescia, Italy.
[Ambrosy, Andrew P.] Stanford Univ, Sch Med, Dept Med, Stanford, CA USA.
[Mentz, Robert J.] Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA.
[Konstam, Marvin A.] Tufts Med Ctr, Dept Med, Div Cardiol, Boston, MA USA.
[Fonarow, Gregg C.] Ahmanson UCLA Cardiomyopathy Ctr, Div Cardiol, Los Angeles, CA USA.
RP Gheorghiade, M (reprint author), Northwestern Univ Feinberg, Sch Med, Ctr Cardiovasc Innovat, Chicago, IL USA.
EM m-gheorghiade@northwestern.edu
OI Subacius, Haris/0000-0003-4061-1220
FU Otsuka, Inc., Rockville, Maryland; Center for Cardiovascular Innovation,
Northwestern University Feinberg School of Medicine, Chicago, Illinois
FX Financial and material support for the Efficacy of Vasopressin
Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) was
provided by Otsuka, Inc., Rockville, Maryland. Database management was
performed by the sponsor. Mr. Subacius conducted all final analyses for
this report with funding from the Center for Cardiovascular Innovation,
Northwestern University Feinberg School of Medicine, Chicago, Illinois.
NR 23
TC 13
Z9 15
U1 0
U2 7
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD FEB 15
PY 2013
VL 111
IS 4
BP 574
EP 581
DI 10.1016/j.amjcard.2012.10.042
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 095GN
UT WOS:000315322800020
PM 23206923
ER
PT J
AU O'Rourke, EJ
Kuballa, P
Xavier, R
Ruvkun, G
AF O'Rourke, Eyleen J.
Kuballa, Petric
Xavier, Ramnik
Ruvkun, Gary
TI omega-6 Polyunsaturated fatty acids extend life span through the
activation of autophagy
SO GENES & DEVELOPMENT
LA English
DT Article
DE C. elegans; fasting; lipid; autophagy; polyunsaturated fatty acids
(PUFA); longevity
ID CAENORHABDITIS-ELEGANS; C. ELEGANS; LINOLEIC-ACID; ARACHIDONIC-ACID;
RECEPTOR NHR-49; GENE-EXPRESSION; PPAR-ALPHA; METABOLISM; RESTRICTION;
INHIBITION
AB Adaptation to nutrient scarcity depends on the activation of metabolic programs to efficiently use internal reserves of energy. Activation of these programs in abundant food regimens can extend life span. However, the common molecular and metabolic changes that promote adaptation to nutritional stress and extend life span are mostly unknown. Here we present a response to fasting, enrichment of omega-6 polyunsaturated fatty acids (PUFAs), which promotes starvation resistance and extends Caenorhabditis elegans life span. Upon fasting, C. elegans induces the expression of a lipase, which in turn leads to an enrichment of omega-6 PUFAs. Supplementing C. elegans culture media with these omega-6 PUFAs increases their resistance to starvation and extends their life span in conditions of food abundance. Supplementation of C. elegans or human epithelial cells with these omega-6 PUFAs activates autophagy, a cell recycling mechanism that promotes starvation survival and slows aging. Inactivation of C. elegans autophagy components reverses the increase in life span conferred by supplementing the C. elegans diet with these fasting-enriched omega-6 PUFAs. We propose that the salubrious effects of dietary supplementation with omega-3/6 PUFAs (fish oils) that have emerged from epidemiological studies in humans may be due to a similar activation of autophagic programs.
C1 [O'Rourke, Eyleen J.; Ruvkun, Gary] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol, Boston, MA 02114 USA.
[O'Rourke, Eyleen J.; Ruvkun, Gary] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.
[Kuballa, Petric; Xavier, Ramnik] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA.
[Kuballa, Petric; Xavier, Ramnik] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
RP Ruvkun, G (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol, Boston, MA 02114 USA.
EM ruvkun@molbio.mgh.harvard.edu
FU [R01DK070147]; [K99DK087928]
FX We thank members of the Ruvkun, Ausubel, and Kaplan laboratories for
helpful comments, especially A. Lee-Conery for help with longevity
experiments; J. Larkins-Ford for performing Biosort analyses; J. Rapley,
J. Avruch, R. Niedra, and B. Seed for sharing expertise and reagents for
mammalian experiments; and H.Y. Mak, A. Soukas, M. Van Gilst, M.
Freeman, A. Saghatelian, and A. Tyler for protocols, access to
equipment, and discussions on lipid measurements. We thank Dr. Mitani
and the National Bioresource Project for strains. We also thank C. Danna
for helpful suggestions and comments on the manuscript. This work was
supported by grants R01DK070147 (to G. R.) and K99DK087928 (to
E.J.O'R.). E.J.O'R. designed the overall studies, performed the
experiments, and wrote the manuscript. G. R. revised the manuscript. P.
K. and R. X. provided GFP-hLC3B and GFP-hLC3B-G120A HeLa cells and
ATG16L1-proficient and ATG16L1-deficient mouse embryonic fibroblasts and
revised the manuscript.
NR 63
TC 35
Z9 36
U1 0
U2 24
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
J9 GENE DEV
JI Genes Dev.
PD FEB 15
PY 2013
VL 27
IS 4
BP 429
EP 440
DI 10.1101/gad.205294.112
PG 12
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 094TI
UT WOS:000315286300008
PM 23392608
ER
PT J
AU Wang, DH
Hoing, S
Patterson, HC
Ahmad, UM
Rathinam, VAK
Rajewsky, K
Fitzgerald, KA
Golenbock, DT
AF Wang, Donghai
Hoeing, Susanne
Patterson, Heide Christine
Ahmad, Umtul M.
Rathinam, Vijay A. K.
Rajewsky, Klaus
Fitzgerald, Katherine A.
Golenbock, Douglas T.
TI Inflammation in Mice Ectopically Expressing Human Pyogenic Arthritis,
Pyoderma Gangrenosum, and Acne (PAPA) Syndrome-associated PSTPIP1 A230T
Mutant Proteins
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID NF-KAPPA-B; AUTOINFLAMMATORY DISEASES; PYRIN; ASC; ACTIVATION;
MUTATIONS; CRE; IL-1-BETA; ANAKINRA; FEVER
AB Pyogenic Arthritis, Pyoderma Gangrenosum, and Acne Syndrome (PAPA syndrome) is an autoinflammatory disease caused by aberrant production of the proinflammatory cytokine interleukin-1. Mutations in the gene encoding proline serine threonine phosphatase-interacting protein-1 (PSTPIP1) have been linked to PAPA syndrome. PSTPIP1 is an adaptor protein that interacts with PYRIN, the protein encoded by the Mediterranean Fever (MEFV) gene whose mutations cause Familial Mediterranean Fever (FMF). However, the pathophysiological function of PSTPIP1 remains to be elucidated. We have generated mouse strains that either are PSTPIP1 deficient or ectopically express mutant PSTPIP1. Results from analyzing these mice suggested that PSTPIP1 is not an essential regulator of the Nlrp3, Aim2, or Nlrc4 inflammasomes. Although common features of human PAPA syndrome such as pyogenic arthritis and skin inflammation were not recapitulated in the mouse model, ectopic expression of the mutant but not the wild type PSTPIP1 in mice lead to partial embryonic lethality, growth retardation, and elevated level of circulating proinflammatory cytokines.
C1 [Wang, Donghai; Ahmad, Umtul M.; Rathinam, Vijay A. K.; Fitzgerald, Katherine A.; Golenbock, Douglas T.] Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA.
[Hoeing, Susanne; Rajewsky, Klaus] Harvard Univ, Sch Med, Immune Dis Inst, Boston Childrens Hosp, Boston, MA 02115 USA.
[Hoeing, Susanne; Rajewsky, Klaus] Harvard Univ, Sch Med, Program Cellular & Mol Immunol, Boston Childrens Hosp, Boston, MA 02115 USA.
[Patterson, Heide Christine] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Patterson, Heide Christine] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Patterson, Heide Christine] Tech Univ Muenchen, Klinikum Rechts Isar, Inst Klin Chem & Pathobiochem, D-81675 Munich, Germany.
RP Wang, DH (reprint author), Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis & Immunol, 364 Plantat St, Worcester, MA 01605 USA.
EM donghai.wang@umassmed.edu; douglas.golenbock@umassmed.edu
FU National Institutes of Health [1 R21 AI095871-01]; New England Regional
Center of Excellence for Biodefense and Emerging Infectious Diseases
postdoctoral fellowship (National Institutes of Health) [U54 AI057159]
FX This work was supported, in whole or in part, by National Institutes of
Health Grant 1 R21 AI095871-01 (to D. G. and D. W.).; Supported by the
New England Regional Center of Excellence for Biodefense and Emerging
Infectious Diseases postdoctoral fellowship (National Institutes of
Health U54 AI057159).
NR 23
TC 16
Z9 16
U1 1
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 15
PY 2013
VL 288
IS 7
BP 4594
EP 4601
DI 10.1074/jbc.M112.443077
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 095ND
UT WOS:000315340400009
PM 23293022
ER
PT J
AU Alessi, C
Vitiello, MV
AF Alessi, Cathy
Vitiello, Michael V.
TI Primary Insomnia in Older Persons
SO AMERICAN FAMILY PHYSICIAN
LA English
DT Editorial Material
C1 [Alessi, Cathy] Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Vitiello, Michael V.] Univ Washington, Seattle, WA 98195 USA.
RP Alessi, C (reprint author), Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 5
PU AMER ACAD FAMILY PHYSICIANS
PI KANSAS CITY
PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA
SN 0002-838X
J9 AM FAM PHYSICIAN
JI Am. Fam. Physician
PD FEB 15
PY 2013
VL 87
IS 4
BP 280
EP 281
PG 2
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA 090UX
UT WOS:000315006600008
ER
PT J
AU An, JB
Liu, HR
Magyar, CE
Guo, YC
Veena, MS
Srivatsan, ES
Huang, JT
Rettig, MB
AF An, Jiabin
Liu, Huiren
Magyar, Clara E.
Guo, Yanchuan
Veena, Mysore S.
Srivatsan, Eri S.
Huang, Jiaoti
Rettig, Matthew B.
TI Hyperactivated JNK Is a Therapeutic Target in pVHL-Deficient Renal Cell
Carcinoma
SO CANCER RESEARCH
LA English
DT Article
ID HIPPEL-LINDAU PROTEIN; HYPOXIA-INDUCIBLE FACTOR; EMBRYONIC STEM-CELLS;
C-JUN; E-CADHERIN; TUMOR SUPPRESSION; KINASE SAPK/JNK; VHL;
PHOSPHORYLATION; GENE
AB Clear cell renal cell carcinomas (RCC), the major histologic subtype of RCC accounting for more than 80% of cases, are typified by biallelic inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. Although accumulation of hypoxia-inducible factor alpha (HIF-alpha) is the most well-studied effect of VHL inactivation, direct inhibition of HIF alpha or restoration of wild-type pVHL protein expression has not proved readily feasible, given the limitations associated with pharmacologic targeting of transcription factors (i.e., HIF-a) and gene replacement therapy of tumor suppressor genes (i.e., VHL). Here, we have established that phosphorylated c-Jun, a substrate of the c-Jun-NH2-kinase (JNK), is selectively activated in clear cell RCC patient specimens. Using multiple isogenic cell lines, we show that HIF-alpha-independent JNK hyperactivation is unique to the pVHL-deficient state. Importantly, pVHL-deficient RCCs are dependent upon JNK activity for in vitro and in vivo growth. A multistep signaling pathway that links pVHL loss to JNK activation involves the formation of a CARD9/BCL10/TRAF6 complex as a proximal signal to sequentially stimulate TAK1 (MAPKKK), MKK4 (MAPKK), and JNK (MAPK). JNK stimulates c-Jun phosphorylation, activation, and dimerization with c-Fos to form a transcriptionally competent AP1 complex that drives transcription of the Twist gene and induces epithelial-mesenchymal transition. Thus, JNK represents a novel molecular target that is selectively activated in and drives the growth of pVHL-deficient clear cell RCCs. These findings can serve as the preclinical foundation for directed efforts to characterize potent pharmacologic inhibitors of the JNK pathway for clinical translation. Cancer Res; 73(4); 1374-85. (C) 2012 AACR.
C1 [An, Jiabin; Liu, Huiren; Rettig, Matthew B.] VA Greater Los Angeles Healthcare Syst, Dept Med, Div Hematol Oncol, Los Angeles, CA USA.
[Veena, Mysore S.; Srivatsan, Eri S.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA.
[An, Jiabin; Liu, Huiren; Rettig, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Dept Urol, Los Angeles, CA 90095 USA.
[Magyar, Clara E.; Huang, Jiaoti] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.
[Veena, Mysore S.; Srivatsan, Eri S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Dept Surg, Los Angeles, CA 90095 USA.
[Rettig, Matthew B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Dept Med, Los Angeles, CA 90095 USA.
[Guo, Yanchuan] Chinese Acad Sci, Tech Inst Phys & Chem, Beijing, Peoples R China.
RP Rettig, MB (reprint author), UCLA VAGLAHS, 11301 Wilshire Blvd,Bldg 500,Room 4237, Los Angeles, CA 90073 USA.
EM mrettig@mednet.ucla.edu
FU Department of Veterans Affairs; NIH [2P30DK041301]
FX The authors thank G. Thomas (Institute of Cancer Research, United
Kingdom) for the isogenic pairs of ACHN and SN12C cell lines, W. Kaelin
(Dana Farber Cancer Institute) for the 786-0 lines and the CARD9
plasmids, and B. Zbar (National Cancer Institute) for the UMRC6 and
UOK121 pairs. The Vector Core (NIH grant 2P30DK041301) at the David
Geffen School of Medicine prepared and titered lentiviral particles.;
This work was supported by a Merit Review grant (M.B. Rettig) from the
Department of Veterans Affairs.
NR 36
TC 15
Z9 20
U1 0
U2 2
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD FEB 15
PY 2013
VL 73
IS 4
BP 1374
EP 1385
DI 10.1158/0008-5472.CAN-12-2362
PG 12
WC Oncology
SC Oncology
GA 091DR
UT WOS:000315029800012
PM 23393199
ER
PT J
AU Mallampalli, RK
Glasser, JR
Coon, TA
Chen, BB
AF Mallampalli, Rama K.
Glasser, Jennifer R.
Coon, Tiffany A.
Chen, Bill B.
TI Calmodulin protects Aurora B on the midbody to regulate the fidelity of
cytokinesis
SO CELL CYCLE
LA English
DT Article
DE Aurora B; FBXL2; calmodulin; mitosis; midbody
ID SPINDLE POLE BODY; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; SCF
UBIQUITIN LIGASE; KINASE INHIBITOR; F-BOX; CHROMOSOME SEGREGATION;
MITOTIC PROGRESSION; CELLS; DEGRADATION; COMPLETION
AB Aurora B kinase is an integral regulator of cytokinesis as it stabilizes the intercellular canal within the midbody to ensure proper chromosomal segregation during cell division. Here we identified an E3 ligase subunit, F-box protein FBXL2, that by recognizing a calmodulin binding signature within Aurora B, ubiquitinates and removes the kinase from the midbody. Calmodulin, by competing with the F-box protein for access to the calmodulin binding signature, protected Aurora B from FBXL2. Calmodulin co-localized with Aurora B on the midbody, preserved Aurora B levels in cells, and stabilized intercellular canals during delayed abscission. Genetic or pharmaceutical depletion of endogenous calmodulin significantly reduced Aurora B protein levels at the midbody resulting in tetraploidy and multi-spindle formation. The calmodulin inhibitor, calmidazolium, reduced Aurora B protein levels resulting in tetraploidy, mitotic arrest, and apoptosis of tumorigenic cells and profoundly inhibited tumor formation in athymic nude mice. These observations indicate molecular interplay between Aurora B and calmodulin in telophase and suggest that calmodulin acts as a checkpoint sensor for chromosomal segregation errors during mitosis.
C1 [Mallampalli, Rama K.; Glasser, Jennifer R.; Coon, Tiffany A.; Chen, Bill B.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA.
[Chen, Bill B.] Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Pittsburgh, PA USA.
[Mallampalli, Rama K.] Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA USA.
[Mallampalli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA.
RP Chen, BB (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA.
EM chenb@upmc.edu
FU US Department of Veterans Affairs; National Institutes of Health
[HL116472, HL096376, HL097376, HL098174]
FX We thank D. W. Gerlich for providing pH2B-mCherry-IRES-puro2 and
pMyrPalm-mEGFP plasmids. This material is based upon work supported, in
part, by the US Department of Veterans Affairs, Veterans Health
Administration, Office of Research and Development, Biomedical
Laboratory Research and Development. This work was supported by a Merit
Review Award from the US Department of Veterans Affairs and National
Institutes of Health R01 grants HL116472 (to B. B. C.), HL096376,
HL097376 and HL098174 (to R.K.M.).
NR 65
TC 5
Z9 5
U1 0
U2 4
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4101
J9 CELL CYCLE
JI Cell Cycle
PD FEB 15
PY 2013
VL 12
IS 4
BP 663
EP 673
DI 10.4161/cc.23586
PG 11
WC Cell Biology
SC Cell Biology
GA 089PR
UT WOS:000314923000022
PM 23370391
ER
PT J
AU Zaid, TM
Yeung, TL
Thompson, MS
Leung, CS
Harding, T
Co, NN
Schmandt, RS
Kwan, SY
Rodriguez-Aguay, C
Lopez-Berestein, G
Sood, AK
Wong, KK
Birrer, MJ
Mok, SC
AF Zaid, Tarrik M.
Yeung, Tsz-Lun
Thompson, Melissa S.
Leung, Cecilia S.
Harding, Tom
Co, Ngai-Na
Schmandt, Rosie S.
Kwan, Suet-Ying
Rodriguez-Aguay, Cristian
Lopez-Berestein, Gabriel
Sood, Anil K.
Wong, Kwong-Kwok
Birrer, Michael J.
Mok, Samuel C.
TI Identification of FGFR4 as a Potential Therapeutic Target for
Advanced-Stage, High-Grade Serous Ovarian Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID FIBROBLAST-GROWTH-FACTOR; FACTOR RECEPTORS; BLADDER-CANCER;
BREAST-CANCER; MUTATIONS; CARCINOMA; EXPRESSION; CISPLATIN; PACLITAXEL;
BINDING
AB Purpose: To evaluate the prognostic value of fibroblast growth factor receptor 4 (FGFR4) protein expression in patients with advanced-stage, high-grade serous ovarian cancer, delineate the functional role of FGFR4 in ovarian cancer progression, and evaluate the feasibility of targeting FGFR4 in serous ovarian cancer treatment.
Experimental Design: Immunolocalization of FGFR4 was conducted on 183 ovarian tumor samples. The collected FGFR4 expression data were correlated with overall survival using Kaplan-Meier and Cox regression analyses. The effects of FGFR4 silencing on ovarian cancer cell growth, survival, invasiveness, apoptosis, and FGF1-mediated signaling pathway activation were evaluated by transfecting cells with FGFR4-specific siRNAs. An orthotopic mouse model was used to evaluate the effect of injection of FGFR4-specific siRNAs and FGFR4 trap protein encapsulated in nanoliposomes on ovarian tumor growth in vivo.
Results: Overexpression of FGFR4 protein was significantly associated with decreased overall survival durations. FGFR4 silencing significantly decreased the proliferation, survival, and invasiveness and increased apoptosis of ovarian cancer cells. Also, downregulation of FGFR4 significantly abrogated the mitogen-activated protein kinase (MAPK), nuclear factor-kappa B (NF-kappa B), and WNT signaling pathways, which are activated by FGF1. Targeting FGFR4 with the FGFR4-specific siRNAs and FGFR4 trap protein significantly decreased ovarian tumor growth in vivo.
Conclusions: FGFR4 is a prognostic marker for advanced-stage, high-grade serous ovarian carcinoma. Silencing FGFR4 and inhibiting ligand-receptor binding significantly decrease ovarian tumor growth both in vitro and in vivo, suggesting that targeting ovarian cancer cells with high levels of FGFR4 protein expression is a new therapeutic modality for this disease and will improve survival of it. Clin Cancer Res; 19(4); 809-20. (c) 2012 AACR.
C1 [Zaid, Tarrik M.; Yeung, Tsz-Lun; Thompson, Melissa S.; Leung, Cecilia S.; Co, Ngai-Na; Schmandt, Rosie S.; Kwan, Suet-Ying; Sood, Anil K.; Wong, Kwong-Kwok; Mok, Samuel C.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA.
[Rodriguez-Aguay, Cristian; Lopez-Berestein, Gabriel] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
[Lopez-Berestein, Gabriel; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.
[Lopez-Berestein, Gabriel; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Houston, TX 77030 USA.
[Harding, Tom] Five Prime Therapeut Inc, San Francisco, CA USA.
[Birrer, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
RP Mok, SC (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Unit 1362, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM scmok@mdanderson.org
OI Wong, Kwong-Kwok/0000-0002-0375-6669; Kwan, Suet
Ying/0000-0002-8222-3827
FU Gilder Foundation; MD Anderson Ovarian Cancer SPORE grant from the
National Institutes of Health [P50 CA083639]; MD Anderson Cancer Center
[CA016672]; [R01 CA133057]; [RC4 CA156551]; [U54 CA151668]
FX This study was supported in part by grants R01 CA133057 (S.C. Mok), RC4
CA156551 (M.J. Birrer), and U54 CA151668 (A.K. Sood); the Gilder
Foundation (A.K. Sood); and MD Anderson Ovarian Cancer SPORE grant P50
CA083639 (S.C. Mok) from the National Institutes of Health. This
research is supported in part by the MD Anderson Cancer Center Support
Grant CA016672.
NR 42
TC 26
Z9 26
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 15
PY 2013
VL 19
IS 4
BP 809
EP 820
DI 10.1158/1078-0432.CCR-12-2736
PG 12
WC Oncology
SC Oncology
GA 091CJ
UT WOS:000315026200007
PM 23344261
ER
PT J
AU Reardon, DA
Groves, MD
Wen, PY
Nabors, L
Mikkelsen, T
Rosenfeld, S
Raizer, J
Barriuso, J
McLendon, RE
Suttle, AB
Ma, B
Curtis, CM
Dar, MM
de Bono, J
AF Reardon, David A.
Groves, Morris D.
Wen, Patrick Y.
Nabors, Louis
Mikkelsen, Tom
Rosenfeld, Steve
Raizer, Jeffrey
Barriuso, Jorge
McLendon, Roger E.
Suttle, A. Benjamin
Ma, Bo
Curtis, C. Martin
Dar, Mohammed M.
de Bono, Johann
TI A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult
Patients with Relapsed Malignant Glioma
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; RECURRENT GLIOBLASTOMA-MULTIFORME; INTEGRATED
GENOMIC ANALYSIS; PROGRESSION-FREE SURVIVAL; HIGH-GRADE GLIOMAS; II
TRIAL; TUMOR ANGIOGENESIS; KINASE INHIBITORS; ANTI-VEGF; IN-VIVO
AB Purpose: Increased mitogenic signaling and angiogenesis, frequently facilitated by somatic activation of EGF receptor (EGFR; ErbB1) and/or loss of PTEN, and VEGF overexpression, respectively, drive malignant glioma growth. We hypothesized that patients with recurrent glioblastoma would exhibit differential antitumor benefit based on tumor PTEN/EGFRvIII status when treated with the antiangiogenic agent pazopanib and the ErbB inhibitor lapatinib.
Experimental Design: A phase II study evaluated the antitumor activity of pazopanib 400 mg/d plus lapatinib 1,000 mg/d in patients with grade 4 malignant glioma and known PTEN/EGFRvIII status not receiving enzyme-inducing anticonvulsants (EIAC). The phase II study used a two-stage Green-Dahlberg design for futility. An independent, parallel phase I component determined the maximum-tolerated regimen (MTR) of pazopanib and lapatinib in patients with grade 3/4 glioma receiving EIACs.
Results: The six-month progression-free survival (PFS) rates in phase II (n = 41) were 0% and 15% in the PTEN/EGFRvIII-positive and PTEN/EGFRvIII-negative cohorts, respectively, leading to early termination. Two patients (5%) had a partial response and 14 patients (34%) had stable disease lasting 8 or more weeks. In phase I (n = 34), the MTR was not reached. On the basis of pharmacokinetic and safety review, a regimen of pazopanib 600 mg plus lapatinib 1,000 mg, each twice daily, was considered safe. Concomitant EIACs reduced exposure to pazopanib and lapatinib.
Conclusions: The antitumor activity of this combination at the phase II dose tested was limited. Pharmacokinetic data indicated that exposure to lapatinib was subtherapeutic in the phase II evaluation. Evaluation of intratumoral drug delivery and activity may be essential for hypothesis-testing trials with targeted agents in malignant glioma. Clin Cancer Res; 19(4); 900-8. (C) 2012 AACR.
C1 [Reardon, David A.; Wen, Patrick Y.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Groves, Morris D.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Nabors, Louis] Univ Alabama Birmingham, Birmingham, AL USA.
[Mikkelsen, Tom] Henry Ford Hlth Syst, Detroit, MI USA.
[Rosenfeld, Steve] Columbia Univ, New York, NY USA.
[Raizer, Jeffrey] Northwestern Univ, Chicago, IL 60611 USA.
[Barriuso, Jorge; de Bono, Johann] Inst Canc Res, Chester Beatty Labs, London SW3 6JB, England.
[Barriuso, Jorge; de Bono, Johann] Royal Marsden Hosp NHS Fdn Trust, London, England.
[McLendon, Roger E.] Duke Univ, Med Ctr, Durham, NC USA.
[Suttle, A. Benjamin; Ma, Bo; Curtis, C. Martin; Dar, Mohammed M.] GlaxoSmithKline, Res Triangle Pk, NC USA.
RP Reardon, DA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM David_Reardon@DFCI.harvard.edu
FU GlaxoSmithKline, Philadelphia
FX This study was sponsored by GlaxoSmithKline, Philadelphia, PA. Medical
editorial assistance was also funded by GlaxoSmithKline.
NR 47
TC 30
Z9 30
U1 1
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 15
PY 2013
VL 19
IS 4
BP 900
EP 908
DI 10.1158/1078-0432.CCR-12-1707
PG 9
WC Oncology
SC Oncology
GA 091CJ
UT WOS:000315026200015
PM 23363814
ER
PT J
AU Yap, TA
Arkenau, HT
Camidge, DR
George, S
Serkova, NJ
Gwyther, SJ
Spratlin, JL
Lal, R
Spicer, J
Desouza, NM
Leach, MO
Chick, J
Poondru, S
Boinpally, R
Gedrich, R
Brock, K
Stephens, A
Eckhardt, SG
Kaye, SB
Demetri, G
Scurr, M
AF Yap, Timothy A.
Arkenau, Hendrik-Tobias
Camidge, D. Ross
George, Suzanne
Serkova, Natalie J.
Gwyther, Stephen J.
Spratlin, Jennifer L.
Lal, Rohit
Spicer, James
Desouza, Nandita M.
Leach, Martin O.
Chick, Jon
Poondru, Srinivasu
Boinpally, Ramesh
Gedrich, Richard
Brock, Katie
Stephens, Andrew
Eckhardt, S. Gail
Kaye, Stan B.
Demetri, George
Scurr, Michelle
TI First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel
Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism
Studies
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID GASTROINTESTINAL STROMAL TUMORS; RECEPTOR TYROSINE KINASES;
CLINICAL-TRIALS; SOLID TUMORS; ANTITUMOR-ACTIVITY; SOFT-TISSUE; C-KIT;
CANCER; ANGIOGENESIS; SUNITINIB
AB Purpose: OSI-930 is a novel, potent, oral small-molecule receptor tyrosine kinase inhibitor, predominantly against VEGF receptors (VEGFR), c-Kit, and platelet-derived growth factor receptors. A phase I trial was undertaken to determine safety, maximum-tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and antitumor activity of OSI-930 in patients with advanced solid tumors.
Experimental Design: OSI-930 was administered once or twice a day using a modified accelerated titration design. Pharmacokinetics and plasma soluble VEGFR2 (sVEGFR2) studies were undertaken. Dynamic contrast-enhanced MRI (DCE-MRI) and 2[18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) MTD expansion cohorts were conducted.
Results: Fifty-eight patients received OSI-930 in 2 schedules; once a day schedule: 12 patients at doses up to 1,600 mg without reaching MTD; twice a day schedule: 46 patients at 400 mg (n = 7), 500 mg (n = 31), and 600 mg(n = 8). Dose-limiting toxicities were observed at 600 mg twice a day (n = 3): G3 rash (n = 2) and G4 gamma-glutamyltransferase, establishing the MTD at 500 mg twice a day. Common G1-2 toxicities included fatigue, diarrhea, nausea, and rash. Antitumor responses were seen in 2 patients with advanced ovarian cancer [Response Evaluation Criteria in Solid Tumors (RECIST) partial response (PR) (n = 1); GCIG CA125 response (n = 1)]. Eleven of 19 heavily pretreated imatinib-resistant patients with gastrointestinal stromal tumors achieved RECIST stable disease (median duration: 126 days), with FDG-PET scans showing PRs in 4 of 9 patients. OSI-930 exposure increased with dose; substantial decreases in sVEGFR levels were observed with OSI-930 twice a day doses >= 400 mg, while DCE-MRI responses were shown in 4 of 6 patients.
Conclusions: OSI-930 is safe and well tolerated, with pharmacokinetic-pharmacodynamic data supporting proof-of-mechanism with clinically relevant antitumor activity. Clin Cancer Res; 19(4); 909-19. (c) 2012 AACR.
C1 [Yap, Timothy A.; Arkenau, Hendrik-Tobias; Lal, Rohit; Spicer, James; Kaye, Stan B.; Scurr, Michelle] Royal Marsden NHS Fdn Trust, Drug Dev Unit, Sutton SM2 5PT, Surrey, England.
[Yap, Timothy A.; Kaye, Stan B.; Scurr, Michelle] Inst Canc Res, Div Clin Studies, Sutton, Surrey, England.
[Desouza, Nandita M.; Leach, Martin O.] Inst Canc Res, Canc Res UK, Sutton, Surrey, England.
[Desouza, Nandita M.; Leach, Martin O.] Inst Canc Res, Engn & Phys Sci Res Council, Canc Imaging Ctr, Sutton, Surrey, England.
[Gwyther, Stephen J.] E Surrey Hosp, Redhill, Surrey, England.
[Camidge, D. Ross; Serkova, Natalie J.; Spratlin, Jennifer L.; Eckhardt, S. Gail] Univ Colorado, Denver, CO 80202 USA.
[George, Suzanne; Demetri, George] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Chick, Jon; Poondru, Srinivasu; Boinpally, Ramesh; Gedrich, Richard; Brock, Katie; Stephens, Andrew] OSI Pharmaceut LLC, Northbrook, IL USA.
RP Kaye, SB (reprint author), Royal Marsden NHS Fdn Trust, Drug Dev Unit, Downs Rd, Sutton SM2 5PT, Surrey, England.
EM stan.kaye@rmh.nhs.uk
RI leach, martin/C-2248-2008
OI leach, martin/0000-0002-0756-5368
FU Bayer; Novartis; OSI Pharmaceuticals LLC; Cancer Research UK;
Engineering and Physical Sciences Research Council; Experimental Cancer
Medicine Centre; NIH Research Biomedical Research Centre
FX D.R. Camidge is a consultant/advisory board member of OSI
Pharmaceuticals. S. George has commercial research grants from Bayer and
Novartis and is a consultant/advisory board member of Bayer, GSK, and
Pfizer. A. Stephens has ownership interest (including patents) in OSI
Pharmaceuticals. S.B. Kaye is a consultant/advisory board member of
Astellas Advisory Board. No potential conflicts of interest were
disclosed by the other authors.; This study was supported by OSI
Pharmaceuticals LLC, a wholly owned subsidiary of Astellas US LLC. The
Drug Development Unit of the Royal Marsden NHS Foundation Trust and The
Institute of Cancer Research is supported in part by a program grant
from Cancer Research UK. The Cancer Imaging Centre at the Institute of
Cancer Research is supported by Cancer Research UK and Engineering and
Physical Sciences Research Council. Support was also provided by the
Experimental Cancer Medicine Centre (to The Institute of Cancer
Research) and the NIH Research Biomedical Research Centre (jointly to
the Royal Marsden NHS Foundation Trust and The Institute of Cancer
Research).
NR 36
TC 7
Z9 7
U1 0
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 15
PY 2013
VL 19
IS 4
BP 909
EP 919
DI 10.1158/1078-0432.CCR-12-2258
PG 11
WC Oncology
SC Oncology
GA 091CJ
UT WOS:000315026200016
PM 23403628
ER
PT J
AU Zhu, AX
Gold, PJ
El-Khoueiry, AB
Abrams, TA
Morikawa, H
Ohishi, N
Ohtomo, T
Philip, PA
AF Zhu, Andrew X.
Gold, Philip J.
El-Khoueiry, Anthony B.
Abrams, Thomas A.
Morikawa, Hideo
Ohishi, Norihisa
Ohtomo, Toshihiko
Philip, Philip A.
TI First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized
Antibody Against Glypican-3, in Patients with Advanced Hepatocellular
Carcinoma
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID EXPRESSION; GROWTH; MARKER; PROMOTES; TUMORS
AB Purpose: GC33 is a novel recombinant fully humanized monoclonal antibody that binds to human glypican-3 (GPC3). The antitumor activity of GC33 was shown in preclinical models of hepatocellular carcinoma (HCC). This first-in-man clinical trial was conducted to evaluate the safety, pharmacokinetic characteristics, and preliminary efficacy of GC33 in patients with advanced HCC.
Experimental Design: Patients with measurable, histologically proven, advanced HCC were enrolled to a dose-escalation study of GC33 (2.5-20 mg/kg) given intravenously weekly. The primary endpoint was to determine the maximum tolerated dose of GC33 for further development. Pharmacokinetic characteristics were measured in serum samples. Immunohistochemistry was conducted on tumor biopsies to evaluate GPC3 expression. Tumor response was assessed every 8 weeks using Response Evaluation Criteria in Solid Tumors criteria.
Results: Twenty patients were enrolled and treated with GC33. A maximum tolerated dose was not reached as there were no dose-limiting toxicities (DLT) up to the highest planned dose level. Common adverse events with all grades included fatigue (50%), constipation (35%), headache (35%), and hyponatremia (35%). The incidence of adverse events seemed not to be dose dependent. Trough serum concentrations at steady state were in excess of target concentration at doses of 5 mg/kg or greater. Median time to progression (TTP) was 26.0 weeks in the GPC3 high expression group and 7.1 weeks in the low expression group (P = 0.033).
Conclusion: This study shows that GC33 was well tolerated in advanced HCC and provides preliminary evidence that GPC3 expression in HCC may be associated with the clinical benefit to GC33 that warrants prospective evaluation. Clin Cancer Res; 19(4); 920-8. (c) 2012 AACR.
C1 [Zhu, Andrew X.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
[Abrams, Thomas A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gold, Philip J.] Swedish Canc Inst, Seattle, WA USA.
[El-Khoueiry, Anthony B.] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
[Morikawa, Hideo; Ohishi, Norihisa; Ohtomo, Toshihiko] Chugai Pharmaceut Co Ltd, Tokyo, Japan.
[Philip, Philip A.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
RP Zhu, AX (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,LH POB 232, Boston, MA 02114 USA.
EM azhu@partners.org
FU Genentech Roche; Chugai Pharmaceutical Co. Ltd.
FX A. El-khoueiry has a commercial research grant, honoraria from speakers'
bureau from, and is a consultant/advisory board member for Genentech
Roche. No potential conflicts of interest were disclosed by the other
authors.; This study was funded by Chugai Pharmaceutical Co. Ltd.
NR 26
TC 43
Z9 45
U1 1
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 15
PY 2013
VL 19
IS 4
BP 920
EP 928
DI 10.1158/1078-0432.CCR-12-2616
PG 9
WC Oncology
SC Oncology
GA 091CJ
UT WOS:000315026200017
PM 23362325
ER
PT J
AU Katholnig, K
Kaltenecker, CC
Hayakawa, H
Rosner, M
Lassnig, C
Zlabinger, GJ
Gaestel, M
Muller, M
Hengstschlager, M
Horl, WH
Park, JM
Saemann, MD
Weichhart, T
AF Katholnig, Karl
Kaltenecker, Christopher C.
Hayakawa, Hiroko
Rosner, Margit
Lassnig, Caroline
Zlabinger, Gerhard J.
Gaestel, Matthias
Mueller, Mathias
Hengstschlaeger, Markus
Hoerl, Walter H.
Park, Jin Mo
Saeemann, Marcus D.
Weichhart, Thomas
TI p38 alpha Senses Environmental Stress To Control Innate Immune Responses
via Mechanistic Target of Rapamycin
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; P38 MAPK; MAMMALIAN TARGET; DENDRITIC CELLS;
COMPLEX 1; MTOR; PHOSPHORYLATION; PATHWAY; TISSUE; AKT
AB The MAPK p38 alpha senses environmental stressors and orchestrates inflammatory and immunomodulatory reactions. However, the molecular mechanism how p38 alpha controls immunomodulatory responses in myeloid cells remains elusive. We found that in monocytes and macrophages, p38 alpha activated the mechanistic target of rapamycin (mTOR) pathway in vitro and in vivo. p38 alpha signaling in myeloid immune cells promoted IL-10 but inhibited IL-12 expression via mTOR and blocked the differentiation of proinflammatory CD4(+) Th1 cells. Cellular stress induced p38 alpha-mediated mTOR activation that was independent of PI3K but dependent on the MAPK-activated protein kinase 2 and on the inhibition of tuberous sclerosis 1 and 2, a negative regulatory complex of mTOR signaling. Remarkably, p38 alpha and PI3K concurrently modulated mTOR to balance IL-12 and IL-10 expression. Our data link p38 alpha to mTOR signaling in myeloid immune cells that is decisive for tuning the immune response in dependence on the environmental milieu. The Journal of Immunology, 2013, 190: 1519-1527.
C1 [Katholnig, Karl; Kaltenecker, Christopher C.; Hoerl, Walter H.; Saeemann, Marcus D.; Weichhart, Thomas] Med Univ Vienna, Dept Internal Med 3, Clin Div Nephrol & Dialysis, A-1090 Vienna, Austria.
[Hayakawa, Hiroko; Park, Jin Mo] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
[Hayakawa, Hiroko; Park, Jin Mo] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Rosner, Margit; Hengstschlaeger, Markus; Weichhart, Thomas] Med Univ Vienna, Inst Med Genet, A-1090 Vienna, Austria.
[Lassnig, Caroline; Mueller, Mathias] Univ Vet Med Vienna, Inst Anim Breeding & Genet & Biomodels Austria, A-1210 Vienna, Austria.
[Zlabinger, Gerhard J.] Med Univ Vienna, Inst Immunol, A-1090 Vienna, Austria.
[Gaestel, Matthias] Hannover Med Sch, Dept Physiol Chem, D-30625 Hannover, Germany.
RP Weichhart, T (reprint author), Med Univ Vienna, Inst Med Genet, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM thomas.weichhart@meduniwien.ac.at
RI Weichhart, Thomas/J-3531-2014
OI Weichhart, Thomas/0000-0002-4349-0797
FU Else-Kroner Fresensius Stiftung; Austrian Science Foundation Fonds zur
Forderung der Wissenschaftlichen Forschung [SFB F28]; Austrian Federal
Ministry for Science and Research (GEN-AU III Austromouse); National
Institutes of Health [AI074957]; Deutsche Forschungsgemeinschaft
FX This work was supported by the Else-Kroner Fresensius Stiftung (to T. W.
and M. D. S.), the Austrian Science Foundation Fonds zur Forderung der
Wissenschaftlichen Forschung (SFB F28 to C. L. and M. M.), the Austrian
Federal Ministry for Science and Research (GEN-AU III Austromouse to C.
L. and M. M.), the National Institutes of Health (Grant AI074957 to
J.M.P.), and the Deutsche Forschungsgemeinschaft (to M.G.).
NR 50
TC 16
Z9 16
U1 1
U2 15
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD FEB 15
PY 2013
VL 190
IS 4
BP 1519
EP 1527
DI 10.4049/jimmunol.1202683
PG 9
WC Immunology
SC Immunology
GA 088HS
UT WOS:000314825400016
PM 23315073
ER
PT J
AU Leonard, DA
Cetrulo, CL
McGrouther, DA
Sachs, DH
AF Leonard, David A.
Cetrulo, Curtis L., Jr.
McGrouther, Duncan A.
Sachs, David H.
TI Induction of Tolerance of Vascularized Composite Allografts
SO TRANSPLANTATION
LA English
DT Review
DE Tolerance; Vascularized composite allotransplantation
ID MAJOR HISTOCOMPATIBILITY COMPLEX; LARGE-ANIMAL-MODEL; DONOR BONE-MARROW;
MIXED LYMPHOHEMATOPOIETIC CHIMERISM; HEMATOPOIETIC-CELL TRANSPLANTATION;
MINIATURE SWINE; NONHUMAN-PRIMATES; TISSUE ALLOTRANSPLANTATION; FACIAL
TRANSPLANTATION; MULTILINEAGE CHIMERISM
AB Vascularized composite allotransplantation has become established as a clinical specialty since the first successful hand transplant was performed in 1998. Data now available indicate that hand and face transplants offer patients good functional outcomes and significant improvements in quality of life. Despite the debilitating nature of the injuries treated by such transplants, the defects are generally not life threatening, making it difficult for physicians to recommend life-long immunosuppression that can itself have grave consequences. One potential solution to this dilemma is the induction of immunologic tolerance of the tissue transplants because tolerance would eliminate the need for such immunosuppression. Transplant tolerance may also prevent chronic rejection, a significant source of late graft loss after organ transplantation.
Induction of mixed hematopoietic chimerism is a robust approach to establishing such transplant tolerance, which recently led to the first clinical application of a tolerance induction protocol for kidney transplantation. In this manuscript, we review the current status of VCA and of research directed toward bringing a tolerance approach to the VCA field. We also discuss the potential clinical significance of these studies and outline the remaining obstacles to introduction of a tolerance induction protocol to clinical practice in hand or face transplantation.
C1 [Leonard, David A.; Cetrulo, Curtis L., Jr.; Sachs, David H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA USA.
[Leonard, David A.; McGrouther, Duncan A.] Univ Manchester, Sch Med, Dept Plast & Reconstruct Surg Res, Manchester, Lancs, England.
RP Sachs, DH (reprint author), Massachusetts Gen Hosp, Transplantat Biol Res Ctr, MGH E Bldg 149,13th St, Boston, MA 02129 USA.
EM david.sachs@tbrc.mgh.harvard.edu
NR 54
TC 16
Z9 16
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0041-1337
J9 TRANSPLANTATION
JI Transplantation
PD FEB 15
PY 2013
VL 95
IS 3
BP 403
EP 409
DI 10.1097/TP.0b013e31826d886d
PG 7
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 088DI
UT WOS:000314813600006
PM 23114532
ER
PT J
AU Stein, DJ
Koenen, KC
Friedman, MJ
Hill, E
McLaughlin, KA
Petukhova, M
Ruscio, AM
Shahly, V
Spiegel, D
Borges, G
Bunting, B
Caldas-de-Almeida, JM
de Girolamo, G
Demyttenaere, K
Florescu, S
Haro, JM
Karam, EG
Kovess-Masfety, V
Lee, S
Matschinger, H
Mladenova, M
Posada-Villa, J
Tachimori, H
Viana, MC
Kessler, RC
AF Stein, Dan J.
Koenen, Karestan C.
Friedman, Matthew J.
Hill, Eric
McLaughlin, Katie A.
Petukhova, Maria
Ruscio, Ayelet Meron
Shahly, Victoria
Spiegel, David
Borges, Guilherme
Bunting, Brendan
Caldas-de-Almeida, Jose Miguel
de Girolamo, Giovanni
Demyttenaere, Koen
Florescu, Silvia
Maria Haro, Josep
Karam, Elie G.
Kovess-Masfety, Viviane
Lee, Sing
Matschinger, Herbert
Mladenova, Maya
Posada-Villa, Jose
Tachimori, Hisateru
Viana, Maria Carmen
Kessler, Ronald C.
TI Dissociation in Posttraumatic Stress Disorder: Evidence from the World
Mental Health Surveys
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Dissociation; dissociative subtype; DSM-5; epidemiology; nosology;
posttraumatic stress disorder; World Mental Health Surveys
ID NATIONAL COMORBIDITY SURVEY; ADULT PSYCHIATRIC-DISORDERS; CHILDHOOD
ADVERSITIES; LATENT STRUCTURE; COMBAT VETERANS; PTSD; TRAUMA;
EXPERIENCES; DSM-5; ABUSE
AB Background: Although the proposal for a dissociative subtype of posttraumatic stress disorder (PTSD) in DSM-5 is supported by considerable clinical and neurobiological evidence, this evidence comes mostly from referred samples in Western countries. Cross-national population epidemiologic surveys were analyzed to evaluate generalizability of the subtype in more diverse samples.
Methods: Interviews were administered to 25,018 respondents in 16 countries in the World Health Organization World Mental Health Surveys. The Composite International Diagnostic Interview was used to assess 12-month DSM-IV PTSD and other common DSM-IV disorders. Items from a checklist of past-month nonspecific psychological distress were used to assess dissociative symptoms of depersonalization and derealization. Differences between PTSD with and without these dissociative symptoms were examined across a variety of domains, including index trauma characteristics, prior trauma history, childhood adversity, sociodemographic characteristics, psychiatric comorbidity, functional impairment, and treatment seeking.
Results: Dissociative symptoms were present in 14.4% of respondents with 12-month DSM-IV/Composite International Diagnostic Interview PTSD and did not differ between high and low/middle income countries. Symptoms of dissociation in PTSD were associated with high counts of re-experiencing symptoms and net of these symptom counts with male sex, childhood onset of PTSD, high exposure to prior (to the onset of PTSD) traumatic events and childhood adversities, prior histories of separation anxiety disorder and specific phobia, severe role impairment, and suicidality.
Conclusion: These results provide community epidemiologic data documenting the value of the dissociative subtype in distinguishing a meaningful proportion of severe and impairing cases of PTSD that have distinct correlates across a diverse set of countries.
C1 [Stein, Dan J.] Univ Cape Town, Dept Psychiat & Mental Hlth, ZA-7925 Cape Town, South Africa.
[Koenen, Karestan C.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA.
[Friedman, Matthew J.] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, Hanover, NH USA.
Geisel Sch Med Dartmouth, Hanover, NH USA.
[Hill, Eric; Petukhova, Maria; Shahly, Victoria; Kessler, Ronald C.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[McLaughlin, Katie A.] Harvard Univ, Sch Med, Div Gen Pediat, Childrens Hosp Boston, Boston, MA 02115 USA.
[Ruscio, Ayelet Meron] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA.
[Spiegel, David] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA.
[Borges, Guilherme] Natl Inst Psychiat Mexico, Div Epidemiol & Psychosocial Res, Dept Epidemiol Res, Mexico City, DF, Mexico.
Metropolitan Autonomous Univ, Mexico City, DF, Mexico.
[Bunting, Brendan] Univ Ulster, Psychol Res Inst, Coleraine BT52 1SA, Londonderry, North Ireland.
[Caldas-de-Almeida, Jose Miguel] Univ Nova Lisboa, Fac Ciencias Med, Chron Dis Res Ctr, P-1200 Lisbon, Portugal.
[Caldas-de-Almeida, Jose Miguel] Univ Nova Lisboa, Fac Ciencias Med, Dept Mental Hlth, P-1200 Lisbon, Portugal.
[de Girolamo, Giovanni] Ctr S Giovanni Dio Fatebenefratelli, Ist Ricovero & Cura Carattere Sci, Brescia, Italy.
[Demyttenaere, Koen] Univ Hosp Gasthuisberg, Dept Psychiat, B-3000 Louvain, Belgium.
[Florescu, Silvia] Natl Sch Publ Hlth Management & Profess Dev, Hlth Serv Res & Evaluat Ctr, Bucharest, Romania.
[Maria Haro, Josep] Ctr Invest Biomed Red Salud Mental, Barcelona, Spain.
[Karam, Elie G.] Balamand Univ, Fac Med, Inst Dev Res Advocacy & Appl Care, Med Inst Neuropsychol Disorders,St George Hosp Un, Beirut, Lebanon.
[Kovess-Masfety, Viviane] Univ Paris 05, Equipes Accueil 4069, Paris, France.
[Kovess-Masfety, Viviane] Ecole Hautes Etud Sante Publ, Sch Publ Hlth, Dept Epidemiol, Paris, France.
[Lee, Sing] Chinese Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China.
[Matschinger, Herbert] Univ Leipzig, Inst Social Med Occupat Hlth & Publ Hlth, Publ Hlth Res Unit, D-04109 Leipzig, Germany.
[Mladenova, Maya] New Bulgarian Univ, Sofia, Bulgaria.
[Posada-Villa, Jose] Pontificia Univ Javeriana, Inst Colombiano Sistema Nervioso, Bogota, Colombia.
[Tachimori, Hisateru] Natl Ctr Neurol & Psychiat, Natl Inst Mental Hlth, Tokyo, Japan.
[Viana, Maria Carmen] Univ Fed Espirito Santo, Dept Social Med, Vitoria, Brazil.
RP Kessler, RC (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.
EM Kessler@hcp.med.harvard.edu
RI Lee, Sing/O-2136-2015; Haro, Josep Maria/D-1423-2011; Stein,
Dan/A-1752-2008; Faculdade de Ciencias Medicas, Nova Medical
School/K-6209-2013;
OI Haro, Josep Maria/0000-0002-3984-277X; Stein, Dan/0000-0001-7218-7810;
Viana, Maria Carmen/0000-0002-0464-4845; caldas de almeida, jose
miguel/0000-0003-1902-6772; Borges, Guilherme/0000-0002-3269-0507;
McLaughlin, Katie/0000-0002-1362-2410
FU United States National Institute of Mental Health [R01MH070884]; John D.
and Catherine T. MacArthur Foundation; Pfizer Foundation; US Public
Health Service [R13-MH066849, R01-MH069864, R01-MH092526, R01-DA016558];
Fogarty International Center [FIRCA R03-TW006481]; Pan American Health
Organization; Eli Lilly & Company Foundation; Ortho-McNeil
Pharmaceutical, Inc.; GlaxoSmithKline; Bristol-Myers Squibb; Shire
Pharmaceuticals; State of Sao Paulo Research Foundation [03/00204-3];
Ministry of Health; National Center for Public Health Protection;
Ministry of Social Protection; European Commission [QLG5-1999-01042,
SANCO 2004123]; Piedmont Region (Italy); Fondo de Investigacion
Sanitaria, Instituto de Salud Carlos III, Spain [FIS 00/0028];
Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]; Departament
de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III
[CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]; Japan Ministry of
Health, Labour and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026,
H16-KOKORO-013]; Lebanese Ministry of Public Health; World Health
Organization (Lebanon), National Institute of Health/Fogarty
International Center [R03 TW006481-01]; Astra Zeneca; Eli Lilly; Hikma
Pharm; Janssen Cilag; MSD; Novartis; Pfizer; Sanofi Aventis; Servier;
National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280];
National Council on Science and Technology [CONACyT-G30544-H];
PanAmerican Health Organization; Health & Social Care Research &
Development Division of the Public Health Agency; Champalimaud
Foundation; Gulbenkian Foundation; Foundation for Science and
Technology; National Institute of Statistics-National Centre for
Training in Statistics, Statistics [70]; Ministry of Public Health; Eli
Lilly Romania Societate cu Responsabilitate Limitata; National Institute
of Mental Health [U01-MH60220]; National Institute of Drug Abuse;
Substance Abuse and Mental Health Services Administration; Robert Wood
Johnson Foundation [044708]; John W. Alden Trust; Abbott; Eli-Lilly;
Jazz Pharmaceuticals; Johnson Johnson; Lundbeck; Orion; Pharmacia;
Roche; Solvay; Sumitomo; Takeda; Tikvah; Wyeth; AstraZeneca; EliLilly;
Analysis Group Inc.; Eli Lilly Company; EPI-Q; Johnson & Johnson
Pharmaceuticals; Ortho-McNeil Janssen Scientific Affairs.; Pfizer Inc.;
Sanofi-Aventis Groupe; Shire US, Inc.
FX The research reported here was carried out in conjunction with the World
Health Organization World Mental Health (WMH) Survey Initiative. These
activities were supported by the United States National Institute of
Mental Health (R01MH070884), the John D. and Catherine T. MacArthur
Foundation, the Pfizer Foundation, the US Public Health Service
(R13-MH066849, R01-MH069864, R01-MH092526, and R01-DA016558), the
Fogarty International Center (FIRCA R03-TW006481), the Pan American
Health Organization, the Eli Lilly & Company Foundation, Ortho-McNeil
Pharmaceutical, Inc., GlaxoSmithKline, Bristol-Myers Squibb, and Shire
Pharmaceuticals. The Sao Paulo Megacity Mental Health Survey is
supported by the State of Sao Paulo Research Foundation Thematic Project
Grant 03/00204-3. The Bulgarian Epidemiological Study of common mental
disorders is supported by the Ministry of Health and the National Center
for Public Health Protection. The Beijing, Peoples Republic of China
World Mental Health Survey Initiative is supported by the Pfizer
Foundation. The Colombian National Study of Mental Health is supported
by the Ministry of Social Protection. The European Study of the
Epidemiology of Mental Disorders project is funded by the European
Commission (Contracts QLG5-1999-01042; SANCO 2004123), the Piedmont
Region (Italy), Fondo de Investigacion Sanitaria, Instituto de Salud
Carlos III, Spain (FIS 00/0028), Ministerio de Ciencia y Tecnologia,
Spain (SAF 2000-158-CE), Departament de Salut, Generalitat de Catalunya,
Spain, Instituto de Salud Carlos III (CIBER CB06/02/0046, RETICS
RD06/0011 REM-TAP), and other local agencies and by an unrestricted
educational grant from GlaxoSmithKline. The World Mental Health Japan
Survey is supported by the Grant for Research on Psychiatric and
Neurological Diseases and Mental Health (H13-SHOGAI-023,
H14-TOKUBETSU-026, H16-KOKORO-013) from the Japan Ministry of Health,
Labour and Welfare. The Lebanese National Mental Health Survey (Lebanese
Evaluation of the Burden of Ailments and Needs Of the Nation) is
supported by the Lebanese Ministry of Public Health, the World Health
Organization (Lebanon), National Institute of Health/Fogarty
International Center (R03 TW006481-01), anonymous private donations to
the Institute for Development, Research, Advocacy & Applied Care,
Lebanon, and unrestricted Grants from Astra Zeneca, Eli Lilly,
GlaxoSmithKline, Hikma Pharm, Janssen Cilag, MSD, Novartis, Pfizer,
Sanofi Aventis, and Servier. The Mexican National Comorbidity Survey is
supported by The National Institute of Psychiatry Ramon de la Fuente
(INPRFMDIES 4280) and by the National Council on Science and Technology
(CONACyT-G30544-H), with supplemental support from the PanAmerican
Health Organization. The Northern Ireland Study of Mental Health was
funded by the Health & Social Care Research & Development Division of
the Public Health Agency. The Portuguese Mental Health Study was carried
out by the Department of Mental Health, Faculty of Medical Sciences,
NOVA University of Lisbon, with collaboration of the Portuguese Catholic
University, and was funded by Champalimaud Foundation, Gulbenkian
Foundation, Foundation for Science and Technology and Ministry of
Health.; The Romania WMH study projects ''Policies in Mental Health
Area'' and ''National Study regarding Mental Health and Services Use''
were carried out by National School of Public Health & Health Services
Management (former National Institute for Research & Development in
Health), with technical support of Metro Media Transilvania, the
National Institute of Statistics-National Centre for Training in
Statistics, Statistics Contract 70, Cheyenne Services Societate cu
Responsabilitate Limitata, Statistics Netherlands and were funded by
Ministry of Public Health (former Ministry of Health) with supplemental
support of Eli Lilly Romania Societate cu Responsabilitate Limitata. The
US National Comorbidity Survey Replication is supported by the National
Institute of Mental Health (U01-MH60220) with supplemental support from
the National Institute of Drug Abuse, the Substance Abuse and Mental
Health Services Administration, the Robert Wood Johnson Foundation
(Grant 044708), and the John W. Alden Trust.; Dr. Stein has received
research grants and/or consultancy honoraria from Abbott, Astra Zeneca,
Eli-Lilly, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson & Johnson,
Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo,
Takeda, Tikvah, and Wyeth. Dr. Demyttenaere has served on advisory
boards and speaker bureaus for and has research grants from AstraZeneca,
EliLilly, GlaxoSmithKline, Lundbeck, Takeda, and Servier. Dr. Haro has
been a consultant for AstraZeneca, Eli Lilly and Co., and Lundbeck. Dr.
Kessler has been a consultant for AstraZeneca, Analysis Group,
Bristol-Myers Squibb, Cerner-Galt Associates, Eli Lilly & Company,
GlaxoSmithKline Inc., HealthCore Inc., Health Dialog, Integrated
Benefits Institute, John Snow Inc., Kaiser Permanente, Matria Inc.,
Mensante, Merck & Co Inc., Ortho-McNeil Janssen Scientific Affairs,
Pfizer Inc., Primary Care Network, Research Triangle Institute,
Sanofi-Aventis Groupe, Shire US Inc., SRA International Inc., Takeda
Global Research & Development, Transcept Pharmaceuticals Inc., and
Wyeth-Ayerst; has served on advisory boards for Appliance Computing II,
Eli Lilly & Company, Mindsite, Ortho-McNeil Janssen Scientific Affairs,
Plus One Health Management, and Wyeth-Ayerst; and has had research
support for his epidemiological studies from Analysis Group Inc.,
Bristol-Myers Squibb, Eli Lilly & Company, EPI-Q, GlaxoSmithKline,
Johnson & Johnson Pharmaceuticals, Ortho-McNeil Janssen Scientific
Affairs., Pfizer Inc., Sanofi-Aventis Groupe, and Shire US, Inc. Drs.
Koenen and Friedman, Mr. Hill, and Drs. McLaughlin, Petukhova, Ruscio,
Shahly, Spiegel, Borges, Bunting, Caldas-de-Almeida, de Girolamo,
Florescu, Karam, Kovess-Masfety, Lee, Matschinger, Mladenova,
Posada-Villa, Tachimori, and Viana report no biomedical financial
interests or potential conflicts of interest.
NR 60
TC 67
Z9 67
U1 5
U2 60
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD FEB 15
PY 2013
VL 73
IS 4
BP 302
EP 312
DI 10.1016/j.biopsych.2012.08.022
PG 11
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 085SG
UT WOS:000314634000004
PM 23059051
ER
PT J
AU Graham, BM
Milad, MR
AF Graham, Bronwyn M.
Milad, Mohammed R.
TI Blockade of Estrogen by Hormonal Contraceptives Impairs Fear Extinction
in Female Rats and Women
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Anxiety; estradiol; estrous cycle; fear conditioning; gonadal hormones;
menstrual cycle
ID PREFRONTAL CORTEX; RHESUS-MONKEYS; RECEPTOR-BETA; DISORDERS; ESTRADIOL;
PROGESTERONE; MECHANISMS; MODULATE; AMYGDALA; STRESS
AB Background: Fear extinction is a laboratory model of fear inhibition and is the basis of exposure therapy for anxiety disorders. Emerging evidence from naturally cycling female rodents and women indicates that estrogens are necessary to the consolidation of fear extinction. Hormonal contraceptives (HCs) inhibit estrogen production; yet, their effects on fear extinction are unknown.
Methods: We used a cross-species translational approach to investigate the impact of HCs and estradiol supplementation on fear extinction in healthy women (n = 76) and female rats (n = 140).
Results: Women using HCs exhibited significantly poorer extinction recall compared with naturally cycling women. The extinction impairment was also apparent in HC-treated female rats and was associated with reduced serum estradiol levels. The impairment could be rescued in HC-treated rats either by terminating HC treatment after fear learning or by systemic injection of estrogen-receptor agonists before fear extinction, all of which restored serum estradiol levels. Finally, a single administration of estradiol to naturally cycling women significantly enhanced their ability to recall extinction memories.
Conclusions: Together, these findings suggest that HCs may impact women's ability to inhibit fear but that this impairment is not permanent and could potentially be alleviated with estrogen treatment.
C1 Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA.
Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
RP Milad, MR (reprint author), Massachusetts Gen Hosp, CNY 2614,Bldg 149,13th St, Charlestown, MA 02129 USA.
EM milad@nmr.mgh.harvard.edu
FU National Institute of Mental Health [K01MH080346, 1R01MH097880-01];
Department of Psychiatry at Massachusetts General Hospital; American
Australian Association; Harvard Clinical and Translational Science
Center Grant from the National Center for Research Resources [1UL1
RR025758-01]
FX This work was supported by National Institute of Mental Health Grants
K01MH080346 and 1R01MH097880-01 and institutional funds from the
Department of Psychiatry at Massachusetts General Hospital to MRM and a
Neurological Fellowship from the American Australian Association to BMG.
The project was also supported by Harvard Clinical and Translational
Science Center Grant (1UL1 RR025758-01) from the National Center for
Research Resources.
NR 33
TC 65
Z9 65
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD FEB 15
PY 2013
VL 73
IS 4
BP 371
EP 378
DI 10.1016/j.biopsych.2012.09.018
PG 8
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 085SG
UT WOS:000314634000012
PM 23158459
ER
PT J
AU Freedman, RA
Hughes, ME
Ottesen, RA
Weeks, JC
He, YL
Wong, YN
Theriault, R
Keating, NL
AF Freedman, Rachel A.
Hughes, Melissa E.
Ottesen, Rebecca A.
Weeks, Jane C.
He, Yulei
Wong, Yu-Ning
Theriault, Richard
Keating, Nancy L.
TI Use of adjuvant trastuzumab in women with human epidermal growth factor
receptor 2 (HER2)-positive breast cancer by race/ethnicity and education
within the National Comprehensive Cancer Network
SO CANCER
LA English
DT Article
DE breast cancer; disparities; trastuzumab; race; socioeconomic status
ID III COLON-CANCER; OLDER WOMEN; SOCIOECONOMIC-STATUS; MEDICARE PATIENTS;
CHEMOTHERAPY; THERAPY; SURVIVAL; DISPARITIES; OUTCOMES; CARDIOTOXICITY
AB BACKGROUND. Trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive breast cancer is highly efficacious yet costly and time-intensive, and few data are available about its use. The authors of this report examined receipt and completion of adjuvant trastuzumab by race/ethnicity and education for women with HER2-positive disease. METHODS. The National Comprehensive Cancer Network Breast Cancer Outcomes Database was used to identify 1109 women who were diagnosed with stage I through III, HER2-positive breast cancer during September 2005 through December 2008 and were followed for 1 year. The authors used multivariable logistic regression to assess the association of race/ethnicity and education with the receipt of trastuzumab and, among those women who initiated trastuzumab, with the completion of > 270 days of therapy. RESULTS. The cohort was 75% white, 8% black, and 9% Hispanic; and 20% of women had attained a high school degree or less. Most women (83%) received trastuzumab, and no significant differences were observed according to race/ethnicity or socioeconomic status. Among the women who initiated trastuzumab, 73% of black women versus 87% of white women (P = .007) and 70% of women with less than a high school education versus 90% of women with a college degree completed > 270 days of therapy (P = .006). In adjusted analyses, black women (vs white women) and women without a high school degree (vs those with a college degree) had lower odds of completing therapy (black women: odds ratio, 0.45; 95% confidence interval, 0.27-074; white women: odds ratio, 0.27, 95% confidence interval, 0.14-0.51). CONCLUSIONS. Differences in completing trastuzumab therapy were observed according to race and educational attainment among women who received treatment at National Comprehensive Cancer Network centers. Efforts to assure the appropriate use of trastuzumab and to understand treatment barriers are needed and may lead to improved outcomes. The authors report differences in the rate at which patients complete treatment with trastuzumab according to race and education among women who receive treatment at National Comprehensive Cancer Network centers. Efforts to assure the appropriate use of trastuzumab and to understand treatment barriers are needed and may lead to improved outcomes. Cancer 2013. (c) 2012 American Cancer Society.
C1 [Freedman, Rachel A.; Hughes, Melissa E.; Weeks, Jane C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Hughes, Melissa E.; Weeks, Jane C.] Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02215 USA.
[Ottesen, Rebecca A.] City Hope Natl Med Ctr, Div Biostat, Duarte, CA 91010 USA.
[He, Yulei; Keating, Nancy L.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Wong, Yu-Ning] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA.
[Theriault, Richard] Univ Texas MD Anderson Canc Ctr, Dept Med Oncol, Houston, TX 77030 USA.
[Keating, Nancy L.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA.
RP Freedman, RA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM rafreedman@partners.org
FU Susan G. Komen for the Cure Foundation; National Cancer Institute [P50
CA89393]
FX This work was funded in part by the Susan G. Komen for the Cure
Foundation and by grant P50 CA89393 from the National Cancer Institute
to Dana-Farber Cancer Institute.
NR 39
TC 22
Z9 22
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD FEB 15
PY 2013
VL 119
IS 4
BP 839
EP 846
DI 10.1002/cncr.27831
PG 8
WC Oncology
SC Oncology
GA 086BC
UT WOS:000314657000020
PM 23011924
ER
PT J
AU Zafar, SY
Malin, JL
Grambow, SC
Abbott, DH
Kolimaga, JT
Zullig, LL
Weeks, JC
Ayanian, JZ
Kahn, KL
Ganz, PA
Catalano, PJ
West, DW
Provenzale, D
AF Zafar, S. Yousuf
Malin, Jennifer L.
Grambow, Steven C.
Abbott, David H.
Kolimaga, Jane T.
Zullig, Leah L.
Weeks, Jane C.
Ayanian, John Z.
Kahn, Katherine L.
Ganz, Patricia A.
Catalano, Paul J.
West, Dee W.
Provenzale, Dawn
CA Canc Care Outcomes Res & Surveilla
TI Chemotherapy Use and Patient Treatment Preferences in Advanced
Colorectal Cancer A Prospective Cohort Study
SO CANCER
LA English
DT Article
DE colorectal cancer; decision making; patient preference; cohort studies;
quality of health care
ID III COLON-CANCER; CARE OUTCOMES RESEARCH; ADJUVANT CHEMOTHERAPY;
DECISION-MAKING; BREAST-CANCER; RANDOMIZED-TRIAL; THERAPY; AGE;
COMORBIDITY; SURGERY
AB BACKGROUND: The objective of this study was to determine how patient preferences guide the course of palliative chemotherapy for advanced colorectal cancer. METHODS: Eligible patients with metastatic colorectal cancer (mCRC) were enrolled nationwide in a prospective, population-based cohort study. Data were obtained through medical record abstraction and patient surveys. Logistic regression analysis was used to evaluate patient characteristics associated with visiting medical oncology and receiving chemotherapy and patient characteristics, beliefs, and preferences associated with receiving >1 line of chemotherapy and receiving combination chemotherapy. RESULTS: Among 702 patients with mCRC, 91% consulted a medical oncologist; and among those, 82% received chemotherapy. Patients ages 65 to 75 years and aged 75 years were less likely to visit an oncologist, as were patients who were too sick to complete their own survey. In adjusted analyses, patients aged 75 years who had moderate or severe comorbidity were less likely to receive chemotherapy, as were patients who were too sick to complete their own survey. Patients received chemotherapy even if they believed that chemotherapy would not extend their life (90%) or that chemotherapy would not likely help with cancer-related problems (89%), or patients preferred treatment focusing on comfort even if it meant not living as long (90%). Older patients were less likely to receive combination first-line therapy. Patient preferences and beliefs were not associated with receipt of >1 line of chemotherapy or combination chemotherapy. CONCLUSIONS: The majority of patients received chemotherapy even if they expressed negative or marginal preferences or beliefs regarding chemotherapy. Patient preferences and beliefs were not associated with the intensity or number of chemotherapy regimens. Cancer 2013. (c) 2012 American Cancer Society.
C1 [Zafar, S. Yousuf] Duke Canc Inst, Durham, NC 27710 USA.
[Zafar, S. Yousuf; Grambow, Steven C.; Abbott, David H.; Kolimaga, Jane T.; Zullig, Leah L.; Provenzale, Dawn] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
[Malin, Jennifer L.] Greater Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
[Malin, Jennifer L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Med Oncol, Los Angeles, CA 90095 USA.
[Grambow, Steven C.] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kolimaga, Jane T.] Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA.
[Zullig, Leah L.] Univ N Carolina, Dept Hlth Policy & Management, Chapel Hill, NC USA.
[Weeks, Jane C.] Dana Farber Canc Inst, Dept Hlth Policy & Management, Boston, MA 02115 USA.
[Ayanian, John Z.] Harvard Univ, Dept Hlth Care Policy, Sch Med, Cambridge, MA 02138 USA.
[Ayanian, John Z.] Brigham & Womens Hosp Boston, Div Gen Med, Boston, MA USA.
[Kahn, Katherine L.] RAND Corp, Santa Monica, CA USA.
[Kahn, Katherine L.] Univ Calif Los Angeles, Dept Med, Div Gen Internal Med, Los Angeles, CA 90024 USA.
[Kahn, Katherine L.] Univ Calif Los Angeles, Dept Med, Div Hlth Serv Res, Los Angeles, CA 90024 USA.
[Ganz, Patricia A.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA.
[Catalano, Paul J.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Catalano, Paul J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[West, Dee W.] Canc Prevent Inst Calif, Fremont, CA USA.
[West, Dee W.] Stanford Sch Med, Stanford, CA USA.
RP Zafar, SY (reprint author), Duke Canc Inst, DUMC 3505, Durham, NC 27710 USA.
EM yousuf.zafar@duke.edu
RI Grambow, Steven/E-1422-2015;
OI Grambow, Steven/0000-0001-6037-3253; Zafar, S.
Yousuf/0000-0002-9039-5258
FU American Cancer Society; Duke Cancer Institute; National Cancer
Institute [5R25CA116339, U01 CA093344, U01 CA093332]; Harvard Medical
School/Northern California Cancer Center [U01 CA093324]; RAND/UCLA [U01
CA093348]; University of Alabama at Birmingham [U01 CA093329];
University of Iowa [U01 CA093339]; Agency for Healthcare Research
Quality [03-438MO-03]; Department of Veterans Affairs [HSRDCRS 02-164]
FX Dr. Zafar is supported by an American Cancer Society Mentored Research
Scholar Grant and the Duke Cancer Institute Cancer Control Pilot Award.
Dr. Zullig is supported by the National Cancer Institute (5R25CA116339).
This work and the CanCORS Consortium are supported by grants from the
National Cancer Institute to the Statistical Coordinating Center (U01
CA093344) and the National Cancer Institute-supported Primary Data
Collection and Research Centers (Dana-Farber Cancer Institute/Cancer
Research Network [U01 CA093332]; Harvard Medical School/Northern
California Cancer Center [U01 CA093324]; RAND/UCLA [U01 CA093348];
University of Alabama at Birmingham [U01 CA093329]; the University of
Iowa [U01 CA093339]; and the University ofNorth Carolina [U01
CA093326]); the Agency for Healthcare Research Quality (03-438MO-03);
and by a Department of Veterans Affairs grant to the Durham Veterans
Affairs Medical Center (HSRDCRS 02-164).
NR 33
TC 20
Z9 20
U1 1
U2 20
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD FEB 15
PY 2013
VL 119
IS 4
BP 854
EP 862
DI 10.1002/cncr.27815
PG 9
WC Oncology
SC Oncology
GA 086BC
UT WOS:000314657000022
PM 22972673
ER
PT J
AU Morgans, AK
Smith, MR
O'Malley, AJ
Keating, NL
AF Morgans, Alicia K.
Smith, Matthew R.
O'Malley, A. James
Keating, Nancy L.
TI Bone density testing among prostate cancer survivors treated with
androgen-deprivation therapy
SO CANCER
LA English
DT Article
DE prostate cancer; cancer survivorship; male osteoporosis; androgen
deprivation therapy; side effects of treatment
ID MINERAL DENSITY; RACIAL-DIFFERENCES; HORMONE AGONISTS; OLDER MEN;
OSTEOPOROSIS; FRACTURE; CARCINOMA; RISK; MASS; MORTALITY
AB BACKGROUND. Androgen-deprivation therapy (ADT) causes bone loss and fractures. Guidelines recommend bone density testing before and during ADT to characterize fracture risk. The authors of the current report assessed bone density testing among men who received ADT for 1 year. METHODS. Surveillance, Epidemiology, and End Results/Medicare data were used to identify 28,960 men aged > 65 years with local/regional prostate cancer diagnosed from 2001 to 2007 who were followed through 2009 and who received 1 year of continuous ADT. Bone density testing was documented in the 18-month period beginning 6 months before ADT initiation. Logistic regression was used to identify the factors associated with bone density testing. RESULTS. Among men who received 1 year of ADT, 10.2% had a bone density assessment from 6 months before starting ADT through 1 year after. Bone density testing increased over time (14.5% of men who initiated ADT in 2007-2008 vs 6% of men who initiated ADT in 2001-2002; odds ratio for 2007-2008 vs 2001-2002, 2.29; 95% confidence interval, 1.83-2.85). Less bone density testing was observed among men aged 85 years versus men ages 66 to 69 years (odds ratio, 0.76; 95% confidence interval, 0.65-0.89), among black men versus white men (odds ratio, 0.72; 95% confidence interval, 0.61-0.86), and among men in areas with lower educational attainment (P < .001). Men who visited a medical oncologist and/or a primary care provider in addition to a urologist had higher odds of testing than men who only consulted a urologist (P < .001). CONCLUSIONS. Few men who received ADT for prostate cancer underwent bone density testing, particularly older men, black men, and those living in areas with low educational attainment. Visiting a medical oncologist was associated with increased odds of testing. Interventions are needed to increase bone density testing among men who receive long-term ADT. Data on bone density testing for nonmilitary populations of prostate cancer survivors in the United States who have received long-term androgen-deprivation therapy (ADT) have not been published. The current analysis of Surveillance, Epidemiology, and End Results/Medicare data suggests that few prostate cancer survivors who receive long-term ADT undergo bone density testing; and several key populations, including African Americans and older men, have considerably lower rates of bone density screening. Cancer 2013. (c) 2012 American Cancer Society.
C1 [Morgans, Alicia K.; Smith, Matthew R.] Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA.
[O'Malley, A. James; Keating, Nancy L.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Keating, Nancy L.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02115 USA.
RP Keating, NL (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.
EM keating@hcp.med.harvard.edu
FU Prostate Cancer Foundation; California Department of Public Health
[103885]; National Cancer Institute [N01-PC-35136, N01-PC-35139,
N02-PC-15105]; Centers for Disease Control and Prevention's National
Program of Cancer Registries [U55/CCR921930-02]
FX This study was funded by the Prostate Cancer Foundation.; The collection
of the California cancer incidence data used in this study was supported
by the California Department of Public Health as part of the statewide
cancer reporting program mandated by California Health and Safety Code
Section 103885; the National Cancer Institute's Surveillance,
Epidemiology and End Results Program under contract N01-PC-35136 awarded
to the Northern California Cancer Center, contract N01-PC-35139 awarded
to the University of Southern California, and contract N02-PC-15105
awarded to the Public Health Institute; and the Centers for Disease
Control and Prevention's National Program of Cancer Registries, under
agreement #U55/CCR921930-02 awarded to the Public Health Institute. The
ideas and opinions expressed herein are those of the author(s) and
endorsement by the State of California, Department of Public Health the
National Cancer Institute, and the Centers for Disease Control and
Prevention or their Contractors and Subcontractors is not intended nor
should be inferred.
NR 35
TC 12
Z9 12
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD FEB 15
PY 2013
VL 119
IS 4
BP 863
EP 870
DI 10.1002/cncr.27830
PG 8
WC Oncology
SC Oncology
GA 086BC
UT WOS:000314657000023
PM 23065626
ER
PT J
AU Friedrich, P
Ortiz, R
Strait, K
Fuentes, S
Gamboa, Y
Arambu, I
Ah-Chu-Sanchez, M
London, W
Rodriguez-Galindo, C
Antillon-Klussmann, F
Baez, F
AF Friedrich, Paola
Ortiz, Roberta
Strait, Kelly
Fuentes, Soad
Gamboa, Yessica
Arambu, Ingrid
Ah-Chu-Sanchez, Maria
London, Wendy
Rodriguez-Galindo, Carlos
Antillon-Klussmann, Federico
Baez, Fulgencio
CA Cent Amer Assoc Pediat Hemtologist
TI Pediatric Sarcoma in Central America Outcomes, Challenges, and Plans for
Improvement
SO CANCER
LA English
DT Article
DE pediatric sarcoma; developing countries; treatment abandonment; outcomes
research; international outreach
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; SOFT-TISSUE SARCOMAS; DEVELOPING-COUNTRY;
INCOME COUNTRIES; EL SALVADOR; CANCER; CHILDREN; ABANDONMENT; THERAPY;
EPIDEMIOLOGY
AB BACKGROUND: Children with cancer in middle-income countries have inferior outcomes compared with similar children in high-income countries. The magnitude and drivers of this survival gap are not well understood. In the current report, the authors sought to describe patterns of clinical presentation, magnitude of treatment abandonment, and survival in children with sarcoma in Central America. METHODS: A retrospective review was conducted of hospital-based registries from national pediatric oncology referral centers. Patients with newly diagnosed osteosarcoma, Ewing sarcoma, rhabdomyosarcoma (RMS), and soft tissue sarcoma (STS) between January 1, 2000 and December 31, 2009 were included. Survival analyses were performed first using standard definitions of overall survival (OS) and event-free survival (EFS) and then with abandonment included as an event (abandonment-sensitive OS and abandonment-sensitive EFS). RESULTS: In total, 785 new cases of pediatric sarcoma were reported (264 diagnoses of osteosarcoma, 175 diagnoses of Ewing sarcoma, 240 diagnoses of RMS, and 106 diagnoses of STS). The rate of metastatic disease at presentation was high (osteosarcoma, 38%; Ewing sarcoma, 39%; RMS, 29%; and STS, 21%). The treatment abandonment rate also was high, particularly among patients with extremity bone sarcomas (osteosarcoma, 30%; Ewing sarcoma, 15%; RMS, 25%; and STS, 15%). Of 559 patients who experienced a first event, 59% had either recurrent or progressive disease. The 4-year OS rate (+/- standard error) was 40% +/- 3%, and the EFS rate was 30% +/- 2%; however, these rates decreased further to 31% +/- 2% and 24% +/- 2%, respectively, when abandonment was taken into account. CONCLUSIONS: The current results indicated that high rates of metastases and treatment abandonment and difficulty with upfront treatment effectiveness are important contributors to the poor survival of children with pediatric sarcomas in Central America. Initiatives for early diagnosis, psychosocial support, quality improvement, and multidisciplinary care are warranted to improve outcomes. Cancer 2013. (c) 2012 American Cancer Society.
C1 [Friedrich, Paola; Strait, Kelly; London, Wendy; Rodriguez-Galindo, Carlos] Dana Farber Childrens Hosp Canc Ctr, Dept Pediat Hematol Oncol, Boston, MA USA.
[Ortiz, Roberta; Baez, Fulgencio] La Mascota Childrens Hosp, Dept Pediat Oncol, Managua, Nicaragua.
[Fuentes, Soad; Antillon-Klussmann, Federico] Benjamin Bloom Natl Childrens Hosp, Dept Pediat Oncol, San Salvador, El Salvador.
[Gamboa, Yessica] Natl Childrens Hosp, Dept Pediat Oncol, San Jose, Costa Rica.
[Arambu, Ingrid] Maternal & Child Hosp, Dept Pediat Oncol, Tegucigalpa, Honduras.
[Ah-Chu-Sanchez, Maria] Childrens Hosp, Dept Pediat Oncol, Panama City, Panama.
Dept Pediat Oncol, Natl Pediat Oncol Unit, Guatemala City, Guatemala.
RP Friedrich, P (reprint author), Dana Farber Canc Inst, 450 Brookline Ave D322A, Boston, MA 02115 USA.
EM paola_friedrich-medina@dfci.harvard.edu
OI Friedrich, Paola/0000-0002-5265-3113
FU Dana-Farber/Children's Hospital Cancer Center Global Health Initiative;
St. Jude Children's Research Hospital International Outreach Program;
National Institutes of Health [T32 HL 7574, R25 CA092203]
FX We gratefully acknowledge support from the Dana-Farber/Children's
Hospital Cancer Center Global Health Initiative and the St. Jude
Children's Research Hospital International Outreach Program, and we
thank the Central American Association of Pediatric Hematologists and
Oncologists data managers and clinical staff for their inspiring work.;
Dr. Friedrich was supported by Pathophysiology of Human Blood Cells (T32
HL 7574) and Program in Cancer Outcomes Research Training (R25
CA092203), both National Institutes of Health training grants.
NR 36
TC 11
Z9 11
U1 0
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD FEB 15
PY 2013
VL 119
IS 4
BP 871
EP 879
DI 10.1002/cncr.27816
PG 9
WC Oncology
SC Oncology
GA 086BC
UT WOS:000314657000024
PM 22972687
ER
PT J
AU Ahearn, EP
Chen, P
Hertzberg, M
Cornette, M
Suvalsky, L
Cooley-Olson, D
Swanlund, J
Eickhoff, J
Becker, T
Krahn, D
AF Ahearn, Eileen P.
Chen, Peijun
Hertzberg, Michael
Cornette, Michelle
Suvalsky, Lori
Cooley-Olson, Deanna
Swanlund, Jamie
Eickhoff, Jens
Becker, Tara
Krahn, Dean
TI Suicide attempts in veterans with bipolar disorder during treatment with
lithium, divalproex, and atypical antipsychotics
SO JOURNAL OF AFFECTIVE DISORDERS
LA English
DT Article
DE Bipolar; Suicide; Atypical antipsychotics
ID SCHIZOPHRENIA-PATIENTS; CLOZAPINE TREATMENT; BEHAVIOR; TRIAL; RISK;
PHARMACOTHERAPY; HALOPERIDOL; RISPERIDONE; AGGRESSION; PREVENTION
AB Suicide attempt rates were assessed in 1306 subjects in this 6 year retrospective study of Bipolar disorder. Participants were Veterans from 5 different Veterans Administration Hospitals who met criteria for bipolar type 1 or 2 and who had at least one prescription for lithium or divalproex or both during the study period. This study focused on the impact of atypical antipsychotics on the suicide attempt rate when used in addition to or in place of lithium or divalproex. Medication exposure was calculated using computerized pharmacy records. Suicide attempts were established through chart review including emergency room records, inpatient records, and outpatient records. There were a total of 117 suicide attempts and 2 suicide completions during the study period. Most attempts (59%) occurred when patients were on no medications. Nearly 90% of subjects spent an average of 45 months during the 6 year period on none of the aforementioned medications. The lowest percentage of suicide attempts (15%) occurred while on lithium, 21% while on divalproex and 24% while on atypical antipsychotics. When total months of exposure were taken into account, the lowest attempt rate occurred on lithium plus divalproex (6.3 attempts per 10,000 months of exposure), followed by divalproex alone (7.0 attempts/10,000 months of exposure), and lithium alone (7.7 attempts per 10,000 months of exposure). Patients on atypical antipsychotics alone had an attempt rate of 26.1 attempts per 10,000 months of exposure. In this study, lithium and divalproex provided protection against suicide attempts. Results need to be replicated in future prospective studies and clearly strategies for improving medication compliance among veterans are warranted. Published by Elsevier B.V.
C1 [Ahearn, Eileen P.; Cooley-Olson, Deanna; Swanlund, Jamie; Krahn, Dean] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.
[Ahearn, Eileen P.; Eickhoff, Jens; Becker, Tara; Krahn, Dean] Univ Wisconsin, Madison, WI USA.
[Chen, Peijun] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA.
[Chen, Peijun] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Hertzberg, Michael] Durham VA Med Ctr, Durham, NC USA.
[Hertzberg, Michael] Duke Univ, Med Ctr, Durham, NC 27706 USA.
[Cornette, Michelle] Med Coll Wisconsin, Milwaukee, WI USA.
[Suvalsky, Lori] Minneapolis VA Med Ctr, Minneapolis, MN USA.
RP Ahearn, EP (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA.
EM Eileen.Ahearn@va.gov
FU American Foundation for Suicide Prevention
FX This work was supported by a grant from the American Foundation for
Suicide Prevention. The Foundation had no direct involvement in the
study other than to provide funding.
NR 30
TC 9
Z9 11
U1 1
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-0327
J9 J AFFECT DISORDERS
JI J. Affect. Disord.
PD FEB 15
PY 2013
VL 145
IS 1
BP 77
EP 82
DI 10.1016/j.jad.2012.07.015
PG 6
WC Clinical Neurology; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 078IK
UT WOS:000314091800011
PM 22871534
ER
PT J
AU Harkness, JH
Hitzemann, RJ
Edmunds, S
Phillips, TJ
AF Harkness, John H.
Hitzemann, Robert J.
Edmunds, Stephanie
Phillips, Tamara J.
TI Effects of sodium butyrate on methamphetamine-sensitized locomotor
activity
SO BEHAVIOURAL BRAIN RESEARCH
LA English
DT Article
DE Sensitization; Psychostimulant; Histone acetylation; Epigenetics;
Addiction
ID INDUCED BEHAVIORAL SENSITIZATION; HISTONE DEACETYLASE INHIBITORS;
INCENTIVE-SENSITIZATION; GENE-EXPRESSION; INBRED MICE; DELTA-FOSB;
ADDICTION; COCAINE; MECHANISMS; STIMULATION
AB Neuroadaptations associated with behavioral sensitization induced by repeated exposure to methamphetamine (MA) appear to be involved in compulsive drug pursuit and use. Increased histone acetylation, an epigenetic effect resulting in altered gene expression, may promote sensitized responses to psychostimulants. The role of histone acetylation in the expression and acquisition of MA-induced locomotor sensitization was examined by measuring the effect of histone deacetylase inhibition by sodium butyrate (NaB). For the effect on expression, mice were treated repeatedly with MA (10 days of 2 mg/kg MA) or saline (10 days), and then vehicle or NaB (630 mg/kg, intraperitoneally) was administered 30 min prior to MA challenge and locomotor response was measured. NaB treatment increased the locomotor response to MA in both acutely MA treated and sensitized animals. For acquisition, NaB was administered 30 min prior to each MA exposure (10 days of 1 or 2 mg/kg), but not prior to the MA challenge test. Treatment with NaB during the sensitization acquisition period significantly increased locomotor activation by MA in sensitized mice only. NaB alone did not significantly alter locomotor activity. Acute NaB or MA, but not the combination, increased striatal acetylation at histone H4. Repeated treatment with MA, but not NaB or MA plus NaB, increased striatal acetylation at histone H3. Although increased histone acetylation may alter the expression of genes involved in acute locomotor response to MA and in the acquisition of MA-induced sensitization, results for acetylation at H3 and H4 showed little correspondence with behavior. Published by Elsevier B.V.
C1 [Harkness, John H.; Hitzemann, Robert J.; Edmunds, Stephanie; Phillips, Tamara J.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
[Harkness, John H.; Hitzemann, Robert J.; Phillips, Tamara J.] Oregon Hlth & Sci Univ, Methamphetamine Abuse Res Ctr, Portland, OR 97239 USA.
[Hitzemann, Robert J.; Edmunds, Stephanie; Phillips, Tamara J.] Portland VA Med Ctr, Portland, OR 97239 USA.
RP Phillips, TJ (reprint author), VA Med Ctr, R&D32,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM harknesj@ohsu.edu; hitzeman@ohsu.edu; edmundss@ohsu.edu;
phillipt@ohsu.edu
FU Department of Veterans Affairs, and NIDA/NIH [T32DA07262, P50DA018165]
FX This work was supported by the Department of Veterans Affairs, and
NIDA/NIH grants T32DA07262 and P50DA018165. Thank you to James Stafford
for helpful discussions regarding the IHC procedure and interpretation.
NR 43
TC 6
Z9 6
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-4328
EI 1872-7549
J9 BEHAV BRAIN RES
JI Behav. Brain Res.
PD FEB 15
PY 2013
VL 239
BP 139
EP 147
DI 10.1016/j.bbr.2012.10.046
PG 9
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 079CA
UT WOS:000314146600017
PM 23137698
ER
PT J
AU Jacobson, KR
Theron, D
Kendall, EA
Franke, MF
Barnard, M
van Helden, PD
Victor, TC
Streicher, EM
Murray, MB
Warren, RM
AF Jacobson, Karen R.
Theron, Danie
Kendall, Emily A.
Franke, Molly F.
Barnard, Marinus
van Helden, Paul D.
Victor, Tommie C.
Streicher, Elizabeth M.
Murray, Megan B.
Warren, Robin M.
TI Implementation of GenoType MTBDRplus Reduces Time to Multidrug-Resistant
Tuberculosis Therapy Initiation in South Africa
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE multidrug-resistant tuberculosis; MTBDRplus; rapid molecular diagnostic
ID TREATMENT OUTCOMES; DIAGNOSIS; METAANALYSIS; TB
AB Background. Diagnosis of drug resistance and timely initiation of multidrug-resistant (MDR) tuberculosis therapy are essential to reduce transmission and improve patient outcomes. We sought to determine whether implementation of the rapid MTBDRplus diagnostic shortened the time from specimen collection to patient MDR tuberculosis therapy initiation.
Methods. We conducted a retrospective cohort analysis of 197 MDR tuberculosis patients treated at Brewels-kloof, a rural tuberculosis hospital in Western Cape Province, South Africa, between 2007 and 2011.
Results. Eighty-nine patients (45%) were tested using conventional liquid culture and drug susceptibility testing (DST) on solid medium and 108 (55%) were tested using the MTBDRplus assay after positive acid-fast bacilli or culture. Median time from sample taken to therapy initiation was reduced from 80 days (interquartile range [IQR] 62-100) for conventional DST to 55 days (IQR 37.5-78) with the MTBDRplus. Although the laboratory processing time declined significantly, operational delays persisted both in the laboratory and the clinical infrastructure for getting patients started on treatment. In multivariate analysis, patients tested using the MTBDRplus test had a reduced risk of starting treatment 60 days or more after sputum collection of 0.52 (P < .0001) compared with patients tested with culture-based DST, after adjustment for smear status and site of disease.
Conclusions. Use of MTBDRplus significantly reduced time to MDR tuberculosis treatment initiation. However, DST reporting to clinics was delayed by more than 1 week due, in part, to laboratory operational delays, including dependence on smear and culture positivity prior to MTBDRplus performance. In addition, once MDR tuberculosis was reported, delays in contacting patients and initiating therapy require improvements in clinical infrastructure.
C1 [Jacobson, Karen R.] Harvard Univ, Massachusetts Gen Hosp, Div Infect Dis, Sch Publ Hlth, Boston, MA 02114 USA.
[Kendall, Emily A.] Harvard Univ, Massachusetts Gen Hosp, Dept Med, Sch Publ Hlth, Boston, MA 02114 USA.
[Franke, Molly F.; Murray, Megan B.] Harvard Univ, Sch Publ Hlth, Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02114 USA.
[Murray, Megan B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02114 USA.
[Jacobson, Karen R.; Barnard, Marinus; van Helden, Paul D.; Victor, Tommie C.; Streicher, Elizabeth M.; Warren, Robin M.] Univ Stellenbosch, Ctr Excellence Biomed TB Res,Dept Sci & Technol, Div Mol Biol & Human Genet,Fac Med & Hlth Sci, Natl Res Fdn,Med Res Council,Ctr Mol & Cellular B, Cape Town, South Africa.
[Barnard, Marinus] Natl Hlth Lab Serv, Cape Town, South Africa.
[Theron, Danie] Brewelskloof Hosp, Worcester, South Africa.
RP Jacobson, KR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Div Infect Dis, Sch Publ Hlth, 55 Fruit St,GRJ5-5, Boston, MA 02114 USA.
EM krjacobson@partners.org
OI Kendall, Emily/0000-0002-0083-422X; Streicher,
Elizabeth/0000-0003-3901-1981; Jacobson, Karen/0000-0003-4239-3685
FU Burroughs Wellcome Fund/American Society of Tropical Medicine and
Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases;
National Institutes of Health/Fogarty International Center [1K01
TW009213]; Partner Center of Excellence Travel Grant
FX This work was supported by a Burroughs Wellcome Fund/American Society of
Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical
Infectious Diseases (K. R. J.), the National Institutes of
Health/Fogarty International Center (1K01 TW009213; K. R. J.), and a
Partner Center of Excellence Travel Grant (E. A. K.).
NR 19
TC 34
Z9 34
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD FEB 15
PY 2013
VL 56
IS 4
BP 503
EP 508
DI 10.1093/cid/cis920
PG 6
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 077UR
UT WOS:000314054400006
PM 23090928
ER
PT J
AU Riley, LE
Beigi, RH
AF Riley, Laura E.
Beigi, Richard H.
TI Maternal Pertussis Vaccination: Protecting Neonates From Infection
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Editorial Material
C1 [Riley, Laura E.] Harvard Univ, Massachusetts Gen Hosp, Dept Obstet Gynecol & Reprod Biol, Sch Med, Boston, MA 02214 USA.
[Beigi, Richard H.] Univ Pittsburgh, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Div Reprod Infect Dis,Med Ctr, Pittsburgh, PA 15213 USA.
[Beigi, Richard H.] Univ Pittsburgh, Magee Womens Hosp, Dept Obstet Gynecol & Reprod Sci, Div Obstet Specialties,Med Ctr, Pittsburgh, PA 15213 USA.
RP Riley, LE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Obstet Gynecol & Reprod Biol, Sch Med, 32 Fruit St, Boston, MA 02214 USA.
EM lriley@partners.org
NR 9
TC 0
Z9 0
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD FEB 15
PY 2013
VL 56
IS 4
BP 545
EP 547
DI 10.1093/cid/cis924
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 077UR
UT WOS:000314054400013
PM 23097590
ER
PT J
AU Levison, JH
Wood, R
Scott, CA
Ciaranello, AL
Martinson, NA
Rusu, C
Losina, E
Freedberg, KA
Walensky, RP
AF Levison, Julie H.
Wood, Robin
Scott, Callie A.
Ciaranello, Andrea L.
Martinson, Neil A.
Rusu, Corina
Losina, Elena
Freedberg, Kenneth A.
Walensky, Rochelle P.
TI The Clinical and Economic Impact of Genotype Testing at First-line
Antiretroviral Therapy Failure for HIV-Infected Patients in South Africa
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
DE HIV; resistance testing; antiretroviral treatment failure;
resource-limited settings
ID COST-EFFECTIVENESS ANALYSIS; RESOURCE-LIMITED SETTINGS; DRUG-RESISTANCE;
VIROLOGICAL FAILURE; RECOMMENDATIONS; EMTRICITABINE; EFAVIRENZ;
MORTALITY; HIV/AIDS; REGIMENS
AB Background. In resource-limited settings, genotype testing at virologic failure on first-line antiretroviral therapy (ART) may identify patients with wild-type (WT) virus. After adherence counseling, these patients may safely and effectively continue first-line ART, thereby delaying more expensive second-line ART.
Methods. We used the Cost-Effectiveness of Preventing AIDS Complications International model of human immunodeficiency virus (HIV) disease to simulate a South African cohort of HIV-infected adults at first-line ART failure. Two strategies were examined: no genotype vs genotype, assuming availability of protease inhibitor-based second-line ART. Model inputs at first-line ART failure were mean age 38 years, mean CD4 173/mu L, and WT virus prevalence 20%; genotype cost was $300 per test and delay to results, 3 months. Outcomes included life expectancy, per-person costs (2010 US dollars), and incremental cost-effectiveness ratios (dollars per years of life saved [YLS]).
Results. No genotype had a projected life expectancy of 106.1 months, which with genotype increased to 108.3 months. Per-person discounted lifetime costs were $16 360 and $16 540, respectively. Compared to no genotype, genotype was very cost-effective, by international guidance, at $900/YLS. The cost-effectiveness of genotype was sensitive to prevalence of WT virus (very cost-effective when prevalence >= 12%), CD4 at first-line ART failure, and ART efficacy. Genotype-associated delays in care >= 5 months decreased survival and made no genotype the preferred strategy. When the test cost was <$100, genotype became cost-saving.
Conclusions. Genotype resistance testing at first-line ART failure is very cost-effective in South Africa. The cost-effectiveness of this strategy will depend on prevalence of WT virus and timely response to genotype results.
C1 [Levison, Julie H.; Ciaranello, Andrea L.; Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Scott, Callie A.; Rusu, Corina; Losina, Elena; Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Levison, Julie H.; Ciaranello, Andrea L.; Rusu, Corina; Losina, Elena; Freedberg, Kenneth A.; Walensky, Rochelle P.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA.
[Wood, Robin] Univ Cape Town, Desmond Tutu HIV Ctr, Inst Infect Dis & Mol Med, Dept Med, Johannesburg, South Africa.
[Martinson, Neil A.] Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa.
[Martinson, Neil A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Losina, Elena] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Freedberg, Kenneth A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Levison, Julie H.; Walensky, Rochelle P.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Losina, Elena] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
[Losina, Elena; Freedberg, Kenneth A.; Walensky, Rochelle P.] Harvard Univ, Harvard Ctr AIDS Res, Boston, MA 02115 USA.
[Levison, Julie H.; Ciaranello, Andrea L.; Losina, Elena; Freedberg, Kenneth A.; Walensky, Rochelle P.] Harvard Univ, Sch Med, Boston, MA USA.
RP Levison, JH (reprint author), Massachusetts Gen Hosp, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM jlevison@partners.org
OI Walensky, Rochelle P./0000-0002-8795-379X
FU National Institute of Allergy and Infectious Diseases [T32 AI007433, R01
AI058736, K01AI078754, K24 AI062476, AI48526]; National Heart, Lung, and
Blood Institute [HL090312]; Fogarty International Center [RTW007370];
Harvard Center for AIDS Research [P30 AI060354]
FX This work was supported by the National Institute of Allergy and
Infectious Diseases (T32 AI007433, R01 AI058736, K01AI078754, K24
AI062476, AI48526); National Heart, Lung, and Blood Institute
(HL090312); Fogarty International Center (RTW007370); and Harvard Center
for AIDS Research (P30 AI060354).
NR 40
TC 14
Z9 14
U1 0
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD FEB 15
PY 2013
VL 56
IS 4
BP 587
EP 597
DI 10.1093/cid/cis887
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 077UR
UT WOS:000314054400022
PM 23087386
ER
PT J
AU Premereur, E
Janssen, P
Vanduffel, W
AF Premereur, Elsie
Janssen, Peter
Vanduffel, Wim
TI FEF-microstimulation causes task-dependent modulation of occipital fMRI
activity
SO NEUROIMAGE
LA English
DT Article
DE Saccades; Attention; Macaque; fMRI; FEF
ID FRONTAL EYE FIELD; LATERAL INTRAPARIETAL AREA; VISUAL-CORTEX; ELECTRICAL
MICROSTIMULATION; SPATIAL ATTENTION; CONTRAST AGENT; MACAQUE; SIGNALS;
MOVEMENTS; MONKEYS
AB Electrical microstimulation of FEF (FEF-EM) modulates neuronal activity in area V4 (Moore and Armstrong, 2003) and elicits functional magnetic resonance imaging (fMRI) activations in visual cortex in a bottom-up dependent manner (Ekstrom et al., 2008). Here we test the hypothesis that FEF-EM-induced modulations of fMRI activity are also function of task demands, which would suggest top-down dependent gating of FEF signals in early visual cortex. We scanned two monkeys performing a visually guided saccade task; a passive fixation task with a very similar visual display; and a passive fixation task without peripheral dots. We found increased effects of FEF-EM on fMRI-activity in visual cortex during saccades compared to fixation, indicating that the FEF-EM induced modulation is task-dependent. Finally, the effect of FEF-EM is mainly present in voxels which were less activated by visual stimuli in the absence of electrical stimulation. Our results show that the FEF-EM-induced pattern of activation in early visual cortex is topographically specific and more pronounced during increased task demands. These results fit with models suggesting that FEF is an important source modulating activity in early sensory cortex and that these influences can be enhanced by coincident bottom-up or top-down signals. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Premereur, Elsie; Janssen, Peter; Vanduffel, Wim] Katholieke Univ Leuven, Lab Neuro Psychofysiol, B-3000 Louvain, Belgium.
[Vanduffel, Wim] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Vanduffel, Wim] Harvard Univ, Dept Radiol, Sch Med, Cambridge, MA 02138 USA.
RP Vanduffel, W (reprint author), Katholieke Univ Leuven, Lab Neuro Psychofysiol, O&N 2 Herestr 49 Bus 1021, B-3000 Louvain, Belgium.
EM wim@nmr.mgh.harvard.edu
FU Fonds voor Wetenschappelijk Onderzoek [G.0713.09, G.0622.08, G.0831.11];
Interuniversity Attraction Poles [P6/29]; Excellentie Financiering
[EF/05/014]; National Science Foundation [BCS-0745436]; Programma
Financiering [PFV/10/008]; Geconcerteerde onderzoeksacties [GOA/10/19]
FX We thank Stijn Verstraeten, Piet Kayenbergh, Gerrit Meulemans, Marc De
Paep, Wouter Depuydt, Inez Puttemans and Marjan Docx for assistance, and
Steve Raiguel for comments on a previous version of this manuscript.
Supported by Fonds voor Wetenschappelijk Onderzoek (G.0713.09,
G.0622.08, and G.0831.11), Interuniversity Attraction Poles (P6/29),
Excellentie Financiering (EF/05/014), National Science Foundation
(BCS-0745436), Programma Financiering (PFV/10/008), Geconcerteerde
onderzoeksacties (GOA/10/19).
NR 40
TC 7
Z9 7
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD FEB 15
PY 2013
VL 67
BP 42
EP 50
DI 10.1016/j.neuroimage.2012.11.017
PG 9
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 079BG
UT WOS:000314144600005
PM 23186918
ER
PT J
AU Xu, JQ
Shimony, JS
Klawiter, EC
Snyder, AZ
Trinkaus, K
Naismith, RT
Benzinger, TLS
Cross, AH
Song, SK
AF Xu, Junqian
Shimony, Joshua S.
Klawiter, Eric C.
Snyder, Abraham Z.
Trinkaus, Kathryn
Naismith, Robert T.
Benzinger, Tammie L. S.
Cross, Anne H.
Song, Sheng-Kwei
TI Improved in vivo diffusion tensor imaging of human cervical spinal cord
SO NEUROIMAGE
LA English
DT Article
DE Directional diffusivity; Outlier rejection; Non-negative eigenvalue
priors; Reduced FOV; Cardiac gating; Cervical spinal cord; Lateral
corticospinal tract; Posterior column; Diffusion tensor imaging;
Reproducibility
ID WHITE-MATTER TRACTS; HIGH-RESOLUTION DTI; MULTIPLE-SCLEROSIS;
OPTIC-NERVE; RADIAL DIFFUSIVITY; FIBER TRACKING; 3 TESLA; TISSUE
ARCHITECTURE; PHYSIOLOGICAL NOISE; ROBUST ESTIMATION
AB We describe a cardiac gated high in-plane resolution axial human cervical spinal cord diffusion tensor imaging (DTI) protocol. Multiple steps were taken to optimize both image acquisition and image processing. The former includes slice-by-slice cardiac triggering and individually tiltable slices. The latter includes (i) iterative 2D retrospective motion correction, (ii) image intensity outlier detection to minimize the influence of physiological noise, (iii) a non-linear DTI estimation procedure incorporating non-negative eigenvalue priors, and (iv) tract-specific region-of-interest (ROI) identification based on an objective geometry reference. Using these strategies in combination, radial diffusivity (lambda(perpendicular to)) was reproducibly measured in white matter (WM) tracts (adjusted mean [95% confidence interval] = 0.25 [0.22, 0.29] mu m(2)/ms), lower than previously reported lambda(perpendicular to) values in the in vivo human spinal cord DTI literature. Radial diffusivity and fractional anisotropy (FA) measured in WM varied from rostral to caudal as did mean translational motion, likely reflecting respiratory motion effect. Given the considerable sensitivity of DTI measurements to motion artifact, we believe outlier detection is indispensable in spinal cord diffusion imaging. We also recommend using a mixed-effects model to account for systematic measurement bias depending on cord segment. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Xu, Junqian; Klawiter, Eric C.; Snyder, Abraham Z.; Naismith, Robert T.; Cross, Anne H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.
[Xu, Junqian] Univ Minnesota, Ctr Magnet Resonance Res, Minneapolis, MN 55455 USA.
[Shimony, Joshua S.; Snyder, Abraham Z.; Benzinger, Tammie L. S.; Song, Sheng-Kwei] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA.
[Klawiter, Eric C.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Trinkaus, Kathryn] Washington Univ, Sch Med, Dept Biostat, St Louis, MO USA.
RP Xu, JQ (reprint author), Univ Minnesota, Ctr Magnet Resonance Res, 2021 6th St SE, Minneapolis, MN 55455 USA.
EM jxu@umn.edu
RI Xu, Junqian/D-2247-2009
OI Xu, Junqian/0000-0001-8438-2066
FU National Institutes of Health [P01 NS059560, R01 NS047592, K23 HD053212,
UL1RR024992, K23 NS052430-01A1]; National Multiple Sclerosis Society [RG
4009]; National MS Society [FG 1782]; American Academy of Neurology
Foundation Clinical Research Training Fellowship; Bracco/American
Roentgen Ray Society Scholar Award; Manny and Rosalyn Rosenthal-Dr John
L Trotter Chair in Neuroimmunology of Barnes-Jewish Hospital Foundation;
institutional Clinical and Translational Science Award [UL1RR024992];
National Center for Research Resources (NCRR), a component of the
National Institutes of Health (NIH); NIH Roadmap for Medical Research
NIH; Neuroclinical Research Unit; NIH (Washington University Institute
of Clinical and Translational Sciences - Brain, Behavioral and
Performance Unit) [CO6 RR020092, RR024992]; [P30 NS048056]
FX This work was supported by the National Institutes of Health (P01
NS059560 to AHC, R01 NS047592 to S-KS) and the National Multiple
Sclerosis Society (RG 4009 to AFIC). JX was supported by a National MS
Society Postdoctoral Fellowship (FG 1782). JSS was supported by National
Institutes of Health (K23 HD053212). ECK was supported by an American
Academy of Neurology Foundation Clinical Research Training Fellowship
and the National Institutes of Health (UL1RR024992). RN was supported by
the National Institutes of Health (K23 NS052430-01A1). TB was supported
by a Bracco/American Roentgen Ray Society Scholar Award. AHC was
supported in part by the Manny and Rosalyn Rosenthal-Dr John L Trotter
Chair in Neuroimmunology of Barnes-Jewish Hospital Foundation. AZS was
supported by P30 NS048056. An institutional Clinical and Translational
Science Award (UL1RR024992) from the National Center for Research
Resources (NCRR), a component of the National Institutes of Health (NIH)
and NIH Roadmap for Medical Research NIH, provided funding for the
Neuroclinical Research Unit where research subjects were examined. This
research was also supported in part by NIH grants CO6 RR020092 and
RR024992 (Washington University Institute of Clinical and Translational
Sciences - Brain, Behavioral and Performance Unit). The funding source
had no role in the study design or in the collection, analysis and
interpretation of data. The contents of the work are solely the
responsibility of the authors and do not necessarily represent the
official view of NCRR or NIH.
NR 93
TC 18
Z9 18
U1 0
U2 22
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD FEB 15
PY 2013
VL 67
BP 64
EP 76
DI 10.1016/j.neuroimage.2012.11.014
PG 13
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 079BG
UT WOS:000314144600007
PM 23178538
ER
PT J
AU Cunha, CB
Varughese, CA
Mylonakis, E
AF Cunha, Cheston B.
Varughese, Christy A.
Mylonakis, Eleftherios
TI Antimicrobial stewardship programs (ASPs) The devil is in the details
SO VIRULENCE
LA English
DT Editorial Material
ID ANTIBIOTIC STEWARDSHIP; COMMUNITY HOSPITALS; STRATEGIES; RESISTANCE;
IMPACT
C1 [Cunha, Cheston B.; Mylonakis, Eleftherios] Brown Univ, Div Infect Dis, Alpert Sch Med, Providence, RI 02912 USA.
[Varughese, Christy A.] Massachusetts Gen Hosp, Dept Pharm, Boston, MA 02114 USA.
RP Cunha, CB (reprint author), Brown Univ, Div Infect Dis, Alpert Sch Med, Providence, RI 02912 USA.
EM ccunha@lifespan.org
NR 29
TC 7
Z9 7
U1 0
U2 7
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2150-5594
EI 2150-5608
J9 VIRULENCE
JI Virulence
PD FEB 15
PY 2013
VL 4
IS 2
BP 147
EP 149
DI 10.4161/viru.23856
PG 3
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 089FI
UT WOS:000314895200005
PM 23381468
ER
PT J
AU Wirth, LJ
Ross, DS
Randolph, GW
Cunnane, ME
Sadow, PM
AF Wirth, Lori J.
Ross, Douglas S.
Randolph, Gregory W.
Cunnane, Mary Elizabeth
Sadow, Peter M.
TI Case 5-2013: A 52-Year-Old Woman with a Mass in the Thyroid
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID CARCINOEMBRYONIC ANTIGEN LEVELS; FINE-NEEDLE-ASPIRATION; METASTATIC
LYMPH-NODES; RET PROTOONCOGENE; FOLLOW-UP; SERUM CALCITONIN; COMPLETION
THYROIDECTOMY; PROGNOSTIC-SIGNIFICANCE; PREOPERATIVE DIAGNOSIS;
CONSECUTIVE PATIENTS
C1 [Wirth, Lori J.; Ross, Douglas S.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Sadow, Peter M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Randolph, Gregory W.] Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Boston, MA 02114 USA.
[Cunnane, Mary Elizabeth] Massachusetts Eye & Ear Infirm, Dept Radiol, Boston, MA 02114 USA.
[Wirth, Lori J.; Ross, Douglas S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Randolph, Gregory W.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Cunnane, Mary Elizabeth] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Sadow, Peter M.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Wirth, LJ (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
FU Bayer; Boehringer Ingelheim; Acceleron; Exelexis; Genzyme; Novo Nordisk
FX Dr. Wirth reports receiving consulting fees from Bayer, Boehringer
Ingelheim, Acceleron, and Exelexis; Dr. Ross, receiving consulting fees
from Genzyme and Novo Nordisk; and Dr. Randolph, providing expert
testimony on behalf of patients or health care providers in medicolegal
cases involving surgery. No other potential conflict of interest
relevant to this article was reported.
NR 52
TC 6
Z9 6
U1 0
U2 4
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD FEB 14
PY 2013
VL 368
IS 7
BP 664
EP 673
DI 10.1056/NEJMcpc1210080
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 194VA
UT WOS:000322659600012
PM 23406032
ER
PT J
AU Chibebe, J
Fuchs, BB
Sabino, CP
Junqueira, JC
Jorge, AC
Ribeiro, MS
Gilmore, MS
Rice, LB
Tegos, GP
Hamblin, MR
Mylonakis, E
AF Chibebe Junior, Jose
Fuchs, Beth B.
Sabino, Caetano P.
Junqueira, Juliana C.
Jorge, AntonioO. C.
Ribeiro, Martha S.
Gilmore, Michael S.
Rice, Louis B.
Tegos, George P.
Hamblin, Michael R.
Mylonakis, Eleftherios
TI Photodynamic and Antibiotic Therapy Impair the Pathogenesis of
Enterococcus faecium in a Whole Animal Insect Model
SO PLOS ONE
LA English
DT Article
ID GALLERIA-MELLONELLA LARVAE; LOW-POWER LASER; CANDIDA-ALBICANS;
CRYPTOCOCCUS-NEOFORMANS; CAENORHABDITIS-ELEGANS; EPITHELIAL-CELLS;
VIRULENCE; FAECALIS; HOST; SUSCEPTIBILITY
AB Enterococcus faecium has emerged as one of the most important pathogens in healthcare-associated infections worldwide due to its intrinsic and acquired resistance to many antibiotics, including vancomycin. Antimicrobial photodynamic therapy (aPDT) is an alternative therapeutic platform that is currently under investigation for the control and treatment of infections. PDT is based on the use of photoactive dye molecules, widely known as photosensitizer (PS). PS, upon irradiation with visible light, produces reactive oxygen species that can destroy lipids and proteins causing cell death. We employed Galleria mellonella (the greater wax moth) caterpillar fatally infected with E. faecium to develop an invertebrate host model system that can be used to study the antimicrobial PDT (alone or combined with antibiotics). In the establishment of infection by E. faecium in G. mellonella, we found that the G. mellonella death rate was dependent on the number of bacterial cells injected into the insect hemocoel and all E. faecium strains tested were capable of infecting and killing G. mellonella. Antibiotic treatment with ampicillin, gentamicin or the combination of ampicillin and gentamicin prolonged caterpillar survival infected by E. faecium (P = 0.0003, P = 0.0001 and P = 0.0001, respectively). In the study of antimicrobial PDT, we verified that methylene blue (MB) injected into the insect followed by whole body illumination prolonged the caterpillar survival (P = 0.0192). Interestingly, combination therapy of larvae infected with vancomycin-resistant E. faecium, with antimicrobial PDT followed by vancomycin, significantly prolonged the survival of the caterpillars when compared to either antimicrobial PDT (P = 0.0095) or vancomycin treatment alone (P = 0.0025), suggesting that the aPDT made the vancomycin resistant E. faecium strain more susceptible to vancomycin action. In summary, G. mellonella provides an invertebrate model host to study the antimicrobial PDT and to explore combinatorial aPDT-based treatments.
C1 [Chibebe Junior, Jose; Junqueira, Juliana C.; Jorge, AntonioO. C.] Univ Estadual Paulista UNESP, Dept Biosci & Oral Diag, Sao Paulo, Brazil.
[Chibebe Junior, Jose; Fuchs, Beth B.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Chibebe Junior, Jose] Fac Pindamonhangaba, Dept Restorat Dent, Sao Paulo, Brazil.
[Sabino, Caetano P.; Tegos, George P.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Sabino, Caetano P.; Ribeiro, Martha S.] Ctr Lasers & Applicat, Nucl & Energy Res Inst, Sao Paulo, Brazil.
[Gilmore, Michael S.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
[Rice, Louis B.; Mylonakis, Eleftherios] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Providence, RI 02903 USA.
[Rice, Louis B.; Mylonakis, Eleftherios] Brown Univ, Miriam Hosp, Warren Alpert Med Sch, Providence, RI USA.
[Tegos, George P.; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Tegos, George P.] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA.
[Tegos, George P.] Univ New Mexico, Ctr Mol Discovery, Albuquerque, NM 87131 USA.
[Hamblin, Michael R.] Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, Cambridge, MA USA.
RP Chibebe, J (reprint author), Univ Estadual Paulista UNESP, Dept Biosci & Oral Diag, Sao Paulo, Brazil.
EM juliana@fosjc.unesp.br; emylonakis@lifespan.org
RI Junqueira, Juliana/F-7785-2012; Sabino, Caetano/K-8356-2013; Ribeiro,
Martha/G-3517-2012; Sabino, Caetano/D-4196-2016;
OI Ribeiro, Martha/0000-0002-4203-1134; Sabino,
Caetano/0000-0002-2048-2823; Hamblin, Michael/0000-0001-6431-4605
FU CAPES [PDEE 2507-11-0]; NIH [RO1 AI050875, 5U54MH084690-02];
Harvard-wide Program on Antibiotic Resistance [P01 AI083214]; US Air
Force MFEL Program [FA9550-04-1-0079]; DTRA [HDTRA1-13-C-0005]
FX The first author thanks CAPES (PDEE 2507-11-0) for the scholarship
during the "Sandwich'' PhD Program at Harvard Medical School. Research
conducted in the Mylonakis Laboratory was supported by NIH (RO1 AI050875
to EM, and the Harvard-wide Program on Antibiotic Resistance [P01
AI083214] to EM and MSG). Research conducted in the Hamblin Laboratory
was supported by NIH (RO1 AI050875 to MRH) and US Air Force MFEL Program
(FA9550-04-1-0079). George P. Tegos is supported by the NIH (grant
5U54MH084690-02) and DTRA (contract HDTRA1-13-C-0005). The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 65
TC 7
Z9 8
U1 1
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 14
PY 2013
VL 8
IS 2
AR e55926
DI 10.1371/journal.pone.0055926
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 099EJ
UT WOS:000315602700027
PM 23457486
ER
PT J
AU Shoji-Kawata, S
Sumpter, R
Leveno, M
Campbell, GR
Zou, ZJ
Kinch, L
Wilkins, AD
Sun, QH
Pallauf, K
MacDuff, D
Huerta, C
Virgin, HW
Helms, JB
Eerland, R
Tooze, SA
Xavier, R
Lenschow, DJ
Yamamoto, A
King, D
Lichtarge, O
Grishin, NV
Spector, SA
Kaloyanova, DV
Levine, B
AF Shoji-Kawata, Sanae
Sumpter, Rhea, Jr.
Leveno, Matthew
Campbell, Grant R.
Zou, Zhongju
Kinch, Lisa
Wilkins, Angela D.
Sun, Qihua
Pallauf, Kathrin
MacDuff, Donna
Huerta, Carlos
Virgin, Herbert W.
Helms, J. Bernd
Eerland, Ruud
Tooze, Sharon A.
Xavier, Ramnik
Lenschow, Deborah J.
Yamamoto, Ai
King, David
Lichtarge, Olivier
Grishin, Nick V.
Spector, Stephen A.
Kaloyanova, Dora V.
Levine, Beth
TI Identification of a candidate therapeutic autophagy-inducing peptide
SO NATURE
LA English
DT Article
ID PROTEIN; DISEASE; PATHOGENESIS; MACROPHAGES; LOCALIZES; INFECTION;
BECLIN-1; PATHWAY; COMPLEX; BINDING
AB The lysosomal degradation pathway of autophagy has a crucial role in defence against infection, neurodegenerative disorders, cancer and ageing. Accordingly, agents that induce autophagy may have broad therapeutic applications. One approach to developing such agents is to exploit autophagy manipulation strategies used by microbial virulence factors. Here we show that a peptide, Tat-beclin 1-derived from a region of the autophagy protein, beclin 1, which binds human immunodeficiency virus (HIV)-1 Nef-is a potent inducer of autophagy, and interacts with a newly identified negative regulator of autophagy, GAPR-1 (also called GLIPR2). Tat-beclin 1 decreases the accumulation of polyglutamine expansion protein aggregates and the replication of several pathogens (including HIV-1) in vitro, and reduces mortality in mice infected with chikungunya or West Nile virus. Thus, through the characterization of a domain of beclin 1 that interacts with HIV-1 Nef, we have developed an autophagy-inducing peptide that has potential efficacy in the treatment of human diseases.
C1 [Shoji-Kawata, Sanae; Sumpter, Rhea, Jr.; Leveno, Matthew; Zou, Zhongju; Sun, Qihua; Pallauf, Kathrin; Levine, Beth] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA.
[Shoji-Kawata, Sanae; Sumpter, Rhea, Jr.; Leveno, Matthew; Zou, Zhongju; Sun, Qihua; Levine, Beth] Univ Texas SW Med Ctr Dallas, Ctr Autophagy Res, Dallas, TX 75390 USA.
[Campbell, Grant R.; Spector, Stephen A.] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA.
[Campbell, Grant R.; Spector, Stephen A.] Rady Childrens Hosp, San Diego, CA 92123 USA.
[Zou, Zhongju; Kinch, Lisa; Grishin, Nick V.; Levine, Beth] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA.
[Kinch, Lisa; Huerta, Carlos; Grishin, Nick V.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA.
[Wilkins, Angela D.; Lichtarge, Olivier] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
[MacDuff, Donna; Virgin, Herbert W.; Lenschow, Deborah J.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
[Helms, J. Bernd; Eerland, Ruud; Kaloyanova, Dora V.] Univ Utrecht, Dept Biochem & Cell Biol, NL-3508 TD Utrecht, Netherlands.
[Helms, J. Bernd; Eerland, Ruud; Kaloyanova, Dora V.] Univ Utrecht, Inst Biomembranes, NL-3508 TD Utrecht, Netherlands.
[Tooze, Sharon A.] Canc Res UK, London Res Inst, London EC1V 4AD, England.
[Xavier, Ramnik] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Xavier, Ramnik] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA.
[Xavier, Ramnik] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA 02142 USA.
[Lenschow, Deborah J.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
[Yamamoto, Ai] Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
[King, David] Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.
[Levine, Beth] Univ Texas SW Med Ctr Dallas, Dept Microbiol, Dallas, TX 75390 USA.
RP Levine, B (reprint author), Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA.
EM beth.levine@utsouthwestern.edu
OI Campbell, Grant/0000-0003-3927-1994
FU NIH [U54AI057156, K08 AI099150, ROI NS077874, RO1 GM094575, ROI
GM066099, ROI GM079656, ROI NS063973, ROI NS050199, U54AI057160, ROI
DK083756, ROI DK086502, T32 GM008297]; NSF [CCF-0905536]; NWO-ALW Open
Program [817.02.023]; Cancer Research UK; Welch Foundation [I-15-5]
FX We thank M. Diamond, J. L Foster, M. Gale, N. Mizushima, D. Sabatini, M.
Shiloh and T. Yoshimori for supplying critical reagent; and H. Ball, A.
Bugde and E.-L Eskelinen for assistance with-peptide synthesis, infrared
imaging and EM interpretation, respectively. This work was supported by
NIH grants U54AI057156 (B.L), K08 AI099150 (R.S.), ROI NS077874 (S.A.S),
RO1 GM094575 (N.V.G.), ROI GM066099 (O.L.), ROI GM079656 (O.L.), ROI
NS063973 (A.Y.), ROI NS050199 (A.Y.), U54AI057160 (H.W.V., D.J.L.), ROI
DK083756 (R.X), ROI DK086502 (R.X.), and T32 GM008297 (C.H.); NSF
CCF-0905536 (O.L); an NWO-ALW Open Program Grant 817.02.023 (J.B.H.);
Cancer Research UK (SAT.); and a Welch Foundation Award I-15-5 (N.V.G.).
NR 27
TC 204
Z9 216
U1 7
U2 148
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD FEB 14
PY 2013
VL 494
IS 7436
BP 201
EP 206
DI 10.1038/nature11866
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 092QS
UT WOS:000315137700032
PM 23364696
ER
PT J
AU Kamberov, YG
Wang, SJ
Tan, JZ
Gerbault, P
Wark, A
Tan, LZ
Yang, YJ
Li, SL
Tang, K
Chen, H
Powell, A
Itan, Y
Fuller, D
Lohmueller, J
Mao, JH
Schachar, A
Paymer, M
Hostetter, E
Byrne, E
Burnett, M
McMahon, AP
Thomas, MG
Lieberman, DE
Jin, L
Tabin, CJ
Morgan, BA
Sabeti, PC
AF Kamberov, Yana G.
Wang, Sijia
Tan, Jingze
Gerbault, Pascale
Wark, Abigail
Tan, Longzhi
Yang, Yajun
Li, Shilin
Tang, Kun
Chen, Hua
Powell, Adam
Itan, Yuval
Fuller, Dorian
Lohmueller, Jason
Mao, Junhao
Schachar, Asa
Paymer, Madeline
Hostetter, Elizabeth
Byrne, Elizabeth
Burnett, Melissa
McMahon, Andrew P.
Thomas, Mark G.
Lieberman, Daniel E.
Jin, Li
Tabin, Clifford J.
Morgan, Bruce A.
Sabeti, Pardis C.
TI Modeling Recent Human Evolution in Mice by Expression of a Selected EDAR
Variant
SO CELL
LA English
DT Article
ID ECTODYSPLASIN-A RECEPTOR; TO-HIP RATIO; NF-KAPPA-B; POSITIVE SELECTION;
ECTODERMAL DYSPLASIA; STATISTICAL EVALUATION; ETHNIC-DIFFERENCES; HAIR
THICKNESS; HUMAN GENOME; BODY-WEIGHT
AB An adaptive variant of the human Ectodysplasin receptor, EDARV370A, is one of the strongest candidates of recent positive selection from genome-wide scans. We have modeled EDAR370A in mice and characterized its phenotype and evolutionary origins in humans. Our computational analysis suggests the allele arose in central China approximately 30,000 years ago. Although EDAR370A has been associated with increased scalp hair thickness and changed tooth morphology in humans, its direct biological significance and potential adaptive role remain unclear. We generated a knockin mouse model and find that, as in humans, hair thickness is increased in EDAR370A mice. We identify new biological targets affected by the mutation, including mammary and eccrine glands. Building on these results, we find that EDAR370A is associated with an increased number of active eccrine glands in the Han Chinese. This interdisciplinary approach yields unique insight into the generation of adaptive variation among modern humans.
C1 [Kamberov, Yana G.; Wark, Abigail; Tabin, Clifford J.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Kamberov, Yana G.; Burnett, Melissa; Morgan, Bruce A.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA.
[Kamberov, Yana G.; Morgan, Bruce A.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Boston, MA 02114 USA.
[Burnett, Melissa] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Kamberov, Yana G.; Wang, Sijia; Tan, Longzhi; Lohmueller, Jason; Schachar, Asa; Paymer, Madeline; Hostetter, Elizabeth; Byrne, Elizabeth; Sabeti, Pardis C.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Kamberov, Yana G.; Lieberman, Daniel E.] Harvard Univ, Dept Human Evolutionary Biol, Cambridge, MA 02138 USA.
[Kamberov, Yana G.; Wang, Sijia; Schachar, Asa; Paymer, Madeline; Sabeti, Pardis C.] Harvard Univ, Ctr Syst Biol, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.
[Mao, Junhao; McMahon, Andrew P.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
[Tan, Jingze; Yang, Yajun; Li, Shilin; Jin, Li] Fudan Univ, MOE Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China.
[Gerbault, Pascale; Itan, Yuval; Thomas, Mark G.] UCL, Dept Genet Evolut & Environm, London WC1H 0PY, England.
[Powell, Adam] UCL, UCL Genet Inst UGI, London WC1H 0PY, England.
[Fuller, Dorian] UCL, Inst Archaeol, London WC1H 0PY, England.
[Tang, Kun; Jin, Li] Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, Shanghai 200031, Peoples R China.
[Chen, Hua] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Sabeti, Pardis C.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
RP Jin, L (reprint author), Fudan Univ, MOE Key Lab Contemporary Anthropol, Shanghai 200433, Peoples R China.
EM lijin.fudan@gmail.com; bruce.morgan@cbrc2.mgh.harvard.edu;
pardis@broadinstitute.org
RI Jin, Li/C-1468-2009; Thomas, Mark/A-2219-2012
OI Jin, Li/0000-0002-4546-2415; Thomas, Mark/0000-0002-2452-981X
FU Harvard University Science and Engineering Committee Seed Fund for
Interdisciplinary Science; Packard Foundation Fellowship in Science and
Engineering; NIH Innovator Award [1DP2OD006514-01]; BIRT Award from
NIAMS [AR055256-04S1]; NIH grant [R37 HD032443]; American School of
Prehistoric Research; NSFC [30890034]; MOST [2011BAI09B00]; MOH
[201002007]; AXA Research Fund; LeCHE Marie Curie FP7; NIH [R37 054364]
FX This project was funded by a grant from the Harvard University Science
and Engineering Committee Seed Fund for Interdisciplinary Science to
CJT, PCS, BAM and DEL; a Packard Foundation Fellowship in Science and
Engineering and an NIH Innovator Award 1DP2OD006514-01 to PCS; a BIRT
Award AR055256-04S1 from NIAMS to BAM; an NIH grant R37 HD032443 to CJT;
and funding from the American School of Prehistoric Research to DEL.
Human association study work was additionally supported by NSFC
30890034; MOST 2011BAI09B00; MOH 201002007 to LJ. YI was funded by an
AXA Research Fund postdoctoral fellowship and PG by the LeCHE Marie
Curie FP7 framework. Work in APM's laboratory was supported by an NIH
R37 054364 grant. We acknowledge the UCL Legion High Performance
Computing Facility and support services and thank O. Bar Yosef, C. Zhao,
E. Rohling, S. Schaffner, L. Gaffney, C. Edwards, J. Vitti, S. Tabrizi
and A. Tariela for feedback on the manuscript and A. Carpenter, C.
Wahlby, and M. Morgan for data analysis help. The authors declare no
conflict of interest.
NR 68
TC 85
Z9 91
U1 10
U2 100
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD FEB 14
PY 2013
VL 152
IS 4
BP 691
EP 702
DI 10.1016/j.cell.2013.01.016
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 089YJ
UT WOS:000314945600006
PM 23415220
ER
PT J
AU Landau, DA
Carter, SL
Stojanov, P
McKenna, A
Stevenson, K
Lawrence, MS
Sougnez, C
Stewart, C
Sivachenko, A
Wang, LL
Wan, YZ
Zhang, WD
Shukla, SA
Vartanov, A
Fernandes, SM
Saksena, G
Cibulskis, K
Tesar, B
Gabriel, S
Hacohen, N
Meyerson, M
Lander, ES
Neuberg, D
Brown, JR
Getz, G
Wu, CJ
AF Landau, Dan A.
Carter, Scott L.
Stojanov, Petar
McKenna, Aaron
Stevenson, Kristen
Lawrence, Michael S.
Sougnez, Carrie
Stewart, Chip
Sivachenko, Andrey
Wang, Lili
Wan, Youzhong
Zhang, Wandi
Shukla, Sachet A.
Vartanov, Alexander
Fernandes, Stacey M.
Saksena, Gordon
Cibulskis, Kristian
Tesar, Bethany
Gabriel, Stacey
Hacohen, Nir
Meyerson, Matthew
Lander, Eric S.
Neuberg, Donna
Brown, Jennifer R.
Getz, Gad
Wu, Catherine J.
TI Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic
Leukemia
SO CELL
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; COPY-NUMBER ALTERATION; B-CELL LYMPHOMA; CLONAL
EVOLUTION; HUMAN CANCER; SOMATIC MUTATIONS; MULTIPLE-MYELOMA; GENOMIC
ABERRATIONS; BREAST CANCERS; SHORT SURVIVAL
AB Clonal evolution is a key feature of cancer progression and relapse. We studied intratumoral heterogeneity in 149 chronic lymphocytic leukemia (CLL) cases by integrating whole-exome sequence and copy number to measure the fraction of cancer cells harboring each somatic mutation. We identified driver mutations as predominantly clonal (e.g., MYD88, trisomy 12, and del(13q)) or subclonal (e.g., SF3B1 and TP53), corresponding to earlier and later events in CLL evolution. We sampled leukemia cells from 18 patients at two time points. Ten of twelve CLL cases treated with chemotherapy (but only one of six without treatment) underwent clonal evolution, predominantly involving subclones with driver mutations (e.g., SF3B1 and TP53) that expanded over time. Furthermore, presence of a subclonal driver mutation was an independent risk factor for rapid disease progression. Our study thus uncovers patterns of clonal evolution in CLL, providing insights into its stepwise transformation, and links the presence of subclones with adverse clinical outcomes.
C1 [Landau, Dan A.; Wang, Lili; Wan, Youzhong; Zhang, Wandi; Shukla, Sachet A.; Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
[Landau, Dan A.; Stojanov, Petar; Wang, Lili; Wan, Youzhong; Zhang, Wandi; Vartanov, Alexander; Fernandes, Stacey M.; Tesar, Bethany; Brown, Jennifer R.; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Stevenson, Kristen; Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Landau, Dan A.; Carter, Scott L.; Stojanov, Petar; McKenna, Aaron; Lawrence, Michael S.; Sougnez, Carrie; Stewart, Chip; Sivachenko, Andrey; Shukla, Sachet A.; Saksena, Gordon; Cibulskis, Kristian; Gabriel, Stacey; Hacohen, Nir; Meyerson, Matthew; Lander, Eric S.; Getz, Gad] Broad Inst, Cambridge, MA 02139 USA.
[Landau, Dan A.] Yale Canc Ctr, Dept Hematol, New Haven, CT 06510 USA.
[Landau, Dan A.] Univ Paris Diderot, F-75013 Paris, France.
[Brown, Jennifer R.; Wu, Catherine J.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med, Boston, MA 02115 USA.
[Hacohen, Nir] Harvard Univ, Div Allergy Immunol & Rheumatol, Dept Med, Massachusetts Gen Hosp,Med Sch, Boston, MA 02114 USA.
[Getz, Gad] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Getz, Gad] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Getz, G (reprint author), Broad Inst, Cambridge, MA 02139 USA.
EM gadgetz@broadinstitute.org; cwu@partners.org
FU American Society of Hematology (ASH) Research Award for
Fellows-in-Training; ACS Postdoctoral Fellowship; NIH [K23 CA115682];
Melton and Rosenbach Funds; Blavatnik Family Foundation; AACR (SU2C
Innovative Research Grant); NHLBI [1RO1HL103532-01]; NCI
[1R01CA155010-01A1]; Damon-Runyon Cancer Research Foundation [CI-38-07]
FX D.A.L. dedicates this manuscript to the loving memory of his mother
Nina, who passed away during the final stages of this work. We thank all
members of the Broad Institute's Biological Samples, Genetic Analysis,
and Genome Sequencing Platforms, who made this work possible
(NHGRI-U54HG003067). D.A.L. is supported by an American Society of
Hematology (ASH) Research Award for Fellows-in-Training and an ACS
Postdoctoral Fellowship. J.R.B. is supported by NIH K23 CA115682, the
Melton and Rosenbach Funds, and is an ASH Scholar and a LLS Clinical
Research Scholar. C.J.W. acknowledges support from the Blavatnik Family
Foundation, AACR (SU2C Innovative Research Grant), NHLBI
(1RO1HL103532-01), NCI (1R01CA155010-01A1), and is a clinical
investigator supported in part by the Damon-Runyon Cancer Research
Foundation (CI-38-07).
NR 59
TC 462
Z9 463
U1 12
U2 87
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD FEB 14
PY 2013
VL 152
IS 4
BP 714
EP 726
DI 10.1016/j.cell.2013.01.019
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 089YJ
UT WOS:000314945600008
PM 23415222
ER
PT J
AU Yildirim, E
Kirby, JE
Brown, DE
Mercier, FE
Sadreyev, RI
Scadden, DT
Lee, JT
AF Yildirim, Eda
Kirby, James E.
Brown, Diane E.
Mercier, Francois E.
Sadreyev, Ruslan I.
Scadden, David T.
Lee, Jeannie T.
TI Xist RNA Is a Potent Suppressor of Hematologic Cancer in Mice
SO CELL
LA English
DT Article
ID X-CHROMOSOME INACTIVATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC
STEM-CELLS; DOSAGE COMPENSATION; MYELODYSPLASTIC SYNDROMES;
MYELOID-LEUKEMIA; NONCODING RNAS; C-KIT; GENE; MOUSE
AB X chromosome aneuploidies have long been associated with human cancers, but causality has not been established. In mammals, X chromosome inactivation (XCI) is triggered by Xist RNA to equalize gene expression between the sexes. Here we delete Xist in the blood compartment of mice and demonstrate that mutant females develop a highly aggressive myeloproliferative neoplasm and myelodysplastic syndrome (mixed MPN/MDS) with 100% penetrance. Significant disease components include primary myelofibrosis, leukemia, histiocytic sarcoma, and vasculitis. Xist-deficient hematopoietic stem cells (HSCs) show aberrant maturation and age-dependent loss. Reconstitution experiments indicate that MPN/MDS and myelofibrosis are of hematopoietic rather than stromal origin. We propose that Xist loss results in X reactivation and consequent genome-wide changes that lead to cancer, thereby causally linking the X chromosome to cancer in mice. Thus, Xist RNA not only is required to maintain XCI but also suppresses cancer in vivo.
C1 [Yildirim, Eda; Sadreyev, Ruslan I.; Lee, Jeannie T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02114 USA.
[Yildirim, Eda; Sadreyev, Ruslan I.; Lee, Jeannie T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol, Boston, MA 02114 USA.
[Brown, Diane E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Comparat Med, Boston, MA 02114 USA.
[Mercier, Francois E.; Scadden, David T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med, Boston, MA 02114 USA.
[Brown, Diane E.; Sadreyev, Ruslan I.; Lee, Jeannie T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA.
[Yildirim, Eda; Sadreyev, Ruslan I.; Lee, Jeannie T.] Harvard Univ, Dept Genet, Sch Med, Boston, MA 02114 USA.
[Kirby, James E.] Harvard Univ, Dept Pathol, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02114 USA.
[Mercier, Francois E.; Scadden, David T.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Mercier, Francois E.; Scadden, David T.] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
RP Lee, JT (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02114 USA.
EM lee@molbio.mgh.harvard.edu
OI Yildirim, Eda/0000-0002-4796-3854
FU MGH ECOR Medical Discovery Fund; Clinician-Scientist Training Award from
the Canadian Institutes of Health Research
FX We are grateful to members of the Lee lab for stimulating discussions.
We thank R. Jaenisch for Xist2lox/Xist2lox mice,
G. Pihan and A. Sohani for hematopathology advice, H. Hock for advice on
Vav-Cre mice, W. Press for maintenance of
Xist2lox/Xist2lox mice colony, the MGH
CCM-Clinical Pathology laboratory for assistance on hematological
analysis, D. Dombkowski for FACS assistance, and A.J. Zall for survival
bleed collections. This work was supported by the MGH ECOR Medical
Discovery Fund (E.Y.), Clinician-Scientist Training Award from the
Canadian Institutes of Health Research (F.E.M.),
NR 63
TC 143
Z9 150
U1 4
U2 57
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD FEB 14
PY 2013
VL 152
IS 4
BP 727
EP 742
DI 10.1016/j.cell.2013.01.034
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 089YJ
UT WOS:000314945600009
PM 23415223
ER
PT J
AU Levine, AJ
Miller, JA
Shapshak, P
Gelman, B
Singer, EJ
Hinkin, CH
Commins, D
Morgello, S
Grant, I
Horvath, S
AF Levine, Andrew J.
Miller, Jeremy A.
Shapshak, Paul
Gelman, Benjamin
Singer, Elyse J.
Hinkin, Charles H.
Commins, Deborah
Morgello, Susan
Grant, Igor
Horvath, Steve
TI Systems analysis of human brain gene expression: mechanisms for
HIV-associated neurocognitive impairment and common pathways with
Alzheimer's disease
SO BMC MEDICAL GENOMICS
LA English
DT Article
DE HIV encephalitis; HIV-associated dementia; HIV-associated neurocognitive
disorder; Weighted gene coexpression network analysis; WGCNA; CNS
penetration effectiveness; National neuroAIDS tissue consortium;
Coexpression module
ID COEXPRESSION NETWORK ANALYSIS; HUMAN-IMMUNODEFICIENCY-VIRUS; NEUROAIDS
TISSUE CONSORTIUM; CENTRAL-NERVOUS-SYSTEM; ANTIRETROVIRAL THERAPY; AIDS
DEMENTIA; CNS PENETRATION; BASAL GANGLIA; WHITE-MATTER; TRANSCRIPTOME
AB Background: Human Immunodeficiency Virus-1 (HIV) infection frequently results in neurocognitive impairment. While the cause remains unclear, recent gene expression studies have identified genes whose transcription is dysregulated in individuals with HIV-association neurocognitive disorder (HAND). However, the methods for interpretation of such data have lagged behind the technical advances allowing the decoding genetic material. Here, we employ systems biology methods novel to the field of NeuroAIDS to further interrogate extant transcriptome data derived from brains of HIV + patients in order to further elucidate the neuropathogenesis of HAND. Additionally, we compare these data to those derived from brains of individuals with Alzheimer's disease (AD) in order to identify common pathways of neuropathogenesis.
Methods: In Study 1, using data from three brain regions in 6 HIV-seronegative and 15 HIV + cases, we first employed weighted gene co-expression network analysis (WGCNA) to further explore transcriptome networks specific to HAND with HIV-encephalitis (HIVE) and HAND without HIVE. We then used a symptomatic approach, employing standard expression analysis and WGCNA to identify networks associated with neurocognitive impairment (NCI), regardless of HIVE or HAND diagnosis. Finally, we examined the association between the CNS penetration effectiveness (CPE) of antiretroviral regimens and brain transcriptome. In Study 2, we identified common gene networks associated with NCI in both HIV and AD by correlating gene expression with pre-mortem neurocognitive functioning.
Results: Study 1: WGCNA largely corroborated findings from standard differential gene expression analyses, but also identified possible meta-networks composed of multiple gene ontology categories and oligodendrocyte dysfunction. Differential expression analysis identified hub genes highly correlated with NCI, including genes implicated in gliosis, inflammation, and dopaminergic tone. Enrichment analysis identified gene ontology categories that varied across the three brain regions, the most notable being downregulation of genes involved in mitochondrial functioning. Finally, WGCNA identified dysregulated networks associated with NCI, including oligodendrocyte and mitochondrial functioning. Study 2: Common gene networks dysregulated in relation to NCI in AD and HIV included mitochondrial genes, whereas upregulation of various cancer-related genes was found.
Conclusions: While under-powered, this study identified possible biologically-relevant networks correlated with NCI in HIV, and common networks shared with AD, opening new avenues for inquiry in the investigation of HAND neuropathogenesis. These results suggest that further interrogation of existing transcriptome data using systems biology methods can yield important information.
C1 [Levine, Andrew J.; Singer, Elyse J.] Univ Calif Los Angeles, David Geffen Sch Med, Natl Neurol AIDS Bank, Dept Neurol, Los Angeles, CA 90095 USA.
[Miller, Jeremy A.; Horvath, Steve] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.
[Shapshak, Paul] Univ S Florida, Morsani Coll Med, Dept Med, Div Infect Dis & Int Med, Tampa, FL USA.
[Shapshak, Paul] Univ S Florida, Morsani Coll Med, Dept Psychiat & Behav Med, Tampa, FL USA.
[Gelman, Benjamin] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
[Gelman, Benjamin] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA.
[Hinkin, Charles H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Hinkin, Charles H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Commins, Deborah] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
[Morgello, Susan] Mt Sinai Sch Med, Manhattan HIV Brain Bank, Dept Neurol, New York, NY USA.
[Morgello, Susan] Mt Sinai Sch Med, Manhattan HIV Brain Bank, Dept Neurosci, New York, NY USA.
[Morgello, Susan] Mt Sinai Sch Med, Manhattan HIV Brain Bank, Dept Pathol, New York, NY USA.
[Grant, Igor] Univ Calif San Diego, Dept Psychiat, Calif NeuroAIDS Tissue Network, San Diego, CA 92103 USA.
[Horvath, Steve] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA USA.
RP Levine, AJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Natl Neurol AIDS Bank, Dept Neurol, Los Angeles, CA 90095 USA.
EM ajlevine@mednet.ucla.edu
FU National NeuroAIDS Tissue Consortium; National Neurological AIDS Bank
[U01-MH08021, R24-NS38841]; Texas NeuroAIDS Research Center
[U01-MH083507, R24-NS45491]; Manhattan HIV Brain Bank [U01-MH083501,
R24-MH59724]; California NeuroAIDS Tissue Network [U01-MH083506,
R24-MH59745]; National Institute for Drug Abuse [R01DA030913]
FX This study was funded in through the National NeuroAIDS Tissue
Consortium, which consists of National Neurological AIDS Bank
(U01-MH08021 and R24-NS38841 - Singer), Texas NeuroAIDS Research Center
(U01-MH083507 and R24-NS45491 - Gelman), Manhattan HIV Brain Bank
(U01-MH083501 and R24-MH59724 - Morgello), and California NeuroAIDS
Tissue Network (U01-MH083506 and R24-MH59745 - Grant). Funding was also
provided by the National Institute for Drug Abuse grant R01DA030913
(Levine & Horvath).
NR 91
TC 13
Z9 14
U1 2
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1755-8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD FEB 13
PY 2013
VL 6
AR 4
DI 10.1186/1755-8794-6-4
PG 20
WC Genetics & Heredity
SC Genetics & Heredity
GA 124MF
UT WOS:000317467800001
PM 23406646
ER
PT J
AU Kullgren, JT
Volpp, KG
Polsky, D
AF Kullgren, Jeffrey T.
Volpp, Kevin G.
Polsky, Daniel
TI Are the Healthy Behaviors of US High-Deductible Health Plan Enrollees
Driven by People Who Chose These Plans? Smoking as a Case Study
SO PLOS ONE
LA English
DT Article
ID ANTE MORAL HAZARD; EMPLOYEE CHOICE; POPULATION; ENROLLMENT; INSURANCE;
BENEFITS
AB Purpose: To determine whether negative associations between enrollment in a high-deductible health plan (HDHP) and one exemplar unhealthy behavior - daily smoking - are found only among people who chose these plans.
Design: Cross-sectional analysis of nationally-representative data.
Setting: United States from 2007 to 2008.
Subjects: 6,941 privately insured non-elderly adult participants in the 2007 Health Tracking Household Survey.
Measures: Self-reported smoking status.
Analysis: We classified subjects as HDHP or traditional health plan enrollees with employer-sponsored insurance (ESI) and no choice of plans, ESI with a choice of plans, or coverage through the non-group market. We used multivariate logistic regression to measure associations between HDHP enrollment and daily smoking within each of the 3 coverage source groups while controlling for potential confounders.
Results: HDHP enrollment was associated with lower odds of smoking among individuals with ESI and a choice of plans (AOR 0.55, 95% CI 0.33-0.90) and those with non-group coverage (AOR 0.64, 95% CI 0.34-1.22), though the latter association was not statistically significant. HDHP enrollment was not associated with lower odds of smoking among individuals with ESI and no choice of plans (AOR 1.04, 95% CI 0.69-1.56).
Conclusions: HDHP enrollment is associated with lower odds of smoking only among individuals who chose to enroll in an HDHP. Lower rates of unhealthy behaviors among HDHP enrollees may be a reflection of individuals who choose these plans.
C1 [Kullgren, Jeffrey T.] Vet Affairs Ann Arbor Healthcare Syst, Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA.
[Kullgren, Jeffrey T.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA.
[Kullgren, Jeffrey T.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA.
[Volpp, Kevin G.; Polsky, Daniel] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.; Polsky, Daniel] Penn Carnegie Mellon Univ, Roybal Ctr Behav Econ & Hlth P30, Philadelphia, PA USA.
[Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA.
[Volpp, Kevin G.; Polsky, Daniel] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.; Polsky, Daniel] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA.
RP Kullgren, JT (reprint author), Vet Affairs Ann Arbor Healthcare Syst, Vet Affairs Ctr Clin Management Res, Ann Arbor, MI USA.
EM jkullgre@med.umich.edu
FU US Department of Veterans Affairs; Robert Wood Johnson Foundation
FX The US Department of Veterans Affairs and the Robert Wood Johnson
Foundation funded the study. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript. These contents do not represent the views of the Department
of Veterans Affairs, the United States Government, or the Robert Wood
Johnson Foundation.
NR 32
TC 1
Z9 1
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 13
PY 2013
VL 8
IS 2
AR e56154
DI 10.1371/journal.pone.0056154
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 104DM
UT WOS:000315970300120
PM 23418528
ER
PT J
AU Samur, MK
Yan, ZY
Wang, XJ
Cao, QY
Munshi, NC
Li, C
Shah, PK
AF Samur, Mehmet Kemal
Yan, Zhenyu
Wang, Xujun
Cao, Qingyi
Munshi, Nikhil C.
Li, Cheng
Shah, Parantu K.
TI canEvolve: A Web Portal for Integrative Oncogenomics
SO PLOS ONE
LA English
DT Article
ID GENE-EXPRESSION PROFILES; COPY NUMBER ALTERATIONS; CELL LUNG-CANCER;
MULTIPLE-MYELOMA; ARRAY DATA; DATABASE; GENOME; MICROARRAY; SURVIVAL;
QUANTIFICATION
AB Background & Objective: Genome-wide profiles of tumors obtained using functional genomics platforms are being deposited to the public repositories at an astronomical scale, as a result of focused efforts by individual laboratories and large projects such as the Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium. Consequently, there is an urgent need for reliable tools that integrate and interpret these data in light of current knowledge and disseminate results to biomedical researchers in a user-friendly manner. We have built the canEvolve web portal to meet this need.
Results: canEvolve query functionalities are designed to fulfill most frequent analysis needs of cancer researchers with a view to generate novel hypotheses. canEvolve stores gene, microRNA (miRNA) and protein expression profiles, copy number alterations for multiple cancer types, and protein-protein interaction information. canEvolve allows querying of results of primary analysis, integrative analysis and network analysis of oncogenomics data. The querying for primary analysis includes differential gene and miRNA expression as well as changes in gene copy number measured with SNP microarrays. canEvolve provides results of integrative analysis of gene expression profiles with copy number alterations and with miRNA profiles as well as generalized integrative analysis using gene set enrichment analysis. The network analysis capability includes storage and visualization of gene co-expression, inferred gene regulatory networks and protein-protein interaction information. Finally, canEvolve provides correlations between gene expression and clinical outcomes in terms of univariate survival analysis.
Conclusion: At present canEvolve provides different types of information extracted from 90 cancer genomics studies comprising of more than 10,000 patients. The presence of multiple data types, novel integrative analysis for identifying regulators of oncogenesis, network analysis and ability to query gene lists/pathways are distinctive features of canEvolve. canEvolve will facilitate integrative and meta-analysis of oncogenomics datasets.
C1 [Samur, Mehmet Kemal; Yan, Zhenyu; Li, Cheng; Shah, Parantu K.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Samur, Mehmet Kemal; Yan, Zhenyu; Li, Cheng; Shah, Parantu K.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Samur, Mehmet Kemal] Akdeniz Univ, Dept Biostat & Med Informat, TR-07058 Antalya, Turkey.
[Wang, Xujun] Tongji Univ, Sch Life Sci & Technol, Dept Bioinformat, Shanghai 200092, Peoples R China.
[Cao, Qingyi] Zhejiang Univ, Sch Med, Affiliated Hosp 1, State Key Lab Diag & Treatment Infect Dis, Hangzhou 310003, Zhejiang, Peoples R China.
[Munshi, Nikhil C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Munshi, Nikhil C.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA USA.
RP Li, C (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
EM cli@hsph.harvard.edu; parantu.shah@gmail.com
FU National Institutes of Health (NIH) [R01 GM077122]; Claudia Adams Barr
Program in Innovative Basic Cancer Research; Multiple Myeloma Career
Development award; National Basic Research [973] Program of China
[2010CB944904]; Department of Veterans Affairs Merit Review Awards [NIH
RO1-124929, PO1-155258, P50-100007, PO1-78378]
FX This work was supported by National Institutes of Health (NIH) R01
GM077122 (C.L.), the Claudia Adams Barr Program in Innovative Basic
Cancer Research (P.K.S.), the Multiple Myeloma Career Development award
(P.K.S.) and National Basic Research [973] Program of China No.
2010CB944904 (X.W.) This work was also supported in part by NIH
RO1-124929, PO1-155258, P50-100007 and PO1-78378 to N.C.M. and C.L. and
from the Department of Veterans Affairs Merit Review Awards to N.C.M.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 52
TC 10
Z9 12
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 13
PY 2013
VL 8
IS 2
AR e56228
DI 10.1371/journal.pone.0056228
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 104DM
UT WOS:000315970300132
PM 23418540
ER
PT J
AU Wu, XQ
Marmarelis, ME
Hodi, FS
AF Wu, Xinqi
Marmarelis, Melina E.
Hodi, F. Stephen
TI Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma
SO PLOS ONE
LA English
DT Article
ID CELL-CYCLE ARREST; HSP90 INHIBITOR; METASTATIC MELANOMA; CANCER-CELLS;
B-RAF; ACQUIRED-RESISTANCE; SIGNAL-TRANSDUCTION; BRAF INHIBITION; KINASE
CASCADE; IN-VITRO
AB Heat shock protein 90 (HSP90) is involved in the regulation of diverse biological processes such as cell signaling, proliferation and survival, and has been recently recognized as a potential target for cancer therapy. Ganetespib is a potent ATP competitive inhibitor of HSP90. Ganetespib downregulated the expression of multiple signal transducing molecules including EGFR, IGF-1R, c-Met, Akt, B-RAF and C- RAF, resulting in pronounced decrease in phosphorylation of Akt and Erk1/2 in a panel of five cutaneous melanoma cell lines including those harboring B-RAF and N-RAS mutations. Ganetespib exhibited potent antiproliferative activity on all five of these cell lines, with IC50 values between 37.5 and 84 nM. Importantly, Ganetespib is active on B-RAF mutated melanoma cells that have acquired resistance to B-RAF inhibition. Ganetespib induced apoptosis and cell cycle arrest at G1 and/or G2/M phase. Ganetespib induced cell cycle arrest was accompanied by altered expression of cyclin-dependent kinase inhibitor (CDKI) p21(Cip1) and p27(Kip1), cyclins B1, D1 and E, and/or cyclin-dependent kinases 1, 2 and 4. HSP90 is functionally important for melanoma cells and HSP90 inhibitors such as ganetespib could potentially be effective therapeutics for melanoma with various genetic mutations and acquired resistance to B-RAF inhibition.
C1 [Wu, Xinqi; Hodi, F. Stephen] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Wu, Xinqi; Marmarelis, Melina E.; Hodi, F. Stephen] Harvard Univ, Sch Med, Boston, MA USA.
[Wu, Xinqi; Hodi, F. Stephen] Dana Farber Brigham & Womens Canc Ctr, Melanoma Dis Ctr, Boston, MA USA.
RP Hodi, FS (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM stephen_hodi@dfci.harvard.edu
FU Sharon Crowley Martin Memorial Fund for Melanoma Research at Dana-Farber
Cancer Institute; Malcolm and Emily Mac Naught Fund for Melanoma
Research at Dana-Farber Cancer Institute
FX This work was supported in part by Sharon Crowley Martin Memorial Fund
for Melanoma Research (F. S. Hodi), the Malcolm and Emily Mac Naught
Fund for Melanoma Research (F. S. Hodi) at Dana-Farber Cancer Institute.
The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 62
TC 17
Z9 17
U1 2
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 13
PY 2013
VL 8
IS 2
AR e56134
DI 10.1371/journal.pone.0056134
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 104DM
UT WOS:000315970300115
PM 23418523
ER
PT J
AU Harrison, WJ
Mattingley, JB
Remington, RW
AF Harrison, William J.
Mattingley, Jason B.
Remington, Roger W.
TI Eye Movement Targets Are Released from Visual Crowding
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID COVERT SPATIAL ATTENTION; OBJECT RECOGNITION; PSYCHOPHYSICS TOOLBOX;
ENHANCEMENT; VISION; FIELD; MICROSTIMULATION; SENSITIVITY; RESPONSES;
SELECTION
AB Our ability to recognize objects in peripheral vision is impaired when other objects are nearby (Bouma, 1970). This phenomenon, known as crowding, is often linked to interactions in early visual processing that depend primarily on the retinal position of visual stimuli (Pelli, 2008; Pelli and Tillman, 2008). Here we tested a new account that suggests crowding is influenced by spatial information derived from an extraretinal signal involved in eye movement preparation. We had human observers execute eye movements to crowded targets and measured their ability to identify those targets just before the eyes began to move. Beginning similar to 50 ms before a saccade toward a crowded object, we found that not only was there a dramatic reduction in the magnitude of crowding, but the spatial area with in which crowding occurred was almost halved. These changes in crowding occurred despite no change in the retinal position of target or flanking stimuli. Contrary to the notion that crowding depends on retinal signals alone, our findings reveal an important role for eye movement signals. Eye movement preparation effectively enhances object discrimination in peripheral vision at the goal of the intended saccade. These presaccadic changes may enable enhanced recognition of visual objects in the periphery during active search of visually cluttered environments.
C1 [Harrison, William J.; Mattingley, Jason B.; Remington, Roger W.] Univ Queensland, Sch Psychol, St Lucia, Qld 4072, Australia.
[Mattingley, Jason B.] Univ Queensland, Queensland Brain Inst, St Lucia, Qld 4072, Australia.
RP Harrison, WJ (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst,Dept Ophthalmol, Boston, MA 02114 USA.
EM willjharri@gmail.com
RI Mattingley, Jason/J-1537-2014;
OI Mattingley, Jason/0000-0003-0929-9216; Harrison,
William/0000-0002-6408-0359
FU Australian Research Council (ARC) Discovery Project [DP0666772]; ARC
Australian Laureate Fellowship [FL110100103]
FX This research was supported by an Australian Research Council (ARC)
Discovery Project awarded to R. W. R. and J.B.M. (DP0666772). J.B.M. was
also supported by an ARC Australian Laureate Fellowship (FL110100103).
Parts of these data were presented at the Australasian Experimental
Psychology Conference in April, 2012. We thank T. S. A. Wallis for his
assistance with analysis of data for Experiment 2.
NR 41
TC 30
Z9 31
U1 2
U2 27
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD FEB 13
PY 2013
VL 33
IS 7
BP 2927
EP 2933
DI 10.1523/JNEUROSCI.4172-12.2013
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 089CQ
UT WOS:000314887200019
PM 23407951
ER
PT J
AU Liu, YY
Slotine, JJ
Barabasi, AL
AF Liu, Yang-Yu
Slotine, Jean-Jacques
Barabasi, Albert-Laszlo
TI Observability of complex systems
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE algebraic observability; biochemical reactions; control theory
ID NETWORKS; CONTROLLABILITY
AB A quantitative description of a complex system is inherently limited by our ability to estimate the system's internal state from experimentally accessible outputs. Although the simultaneous measurement of all internal variables, like all metabolite concentrations in a cell, offers a complete description of a system's state, in practice experimental access is limited to only a subset of variables, or sensors. A system is called observable if we can reconstruct the system's complete internal state from its outputs. Here, we adopt a graphical approach derived from the dynamical laws that govern a system to determine the sensors that are necessary to reconstruct the full internal state of a complex system. We apply this approach to biochemical reaction systems, finding that the identified sensors are not only necessary but also sufficient for observability. The developed approach can also identify the optimal sensors for target or partial observability, helping us reconstruct selected state variables from appropriately chosen outputs, a prerequisite for optimal biomarker design. Given the fundamental role observability plays in complex systems, these results offer avenues to systematically explore the dynamics of a wide range of natural, technological and socioeconomic systems.
C1 [Liu, Yang-Yu; Barabasi, Albert-Laszlo] Northeastern Univ, Ctr Complex Network Res, Boston, MA 02115 USA.
[Liu, Yang-Yu; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Phys, Boston, MA 02115 USA.
[Liu, Yang-Yu; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Comp Sci, Boston, MA 02115 USA.
[Liu, Yang-Yu; Barabasi, Albert-Laszlo] Northeastern Univ, Dept Biol, Boston, MA 02115 USA.
[Liu, Yang-Yu; Barabasi, Albert-Laszlo] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA.
[Slotine, Jean-Jacques] MIT, Nonlinear Syst Lab, Cambridge, MA 02138 USA.
[Slotine, Jean-Jacques] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
[Slotine, Jean-Jacques] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Barabasi, Albert-Laszlo] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
RP Barabasi, AL (reprint author), Northeastern Univ, Ctr Complex Network Res, Boston, MA 02115 USA.
EM alb@neu.edu
RI Liu, Yang-Yu/G-8885-2011
OI Liu, Yang-Yu/0000-0003-2728-4907
FU Network Science Collaborative Technology Alliance; US Army Research
Laboratory [W911NF-09-2-0053]; Defense Advanced Research Projects Agency
[11645021]; Defense Threat Reduction Agency [WMD BRBAA07-J-2-0035]
FX We thank J. Loscalzo, A. Sedoglavic, R. Albert, J. Faeder, J. Baranyi,
A. Sharma, G. Basler, P.-J. Kim, Y.-Y. Ahn, C. Song, T. Jia, B. Barzel,
and Y. Li for discussions. This work was supported by the Network
Science Collaborative Technology Alliance sponsored by the US Army
Research Laboratory under Agreement W911NF-09-2-0053; the Defense
Advanced Research Projects Agency under Agreement 11645021; the Defense
Threat Reduction Agency Award WMD BRBAA07-J-2-0035; and the generous
support of Lockheed Martin.
NR 32
TC 107
Z9 112
U1 5
U2 99
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 12
PY 2013
VL 110
IS 7
BP 2460
EP 2465
DI 10.1073/pnas.1215508110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 101ZL
UT WOS:000315812800024
PM 23359701
ER
PT J
AU Kohli, P
Wallentin, L
Reyes, E
Horrow, J
Husted, S
Angiolillo, DJ
Ardissino, D
Maurer, G
Morais, J
Nicolau, JC
Oto, A
Storey, RF
James, SK
Cannon, CP
AF Kohli, Payal
Wallentin, Lars
Reyes, Eric
Horrow, Jay
Husted, Steen
Angiolillo, Dominick J.
Ardissino, Diego
Maurer, Gerald
Morais, Joao
Nicolau, Jose C.
Oto, Ali
Storey, Robert F.
James, Stefan K.
Cannon, Christopher P.
TI Reduction in First and Recurrent Cardiovascular Events With Ticagrelor
Compared With Clopidogrel in the PLATO Study
SO CIRCULATION
LA English
DT Article
DE antiplatelet agents; outcomes assessment
ID ACUTE CORONARY SYNDROMES; TRITON-TIMI 38; MYOCARDIAL-INFARCTION;
COST-EFFECTIVENESS; STATIN THERAPY; TRIAL; THROMBOLYSIS; INSIGHTS;
STRATEGY; DISEASE
AB Background-We sought to evaluate the effect of potent platelet inhibition after acute coronary syndrome on total (ie, first and recurrent) occurrences of any of the primary outcome events (eg, cardiovascular death, myocardial infarction, and stroke) as well as on other ischemic events, such as urgent revascularization, (severe) recurrent ischemia, transient ischemic attacks, and arterial thrombotic events.
Methods and Results-In the PLATelet inhibition and patient Outcomes (PLATO) study, 18 624 patients presenting with acute coronary syndromes randomly received ticagrelor (n=9333) or clopidogrel (n=9291). Cox proportional hazard models were used to calculate time to first event and hazard ratios. Total events were compared using a Poisson regression model, and time to second event or death was calculated with the Wei Lin Weissfeld method. Patients randomized to ticagrelor had 1057 total primary end point events versus 1225 for patients on clopidogrel (rate ratio, 0.86; 95% confidence interval, 0.79-0.93; P=0.003). The number of additional events was numerically lower for ticagrelor (189 versus 205; P=0.40), resulting in a hazard for time to second event/death of 0.80 (95% confidence interval, 0.70-0.90; P<0.001) and a number needed to treat of 54. For cardiovascular death/myocardial infarction/stroke/(severe) recurrent ischemia/transient ischemic attack/arterial thrombotic events, total events were fewer with ticagrelor (2030 versus 2290; rate ratio, 0.88; 95% confidence interval, 0.82-0.95; P<0.001), with fewer recurrent events with ticagrelor (740 versus 834; P=0.01) and a highly significant concurrent reduction in hazard for time to second event or death of 0.83 (95% confidence interval, 0.75-0.91; P<0.001). Recurrent PLATO major or Thrombolysis in Myocardial Infarction (TIMI) major non-coronary artery bypass graft bleeding events were infrequent and not different between the two therapies (P=0.96 and 0.38, respectively).
Conclusions-In PLATO, treatment with ticagrelor compared with clopidogrel resulted in a reduction in total events, including first and subsequent recurrent cardiovascular events, when compared with clopidogrel. These types of analyses demonstrate an even greater absolute benefit of ticagrelor over clopidogrel than previously reported.
C1 [Kohli, Payal; Cannon, Christopher P.] Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, Boston, MA 02115 USA.
[Kohli, Payal; Cannon, Christopher P.] Harvard Univ, Sch Med, Boston, MA USA.
[Kohli, Payal] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA.
[Wallentin, Lars] Uppsala Univ, Dept Med Sci, Uppsala, Sweden.
[Wallentin, Lars] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden.
[Reyes, Eric] Duke Clin Res Inst, Durham, NC USA.
[Horrow, Jay] AstraZeneca R&D, Wilmington, DE USA.
[Husted, Steen] Arhus Univ Hosp, Dept Cardiol, Aarhus, Denmark.
[Angiolillo, Dominick J.] Univ Florida, Coll Med, Div Cardiovasc, Jacksonville, FL USA.
[Ardissino, Diego] Azienda Osped Univ Parma, Parma, Italy.
[Maurer, Gerald] Med Univ Vienna, Div Cardiol, Vienna, Austria.
[Morais, Joao] Santo Andres Hosp, Leiria, Portugal.
[Nicolau, Jose C.] Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil.
[Oto, Ali] Hacettepe Univ, Fac Med, TR-06100 Ankara, Turkey.
[James, Stefan K.] Univ Sheffield, Dept Cardiovasc Sci, Sheffield, S Yorkshire, England.
RP Cannon, CP (reprint author), Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, 350 Longwood Ave,1st Floor Off, Boston, MA 02115 USA.
EM cpcannon@partners.org
RI Nicolau, Jose/E-1487-2012
FU AstraZeneca [NCT00391872]; AstraZeneca; Merck/Schering-Plow;
Boehringer-Ingelheim; Bristol-Myers Squibb/Pfizer; GlaxoSmithKline;
Schering-Plow; Bristol-Myers Squibb; Bayer; Bristol Myers Squibb;
Sanofi-Aventis; Eli Lilly Co; Daiichi Sankyo, Inc; Medicines Company;
Portola; Novartis; Medicure; Accumetrics; Arena Pharmaceuticals; Astra
Zeneca; Merck; Evolva; Abbott Vascular; Otsuka; Daiichi Sankyo Inc;
Eisai; CSL Parexel; Roche; MSD; Eli-Lilly/Daiichi Sankyo; Sanofi; Eli
Lilly/Daiichi Sankyo; Essentialis; Regeneron; Takeda
FX The PLATO trial (NCT00391872) was funded by AstraZeneca.; Dr Kohli
reports honoraria from serving on an advisory board for Daiichi-Sankyo.
Dr Wallentin reports research grants from AstraZeneca,
Merck/Schering-Plow, Boehringer-Ingelheim, Bristol-Myers Squibb/Pfizer,
and GlaxoSmithKline; being a consultant for Merck/Schering-Plow, Regado
Biosciences, Evolva, Protola, C. S. L. Behring, Athera Biotechnologies,
Boehringer-Ingelheim, AstraZeneca, GlaxoSmithKline, and Bristol-Myers
Squibb/Pfizer; lecture fees from AstraZeneca, Boehringer-Ingelheim,
Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, Schering-Plow; and
honoraria from Boehringer Ingelheim, AstraZeneca, Bristol-Myers
Squibb/Pfizer, GlaxoSmithKline, and Schering-Plow/Merck. Dr Horrow is an
employee of AstraZeneca and has equity ownership in AstraZeneca. Dr
Husted reports receiving advisory board fees from AstraZeneca,
Bristol-Myers Squibb, and Bayer. Dr Angiolillo has received honoraria
for lectures from Bristol Myers Squibb, Sanofi-Aventis, Eli Lilly Co,
Daiichi Sankyo Inc, Astra Zeneca; and consulting fees from Bristol Myers
Squibb, Sanofi-Aventis, Eli Lilly Co, Daiichi Sankyo, Inc, The Medicines
Company, Portola, Novartis, Medicure, Accumetrics, Arena
Pharmaceuticals, Astra Zeneca, Merck, Evolva, and Abbott Vascular; and
research nd grants paid to Institution from Bristol Myers Squibb,
Sanofi-Aventis, GlaxoSmithKline, Otsuka, Eli Lilly Co, Daiichi Sankyo
Inc, The Medicines Company, Portola, Accumetrics, Schering-Plow,
AstraZeneca, Eisai, CSL Parexel. Dr Maurer reports receiving advisory
board fees from AstraZeneca, Merck, Boehringer-Ingelheim, Roche, and
Bayer. Dr Morais has received payments from speakers' bureau from
AstraZeneca, Bayer, and MSD; honoraria from AstraZeneca, Bayer, JABA
Recordati, and MSD. Dr Nicolau reports receiving research grants and
honoraria from AstraZeneca, Eli-Lilly/Daiichi Sankyo, Sanofi, MSD, and
Bayer. Dr Oto reports receiving honoraria from AstraZeneca,
Bristol-Myers Squibb, Servier, and serving as an advisory board member
for MSD. Dr Storey reports having research grants from AstraZeneca, Eli
Lilly/Daiichi Sankyo, and Merck; receiving research support from
Accumetrics; and honoraria from AstraZeneca, Eli Lilly/Daiichi Sankyo,
Merck, Novartis, The Medicines Company, Iroko, Sanofi-Aventis/BMS,
GlaxoSmithKline, Accumetrics, Medscape, and Eisai; he also reports
receiving consultancy fees from AstraZeneca, Merck, Novartis,
Accumetrics, and Eisai. Dr James reports receiving institutional
research grant and honoraria from AstraZeneca, Eli Lilly, Merck, and
Bristol-Myers Squibb and being an advisory board member for AstraZeneca,
Eli Lilly, and Merck. He also has received honoraria from The Medicines
Company. Dr Cannon reports having research grants/support: Accumetrics,
AstraZeneca, Essentialis, GlaxoSmithKline, Merck, Regeneron, Sanofi,
Takeda. He also has served on advisory boards for Alnylam, Bristol-Myers
Squibb, CSL Behring, and Pfizer, but all funds are donated to charity.
He is a clinical Advisor, and holds equity in Automedics Medical
Systems.
NR 12
TC 33
Z9 34
U1 1
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD FEB 12
PY 2013
VL 127
IS 6
BP 673
EP +
DI 10.1161/CIRCULATIONAHA.112.124248
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 088XR
UT WOS:000314871700011
PM 23277305
ER
PT J
AU Bangalore, S
Fusaro, M
Amoroso, N
Attubato, MJ
Feit, F
Slater, J
Kumar, S
Bhatt, DL
AF Bangalore, Sripal
Fusaro, Mario
Amoroso, Nicholas
Attubato, Michael J.
Feit, Frederick
Slater, James
Kumar, Sunil
Bhatt, Deepak L.
TI Response to Letter Regarding Article, "Short- and Long-Term Outcomes
With Drug-Eluting and Bare-Metal Coronary Stents: A Mixed-Treatment
Comparison Analysis of 117 762 Patient-years of Follow-up From
Randomized Trials"
SO CIRCULATION
LA English
DT Letter
C1 [Bangalore, Sripal; Fusaro, Mario; Amoroso, Nicholas; Attubato, Michael J.; Feit, Frederick; Slater, James] NYU, Sch Med, New York, NY 10003 USA.
[Kumar, Sunil] Univ Nebraska, Omaha, NE 68182 USA.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Bangalore, S (reprint author), NYU, Sch Med, New York, NY 10003 USA.
OI Bangalore, Sripal/0000-0001-9485-0652
NR 2
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD FEB 12
PY 2013
VL 127
IS 6
BP E447
EP E447
DI 10.1161/CIRCULATIONAHA.112.145169
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 088XR
UT WOS:000314871700003
PM 23534060
ER
PT J
AU Patel, MR
Hellkamp, AS
Lokhnygina, Y
Piccini, JP
Zhang, ZX
Mohanty, S
Singer, DE
Hacke, W
Breithardt, G
Halperin, JL
Hankey, GJ
Becker, RC
Nessel, CC
Berkowitz, SD
Califf, RM
Fox, KAA
Mahaffey, KW
AF Patel, Manesh R.
Hellkamp, Anne S.
Lokhnygina, Yuliya
Piccini, Jonathan P.
Zhang, Zhongxin
Mohanty, Surya
Singer, Daniel E.
Hacke, Werner
Breithardt, Guenter
Halperin, Jonathan L.
Hankey, Graeme J.
Becker, Richard C.
Nessel, Christopher C.
Berkowitz, Scott D.
Califf, Robert M.
Fox, Keith A. A.
Mahaffey, Kenneth W.
TI Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients
With Nonvalvular Atrial Fibrillation Analysis From the ROCKET AF Trial
(Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With
Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in
Atrial Fibrillation)
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE atrial fibrillation; factor Xa; rivaroxaban; stroke; warfarin
ID THERAPY
AB Objectives The purpose of this study was to understand the possible risk of discontinuation in the context of clinical care.
Background Rivaroxaban is noninferior to warfarin for preventing stroke in atrial fibrillation patients. Concerns exist regarding possible increased risk of stroke and non-central nervous system (CNS) thromboembolic events early after discontinuation of rivaroxaban.
Methods We undertook a post-hoc analysis of data from the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation, n = 14,624) for stroke or non-CNS embolism within 30 days after temporary interruptions of 3 days or more, early permanent study drug discontinuation, and end-of-study transition to open-label therapy.
Results Stroke and non-CNS embolism occurred at similar rates after temporary interruptions (rivaroxaban: n = 9, warfarin: n = 8, 6.20 vs. 5.05/100 patient-years, hazard ratio [HR]: 1.28, 95% confidence interval [CI]: 0.49 to 3.31, p = 0.62) and after early permanent discontinuation (rivaroxaban: n = 42, warfarin: n = 36, 25.60 vs. 23.28/100 patient-years, HR: 1.10, 95% CI: 0.71 to 1.72, p = 0.66). Patients transitioning to open-label therapy at the end of the study had more strokes with rivaroxaban (n = 22) versus warfarin (n = 6, 6.42 vs. 1.73/100 patient-years, HR: 3.72, 95% CI: 1.51 to 9.16, p = 0.0044) and took longer to reach a therapeutic international normalized ratio with rivaroxaban versus warfarin. All thrombotic events within 30 days of any study drug cessation (including stroke, non-CNS embolism, myocardial infarction, and vascular death) were similar between groups (HR: 1.02, 95% CI: 0.83 to 1.26, p = 0.85).
Conclusions In atrial fibrillation patients who temporarily or permanently discontinued anticoagulation, the risk of stroke or non-CNS embolism was similar with rivaroxaban or warfarin. An increased risk of stroke and non-CNS embolism was observed in rivaroxaban-treated patients compared with warfarin-treated patients after the end of the study, underscoring the importance of therapeutic anticoagulation coverage during such a transition. (J Am Coll Cardiol 2013;61:651-8) (C) 2013 by the American College of Cardiology Foundation
C1 [Patel, Manesh R.; Hellkamp, Anne S.; Lokhnygina, Yuliya; Piccini, Jonathan P.; Becker, Richard C.; Mahaffey, Kenneth W.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27705 USA.
[Zhang, Zhongxin; Mohanty, Surya; Nessel, Christopher C.] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA.
[Singer, Daniel E.] Massachusetts Gen Hosp, Div Gen Med, Clin Epidemiol Unit, Boston, MA 02114 USA.
[Singer, Daniel E.] Harvard Univ, Sch Med, Boston, MA USA.
[Hacke, Werner] Heidelberg Univ, Dept Neurol, Heidelberg, Germany.
[Breithardt, Guenter] Hosp Univ Munster, Dept Cardiol & Angiol, Munster, Germany.
[Halperin, Jonathan L.] Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA.
[Hankey, Graeme J.] Royal Perth Hosp, Dept Neurol, Perth, WA, Australia.
[Berkowitz, Scott D.] Bayer HealthCare Pharmaceut, Montville, NJ USA.
[Califf, Robert M.] Duke Univ, Med Ctr, Duke Translat Med Inst, Durham, NC USA.
[Fox, Keith A. A.] Univ Edinburgh, Edinburgh, Midlothian, Scotland.
[Fox, Keith A. A.] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland.
RP Patel, MR (reprint author), Duke Univ, Med Ctr, Dept Med, Duke Clin Res Inst, Room 0311 Terrace Level,2400 Pratt St, Durham, NC 27705 USA.
EM manesh.patel@duke.edu
RI Hankey, Graeme /H-4968-2014
OI Hankey, Graeme /0000-0002-6044-7328
FU Johnson & Johnson Pharmaceutical Research & Development, Raritan, New
Jersey; Bayer HealthCare AG, Leverkusen, Germany; Astra Zeneca; Johnson
Johnson; Janssen Pharmaceuticals; BI; Boehringer Ingelheim; Bayer Health
Care; Bristol-Myers Squibb; Sanofi-Aventis; Bayer Pharmaceuticals;
Bayer; Lilly; Boehringer; AstraZeneca; Bristol Myers-Squibb; Daiichi
Sankyo; Eli Lilly; GlaxoSmithKline; Merck; Novartis; Sanofi; Pfizer;
Polymedix; Pozen; Regado; Schering-Plough; Medicines Company
FX The ROCKET AF study was sponsored by Johnson & Johnson Pharmaceutical
Research & Development, Raritan, New Jersey, and Bayer HealthCare AG,
Leverkusen, Germany. Dr. Patel is on the advisory board of and
consulting to Baxter, Bayer Healthcare, Otsuka, CSI, Volcano, and
Jansen, and receiving research grants from Astra Zeneca and Johnson &
Johnson. Dr. Lokhnygina is a consultant to Johnson & Johnson and Bayer.
Dr. Piccini reports that his institution receiving a research grant from
Janssen Pharmaceuticals and consulting to Janssen Pharmaceuticals,
Forest Research Laboratories, Medtronic, and Titan Pharmaceuticals. Dr.
Mohanty is an employee of Johnson & Johnson. Dr. Singer is a consultant
to Johnson & Johnson, Bayer Healthcare, Boehringer Ingelheim,
Bristol-Myers Squibb, Daiichi Sankyo, Inc., Pfizer, and CSL Behring; has
received research support from Johnson & Johnson; and participating in
the executive committee of a trial sponsored by Johnson & Johnson. Dr.
Hacke has received honoraria, consulting to, and speaking to Boehringer
Ingelheim, Bayer, and Photo-thera and receiving an unrestricted grant
from BI. Dr. Breithardt is a member of scientific advisory boards of
Bayer Health Care, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer,
Otsuka Pharma, Sanofi-Aventis, and MSD and receiving fees for lectures
at symposia organized by Boehringer Ingelheim, Bayer Health Care,
Bristol-Myers Squibb, and Sanofi-Aventis. Dr. Halperin is a consultant
to Johnson & Johnson and Bayer Healthcare. Dr. Hankey is a member of the
executive committee of the ROCKET AF I study, receiving honoraria from
Duke, and receiving clinical research support from the study sponsors,
Bayer Pharmaceuticals and Johnson & Johnson. Dr. Becker has received
research support and acting as a scientific advisor to Bayer, and
Johnson & Johnson. Dr. Nessel is an employee of Johnson & Johnson. Dr.
Berkowitz is an employee of Bayer HealthCare Pharmaceuticals. Dr. Califf
has received research grants and consulting from Bayer and Johnson &
Johnson. Dr. Fox has received research grants from Bayer, Johnson &
Johnson, and Lilly; receiving hononaria and being a speaker for Bayer,
Johnson & Johnson, Sanofi Aventis, and Astra Zeneca; and receiving a
travel grant from Boehringer. Dr. Mahaffey has relationships with
AstraZeneca, Bayer, Boehringer Ingleheim, Bristol-Myers Squibb, Daiichi
Sankyo, Eli Lilly, Glaxo Smith Kline, Johnson & Johnson, Merck,
Novartis, Pfizer, Polymedix, Pozen, Regado Biotechnologies, Sanofi,
Schering-Plough, and The Medicines Company; has received consulting fees
and research grants from AstraZeneca, Bayer, Boehringer Ingelheim,
Bristol Myers-Squibb, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline,
Johnson & Johnson, Merck, Novartis, and Sanofi; and consulting fees
from: Pfizer and Polymedix; and grant support from: Pozen, Regado,
Schering-Plough, and The Medicines Company.
NR 10
TC 75
Z9 76
U1 0
U2 36
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD FEB 12
PY 2013
VL 61
IS 6
BP 651
EP 658
DI 10.1016/j.jacc.2012.09.057
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 086CM
UT WOS:000314660700010
PM 23391196
ER
PT J
AU Reynolds, MR
AF Reynolds, Matthew R.
TI Discontinuation of Rivaroxaban Filling in the Gaps
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Editorial Material
ID NONVALVULAR ATRIAL-FIBRILLATION; WARFARIN; METAANALYSIS; THERAPY
C1 VA Boston Healthcare Syst, Harvard Clin Res Inst, Boston, MA 02215 USA.
RP Reynolds, MR (reprint author), VA Boston Healthcare Syst, Harvard Clin Res Inst, 930-W Commonwealth Ave, Boston, MA 02215 USA.
EM mreynold@bidmc.harvard.edu
NR 8
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD FEB 12
PY 2013
VL 61
IS 6
BP 659
EP 660
DI 10.1016/j.jacc.2012.09.056
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 086CM
UT WOS:000314660700011
PM 23391197
ER
PT J
AU Albers, M
Yan, S
Kelly, K
Albers, A
AF Albers, Mark
Yan, Sandra
Kelly, Kathleen
Albers, Alefiya
TI Deficits in Episodic Memory of Olfactory Percepts as a Potential
Biomarker for Preclinical Alzheimer's Disease
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Albers, Mark; Yan, Sandra; Kelly, Kathleen] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Albers, Alefiya] Endicott Coll, Beverly, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P03081
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068602050
ER
PT J
AU Ali, S
Singhal, A
Rost, N
Schwamm, L
AF Ali, Syed
Singhal, Aneesh
Rost, Natalia
Schwamm, Lee
TI Characteristics and Outcomes among Acute Ischemic Stroke Patients
Arriving to the Hospital Via the "Front Door" vs. Transfer from Another
Acute Care Hospital
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Ali, Syed] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Singhal, Aneesh; Rost, Natalia; Schwamm, Lee] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S49006
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068606255
ER
PT J
AU Ali, S
Cohen, A
Viswanathan, A
Feske, S
Rost, N
Silverman, S
Anderson, C
Schwamm, L
AF Ali, Syed
Cohen, Adam
Viswanathan, Anand
Feske, Steven
Rost, Natalia
Silverman, Scott
Anderson, Christopher
Schwamm, Lee
TI Separating Acute Stroke from Stroke Mimics in a TeleStroke Network:
Differential Patient Characteristics and Exam Findings
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Ali, Syed] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Cohen, Adam; Viswanathan, Anand; Rost, Natalia; Silverman, Scott; Anderson, Christopher; Schwamm, Lee] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Feske, Steven] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P07241
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068605223
ER
PT J
AU Ali, S
Singhal, A
Rost, N
Schwamm, L
AF Ali, Syed
Singhal, Aneesh
Rost, Natalia
Schwamm, Lee
TI Characteristics and Outcomes among Acute Ischemic Stroke Patients
Arriving to the Hospital Via the "Front Door" vs. Transfer from Another
Acute Care Hospital
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Ali, Syed] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Singhal, Aneesh; Rost, Natalia; Schwamm, Lee] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA IN71003
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068600089
ER
PT J
AU Anderson, C
Biffi, A
Nalls, M
Devan, W
Schwab, K
Ayres, A
Valant, V
Ross, O
Rost, N
Saxena, R
Viswanathan, A
Worrall, B
Brott, T
Goldstein, J
Brown, D
Broderick, J
Norrving, B
Greenberg, S
Silliman, S
Hansen, B
Tirschwell, D
Lindgren, A
Slowik, A
Schmidt, R
Selim, M
Gonzalez, JR
Montaner, J
Singleton, A
Kidwell, C
Woo, D
Furie, K
Meschia, J
Rosand, J
AF Anderson, Christopher
Biffi, Alessandro
Nalls, Michael
Devan, William
Schwab, Kristin
Ayres, Alison
Valant, Valerie
Ross, Owen
Rost, Natalia
Saxena, Richa
Viswanathan, Anand
Worrall, Bradford
Brott, Thomas
Goldstein, Joshua
Brown, Devin
Broderick, Joseph
Norrving, Bo
Greenberg, Steven
Silliman, Scott
Hansen, Bjorn
Tirschwell, David
Lindgren, Arne
Slowik, Agnieszka
Schmidt, Reinhold
Selim, Magdy
Roquer Gonzalez, Jaume
Montaner, Joan
Singleton, Andrew
Kidwell, Chelsea
Woo, Daniel
Furie, Karen
Meschia, James
Rosand, Jonathan
TI Common Variants within Oxidative Phosphorylation Genes Influence Risk of
Ischemic Stroke and Intracerebral Hemorrhage
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Anderson, Christopher; Biffi, Alessandro; Devan, William; Schwab, Kristin; Ayres, Alison; Valant, Valerie; Rost, Natalia; Saxena, Richa; Viswanathan, Anand; Goldstein, Joshua; Greenberg, Steven; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Nalls, Michael; Singleton, Andrew] NIA, Bethesda, MD 20892 USA.
[Ross, Owen; Brott, Thomas; Meschia, James] Mayo Clin, Jacksonville, FL 32224 USA.
[Worrall, Bradford] Univ Virginia, Charlottesville, VA USA.
[Brown, Devin] Univ Michigan, Ann Arbor, MI 48109 USA.
[Broderick, Joseph; Woo, Daniel] Univ Cincinnati, Cincinnati, OH USA.
[Norrving, Bo; Hansen, Bjorn; Lindgren, Arne] Lund Univ, Lund, Sweden.
[Silliman, Scott] Univ Florida, Jacksonville, FL USA.
[Tirschwell, David] Univ Washington, Seattle, WA 98195 USA.
[Slowik, Agnieszka] Jagiellonian Univ, Krakow, Poland.
[Schmidt, Reinhold] Graz Univ, St Radegund, Austria.
[Selim, Magdy] BIDMC, Boston, MA USA.
[Roquer Gonzalez, Jaume] Hosp del Mar, Barcelona, Spain.
[Montaner, Joan] Univ Vall Dhebron, Barcelona, Spain.
[Kidwell, Chelsea] Georgetown Univ, Washington, DC USA.
[Furie, Karen] Brown Univ, Providence, RI 02912 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S42002
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068606203
ER
PT J
AU Anderson, C
Biffi, A
Nalls, M
Devan, W
Schwab, K
Ayres, A
Valant, V
Ross, O
Rost, N
Saxena, R
Viswanathan, A
Worrall, B
Brott, T
Goldstein, J
Brown, D
Broderick, J
Norrving, B
Greenberg, S
Silliman, S
Hansen, B
Tirschwell, D
Lindgren, A
Slowik, A
Schmidt, R
Selim, M
Gonzalez, JR
Montaner, J
Singleton, A
Kidwell, C
Woo, D
Furie, K
Meschia, J
Rosand, J
AF Anderson, Christopher
Biffi, Alessandro
Nalls, Michael
Devan, William
Schwab, Kristin
Ayres, Alison
Valant, Valerie
Ross, Owen
Rost, Natalia
Saxena, Richa
Viswanathan, Anand
Worrall, Bradford
Brott, Thomas
Goldstein, Joshua
Brown, Devin
Broderick, Joseph
Norrving, Bo
Greenberg, Steven
Silliman, Scott
Hansen, Bjorn
Tirschwell, David
Lindgren, Arne
Slowik, Agnieszka
Schmidt, Reinhold
Selim, Magdy
Roquer Gonzalez, Jaume
Montaner, Joan
Singleton, Andrew
Kidwell, Chelsea
Woo, Daniel
Furie, Karen
Meschia, James
Rosand, Jonathan
TI Common Variants within Oxidative Phosphorylation Genes Influence Risk of
Ischemic Stroke and Intracerebral Hemorrhage
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Anderson, Christopher; Biffi, Alessandro; Devan, William; Schwab, Kristin; Ayres, Alison; Valant, Valerie; Rost, Natalia; Saxena, Richa; Viswanathan, Anand; Goldstein, Joshua; Greenberg, Steven; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Nalls, Michael] NIA, Bethesda, MD 20892 USA.
[Ross, Owen; Brott, Thomas; Meschia, James] Mayo Clin, Jacksonville, FL 32224 USA.
[Worrall, Bradford] Univ Virginia, Charlottesville, VA USA.
[Brown, Devin] Univ Michigan, Ann Arbor, MI 48109 USA.
[Broderick, Joseph; Woo, Daniel] Univ Cincinnati, Cincinnati, OH USA.
[Norrving, Bo; Hansen, Bjorn; Lindgren, Arne] Lund Univ, Lund, Sweden.
[Silliman, Scott] Univ Florida, Jacksonville, FL USA.
[Tirschwell, David] Univ Washington, Seattle, WA 98195 USA.
[Slowik, Agnieszka] Jagiellonian Univ, Krakow, Poland.
[Schmidt, Reinhold] Graz Univ, St Radegund, Austria.
[Selim, Magdy] BIDMC, Boston, MA USA.
[Roquer Gonzalez, Jaume] Hosp del Mar, Barcelona, Spain.
[Montaner, Joan] Univ Vall Dhebron, Barcelona, Spain.
[Kidwell, Chelsea] Georgetown Univ, Washington, DC USA.
[Furie, Karen] Brown Univ, Providence, RI 02912 USA.
RI Montaner, Joan/D-3063-2015; IBIS, NEUROVASCULAR/O-1855-2015
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA IN71001
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068600087
ER
PT J
AU Ay, H
Arsava, EM
Brown, R
Kittner, S
McArdle, P
Rosand, J
Rundek, T
Worrall, B
Woo, D
Arnett, D
Rexrode, K
Smoller, S
Grewal, R
Sacco, R
Cole, J
Slowik, A
Lindgren, A
Jimenez-Conde, J
Jern, C
Thijs, V
Schmidt, R
Sharma, P
Rothwell, P
Dichgans, M
Lee, JM
Sudlow, C
Marcus, H
Fornage, M
Rich, S
deBaker, P
Mitchell, B
Meschia, J
AF Ay, Hakan
Arsava, Ethem Murat
Brown, Robert
Kittner, Steven
McArdle, Patrick
Rosand, Jonathan
Rundek, Tatjana
Worrall, Bradford
Woo, Daniel
Arnett, Donna
Rexrode, Kathryn
Smoller, Sylvia
Grewal, Raji
Sacco, Ralph
Cole, John
Slowik, Agnieszka
Lindgren, Arne
Jimenez-Conde, Jordi
Jern, Christina
Thijs, Vincent
Schmidt, Reinhold
Sharma, Pankja
Rothwell, Peter
Dichgans, Martin
Lee, Jin-Moo
Sudlow, Cathie
Marcus, Hugh
Fornage, Myriam
Rich, Stephen
deBaker, Paul
Mitchell, Braxton
Meschia, James
TI Etiologic Stroke Subtypes in the NINDS Stroke Genetics Network Study
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Ay, Hakan] Massachusetts Gen Hosp, Charlestown, MA USA.
[Arsava, Ethem Murat] Univ Turkey, Ankara, Turkey.
[Brown, Robert] Mayo Clin Rochester, Rochester, MN USA.
[Kittner, Steven; McArdle, Patrick; Cole, John; Mitchell, Braxton] Univ Maryland, Baltimore, MD 21201 USA.
[Rosand, Jonathan] Univ Massachusetts, Boston, MA 02125 USA.
[Rundek, Tatjana; Sacco, Ralph] Univ Miami, Miami, FL USA.
[Worrall, Bradford; Rich, Stephen] Univ Virginia, Charlottesville, VA USA.
[Woo, Daniel] Univ Cincinnati, Cincinnati, OH USA.
[Arnett, Donna] Univ Alabama Birmingham, Birmingham, AL USA.
[Rexrode, Kathryn; deBaker, Paul] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Smoller, Sylvia] Einstein Coll Med, Bronx, NY USA.
[Grewal, Raji] New Jersey Neurosci Inst, Cranbury, NJ USA.
[Slowik, Agnieszka] Jagiellonian Univ, Coll Med, Krakow, Poland.
[Lindgren, Arne] Skane Univ Hosp, Lund, Sweden.
[Jimenez-Conde, Jordi] Hosp del Mar, IMIM, Barcelona, Spain.
[Jern, Christina] Univ Gothenburg, Sahigrenska Acad, Gothenburg, Sweden.
[Thijs, Vincent] Katholieke Univ Leuven Hosp, Louvain, Belgium.
[Schmidt, Reinhold] Med Univ Graz, St Radegund, Austria.
[Sharma, Pankja] Univ London Imperial Coll Sci Technol & Med, London, England.
[Rothwell, Peter] Univ Oxford, Oxford, England.
[Dichgans, Martin] Univ Munich, Munich, Germany.
[Lee, Jin-Moo] Washington Univ, St Louis, MO USA.
[Sudlow, Cathie] Univ Edinburgh, Edinburgh, Midlothian, Scotland.
[Marcus, Hugh] St Georges Univ London, London, England.
[Fornage, Myriam] Univ Texas Hlth Sci, Houston, TX USA.
[Meschia, James] Mayo Clin, Florida Jacksonville, FL USA.
RI Lee, Jin-Moo/K-2024-2015; JIMENEZ-CONDE, JORDI/C-1941-2012
OI Lee, Jin-Moo/0000-0002-3979-0906;
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S32001
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068606142
ER
PT J
AU Boes, A
Prasad, S
Caviness, V
Fox, M
AF Boes, Aaron
Prasad, Sashank
Caviness, Verne
Fox, Michael
TI The Neuroanatomy of Peduncular Hallucinosis: A Case Series and Lesion
Overlap Analysis
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Boes, Aaron; Caviness, Verne] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Prasad, Sashank] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S18004
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068606057
ER
PT J
AU Bove, R
Musallam, A
Healy, B
Raghavan, K
Khoury, S
Weiner, H
De Jager, P
Miller, K
Chitnis, T
AF Bove, Riley
Musallam, Alexander
Healy, Brian
Raghavan, Kesav
Khoury, Samia
Weiner, Howard
De Jager, Philip
Miller, Karen
Chitnis, Tanuja
TI Hormonal Associations in the Early Disease Course in Men with Relapsing
Remitting Multiple Sclerosis
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Bove, Riley] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Musallam, Alexander] Harvard Univ, Brigham & Womens Hosp, Sch Med, Brookline, MA USA.
[Healy, Brian] Brigham & Womens Hosp, Brookline, MA USA.
[Raghavan, Kesav; Khoury, Samia; De Jager, Philip] Harvard Univ, Sch Med, Boston, MA USA.
[Weiner, Howard] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Miller, Karen] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Chitnis, Tanuja] Harvard Univ, Sch Med, Brookline, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P02128
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068601192
ER
PT J
AU Bove, R
Musallam, A
Healy, B
Raghavan, K
Khoury, S
Weiner, H
De Jager, P
Miller, K
Chitnis, T
AF Bove, Riley
Musallam, Alexander
Healy, Brian
Raghavan, Kesav
Khoury, Samia
Weiner, Howard
De Jager, Philip
Miller, Karen
Chitnis, Tanuja
TI Hormonal Associations in the Early Disease Course in Men with Relapsing
Remitting Multiple Sclerosis
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Bove, Riley] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Musallam, Alexander] Harvard Univ, Sch Med, Brigham & Womens Hosp, Brookline, MA USA.
[Healy, Brian] Brigham & Womens Hosp, Brookline, MA USA.
[Raghavan, Kesav; Khoury, Samia; De Jager, Philip] Harvard Univ, Sch Med, Boston, MA USA.
[Weiner, Howard] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Miller, Karen] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Chitnis, Tanuja] Harvard Univ, Sch Med, Brookline, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA IN82003
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068600111
ER
PT J
AU Chow, F
Regan, S
He, W
Feske, S
Meigs, J
Grinspoon, S
Triant, V
AF Chow, Felicia
Regan, Susan
He, Wei
Feske, Steven
Meigs, James
Grinspoon, Steven
Triant, Virginia
TI Incidence Rates of Intracerebral Hemorrhage Are Increased in Young and
Female HIV-Infected Individuals
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Chow, Felicia] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Regan, Susan; He, Wei; Meigs, James; Grinspoon, Steven; Triant, Virginia] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Feske, Steven] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S38004
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068606180
ER
PT J
AU Cudkowicz, M
Shefner, J
AF Cudkowicz, Merit
Shefner, Jeremy
CA NEALS Consortium
TI STAGE 3 Clinical Trial of Ceftriaxone in Subjects with ALS
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Cudkowicz, Merit] Massachusetts Gen Hosp, Charlestown, MA USA.
[Shefner, Jeremy] SUNY Upstate, Syracuse, NY USA.
[NEALS Consortium] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S36001
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068606165
ER
PT J
AU Daniello, K
Pathmanathan, J
AF Daniello, Kate
Pathmanathan, Jay
TI A Case of Rapidly Progressive Dementia: Differentiating Dementia with
Lewy Body from Creutzfeldt-Jacob Disease
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Daniello, Kate] Boston Univ, Brookline, MA USA.
[Pathmanathan, Jay] Massachusetts Gen Hosp, Newton, MA USA.
[Pathmanathan, Jay] Boston Vet Hosp, Newton, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P04214
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068603103
ER
PT J
AU Dickerson, B
Bickart, K
Brickhouse, M
Sapolsky, D
Barrett, L
AF Dickerson, Bradford
Bickart, Kevin
Brickhouse, Michael
Sapolsky, Daisy
Barrett, Lisa
TI Atrophy in Distinct Corticolimbic Networks Predicts Specific Social
Symptoms in Frontotemporal Dementia
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Dickerson, Bradford; Brickhouse, Michael; Sapolsky, Daisy] Massachusetts Gen Hosp, Charlestown, MA USA.
[Bickart, Kevin] Boston Univ, Boston, MA 02215 USA.
[Barrett, Lisa] Northeastern Univ, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P06055
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068604123
ER
PT J
AU Dickerson, B
Domoto-Reilly, K
Hollenbeck, M
Sapolsky, D
Brickhouse, M
AF Dickerson, Bradford
Domoto-Reilly, Kimiko
Hollenbeck, Mark
Sapolsky, Daisy
Brickhouse, Michael
TI Quantitative MRI Biomarkers of Neurodegenerative Diseases: Moving from
Scientific Insights toward Clinical Practice
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Dickerson, Bradford; Hollenbeck, Mark; Sapolsky, Daisy; Brickhouse, Michael] Massachusetts Gen Hosp, Charlestown, MA USA.
[Domoto-Reilly, Kimiko] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P06030
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068604098
ER
PT J
AU Dickerson, B
Domoto-Reilly, K
Hollenbeck, M
Sapolsky, D
Brickhouse, M
AF Dickerson, Bradford
Domoto-Reilly, Kimiko
Hollenbeck, Mark
Sapolsky, Daisy
Brickhouse, Michael
TI Quantitative MRI Biomarkers of Neurodegenerative Diseases: Moving from
Scientific Insights toward Clinical Practice
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Dickerson, Bradford; Hollenbeck, Mark; Sapolsky, Daisy; Brickhouse, Michael] Massachusetts Gen Hosp, Charlestown, MA USA.
[Domoto-Reilly, Kimiko] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA IN31010
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068600041
ER
PT J
AU Domoto-Reilly, K
Sapolsky, D
Negreira, A
McGinnis, S
Brickhouse, M
Dickerson, B
AF Domoto-Reilly, Kimiko
Sapolsky, Daisy
Negreira, Alyson
McGinnis, Scott
Brickhouse, Michael
Dickerson, Bradford
TI Regionally Specific Cortical Thinning Predicts Conversion to Dementia in
Prodromal Frontotemporal Dementia (FTD)
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Domoto-Reilly, Kimiko] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Sapolsky, Daisy; Negreira, Alyson; Brickhouse, Michael; Dickerson, Bradford] Massachusetts Gen Hosp, Charlestown, MA USA.
[McGinnis, Scott] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P05103
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068603256
ER
PT J
AU Esposito, F
Sorosina, M
Lim, E
Brambilla, P
Romeo, M
Rodegher, M
Patsopoulos, N
Osiceanu, A
Keenan, B
Martinelli, V
Brassat, D
Comi, G
De Jager, P
Boneschi, FM
AF Esposito, Federica
Sorosina, Melissa
Lim, Elaine
Brambilla, Paola
Romeo, Marzia
Rodegher, Mariaemma
Patsopoulos, Nikolaos
Osiceanu, Ana
Keenan, Brendan
Martinelli, Vittorio
Brassat, David
Comi, Giancarlo
De Jager, Philip
Boneschi, Filippo Martinelli
TI An SLC9A9 Variant Influences Treatment Response in Interferon beta
Treated Multiple Sclerosis Patients
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Esposito, Federica; Sorosina, Melissa; Brambilla, Paola; Romeo, Marzia; Rodegher, Mariaemma; Osiceanu, Ana; Martinelli, Vittorio; Comi, Giancarlo; Boneschi, Filippo Martinelli] Ist Sci San Raffaele, I-20132 Milan, Italy.
[Lim, Elaine] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lim, Elaine] Broad Inst Harvard & MIT, Boston, MA USA.
[Patsopoulos, Nikolaos; Keenan, Brendan; De Jager, Philip] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Patsopoulos, Nikolaos; De Jager, Philip] Harvard Univ, Sch Med, Boston, MA USA.
[Brassat, David] Univ Toulouse, Toulouse, France.
RI brassat, david/L-2173-2014
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P05141
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068603294
ER
PT J
AU Foreman, P
Van Cott, A
Pugh, MJ
AF Foreman, Perry
Van Cott, Anne
Pugh, Mary Jo
TI Increased Mortality in Elderly Veterans Diagnosed with Epilepsy
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Foreman, Perry] Sinai Hosp, Berman Brain & Spine Inst, Baltimore, MD 21215 USA.
[Van Cott, Anne] Univ Pittsburgh, Pittsburgh, PA USA.
[Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P03117
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068602086
ER
PT J
AU Forst, D
Chi, A
Dietrich, J
Gerstner, E
Jones, S
Byrne, T
Hochberg, F
Plotkin, S
Batchelor, T
AF Forst, Deborah
Chi, Andrew
Dietrich, Jorg
Gerstner, Elizabeth
Jones, SooAe
Byrne, Thomas
Hochberg, Fred
Plotkin, Scott
Batchelor, Tracy
TI Methotrexate, Rituximab, Temozolomide (MRT) Induction Therapy for
Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL)
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Forst, Deborah; Chi, Andrew; Dietrich, Jorg; Gerstner, Elizabeth; Jones, SooAe; Byrne, Thomas; Hochberg, Fred; Plotkin, Scott; Batchelor, Tracy] Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S56003
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068606293
ER
PT J
AU Forst, D
Chi, A
Dietrich, J
Gerstner, E
Jones, S
Byrne, T
Hochberg, F
Plotkin, S
Batchelor, T
AF Forst, Deborah
Chi, Andrew
Dietrich, Jorg
Gerstner, Elizabeth
Jones, SooAe
Byrne, Thomas
Hochberg, Fred
Plotkin, Scott
Batchelor, Tracy
TI Methotrexate, Rituximab, Temozolomide (MRT) Induction Therapy for
Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL)
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Forst, Deborah; Chi, Andrew; Dietrich, Jorg; Gerstner, Elizabeth; Jones, SooAe; Byrne, Thomas; Hochberg, Fred; Plotkin, Scott; Batchelor, Tracy] Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA IN101002
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068600129
ER
PT J
AU Fridman, V
David, W
Pan, J
Eichler, F
AF Fridman, Vera
David, William
Pan, Jessica
Eichler, Florian
TI Disease Progression in Hereditary Sensory and Autonomic Neuropathy Type
I (HSAN1)
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Fridman, Vera; David, William; Pan, Jessica] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Eichler, Florian] Massachusetts Gen Hosp, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S26003
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068606103
ER
PT J
AU Goetz, C
Stebbins, G
Chung, K
Hauser, R
Miyasaki, J
Nicholas, A
Poewe, W
Seppi, K
Rascol, O
Stacy, M
Nutt, J
Tanner, C
Urkowitz, A
Jaglin, J
Ge, S
AF Goetz, Christopher
Stebbins, Glenn
Chung, Kathryn
Hauser, Robert
Miyasaki, Janis
Nicholas, Anthony
Poewe, Werner
Seppi, Klaus
Rascol, Olivier
Stacy, Mark
Nutt, John
Tanner, Caroline
Urkowitz, Alison
Jaglin, Jean
Ge, Song
TI No PD Dyskinesia Scale Protects Against Placebo Responses: A Comparison
of Multiple Scales
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Goetz, Christopher] Rush Univ, Med Ctr, Neurol Sci Movement Disorder Sect, Chicago, IL 60612 USA.
[Stebbins, Glenn; Jaglin, Jean; Ge, Song] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Chung, Kathryn] Oregon Hlth & Sci Univ, Lake Oswego, OR USA.
[Chung, Kathryn] Portland VA Med Ctr, Lake Oswego, OR USA.
[Hauser, Robert] Univ S Florida, Tampa, FL USA.
[Miyasaki, Janis] Univ Toronto, Edmond J Safra Program Parkinsons Dis, Toronto, ON, Canada.
[Nicholas, Anthony] Univ Alabama Birmingham, Birmingham, AL USA.
[Nicholas, Anthony] Birmingham VA Med Ctr, Birmingham, AL USA.
[Poewe, Werner; Seppi, Klaus] Med Univ Innsbruck, A-6020 Innsbruck, Austria.
[Rascol, Olivier] Univ Hosp Toulouse, Clin Invest Ctr CIC9302, Toulouse, France.
[Rascol, Olivier] Univ Hosp Toulouse, Dept Clin Pharmacol, INSERM, Toulouse, France.
[Rascol, Olivier] Univ Hosp Toulouse, Dept Neurosci, INSERM, Toulouse, France.
[Rascol, Olivier] Univ Toulouse 3, F-31062 Toulouse, France.
[Stacy, Mark] Duke Univ, Durham, NC USA.
[Nutt, John] Oregon Hlth & Sci Univ, Portland, OR USA.
[Nutt, John] Portland VA Med Ctr, Portland, OR USA.
[Tanner, Caroline] Parkinsons Inst & Clin Ctr, Sunnyvale, CA USA.
[Urkowitz, Alison] Michael J Fox Fdn Parkinsons Res, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P04187
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068603076
ER
PT J
AU Guercio, B
Donovan, N
Ward, A
Schultz, A
Lorius, N
Amariglio, R
Rentz, D
Johnson, K
Sperling, R
Marshall, G
AF Guercio, Brendan
Donovan, Nancy
Ward, Andrew
Schultz, Aaron
Lorius, Natacha
Amariglio, Rebecca
Rentz, Dorene
Johnson, Keith
Sperling, Reisa
Marshall, Gad
TI Apathy Is Associated with Inferior Temporal Atrophy in Amnestic Mild
Cognitive Impairment and Clinically Normal Elderly
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Guercio, Brendan] Harvard Univ, Sch Med, Boston, MA USA.
[Donovan, Nancy] Brigham & Womens Hosp, Hingham, MA USA.
[Ward, Andrew; Schultz, Aaron] Massachusetts Gen Hosp, Charlestown, MA USA.
[Lorius, Natacha] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Amariglio, Rebecca; Rentz, Dorene; Sperling, Reisa] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Johnson, Keith] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Marshall, Gad] Brigham & Womens Hosp, Brookline, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P07149
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068605131
ER
PT J
AU Hammond, E
Young, C
Chio, A
Van den Berg, L
Al-Chalabi, A
Berry, J
Brooks, B
Shefner, J
Turner, M
Williams, J
Li, XX
Kerr, D
AF Hammond, Edward
Young, Carolyn
Chio, Adriano
Van den Berg, Leonard
Al-Chalabi, Ammar
Berry, James
Brooks, Benjamin
Shefner, Jeremy
Turner, Martin
Williams, James
Li, Xiaoxi
Kerr, Douglas
TI Evaluation of a Health State Staging System Defined by Loss of
Independence in Amyotrophic Lateral Sclerosis: Assessment in a Second
Dataset
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Hammond, Edward] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Young, Carolyn] Walton Ctr Neurol, Liverpool, Merseyside, England.
[Chio, Adriano] Univ Turin, Turin, Italy.
[Van den Berg, Leonard] Univ Med Ctr Utrecht, Netherlands ALS Ctr, Utrecht, Netherlands.
[Al-Chalabi, Ammar] Kings Coll London, Inst Psychiat, Dept Clin Neurosci, London WC2R 2LS, England.
[Berry, James] Massachussetts Gen Hosp, Boston, MA USA.
[Brooks, Benjamin] Univ N Carolina, Carolinas Med Ctr, Sch Med, Charlotte, NC 28223 USA.
[Shefner, Jeremy] SUNY Upstate Med Univ, Syracuse, NY 13210 USA.
[Turner, Martin] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England.
[Williams, James; Li, Xiaoxi; Kerr, Douglas] Biogen Idec Inc, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P07066
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068605048
ER
PT J
AU Hellman, A
Duda, J
Morley, J
AF Hellman, Amy
Duda, John
Morley, James
TI Continuous Non-Invasive Arterial Pressure Monitoring To Detect Autonomic
Dysfunction in Parkinson's Disease
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Hellman, Amy; Duda, John; Morley, James] Univ Penn, Sch Med, Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA.
[Hellman, Amy; Duda, John; Morley, James] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P06101
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068604169
ER
PT J
AU Hsiao, J
Lee, G
Lu, P
Teng, E
AF Hsiao, Julia
Lee, Grace
Lu, Po
Teng, Edmond
TI Longitudinal Declines in Instrumental Activities of Daily Living in
Stable and Progressive Mild Cognitive Impairment
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Hsiao, Julia] VA Greater Los Angeles Healthcare Syst, Neurol, Los Angeles, CA USA.
[Lee, Grace; Teng, Edmond] Univ Calif Los Angeles, Los Angeles, CA USA.
[Lu, Po] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Teng, Edmond] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P07154
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068605136
ER
PT J
AU Huang, R
Chen, C
Maclean, A
Mukundan, S
Wen, P
Norden, A
AF Huang, Raymond
Chen, Christina
Maclean, Ainsley
Mukundan, Srinivasan
Wen, Patrick
Norden, Andrew
TI Recurrent High-Grade Glioma Treated with Bevacizumab: Predictive Value
of Biomarkers and Pretreatment MRI in Determining Response and Survival
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Huang, Raymond; Maclean, Ainsley; Mukundan, Srinivasan] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Chen, Christina] Harvard Univ, Sch Med, Boston, MA USA.
[Wen, Patrick; Norden, Andrew] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P06141
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068604209
ER
PT J
AU Huang, R
Chen, C
Maclean, A
Mukundan, S
Wen, P
Norden, A
AF Huang, Raymond
Chen, Christina
Maclean, Ainsley
Mukundan, Srinivasan
Wen, Patrick
Norden, Andrew
TI Recurrent High-Grade Glioma Treated with Bevacizumab: Predictive Value
of Biomarkers and Pretreatment MRI in Determining Response and Survival
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Huang, Raymond; Maclean, Ainsley; Mukundan, Srinivasan] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Chen, Christina] Harvard Univ, Sch Med, Boston, MA USA.
[Wen, Patrick; Norden, Andrew] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA IN101008
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068600135
ER
PT J
AU Jette, N
Pringsheim, T
Day, L
De Robles, P
Fiest, K
Hamilton, M
Hogan, D
Korngut, L
Kwon, CS
Lam, D
Mah, J
Marrie, RA
Maxwell, C
Metcalfe, A
Oskoui, M
Patten, S
Pearson, D
Reid, A
Smith, E
Steeves, T
Svenson, L
Wiebe, S
Dykeman, J
AF Jette, Nathalie
Pringsheim, Tamara
Day, Lundy
De Robles, Paula
Fiest, Kirsten
Hamilton, Mark
Hogan, David
Korngut, Lawrence
Kwon, Churl-Su
Lam, Darren
Mah, Jean
Marrie, Ruth-Ann
Maxwell, Colleen
Metcalfe, Amy
Oskoui, Maryam
Patten, Scott
Pearson, Dawn
Reid, Aylin
Smith, Eric
Steeves, Thomas
Svenson, Larry
Wiebe, Samuel
Dykeman, Jonathan
TI The International Incidence and Prevalence of Neurological Diseases - Do
We Really Know How Common Neurological Conditions Are? Challenges in
Interpreting International Epidemiological Studies
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Jette, Nathalie; Pringsheim, Tamara; Day, Lundy; De Robles, Paula; Fiest, Kirsten; Hamilton, Mark; Hogan, David; Korngut, Lawrence; Lam, Darren; Mah, Jean; Metcalfe, Amy; Patten, Scott; Pearson, Dawn; Reid, Aylin; Smith, Eric; Wiebe, Samuel; Dykeman, Jonathan] Univ Calgary, Calgary, AB, Canada.
[Kwon, Churl-Su] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Marrie, Ruth-Ann] Univ Manitoba, Winnipeg, MB, Canada.
[Maxwell, Colleen] Univ Waterloo, Waterloo, ON N2L 3G1, Canada.
[Oskoui, Maryam] McGill Univ, Montreal, PQ, Canada.
[Steeves, Thomas] Univ Toronto, Toronto, ON, Canada.
[Svenson, Larry] Alberta Hlth & Wellness, Edmonton, AB, Canada.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P04235
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068603124
ER
PT J
AU Jette, N
Pringsheim, T
Day, L
De Robles, P
Fiest, K
Hamilton, M
Hogan, D
Korngut, L
Kwon, CS
Lam, D
Mah, J
Marrie, RA
Maxwell, C
Metcalfe, A
Oskoui, M
Patten, S
Pearson, D
Reid, A
Smith, E
Steeves, T
Svenson, L
Wiebe, S
Dykeman, J
AF Jette, Nathalie
Pringsheim, Tamara
Day, Lundy
De Robles, Paula
Fiest, Kirsten
Hamilton, Mark
Hogan, David
Korngut, Lawrence
Kwon, Churl-Su
Lam, Darren
Mah, Jean
Marrie, Ruth-Ann
Maxwell, Colleen
Metcalfe, Amy
Oskoui, Maryam
Patten, Scott
Pearson, Dawn
Reid, Aylin
Smith, Eric
Steeves, Thomas
Svenson, Larry
Wiebe, Samuel
Dykeman, Jonathan
TI The International Incidence and Prevalence of Neurological Diseases - Do
We Really Know How Common Neurological Conditions Are? Challenges in
Interpreting International Epidemiological Studies
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Jette, Nathalie; Pringsheim, Tamara; Day, Lundy; De Robles, Paula; Fiest, Kirsten; Hamilton, Mark; Hogan, David; Korngut, Lawrence; Lam, Darren; Mah, Jean; Metcalfe, Amy; Patten, Scott; Pearson, Dawn; Reid, Aylin; Smith, Eric; Wiebe, Samuel; Dykeman, Jonathan] Univ Calgary, Calgary, AB, Canada.
[Kwon, Churl-Su] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Marrie, Ruth-Ann] Univ Manitoba, Winnipeg, MB, Canada.
[Maxwell, Colleen] Univ Waterloo, Waterloo, ON N2L 3G1, Canada.
[Oskoui, Maryam] McGill Univ, Montreal, PQ, Canada.
[Steeves, Thomas] Univ Toronto, Toronto, ON, Canada.
[Svenson, Larry] Alberta Hlth & Wellness, Edmonton, AB, Canada.
RI Patten, Scott/B-4434-2011
OI Patten, Scott/0000-0001-9871-4041
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA IN62002
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068600083
ER
PT J
AU Joshi, A
Teng, E
Tassniyom, K
Shapira, J
Mendez, M
AF Joshi, Aditi
Teng, Edmond
Tassniyom, Kanida
Shapira, Jill
Mendez, Mario
TI Hippocampal and Medial Temporal Sclerosis in Behavioral Variant
Frontotemporal Dementia
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Joshi, Aditi; Shapira, Jill; Mendez, Mario] Univ Calif Los Angeles, Los Angeles, CA USA.
[Teng, Edmond] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Tassniyom, Kanida] Khon Kaen Univ, Khon Kaen, Thailand.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S44007
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068606222
ER
PT J
AU Joshi, A
Shapiro, D
Jimenez, E
Mather, M
Shapira, J
Kaiser, N
Mendez, M
AF Joshi, Aditi
Shapiro, David
Jimenez, Elvira
Mather, Michelle
Shapira, Jill
Kaiser, Natalie
Mendez, Mario
TI Auditory Startle in Behavioral Variant Frontotemporal Dementia Compared
to Alzheimer's Disease and Healthy Controls
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Joshi, Aditi; Mather, Michelle] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
[Jimenez, Elvira; Shapira, Jill; Mendez, Mario] Univ Calif Los Angeles, Los Angeles, CA USA.
[Kaiser, Natalie] VA Greater Los Angeles Healthcare Ctr, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P07167
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068605149
ER
PT J
AU Kearney, M
Ecklund, D
Simpson, E
Bosch, M
Sweet, B
Jackson, K
Mahoney, K
McCourt, M
Thornell, B
Titus, S
Soodoo, N
O'Brien, J
Gloer, K
Costigan, M
Logsden-Sackett, N
Huff, T
Shefner, J
Gutmann, L
Clarke, W
Torner, J
Long, J
Chaloner, K
Bayman, E
McNeil, D
Koroshetz, W
Kaufmann, P
Cudkowicz, M
Coffey, C
AF Kearney, Marianne
Ecklund, Dixie
Simpson, Elizabeth
Bosch, Michael
Sweet, Bryan
Jackson, Katherine
Mahoney, Katy
McCourt, Michelle
Thornell, Brenda
Titus, Sarah
Soodoo, Natasha
O'Brien, Janice
Gloer, Katherine
Costigan, Michele
Logsden-Sackett, Nyla
Huff, Trevis
Shefner, Jeremy
Gutmann, Laurie
Clarke, William
Torner, James
Long, Jeffrey
Chaloner, Kathryn
Bayman, Emine
McNeil, Dawn
Koroshetz, Walter
Kaufmann, Petra
Cudkowicz, Merit
Coffey, Christopher
TI Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT:
Concept to Implementation
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Kearney, Marianne; Simpson, Elizabeth; Mahoney, Katy; McCourt, Michelle; Thornell, Brenda; Titus, Sarah; Soodoo, Natasha; O'Brien, Janice; Cudkowicz, Merit] MGH, Charlestown, MA USA.
[Ecklund, Dixie; Bosch, Michael; Gloer, Katherine; Costigan, Michele; Logsden-Sackett, Nyla; Huff, Trevis; Clarke, William; Torner, James; Long, Jeffrey; Chaloner, Kathryn; Bayman, Emine; Coffey, Christopher] U Iowa, Iowa City, IA USA.
[Sweet, Bryan; Jackson, Katherine] Massachusetts Gen Hosp, Charlestown, MA USA.
[Shefner, Jeremy] SUNY Upstate Med Ctr, Syracuse, NY USA.
[Gutmann, Laurie] W Virginia Univ, Morgantown, WV 26506 USA.
[McNeil, Dawn; Koroshetz, Walter] NINDS, Bethesda, MD 20892 USA.
[Kaufmann, Petra] NINDS, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P04245
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068603134
ER
PT J
AU Klawiter, E
Alvarez, E
Elsone, L
Mateen, F
Borisow, N
Bove, R
Sorum, J
Mutch, K
Tobyne, S
Musallam, A
Ruprecht, K
Buckle, G
Paul, F
Levy, M
Cross, A
Jacob, A
Chitnis, T
Weinshenker, B
AF Klawiter, Eric
Alvarez, Enrique
Elsone, Liene
Mateen, Farrah
Borisow, Nadja
Bove, Riley
Sorum, Jaime
Mutch, Kerry
Tobyne, Sean
Musallam, Alexander
Ruprecht, Klemens
Buckle, Guy
Paul, Friedemann
Levy, Michael
Cross, Anne
Jacob, Anu
Chitnis, Tanuja
Weinshenker, Brian
TI High Risk of Initial Symptom Onset Post-Partum in Neuromyelitis Optica
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Klawiter, Eric; Tobyne, Sean] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Alvarez, Enrique; Cross, Anne] Washington Univ, Sch Med, St Louis, MO USA.
[Elsone, Liene; Mutch, Kerry; Jacob, Anu] Walton Ctr, Liverpool, Merseyside, England.
[Mateen, Farrah; Levy, Michael] Johns Hopkins Univ, Baltimore, MD USA.
[Borisow, Nadja; Ruprecht, Klemens; Paul, Friedemann] Charite, D-13353 Berlin, Germany.
[Bove, Riley; Musallam, Alexander; Buckle, Guy; Chitnis, Tanuja] Brigham & Womens Hosp, Partners MS Ctr, Boston, MA 02115 USA.
[Sorum, Jaime; Weinshenker, Brian] Mayo Clin, Rochester, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S60001
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068606313
ER
PT J
AU Kraakevik, J
Heath, S
AF Kraakevik, Jeff
Heath, Susan
TI My Parkinson's Story: A Novel Format For a Patient Education Video
Series
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Kraakevik, Jeff] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Heath, Susan] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P04257
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068603146
ER
PT J
AU Kremen, S
Tassniyom, K
Mendez, M
Teng, E
AF Kremen, Sarah
Tassniyom, Kanida
Mendez, Mario
Teng, Edmond
TI Extrapyramidal Signs in Primary Progressive Aphasia: Analyses of the
NACC UDS Cohort
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Kremen, Sarah] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Kremen, Sarah] Univ Calif Los Angeles, Easton Alzheimers Dis Res Ctr, Los Angeles, CA USA.
[Tassniyom, Kanida] Khon Kaen Univ, Fac Med, Dept Psychiat, Khon Kaen, Thailand.
[Mendez, Mario; Teng, Edmond] Greater Los Angeles VA Med Ctr, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P06071
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068604139
ER
PT J
AU Krupp, L
Charvet, L
Serafin, D
Julian, L
Ackerson, J
Benedict, R
Braaten, E
Brown, T
O'Donnell, E
Parrish, J
Preston, T
Zaccariello, M
Belman, A
Chitnis, T
Gorman, M
Kaufman, E
Ness, J
Patterson, M
Rodriguez, M
Waubant, E
Weinstock-Guttman, B
Yeh, A
AF Krupp, Lauren
Charvet, Leigh
Serafin, Dana
Julian, Laura
Ackerson, Joseph
Benedict, Ralph
Braaten, Ellen
Brown, Tanya
O'Donnell, Ellen
Parrish, Joy
Preston, Thomas
Zaccariello, Michael
Belman, Anita
Chitnis, Tanuja
Gorman, Mark
Kaufman, Emma
Ness, Jayne
Patterson, Marc
Rodriguez, Moses
Waubant, Emmanuelle
Weinstock-Guttman, Bianca
Yeh, Ann
TI Impaired Cognition without Behavioral Problems in Pediatric Clinically
Isolated Syndrome (CIS)
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Krupp, Lauren] SUNY Stony Brook, Stony Brook, NY 11794 USA.
[Charvet, Leigh] SUNY Stony Brook, Rockville Ctr, NY USA.
[Serafin, Dana] SUNY Stony Brook, Dept Neurol, Stony Brook, NY 11794 USA.
[Julian, Laura] Univ Calif San Francisco, Dept Neuropsychol, San Francisco, CA 94143 USA.
[Ackerson, Joseph; Ness, Jayne] Univ Alabama Birmingham, Birmingham, AL USA.
[Benedict, Ralph; Parrish, Joy] SUNY Buffalo, Jacobs Neurol Inst, Buffalo, NY 14260 USA.
[Braaten, Ellen] Massachusettes Gen Hosp, Boston, MA USA.
[Brown, Tanya; Zaccariello, Michael] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA.
[O'Donnell, Ellen; Gorman, Mark] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Preston, Thomas] SUNY Stony Brook, Med Ctr, Dept Neuropsychol, East Setauket, NY USA.
[Belman, Anita] SUNY Stony Brook, Huntington, NY USA.
[Chitnis, Tanuja] Massachusetts Gen Hosp, Brookline, MA USA.
[Kaufman, Emma] SUNY Stony Brook, Dept Neurol, Med Ctr, Stony Brook, NY 11794 USA.
[Patterson, Marc; Rodriguez, Moses] Mayo Clin, Rochester, MN USA.
[Waubant, Emmanuelle] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Weinstock-Guttman, Bianca] Jacobs Neurol Inst, Buffalo, NY USA.
[Yeh, Ann] SUNY Buffalo, Dept Neurol, Jacobs Neurol Inst, Buffalo, NY 14260 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P02113
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068601177
ER
PT J
AU Kursun, O
Singhal, A
AF Kursun, Oguzhan
Singhal, Aneesh
TI High Frequency of Incidental Angiographic Abnormalities in RCVS:
Implications For Pathophysiology? ( P03.164)
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Kursun, Oguzhan] Massachusetts Gen Hosp, Dept Neurol, Stroke Serv, Boston, MA 02114 USA.
[Singhal, Aneesh] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P03164
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068602133
ER
PT J
AU Labuzetta, J
Yoo, A
Ali, S
Fitzpatrick, K
Hirsch, J
Schwamm, L
Rost, N
AF Labuzetta, Jamie
Yoo, Albert
Ali, Syed
Fitzpatrick, Kaitlin
Hirsch, Joshua
Schwamm, Lee
Rost, Natalia
TI Determinants of Early Outcomes in Patients with Acute Ischemic Stroke
and Proximal Artery Occlusion
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Labuzetta, Jamie] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Yoo, Albert; Ali, Syed; Fitzpatrick, Kaitlin; Hirsch, Joshua; Schwamm, Lee; Rost, Natalia] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S02005
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068605344
ER
PT J
AU Lawson, R
McCarthy, P
Sawicki, D
Berry, J
Chonde, D
Akeju, O
Loggia, M
Catana, C
Hooker, J
Rosen, B
Cudkowicz, M
Atassi, N
AF Lawson, Robert
McCarthy, Patricia
Sawicki, Darlene
Berry, James
Chonde, Daniel
Akeju, Oluwaseun
Loggia, Marco
Catana, Ciprian
Hooker, Jacob
Rosen, Bruce
Cudkowicz, Merit
Atassi, Nazem
TI Microglial Activation in People with Amyotrophic Lateral Sclerosis
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Lawson, Robert; Sawicki, Darlene; Berry, James; Akeju, Oluwaseun; Rosen, Bruce; Atassi, Nazem] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[McCarthy, Patricia; Loggia, Marco; Catana, Ciprian; Hooker, Jacob; Cudkowicz, Merit] Massachusetts Gen Hosp, Charlestown, MA USA.
[Chonde, Daniel] Harvard Univ, Harvard MIT Dept Hlth Sci & Technol, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P06132
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068604200
ER
PT J
AU Lee, E
Reardon, D
Schiff, D
Drappatz, J
Hammond, S
Grimm, S
Norden, A
Beroukhim, R
McCluskey, C
Chi, A
Batchelor, T
Doherty, L
Lafrankie, D
Ruland, S
Rifenburg, J
Jacobs, J
Smith, K
Gaffey, S
Gerard, M
Snodgrass, S
Raizer, J
Wen, P
AF Lee, Eudocia
Reardon, David
Schiff, David
Drappatz, Jan
Hammond, Samantha
Grimm, Sean
Norden, Andrew
Beroukhim, Rameen
McCluskey, Christine
Chi, Andrew
Batchelor, Tracy
Doherty, Lisa
Lafrankie, Debra
Ruland, Sandra
Rifenburg, Jennifer
Jacobs, Jeanne
Smith, Katrina
Gaffey, Sarah
Gerard, Mary
Snodgrass, Susan
Raizer, Jeffrey
Wen, Patrick
TI Interim Analysis of a Phase I/II Study of Panobinostat in Combination
with Bevacizumab for Recurrent Glioblastoma
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Lee, Eudocia; Reardon, David; Hammond, Samantha; Norden, Andrew; Beroukhim, Rameen; McCluskey, Christine; Doherty, Lisa; Lafrankie, Debra; Ruland, Sandra; Rifenburg, Jennifer; Jacobs, Jeanne; Smith, Katrina; Gaffey, Sarah; Gerard, Mary; Wen, Patrick] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Schiff, David] Univ Virginia, Charlottesville, VA USA.
[Drappatz, Jan] Univ Pittsburgh, Pittsburgh, PA USA.
[Grimm, Sean] Univ Minnesota, Minneapolis, MN USA.
[Chi, Andrew; Batchelor, Tracy] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Snodgrass, Susan] Novartis, E Hanover, NJ USA.
[Raizer, Jeffrey] Northwestern Univ, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P01094
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068600251
ER
PT J
AU Lee, E
Reardon, D
Schiff, D
Drappatz, J
Hammond, S
Grimm, S
Norden, A
Beroukhim, R
McCluskey, C
Chi, A
Batchelor, T
Doherty, L
Lafrankie, D
Ruland, S
Rifenburg, J
Jacobs, J
Smith, K
Gaffey, S
Gerard, M
Snodgrass, S
Raizer, J
Wen, P
AF Lee, Eudocia
Reardon, David
Schiff, David
Drappatz, Jan
Hammond, Samantha
Grimm, Sean
Norden, Andrew
Beroukhim, Rameen
McCluskey, Christine
Chi, Andrew
Batchelor, Tracy
Doherty, Lisa
Lafrankie, Debra
Ruland, Sandra
Rifenburg, Jennifer
Jacobs, Jeanne
Smith, Katrina
Gaffey, Sarah
Gerard, Mary
Snodgrass, Susan
Raizer, Jeffrey
Wen, Patrick
TI Interim Analysis of a Phase I/II Study of Panobinostat in Combination
with Bevacizumab for Recurrent Glioblastoma
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Lee, Eudocia; Reardon, David; Hammond, Samantha; Norden, Andrew; Beroukhim, Rameen; McCluskey, Christine; Doherty, Lisa; Lafrankie, Debra; Ruland, Sandra; Rifenburg, Jennifer; Jacobs, Jeanne; Smith, Katrina; Gaffey, Sarah; Gerard, Mary; Wen, Patrick] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Schiff, David] Univ Virginia, Charlottesville, VA USA.
[Drappatz, Jan] Univ Pittsburgh, Pittsburgh, PA USA.
[Grimm, Sean] Univ Minnesota, Minneapolis, MN USA.
[Chi, Andrew; Batchelor, Tracy] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Snodgrass, Susan] Novartis, E Hanover, NJ USA.
[Raizer, Jeffrey] Northwestern Univ, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA IN101005
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068600132
ER
PT J
AU Leitner, M
Sherman, A
Atassi, N
Berry, J
Shui, A
Zach, N
Walker, J
Sinani, E
Katsovskiy, I
Schoenfeld, D
Cudkowicz, M
AF Leitner, Melanie
Sherman, Alexander
Atassi, Nazem
Berry, James
Shui, Amy
Zach, Neta
Walker, Jason
Sinani, Ervin
Katsovskiy, Igor
Schoenfeld, David
Cudkowicz, Merit
TI ALS Enters the World of Big Data: Initial Description of and Results
from the PRO-ACT Platform
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Leitner, Melanie; Zach, Neta] Prize4Life, Cambridge, MA USA.
[Sherman, Alexander; Atassi, Nazem; Cudkowicz, Merit] Massachusetts Gen Hosp, Charlestown, MA USA.
[Berry, James; Shui, Amy; Walker, Jason; Sinani, Ervin; Katsovskiy, Igor; Schoenfeld, David] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P07064
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068605046
ER
PT J
AU Lu-Emerson, C
Snuderl, M
Kirkpatrick, N
Goveia, J
Davidson, C
Huang, Y
Riedemann, L
Ivy, P
Ancukiewicz, M
Stemmer-Rachamimov, A
Batchelor, T
Jain, R
AF Lu-Emerson, Christine
Snuderl, Matija
Kirkpatrick, Nathaniel
Goveia, Jermaine
Davidson, Christian
Huang, Yuhui
Riedemann, Lars
Ivy, Percy
Ancukiewicz, Marek
Stemmer-Rachamimov, Anat
Batchelor, Tracy
Jain, Rakesh
TI Direct Evidence That Increase in Tumor-Associated Macrophages (TAMs)
after Antiangiogenic Therapy Is Associated with Poor Survival in
Recurrent Glioblastoma (GBM) Patients
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Lu-Emerson, Christine] Massachusetts Gen Hosp, Dept Neurooncol, Boston, MA 02114 USA.
[Snuderl, Matija; Batchelor, Tracy] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kirkpatrick, Nathaniel; Goveia, Jermaine; Huang, Yuhui; Riedemann, Lars; Ancukiewicz, Marek; Jain, Rakesh] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Davidson, Christian; Stemmer-Rachamimov, Anat] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Ivy, Percy] NCI, Invest Drug Branch, Rockville, MD USA.
RI Riedemann, Lars/J-5725-2014
OI Riedemann, Lars/0000-0002-9510-1845
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S35001
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068606159
ER
PT J
AU Lu-Emerson, C
Snuderl, M
Kirkpatrick, N
Goveia, J
Davidson, C
Huang, YH
Riedemann, L
Ivy, P
Ancukiewicz, M
Stemmer-Rachamimov, A
Batchelor, T
Jain, R
AF Lu-Emerson, Christine
Snuderl, Matija
Kirkpatrick, Nathaniel
Goveia, Jermaine
Davidson, Christian
Huang, Yuhui
Riedemann, Lars
Ivy, Percy
Ancukiewicz, Marek
Stemmer-Rachamimov, Anat
Batchelor, Tracy
Jain, Rakesh
TI Direct Evidence That Increase in Tumor-Associated Macrophages (TAMs)
after Antiangiogenic Therapy Is Associated with Poor Survival in
Recurrent Glioblastoma (GBM) Patients
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Lu-Emerson, Christine] Massachusetts Gen Hosp, Dept Neurooncol, Boston, MA 02114 USA.
[Snuderl, Matija; Batchelor, Tracy] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kirkpatrick, Nathaniel; Goveia, Jermaine; Huang, Yuhui; Riedemann, Lars; Ancukiewicz, Marek; Jain, Rakesh] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Davidson, Christian; Stemmer-Rachamimov, Anat] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Ivy, Percy] NCI, Invest Drug Branch, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA IN102001
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068600138
ER
PT J
AU Maraka, S
Jiang, Q
Jafari-Khouzani, K
Hamidian, N
Li, L
Malik, S
Zhang, TL
Lu, M
Soltanian-Zadeh, H
Mitsias, P
AF Maraka, Stefania
Jiang, Quan
Jafari-Khouzani, Kourosh
Hamidian, Nasim
Li, Lian
Malik, Shaneela
Zhang, Talan
Lu, Mai
Soltanian-Zadeh, Hamid
Mitsias, Panayiotis
TI Quantitative Assessment of Corticospinal Tract Injury on Diffusion
Tensor Imaging Correlates with Motor Outcome after Ischemic Stroke
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Maraka, Stefania; Jiang, Quan; Hamidian, Nasim; Li, Lian; Malik, Shaneela; Zhang, Talan; Lu, Mai; Soltanian-Zadeh, Hamid] Henry Ford Hosp, Detroit, MI 48202 USA.
[Jafari-Khouzani, Kourosh] Massachussetts Gen Hosp, Boston, MA USA.
[Mitsias, Panayiotis] Stroke & Neurovasc Ctr, Detroit, MI USA.
RI Soltanian-Zadeh, Hamid/K-2903-2016
OI Soltanian-Zadeh, Hamid/0000-0002-7302-6856
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P03163
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068602132
ER
PT J
AU Maski, K
Holbrook, H
Manoach, D
Hanson, E
Stickgold, R
AF Maski, Kiran
Holbrook, Hannah
Manoach, Dara
Hanson, Ellen
Stickgold, Robert
TI Sleep Architecture and Neurobehavioral and Cognitive Functioning in
Children with Autistic Spectrum Disorders
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Maski, Kiran; Holbrook, Hannah; Hanson, Ellen] Boston Childrens Hosp, Boston, MA USA.
[Manoach, Dara] Massachusetts Gen Hosp, Martinos Ctr, Charlestown, MA USA.
[Stickgold, Robert] Beth Israel Deaconess Med Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P03011
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068601329
ER
PT J
AU McKenery, M
Yu, H
Li, HN
Lee, A
Chang, J
Jankowski, S
Bozik, A
Orbey, A
Zipf, A
Cudkowicz, M
Atassi, N
AF McKenery, Michael
Yu, Hong
Li, Haining
Lee, Alexandra
Chang, Judith
Jankowski, Stacey
Bozik, Anne
Orbey, Aaron
Zipf, Amanda
Cudkowicz, Merit
Atassi, Nazem
TI Regional Pattern of Symptom Spread in Amyotrophic Lateral Sclerosis
(ALS)
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [McKenery, Michael; Yu, Hong; Li, Haining; Lee, Alexandra; Chang, Judith; Jankowski, Stacey; Bozik, Anne; Orbey, Aaron; Zipf, Amanda; Cudkowicz, Merit; Atassi, Nazem] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P06130
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068604198
ER
PT J
AU Mejia, N
Cook, B
AF Mejia, Nicte
Cook, Benjamin
TI Racial/Ethnic Disparities in Parkinson Disease Patient Care in the
United States: 1996-2009 Medical Expenditure Panel Survey
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Mejia, Nicte] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Cook, Benjamin] Cambridge Hlth Alliance, Ctr Multicultural Mental Hlth Res, Somerville, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S03001
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068605347
ER
PT J
AU Miglis, M
Gibbons, C
Freeman, R
AF Miglis, Mitchell
Gibbons, Christopher
Freeman, Roy
TI Sleep Disorders in Patients with Postural Tachycardia Syndrome
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Miglis, Mitchell] Stanford Univ, Redwood City, CA USA.
[Gibbons, Christopher; Freeman, Roy] BIDMC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P03026
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068601344
ER
PT J
AU Moore, W
Roubin, G
Rosenfield, K
Altafullah, I
Ansel, G
Voeks, J
Meschia, J
Lal, B
Howard, G
Brott, T
AF Moore, Wesley
Roubin, Gary
Rosenfield, Kenneth
Altafullah, Irfan
Ansel, Gary
Voeks, Jenifer
Meschia, James
Lal, Brajesh
Howard, George
Brott, Thomas
TI Can Patient or Arterial Characteristics Guide the Choice between Carotid
Angioplasty and Carotid Endarterectomy? The Carotid Revascularization
Endarterectomy Versus Stenting Trial (CREST)
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Moore, Wesley] Univ Calif Los Angeles, Los Angeles Med Ctr, Los Angeles, CA USA.
[Roubin, Gary] Continuum Hlth Partners, New York, NY USA.
[Rosenfield, Kenneth] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Altafullah, Irfan] North Mem Med Ctr, Robbinsdale, MN USA.
[Ansel, Gary] Ohio Hlth Res Inst, Columbus, OH USA.
[Voeks, Jenifer] Med Univ S Carolina, Charleston, SC 29425 USA.
[Meschia, James; Brott, Thomas] Mayo Clin, Jacksonville, FL 32224 USA.
[Lal, Brajesh] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Howard, George] Univ Alabama Birmingham, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P01225
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068601024
ER
PT J
AU Nayak, L
Abrey, L
DeAngelis, L
Gadgeel, S
Garst, J
Govindan, R
Kelly, K
Omuro, A
Peereboom, D
Ramnath, N
Reimers, HJ
Rigas, J
Robbins, HI
Rosenfeld, S
Wen, P
AF Nayak, Lakshmi
Abrey, Lauren
DeAngelis, Lisa
Gadgeel, Shirish
Garst, Jennifer
Govindan, Ramaswamy
Kelly, Karen
Omuro, Antonio
Peereboom, David
Ramnath, Nithya
Reimers, Hans-Joachim
Rigas, James
Robbins, H. Ian
Rosenfeld, Steven
Wen, Patrick
TI An Open-Label, Multi-Center, Phase II Study of Patupilone (EPO906), in
the Treatment of Recurrent or Progressive Brain Metastases in Patients
with Non-Small Cell Lung Cancer (NSCLC)
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Nayak, Lakshmi; Wen, Patrick] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Abrey, Lauren] Roche Pharmaceut, Wyalusing, PA USA.
[DeAngelis, Lisa] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Gadgeel, Shirish] Wayne State Univ, Wertz Clin Canc Ctr, Detroit, MI USA.
[Garst, Jennifer] Duke Univ, Med Ctr, Durham, NC USA.
[Govindan, Ramaswamy] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63130 USA.
[Kelly, Karen] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA.
[Omuro, Antonio] MSKCC, New York, NY USA.
[Peereboom, David] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Ramnath, Nithya] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Reimers, Hans-Joachim] St Louis Univ, Ctr Canc, St Louis, MO 63103 USA.
[Rigas, James] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
[Robbins, H. Ian] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA.
[Rosenfeld, Steven] Columbia Univ, Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S56002
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068606292
ER
PT J
AU Nayak, L
Abrey, L
DeAngelis, L
Gadgeel, S
Garst, J
Govindan, R
Kelly, K
Omuro, A
Peereboom, D
Ramnath, N
Reimers, HJ
Rigas, J
Robbins, HI
Rosenfeld, S
Wen, P
AF Nayak, Lakshmi
Abrey, Lauren
DeAngelis, Lisa
Gadgeel, Shirish
Garst, Jennifer
Govindan, Ramaswamy
Kelly, Karen
Omuro, Antonio
Peereboom, David
Ramnath, Nithya
Reimers, Hans-Joachim
Rigas, James
Robbins, H. Ian
Rosenfeld, Steven
Wen, Patrick
TI An Open-Label, Multi-Center, Phase II Study of Patupilone (EPO906), in
the Treatment of Recurrent or Progressive Brain Metastases in Patients
with Non-Small Cell Lung Cancer (NSCLC)
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Nayak, Lakshmi; Wen, Patrick] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Abrey, Lauren] Roche Pharmaceut, Wyalusing, PA USA.
[DeAngelis, Lisa] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Gadgeel, Shirish] Wayne State Univ, Wertz Clin Canc Ctr, Detroit, MI USA.
[Garst, Jennifer] Duke Univ, Med Ctr, Durham, NC USA.
[Govindan, Ramaswamy] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63130 USA.
[Kelly, Karen] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA.
[Omuro, Antonio] MSKCC, New York, NY USA.
[Peereboom, David] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Ramnath, Nithya] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Reimers, Hans-Joachim] St Louis Univ, Ctr Canc, St Louis, MO 63103 USA.
[Rigas, James] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
[Robbins, H. Ian] Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA.
[Rosenfeld, Steven] Columbia Univ, Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA IN102005
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068600142
ER
PT J
AU Neagu, M
Lyons, J
Norton, I
Klein, J
AF Neagu, Martha
Lyons, Jennifer
Norton, Isaiah
Klein, Joshua
TI Diffusion Tensor Imaging in Brainstem Tuberculoma
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Neagu, Martha] Brigham & Womens Hosp, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Lyons, Jennifer; Norton, Isaiah; Klein, Joshua] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P06184
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068604252
ER
PT J
AU Ng, M
Kilbride, R
Simon, M
Eskandar, E
Cole, A
AF Ng, Marcus
Kilbride, Ronan
Simon, Mirela
Eskandar, Emad
Cole, Andrew
TI The Role of Hippocampography and Hippocampectomy in Symptomatic
Extrahippocampal Temporal Lobe Epilepsy
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Ng, Marcus; Simon, Mirela; Cole, Andrew] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kilbride, Ronan] Massachusetts Gen Hosp, Somerville, MA USA.
[Eskandar, Emad] Massachusetts Gen Hosp, Neurosurg Serv, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P04197
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068603086
ER
PT J
AU Pantelyat, A
Freedman, R
Pawlowski, S
Kesari, A
Duda, J
Morley, J
AF Pantelyat, Alexander
Freedman, Rebecca
Pawlowski, Stephanie
Kesari, Adhithi
Duda, John
Morley, James
TI Quantitative Assessment of Bradykinesia in Parkinson's Disease (PD)
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Pantelyat, Alexander; Duda, John; Morley, James] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Freedman, Rebecca; Kesari, Adhithi] Univ Penn, Philadelphia, PA USA.
[Pawlowski, Stephanie] Philadelphia VA Med Ctr PADRECC, Philadelphia, PA USA.
[Morley, James] Hosp Univ Penn, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P04192
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068603081
ER
PT J
AU Park, KY
Avery, R
Ay, H
AF Park, Kwang-Yeol
Avery, Ross
Ay, Hakan
TI Prior beta Blocker Use Is Associated with Favorable Outcome in Patients
with Acute Insular Stroke
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Park, Kwang-Yeol] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Avery, Ross] Massachusetts Gen Hosp, Charlestown, MA USA.
[Ay, Hakan] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P01217
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068601016
ER
PT J
AU Pati, S
Rosenthal, E
Cash, S
Hochberg, L
Brown, E
Westover, M
AF Pati, Sandipan
Rosenthal, Eric
Cash, Sydney
Hochberg, Leigh
Brown, Emery
Westover, M.
TI Unexpected Burst-Suppression during Sedation with Anesthetic Agents in
the ICU
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Pati, Sandipan; Rosenthal, Eric; Cash, Sydney; Hochberg, Leigh; Brown, Emery; Westover, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P01027
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068600184
ER
PT J
AU Peterson, A
Murchison, C
Zabetian, C
Leverenz, J
Watson, G
Montine, T
Carney, N
Bowman, G
Quinn, J
AF Peterson, Amie
Murchison, Charles
Zabetian, Cyrus
Leverenz, James
Watson, G.
Montine, Thomas
Carney, Natasha
Bowman, Gene
Quinn, Joseph
TI The Relationship between Vitamin D and Cognitive Performance in Persons
with Parkinson's
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Peterson, Amie] Portland VA OHSU, Portland, OR USA.
[Murchison, Charles] OHSU, Portland, OR USA.
[Zabetian, Cyrus] Univ Washington, Seattle, WA 98195 USA.
[Leverenz, James] Univ Washington, Seattle, WA 98195 USA.
[Watson, G.] Univ Washington, VA Puget Sound, Seattle, WA 98195 USA.
[Montine, Thomas] Univ Washington, Bellevue, WA USA.
[Carney, Natasha] Portland VA, Portland, OR USA.
[Bowman, Gene; Quinn, Joseph] OHSU, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P04170
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068603059
ER
PT J
AU Rascovsky, K
Hodges, J
Knopman, D
Mendez, M
Kramer, J
Neuhaus, J
Van Swieten, J
Seelaar, H
Dopper, E
Onyike, C
Hillis, A
Josephs, K
Boeve, B
Kertesz, A
Seeley, W
Rankin, K
Johnson, J
Tempini, MG
Rosen, H
Latham, C
Lee, A
Kipps, C
Lillo, P
Piguet, O
Rohrer, J
Rossor, M
Warren, J
Fox, N
Galasko, D
Salmon, D
Black, S
Mesulam, M
Weintraub, S
Dickerson, B
Diehl, J
Pasquier, F
Deramecourt, V
Lebert, F
Pijnenburg, Y
Chow, T
Manes, F
Grafman, J
Cappa, S
Freedman, M
Miller, B
Grossman, M
AF Rascovsky, Katya
Hodges, John
Knopman, David
Mendez, Mario
Kramer, Joel
Neuhaus, John
Van Swieten, John
Seelaar, Harro
Dopper, Elise
Onyike, Chiadi
Hillis, Argye
Josephs, Keith
Boeve, Bradley
Kertesz, Andrew
Seeley, William
Rankin, Katherine
Johnson, Julene
Tempini, Maria Gorno
Rosen, Howard
Latham, Caroline
Lee, Albert
Kipps, Christopher
Lillo, Patricia
Piguet, Olivier
Rohrer, Jonathan
Rossor, Martin
Warren, Jason
Fox, Nic
Galasko, Douglas
Salmon, David
Black, Sandra
Mesulam, M.
Weintraub, Sandra
Dickerson, Bradford
Diehl, Janine
Pasquier, Florence
Deramecourt, Vincent
Lebert, Florence
Pijnenburg, Yolande
Chow, Tiffany
Manes, Facundo
Grafman, Jordan
Cappa, Stefano
Freedman, Morris
Miller, Bruce
Grossman, Murray
TI Can Clinical Features Predict Tau Pathology in Patients with Behavioral
Variant Frontotemporal Dementia (bvFTD)?
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Rascovsky, Katya; Grossman, Murray] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Hodges, John; Lillo, Patricia; Piguet, Olivier] Res Australia, Neurosci, Randwick, NSW, Australia.
[Hodges, John; Lillo, Patricia; Piguet, Olivier] Univ New S Wales, Randwick, NSW, Australia.
[Knopman, David; Josephs, Keith; Boeve, Bradley] Mayo Clin, Rochester, MN USA.
[Mendez, Mario] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA.
[Kramer, Joel; Seeley, William; Rankin, Katherine; Tempini, Maria Gorno; Rosen, Howard; Latham, Caroline; Lee, Albert; Miller, Bruce] Univ Calif San Francisco, Memory & Aging Ctr, San Francisco, CA 94143 USA.
[Neuhaus, John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Van Swieten, John; Seelaar, Harro; Dopper, Elise] Erasmus MC, Rotterdam, Netherlands.
[Onyike, Chiadi; Hillis, Argye] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Kertesz, Andrew] Univ Western Ontario, London, ON, Canada.
[Johnson, Julene] Univ Calif San Francisco, Inst Hlth & Aging Univ, San Francisco, CA 94143 USA.
[Kipps, Christopher] Univ Southampton, Wessex Neurol Ctr, Southampton, Hants, England.
[Rohrer, Jonathan; Rossor, Martin; Warren, Jason; Fox, Nic] UCL Inst Neurol, Dementia Res Ctr, London, England.
[Galasko, Douglas; Salmon, David] Univ Calif San Diego, San Diego, CA 92103 USA.
[Galasko, Douglas] Univ Calif San Diego, VA Med Ctr, San Diego, CA 92103 USA.
[Black, Sandra] Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
[Mesulam, M.; Weintraub, Sandra] Northwestern Univ, Feinberg Sch Med, Cognit Neurol & Alzheimers Dis Ctr, Chicago, IL 60611 USA.
[Dickerson, Bradford] Massachusetts Gen Hosp, Charlestown, MA USA.
[Dickerson, Bradford] Harvard Univ, Sch Med, Charlestown, MA USA.
[Diehl, Janine] Tech Univ Munich, D-80290 Munich, Germany.
[Pasquier, Florence; Deramecourt, Vincent; Lebert, Florence] Univ Lille Nord France, Lille, France.
[Pijnenburg, Yolande] Vrije Univ Amsterdam, Med Ctr, Alzheimers Res Ctr, Amsterdam, Netherlands.
[Pijnenburg, Yolande] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands.
[Chow, Tiffany] Univ Toronto, Rotman Res Inst, Toronto, ON, Canada.
[Manes, Facundo] Univ Buenos Aires, Inst Cognit Neurol Favaloro, RA-1053 Buenos Aires, DF, Argentina.
[Grafman, Jordan] Brain Injury Res Rehabil Inst Chicago, Chicago, IL USA.
[Cappa, Stefano] Univ Vita Salutte San Raffaele, Milan, Italy.
[Freedman, Morris] Baycrest, Neurol, Toronto, ON, Canada.
[Freedman, Morris] Univ Toronto, Toronto, ON, Canada.
NR 0
TC 0
Z9 0
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P05101
PG 3
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068603254
ER
PT J
AU Ringman, J
Liang, LJ
Flores, M
Wharton, D
Goate, A
Schofield, P
Cairns, N
Benzinger, T
Fagan, A
Xiong, CJ
Ghetti, B
McDade, E
Masters, C
Mayeux, R
Rossor, M
Sperling, R
Salloway, S
Marcus, D
Martins, R
Bateman, R
Morris, J
AF Ringman, John
Liang, Li-Jung
Flores, Martin
Wharton, David
Goate, Alison
Schofield, Peter
Cairns, Nigel
Benzinger, Tammie
Fagan, Anne
Xiong, Chengjie
Ghetti, Bernardino
McDade, Eric
Masters, Colin
Mayeux, Richard
Rossor, Martin
Sperling, Reisa
Salloway, Stephen
Marcus, Daniel
Martins, Ralph
Bateman, Randall
Morris, John
TI Early Behavioral Changes in Familial Alzheimer's Disease: Results from
the Dominantly Inherited Alzheimer Network
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Ringman, John] Easton Ctr Alzheimers Dis Res, Los Angeles, CA USA.
[Liang, Li-Jung; Flores, Martin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Internal Med, Los Angeles, CA 90095 USA.
[Wharton, David] UCLA Dept Neurol, Easton Ctr Alzheimers Dis Res, Los Angeles, CA USA.
[Goate, Alison; Cairns, Nigel; Benzinger, Tammie; Fagan, Anne; Xiong, Chengjie; Marcus, Daniel; Bateman, Randall; Morris, John] Washington Univ, Sch Med, St Louis, MO USA.
[Schofield, Peter] Neurosci Res Australia, Randwick, NSW, Australia.
[Ghetti, Bernardino] Indiana Univ, Indianapolis, IN 46204 USA.
[McDade, Eric] Univ Pittsburgh, Pittsburgh, PA USA.
[Masters, Colin] Univ Melbourne, Melbourne, Vic 3010, Australia.
[Mayeux, Richard] Columbia Univ, New York, NY USA.
[Rossor, Martin] UCL, London, England.
[Sperling, Reisa] Brigham & Womens Univ, Massachusetts Gen Hosp, Boston, MA USA.
[Salloway, Stephen] Brown Univ, Providence, RI 02912 USA.
[Martins, Ralph] Edith Cowan Univ, Joondalup, Australia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S24005
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068606091
ER
PT J
AU Rost, N
Metterville, D
Cloonan, L
Fitzpatrick, K
Kanakis, A
Politei, J
Sims, K
AF Rost, Natalia
Metterville, Danielle
Cloonan, Lisa
Fitzpatrick, Kaitlin
Kanakis, Allison
Politei, Juan
Sims, Katherine
TI Determinants of White Matter Hyperintensity Burden in Patients with
Fabry Disease
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Rost, Natalia; Metterville, Danielle; Cloonan, Lisa; Fitzpatrick, Kaitlin; Kanakis, Allison; Sims, Katherine] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Politei, Juan] Hosp Gen Agudos, Buenos Aires, DF, Argentina.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P03171
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068602140
ER
PT J
AU Schultz, A
Marshall, G
Chhatwal, J
Rentz, D
Johnson, K
Ward, A
Wigman, S
Hedden, T
Van Dijk, K
McLaren, D
Huijbers, W
Sperling, R
AF Schultz, Aaron
Marshall, Gad
Chhatwal, Jasmeer
Rentz, Dorene
Johnson, Keith
Ward, Andrew
Wigman, Sarah
Hedden, Trey
Van Dijk, Koene
McLaren, Donald
Huijbers, Willem
Sperling, Reisa
TI Test-Retest Reliability of Resting State Functional Connectivity MRI in
Mild Cognitive Impairment
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Schultz, Aaron] MGH, Dept Neurol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Marshall, Gad] Brigham & Womens Hosp, Brookline, MA USA.
[Chhatwal, Jasmeer] Massachusetts Gen Hosp, Cambridge, MA USA.
[Rentz, Dorene; Ward, Andrew; Wigman, Sarah; Huijbers, Willem; Sperling, Reisa] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Johnson, Keith] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hedden, Trey; Van Dijk, Koene] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[McLaren, Donald] Mass Gen Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P06024
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068604092
ER
PT J
AU Schwamm, L
Ali, S
Davis, L
Forducey, P
Nystrom, K
Schindler, J
Schlegel, S
Likosky, W
Solenski, N
Burt, D
AF Schwamm, Lee
Ali, Syed
Davis, Lawrence
Forducey, Pamela
Nystrom, Karin
Schindler, Joseph
Schlegel, Sherene
Likosky, William
Solenski, Nina
Burt, David
CA Partners TeleStroke Network
TI Independent Predictors of IV tPA Use in the Partners Telestroke Network:
A Multistate, Multicenter Hospital Alliance in the Remote Management of
Acute Ischemic Stroke
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Schwamm, Lee; Ali, Syed; Partners TeleStroke Network] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Davis, Lawrence; Forducey, Pamela] INTEGRIS Hlth, Oklahoma City, OK USA.
[Nystrom, Karin; Schindler, Joseph] Yale New Haven Stroke Ctr, New Haven, CT USA.
[Schlegel, Sherene; Likosky, William] Swedish Med Ctr, Seattle, WA USA.
[Solenski, Nina] Univ Virginia, Charlottesville, VA USA.
[Burt, David] Univ Virginia, Dept Emergency Med, Charlottesville, VA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P05222
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068604027
ER
PT J
AU Schwamm, L
Ali, S
Davis, L
Forducey, P
Nystrom, K
Schindler, J
Schlegel, S
Likosky, W
Solenski, N
Burt, D
AF Schwamm, Lee
Ali, Syed
Davis, Lawrence
Forducey, Pamela
Nystrom, Karin
Schindler, Joseph
Schlegel, Sherene
Likosky, William
Solenski, Nina
Burt, David
CA Partners TeleStroke Network
TI Partners Telestroke Network: Experience of a Multistate, Multicenter
Hospital Alliance in the Remote Management of Acute Ischemic Stroke
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Schwamm, Lee; Partners TeleStroke Network] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ali, Syed] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Davis, Lawrence; Forducey, Pamela] INTEGRIS Hlth, Oklahoma City, OK USA.
[Nystrom, Karin; Schindler, Joseph] Yale New Haven Stroke Ctr, New Haven, CT USA.
[Schlegel, Sherene; Likosky, William] Swedish Med Ctr, Seattle, WA USA.
[Solenski, Nina] Univ Virginia, Charlottesville, VA USA.
[Burt, David] Univ Virginia, Dept Emergency Med, Charlottesville, VA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P05213
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068604018
ER
PT J
AU Sherman, A
Heiman-Patterson, T
Katz, J
Katsovskiy, I
Selsov, R
Sinani, E
Walker, J
Cudkowicz, M
AF Sherman, Alexander
Heiman-Patterson, Terry
Katz, Jonathan
Katsovskiy, Igor
Selsov, Roger
Sinani, Ervin
Walker, Jason
Cudkowicz, Merit
TI NeuroBANK (TM): Integrated Clinical Data Repository Platform as a Model
for Clinical Research
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Sherman, Alexander; Katsovskiy, Igor; Selsov, Roger; Sinani, Ervin; Walker, Jason] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Heiman-Patterson, Terry] Drexel Univ, Radnor, PA USA.
[Katz, Jonathan] Calif Pacific Med Ctr, San Francisco, CA USA.
[Cudkowicz, Merit] MGH, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P07072
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068605054
ER
PT J
AU Singhal, A
AF Singhal, Aneesh
CA Partners SPOTRIAS Investigators
TI Serial MRI Findings in a Phase 2B Clinical Trial of Normobaric Oxygen
Therapy (NBO) in Acute Ischemic Stroke (AIS)
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Singhal, Aneesh] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Partners SPOTRIAS Investigators] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S42001
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068606202
ER
PT J
AU Singhal, A
AF Singhal, Aneesh
CA Partners SPOTRIAS Investigators
TI A Phase IIB Clinical Trial of Normobaric Oxygen Therapy (NBO) in Acute
Ischemic Stroke (AIS)
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Singhal, Aneesh; Partners SPOTRIAS Investigators] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA S02001
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068605340
ER
PT J
AU Singhal, A
AF Singhal, Aneesh
CA Partners SPOTRIAS Investigators
TI Serial MRI Findings in a Phase 2B Clinical Trial of Normobaric Oxygen
Therapy (NBO) in Acute Ischemic Stroke (AIS)
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Singhal, Aneesh] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Partners SPOTRIAS Investigators] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA IN72002
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068600098
ER
PT J
AU Singhal, T
Sheth, K
Cho, T
AF Singhal, Tarun
Sheth, Kevin
Cho, Tracey
TI Morbidity and Mortality Conferences in ACGME Core Competencies Education
for Neurology Residents
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Singhal, Tarun; Cho, Tracey] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Sheth, Kevin] U Maryland, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P04248
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068603137
ER
PT J
AU Tate, J
Brashear, A
Whitlow, C
Snively, B
Ozelius, L
Sweadner, K
Stacy, M
Haq, I
AF Tate, Jessica
Brashear, Allison
Whitlow, Christopher
Snively, Beverly
Ozelius, Laurie
Sweadner, Kathleen
Stacy, Mark
Haq, Ihtsham
TI Rapid-Onset Dystonia-Parkinsonism Presenting as Tremor-Dominant
Parkinson's Disease
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Tate, Jessica; Brashear, Allison; Haq, Ihtsham] Wake Forest Baptist Hlth, Wake Forest Sch Med, Winston Salem, NC USA.
[Whitlow, Christopher] Wake Forest Baptist Hlth, Wake Forest Sch Med, Dept Radiol, Winston Salem, NC USA.
[Snively, Beverly] Wake Forest Baptist Hlth, Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA.
[Ozelius, Laurie] Mt Sinai Sch Med, New York, NY USA.
[Sweadner, Kathleen] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Stacy, Mark] Duke Univ, Sch Med, Duke Hlth, Durham, NC USA.
RI Brashear, Allison/G-3853-2015
NR 0
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P04161
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068603050
ER
PT J
AU Thakur, K
Marmarelis, M
Wahlster, S
Bakhadirov, K
Bhattacharyya, R
Dunn, I
AF Thakur, Kiran
Marmarelis, Melissa
Wahlster, Sarah
Bakhadirov, Khamidulla
Bhattacharyya, Roby
Dunn, Ian
TI Management of Refractory Elevated Intracranial Pressure (ICP) in an
Immunocompetant Host with Cryptococcal Meningitis
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Thakur, Kiran] Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21287 USA.
[Marmarelis, Melissa; Wahlster, Sarah] Harvard Univ, Sch Med, Boston, MA USA.
[Bakhadirov, Khamidulla] Brigham & Womens Hosp, Brookline, MA USA.
[Bhattacharyya, Roby] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Dunn, Ian] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P03249
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068602217
ER
PT J
AU Topcuoglu, M
Kursun, O
Karatas, H
Buonanno, F
Singhal, A
AF Topcuoglu, Mehmet
Kursun, Oguzhan
Karatas, Hulya
Buonanno, Ferdinando
Singhal, Aneesh
TI Stroke in Non-Bacterial Thrombotic Endocarditis: 31-Year Experience
SO NEUROLOGY
LA English
DT Meeting Abstract
CT 65th Annual Meeting of the American-Academy-of-Neurology (AAN)
CY MAR 16-23, 2013
CL San Diego, CA
SP Amer Acad Neurol
C1 [Topcuoglu, Mehmet] Hacettepe Univ, Dept Neurol, Ankara, Turkey.
[Kursun, Oguzhan] Massachusetts Gen Hosp, Dept Neurol, Stroke Serv, Boston, MA 02114 USA.
[Karatas, Hulya] Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, Boston, MA 02114 USA.
[Buonanno, Ferdinando; Singhal, Aneesh] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RI Karatas, Hulya/J-1459-2013
OI Karatas, Hulya/0000-0003-4838-6320
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD FEB 12
PY 2013
VL 80
SU S
MA P02023
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AB8VR
UT WOS:000332068601087
ER
EF